Apontic	O
binds	O
the	O
translational	O
repressor	O
Bruno	O
and	O
is	O
implicated	O
in	O
regulation	O
of	O
oskar	O
mRNA	O
translation	O
.	O

The	O
product	O
of	O
the	O
oskar	O
gene	O
directs	O
posterior	O
patterning	O
in	O
the	O
Drosophila	O
oocyte	O
,	O
where	O
it	O
must	O
be	O
deployed	O
specifically	O
at	O
the	O
posterior	O
pole	O
.	O

Proper	O
expression	O
relies	O
on	O
the	O
coordinated	O
localization	O
and	O
translational	O
control	O
of	O
the	O
oskar	O
mRNA	O
.	O

Translational	O
repression	O
prior	O
to	O
localization	O
of	O
the	O
transcript	O
is	O
mediated	O
,	O
in	O
part	O
,	O
by	O
the	O
Bruno	O
protein	O
,	O
which	O
binds	O
to	O
discrete	O
sites	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
the	O
oskar	O
mRNA	O
.	O

To	O
begin	O
to	O
understand	O
how	O
Bruno	O
acts	O
in	O
translational	O
repression	O
,	O
we	O
performed	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
to	O
identify	O
Bruno	O
-	O
interacting	O
proteins	O
.	O

One	O
interactor	O
,	O
described	O
here	O
,	O
is	O
the	O
product	O
of	O
the	O
apontic	O
gene	O
.	O

Coimmunoprecipitation	O
experiments	O
lend	O
biochemical	O
support	O
to	O
the	O
idea	O
that	O
Bruno	O
and	O
Apontic	O
proteins	O
physically	O
interact	O
in	O
Drosophila	O
.	O

Genetic	O
experiments	O
using	O
mutants	O
defective	O
in	O
apontic	O
and	O
bruno	O
reveal	O
a	O
functional	O
interaction	O
between	O
these	O
genes	O
.	O

Given	O
this	O
interaction	O
,	O
Apontic	O
is	O
likely	O
to	O
act	O
together	O
with	O
Bruno	O
in	O
translational	O
repression	O
of	O
oskar	O
mRNA	O
.	O

Interestingly	O
,	O
Apontic	O
,	O
like	O
Bruno	O
,	O
is	O
an	O
RNA	O
-	O
binding	O
protein	O
and	O
specifically	O
binds	O
certain	O
regions	O
of	O
the	O
oskar	O
mRNA	O
3	O
'	O
untranslated	O
region	O
.	O

A	O
novel	O
skeletal	O
dysplasia	O
with	O
developmental	O
delay	O
and	O
acanthosis	O
nigricans	O
is	O
caused	O
by	O
a	O
Lys650Met	O
mutation	O
in	O
the	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
gene	O
.	O

We	O
have	O
identified	O
a	O
novel	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
missense	O
mutation	O
in	O
four	O
unrelated	O
individuals	O
with	O
skeletal	O
dysplasia	O
that	O
approaches	O
the	O
severity	O
observed	O
in	O
thanatophoric	O
dysplasia	O
type	O
I	O
(	O
TD1	O
)	O
.	O

However	O
,	O
three	O
of	O
the	O
four	O
individuals	O
developed	O
extensive	O
areas	O
of	O
acanthosis	O
nigricans	O
beginning	O
in	O
early	O
childhood	O
,	O
suffer	O
from	O
severe	O
neurological	O
impairments	O
,	O
and	O
have	O
survived	O
past	O
infancy	O
without	O
prolonged	O
life	O
-	O
support	O
measures	O
.	O

The	O
FGFR3	O
mutation	O
(	O
A1949T	O
:	O
Lys650Met	O
)	O
occurs	O
at	O
the	O
nucleotide	O
adjacent	O
to	O
the	O
TD	O
type	O
II	O
(	O
TD2	O
)	O
mutation	O
(	O
A1948G	O
:	O
Lys650Glu	O
)	O
and	O
results	O
in	O
a	O
different	O
amino	O
acid	O
substitution	O
at	O
a	O
highly	O
conserved	O
codon	O
in	O
the	O
kinase	O
domain	O
activation	O
loop	O
.	O

Transient	O
transfection	O
studies	O
with	O
FGFR3	O
mutant	O
constructs	O
show	O
that	O
the	O
Lys650Met	O
mutation	O
causes	O
a	O
dramatic	O
increase	O
in	O
constitutive	O
receptor	O
kinase	O
activity	O
,	O
approximately	O
three	O
times	O
greater	O
than	O
that	O
observed	O
with	O
the	O
Lys650Glu	O
mutation	O
.	O

We	O
refer	O
to	O
the	O
phenotype	O
caused	O
by	O
the	O
Lys650Met	O
mutation	O
as	O
"	O
severe	O
achondroplasia	O
with	O
developmental	O
delay	O
and	O
acanthosis	O
nigricans	O
"	O
(	O
SADDAN	O
)	O
because	O
it	O
differs	O
significantly	O
from	O
the	O
phenotypes	O
of	O
other	O
known	O
FGFR3	O
mutations	O
.	O

Mutations	O
in	O
CUBN	O
,	O
encoding	O
the	O
intrinsic	O
factor	O
-	O
vitamin	O
B12	O
receptor	O
,	O
cubilin	O
,	O
cause	O
hereditary	O
megaloblastic	O
anaemia	O
1	O
.	O

Megaloblastic	O
anaemia	O
1	O
(	O
MGA1	O
,	O
OMIM	O
261100	O
)	O
is	O
a	O
rare	O
,	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
juvenile	O
megaloblastic	O
anaemia	O
,	O
as	O
well	O
as	O
neurological	O
symptoms	O
that	O
may	O
be	O
the	O
only	O
manifestations	O
.	O

At	O
the	O
cellular	O
level	O
,	O
MGA1	O
is	O
characterized	O
by	O
selective	O
intestinal	O
vitamin	O
B12	O
(	O
B12	O
,	O
cobalamin	O
)	O
malabsorption	O
.	O

MGA1	O
occurs	O
worldwide	O
,	O
but	O
its	O
prevalence	O
is	O
higher	O
in	O
several	O
Middle	O
Eastern	O
countries	O
and	O
Norway	O
,	O
and	O
highest	O
in	O
Finland	O
(	O
0	O
.	O
8	O
/	O
100	O
,	O
000	O
)	O
.	O

We	O
previously	O
mapped	O
the	O
MGA1	O
locus	O
by	O
linkage	O
analysis	O
in	O
Finnish	O
and	O
Norwegian	O
families	O
to	O
a	O
6	O
-	O
cM	O
region	O
on	O
chromosome	O
10p12	O
.	O
1	O
(	O
ref	O
.	O
8	O
)	O
.	O

A	O
functional	O
candidate	O
gene	O
encoding	O
the	O
intrinsic	O
factor	O
(	O
IF	O
)	O
-	O
B12	O
receptor	O
,	O
cubilin	O
,	O
was	O
recently	O
cloned	O
;	O
the	O
human	O
homologue	O
,	O
CUBN	O
,	O
was	O
mapped	O
to	O
the	O
same	O
region	O
.	O

We	O
have	O
now	O
refined	O
the	O
MGA1	O
region	O
by	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
mapping	O
,	O
fine	O
-	O
mapped	O
CUBN	O
and	O
identified	O
two	O
independent	O
disease	O
-	O
specific	O
CUBN	O
mutations	O
in	O
17	O
Finnish	O
MGA1	O
families	O
.	O

Our	O
genetic	O
and	O
molecular	O
data	O
indicate	O
that	O
mutations	O
in	O
CUBN	O
cause	O
MGA1	O
.	O

NuMA	O
is	O
well	O
known	O
for	O
its	O
role	O
in	O
the	O
formation	O
and	O
stabilization	O
of	O
the	O
mitotic	O
spindle	O
.	O

Accumulation	O
of	O
NuMA	O
has	O
been	O
shown	O
at	O
the	O
mitotic	O
spindle	O
poles	O
and	O
at	O
or	O
near	O
the	O
minus	O
ends	O
of	O
microtubules	O
.	O

Sequestration	O
of	O
endogenous	O
NuMA	O
by	O
microinjection	O
of	O
anti	O
-	O
NuMA	O
antibodies	O
into	O
mitotic	O
cultured	O
cells	O
was	O
shown	O
to	O
disrupt	O
the	O
bipolar	O
mitotic	O
spindles	O
.	O

The	O
spindle	O
association	O
activity	O
of	O
NuMA	O
was	O
mapped	O
to	O
its	O
COOH	O
-	O
terminal	O
part	O
(	O
residues	O
1538	O
-	O
2115	O
)	O
.	O

A	O
recent	O
study	O
showed	O
that	O
the	O
critical	O
sequences	O
for	O
spindle	O
pole	O
localization	O
are	O
contained	O
within	O
the	O
amino	O
acid	O
residues	O
1750	O
-	O
1800	O
of	O
NuMA	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
NuMA	O
binds	O
to	O
microtubules	O
is	O
not	O
clear	O
.	O

NuMA	O
does	O
not	O
contain	O
a	O
microtubule	O
-	O
binding	O
region	O
of	O
kinesin	O
,	O
Map2	O
,	O
or	O
tau	O
,	O
but	O
has	O
been	O
shown	O
to	O
directly	O
bind	O
to	O
tubulin	O
and	O
organize	O
microtubule	O
formation	O
through	O
the	O
distal	O
portion	O
of	O
its	O
COOH	O
-	O
terminal	O
domain	O
.	O

Nuclear	O
import	O
of	O
sterol	O
regulatory	O
element	O
-	O
binding	O
protein	O
-	O
2	O
,	O
a	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
-	O
leucine	O
zipper	O
(	O
bHLH	O
-	O
Zip	O
)	O
-	O
containing	O
transcription	O
factor	O
,	O
occurs	O
through	O
the	O
direct	O
interaction	O
of	O
importin	O
beta	O
with	O
HLH	O
-	O
Zip	O
.	O

The	O
sterol	O
regulatory	O
element	O
-	O
binding	O
protein	O
-	O
2	O
(	O
SREBP	O
-	O
2	O
)	O
is	O
produced	O
as	O
a	O
large	O
precursor	O
molecule	O
attached	O
to	O
the	O
endoplasmic	O
reticulum	O
membrane	O
.	O

In	O
response	O
to	O
the	O
sterol	O
depletion	O
,	O
the	O
N	O
-	O
terminal	O
segment	O
of	O
the	O
precursor	O
,	O
which	O
contains	O
a	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
-	O
leucine	O
zipper	O
domain	O
,	O
is	O
released	O
by	O
two	O
sequential	O
cleavages	O
and	O
is	O
translocated	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
activates	O
the	O
transcription	O
of	O
target	O
genes	O
.	O

The	O
data	O
herein	O
show	O
that	O
released	O
SREBP	O
-	O
2	O
uses	O
a	O
distinct	O
nuclear	O
transport	O
pathway	O
,	O
which	O
is	O
mediated	O
by	O
importin	O
beta	O
.	O

The	O
mature	O
form	O
of	O
SREBP	O
-	O
2	O
is	O
actively	O
transported	O
into	O
the	O
nucleus	O
when	O
injected	O
into	O
the	O
cell	O
cytoplasm	O
.	O

SREBP	O
-	O
2	O
binds	O
directly	O
to	O
importin	O
beta	O
in	O
the	O
absence	O
of	O
importin	O
alpha	O
.	O

Ran	O
-	O
GTP	O
but	O
not	O
Ran	O
-	O
GDP	O
causes	O
the	O
dissociation	O
of	O
the	O
SREBP	O
-	O
2	O
-	O
importin	O
beta	O
complex	O
.	O

G19VRan	O
-	O
GTP	O
inhibits	O
the	O
nuclear	O
import	O
of	O
SREBP	O
-	O
2	O
in	O
living	O
cells	O
.	O

In	O
the	O
permeabilized	O
cell	O
in	O
vitro	O
transport	O
system	O
,	O
nuclear	O
import	O
of	O
SREBP	O
-	O
2	O
is	O
reconstituted	O
only	O
by	O
importin	O
beta	O
in	O
conjunction	O
with	O
Ran	O
and	O
its	O
interacting	O
protein	O
p10	O
/	O
NTF2	O
.	O

We	O
further	O
demonstrate	O
that	O
the	O
helix	O
-	O
loop	O
-	O
helix	O
-	O
leucine	O
zipper	O
motif	O
of	O
SREBP	O
-	O
2	O
contains	O
a	O
novel	O
type	O
of	O
nuclear	O
localization	O
signal	O
,	O
which	O
binds	O
directly	O
to	O
importin	O
beta	O
.	O

HIV	O
-	O
1	O
Nef	O
alters	O
the	O
expression	O
of	O
betaII	O
and	O
epsilon	O
isoforms	O
of	O
protein	O
kinase	O
C	O
and	O
the	O
activation	O
of	O
the	O
long	O
terminal	O
repeat	O
promoter	O
in	O
human	O
astrocytoma	O
cells	O
.	O

In	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
-	O
infected	O
brain	O
,	O
the	O
virus	O
does	O
not	O
replicate	O
in	O
astrocytes	O
,	O
but	O
a	O
synthesis	O
of	O
viral	O
regulatory	O
proteins	O
occurs	O
in	O
these	O
cells	O
,	O
leading	O
to	O
accumulation	O
of	O
Nef	O
.	O

As	O
an	O
approach	O
to	O
understand	O
the	O
effects	O
of	O
Nef	O
on	O
astrocyte	O
functional	O
activity	O
,	O
we	O
analyzed	O
whether	O
intracellular	O
Nef	O
interferes	O
with	O
the	O
expression	O
and	O
activation	O
of	O
the	O
enzyme	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
which	O
is	O
an	O
important	O
regulator	O
of	O
astroglial	O
functions	O
and	O
HIV	O
-	O
1	O
replication	O
.	O

Astrocytoma	O
clones	O
(	O
U251	O
MG	O
)	O
not	O
expressing	O
Nef	O
(	O
Neo	O
)	O
,	O
or	O
expressing	O
wild	O
-	O
type	O
Nef	O
(	O
Bru	O
)	O
or	O
nonmyristoylated	O
Nef	O
(	O
TH	O
)	O
were	O
used	O
to	O
monitor	O
the	O
expression	O
and	O
activation	O
of	O
10	O
PKC	O
isoforms	O
.	O

The	O
same	O
clones	O
were	O
used	O
to	O
evaluate	O
the	O
effect	O
of	O
Nef	O
on	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
promoter	O
after	O
activation	O
of	O
PKC	O
with	O
the	O
phorbol	O
ester	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
.	O

PKC	O
intracellular	O
distribution	O
and	O
activation	O
were	O
evaluated	O
by	O
Western	O
blot	O
analysis	O
of	O
cytosolic	O
and	O
membrane	O
fractions	O
of	O
control	O
and	O
Nef	O
-	O
expressing	O
clones	O
.	O

PMA	O
-	O
induced	O
LTR	O
activation	O
was	O
analyzed	O
in	O
clones	O
transfected	O
with	O
a	O
plasmid	O
encoding	O
for	O
the	O
CAT	O
reporter	O
gene	O
controlled	O
by	O
the	O
LTR	O
promoter	O
,	O
by	O
using	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
to	O
measure	O
CAT	O
expression	O
.	O

Nef	O
selectively	O
downregulated	O
the	O
expression	O
and	O
activation	O
of	O
betaII	O
and	O
epsilon	O
PKC	O
isoforms	O
in	O
astrocytoma	O
cells	O
.	O

Such	O
downregulation	O
correlated	O
with	O
an	O
inhibition	O
of	O
LTR	O
activation	O
after	O
PMA	O
stimulation	O
.	O

The	O
myristoylation	O
of	O
Nef	O
and	O
its	O
membrane	O
localization	O
were	O
essential	O
for	O
these	O
effects	O
.	O

These	O
results	O
suggest	O
that	O
Nef	O
may	O
alter	O
astrocytic	O
functions	O
by	O
interfering	O
with	O
PKC	O
expression	O
and	O
activation	O
and	O
contribute	O
to	O
the	O
restriction	O
of	O
HIV	O
-	O
1	O
replication	O
in	O
astrocytes	O
.	O

Coupling	O
of	O
mGluR	O
/	O
Homer	O
and	O
PSD	B-OOS
-	I-OOS
95	I-OOS
complexes	O
by	O
the	O
Shank	O
family	O
of	O
postsynaptic	O
density	O
proteins	O
.	O

Shank	O
is	O
a	O
recently	O
described	O
family	O
of	O
postsynaptic	O
proteins	O
that	O
function	O
as	O
part	O
of	O
the	O
NMDA	O
receptor	O
-	O
associated	O
PSD	B-OOS
-	I-OOS
95	I-OOS
complex	O
(	O
Naisbitt	O
et	O
al	O
.	O
,	O
1999	O
[	O
this	O
issue	O
of	O
Neuron	O
]	O
)	O
.	O

Here	O
,	O
we	O
report	O
that	O
Shank	O
proteins	O
also	O
bind	O
to	O
Homer	O
.	O

Homer	O
proteins	O
form	O
multivalent	O
complexes	O
that	O
bind	O
proline	O
-	O
rich	O
motifs	O
in	O
group	O
1	O
metabotropic	O
glutamate	O
receptors	O
and	O
inositol	O
trisphosphate	O
receptors	O
,	O
thereby	O
coupling	O
these	O
receptors	O
in	O
a	O
signaling	O
complex	O
.	O

A	O
single	O
Homer	O
-	O
binding	O
site	O
is	O
identified	O
in	O
Shank	O
,	O
and	O
Shank	O
and	O
Homer	O
coimmunoprecipitate	O
from	O
brain	O
and	O
colocalize	O
at	O
postsynaptic	O
densities	O
.	O

Moreover	O
,	O
Shank	O
clusters	O
mGluR5	O
in	O
heterologous	O
cells	O
in	O
the	O
presence	O
of	O
Homer	O
and	O
mediates	O
the	O
coclustering	O
of	O
Homer	O
with	O
PSD	O
-	O
95	O
/	O
GKAP	O
.	O

Thus	O
,	O
Shank	O
may	O
cross	O
-	O
link	O
Homer	O
and	O
PSD	O
-	O
95	O
complexes	O
in	O
the	O
PSD	O
and	O
play	O
a	O
role	O
in	O
the	O
signaling	O
mechanisms	O
of	O
both	O
mGluRs	O
and	O
NMDA	O
receptors	O
.	O

Interaction	O
of	O
Alzheimer	O
'	O
s	O
presenilin	O
-	O
1	O
and	O
presenilin	O
-	O
2	O
with	O
Bcl	O
-	O
X	O
(	O
L	O
)	O
.	O

A	O
potential	O
role	O
in	O
modulating	O
the	O
threshold	O
of	O
cell	O
death	O
.	O

The	O
familial	O
Alzheimer	O
'	O
s	O
disease	O
gene	O
products	O
,	O
presenilin	O
-	O
1	O
and	O
presenilin	O
-	O
2	O
,	O
have	O
been	O
reported	O
to	O
be	O
functionally	O
involved	O
in	O
amyloid	O
precursor	O
protein	O
processing	O
,	O
notch	O
receptor	O
signaling	O
,	O
and	O
programmed	O
cell	O
death	O
or	O
apoptosis	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
by	O
which	O
presenilins	O
regulate	O
these	O
processes	O
remain	O
unknown	O
.	O

With	O
regard	O
to	O
the	O
latter	O
,	O
we	O
describe	O
a	O
molecular	O
link	O
between	O
presenilins	O
and	O
the	O
apoptotic	O
pathway	O
.	O

Bcl	O
-	O
X	O
(	O
L	O
)	O
,	O
an	O
anti	O
-	O
apoptotic	O
member	O
of	O
the	O
Bcl	O
-	O
2	O
family	O
was	O
shown	O
to	O
interact	O
with	O
the	O
carboxyl	O
-	O
terminal	O
fragments	O
of	O
PS1	O
and	O
PS2	O
by	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
.	O

In	O
vivo	O
interaction	O
analysis	O
revealed	O
that	O
both	O
PS2	O
and	O
its	O
naturally	O
occurring	O
carboxyl	O
-	O
terminal	O
products	O
,	O
PS2short	O
and	O
PS2Ccas	O
,	O
associated	O
with	O
Bcl	O
-	O
X	O
(	O
L	O
)	O
,	O
whereas	O
the	O
caspase	O
-	O
3	O
-	O
generated	O
amino	O
-	O
terminal	O
PS2Ncas	O
fragment	O
did	O
not	O
.	O

This	O
interaction	O
was	O
corroborated	O
by	O
demonstrating	O
that	O
Bcl	O
-	O
X	O
(	O
L	O
)	O
and	O
PS2	O
partially	O
co	O
-	O
localized	O
to	O
sites	O
of	O
the	O
vesicular	O
transport	O
system	O
.	O

Functional	O
analysis	O
revealed	O
that	O
presenilins	O
can	O
influence	O
mitochondrial	O
-	O
dependent	O
apoptotic	O
activities	O
,	O
such	O
as	O
cytochrome	O
c	O
release	O
and	O
Bax	O
-	O
mediated	O
apoptosis	O
.	O

Together	O
,	O
these	O
data	O
support	O
a	O
possible	O
role	O
of	O
the	O
Alzheimer	O
'	O
s	O
presenilins	O
in	O
modulating	O
the	O
anti	O
-	O
apoptotic	O
effects	O
of	O
Bcl	O
-	O
X	O
(	O
L	O
)	O
.	O

Identification	O
of	O
the	O
major	O
intestinal	O
fatty	O
acid	O
transport	O
protein	O
.	O

While	O
intestinal	O
transport	O
systems	O
for	O
metabolites	O
such	O
as	O
carbohydrates	O
have	O
been	O
well	O
characterized	O
,	O
the	O
molecular	O
mechanisms	O
of	O
fatty	O
acid	O
(	O
FA	O
)	O
transport	O
across	O
the	O
apical	O
plasmalemma	O
of	O
enterocytes	O
have	O
remained	O
largely	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
FATP4	O
,	O
a	O
member	O
of	O
a	O
large	O
family	O
of	O
FA	O
transport	O
proteins	O
(	O
FATPs	O
)	O
,	O
is	O
expressed	O
at	O
high	O
levels	O
on	O
the	O
apical	O
side	O
of	O
mature	O
enterocytes	O
in	O
the	O
small	O
intestine	O
.	O

Further	O
,	O
overexpression	O
of	O
FATP4	O
in	O
293	O
cells	O
facilitates	O
uptake	O
of	O
long	O
chain	O
FAs	O
with	O
the	O
same	O
specificity	O
as	O
enterocytes	O
,	O
while	O
reduction	O
of	O
FATP4	O
expression	O
in	O
primary	O
enterocytes	O
by	O
antisense	O
oligonucleotides	O
inhibits	O
FA	O
uptake	O
by	O
50	O
%	O
.	O

This	O
suggests	O
that	O
FATP4	O
is	O
the	O
principal	O
fatty	O
acid	O
transporter	O
in	O
enterocytes	O
and	O
may	O
constitute	O
a	O
novel	O
target	O
for	O
antiobesity	O
therapy	O
.	O

Cell	O
cycle	O
-	O
regulated	O
attachment	O
of	O
the	O
ubiquitin	O
-	O
related	O
protein	O
SUMO	O
to	O
the	O
yeast	O
septins	O
.	O

SUMO	O
is	O
a	O
ubiquitin	O
-	O
related	O
protein	O
that	O
functions	O
as	O
a	O
posttranslational	O
modification	O
on	O
other	O
proteins	O
.	O

SUMO	O
conjugation	O
is	O
essential	O
for	O
viability	O
in	O
Saccharomyces	O
cerevisiae	O
and	O
is	O
required	O
for	O
entry	O
into	O
mitosis	O
.	O

We	O
have	O
found	O
that	O
SUMO	O
is	O
attached	O
to	O
the	O
septins	O
Cdc3	O
,	O
Cdc11	O
,	O
and	O
Shs1	O
/	O
Sep7	O
specifically	O
during	O
mitosis	O
,	O
with	O
conjugates	O
appearing	O
shortly	O
before	O
anaphase	O
onset	O
and	O
disappearing	O
abruptly	O
at	O
cytokinesis	O
.	O

Septins	O
are	O
components	O
of	O
a	O
belt	O
of	O
10	O
-	O
nm	O
filaments	O
encircling	O
the	O
yeast	O
bud	O
neck	O
.	O

Intriguingly	O
,	O
only	O
septins	O
on	O
the	O
mother	O
cell	O
side	O
of	O
the	O
bud	O
neck	O
are	O
sumoylated	O
.	O

We	O
have	O
identified	O
four	O
major	O
SUMO	O
attachment	O
-	O
site	O
lysine	O
residues	O
in	O
Cdc3	O
,	O
one	O
in	O
Cdc11	O
,	O
and	O
two	O
in	O
Shs1	O
,	O
all	O
within	O
the	O
consensus	O
sequence	O
(	O
IVL	O
)	O
KX	O
(	O
ED	O
)	O
.	O

Mutating	O
these	O
sites	O
eliminated	O
the	O
vast	O
majority	O
of	O
bud	O
neck	O
-	O
associated	O
SUMO	O
,	O
as	O
well	O
as	O
the	O
bulk	O
of	O
total	O
SUMO	O
conjugates	O
in	O
G	O
(	O
2	O
)	O
/	O
M	O
-	O
arrested	O
cells	O
,	O
indicating	O
that	O
sumoylated	O
septins	O
are	O
the	O
most	O
abundant	O
SUMO	O
conjugates	O
at	O
this	O
point	O
in	O
the	O
cell	O
cycle	O
.	O

This	O
mutant	O
has	O
a	O
striking	O
defect	O
in	O
disassembly	O
of	O
septin	O
rings	O
,	O
resulting	O
in	O
accumulation	O
of	O
septin	O
rings	O
marking	O
previous	O
division	O
sites	O
.	O

Thus	O
,	O
SUMO	O
conjugation	O
plays	O
a	O
role	O
in	O
regulating	O
septin	O
ring	O
dynamics	O
during	O
the	O
cell	O
cycle	O
.	O

SOCS	O
/	O
CIS	O
protein	O
inhibition	O
of	O
growth	O
hormone	O
-	O
stimulated	O
STAT5	O
signaling	O
by	O
multiple	O
mechanisms	O
.	O

The	O
inhibition	O
of	O
growth	O
hormone	O
(	O
GH	O
)	O
signaling	O
by	O
five	O
members	O
of	O
the	O
GH	O
-	O
inducible	O
suppressor	O
of	O
cytokine	O
signaling	O
(	O
SOCS	O
/	O
CIS	O
)	O
family	O
was	O
investigated	O
in	O
transfected	O
COS	O
cells	O
.	O

Complete	O
inhibition	O
of	O
GH	O
activation	O
of	O
the	O
signal	O
transducer	O
STAT5b	O
and	O
STAT5b	O
-	O
dependent	O
transcriptional	O
activity	O
was	O
observed	O
upon	O
expression	O
of	O
SOCS	O
-	O
1	O
or	O
SOCS	O
-	O
3	O
,	O
while	O
partial	O
inhibition	O
(	O
CIS	O
,	O
SOCS	O
-	O
2	O
)	O
or	O
no	O
inhibition	O
(	O
SOCS	O
-	O
6	O
)	O
was	O
seen	O
with	O
other	O
SOCS	O
/	O
CIS	O
family	O
members	O
.	O

SOCS	O
-	O
1	O
,	O
SOCS	O
-	O
2	O
,	O
SOCS	O
-	O
3	O
,	O
and	O
CIS	O
each	O
strongly	O
inhibited	O
the	O
GH	O
receptor	O
(	O
GHR	O
)	O
-	O
dependent	O
tyrosine	O
phosphorylation	O
of	O
JAK2	O
seen	O
at	O
low	O
levels	O
of	O
transfected	O
JAK2	O
;	O
however	O
,	O
only	O
SOCS	O
-	O
1	O
strongly	O
inhibited	O
the	O
GHR	O
-	O
independent	O
tyrosine	O
phosphorylation	O
of	O
JAK2	O
seen	O
at	O
higher	O
JAK2	O
levels	O
.	O

To	O
probe	O
for	O
interactions	O
with	O
GHR	O
,	O
in	O
vitro	O
binding	O
assays	O
were	O
carried	O
out	O
using	O
glutathione	O
S	O
-	O
transferase	O
-	O
GHR	O
fusion	O
proteins	O
containing	O
variable	O
lengths	O
of	O
GHR	O
'	O
s	O
COOH	O
-	O
terminal	O
cytoplasmic	O
domain	O
.	O

CIS	O
and	O
SOCS	O
-	O
2	O
bound	O
to	O
fusions	O
containing	O
as	O
few	O
as	O
80	O
COOH	O
-	O
terminal	O
GHR	O
residues	O
,	O
provided	O
the	O
fusion	O
protein	O
was	O
tyrosine	O
-	O
phosphorylated	O
.	O

By	O
contrast	O
,	O
SOCS	O
-	O
3	O
binding	O
required	O
tyrosine	O
-	O
phosphorylated	O
GHR	O
membrane	O
-	O
proximal	O
sequences	O
,	O
SOCS	O
-	O
1	O
binding	O
was	O
tyrosine	O
phosphorylation	O
-	O
independent	O
,	O
and	O
SOCS	O
-	O
6	O
did	O
not	O
bind	O
the	O
GHR	O
fusion	O
proteins	O
at	O
all	O
.	O

Mutation	O
of	O
GHR	O
'	O
s	O
membrane	O
-	O
proximal	O
tyrosine	O
residues	O
333	O
and	O
338	O
to	O
phenylalanine	O
suppressed	O
the	O
inhibition	O
by	O
SOCS	O
-	O
3	O
,	O
but	O
not	O
by	O
CIS	O
,	O
of	O
GH	O
signaling	O
to	O
STAT5b	O
.	O

SOCS	O
/	O
CIS	O
proteins	O
can	O
thus	O
inhibit	O
GH	O
signaling	O
to	O
STAT5b	O
by	O
three	O
distinct	O
mechanisms	O
,	O
distinguished	O
by	O
their	O
molecular	O
targets	O
within	O
the	O
GHR	O
-	O
JAK2	O
signaling	O
complex	O
,	O
as	O
exemplified	O
by	O
SOCS	O
-	O
1	O
(	O
direct	O
JAK2	O
kinase	O
inhibition	O
)	O
,	O
SOCS	O
-	O
3	O
(	O
inhibition	O
of	O
JAK2	O
signaling	O
via	O
membrane	O
-	O
proximal	O
GHR	O
tyrosines	O
333	O
and	O
338	O
)	O
,	O
and	O
CIS	O
and	O
SOCS	O
-	O
2	O
(	O
inhibition	O
via	O
membrane	O
-	O
distal	O
tyrosine	O
(	O
s	O
)	O
)	O
.	O

Iontophoresis	O
of	O
lysophosphatidic	O
acid	O
into	O
rabbit	O
cornea	O
induces	O
HSV	O
-	O
1	O
reactivation	O
:	O
evidence	O
that	O
neuronal	O
signaling	O
changes	O
after	O
infection	O
.	O

PURPOSE	O
:	O
Lysophosphatidic	O
acid	O
induces	O
neurite	O
retraction	O
;	O
it	O
is	O
also	O
present	O
in	O
tears	O
and	O
aqueous	O
humor	O
.	O

We	O
determined	O
whether	O
lysophosphatidic	O
acid	O
induces	O
HSV	O
-	O
1	O
reactivation	O
in	O
latently	O
infected	O
rabbits	O
and	O
whether	O
the	O
nerve	O
growth	O
associated	O
protein	O
GAP	O
-	O
43	O
undergoes	O
posttranslational	O
modification	O
during	O
the	O
course	O
of	O
HSV	O
-	O
1	O
infection	O
.	O

METHODS	O
:	O
Rabbits	O
were	O
infected	O
with	O
HSV	O
-	O
1	O
and	O
acute	O
infection	O
was	O
documented	O
by	O
slit	O
lamp	O
examination	O
.	O

Corneas	O
of	O
latently	O
infected	O
rabbits	O
were	O
treated	O
with	O
lysophosphatidic	O
acid	O
or	O
lysophosphatidylserine	O
(	O
structurally	O
similar	O
but	O
lacking	O
biological	O
potency	O
)	O
.	O

For	O
application	O
to	O
the	O
cornea	O
,	O
these	O
compounds	O
were	O
impregnated	O
into	O
collagen	B-Complex
shields	O
,	O
applied	O
as	O
topical	O
drops	O
,	O
or	O
iontophoresed	O
.	O

In	O
another	O
experiment	O
,	O
corneas	O
of	O
latently	O
infected	O
rabbits	O
were	O
either	O
untreated	O
or	O
treated	O
iontophoretically	O
with	O
lysophosphatidic	O
acid	O
,	O
lysophosphatidylserine	O
,	O
or	O
saline	O
.	O

Ocular	O
swabs	O
detected	O
shedding	O
of	O
infectious	O
virus	O
.	O

Western	O
blot	O
and	O
immunoprecipitation	O
identified	O
GAP	O
-	O
43	O
in	O
corneal	O
extracts	O
and	O
densitometry	O
of	O
silver	O
-	O
stained	O
isoelectric	O
focusing	O
gels	O
measured	O
changes	O
in	O
GAP	O
-	O
43	O
isoform	O
abundance	O
.	O

RESULTS	O
:	O
Iontophoresis	O
of	O
lysophosphatidic	O
acid	O
induced	O
HSV	O
-	O
1	O
shedding	O
more	O
frequently	O
than	O
lysophosphatidylserine	O
or	O
saline	O
.	O

Viral	O
shedding	O
induced	O
by	O
collagen	B-Complex
shield	O
and	O
topical	O
drop	O
administration	O
was	O
low	O
and	O
not	O
significantly	O
different	O
for	O
lysophosphatidic	O
acid	O
and	O
lysophosphatidylserine	O
.	O

Five	O
discrete	O
GAP	O
-	O
43	O
isoforms	O
predominated	O
in	O
the	O
IEF	O
gels	O
.	O

Most	O
abundant	O
were	O
the	O
pI	O
4	O
.	O
7	O
band	O
in	O
uninfected	O
cornea	O
and	O
the	O
pI	O
5	O
.	O
05	O
band	O
in	O
latently	O
-	O
infected	O
cornea	O
.	O

Compared	O
to	O
latently	O
-	O
infected	O
cornea	O
,	O
there	O
was	O
no	O
significant	O
change	O
in	O
isoform	O
abundance	O
1	O
h	O
after	O
lysophosphatidic	O
acid	O
iontophoresis	O
,	O
but	O
24	O
and	O
72	O
h	O
later	O
,	O
the	O
pI	O
5	O
.	O

05	O
band	O
was	O
diminished	O
.	O

CONCLUSIONS	O
:	O
Lysophosphatidic	O
acid	O
can	O
induce	O
HSV	O
-	O
1	O
reactivation	O
and	O
changes	O
in	O
GAP	O
-	O
43	O
pI	O
suggest	O
that	O
posttranslational	O
modifications	O
,	O
possibly	O
related	O
to	O
phosphorylation	O
and	O
ADP	O
-	O
ribosylation	O
,	O
are	O
occurring	O
during	O
HSV	O
-	O
1	O
latency	O
and	O
after	O
LPA	O
is	O
iontophoretically	O
applied	O
to	O
the	O
cornea	O
.	O

How	O
lysophosphatidic	O
acid	O
-	O
induced	O
signaling	O
,	O
HSV	O
-	O
1	O
reactivation	O
,	O
and	O
GAP	O
-	O
43	O
pI	O
are	O
related	O
remains	O
to	O
be	O
determined	O
.	O

Nramp2	O
expression	O
is	O
associated	O
with	O
pH	O
-	O
dependent	O
iron	O
uptake	O
across	O
the	O
apical	O
membrane	O
of	O
human	O
intestinal	O
Caco	O
-	O
2	O
cells	O
.	O

The	O
absorption	O
of	O
dietary	O
non	O
-	O
heme	O
iron	O
by	O
intestinal	O
enterocytes	O
is	O
crucial	O
to	O
the	O
maintenance	O
of	O
body	O
iron	O
homeostasis	O
.	O

This	O
process	O
must	O
be	O
tightly	O
regulated	O
since	O
there	O
are	O
no	O
distinct	O
mechanisms	O
for	O
the	O
excretion	O
of	O
excess	O
iron	O
from	O
the	O
body	O
.	O

An	O
insight	O
into	O
the	O
cellular	O
mechanisms	O
has	O
recently	O
been	O
provided	O
by	O
expression	O
cloning	O
of	O
a	O
divalent	O
cation	O
transporter	O
(	O
DCT1	O
)	O
from	O
rat	O
duodenum	O
and	O
positional	O
cloning	O
of	O
its	O
human	O
homologue	O
,	O
Nramp2	O
.	O

Here	O
we	O
demonstrate	O
that	O
Nramp2	O
is	O
expressed	O
in	O
the	O
apical	O
membrane	O
of	O
the	O
human	O
intestinal	O
epithelial	O
cell	O
line	O
,	O
Caco	O
2	O
TC7	O
,	O
and	O
is	O
associated	O
with	O
functional	O
iron	O
transport	O
in	O
these	O
cells	O
with	O
a	O
substrate	O
preference	O
for	O
iron	O
over	O
other	O
divalent	O
cations	O
.	O

Iron	O
transport	O
occurs	O
by	O
a	O
proton	O
-	O
dependent	O
mechanism	O
,	O
exhibiting	O
a	O
concurrent	O
intracellular	O
acidification	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
expression	O
of	O
the	O
Nramp2	O
transporter	O
in	O
human	O
enterocytes	O
may	O
play	O
an	O
important	O
role	O
in	O
intestinal	O
iron	O
absorption	O
.	O

GATA	O
-	O
6	O
activates	O
transcription	O
of	O
surfactant	O
protein	O
A	O
.	O

Surfactant	O
protein	O
A	O
(	O
SP	O
-	O
A	O
)	O
is	O
a	O
member	O
of	O
the	O
collectin	O
family	O
of	O
innate	O
host	O
defense	O
molecules	O
expressed	O
primarily	O
in	O
respiratory	O
epithelial	O
cells	O
of	O
the	O
lung	O
.	O

SP	O
-	O
A	O
concentrations	O
are	O
influenced	O
by	O
both	O
cell	O
-	O
specific	O
and	O
ubiquitous	O
nuclear	O
proteins	O
that	O
regulate	O
SP	O
-	O
A	O
gene	O
transcription	O
in	O
a	O
cell	O
-	O
selective	O
and	O
temporally	O
regulated	O
manner	O
.	O

In	O
this	O
work	O
,	O
a	O
consensus	O
GATA	O
-	O
binding	O
site	O
(	O
GBS	O
)	O
was	O
identified	O
at	O
positions	O
-	O
69	O
to	O
-	O
64	O
of	O
the	O
mouse	O
SP	O
-	O
A	O
gene	O
.	O

The	O
transcriptional	O
activity	O
of	O
wild	O
-	O
type	O
SP	O
-	O
A	O
reporter	O
constructs	O
in	O
HeLa	O
cells	O
was	O
increased	O
5	O
-	O
10	O
-	O
fold	O
when	O
cotransfected	O
with	O
a	O
GATA	O
-	O
6	O
expression	O
plasmid	O
.	O

Deletion	O
of	O
the	O
GBS	O
completely	O
blocked	O
transactivation	O
by	O
GATA	O
-	O
6	O
.	O

Transfection	O
of	O
a	O
construct	O
expressing	O
GATA	O
-	O
6	O
-	O
engrailed	O
fusion	O
protein	O
inhibited	O
basal	O
expression	O
of	O
the	O
SP	O
-	O
A	O
/	O
chloramphenicol	O
acetyltransferase	O
construct	O
in	O
MLE	O
-	O
15	O
cells	O
.	O

Nuclear	O
extract	O
proteins	O
from	O
MLE	O
-	O
15	O
cells	O
bound	O
to	O
the	O
GBS	O
in	O
the	O
mouse	O
SP	O
-	O
A	O
gene	O
,	O
and	O
a	O
supershifted	O
band	O
was	O
detected	O
with	O
a	O
GATA	O
-	O
6	O
-	O
specific	O
antibody	O
.	O

Transactivation	O
of	O
the	O
wild	O
-	O
type	O
SP	O
-	O
A	O
constructs	O
by	O
GATA	O
-	O
6	O
increased	O
transcriptional	O
activity	O
7	O
-	O
10	O
-	O
fold	O
,	O
whereas	O
thyroid	O
transcription	O
factor	O
-	O
1	O
(	O
TTF	O
-	O
1	O
)	O
increased	O
the	O
activity	O
of	O
these	O
constructs	O
12	O
-	O
18	O
-	O
fold	O
.	O

The	O
effects	O
of	O
cotransactivating	O
with	O
both	O
GATA	O
-	O
6	O
and	O
TTF	O
-	O
1	O
expression	O
constructs	O
were	O
additive	O
.	O

However	O
,	O
mutation	O
of	O
the	O
TTF	O
-	O
1	O
-	O
binding	O
sites	O
alone	O
or	O
in	O
combination	O
decreased	O
GATA	O
-	O
6	O
transactivation	O
.	O

Likewise	O
,	O
mutation	O
of	O
the	O
GBS	O
blocked	O
TTF	O
-	O
1	O
activation	O
of	O
the	O
SP	O
-	O
A	O
promoter	O
.	O

In	O
situ	O
hybridization	O
demonstrated	O
GATA	O
-	O
6	O
mRNA	O
in	O
the	O
peripheral	O
epithelial	O
cells	O
of	O
fetal	O
mouse	O
lung	O
,	O
consistent	O
with	O
the	O
sites	O
of	O
SP	O
-	O
A	O
expression	O
.	O

GATA	O
-	O
6	O
is	O
expressed	O
in	O
respiratory	O
epithelial	O
cells	O
and	O
binds	O
to	O
a	O
cis	O
-	O
acting	O
element	O
in	O
the	O
SP	O
-	O
A	O
gene	O
promoter	O
,	O
activating	O
the	O
transcriptional	O
activity	O
of	O
the	O
gene	O
.	O

Human	O
topoisomerase	O
IIalpha	O
and	O
IIbeta	O
interact	O
with	O
the	O
C	O
-	O
terminal	O
region	O
of	O
p53	O
.	O

The	O
p53	O
tumor	O
suppressor	O
protein	O
is	O
a	O
critical	O
regulator	O
of	O
cell	O
cycle	O
progression	O
and	O
apoptosis	O
following	O
exposure	O
of	O
cells	O
to	O
DNA	O
damaging	O
agents	O
such	O
as	O
ionizing	O
radiation	O
or	O
anticancer	O
drugs	O
.	O

An	O
important	O
group	O
of	O
anticancer	O
drugs	O
,	O
including	O
compounds	O
such	O
as	O
etoposide	O
and	O
doxorubicin	O
(	O
Adriamycin	O
)	O
,	O
interacts	O
with	O
DNA	O
topoisomerase	O
II	O
(	O
topo	O
II	O
)	O
,	O
causing	O
the	O
accumulation	O
of	O
enzyme	O
-	O
DNA	O
adducts	O
that	O
ultimately	O
lead	O
to	O
double	O
-	O
strand	O
breaks	O
and	O
cell	O
death	O
via	O
apoptosis	O
.	O

Human	O
topo	O
IIbeta	O
has	O
previously	O
been	O
shown	O
to	O
interact	O
with	O
p53	O
,	O
and	O
we	O
have	O
extended	O
this	O
analysis	O
to	O
show	O
that	O
both	O
topo	O
IIalpha	O
and	O
IIbeta	O
interact	O
with	O
p53	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
the	O
regulatory	O
C	O
-	O
terminal	O
basic	O
region	O
of	O
p53	O
(	O
residues	O
364	O
-	O
393	O
)	O
is	O
necessary	O
and	O
sufficient	O
for	O
interaction	O
with	O
DNA	O
topo	O
II	O
.	O

The	O
Saccharomyces	O
cerevisiae	O
Cdc14	O
phosphatase	O
is	O
implicated	O
in	O
the	O
structural	O
organization	O
of	O
the	O
nucleolus	O
.	O

Cdc14	O
,	O
a	O
dual	O
-	O
specificity	O
protein	O
phosphatase	O
,	O
has	O
been	O
previously	O
implicated	O
in	O
triggering	O
exit	O
from	O
mitosis	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

Using	O
immunofluorescence	O
microscopy	O
and	O
immunogold	O
labeling	O
,	O
we	O
demonstrate	O
that	O
a	O
functional	O
HA	O
-	O
tagged	O
version	O
of	O
the	O
phosphatase	O
Cdc14	O
localizes	O
to	O
the	O
nucleolus	O
.	O

Moreover	O
,	O
Cdc14	O
-	O
HA	O
co	O
-	O
localized	O
with	O
the	O
nucleolar	O
NOP2	O
and	O
GAR1	O
proteins	O
.	O

By	O
immunofluorescence	O
,	O
Cdc14	O
-	O
HA	O
was	O
found	O
in	O
the	O
nucleolus	O
during	O
most	O
of	O
the	O
mitotic	O
cell	O
cycle	O
,	O
except	O
during	O
anaphase	O
-	O
telophase	O
when	O
it	O
redistributed	O
along	O
the	O
mitotic	O
spindle	O
.	O

While	O
this	O
work	O
was	O
in	O
progress	O
,	O
the	O
same	O
pattern	O
of	O
Cdc14	O
localization	O
was	O
described	O
by	O
others	O
(	O
Visintin	O
et	O
al	O
,	O
Nature	O
398	O
(	O
1999	O
)	O
818	O
)	O
.	O

Constitutive	O
overexpression	O
of	O
CDC14	O
was	O
toxic	O
and	O
led	O
to	O
cell	O
cycle	O
arrest	O
of	O
cells	O
,	O
mainly	O
in	O
G1	O
.	O

This	O
correlated	O
with	O
the	O
appearance	O
of	O
abnormal	O
nuclear	O
structures	O
.	O

A	O
genetic	O
search	O
for	O
suppressors	O
of	O
the	O
lethality	O
associated	O
with	O
CDC14	O
overexpression	O
identified	O
YJL076W	O
.	O

Because	O
overproduction	O
of	O
Yj1076w	O
buffered	O
the	O
toxic	O
effect	O
of	O
Cdc14	O
overproduction	O
,	O
this	O
suggested	O
that	O
it	O
might	O
be	O
a	O
substrate	O
of	O
Cdc14	O
.	O

This	O
has	O
indeed	O
been	O
found	O
to	O
be	O
the	O
case	O
by	O
others	O
who	O
recently	O
described	O
Yj1076w	O
/	O
Netl	O
as	O
a	O
nucleolar	O
protein	O
that	O
physically	O
associates	O
with	O
Cdc14	O
(	O
Shou	O
et	O
al	O
,	O
Cell	O
97	O
(	O
1999	O
)	O
233	O
)	O
.	O

The	O
present	O
data	O
confirm	O
several	O
recently	O
uncovered	O
aspects	O
of	O
the	O
regulation	O
of	O
Cdc14	O
localization	O
and	O
activity	O
and	O
suggest	O
that	O
the	O
level	O
of	O
expression	O
of	O
CDC14	O
influences	O
the	O
structural	O
organization	O
of	O
the	O
nucleolus	O
.	O

PEX7	O
gene	O
structure	O
,	O
alternative	O
transcripts	O
,	O
and	O
evidence	O
for	O
a	O
founder	O
haplotype	O
for	O
the	O
frequent	O
RCDP	O
allele	O
,	O
L292ter	O
.	O

We	O
recently	O
reported	O
cloning	O
a	O
cDNA	O
encoding	O
Pex7p	O
,	O
the	O
peroxisomal	O
PTS2	O
receptor	O
.	O

PEX7	O
mutations	O
cause	O
the	O
peroxisome	O
biogenesis	O
disorder	O
(	O
PBD	O
)	O
rhizomelic	O
chondrodysplasia	O
punctata	O
(	O
RCDP	O
)	O
.	O

In	O
a	O
survey	O
of	O
44	O
RCDP	O
probands	O
,	O
we	O
found	O
that	O
one	O
PEX7	O
allele	O
,	O
L292ter	O
,	O
accounted	O
for	O
50	O
%	O
of	O
mutant	O
PEX7	O
genes	O
.	O

Here	O
we	O
report	O
the	O
characterization	O
of	O
the	O
PEX7	O
structural	O
gene	O
,	O
which	O
spans	O
102	O
kb	O
on	O
chromosome	O
6q21	O
-	O
q22	O
.	O
2	O
and	O
contains	O
at	O
least	O
10	O
exons	O
.	O

In	O
addition	O
to	O
the	O
predominant	O
full	O
-	O
length	O
transcript	O
,	O
we	O
identified	O
eight	O
smaller	O
PEX7	O
transcripts	O
generated	O
by	O
alternative	O
exon	O
splicing	O
in	O
several	O
tissues	O
.	O

However	O
,	O
none	O
of	O
these	O
splice	O
forms	O
was	O
able	O
to	O
restore	O
PTS2	O
protein	O
import	O
into	O
peroxisomes	O
when	O
expressed	O
in	O
RCDP	O
fibroblasts	O
nor	O
did	O
they	O
inhibit	O
PTS2	O
protein	O
import	O
when	O
expressed	O
in	O
normal	O
fibroblasts	O
.	O

To	O
determine	O
whether	O
the	O
high	O
frequency	O
of	O
the	O
L292ter	O
allele	O
is	O
due	O
to	O
a	O
founder	O
effect	O
,	O
we	O
identified	O
five	O
polymorphic	O
markers	O
(	O
four	O
diallelic	O
markers	O
and	O
one	O
CA	O
repeat	O
)	O
spanning	O
the	O
PEX7	O
gene	O
.	O

We	O
show	O
that	O
all	O
12	O
L292ter	O
homozygotes	O
in	O
our	O
patient	O
sample	O
have	O
an	O
identical	O
haplotype	O
at	O
these	O
five	O
sites	O
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
L292ter	O
mutation	O
arose	O
once	O
on	O
an	O
ancestral	O
chromosome	O
in	O
the	O
Caucasian	O
population	O
.	O

Hedgehog	O
-	O
regulated	O
processing	O
of	O
Gli3	O
produces	O
an	O
anterior	O
/	O
posterior	O
repressor	O
gradient	O
in	O
the	O
developing	O
vertebrate	O
limb	O
.	O

Ci	O
/	O
Gli	O
zinc	O
finger	O
proteins	O
mediate	O
the	O
transcriptional	O
effects	O
of	O
Hedgehog	O
protein	O
signals	O
.	O

In	O
Drosophila	O
,	O
Ci	O
action	O
as	O
transcriptional	O
repressor	O
or	O
activator	O
is	O
contingent	O
upon	O
Hedgehog	O
-	O
regulated	O
,	O
PKA	O
-	O
dependent	O
proteolytic	O
processing	O
.	O

We	O
demonstrate	O
that	O
PKA	O
-	O
dependent	O
processing	O
of	O
vertebrate	O
Gli3	O
in	O
developing	O
limb	O
similarly	O
generates	O
a	O
potent	O
repressor	O
in	O
a	O
manner	O
antagonized	O
by	O
apparent	O
long	O
-	O
range	O
signaling	O
from	O
posteriorly	O
localized	O
Sonic	O
hedgehog	O
protein	O
.	O

The	O
resulting	O
anterior	O
/	O
posterior	O
Gli3	O
repressor	O
gradient	O
can	O
be	O
perturbed	O
by	O
mutations	O
of	O
Gli3	O
in	O
human	O
genetic	O
syndromes	O
or	O
by	O
misregulation	O
of	O
Gli3	O
processing	O
in	O
the	O
chicken	O
mutant	O
talpid2	O
,	O
producing	O
a	O
range	O
of	O
limb	O
patterning	O
malformations	O
.	O

The	O
high	O
relative	O
abundance	O
and	O
potency	O
of	O
Gli3	O
repressor	O
suggest	O
specialization	O
of	O
Gli3	O
and	O
its	O
products	O
for	O
negative	O
Hedgehog	O
pathway	O
regulation	O
.	O

Nedd8	O
modification	O
of	O
cul	O
-	O
1	O
activates	O
SCF	B-Complex
(	I-Complex
beta	I-Complex
(	I-Complex
TrCP	I-Complex
)	I-Complex
)	I-Complex
-	O
dependent	O
ubiquitination	O
of	O
IkappaBalpha	O
.	O

Regulation	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
occurs	O
through	O
phosphorylation	O
-	O
dependent	O
ubiquitination	O
of	O
IkappaBalpha	O
,	O
which	O
is	O
degraded	O
by	O
the	O
26S	B-Complex
proteasome	I-Complex
.	O

Recent	O
studies	O
have	O
shown	O
that	O
ubiquitination	O
of	O
IkappaBalpha	O
is	O
carried	O
out	O
by	O
a	O
ubiquitin	O
-	O
ligase	O
enzyme	O
complex	O
called	O
SCF	B-Complex
(	I-Complex
beta	I-Complex
(	I-Complex
TrCP	I-Complex
)	I-Complex
)	I-Complex
.	O

Here	O
we	O
show	O
that	O
Nedd8	O
modification	O
of	O
the	O
Cul	O
-	O
1	O
component	O
of	O
SCF	B-Complex
(	I-Complex
beta	I-Complex
(	I-Complex
TrCP	I-Complex
)	I-Complex
)	I-Complex
is	O
important	O
for	O
function	O
of	O
SCF	B-Complex
(	I-Complex
beta	I-Complex
(	I-Complex
TrCP	I-Complex
)	I-Complex
)	I-Complex
in	O
ubiquitination	O
of	O
IkappaBalpha	O
.	O

In	O
cells	O
,	O
Nedd8	O
-	O
conjugated	O
Cul	O
-	O
1	O
was	O
complexed	O
with	O
two	O
substrates	O
of	O
SCF	B-Complex
(	I-Complex
beta	I-Complex
(	I-Complex
TrCP	I-Complex
)	I-Complex
)	I-Complex
,	O
phosphorylated	O
IkappaBalpha	O
and	O
beta	O
-	O
catenin	O
,	O
indicating	O
that	O
Nedd8	O
-	O
Cul	O
-	O
1	O
conjugates	O
are	O
part	O
of	O
SCF	B-Complex
(	I-Complex
beta	I-Complex
(	I-Complex
TrCP	I-Complex
)	I-Complex
)	I-Complex
in	O
vivo	O
.	O

Although	O
only	O
a	O
minute	O
fraction	O
of	O
total	O
cellular	O
Cul	O
-	O
1	O
is	O
modified	O
by	O
Nedd8	O
,	O
the	O
Cul	O
-	O
1	O
associated	O
with	O
ectopically	O
expressed	O
betaTrCP	O
was	O
highly	O
enriched	O
for	O
the	O
Nedd8	O
-	O
conjugated	O
form	O
.	O

Moreover	O
,	O
optimal	O
ubiquitination	O
of	O
IkappaBalpha	O
required	O
Nedd8	O
and	O
the	O
Nedd8	O
-	O
conjugating	O
enzyme	O
,	O
Ubc12	O
.	O

The	O
site	O
of	O
Nedd8	O
ligation	O
to	O
Cul	O
-	O
1	O
is	O
essential	O
,	O
as	O
SCF	B-Complex
(	I-Complex
beta	I-Complex
(	I-Complex
TrCP	I-Complex
)	I-Complex
)	I-Complex
containing	O
a	O
K720R	O
mutant	O
of	O
Cul	O
-	O
1	O
only	O
weakly	O
supported	O
IkappaBalpha	O
ubiquitination	O
compared	O
to	O
SCF	B-Complex
(	I-Complex
beta	I-Complex
(	I-Complex
TrCP	I-Complex
)	I-Complex
)	I-Complex
containing	O
WT	O
Cul	O
-	O
1	O
,	O
suggesting	O
that	O
the	O
Nedd8	O
ligation	O
of	O
Cul	O
-	O
1	O
affects	O
the	O
ubiquitination	O
activity	O
of	O
SCF	B-Complex
(	I-Complex
beta	I-Complex
(	I-Complex
TrCP	I-Complex
)	I-Complex
)	I-Complex
.	O

These	O
observations	O
provide	O
a	O
functional	O
link	O
between	O
the	O
highly	O
related	O
ubiquitin	O
and	O
Nedd8	O
pathways	O
of	O
protein	O
modification	O
and	O
show	O
how	O
they	O
operate	O
together	O
to	O
selectively	O
target	O
the	O
signal	O
-	O
dependent	O
degradation	O
of	O
IkappaBalpha	O
.	O

Autoinhibition	O
and	O
activation	O
mechanisms	O
of	O
the	O
Wiskott	O
-	O
Aldrich	O
syndrome	O
protein	O
.	O

The	O
Rho	O
-	O
family	O
GTPase	O
,	O
Cdc42	O
,	O
can	O
regulate	O
the	O
actin	O
cytoskeleton	O
through	O
activation	O
of	O
Wiskott	O
-	O
Aldrich	O
syndrome	O
protein	O
(	O
WASP	O
)	O
family	O
members	O
.	O

Activation	O
relieves	O
an	O
autoinhibitory	O
contact	O
between	O
the	O
GTPase	O
-	O
binding	O
domain	O
and	O
the	O
carboxy	O
-	O
terminal	O
region	O
of	O
WASP	O
proteins	O
.	O

Here	O
we	O
report	O
the	O
autoinhibited	O
structure	O
of	O
the	O
GTPase	O
-	O
binding	O
domain	O
of	O
WASP	O
,	O
which	O
can	O
be	O
induced	O
by	O
the	O
C	O
-	O
terminal	O
region	O
or	O
by	O
organic	O
co	O
-	O
solvents	O
.	O

In	O
the	O
autoinhibited	O
complex	O
,	O
intramolecular	O
interactions	O
with	O
the	O
GTPase	O
-	O
binding	O
domain	O
occlude	O
residues	O
of	O
the	O
C	O
terminus	O
that	O
regulate	O
the	O
Arp2	B-Complex
/	I-Complex
3	I-Complex
actin	O
-	O
nucleating	O
complex	O
.	O

Binding	O
of	O
Cdc42	O
to	O
the	O
GTPase	O
-	O
binding	O
domain	O
causes	O
a	O
dramatic	O
conformational	O
change	O
,	O
resulting	O
in	O
disruption	O
of	O
the	O
hydrophobic	O
core	O
and	O
release	O
of	O
the	O
C	O
terminus	O
,	O
enabling	O
its	O
interaction	O
with	O
the	O
actin	O
regulatory	O
machinery	O
.	O

These	O
data	O
show	O
that	O
'	O
intrinsically	O
unstructured	O
'	O
peptides	O
such	O
as	O
the	O
GTPase	O
-	O
binding	O
domain	O
of	O
WASP	O
can	O
be	O
induced	O
into	O
distinct	O
structural	O
and	O
functional	O
states	O
depending	O
on	O
context	O
.	O

v	O
-	O
Src	O
suppresses	O
SHPS	O
-	O
1	O
expression	O
via	O
the	O
Ras	O
-	O
MAP	O
kinase	O
pathway	O
to	O
promote	O
the	O
oncogenic	O
growth	O
of	O
cells	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
cell	O
transformation	O
by	O
v	O
-	O
src	O
on	O
the	O
expression	O
and	O
tyrosine	O
phosphorylation	O
of	O
SHPS	O
-	O
1	O
,	O
a	O
putative	O
docking	O
protein	O
for	O
SHP	O
-	O
1	O
and	O
SHP	O
-	O
2	O
.	O

We	O
found	O
that	O
transformation	O
by	O
v	O
-	O
src	O
virtually	O
inhibited	O
the	O
SHPS	O
-	O
1	O
expression	O
at	O
mRNA	O
level	O
.	O

While	O
nontransforming	O
Src	O
kinases	O
including	O
c	O
-	O
Src	O
,	O
nonmyristoylated	O
forms	O
of	O
v	O
-	O
Src	O
had	O
no	O
inhibitory	O
effect	O
on	O
SHPS	O
-	O
1	O
expression	O
,	O
transforming	O
Src	O
kinases	O
including	O
wild	O
-	O
type	O
v	O
-	O
Src	O
and	O
chimeric	O
mutant	O
of	O
c	O
-	O
Src	O
bearing	O
v	O
-	O
Src	O
SH3	O
substantially	O
suppressed	O
the	O
SHPS	O
-	O
1	O
expression	O
.	O

In	O
cells	O
expressing	O
temperature	O
sensitive	O
mutant	O
of	O
v	O
-	O
Src	O
,	O
suppression	O
of	O
the	O
SHPS	O
-	O
1	O
expression	O
was	O
temperature	O
-	O
dependent	O
.	O

In	O
contrast	O
,	O
tyrosine	O
phosphorylation	O
of	O
SHPS	O
-	O
1	O
was	O
rather	O
activated	O
in	O
cells	O
expressing	O
c	O
-	O
Src	O
or	O
nonmyristoylated	O
forms	O
of	O
v	O
-	O
Src	O
.	O

SHPS	O
-	O
1	O
expression	O
in	O
SR3Y1	O
was	O
restored	O
by	O
treatment	O
with	O
herbimycin	O
A	O
,	O
a	O
potent	O
inhibitor	O
of	O
tyrosine	O
kinase	O
,	O
or	O
by	O
the	O
expression	O
of	O
dominant	O
negative	O
form	O
of	O
Ras	O
.	O

Contrary	O
,	O
active	O
form	O
of	O
Mekl	O
markedly	O
suppressed	O
SHPS	O
-	O
1	O
expression	O
.	O

Finally	O
,	O
overexpression	O
of	O
SHPS	O
-	O
1	O
in	O
SR3Y1	O
led	O
to	O
the	O
drastic	O
reduction	O
of	O
anchorage	O
independent	O
growth	O
of	O
the	O
cells	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
the	O
suppression	O
of	O
SHPS	O
-	O
1	O
expression	O
is	O
a	O
pivotal	O
event	O
for	O
cell	O
transformation	O
by	O
v	O
-	O
src	O
,	O
and	O
the	O
Ras	O
-	O
MAP	O
kinase	O
cascade	O
plays	O
a	O
critical	O
role	O
in	O
the	O
suppression	O
.	O

Functional	O
interactions	O
between	O
the	O
estrogen	O
receptor	O
and	O
DRIP205	O
,	O
a	O
subunit	O
of	O
the	O
heteromeric	O
DRIP	B-Complex
coactivator	O
complex	O
.	O

Nuclear	O
receptors	O
regulate	O
transcription	O
in	O
direct	O
response	O
to	O
their	O
cognate	O
hormonal	O
ligands	O
.	O

Ligand	O
binding	O
leads	O
to	O
the	O
dissociation	O
of	O
corepressors	O
and	O
the	O
recruitment	O
of	O
coactivators	O
.	O

Many	O
of	O
these	O
factors	O
,	O
acting	O
in	O
large	O
complexes	O
,	O
have	O
emerged	O
as	O
potential	O
chromatin	O
remodelers	O
through	O
intrinsic	O
histone	O
modifying	O
activities	O
.	O

In	O
addition	O
,	O
other	O
ligand	O
-	O
recruited	O
complexes	O
appear	O
to	O
act	O
more	O
directly	O
on	O
the	O
transcriptional	O
apparatus	O
.	O

The	O
DRIP	B-Complex
complex	O
is	O
a	O
15	O
-	O
subunit	O
complex	O
required	O
for	O
nuclear	O
receptor	O
transcriptional	O
activation	O
in	O
vitro	O
.	O

It	O
is	O
recruited	O
to	O
the	O
receptor	O
in	O
response	O
to	O
ligand	O
through	O
specific	O
interactions	O
of	O
one	O
subunit	O
,	O
DRIP205	O
.	O

We	O
present	O
evidence	O
that	O
DRIP205	O
interacts	O
with	O
another	O
member	O
of	O
the	O
steroid	O
receptor	O
subfamily	O
,	O
estrogen	O
receptor	O
(	O
ER	O
)	O
.	O

This	O
interaction	O
occurs	O
in	O
an	O
agonist	O
-	O
stimulated	O
fashion	O
which	O
in	O
turn	O
is	O
inhibited	O
by	O
several	O
ER	O
antagonists	O
.	O

In	O
vivo	O
,	O
a	O
fragment	O
of	O
DRIP205	O
containing	O
only	O
its	O
receptor	O
interacting	O
region	O
acts	O
to	O
selectively	O
inhibit	O
ER	O
'	O
s	O
ability	O
to	O
activate	O
transcription	O
in	O
response	O
to	O
estradiol	O
.	O

These	O
observations	O
suggest	O
a	O
key	O
role	O
for	O
the	O
DRIP	B-Complex
coactivator	O
complex	O
in	O
estrogen	O
-	O
ER	O
signaling	O
.	O

Akr1p	O
and	O
the	O
type	O
I	O
casein	O
kinases	O
act	O
prior	O
to	O
the	O
ubiquitination	O
step	O
of	O
yeast	O
endocytosis	O
:	O
Akr1p	O
is	O
required	O
for	O
kinase	O
localization	O
to	O
the	O
plasma	O
membrane	O
.	O

Ubiquitination	O
of	O
the	O
plasma	O
membrane	O
-	O
localized	O
yeast	O
a	O
-	O
factor	O
receptor	O
(	O
Ste3p	O
)	O
triggers	O
a	O
rapid	O
,	O
ligand	O
-	O
independent	O
endocytosis	O
leading	O
to	O
its	O
vacuolar	O
degradation	O
.	O

This	O
report	O
identifies	O
two	O
mutants	O
that	O
block	O
uptake	O
by	O
blocking	O
ubiquitination	O
,	O
these	O
being	O
mutant	O
either	O
for	O
the	O
ankyrin	O
repeat	O
protein	O
Akr1p	O
or	O
for	O
the	O
redundant	O
type	O
I	O
casein	O
kinases	O
Yck1p	O
and	O
Yck2p	O
.	O

While	O
no	O
obvious	O
defect	O
was	O
seen	O
for	O
wild	O
-	O
type	O
Ste3p	O
phosphorylation	O
in	O
akr1	O
or	O
yck	O
mutant	O
backgrounds	O
,	O
examination	O
of	O
the	O
Delta320	O
-	O
413	O
Ste3p	O
deletion	O
mutant	O
phosphorylation	O
did	O
reveal	O
a	O
clear	O
defect	O
in	O
both	O
mutants	O
.	O

The	O
Delta320	O
-	O
413	O
deletion	O
removes	O
18	O
Ser	O
-	O
Thr	O
residues	O
(	O
possible	O
YCK	O
-	O
independent	O
phosphorylation	O
sites	O
)	O
yet	O
retains	O
the	O
15	O
Ser	O
-	O
Thr	O
residues	O
of	O
the	O
Ste3p	O
PEST	O
-	O
like	O
ubiquitination	O
-	O
endocytosis	O
signal	O
.	O

Two	O
other	O
phenotypes	O
link	O
akr1	O
and	O
yck	O
mutants	O
:	O
both	O
are	O
defective	O
in	O
phosphorylation	O
of	O
wild	O
-	O
type	O
alpha	O
-	O
factor	O
receptor	O
,	O
and	O
while	O
both	O
are	O
defective	O
for	O
Ste3p	O
constitutive	O
internalization	O
,	O
both	O
remain	O
partially	O
competent	O
for	O
the	O
Ste3p	O
ligand	O
-	O
dependent	O
uptake	O
mode	O
.	O

Yck1p	O
-	O
Yck2p	O
may	O
be	O
the	O
function	O
responsible	O
in	O
phosphorylation	O
of	O
the	O
PEST	O
-	O
like	O
ubiquitination	O
-	O
endocytosis	O
signal	O
.	O

Akr1p	O
appears	O
to	O
function	O
in	O
localizing	O
Yck1p	O
-	O
Yck2p	O
to	O
the	O
plasma	O
membrane	O
,	O
a	O
localization	O
that	O
depends	O
on	O
prenylation	O
of	O
C	O
-	O
terminal	O
dicysteinyl	O
motifs	O
.	O

In	O
akr1Delta	O
cells	O
,	O
Yck2p	O
is	O
mislocalized	O
,	O
showing	O
a	O
diffuse	O
cytoplasmic	O
localization	O
identical	O
to	O
that	O
seen	O
for	O
a	O
Yck2p	O
mutant	O
that	O
lacks	O
the	O
C	O
-	O
terminal	O
Cys	O
-	O
Cys	O
,	O
indicating	O
a	O
likely	O
Akr1p	O
requirement	O
for	O
the	O
lipid	O
modification	O
of	O
Yck2p	O
,	O
for	O
prenylation	O
,	O
or	O
possibly	O
for	O
palmitoylation	O
.	O

Genomic	O
organization	O
of	O
the	O
human	O
phosphomannose	O
isomerase	O
(	O
MPI	O
)	O
gene	O
and	O
mutation	O
analysis	O
in	O
patients	O
with	O
congenital	O
disorders	O
of	O
glycosylation	O
type	O
Ib	O
(	O
CDG	O
-	O
Ib	O
)	O
.	O

CDG	O
-	O
Ib	O
is	O
the	O
"	O
gastro	O
-	O
intestinal	O
"	O
type	O
of	O
the	O
congenital	O
disorders	O
of	O
glycosylation	O
(	O
CDG	O
)	O
and	O
a	O
potentially	O
treatable	O
disorder	O
.	O

It	O
has	O
been	O
described	O
in	O
patients	O
presenting	O
with	O
congenital	O
hepatic	O
fibrosis	O
and	O
protein	O
losing	O
enteropathy	O
.	O

The	O
symptoms	O
result	O
from	O
hypoglycosylation	O
of	O
serum	O
-	O
and	O
other	O
glycoproteins	O
.	O

CDG	O
-	O
Ib	O
is	O
caused	O
by	O
a	O
deficiency	O
of	O
mannose	O
-	O
6	O
-	O
phosphate	O
isomerase	O
(	O
synonym	O
:	O
phosphomannose	O
isomerase	O
,	O
EC	O
5	O
.	O
3	O
.	O
1	O
.	O
8	O
)	O
,	O
due	O
to	O
mutations	O
in	O
the	O
MPI	O
gene	O
.	O

We	O
determined	O
the	O
genomic	O
structure	O
of	O
the	O
MPI	O
gene	O
in	O
order	O
to	O
simplify	O
mutation	O
detection	O
.	O

The	O
gene	O
is	O
composed	O
of	O
8	O
exons	O
and	O
spans	O
only	O
5	O
kb	O
.	O

Eight	O
(	O
7	O
novel	O
)	O
different	O
mutations	O
were	O
found	O
in	O
seven	O
patients	O
with	O
a	O
confirmed	O
phosphomannose	O
isomerase	O
deficiency	O
,	O
analyzed	O
in	O
the	O
context	O
of	O
this	O
study	O
:	O
six	O
missense	O
mutations	O
,	O
a	O
splice	O
mutation	O
and	O
one	O
insertion	O
.	O

In	O
the	O
last	O
,	O
the	O
mutation	O
resulted	O
in	O
an	O
unstable	O
transcript	O
,	O
and	O
was	O
hardly	O
detectable	O
at	O
the	O
mRNA	O
level	O
.	O

This	O
emphasizes	O
the	O
importance	O
of	O
mutation	O
analysis	O
at	O
the	O
genomic	O
DNA	O
level	O
.	O

Ski	O
represses	O
bone	O
morphogenic	O
protein	O
signaling	O
in	O
Xenopus	O
and	O
mammalian	O
cells	O
.	O

The	O
bone	O
morphogenic	O
proteins	O
(	O
BMPs	O
)	O
play	O
important	O
roles	O
in	O
vertebrate	O
development	O
.	O

In	O
Xenopus	O
,	O
BMPs	O
act	O
as	O
epidermal	O
inducers	O
and	O
also	O
as	O
negative	O
regulators	O
of	O
neurogenesis	O
.	O

Antagonism	O
of	O
BMP	O
signaling	O
results	O
in	O
neuralization	O
.	O

BMPs	O
signal	O
through	O
the	O
cell	O
-	O
surface	O
receptors	O
and	O
downstream	O
Smad	O
molecules	O
.	O

Upon	O
stimulation	O
with	O
BMP	O
,	O
Smad1	O
,	O
Smad5	O
,	O
and	O
Smad8	O
are	O
phosphorylated	O
by	O
the	O
activated	O
BMP	O
receptors	O
,	O
form	O
a	O
complex	O
with	O
Smad4	O
,	O
and	O
translocate	O
into	O
the	O
nucleus	O
,	O
where	O
they	O
regulate	O
the	O
expression	O
of	O
BMP	O
target	O
genes	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
Ski	O
oncoprotein	O
can	O
block	O
BMP	O
signaling	O
and	O
the	O
expression	O
of	O
BMP	O
-	O
responsive	O
genes	O
in	O
both	O
Xenopus	O
and	O
mammalian	O
cells	O
by	O
directly	O
interacting	O
with	O
and	O
repressing	O
the	O
activity	O
of	O
BMP	O
-	O
specific	O
Smad	O
complexes	O
.	O

This	O
ability	O
to	O
antagonize	O
BMP	O
signaling	O
results	O
in	O
neuralization	O
by	O
Ski	O
in	O
the	O
Xenopus	O
embryo	O
and	O
blocking	O
of	O
osteoblast	O
differentiation	O
of	O
murine	O
W	O
-	O
20	O
-	O
17	O
cells	O
.	O

Thus	O
,	O
Ski	O
is	O
able	O
to	O
repress	O
the	O
activity	O
of	O
all	O
receptor	O
-	O
associated	O
Smads	O
and	O
may	O
regulate	O
vertebrate	O
development	O
by	O
modulating	O
the	O
signaling	O
activity	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
family	O
members	O
.	O

Heat	O
shock	O
protein	O
70	O
binds	O
to	O
human	O
apurinic	O
/	O
apyrimidinic	O
endonuclease	O
and	O
stimulates	O
endonuclease	O
activity	O
at	O
abasic	O
sites	O
.	O

The	O
interaction	O
of	O
human	O
heat	O
shock	O
protein	O
70	O
(	O
HSP70	O
)	O
with	O
human	O
apurinic	O
/	O
apyrimidinic	O
endonuclease	O
(	O
HAP1	O
)	O
was	O
demonstrated	O
by	O
coimmunoprecipitation	O
.	O

A	O
combination	O
of	O
HSP70	O
and	O
HAP1	O
also	O
caused	O
a	O
shift	O
in	O
the	O
electrophoretic	O
mobility	O
of	O
a	O
DNA	O
fragment	O
containing	O
an	O
apurinic	O
/	O
apyrimidinic	O
site	O
.	O

The	O
functional	O
consequence	O
of	O
the	O
HSP70	O
/	O
HAP1	O
interaction	O
was	O
a	O
10	O
-	O
100	O
-	O
fold	O
enhancement	O
of	O
endonuclease	O
activity	O
at	O
abasic	O
sites	O
.	O

The	O
physical	O
and	O
functional	O
interaction	O
between	O
HSP70	O
and	O
HAP1	O
did	O
not	O
require	O
the	O
addition	O
of	O
ATP	O
.	O

The	O
association	O
of	O
HSP70	O
and	O
a	O
key	O
base	O
excision	O
repair	O
enzyme	O
suggests	O
a	O
role	O
for	O
heat	O
shock	O
proteins	O
in	O
promoting	O
base	O
excision	O
repair	O
.	O

These	O
findings	O
provide	O
a	O
possible	O
mechanism	O
by	O
which	O
HSP70	O
protects	O
cells	O
against	O
oxidative	O
stress	O
.	O

Smad7	O
binds	O
to	O
Smurf2	O
to	O
form	O
an	O
E3	O
ubiquitin	O
ligase	O
that	O
targets	O
the	O
TGF	O
beta	O
receptor	O
for	O
degradation	O
.	O

Ubiquitin	O
-	O
mediated	O
proteolysis	O
regulates	O
the	O
activity	O
of	O
diverse	O
receptor	O
systems	O
.	O

Here	O
,	O
we	O
identify	O
Smurf2	O
,	O
a	O
C2	O
-	O
WW	O
-	O
HECT	O
domain	O
ubiquitin	O
ligase	O
and	O
show	O
that	O
Smurf2	O
associates	O
constitutively	O
with	O
Smad7	O
.	O

Smurf2	O
is	O
nuclear	O
,	O
but	O
binding	O
to	O
Smad7	O
induces	O
export	O
and	O
recruitment	O
to	O
the	O
activated	O
TGF	O
beta	O
receptor	O
,	O
where	O
it	O
causes	O
degradation	O
of	O
receptors	O
and	O
Smad7	O
via	O
proteasomal	O
and	O
lysosomal	O
pathways	O
.	O

IFN	O
gamma	O
,	O
which	O
stimulates	O
expression	O
of	O
Smad7	O
,	O
induces	O
Smad7	O
-	O
Smurf2	O
complex	O
formation	O
and	O
increases	O
TGF	O
beta	O
receptor	O
turnover	O
,	O
which	O
is	O
stabilized	O
by	O
blocking	O
Smad7	O
or	O
Smurf2	O
expression	O
.	O

Furthermore	O
,	O
Smad7	O
mutants	O
that	O
interfere	O
with	O
recruitment	O
of	O
Smurf2	O
to	O
the	O
receptors	O
are	O
compromised	O
in	O
their	O
inhibitory	O
activity	O
.	O

These	O
studies	O
thus	O
define	O
Smad7	O
as	O
an	O
adaptor	O
in	O
an	O
E3	O
ubiquitin	O
-	O
ligase	O
complex	O
that	O
targets	O
the	O
TGF	O
beta	O
receptor	O
for	O
degradation	O
.	O

Inactivation	O
of	O
menin	O
,	O
a	O
Smad3	O
-	O
interacting	O
protein	O
,	O
blocks	O
transforming	O
growth	O
factor	O
type	O
beta	O
signaling	O
.	O

Multiple	O
endocrine	O
neoplasia	O
type	O
1	O
(	O
MEN1	O
)	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
characterized	O
by	O
endocrine	O
tumors	O
of	O
parathyroids	O
,	O
pancreatic	O
islets	O
,	O
and	O
anterior	O
pituitary	O
.	O

The	O
MEN1	O
gene	O
encodes	O
a	O
nuclear	O
protein	O
called	O
menin	O
.	O

In	O
MEN1	O
carriers	O
inactivating	O
mutations	O
give	O
rise	O
to	O
a	O
truncated	O
product	O
consistent	O
with	O
menin	O
acting	O
as	O
a	O
tumor	O
suppressor	O
gene	O
.	O

However	O
,	O
the	O
role	O
of	O
menin	O
in	O
tumorigenesis	O
and	O
its	O
physiological	O
functions	O
are	O
not	O
known	O
.	O

Here	O
,	O
we	O
show	O
that	O
menin	O
inactivation	O
by	O
antisense	O
RNA	O
antagonizes	O
transforming	O
growth	O
factor	O
type	O
beta	O
-	O
mediated	O
cell	O
growth	O
inhibition	O
.	O

Menin	O
interacts	O
with	O
Smad3	O
,	O
and	O
antisense	O
menin	O
suppresses	O
transforming	O
growth	O
factor	O
type	O
beta	O
-	O
induced	O
and	O
Smad3	O
-	O
induced	O
transcriptional	O
activity	O
by	O
inhibiting	O
Smad3	O
/	O
4	O
-	O
DNA	O
binding	O
at	O
specific	O
transcriptional	O
regulatory	O
sites	O
.	O

These	O
results	O
implicate	O
a	O
mechanism	O
of	O
tumorigenesis	O
by	O
menin	O
inactivation	O
.	O

JAK2	O
activates	O
TFII	O
-	O
I	O
and	O
regulates	O
its	O
interaction	O
with	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
.	O

TFII	O
-	O
I	O
is	O
a	O
transcription	O
factor	O
that	O
shuttles	O
between	O
the	O
cytoplasm	O
and	O
nucleus	O
and	O
is	O
regulated	O
by	O
serine	O
and	O
tyrosine	O
phosphorylation	O
.	O

Tyrosine	O
phosphorylation	O
of	O
TFII	O
-	O
I	O
can	O
be	O
regulated	O
in	O
a	O
signal	O
-	O
dependent	O
manner	O
in	O
various	O
cell	O
types	O
.	O

In	O
B	O
lymphocytes	O
,	O
Bruton	O
'	O
s	O
tyrosine	O
kinase	O
has	O
been	O
identified	O
as	O
a	O
TFII	O
-	O
I	O
tyrosine	O
kinase	O
.	O

Here	O
we	O
report	O
that	O
JAK2	O
can	O
phosphorylate	O
and	O
regulate	O
TFII	O
-	O
I	O
in	O
nonlymphoid	O
cells	O
.	O

The	O
activity	O
of	O
TFII	O
-	O
I	O
on	O
the	O
c	O
-	O
fos	O
promoter	O
in	O
response	O
to	O
serum	O
can	O
be	O
abolished	O
by	O
dominant	O
negative	O
JAK2	O
or	O
the	O
specific	O
JAK2	O
kinase	O
inhibitor	O
AG490	O
.	O

Consistent	O
with	O
this	O
,	O
we	O
have	O
also	O
found	O
that	O
JAK2	O
is	O
activated	O
by	O
serum	O
stimulation	O
of	O
fibroblasts	O
.	O

Tyrosine	O
248	O
of	O
TFII	O
-	O
I	O
is	O
phosphorylated	O
in	O
vivo	O
upon	O
serum	O
stimulation	O
or	O
JAK2	O
overexpression	O
,	O
and	O
mutation	O
of	O
tyrosine	O
248	O
to	O
phenylalanine	O
inhibits	O
the	O
ability	O
of	O
JAK2	O
to	O
phosphorylate	O
TFII	O
-	O
I	O
in	O
vitro	O
.	O

Tyrosine	O
248	O
of	O
TFII	O
-	O
I	O
is	O
required	O
for	O
its	O
interaction	O
with	O
and	O
phosphorylation	O
by	O
ERK	O
and	O
its	O
in	O
vivo	O
activity	O
on	O
the	O
c	O
-	O
fos	O
promoter	O
.	O

These	O
results	O
indicate	O
that	O
the	O
interaction	O
between	O
TFII	O
-	O
I	O
and	O
ERK	O
,	O
which	O
is	O
essential	O
for	O
its	O
activity	O
,	O
can	O
be	O
regulated	O
by	O
JAK2	O
through	O
phosphorylation	O
of	O
TFII	O
-	O
I	O
at	O
tyrosine	O
248	O
.	O

Thus	O
,	O
like	O
the	O
STAT	O
factors	O
,	O
TFII	O
-	O
I	O
is	O
a	O
direct	O
substrate	O
of	O
JAK2	O
and	O
a	O
signal	O
-	O
dependent	O
transcription	O
factor	O
that	O
integrates	O
signals	O
from	O
both	O
tyrosine	O
kinase	O
and	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
pathways	O
to	O
regulate	O
transcription	O
.	O

Differential	O
regulation	O
of	O
retinoblastoma	O
tumor	O
suppressor	O
protein	O
by	O
G	O
(	O
1	O
)	O
cyclin	O
-	O
dependent	O
kinase	O
complexes	O
in	O
vivo	O
.	O

The	O
retinoblastoma	O
tumor	O
suppressor	O
protein	O
(	O
pRB	O
)	O
negatively	O
regulates	O
early	O
-	O
G	O
(	O
1	O
)	O
cell	O
cycle	O
progression	O
,	O
in	O
part	O
,	O
by	O
sequestering	O
E2F	O
transcription	O
factors	O
and	O
repressing	O
E2F	O
-	O
responsive	O
genes	O
.	O

Although	O
pRB	O
is	O
phosphorylated	O
on	O
up	O
to	O
16	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
Cdk	O
)	O
sites	O
by	O
multiple	O
G	O
(	O
1	O
)	O
cyclin	O
-	O
Cdk	O
complexes	O
,	O
the	O
active	O
form	O
(	O
s	O
)	O
of	O
pRB	O
in	O
vivo	O
remains	O
unknown	O
.	O

pRB	O
is	O
present	O
as	O
an	O
unphosphorylated	O
protein	O
in	O
G	O
(	O
0	O
)	O
quiescent	O
cells	O
and	O
becomes	O
hypophosphorylated	O
(	O
approximately	O
2	O
mol	O
of	O
PO	O
(	O
4	O
)	O
to	O
1	O
mol	O
of	O
pRB	O
)	O
in	O
early	O
G	O
(	O
1	O
)	O
and	O
hyperphosphorylated	O
(	O
approximately	O
10	O
mol	O
of	O
PO	O
(	O
4	O
)	O
to	O
1	O
mol	O
of	O
pRB	O
)	O
in	O
late	O
G	O
(	O
1	O
)	O
phase	O
.	O

Here	O
,	O
we	O
report	O
that	O
hypophosphorylated	O
pRB	O
,	O
present	O
in	O
early	O
G	O
(	O
1	O
)	O
,	O
represents	O
the	O
biologically	O
active	O
form	O
of	O
pRB	O
in	O
vivo	O
that	O
is	O
assembled	O
with	O
E2Fs	O
and	O
E1A	O
but	O
that	O
both	O
unphosphorylated	O
pRB	O
in	O
G	O
(	O
0	O
)	O
and	O
hyperphosphorylated	O
pRB	O
in	O
late	O
G	O
(	O
1	O
)	O
fail	O
to	O
become	O
assembled	O
with	O
E2Fs	O
and	O
E1A	O
.	O

Furthermore	O
,	O
using	O
transducible	O
dominant	O
-	O
negative	O
TAT	O
fusion	O
proteins	O
that	O
differentially	O
target	O
cyclin	O
D	O
-	O
Cdk4	O
or	O
cyclin	O
D	O
-	O
Cdk6	O
(	O
cyclin	O
D	O
-	O
Cdk4	O
/	O
6	O
)	O
and	O
cyclin	O
E	O
-	O
Cdk2	O
complexes	O
,	O
namely	O
,	O
TAT	O
-	O
p16	O
and	O
TAT	O
-	O
dominant	O
-	O
negative	O
Cdk2	O
,	O
respectively	O
,	O
we	O
found	O
that	O
,	O
in	O
vivo	O
,	O
cyclin	O
D	O
-	O
Cdk4	O
/	O
6	O
complexes	O
hypophosphorylate	O
pRB	O
in	O
early	O
G	O
(	O
1	O
)	O
and	O
that	O
cyclin	O
E	O
-	O
Cdk2	O
complexes	O
inactivate	O
pRB	O
by	O
hyperphosphorylation	O
in	O
late	O
G	O
(	O
1	O
)	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
cycling	O
human	O
tumor	O
cells	O
expressing	O
deregulated	O
cyclin	O
D	O
-	O
Cdk4	O
/	O
6	O
complexes	O
,	O
due	O
to	O
deletion	O
of	O
the	O
p16	O
(	O
INK4a	O
)	O
gene	O
,	O
contained	O
hypophosphorylated	O
pRB	O
that	O
was	O
bound	O
to	O
E2Fs	O
in	O
early	O
G	O
(	O
1	O
)	O
and	O
that	O
E2F	O
-	O
responsive	O
genes	O
,	O
including	O
those	O
for	O
dihydrofolate	O
reductase	O
and	O
cyclin	O
E	O
,	O
were	O
transcriptionally	O
repressed	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
,	O
physiologically	O
,	O
pRB	O
is	O
differentially	O
regulated	O
by	O
G	O
(	O
1	O
)	O
cyclin	O
-	O
Cdk	O
complexes	O
.	O

BAG	O
-	O
1M	O
,	O
an	O
isoform	O
of	O
Bcl	O
-	O
2	O
-	O
interacting	O
protein	O
BAG	O
-	O
1	O
,	O
enhances	O
gene	O
expression	O
driven	O
by	O
CMV	O
promoter	O
.	O

BAG	O
-	O
1M	O
,	O
one	O
of	O
the	O
isoforms	O
of	O
BAG	O
-	O
1	O
,	O
was	O
reported	O
to	O
bind	O
to	O
DNA	O
and	O
stimulate	O
general	O
transcription	O
when	O
cells	O
were	O
stressed	O
by	O
heat	O
shock	O
(	O
Zeiner	O
,	O
M	O
.	O
,	O
et	O
al	O
.	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
96	O
,	O
10194	O
-	O
10199	O
,	O
1999	O
)	O
.	O

Here	O
we	O
show	O
that	O
BAG	O
-	O
1M	O
binds	O
and	O
enhances	O
transcriptional	O
activity	O
of	O
Cytomegalovirus	O
(	O
CMV	O
)	O
early	O
gene	O
promoter	O
under	O
unstressed	O
conditions	O
.	O

This	O
activity	O
is	O
unique	O
to	O
BAG	O
-	O
1M	O
in	O
that	O
other	O
isoforms	O
,	O
BAG	O
-	O
1S	O
and	O
BAG	O
-	O
1L	O
,	O
are	O
much	O
weaker	O
in	O
this	O
activity	O
,	O
although	O
all	O
of	O
the	O
isoforms	O
share	O
common	O
ubiquitin	O
-	O
like	O
domain	O
and	O
BAG	O
domain	O
interacting	O
with	O
Hsp70	O
/	O
Hsc70	O
.	O

Deletion	O
analysis	O
of	O
BAG	O
-	O
1M	O
showed	O
that	O
C	O
-	O
terminal	O
BAG	O
domain	O
is	O
necessary	O
to	O
enhance	O
the	O
CMV	O
promoter	O
activity	O
,	O
suggesting	O
that	O
interaction	O
with	O
Hsp70	O
/	O
Hsc70	O
proteins	O
may	O
mediate	O
this	O
function	O
.	O

Another	O
mutation	O
in	O
N	O
-	O
terminus	O
,	O
BAG	O
-	O
1M	O
K	O
(	O
2	O
-	O
4	O
)	O
A	O
,	O
lost	O
DNA	O
binding	O
capacity	O
and	O
majority	O
of	O
the	O
promoter	O
-	O
enhancing	O
activity	O
.	O

Our	O
study	O
demonstrates	O
that	O
both	O
N	O
-	O
terminal	O
DNA	O
binding	O
site	O
and	O
C	O
-	O
terminal	O
Hsp70	O
/	O
Hsc70	O
binding	O
site	O
of	O
BAG	O
-	O
1M	O
play	O
an	O
important	O
role	O
in	O
enhancing	O
the	O
CMV	O
promoter	O
activity	O
.	O

Expression	O
,	O
cellular	O
distribution	O
and	O
protein	O
binding	O
of	O
the	O
glioma	O
amplified	O
sequence	O
(	O
GAS41	O
)	O
,	O
a	O
highly	O
conserved	O
putative	O
transcription	O
factor	O
.	O

The	O
glioma	O
amplified	O
sequence	O
41	O
(	O
GAS41	O
)	O
was	O
previously	O
isolated	O
by	O
microdissection	O
mediated	O
cDNA	O
capture	O
from	O
the	O
glioblastoma	O
multiforme	O
cell	O
line	O
TX3868	O
and	O
shown	O
to	O
be	O
frequently	O
amplified	O
in	O
human	O
gliomas	O
.	O

We	O
determined	O
the	O
complete	O
cDNA	O
sequence	O
of	O
the	O
GAS41	O
gene	O
,	O
demonstrated	O
that	O
the	O
GAS41	O
protein	O
is	O
evolutionarily	O
conserved	O
,	O
specifically	O
at	O
the	O
N	O
-	O
terminus	O
,	O
and	O
identified	O
the	O
yeast	O
transcription	O
factor	O
tf2f	O
domain	O
within	O
the	O
GAS41	O
sequence	O
.	O

A	O
human	O
multiple	O
-	O
tissue	O
Northern	O
blot	O
revealed	O
ubiquitous	O
expression	O
of	O
GAS41	O
with	O
the	O
highest	O
expression	O
in	O
human	O
brain	O
.	O

After	O
generating	O
polyclonal	O
antibodies	O
we	O
found	O
GAS41	O
protein	O
expression	O
in	O
the	O
nucleus	O
of	O
the	O
TX3868	O
cell	O
line	O
by	O
Western	O
blot	O
analysis	O
and	O
immunofluorescence	O
microscopy	O
.	O

The	O
nuclear	O
localization	O
was	O
confirmed	O
for	O
several	O
human	O
tumors	O
including	O
gliomas	O
of	O
different	O
grades	O
of	O
malignancy	O
.	O

In	O
neuroblastoma	O
however	O
,	O
GAS41	O
was	O
found	O
in	O
the	O
nucleoli	O
but	O
not	O
in	O
the	O
nucleoplasm	O
.	O

Yeast	O
two	O
-	O
hybrid	O
screening	O
of	O
the	O
TX3868	O
cell	O
line	O
identified	O
the	O
nuclear	O
mitotic	O
apparatus	O
protein	O
(	O
NuMA	O
)	O
,	O
the	O
KIAA1009	O
protein	O
,	O
and	O
prefoldin	O
subunit	O
1	O
(	O
PFDN1	O
)	O
as	O
potential	O
interacting	O
partners	O
of	O
GAS41	O
.	O

We	O
generated	O
a	O
polyclonal	O
antibody	O
against	O
the	O
KIAA1009	O
protein	O
and	O
we	O
demonstrated	O
that	O
the	O
KIAA1009	O
protein	O
is	O
a	O
nuclear	O
protein	O
,	O
which	O
appears	O
to	O
be	O
co	O
-	O
localized	O
with	O
the	O
GAS41	O
protein	O
and	O
NuMA	O
.	O

A	O
conserved	O
family	O
of	O
prolyl	O
-	O
4	O
-	O
hydroxylases	O
that	O
modify	O
HIF	O
.	O

Mammalian	O
cells	O
respond	O
to	O
changes	O
in	O
oxygen	O
availability	O
through	O
a	O
conserved	O
pathway	O
that	O
is	O
regulated	O
by	O
the	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
.	O

The	O
alpha	O
subunit	O
of	O
HIF	O
is	O
targeted	O
for	O
degradation	O
under	O
normoxic	O
conditions	O
by	O
a	O
ubiquitin	O
-	O
ligase	O
complex	O
that	O
recognizes	O
a	O
hydroxylated	O
proline	O
residue	O
in	O
HIF	O
.	O

We	O
identified	O
a	O
conserved	O
family	O
of	O
HIF	O
prolyl	O
hydoxylase	O
(	O
HPH	O
)	O
enzymes	O
that	O
appear	O
to	O
be	O
responsible	O
for	O
this	O
posttranslational	O
modification	O
.	O

In	O
cultured	O
mammalian	O
cells	O
,	O
inappropriate	O
accumulation	O
of	O
HIF	O
caused	O
by	O
forced	O
expression	O
of	O
the	O
HIF	O
-	O
1alpha	O
subunit	O
under	O
normoxic	O
conditions	O
was	O
attenuated	O
by	O
coexpression	O
of	O
HPH	O
.	O

Suppression	O
of	O
HPH	O
in	O
cultured	O
Drosophila	O
melanogaster	O
cells	O
by	O
RNA	O
interference	O
resulted	O
in	O
elevated	O
expression	O
of	O
a	O
hypoxia	O
-	O
inducible	O
gene	O
(	O
LDH	O
,	O
encoding	O
lactate	O
dehydrogenase	O
)	O
under	O
normoxic	O
conditions	O
.	O

These	O
findings	O
indicate	O
that	O
HPH	O
is	O
an	O
essential	O
component	O
of	O
the	O
pathway	O
through	O
which	O
cells	O
sense	O
oxygen	O
.	O

A	O
novel	O
Rtg2p	O
activity	O
regulates	O
nitrogen	O
catabolism	O
in	O
yeast	O
.	O

The	O
inactivity	O
of	O
Ure2p	O
,	O
caused	O
by	O
either	O
a	O
ure2	O
mutation	O
or	O
the	O
presence	O
of	O
the	O
[	O
URE3	O
]	O
prion	O
,	O
increases	O
DAL5	O
transcription	O
and	O
thus	O
enables	O
Saccharomyces	O
cerevisiae	O
to	O
take	O
up	O
ureidosuccinate	O
(	O
USA	O
+	O
)	O
.	O

Rtg2p	O
regulates	O
transcription	O
of	O
glutamate	O
-	O
repressible	O
genes	O
by	O
facilitation	O
of	O
the	O
nuclear	O
entry	O
of	O
the	O
Rtg1	O
and	O
Rtg3	O
proteins	O
.	O

We	O
find	O
that	O
rtg2	O
Delta	O
cells	O
take	O
up	O
USA	O
even	O
without	O
the	O
presence	O
of	O
[	O
URE3	O
]	O
.	O

Thus	O
,	O
the	O
USA	O
+	O
phenotype	O
of	O
rtg2	O
Delta	O
strains	O
is	O
not	O
the	O
result	O
generation	O
of	O
the	O
[	O
URE3	O
]	O
prion	O
but	O
is	O
a	O
regulatory	O
effect	O
.	O

Because	O
rtg1	O
Delta	O
or	O
rtg3	O
Delta	O
mutations	O
or	O
the	O
presence	O
of	O
glutamate	O
do	O
not	O
produce	O
the	O
USA	O
+	O
phenotype	O
,	O
this	O
is	O
a	O
novel	O
function	O
of	O
Rtg2p	O
.	O

The	O
USA	O
+	O
phenotype	O
of	O
rtg2	O
Delta	O
strains	O
depends	O
on	O
GLN3	O
,	O
is	O
caused	O
by	O
overexpression	O
of	O
DAL5	O
,	O
and	O
is	O
blocked	O
by	O
mks1	O
Delta	O
,	O
but	O
not	O
by	O
overexpression	O
of	O
Ure2p	O
.	O

These	O
characteristics	O
suggest	O
that	O
Rtg2p	O
acts	O
in	O
the	O
upstream	O
part	O
of	O
the	O
nitrogen	O
catabolism	O
regulation	O
pathway	O
.	O

Domain	O
structure	O
of	O
the	O
NRIF3	O
family	O
of	O
coregulators	O
suggests	O
potential	O
dual	O
roles	O
in	O
transcriptional	O
regulation	O
.	O

The	O
identification	O
of	O
a	O
novel	O
coregulator	O
for	O
nuclear	O
hormone	O
receptors	O
,	O
designated	O
NRIF3	O
,	O
was	O
recently	O
reported	O
(	O
D	O
.	O
Li	O
et	O
al	O
.	O
,	O
Mol	O
.	O
Cell	O
.	O
Biol	O
.	O
19	O
:	O
7191	O
-	O
7202	O
,	O
1999	O
)	O
.	O

Unlike	O
most	O
known	O
coactivators	O
,	O
NRIF3	O
exhibits	O
a	O
distinct	O
receptor	O
specificity	O
in	O
interacting	O
with	O
and	O
potentiating	O
the	O
activity	O
of	O
only	O
TRs	O
and	O
RXRs	O
but	O
not	O
other	O
examined	O
nuclear	O
receptors	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
underlying	O
such	O
specificity	O
is	O
unclear	O
.	O

In	O
this	O
report	O
,	O
we	O
extended	O
our	O
study	O
of	O
NRIF3	O
-	O
receptor	O
interactions	O
.	O

Our	O
results	O
suggest	O
a	O
bivalent	O
interaction	O
model	O
,	O
where	O
a	O
single	O
NRIF3	O
molecule	O
utilizes	O
both	O
the	O
C	O
-	O
terminal	O
LXXIL	O
(	O
receptor	O
-	O
interacting	O
domain	O
1	O
[	O
RID1	O
]	O
)	O
and	O
the	O
N	O
-	O
terminal	O
LXXLL	O
(	O
RID2	O
)	O
modules	O
to	O
cooperatively	O
interact	O
with	O
TR	O
or	O
RXR	O
(	O
presumably	O
a	O
receptor	O
dimer	O
)	O
,	O
with	O
the	O
spacing	O
between	O
RID1	O
and	O
RID2	O
playing	O
an	O
important	O
role	O
in	O
influencing	O
the	O
affinity	O
of	O
the	O
interactions	O
.	O

During	O
the	O
course	O
of	O
these	O
studies	O
,	O
we	O
also	O
uncovered	O
an	O
NRIF3	O
-	O
NRIF3	O
interaction	O
domain	O
.	O

Deletion	O
and	O
mutagenesis	O
analyses	O
mapped	O
the	O
dimerization	O
domain	O
to	O
a	O
region	O
in	O
the	O
middle	O
of	O
NRIF3	O
(	O
residues	O
84	O
to	O
112	O
)	O
,	O
which	O
is	O
predicted	O
to	O
form	O
a	O
coiled	O
-	O
coil	O
structure	O
and	O
contains	O
a	O
putative	O
leucine	O
zipper	O
-	O
like	O
motif	O
.	O

By	O
using	O
Gal4	O
fusion	O
constructs	O
,	O
we	O
identified	O
an	O
autonomous	O
transactivation	O
domain	O
(	O
AD1	O
)	O
at	O
the	O
C	O
terminus	O
of	O
NRIF3	O
.	O

Somewhat	O
surprisingly	O
,	O
full	O
-	O
length	O
NRIF3	O
fused	O
to	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
Gal4	O
was	O
found	O
to	O
repress	O
transcription	O
of	O
a	O
Gal4	O
reporter	O
.	O

Further	O
analyses	O
mapped	O
a	O
novel	O
repression	O
domain	O
(	O
RepD1	O
)	O
to	O
a	O
small	O
region	O
at	O
the	O
N	O
-	O
terminal	O
portion	O
of	O
NRIF3	O
(	O
residues	O
20	O
to	O
50	O
)	O
.	O

The	O
NRIF3	O
gene	O
encodes	O
at	O
least	O
two	O
additional	O
isoforms	O
due	O
to	O
alternative	O
splicing	O
.	O

These	O
two	O
isoforms	O
contain	O
the	O
same	O
RepD1	O
region	O
as	O
NRIF3	O
.	O

Consistent	O
with	O
this	O
,	O
Gal4	O
fusions	O
of	O
these	O
two	O
isoforms	O
were	O
also	O
found	O
to	O
repress	O
transcription	O
.	O

Cotransfection	O
of	O
NRIF3	O
or	O
its	O
two	O
isoforms	O
did	O
not	O
relieve	O
the	O
transrepression	O
function	O
mediated	O
by	O
their	O
corresponding	O
Gal4	O
fusion	O
proteins	O
,	O
suggesting	O
that	O
the	O
repression	O
involves	O
a	O
mechanism	O
(	O
s	O
)	O
other	O
than	O
the	O
recruitment	O
of	O
a	O
titratable	O
corepressor	O
.	O

Interestingly	O
,	O
a	O
single	O
amino	O
acid	O
residue	O
change	O
of	O
a	O
potential	O
phosphorylation	O
site	O
in	O
RepD1	O
(	O
Ser	O
(	O
28	O
)	O
to	O
Ala	O
)	O
abolishes	O
its	O
transrepression	O
function	O
,	O
suggesting	O
that	O
the	O
coregulatory	O
property	O
of	O
NRIF3	O
(	O
or	O
its	O
isoforms	O
)	O
might	O
be	O
subjected	O
to	O
regulation	O
by	O
cellular	O
signaling	O
.	O

Taken	O
together	O
,	O
our	O
results	O
identify	O
NRIF3	O
as	O
an	O
interesting	O
coregulator	O
that	O
possesses	O
both	O
transactivation	O
and	O
transrepression	O
domains	O
and	O
/	O
or	O
functions	O
.	O

Collectively	O
,	O
the	O
NRIF3	O
family	O
of	O
coregulators	O
(	O
which	O
includes	O
NRIF3	O
and	O
its	O
other	O
isoforms	O
)	O
may	O
play	O
dual	O
roles	O
in	O
mediating	O
both	O
positive	O
and	O
negative	O
regulatory	O
effects	O
on	O
gene	O
expression	O
.	O

Impairment	O
of	O
mineralocorticoid	O
receptor	O
(	O
MR	O
)	O
-	O
dependent	O
biological	O
response	O
by	O
oxidative	O
stress	O
and	O
aging	O
:	O
correlation	O
with	O
post	O
-	O
translational	O
modification	O
of	O
MR	O
and	O
decreased	O
ADP	O
-	O
ribosylatable	O
level	O
of	O
elongating	O
factor	O
2	O
in	O
kidney	O
cells	O
.	O

Acute	O
and	O
chronic	O
treatments	O
of	O
mice	O
with	O
the	O
glutathione	O
-	O
depleting	O
agent	O
,	O
L	O
-	O
buthionine	O
-	O
(	O
SR	O
)	O
-	O
sulfoximine	O
(	O
BSO	O
)	O
,	O
impaired	O
the	O
mineralocorticoid	O
receptor	O
(	O
MR	O
)	O
-	O
dependent	O
biological	O
response	O
by	O
inhibiting	O
aldosterone	O
binding	O
.	O

This	O
steroid	O
-	O
binding	O
inhibition	O
was	O
fully	O
reversed	O
when	O
reducing	O
agents	O
were	O
added	O
to	O
kidney	O
cytosol	O
obtained	O
from	O
mice	O
treated	O
for	O
5	O
h	O
,	O
but	O
it	O
was	O
only	O
partially	O
reversed	O
in	O
cytosol	O
obtained	O
from	O
mice	O
treated	O
for	O
10	O
days	O
.	O

Although	O
the	O
oligomeric	O
structure	O
of	O
the	O
MR	O
-	O
hsp90	O
heterocomplex	O
was	O
always	O
unaffected	O
,	O
a	O
decreased	O
amount	O
of	O
MR	O
protein	O
was	O
evidenced	O
after	O
the	O
long	O
term	O
treatment	O
.	O

Such	O
a	O
deleterious	O
effect	O
was	O
correlated	O
with	O
a	O
post	O
-	O
translational	O
modification	O
of	O
MR	O
,	O
as	O
demonstrated	O
by	O
an	O
increased	O
level	O
of	O
receptor	O
carbonylation	O
.	O

In	O
addition	O
,	O
a	O
failure	O
at	O
the	O
elongation	O
/	O
termination	O
step	O
was	O
also	O
observed	O
during	O
the	O
receptor	O
translation	O
process	O
in	O
a	O
reticulocyte	O
lysate	O
system	O
.	O

Thus	O
,	O
a	O
high	O
polyribosomes	B-OOS
/	O
monomers	O
ratio	O
and	O
both	O
increased	O
proteolysis	O
and	O
decreased	O
ADP	O
-	O
ribosylatable	O
concentration	O
of	O
elongation	O
factor	O
2	O
(	O
EF	O
-	O
2	O
)	O
were	O
shown	O
.	O

Importantly	O
,	O
similar	O
observations	O
were	O
also	O
performed	O
in	O
vivo	O
after	O
depletion	O
of	O
glutathione	O
.	O

Notwithstanding	O
the	O
EF	O
-	O
2	O
functional	O
disruption	O
,	O
not	O
all	O
renal	O
proteins	O
were	O
equally	O
affected	O
as	O
the	O
MR	O
.	O

Interestingly	O
,	O
both	O
EF	O
-	O
2	O
and	O
MR	O
expressed	O
in	O
old	O
mice	O
were	O
similarly	O
affected	O
as	O
in	O
L	O
-	O
buthionine	O
-	O
(	O
SR	O
)	O
-	O
sulfoximine	O
-	O
treated	O
young	O
mice	O
.	O

We	O
therefore	O
propose	O
that	O
a	O
dramatic	O
depletion	O
of	O
glutathione	O
in	O
kidney	O
cells	O
mimics	O
the	O
cumulative	O
effect	O
of	O
aging	O
which	O
,	O
at	O
the	O
end	O
,	O
may	O
lead	O
to	O
a	O
renal	O
mineralocorticoid	O
dysfunction	O
.	O

The	O
Khd1	O
protein	O
,	O
which	O
has	O
three	O
KH	O
RNA	O
-	O
binding	O
motifs	O
,	O
is	O
required	O
for	O
proper	O
localization	O
of	O
ASH1	O
mRNA	O
in	O
yeast	O
.	O

RNA	O
localization	O
is	O
a	O
widespread	O
mechanism	O
for	O
achieving	O
localized	O
protein	O
synthesis	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
Ash1	O
is	O
a	O
specific	O
repressor	O
of	O
transcription	O
that	O
localizes	O
asymmetrically	O
to	O
the	O
daughter	O
cell	O
nucleus	O
through	O
the	O
localization	O
of	O
ASH1	O
mRNA	O
to	O
the	O
distal	O
tip	O
of	O
the	O
daughter	O
cell	O
.	O

This	O
localization	O
depends	O
on	O
the	O
actin	O
cytoskeleton	O
and	O
five	O
She	O
proteins	O
,	O
one	O
of	O
which	O
is	O
a	O
type	O
V	O
myosin	O
motor	O
,	O
Myo4	O
.	O

We	O
show	O
here	O
that	O
a	O
novel	O
RNA	O
-	O
binding	O
protein	O
,	O
Khd1	O
(	O
KH	O
-	O
domain	O
protein	O
1	O
)	O
,	O
is	O
required	O
for	O
efficient	O
localization	O
of	O
ASH1	O
mRNA	O
to	O
the	O
distal	O
tip	O
of	O
the	O
daughter	O
cell	O
.	O

Visualization	O
of	O
ASH1	O
mRNA	O
in	O
vivo	O
using	O
GFP	O
-	O
tagged	O
RNA	O
demonstrated	O
that	O
Khd1	O
associates	O
with	O
the	O
N	O
element	O
,	O
a	O
cis	O
-	O
acting	O
localization	O
sequence	O
within	O
the	O
ASH1	O
mRNA	O
.	O

Co	O
-	O
immunoprecipitation	O
studies	O
also	O
indicated	O
that	O
Khd1	O
associates	O
with	O
ASH1	O
mRNA	O
through	O
the	O
N	O
element	O
.	O

A	O
khd1Delta	O
mutation	O
exacerbates	O
the	O
phenotype	O
of	O
a	O
weak	O
myo4	O
mutation	O
,	O
whereas	O
overexpression	O
of	O
KHD1	O
decreases	O
the	O
concentration	O
of	O
Ash1	O
protein	O
and	O
restores	O
HO	O
expression	O
to	O
she	O
mutants	O
.	O

These	O
results	O
suggest	O
that	O
Khd1	O
may	O
function	O
in	O
the	O
linkage	O
between	O
ASH1	O
mRNA	O
localization	O
and	O
its	O
translation	O
.	O

Drosophila	O
myosin	B-Complex
phosphatase	I-Complex
and	O
its	O
role	O
in	O
dorsal	O
closure	O
.	O

Myosin	B-Complex
phosphatase	I-Complex
negatively	O
regulates	O
nonmuscle	O
myosin	O
II	O
through	O
dephosphorylation	O
of	O
the	O
myosin	O
regulatory	O
light	O
chain	O
(	O
MRLC	O
)	O
.	O

Its	O
regulatory	O
myosin	O
-	O
binding	O
subunit	O
,	O
MBS	O
,	O
is	O
responsible	O
for	O
regulating	O
the	O
catalytic	O
subunit	O
in	O
response	O
to	O
upstream	O
signals	O
and	O
for	O
determining	O
the	O
substrate	O
specificity	O
.	O

DMBS	O
,	O
the	O
Drosophila	O
homolog	O
of	O
MBS	O
,	O
was	O
identified	O
to	O
study	O
the	O
roles	O
of	O
myosin	B-Complex
phosphatase	I-Complex
in	O
morphogenesis	O
.	O

The	O
embryos	O
defective	O
for	O
both	O
maternal	O
and	O
zygotic	O
DMBS	O
demonstrated	O
a	O
failure	O
in	O
dorsal	O
closure	O
.	O

In	O
the	O
mutant	O
embryos	O
,	O
the	O
defects	O
were	O
mainly	O
confined	O
to	O
the	O
leading	O
edge	O
cells	O
which	O
failed	O
to	O
fully	O
elongate	O
.	O

Ectopic	O
accumulation	O
of	O
phosphorylated	O
MRLC	O
was	O
detected	O
in	O
lateral	O
region	O
of	O
the	O
leading	O
edge	O
cells	O
,	O
suggesting	O
that	O
the	O
role	O
of	O
DMBS	O
is	O
to	O
repress	O
the	O
activation	O
of	O
nonmuscle	O
myosin	O
II	O
at	O
the	O
subcellular	O
location	O
for	O
coordinated	O
cell	O
shape	O
change	O
.	O

Aberrant	O
accumulation	O
of	O
F	O
-	O
actin	O
within	O
the	O
leading	O
edge	O
cells	O
may	O
correspond	O
to	O
the	O
morphological	O
aberrations	O
of	O
such	O
cells	O
.	O

Similar	O
defects	O
were	O
seen	O
in	O
embryos	O
overexpressing	O
Rho	O
-	O
kinase	O
,	O
suggesting	O
that	O
myosin	B-Complex
phosphatase	I-Complex
and	O
Rho	O
-	O
kinase	O
function	O
antagonistically	O
.	O

The	O
genetic	O
interaction	O
of	O
DMBS	O
with	O
mutations	O
in	O
the	O
components	O
of	O
the	O
Rho	O
signaling	O
cascade	O
also	O
indicates	O
that	O
DMBS	O
functions	O
antagonistically	O
to	O
the	O
Rho	O
signal	O
transduction	O
pathway	O
.	O

The	O
results	O
indicate	O
an	O
important	O
role	O
for	O
myosin	B-Complex
phosphatase	I-Complex
in	O
morphogenesis	O
.	O

Formation	O
of	O
the	O
approximately	O
350	O
-	O
kDa	O
Apg12	O
-	O
Apg5	O
.	O
Apg16	O
multimeric	O
complex	O
,	O
mediated	O
by	O
Apg16	O
oligomerization	O
,	O
is	O
essential	O
for	O
autophagy	O
in	O
yeast	O
.	O

Autophagy	O
,	O
responsible	O
for	O
the	O
delivery	O
of	O
cytoplasmic	O
components	O
to	O
the	O
lysosome	O
/	O
vacuole	O
for	O
degradation	O
,	O
is	O
the	O
major	O
degradative	O
pathway	O
in	O
eukaryotic	O
cells	O
.	O

This	O
process	O
requires	O
a	O
ubiquitin	O
-	O
like	O
protein	O
conjugation	O
system	O
,	O
in	O
which	O
Apg12	O
is	O
covalently	O
bound	O
to	O
Apg5	O
.	O

In	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
the	O
Apg12	O
-	O
Apg5	O
conjugate	O
further	O
interacts	O
with	O
a	O
small	O
coiled	O
-	O
coil	O
protein	O
,	O
Apg16	O
.	O

The	O
Apg12	O
-	O
Apg5	O
and	O
Apg16	O
are	O
localized	O
in	O
the	O
cytosol	O
and	O
pre	O
-	O
autophagosomal	O
structures	O
and	O
play	O
an	O
essential	O
role	O
in	O
autophagosome	O
formation	O
.	O

Here	O
we	O
show	O
that	O
the	O
Apg12	O
-	O
Apg5	O
conjugate	O
and	O
Apg16	O
form	O
a	O
approximately	O
350	O
-	O
kDa	O
complex	O
in	O
the	O
cytosol	O
.	O

Because	O
Apg16	O
was	O
suggested	O
to	O
form	O
a	O
homo	O
-	O
oligomer	O
,	O
we	O
generated	O
an	O
in	O
vivo	O
system	O
that	O
allowed	O
us	O
to	O
control	O
the	O
oligomerization	O
state	O
of	O
Apg16	O
.	O

With	O
this	O
system	O
,	O
we	O
demonstrated	O
that	O
formation	O
of	O
the	O
approximately	O
350	O
-	O
kDa	O
complex	O
and	O
autophagic	O
activity	O
depended	O
on	O
the	O
oligomerization	O
state	O
of	O
Apg16	O
.	O

These	O
results	O
suggest	O
that	O
the	O
Apg12	O
-	O
Apg5	O
conjugate	O
and	O
Apg16	O
form	O
a	O
multimeric	O
complex	O
mediated	O
by	O
the	O
Apg16	O
homo	O
-	O
oligomer	O
,	O
and	O
formation	O
of	O
the	O
approximately	O
350	O
-	O
kDa	O
complex	O
is	O
required	O
for	O
autophagy	O
in	O
yeast	O
.	O

Paracrine	O
regulation	O
of	O
fat	O
cell	O
formation	O
in	O
bone	O
marrow	O
cultures	O
via	O
adiponectin	O
and	O
prostaglandins	O
.	O

Adiponectin	O
,	O
an	O
adipocyte	O
-	O
derived	O
hormone	O
,	O
was	O
recently	O
shown	O
to	O
have	O
potential	O
therapeutic	O
applications	O
in	O
diabetes	O
and	O
obesity	O
because	O
of	O
its	O
influence	O
on	O
glucose	O
and	O
lipid	O
metabolism	O
.	O

We	O
found	O
that	O
brown	O
fat	O
in	O
normal	O
human	O
bone	O
marrow	O
contains	O
this	O
protein	O
and	O
used	O
marrow	O
-	O
derived	O
preadipocyte	O
lines	O
and	O
long	O
-	O
term	O
cultures	O
to	O
explore	O
potential	O
roles	O
in	O
hematopoiesis	O
.	O

Recombinant	O
adiponectin	O
blocked	O
fat	O
cell	O
formation	O
in	O
long	O
-	O
term	O
bone	O
marrow	O
cultures	O
and	O
inhibited	O
the	O
differentiation	O
of	O
cloned	O
stromal	O
preadipocytes	O
.	O

Adiponectin	O
also	O
caused	O
elevated	O
expression	O
of	O
cyclooxygenase	O
-	O
2	O
(	O
COX	O
-	O
2	O
)	O
by	O
these	O
stromal	O
cells	O
and	O
induced	O
release	O
of	O
prostaglandin	O
E	O
(	O
2	O
)	O
(	O
PGE	O
(	O
2	O
)	O
)	O
.	O

The	O
COX	O
-	O
2	O
inhibitor	O
Dup	O
-	O
697	O
prevented	O
the	O
inhibitory	O
action	O
of	O
adiponectin	O
on	O
preadipocyte	O
differentiation	O
,	O
suggesting	O
involvement	O
of	O
stromal	O
cell	O
-	O
derived	O
prostanoids	O
.	O

Furthermore	O
,	O
adiponectin	O
failed	O
to	O
block	O
fat	O
cell	O
generation	O
when	O
bone	O
marrow	O
cells	O
were	O
derived	O
from	O
B6	O
,	O
129S	O
(	O
Ptgs2tm1Jed	O
)	O
(	O
COX	O
-	O
2	O
(	O
+	O
/	O
-	O
)	O
)	O
mice	O
.	O

These	O
observations	O
show	O
that	O
preadipocytes	O
represent	O
direct	O
targets	O
for	O
adiponectin	O
action	O
,	O
establishing	O
a	O
paracrine	O
negative	O
feedback	O
loop	O
for	O
fat	O
regulation	O
.	O

They	O
also	O
link	O
adiponectin	O
to	O
the	O
COX	O
-	O
2	O
-	O
dependent	O
PGs	O
that	O
are	O
critical	O
in	O
this	O
process	O
.	O

SHPS	O
-	O
1	O
,	O
a	O
multifunctional	O
transmembrane	O
glycoprotein	O
.	O

Src	O
homology	O
2	O
(	O
SH2	O
)	O
domain	O
-	O
containing	O
protein	O
tyrosine	O
phosphatase	O
substrate	O
1	O
(	O
SHPS	O
-	O
1	O
)	O
is	O
a	O
member	O
of	O
the	O
signal	O
regulatory	O
protein	O
(	O
SIRP	O
)	O
family	O
.	O

The	O
amino	O
-	O
terminal	O
immunoglobulin	O
-	O
like	O
domain	O
of	O
SHPS	O
-	O
1	O
is	O
necessary	O
for	O
interaction	O
with	O
CD47	O
,	O
a	O
ligand	O
for	O
SHPS	O
-	O
1	O
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
cell	O
-	O
cell	O
interaction	O
.	O

The	O
intracellular	O
region	O
of	O
SHPS	O
-	O
1	O
,	O
on	O
the	O
other	O
hand	O
,	O
may	O
act	O
as	O
a	O
scaffold	O
protein	O
,	O
binding	O
to	O
various	O
adapter	O
proteins	O
.	O

Interestingly	O
,	O
increasing	O
evidence	O
has	O
shown	O
that	O
SHPS	O
-	O
1	O
is	O
involved	O
in	O
various	O
biological	O
phenomena	O
,	O
including	O
suppression	O
of	O
anchorage	O
-	O
independent	O
cell	O
growth	O
,	O
negative	O
regulation	O
of	O
immune	O
cells	O
,	O
self	O
-	O
recognition	O
of	O
red	O
blood	O
cells	O
,	O
mediation	O
of	O
macrophage	O
multinucleation	O
,	O
skeletal	O
muscle	O
differentiation	O
,	O
entrainment	O
of	O
circadian	O
clock	O
,	O
neuronal	O
survival	O
and	O
synaptogenesis	O
.	O

Recent	O
progress	O
has	O
been	O
made	O
in	O
attributing	O
these	O
novel	O
exciting	O
functions	O
.	O

Here	O
we	O
discuss	O
how	O
this	O
interesting	O
molecule	O
works	O
and	O
consider	O
its	O
true	O
role	O
in	O
biology	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
platelet	O
glycoprotein	O
Ib	O
alpha	O
demonstrating	O
residues	O
involved	O
in	O
the	O
sulfation	O
of	O
tyrosines	O
276	O
,	O
278	O
,	O
and	O
279	O
.	O

The	O
interaction	O
between	O
platelet	O
glycoprotein	O
(	O
GP	O
)	O
Ib	O
alpha	O
and	O
von	O
Willebrand	O
factor	O
(	O
VWF	O
)	O
is	O
essential	O
for	O
initiation	O
of	O
hemostasis	O
.	O

The	O
sulfation	O
of	O
the	O
3	O
tyrosine	O
residues	O
276	O
,	O
278	O
,	O
and	O
279	O
in	O
GPIb	O
alpha	O
is	O
an	O
important	O
posttranslational	O
modification	O
that	O
seems	O
to	O
promote	O
the	O
interaction	O
with	O
VWF	O
.	O

The	O
environment	O
where	O
sulfation	O
of	O
tyrosines	O
occurs	O
has	O
been	O
proposed	O
to	O
contain	O
highly	O
acidic	O
residues	O
.	O

This	O
investigation	O
has	O
examined	O
the	O
highly	O
acidic	O
region	O
from	O
Asp249	O
to	O
Asp287	O
in	O
the	O
mature	O
GPIb	O
alpha	O
protein	O
.	O

Changes	O
to	O
most	O
of	O
the	O
carboxylic	O
acids	O
in	O
this	O
region	O
resulted	O
in	O
decreased	O
reactivity	O
to	O
VWF	O
.	O

Only	O
3	O
mutants	O
(	O
Glu270Gln	O
,	O
Asp283Asn	O
,	O
Asp283Asn	O
/	O
Glu285Gln	O
/	O
Asp287Asn	O
)	O
resulted	O
in	O
the	O
abolition	O
of	O
sulfation	O
.	O

Two	O
novel	O
mutations	O
were	O
also	O
created	O
.	O

First	O
,	O
a	O
deletion	O
of	O
the	O
7	O
amino	O
acids	O
from	O
Tyr276	O
to	O
Glu282	O
led	O
to	O
a	O
loss	O
of	O
sulfation	O
and	O
totally	O
abolished	O
VWF	O
binding	O
in	O
the	O
presence	O
of	O
botrocetin	O
.	O

This	O
confirms	O
that	O
it	O
is	O
these	O
3	O
tyrosines	O
that	O
undergo	O
sulfation	O
and	O
that	O
this	O
region	O
is	O
crucial	O
for	O
botrocetin	O
-	O
mediated	O
VWF	O
binding	O
.	O

The	O
second	O
mutation	O
involves	O
changing	O
the	O
lysine	O
residues	O
at	O
253	O
,	O
258	O
,	O
and	O
262	O
to	O
alanine	O
.	O

This	O
also	O
led	O
to	O
distinct	O
changes	O
in	O
VWF	O
binding	O
and	O
abolition	O
of	O
sulfation	O
.	O

A	O
novel	O
phosphatidic	O
acid	O
-	O
selective	O
phospholipase	O
A1	O
that	O
produces	O
lysophosphatidic	O
acid	O
.	O

Lysophosphatidic	O
acid	O
(	O
LPA	O
)	O
is	O
a	O
lipid	O
mediator	O
with	O
diverse	O
biological	O
properties	O
,	O
although	O
its	O
synthetic	O
pathways	O
have	O
not	O
been	O
completely	O
solved	O
.	O

We	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
phosphatidic	O
acid	O
(	O
PA	O
)	O
-	O
selective	O
phospholipase	O
A	O
(	O
1	O
)	O
(	O
PLA	O
(	O
1	O
)	O
)	O
that	O
produces	O
2	O
-	O
acyl	O
-	O
LPA	O
.	O

The	O
PLA	O
(	O
1	O
)	O
was	O
identified	O
in	O
the	O
GenBank	O
(	O
TM	O
)	O
data	O
base	O
as	O
a	O
close	O
homologue	O
of	O
phosphatidylserine	O
(	O
PS	O
)	O
-	O
specific	O
PLA	O
(	O
1	O
)	O
(	O
PS	O
-	O
PLA	O
(	O
1	O
)	O
)	O
.	O

When	O
expressed	O
in	O
insect	O
Sf9	O
cells	O
,	O
this	O
enzyme	O
was	O
recovered	O
from	O
the	O
Triton	O
X	O
-	O
100	O
-	O
insoluble	O
fraction	O
and	O
did	O
not	O
show	O
any	O
catalytic	O
activity	O
toward	O
exogenously	O
added	O
phospholipid	O
substrates	O
.	O

However	O
,	O
culture	O
medium	O
obtained	O
from	O
Sf9	O
cells	O
expressing	O
the	O
enzyme	O
was	O
found	O
to	O
activate	O
EDG7	O
/	O
LPA	O
(	O
3	O
)	O
,	O
a	O
cellular	O
receptor	O
for	O
2	O
-	O
acyl	O
-	O
LPA	O
.	O

The	O
activation	O
of	O
EDG7	O
was	O
further	O
enhanced	O
when	O
the	O
cells	O
were	O
treated	O
with	O
phorbol	O
ester	O
or	O
a	O
bacterial	O
phospholipase	O
D	O
,	O
suggesting	O
involvement	O
of	O
phospholipase	O
D	O
in	O
the	O
process	O
.	O

In	O
the	O
latter	O
condition	O
,	O
an	O
increased	O
level	O
of	O
LPA	O
,	O
but	O
not	O
other	O
lysophospholipids	O
,	O
was	O
confirmed	O
by	O
mass	O
spectrometry	O
analyses	O
.	O

Expression	O
of	O
the	O
enzyme	O
is	O
observed	O
in	O
several	O
human	O
tissues	O
such	O
as	O
prostate	O
,	O
testis	O
,	O
ovary	O
,	O
pancreas	O
,	O
and	O
especially	O
platelets	O
.	O

These	O
data	O
show	O
that	O
the	O
enzyme	O
is	O
a	O
membrane	O
-	O
associated	O
PA	O
-	O
selective	O
PLA	O
(	O
1	O
)	O
and	O
suggest	O
that	O
it	O
has	O
a	O
role	O
in	O
LPA	O
production	O
.	O

Phosphatidylinositol	O
3	O
-	O
kinase	O
regulates	O
glycosylphosphatidylinositol	O
hydrolysis	O
through	O
PLC	O
-	O
gamma	O
(	O
2	O
)	O
activation	O
in	O
erythropoietin	O
-	O
stimulated	O
cells	O
.	O

Erythropoietin	O
(	O
Epo	O
)	O
-	O
induced	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
hydrolysis	O
was	O
previously	O
described	O
to	O
be	O
correlated	O
with	O
phospholipase	O
C	O
-	O
gamma	O
2	O
(	O
PLC	O
-	O
gamma2	O
)	O
activation	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
involvement	O
of	O
phosphatidylinositol	O
(	O
PtdIns	O
)	O
3	O
-	O
kinase	O
in	O
GPI	O
hydrolysis	O
through	O
PLC	O
-	O
gamma2	O
tyrosine	O
phosphorylation	O
in	O
response	O
to	O
Epo	O
in	O
FDC	O
-	O
P1	O
cells	O
transfected	O
with	O
a	O
wild	O
type	O
(	O
WT	O
)	O
erythropoietin	O
-	O
receptor	O
(	O
Epo	O
-	O
R	O
)	O
.	O

We	O
showed	O
that	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PtdIns	O
3	O
-	O
kinase	O
)	O
inhibitor	O
LY294002	O
inhibits	O
Epo	O
-	O
induced	O
hydrolysis	O
of	O
endogenous	O
GPI	O
and	O
Epo	O
-	O
induced	O
PLC	O
-	O
gamma2	O
tyrosine	O
phosphorylation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Wortmannin	O
,	O
another	O
PtdIns	O
3	O
-	O
kinase	O
inhibitor	O
,	O
also	O
suppressed	O
Epo	O
-	O
induced	O
PLC	O
-	O
gamma2	O
tyrosine	O
phosphorylation	O
.	O

We	O
also	O
present	O
evidence	O
that	O
PLC	O
-	O
gamma2	O
translocation	O
to	O
the	O
membrane	O
fraction	O
on	O
Epo	O
stimulation	O
is	O
completely	O
inhibited	O
by	O
LY294002	O
.	O

Upon	O
Epo	O
stimulation	O
,	O
the	O
tyrosine	O
-	O
phosphorylated	O
PLC	O
-	O
gamma2	O
was	O
found	O
to	O
be	O
associated	O
with	O
the	O
tyrosine	O
-	O
phosphorylated	O
Grb2	O
-	O
associated	O
binder	O
(	O
GAB	O
)	O
2	O
,	O
SHC	O
and	O
SHP2	O
proteins	O
.	O

LY294002	O
cell	O
preincubation	O
did	O
not	O
affect	O
GAB2	O
,	O
SHC	O
and	O
SHP2	O
tyrosine	O
phosphorylation	O
but	O
inhibited	O
the	O
binding	O
of	O
PLC	O
-	O
gamma2	O
to	O
GAB2	O
and	O
SHP2	O
.	O

Taken	O
together	O
,	O
these	O
results	O
show	O
that	O
PtdIns	O
3	O
-	O
kinase	O
controls	O
Epo	O
-	O
induced	O
GPI	O
hydrolysis	O
through	O
PLC	O
-	O
gamma2	O
.	O

Smurf1	O
regulates	O
the	O
inhibitory	O
activity	O
of	O
Smad7	O
by	O
targeting	O
Smad7	O
to	O
the	O
plasma	O
membrane	O
.	O

Smad	O
ubiquitin	O
regulatory	O
factor	O
1	O
(	O
Smurf1	O
)	O
,	O
a	O
HECT	O
-	O
type	O
E3	O
ubiquitin	O
ligase	O
,	O
interacts	O
with	O
inhibitory	O
Smad7	O
and	O
induces	O
cytoplasmic	O
localization	O
of	O
Smad7	O
.	O

Smurf1	O
then	O
associates	O
with	O
transforming	O
growth	O
factor	O
-	O
beta	O
type	O
I	O
receptor	O
(	O
TbetaR	O
-	O
I	O
)	O
and	O
enhances	O
the	O
turnover	O
of	O
this	O
receptor	O
.	O

However	O
,	O
the	O
mechanisms	O
of	O
the	O
nuclear	O
export	O
and	O
plasma	O
membrane	O
localization	O
of	O
the	O
Smurf1	O
.	O
Smad7	O
complex	O
have	O
not	O
been	O
elucidated	O
.	O

We	O
show	O
here	O
that	O
Smurf1	O
targets	O
Smad7	O
to	O
the	O
plasma	O
membrane	O
through	O
its	O
N	O
-	O
terminal	O
conserved	O
2	O
(	O
C2	O
)	O
domain	O
.	O

Both	O
wild	O
-	O
type	O
Smurf1	O
(	O
Smurf1	O
(	O
WT	O
)	O
)	O
and	O
Smurf1	O
lacking	O
the	O
C2	O
domain	O
(	O
Smurf1	O
(	O
deltaC2	O
)	O
)	O
bound	O
to	O
Smad7	O
and	O
translocated	O
nuclear	O
Smad7	O
to	O
the	O
cytoplasm	O
.	O

However	O
,	O
unlike	O
Smurf1	O
(	O
WT	O
)	O
,	O
Smurf1	O
(	O
deltaC2	O
)	O
did	O
not	O
move	O
to	O
the	O
plasma	O
membrane	O
and	O
failed	O
to	O
recruit	O
Smad7	O
to	O
the	O
cell	O
surface	O
TbetaR	O
-	O
II	O
.	O
TbetaR	O
-	O
I	O
complex	O
.	O

Moreover	O
,	O
although	O
Smurf1	O
(	O
deltaC2	O
)	O
induced	O
ubiquitination	O
of	O
Smad7	O
,	O
it	O
failed	O
to	O
induce	O
the	O
ubiquitination	O
and	O
degradation	O
of	O
TbetaR	O
-	O
I	O
and	O
did	O
not	O
enhance	O
the	O
inhibitory	O
activity	O
of	O
Smad7	O
.	O

Thus	O
,	O
these	O
results	O
suggest	O
that	O
the	O
plasma	O
membrane	O
localization	O
of	O
Smad7	O
by	O
Smurf1	O
requires	O
the	O
C2	O
domain	O
of	O
Smurf1	O
and	O
is	O
essential	O
for	O
the	O
inhibitory	O
effect	O
of	O
Smad7	O
in	O
the	O
transforming	O
growth	O
factor	O
-	O
beta	O
signaling	O
pathway	O
.	O

The	O
postsynaptic	O
glutamate	O
receptor	O
subunit	O
DGluR	O
-	O
IIA	O
mediates	O
long	O
-	O
term	O
plasticity	O
in	O
Drosophila	O
.	O

The	O
developing	O
neuromuscular	O
junctions	O
(	O
NMJs	O
)	O
of	O
Drosophila	O
larvae	O
can	O
undergo	O
long	O
-	O
term	O
strengthening	O
of	O
signal	O
transmission	O
,	O
a	O
process	O
that	O
has	O
been	O
shown	O
recently	O
to	O
involve	O
local	O
subsynaptic	O
protein	O
synthesis	O
and	O
that	O
is	O
associated	O
with	O
an	O
elevated	O
synaptic	O
accumulation	O
of	O
the	O
postsynaptic	O
glutamate	O
receptor	O
subunit	O
DGluR	O
-	O
IIA	O
.	O

To	O
analyze	O
the	O
role	O
of	O
altered	O
postsynaptic	O
glutamate	O
receptor	O
expression	O
during	O
this	O
form	O
of	O
genetically	O
induced	O
junctional	O
plasticity	O
,	O
we	O
manipulated	O
the	O
expression	O
levels	O
of	O
two	O
so	O
far	O
-	O
described	O
postsynaptic	O
receptor	O
subunit	O
genes	O
,	O
dglur	O
-	O
IIA	O
and	O
dglur	O
-	O
IIB	O
,	O
in	O
wild	O
-	O
type	O
animals	O
and	O
plasticity	O
mutants	O
.	O

Here	O
we	O
show	O
that	O
elevated	O
synaptic	O
expression	O
of	O
DGluR	O
-	O
IIA	O
,	O
which	O
was	O
achieved	O
by	O
direct	O
transgenic	O
overexpression	O
,	O
by	O
genetically	O
increased	O
subsynaptic	O
protein	O
synthesis	O
,	O
or	O
by	O
a	O
reduced	O
dglur	O
-	O
IIB	O
gene	O
copy	O
number	O
,	O
results	O
in	O
an	O
increased	O
recruitment	O
of	O
active	O
zones	O
,	O
a	O
corresponding	O
enhancement	O
in	O
the	O
strength	O
of	O
junctional	O
signal	O
transmission	O
,	O
and	O
a	O
correlated	O
addition	O
of	O
boutons	O
to	O
the	O
NMJ	O
.	O

Ultrastructural	O
evidence	O
demonstrates	O
that	O
active	O
zones	O
appear	O
throughout	O
NMJs	O
at	O
a	O
typical	O
density	O
regardless	O
of	O
genotype	O
,	O
suggesting	O
that	O
the	O
space	O
requirements	O
of	O
active	O
zones	O
are	O
responsible	O
for	O
the	O
homogeneous	O
synapse	O
distribution	O
and	O
that	O
this	O
regulation	O
results	O
in	O
the	O
observed	O
growth	O
of	O
additional	O
boutons	O
at	O
strengthened	O
NMJs	O
.	O

These	O
phenotypes	O
were	O
suppressed	O
by	O
reduced	O
or	O
eliminated	O
DGluR	O
-	O
IIA	O
expression	O
,	O
which	O
resulted	O
from	O
either	O
a	O
reduced	O
dglur	O
-	O
IIA	O
gene	O
copy	O
number	O
or	O
transgenic	O
overexpression	O
of	O
DGluR	O
-	O
IIB	O
.	O

Our	O
results	O
demonstrate	O
that	O
persistent	O
alterations	O
of	O
neuronal	O
activity	O
and	O
subsynaptic	O
translation	O
result	O
in	O
an	O
elevated	O
synaptic	O
accumulation	O
of	O
DGluR	O
-	O
IIA	O
,	O
which	O
mediates	O
the	O
observed	O
functional	O
strengthening	O
and	O
morphological	O
growth	O
apparently	O
through	O
the	O
recruitment	O
of	O
additional	O
active	O
zones	O
.	O

CAND1	O
binds	O
to	O
unneddylated	O
CUL1	O
and	O
regulates	O
the	O
formation	O
of	O
SCF	B-Complex
ubiquitin	I-Complex
E3	I-Complex
ligase	I-Complex
complex	O
.	O

The	O
SCF	B-Complex
ubiquitin	I-Complex
E3	I-Complex
ligase	I-Complex
regulates	O
ubiquitin	O
-	O
dependent	O
proteolysis	O
of	O
many	O
regulatory	O
proteins	O
such	O
as	O
p27	O
(	O
Kip1	O
)	O
,	O
IkappaB	B-Complex
,	O
and	O
beta	O
-	O
catenin	O
.	O

We	O
report	O
the	O
isolation	O
of	O
a	O
CUL1	O
binding	O
protein	O
,	O
p120	O
(	O
CAND1	O
)	O
.	O

We	O
found	O
the	O
majority	O
of	O
CUL1	O
is	O
in	O
a	O
complex	O
with	O
CAND1	O
and	O
ROC1	O
independent	O
of	O
SKP1	O
and	O
F	O
box	O
protein	O
SKP2	O
.	O

Both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
CAND1	O
prevents	O
the	O
binding	O
of	O
SKP1	O
and	O
SKP2	O
to	O
CUL1	O
while	O
dissociation	O
of	O
CAND1	O
from	O
CUL1	O
promotes	O
the	O
reverse	O
reaction	O
.	O

Neddylation	O
of	O
CUL1	O
or	O
the	O
presence	O
of	O
SKP1	O
and	O
ATP	O
causes	O
CAND1	O
dissociation	O
.	O

Our	O
data	O
suggest	O
that	O
CAND1	O
regulates	O
the	O
formation	O
of	O
the	O
SCF	B-Complex
complex	O
,	O
and	O
its	O
dissociation	O
from	O
CUL1	O
is	O
coupled	O
with	O
the	O
incorporation	O
of	O
F	O
box	O
proteins	O
into	O
the	O
SCF	B-Complex
complex	O
,	O
causing	O
their	O
destabilization	O
.	O

Genotoxic	O
stress	O
-	O
induced	O
activation	O
of	O
Plk3	O
is	O
partly	O
mediated	O
by	O
Chk2	O
.	O

Polo	O
-	O
like	O
kinase	O
3	O
(	O
Plk3	O
,	O
alternatively	O
termed	O
Prk	O
)	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
DNA	O
damage	O
checkpoint	O
as	O
well	O
as	O
in	O
M	O
-	O
phase	O
function	O
.	O

Plk3	O
physically	O
interacts	O
with	O
p53	O
and	O
phosphorylates	O
this	O
tumor	O
suppressor	O
protein	O
on	O
serine	O
-	O
20	O
,	O
suggesting	O
that	O
the	O
role	O
of	O
Plk3	O
in	O
cell	O
cycle	O
progression	O
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
direct	O
regulation	O
of	O
p53	O
.	O

Here	O
we	O
show	O
that	O
Plk3	O
is	O
rapidly	O
activated	O
by	O
reactive	O
oxygen	O
species	O
in	O
normal	O
diploid	O
fibroblast	O
cells	O
(	O
WI	O
-	O
38	O
)	O
,	O
correlating	O
with	O
a	O
subsequent	O
increase	O
in	O
p53	O
protein	O
level	O
.	O

Plk3	O
physically	O
interacts	O
with	O
Chk2	O
and	O
the	O
interaction	O
is	O
enhanced	O
upon	O
DNA	O
damage	O
.	O

In	O
addition	O
,	O
Chk2	O
immunoprecipitated	O
from	O
cell	O
lysates	O
of	O
Daudi	O
(	O
which	O
expressed	O
little	O
Plk3	O
)	O
is	O
capable	O
of	O
stimulating	O
the	O
kinase	O
activity	O
of	O
purified	O
recombinant	O
Plk3	O
in	O
vitro	O
,	O
and	O
this	O
stimulation	O
is	O
more	O
pronounced	O
when	O
Plk3	O
is	O
supplemented	O
with	O
Chk2	O
immunoprecipitated	O
from	O
Daudi	O
after	O
DNA	O
damage	O
.	O

Furthermore	O
,	O
ectopic	O
expression	O
Chk2	O
activates	O
cellular	O
Plk3	O
.	O

Together	O
,	O
our	O
studies	O
suggest	O
Chk2	O
may	O
mediate	O
direct	O
activation	O
of	O
Plk3	O
in	O
response	O
to	O
genotoxic	O
stresses	O
.	O

TIP120A	O
associates	O
with	O
cullins	O
and	O
modulates	O
ubiquitin	O
ligase	O
activity	O
.	O

The	O
cullin	O
-	O
containing	O
ubiquitin	O
-	O
protein	O
isopeptide	O
ligases	O
(	O
E3s	O
)	O
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
abundance	O
of	O
key	O
proteins	O
involved	O
in	O
cellular	O
processes	O
such	O
as	O
cell	O
cycle	O
and	O
cytokine	O
signaling	O
.	O

They	O
have	O
multisubunit	O
modular	O
structures	O
in	O
which	O
substrate	O
recognition	O
and	O
the	O
catalysis	O
of	O
ubiquitination	O
are	O
carried	O
out	O
by	O
distinct	O
polypeptides	O
.	O

In	O
a	O
search	O
for	O
proteins	O
involved	O
in	O
regulation	O
of	O
cullin	O
-	O
containing	O
E3	O
ubiquitin	O
ligases	O
we	O
immunopurified	O
CUL4B	O
-	O
containing	O
complex	O
from	O
HeLa	O
cells	O
and	O
identified	O
TIP120A	O
as	O
an	O
associated	O
protein	O
by	O
mass	O
spectrometry	O
.	O

Immunoprecipitation	O
of	O
cullins	O
revealed	O
that	O
all	O
cullins	O
tested	O
specifically	O
interacted	O
with	O
TIP120A	O
.	O

Reciprocal	O
immunoaffinity	O
purification	O
of	O
TIP120A	O
confirmed	O
the	O
stable	O
interaction	O
of	O
TIP120A	O
with	O
cullin	O
family	O
proteins	O
.	O

TIP120A	O
formed	O
a	O
complex	O
with	O
CUL1	O
and	O
Rbx1	O
,	O
but	O
interfered	O
with	O
the	O
binding	O
of	O
Skp1	O
and	O
F	O
-	O
box	O
proteins	O
to	O
CUL1	O
.	O

TIP120A	O
greatly	O
reduced	O
the	O
ubiquitination	O
of	O
phosphorylated	O
IkappaBalpha	O
by	O
SCF	B-Complex
(	I-Complex
beta	I-Complex
-	I-Complex
TrCP	I-Complex
)	I-Complex
ubiquitin	I-Complex
ligase	I-Complex
.	O

These	O
results	O
suggest	O
that	O
TIP120A	O
functions	O
as	O
a	O
negative	O
regulator	O
of	O
SCF	B-Complex
E3	I-Complex
ubiquitin	I-Complex
ligases	I-Complex
and	O
may	O
modulate	O
other	O
cullin	O
ligases	O
in	O
a	O
similar	O
fashion	O
.	O

Modulation	O
of	O
p120E4F	O
transcriptional	O
activity	O
by	O
the	O
Gam1	O
adenoviral	O
early	O
protein	O
.	O

Gam1	O
,	O
an	O
early	O
adenoviral	O
CELO	O
protein	O
,	O
is	O
required	O
for	O
viral	O
replication	O
.	O

Consistent	O
with	O
its	O
ability	O
to	O
inhibit	O
histone	O
deacetylation	O
by	O
HDAC1	O
,	O
Gam1	O
activates	O
transcription	O
.	O

In	O
this	O
report	O
,	O
we	O
identify	O
the	O
cellular	O
transcription	O
factor	O
p120	O
(	O
E4F	O
)	O
as	O
a	O
Gam1	O
interaction	O
partner	O
.	O

p120	O
(	O
E4F	O
)	O
is	O
a	O
low	O
-	O
abundance	O
transcription	O
factor	O
that	O
represses	O
the	O
adenovirus	O
E4	O
promoter	O
.	O

Here	O
we	O
demonstrate	O
that	O
p120	O
(	O
E4F	O
)	O
interacts	O
with	O
HDAC1	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
and	O
that	O
E4F	O
-	O
mediated	O
transcriptional	O
repression	O
is	O
alleviated	O
by	O
the	O
HDAC	O
inhibitor	O
trichostatin	O
A	O
or	O
by	O
overexpressing	O
Gam1	O
.	O

A	O
mutant	O
E4	O
promoter	O
unresponsive	O
to	O
E4F	O
-	O
mediated	O
transcriptional	O
repression	O
is	O
also	O
not	O
stimulated	O
by	O
Gam1	O
.	O

Moreover	O
,	O
our	O
cofractionation	O
experiments	O
demonstrate	O
that	O
p120	O
(	O
E4F	O
)	O
,	O
HDAC1	O
and	O
Gam1	O
may	O
be	O
concomitantly	O
present	O
in	O
protein	O
complexes	O
.	O

We	O
conclude	O
that	O
Gam1	O
activates	O
E4	O
-	O
dependent	O
transcription	O
possibly	O
by	O
inactivating	O
HDAC1	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
nuclear	O
interacting	O
partner	O
of	O
anaplastic	O
lymphoma	O
kinase	O
(	O
NIPA	O
)	O
.	O

Anaplastic	O
large	O
-	O
cell	O
lymphoma	O
is	O
a	O
subtype	O
of	O
non	O
-	O
Hodgkin	O
lymphomas	O
characterized	O
by	O
the	O
expression	O
of	O
CD30	O
.	O

More	O
than	O
half	O
of	O
these	O
lymphomas	O
carry	O
a	O
chromosomal	O
translocation	O
t	O
(	O
2	O
;	O
5	O
)	O
leading	O
to	O
expression	O
of	O
the	O
oncogenic	O
tyrosine	O
kinase	O
nucleophosmin	O
-	O
anaplastic	O
lymphoma	O
kinase	O
(	O
NPM	O
-	O
ALK	O
)	O
.	O

NPM	O
-	O
ALK	O
is	O
capable	O
of	O
transforming	O
fibroblasts	O
and	O
lymphocytes	O
in	O
vitro	O
and	O
of	O
causing	O
lymphomas	O
in	O
mice	O
.	O

Previously	O
,	O
we	O
and	O
others	O
demonstrated	O
phospholipase	O
C	O
-	O
gamma	O
and	O
phosphatidylinositol	O
3	O
-	O
kinase	O
as	O
crucial	O
downstream	O
signaling	O
mediators	O
of	O
NPM	O
-	O
ALK	O
-	O
induced	O
oncogenicity	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
an	O
ALK	O
fusion	O
protein	O
as	O
bait	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
identifying	O
NIPA	O
(	O
nuclear	O
interacting	O
partner	O
of	O
ALK	O
)	O
as	O
a	O
novel	O
downstream	O
target	O
of	O
NPM	O
-	O
ALK	O
.	O

NIPA	O
encodes	O
a	O
60	O
-	O
kDa	O
protein	O
that	O
is	O
expressed	O
in	O
a	O
broad	O
range	O
of	O
human	O
tissues	O
and	O
contains	O
a	O
classical	O
nuclear	O
translocation	O
signal	O
in	O
its	O
C	O
terminus	O
,	O
which	O
directs	O
its	O
nuclear	O
localization	O
.	O

NIPA	O
interacts	O
with	O
NPM	O
-	O
ALK	O
and	O
other	O
ALK	O
fusions	O
in	O
a	O
tyrosine	O
kinase	O
-	O
dependent	O
manner	O
and	O
is	O
phosphorylated	O
in	O
NPM	O
-	O
ALK	O
-	O
expressing	O
cells	O
on	O
tyrosine	O
and	O
serine	O
residues	O
with	O
serine	O
354	O
as	O
a	O
major	O
phosphorylation	O
site	O
.	O

Overexpression	O
of	O
NIPA	O
in	O
Ba	O
/	O
F3	O
cells	O
was	O
able	O
to	O
protect	O
from	O
apoptosis	O
induced	O
by	O
IL	O
-	O
3	O
withdrawal	O
.	O

Mutations	O
of	O
the	O
nuclear	O
translocation	O
signal	O
or	O
the	O
Ser	O
-	O
354	O
phosphorylation	O
site	O
impaired	O
the	O
antiapoptotic	O
function	O
of	O
NIPA	O
.	O

In	O
NPM	O
-	O
ALK	O
-	O
transformed	O
Ba	O
/	O
F3	O
cells	O
,	O
apoptosis	O
triggered	O
by	O
wortmannin	O
treatment	O
was	O
enhanced	O
by	O
overexpression	O
of	O
putative	O
dominant	O
-	O
negative	O
NIPA	O
mutants	O
.	O

These	O
results	O
implicate	O
an	O
antiapoptotic	O
role	O
for	O
NIPA	O
in	O
NPM	O
-	O
ALK	O
-	O
mediated	O
signaling	O
events	O
.	O

Molecular	O
cloning	O
,	O
expression	O
,	O
and	O
characterization	O
of	O
a	O
novel	O
class	O
of	O
synaptotagmin	O
(	O
Syt	O
XIV	O
)	O
conserved	O
from	O
Drosophila	O
to	O
humans	O
.	O

Synaptotagmins	O
(	O
Syts	O
)	O
represent	O
a	O
large	O
family	O
of	O
putative	O
membrane	O
trafficking	O
proteins	O
found	O
in	O
various	O
species	O
from	O
different	O
phyla	O
.	O

In	O
this	O
study	O
,	O
I	O
identified	O
a	O
novel	O
class	O
of	O
Syt	O
(	O
named	O
Syt	O
XIV	O
)	O
conserved	O
from	O
Drosophila	O
to	O
humans	O
and	O
its	O
highly	O
related	O
molecule	O
,	O
Strep14	O
(	O
Syt	O
XIV	O
-	O
related	O
protein	O
)	O
.	O

Although	O
both	O
Syt	O
XIV	O
and	O
Strep14	O
belong	O
to	O
the	O
C	O
-	O
terminal	O
-	O
type	O
(	O
C	O
-	O
type	O
)	O
tandem	O
C2	O
protein	O
family	O
,	O
only	O
Syt	O
XIV	O
has	O
a	O
single	O
transmembrane	O
domain	O
at	O
the	O
N	O
-	O
terminus	O
and	O
a	O
putative	O
fatty	O
-	O
acylation	O
site	O
just	O
downstream	O
of	O
the	O
transmembrane	O
domain	O
.	O

Biochemical	O
analyses	O
have	O
indicated	O
that	O
Syt	O
XIV	O
is	O
a	O
Ca	O
(	O
2	O
+	O
)	O
-	O
independent	O
Syt	O
(	O
e	O
.	O
g	O
.	O
,	O
Syts	O
VIII	O
,	O
XII	O
,	O
and	O
XIII	O
)	O
and	O
that	O
,	O
like	O
other	O
Syt	O
family	O
proteins	O
,	O
it	O
is	O
capable	O
of	O
forming	O
a	O
Ca	O
(	O
2	O
+	O
)	O
-	O
independent	O
oligomer	O
.	O

Unlike	O
other	O
Syt	O
isoforms	O
,	O
however	O
,	O
expression	O
of	O
Syt	O
XIV	O
and	O
Strep14	O
mRNA	O
is	O
highly	O
restricted	O
to	O
mouse	O
heart	O
and	O
testis	O
and	O
absent	O
in	O
the	O
brain	O
,	O
where	O
most	O
other	O
Syts	O
are	O
abundantly	O
expressed	O
,	O
suggesting	O
that	O
Syt	O
XIV	O
and	O
Strep14	O
may	O
be	O
involved	O
in	O
membrane	O
trafficking	O
in	O
specific	O
tissues	O
outside	O
the	O
brain	O
.	O

I	O
also	O
identified	O
all	O
of	O
the	O
C	O
-	O
type	O
tandem	O
C2	O
proteins	O
in	O
humans	O
,	O
the	O
mouse	O
,	O
the	O
fruit	O
fly	O
,	O
a	O
nematode	O
,	O
a	O
plant	O
,	O
and	O
a	O
yeast	O
and	O
discuss	O
the	O
molecular	O
evolution	O
of	O
the	O
C	O
-	O
type	O
tandem	O
C2	O
protein	O
families	O
,	O
including	O
the	O
Syt	O
family	O
,	O
the	O
Syt	O
-	O
like	O
protein	O
(	O
Slp	O
)	O
family	O
,	O
and	O
the	O
Doc2	O
family	O
.	O

The	O
B	O
cell	O
-	O
specific	O
major	O
raft	O
protein	O
,	O
Raftlin	O
,	O
is	O
necessary	O
for	O
the	O
integrity	O
of	O
lipid	O
raft	O
and	O
BCR	O
signal	O
transduction	O
.	O

Recent	O
evidence	O
indicates	O
that	O
membrane	O
microdomains	O
,	O
termed	O
lipid	O
rafts	O
,	O
have	O
a	O
role	O
in	O
B	O
-	O
cell	O
activation	O
as	O
platforms	O
for	O
B	O
-	O
cell	O
antigen	O
receptor	O
(	O
BCR	O
)	O
signal	O
initiation	O
.	O

To	O
gain	O
an	O
insight	O
into	O
the	O
possible	O
functioning	O
of	O
lipid	O
rafts	O
in	O
B	O
cells	O
,	O
we	O
applied	O
liquid	O
chromatography	O
electrospray	O
ionization	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
ESI	O
-	O
MS	O
/	O
MS	O
)	O
methodologies	O
to	O
the	O
identification	O
of	O
proteins	O
that	O
co	O
-	O
purified	O
with	O
lipid	O
rafts	O
of	O
Raji	O
cells	O
.	O

Among	O
these	O
raft	O
proteins	O
,	O
we	O
characterized	O
a	O
novel	O
protein	O
termed	O
Raftlin	O
(	O
raft	O
-	O
linking	O
protein	O
)	O
.	O

Like	O
the	O
Src	O
family	O
kinase	O
,	O
Raftlin	O
is	O
localized	O
exclusively	O
in	O
lipid	O
rafts	O
by	O
fatty	O
acylation	O
of	O
N	O
-	O
terminal	O
Gly2	O
and	O
Cys3	O
,	O
and	O
is	O
co	O
-	O
localized	O
with	O
BCR	O
before	O
and	O
after	O
BCR	O
stimulation	O
.	O

Disruption	O
of	O
the	O
Raftlin	O
gene	O
in	O
the	O
DT40	O
B	O
-	O
cell	O
line	O
resulted	O
in	O
a	O
marked	O
reduction	O
in	O
the	O
quantity	O
of	O
lipid	O
raft	O
components	O
,	O
including	O
Lyn	O
and	O
ganglioside	O
GM1	O
,	O
while	O
overexpression	O
of	O
Raftlin	O
increased	O
the	O
content	O
of	O
raft	O
protein	O
.	O

Moreover	O
,	O
BCR	O
-	O
mediated	O
tyrosine	O
phosphorylation	O
and	O
calcium	O
mobilization	O
were	O
impaired	O
by	O
the	O
lack	O
of	O
Raftlin	O
and	O
actually	O
potentiated	O
by	O
overexpression	O
of	O
Raftlin	O
.	O

These	O
data	O
suggest	O
that	O
Raftlin	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
formation	O
and	O
/	O
or	O
maintenance	O
of	O
lipid	O
rafts	O
,	O
therefore	O
regulating	O
BCR	O
-	O
mediated	O
signaling	O
.	O

Omi	O
/	O
HtrA2	O
catalytic	O
cleavage	O
of	O
inhibitor	O
of	O
apoptosis	O
(	O
IAP	O
)	O
irreversibly	O
inactivates	O
IAPs	O
and	O
facilitates	O
caspase	O
activity	O
in	O
apoptosis	O
.	O

Omi	O
/	O
HtrA2	O
is	O
a	O
mitochondrial	O
serine	O
protease	O
that	O
is	O
released	O
into	O
the	O
cytosol	O
during	O
apoptosis	O
to	O
antagonize	O
inhibitors	O
of	O
apoptosis	O
(	O
IAPs	O
)	O
and	O
contribute	O
to	O
caspase	O
-	O
independent	O
cell	O
death	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
Omi	O
/	O
HtrA2	O
directly	O
cleaves	O
various	O
IAPs	O
in	O
vitro	O
,	O
and	O
the	O
cleavage	O
efficiency	O
is	O
determined	O
by	O
its	O
IAP	O
-	O
binding	O
motif	O
,	O
AVPS	O
.	O

Cleavage	O
of	O
IAPs	O
such	O
as	O
c	O
-	O
IAP1	O
substantially	O
reduces	O
its	O
ability	O
to	O
inhibit	O
and	O
ubiquitylate	O
caspases	O
.	O

In	O
contrast	O
to	O
the	O
stoichiometric	O
anti	O
-	O
IAP	O
activity	O
by	O
Smac	O
/	O
DIABLO	O
,	O
Omi	O
/	O
HtrA2	O
cleavage	O
of	O
c	O
-	O
IAP1	O
is	O
catalytic	O
and	O
irreversible	O
,	O
thereby	O
more	O
efficiently	O
inactivating	O
IAPs	O
and	O
promoting	O
caspase	O
activity	O
.	O

Elimination	O
of	O
endogenous	O
Omi	O
by	O
RNA	O
interference	O
abolishes	O
c	O
-	O
IAP1	O
cleavage	O
and	O
desensitizes	O
cells	O
to	O
apoptosis	O
induced	O
by	O
TRAIL	B-Complex
.	O

In	O
addition	O
,	O
overexpression	O
of	O
cleavage	O
-	O
site	O
mutant	O
c	O
-	O
IAP1	O
makes	O
cells	O
more	O
resistant	O
to	O
TRAIL	B-Complex
-	O
induced	O
caspase	O
activation	O
.	O

This	O
IAP	O
cleavage	O
by	O
Omi	O
is	O
independent	O
of	O
caspase	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
unlike	O
Smac	O
/	O
DIABLO	O
,	O
Omi	O
/	O
HtrA2	O
'	O
s	O
catalytic	O
cleavage	O
of	O
IAPs	O
is	O
a	O
key	O
mechanism	O
for	O
it	O
to	O
irreversibly	O
inactivate	O
IAPs	O
and	O
promote	O
apoptosis	O
.	O

Golgi	O
localization	O
of	O
carbohydrate	O
sulfotransferases	O
is	O
a	O
determinant	O
of	O
L	O
-	O
selectin	O
ligand	O
biosynthesis	O
.	O

Sulfation	O
of	O
endothelial	O
glycoproteins	O
by	O
the	O
sulfotransferase	O
GlcNAc6ST	O
-	O
2	O
is	O
a	O
regulatory	O
modification	O
that	O
promotes	O
binding	O
of	O
the	O
leukocyte	O
adhesion	O
molecule	O
L	O
-	O
selectin	O
.	O

GlcNAc6ST	O
-	O
2	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
related	O
enzymes	O
that	O
act	O
on	O
similar	O
carbohydrate	O
substrates	O
in	O
vitro	O
but	O
discrete	O
glycoproteins	O
in	O
vivo	O
.	O

We	O
demonstrate	O
that	O
GlcNAc6ST	O
-	O
1	O
,	O
-	O
2	O
,	O
and	O
-	O
3	O
have	O
distinct	O
Golgi	O
distributions	O
,	O
with	O
GlcNAc6ST	O
-	O
1	O
confined	O
to	O
the	O
trans	O
-	O
Golgi	O
network	O
,	O
GlcNAc6ST	O
-	O
3	O
confined	O
to	O
the	O
early	O
secretory	O
pathway	O
,	O
and	O
GlcNAc6ST	O
-	O
2	O
distributed	O
throughout	O
the	O
Golgi	O
.	O

Their	O
localization	O
was	O
correlated	O
with	O
preferred	O
activity	O
on	O
either	O
N	O
-	O
linked	O
or	O
O	O
-	O
linked	O
glycoproteins	O
.	O

A	O
chimera	O
comprising	O
the	O
localization	O
domain	O
of	O
GlcNAc6ST	O
-	O
1	O
fused	O
to	O
the	O
catalytic	O
domain	O
of	O
GlcNAc6ST	O
-	O
2	O
was	O
confined	O
to	O
the	O
trans	O
-	O
Golgi	O
network	O
and	O
adopted	O
the	O
substrate	O
preference	O
of	O
GlcNAc6ST	O
-	O
1	O
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
Golgi	O
enzyme	O
localization	O
and	O
competition	O
orchestrate	O
the	O
biosynthesis	O
of	O
L	O
-	O
selectin	O
ligands	O
.	O

Aurora	O
-	O
A	O
and	O
an	O
interacting	O
activator	O
,	O
the	O
LIM	O
protein	O
Ajuba	O
,	O
are	O
required	O
for	O
mitotic	O
commitment	O
in	O
human	O
cells	O
.	O

Aurora	O
family	O
kinases	O
contribute	O
to	O
regulation	O
of	O
mitosis	O
.	O

Using	O
RNA	O
interference	O
in	O
synchronized	O
HeLa	O
cells	O
,	O
we	O
now	O
show	O
that	O
Aurora	O
-	O
A	O
is	O
required	O
for	O
mitotic	O
entry	O
.	O

We	O
found	O
that	O
initial	O
activation	O
of	O
Aurora	O
-	O
A	O
in	O
late	O
G2	O
phase	O
of	O
the	O
cell	O
cycle	O
is	O
essential	O
for	O
recruitment	O
of	O
the	O
cyclin	O
B1	O
-	O
Cdk1	O
complex	O
to	O
centrosomes	O
,	O
where	O
it	O
becomes	O
activated	O
and	O
commits	O
cells	O
to	O
mitosis	O
.	O

A	O
two	O
-	O
hybrid	O
screen	O
identified	O
the	O
LIM	O
protein	O
Ajuba	O
as	O
an	O
Aurora	O
-	O
A	O
binding	O
protein	O
.	O

Ajuba	O
and	O
Aurora	O
-	O
A	O
interact	O
in	O
mitotic	O
cells	O
and	O
become	O
phosphorylated	O
as	O
they	O
do	O
so	O
.	O

In	O
vitro	O
analyses	O
revealed	O
that	O
Ajuba	O
induces	O
the	O
autophosphorylation	O
and	O
consequent	O
activation	O
of	O
Aurora	O
-	O
A	O
.	O

Depletion	O
of	O
Ajuba	O
prevented	O
activation	O
of	O
Aurora	O
-	O
A	O
at	O
centrosomes	O
in	O
late	O
G2	O
phase	O
and	O
inhibited	O
mitotic	O
entry	O
.	O

Overall	O
,	O
our	O
data	O
suggest	O
that	O
Ajuba	O
is	O
an	O
essential	O
activator	O
of	O
Aurora	O
-	O
A	O
in	O
mitotic	O
commitment	O
.	O

Molecular	O
cloning	O
of	O
the	O
interleukin	O
-	O
1	O
beta	O
converting	O
enzyme	O
.	O

Interleukin	O
-	O
1	O
beta	O
(	O
IL	O
-	O
1	O
beta	O
)	O
mediates	O
a	O
wide	O
range	O
of	O
immune	O
and	O
inflammatory	O
responses	O
.	O

The	O
active	O
cytokine	O
is	O
generated	O
by	O
proteolytic	O
cleavage	O
of	O
an	O
inactive	O
precursor	O
.	O

A	O
complementary	O
DNA	O
encoding	O
a	O
protease	O
that	O
carries	O
out	O
this	O
cleavage	O
has	O
been	O
cloned	O
.	O

Recombinant	O
expression	O
in	O
COS	O
-	O
7	O
cells	O
enabled	O
the	O
cells	O
to	O
process	O
precursor	O
IL	O
-	O
1	O
beta	O
to	O
the	O
mature	O
form	O
.	O

Sequence	O
analysis	O
indicated	O
that	O
the	O
enzyme	O
itself	O
may	O
undergo	O
proteolytic	O
processing	O
.	O

The	O
gene	O
encoding	O
the	O
protease	O
was	O
mapped	O
to	O
chromosomal	O
band	O
11q23	O
,	O
a	O
site	O
frequently	O
involved	O
in	O
rearrangement	O
in	O
human	O
cancers	O
.	O

Enhanced	O
gene	O
activation	O
by	O
Notch	O
and	O
BMP	O
signaling	O
cross	O
-	O
talk	O
.	O

The	O
signaling	O
systems	O
of	O
Notch	O
and	O
bone	O
morphogenetic	O
protein	O
(	O
BMP	O
)	O
are	O
highly	O
conserved	O
from	O
flies	O
to	O
mammals	O
and	O
have	O
been	O
shown	O
to	O
be	O
important	O
in	O
the	O
development	O
of	O
multiple	O
organs	O
.	O

For	O
instance	O
,	O
in	O
the	O
fate	O
determination	O
of	O
mouse	O
neuroepithelial	O
cells	O
,	O
Notch	O
signaling	O
plays	O
a	O
role	O
in	O
keeping	O
the	O
progenitors	O
from	O
differentiating	O
into	O
neurons	O
.	O

BMP	O
is	O
also	O
known	O
to	O
inhibit	O
neuronal	O
differentiation	O
.	O

In	O
this	O
paper	O
,	O
we	O
show	O
that	O
BMP2	O
enhances	O
Notch	O
-	O
induced	O
transcriptional	O
activation	O
of	O
Hes	O
-	O
5	O
and	O
Hesr	O
-	O
1	O
in	O
mouse	O
neuroepithelial	O
cells	O
.	O

BMP2	O
stimulation	O
,	O
in	O
addition	O
to	O
the	O
introduction	O
of	O
the	O
intracellular	O
domain	O
of	O
Notch	O
(	O
NIC	O
)	O
,	O
resulted	O
in	O
enhanced	O
activation	O
of	O
the	O
Hes	O
-	O
5	O
gene	O
promoter	O
.	O

RBP	O
-	O
Jkappa	O
binding	O
to	O
its	O
target	O
sequence	O
is	O
important	O
not	O
only	O
for	O
Notch	O
signaling	O
,	O
but	O
also	O
for	O
BMP2	O
signaling	O
,	O
to	O
activate	O
the	O
Hes	O
-	O
5	O
gene	O
promoter	O
.	O

Smad1	O
,	O
a	O
Smad	O
species	O
that	O
is	O
activated	O
by	O
BMP2	O
,	O
barely	O
interacted	O
with	O
NIC	O
,	O
but	O
did	O
form	O
a	O
complex	O
with	O
NIC	O
in	O
the	O
simultaneous	O
presence	O
of	O
the	O
coactivators	O
P	O
/	O
CAF	O
and	O
p300	O
.	O

Recruitment	O
of	O
p300	O
to	O
the	O
NIC	O
-	O
containing	O
complex	O
was	O
facilitated	O
by	O
activated	O
Smad1	O
,	O
which	O
is	O
suggested	O
to	O
contribute	O
to	O
BMP2	O
-	O
mediated	O
enhancement	O
of	O
Notch	O
-	O
induced	O
Hes	O
-	O
5	O
expression	O
.	O

These	O
data	O
suggest	O
a	O
novel	O
functional	O
cooperation	O
between	O
Notch	O
signaling	O
and	O
BMP	O
signaling	O
.	O

Functional	O
cloning	O
of	O
TUG	O
as	O
a	O
regulator	O
of	O
GLUT4	O
glucose	O
transporter	O
trafficking	O
.	O

Insulin	O
stimulates	O
glucose	O
uptake	O
in	O
fat	O
and	O
muscle	O
by	O
mobilizing	O
the	O
GLUT4	O
glucose	O
transporter	O
.	O

GLUT4	O
is	O
sequestered	O
intracellularly	O
in	O
the	O
absence	O
of	O
insulin	O
,	O
and	O
is	O
redistributed	O
to	O
the	O
plasma	O
membrane	O
within	O
minutes	O
of	O
insulin	O
stimulation	O
.	O

But	O
the	O
trafficking	O
mechanisms	O
that	O
control	O
GLUT4	O
sequestration	O
have	O
remained	O
elusive	O
.	O

Here	O
we	O
describe	O
a	O
functional	O
screen	O
to	O
identify	O
proteins	O
that	O
modulate	O
GLUT4	O
distribution	O
,	O
and	O
identify	O
TUG	O
as	O
a	O
putative	O
tether	O
,	O
containing	O
a	O
UBX	O
domain	O
,	O
for	O
GLUT4	O
.	O

In	O
truncated	O
form	O
,	O
TUG	O
acts	O
in	O
a	O
dominant	O
-	O
negative	O
manner	O
to	O
inhibit	O
insulin	O
-	O
stimulated	O
GLUT4	O
redistribution	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
and	O
3T3	O
-	O
L1	O
adipocytes	O
.	O

Full	O
-	O
length	O
TUG	O
forms	O
a	O
complex	O
specifically	O
with	O
GLUT4	O
;	O
in	O
3T3	O
-	O
L1	O
adipocytes	O
,	O
this	O
complex	O
is	O
present	O
in	O
unstimulated	O
cells	O
and	O
is	O
largely	O
disassembled	O
by	O
insulin	O
.	O

Endogenous	O
TUG	O
is	O
localized	O
with	O
the	O
insulin	O
-	O
mobilizable	O
pool	O
of	O
GLUT4	O
in	O
unstimulated	O
3T3	O
-	O
L1	O
adipocytes	O
,	O
and	O
is	O
not	O
mobilized	O
to	O
the	O
plasma	O
membrane	O
by	O
insulin	O
.	O

Distinct	O
regions	O
of	O
TUG	O
are	O
required	O
to	O
bind	O
GLUT4	O
and	O
to	O
retain	O
GLUT4	O
intracellularly	O
in	O
transfected	O
,	O
non	O
-	O
adipose	O
cells	O
.	O

Our	O
data	O
suggest	O
that	O
TUG	O
traps	O
endocytosed	O
GLUT4	O
and	O
tethers	O
it	O
intracellularly	O
,	O
and	O
that	O
insulin	O
mobilizes	O
this	O
pool	O
of	O
retained	O
GLUT4	O
by	O
releasing	O
this	O
tether	O
.	O

Origin	O
of	O
endogenous	O
DNA	O
abasic	O
sites	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Abasic	O
(	O
AP	O
)	O
sites	O
are	O
among	O
the	O
most	O
frequent	O
endogenous	O
lesions	O
in	O
DNA	O
and	O
present	O
a	O
strong	O
block	O
to	O
replication	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
an	O
apn1	O
apn2	O
rad1	O
triple	O
mutant	O
is	O
inviable	O
because	O
of	O
its	O
incapacity	O
to	O
repair	O
AP	O
sites	O
and	O
related	O
3	O
'	O
-	O
blocked	O
single	O
-	O
strand	O
breaks	O
(	O
M	O
.	O
Guillet	O
and	O
S	O
.	O
Boiteux	O
,	O
EMBO	O
J	O
.	O
21	O
:	O
2833	O
,	O
2002	O
)	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
origin	O
of	O
endogenous	O
AP	O
sites	O
in	O
yeast	O
.	O

Our	O
results	O
show	O
that	O
the	O
deletion	O
of	O
the	O
UNG1	O
gene	O
encoding	O
the	O
uracil	O
DNA	O
glycosylase	O
suppresses	O
the	O
lethality	O
of	O
the	O
apn1	O
apn2	O
rad1	O
mutant	O
.	O

In	O
contrast	O
,	O
inactivation	O
of	O
the	O
MAG1	O
,	O
OGG1	O
,	O
or	O
NTG1	O
and	O
NTG2	O
genes	O
encoding	O
DNA	O
glycosylases	O
involved	O
in	O
the	O
repair	O
of	O
alkylation	O
or	O
oxidation	O
damages	O
does	O
not	O
suppress	O
lethality	O
.	O

Although	O
viable	O
,	O
the	O
apn1	O
apn2	O
rad1	O
ung1	O
mutant	O
presents	O
growth	O
delay	O
due	O
to	O
a	O
G	O
(	O
2	O
)	O
/	O
M	O
checkpoint	O
.	O

These	O
results	O
point	O
to	O
uracil	O
as	O
a	O
critical	O
source	O
of	O
the	O
formation	O
of	O
endogenous	O
AP	O
sites	O
in	O
DNA	O
.	O

Uracil	O
can	O
arise	O
in	O
DNA	O
by	O
cytosine	O
deamination	O
or	O
by	O
the	O
incorporation	O
of	O
dUMP	O
during	O
replication	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
overexpression	O
of	O
the	O
DUT1	O
gene	O
encoding	O
the	O
dUTP	O
pyrophosphatase	O
(	O
Dut1	O
)	O
suppresses	O
the	O
lethality	O
of	O
the	O
apn1	O
apn2	O
rad1	O
mutant	O
.	O

Therefore	O
,	O
this	O
result	O
points	O
to	O
the	O
dUTP	O
pool	O
as	O
an	O
important	O
source	O
of	O
the	O
formation	O
of	O
endogenous	O
AP	O
sites	O
in	O
eukaryotes	O
.	O

Novel	O
compound	O
heterozygous	O
mutations	O
in	O
SLC5A2	O
are	O
responsible	O
for	O
autosomal	O
recessive	O
renal	O
glucosuria	O
.	O

Familial	O
renal	O
glucosuria	O
is	O
an	O
inherited	O
renal	O
tubular	O
disorder	O
.	O

A	O
homozygous	O
nonsense	O
mutation	O
in	O
the	O
SLC5A2	O
gene	O
,	O
encoding	O
the	O
sodium	O
/	O
glucose	O
co	O
-	O
transporter	O
SGLT2	O
,	O
has	O
recently	O
been	O
identified	O
in	O
an	O
affected	O
child	O
of	O
consanguineous	O
parents	O
.	O

We	O
now	O
report	O
novel	O
compound	O
heterozygous	O
mutations	O
in	O
the	O
son	O
of	O
non	O
-	O
consanguineous	O
parents	O
.	O

One	O
allele	O
has	O
a	O
p	O
.	O
Q167fsX186	O
mutation	O
,	O
which	O
is	O
expected	O
to	O
produce	O
a	O
truncated	O
protein	O
,	O
and	O
the	O
other	O
a	O
p	O
.	O
N654S	O
mutation	O
involving	O
a	O
highly	O
conserved	O
residue	O
.	O

These	O
findings	O
confirm	O
that	O
mutations	O
in	O
the	O
SLC5A2	O
gene	O
are	O
responsible	O
for	O
recessive	O
renal	O
glucosuria	O
.	O

A	O
novel	O
transmembrane	O
protein	O
recruits	O
numb	O
to	O
the	O
plasma	O
membrane	O
during	O
asymmetric	O
cell	O
division	O
.	O

Numb	O
,	O
an	O
evolutionarily	O
conserved	O
cell	O
fate	O
-	O
determining	O
factor	O
,	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
development	O
of	O
Drosophila	O
and	O
vertebrate	O
nervous	O
systems	O
.	O

Despite	O
lacking	O
a	O
transmembrane	O
segment	O
,	O
Numb	O
is	O
associated	O
with	O
the	O
cell	O
membrane	O
during	O
the	O
asymmetric	O
cell	O
division	O
of	O
Drosophila	O
neural	O
precursor	O
cells	O
and	O
is	O
selectively	O
partitioned	O
to	O
one	O
of	O
the	O
two	O
progeny	O
cells	O
from	O
a	O
binary	O
cell	O
division	O
.	O

Numb	O
contains	O
an	O
N	O
-	O
terminal	O
phosphotyrosine	O
-	O
binding	O
(	O
PTB	O
)	O
domain	O
that	O
is	O
essential	O
for	O
both	O
the	O
asymmetric	O
localization	O
and	O
the	O
fate	O
specification	O
function	O
of	O
Numb	O
.	O

We	O
report	O
here	O
the	O
isolation	O
and	O
characterization	O
of	O
a	O
novel	O
PTB	O
domain	O
-	O
binding	O
protein	O
,	O
NIP	O
(	O
Numb	O
-	O
interacting	O
protein	O
)	O
.	O

NIP	O
is	O
a	O
multipass	O
transmembrane	O
protein	O
that	O
contains	O
two	O
PTB	O
domain	O
-	O
binding	O
,	O
NXXF	O
motifs	O
required	O
for	O
the	O
interaction	O
with	O
Numb	O
.	O

In	O
dividing	O
Drosophila	O
neuroblasts	O
,	O
NIP	O
is	O
colocalized	O
to	O
the	O
cell	O
membrane	O
with	O
Numb	O
in	O
a	O
basal	O
cortical	O
crescent	O
.	O

Expression	O
of	O
NIP	O
in	O
Cos	O
-	O
7	O
cells	O
recruited	O
Numb	O
from	O
the	O
cytosol	O
to	O
the	O
plasma	O
membrane	O
.	O

This	O
recruitment	O
of	O
Numb	O
to	O
membrane	O
by	O
NIP	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
at	O
least	O
one	O
NXXF	O
site	O
.	O

In	O
Drosophila	O
Schneider	O
2	O
cells	O
,	O
NIP	O
and	O
Numb	O
were	O
colocalized	O
at	O
the	O
plasma	O
membrane	O
.	O

Inhibition	O
of	O
NIP	O
expression	O
by	O
RNA	O
interference	O
released	O
Numb	O
to	O
the	O
cytosol	O
.	O

These	O
results	O
suggest	O
that	O
a	O
direct	O
protein	O
-	O
protein	O
interaction	O
between	O
NIP	O
and	O
Numb	O
is	O
necessary	O
and	O
sufficient	O
for	O
the	O
recruitment	O
of	O
Numb	O
to	O
the	O
plasma	O
membrane	O
.	O

Recruitment	O
of	O
Numb	O
to	O
a	O
basal	O
cortical	O
crescent	O
in	O
a	O
dividing	O
neuroblast	O
is	O
essential	O
for	O
Numb	O
to	O
function	O
as	O
an	O
intrinsic	O
cell	O
fate	O
determinant	O
.	O

Analysis	O
of	O
SOCS	O
-	O
3	O
promoter	O
responses	O
to	O
interferon	O
gamma	O
.	O

SOCS	O
-	O
3	O
(	O
suppressor	O
of	O
cytokine	O
signaling	O
3	O
)	O
is	O
an	O
intracellular	O
protein	O
that	O
is	O
selectively	O
and	O
rapidly	O
induced	O
by	O
appropriate	O
agonists	O
and	O
that	O
modulates	O
responses	O
of	O
immune	O
cells	O
to	O
cytokines	O
by	O
interfering	O
with	O
the	O
Janus	O
kinase	O
/	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
Jak	O
/	O
STAT	O
)	O
pathway	O
.	O

On	O
the	O
basis	O
of	O
the	O
observations	O
that	O
interferon	O
gamma	O
(	O
IFNgamma	O
)	O
up	O
-	O
regulates	O
SOCS	O
-	O
3	O
gene	O
and	O
protein	O
expression	O
in	O
primary	O
mouse	O
macrophages	O
,	O
J774	O
macrophage	O
cell	O
line	O
and	O
embryonal	O
fibroblasts	O
,	O
we	O
investigated	O
which	O
sequences	O
of	O
the	O
5	O
'	O
SOCS	O
-	O
3	O
gene	O
are	O
responsive	O
to	O
IFNgamma	O
.	O

By	O
promoter	O
deletion	O
analysis	O
we	O
identified	O
a	O
functional	O
IFNgamma	O
-	O
responsive	O
element	O
,	O
located	O
at	O
nucleotides	O
-	O
72	O
/	O
-	O
64	O
upstream	O
from	O
the	O
transcription	O
initiation	O
,	O
whose	O
presence	O
and	O
integrity	O
is	O
necessary	O
to	O
ensure	O
responsiveness	O
to	O
IFNgamma	O
.	O

This	O
element	O
contains	O
a	O
STAT	O
consensus	O
binding	O
sequence	O
(	O
SOCS	O
-	O
3	O
/	O
STAT	O
-	O
binding	O
element	O
(	O
SBE	O
)	O
)	O
whose	O
specific	O
mutation	O
totally	O
abolished	O
the	O
responsiveness	O
to	O
IFNgamma	O
.	O

In	O
contrast	O
,	O
discrete	O
deletion	O
of	O
other	O
5	O
'	O
regions	O
of	O
the	O
SOCS	O
-	O
3	O
promoter	O
did	O
not	O
substantially	O
modify	O
the	O
inducibility	O
by	O
IFNgamma	O
.	O

Electromobility	O
shift	O
assay	O
analyses	O
revealed	O
that	O
IFNgamma	O
promotes	O
specific	O
DNA	O
binding	O
activities	O
to	O
an	O
oligonucleotide	O
probe	O
containing	O
the	O
SOCS	O
-	O
3	O
/	O
SBE	O
sequence	O
.	O

Even	O
though	O
IFNgamma	O
triggered	O
tyrosine	O
phosphorylation	O
of	O
both	O
STAT1	O
and	O
STAT3	O
in	O
macrophages	O
and	O
J774	O
cells	O
,	O
only	O
STAT1	O
was	O
appropriately	O
activated	O
and	O
thus	O
found	O
to	O
specifically	O
bind	O
to	O
the	O
SOCS	O
-	O
3	O
/	O
SBE	O
oligonucleotide	O
probe	O
.	O

Accordingly	O
,	O
IFNgamma	O
-	O
induced	O
SOCS	O
-	O
3	O
protein	O
expression	O
was	O
not	O
impaired	O
in	O
STAT3	O
-	O
deficient	O
embryonal	O
fibroblasts	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
the	O
induction	O
of	O
SOCS	O
-	O
3	O
by	O
IFNgamma	O
depends	O
upon	O
the	O
presence	O
of	O
a	O
STAT	O
-	O
binding	O
element	O
in	O
the	O
SOCS	O
-	O
3	O
promoter	O
that	O
is	O
specifically	O
activated	O
by	O
STAT1	O
.	O

AML1	O
is	O
functionally	O
regulated	O
through	O
p300	O
-	O
mediated	O
acetylation	O
on	O
specific	O
lysine	O
residues	O
.	O

AML1	O
(	O
RUNX1	O
)	O
is	O
one	O
of	O
the	O
most	O
frequently	O
disrupted	O
genes	O
in	O
human	O
leukemias	O
.	O

AML1	O
encodes	O
transcription	O
factors	O
,	O
which	O
play	O
a	O
pivotal	O
role	O
in	O
hematopoietic	O
differentiation	O
,	O
and	O
their	O
inappropriate	O
expression	O
is	O
associated	O
with	O
leukemic	O
transformation	O
of	O
hematopoietic	O
cells	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
the	O
transcription	O
cofactor	O
p300	O
binds	O
to	O
the	O
C	O
-	O
terminal	O
region	O
of	O
AML1	O
and	O
stimulates	O
AML1	O
-	O
dependent	O
transcription	O
during	O
myeloid	O
cell	O
differentiation	O
.	O

Here	O
,	O
we	O
report	O
that	O
AML1	O
is	O
specifically	O
acetylated	O
by	O
p300	O
in	O
vitro	O
.	O

Mutagenesis	O
analyses	O
reveal	O
that	O
p300	O
acetylates	O
AML1	O
at	O
the	O
two	O
conserved	O
lysine	O
residues	O
(	O
Lys	O
-	O
24	O
and	O
Lys	O
-	O
43	O
)	O
.	O

AML1	O
is	O
subject	O
to	O
acetylation	O
at	O
the	O
same	O
sites	O
in	O
vivo	O
,	O
and	O
p300	O
-	O
mediated	O
acetylation	O
significantly	O
augments	O
the	O
DNA	O
binding	O
activity	O
of	O
AML1	O
.	O

Disruption	O
of	O
these	O
two	O
lysines	O
severely	O
impairs	O
DNA	O
binding	O
of	O
AML1	O
and	O
reduced	O
the	O
transcriptional	O
activity	O
and	O
the	O
transforming	O
potential	O
of	O
AML1	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
acetylation	O
of	O
AML1	O
through	O
p300	O
is	O
a	O
critical	O
manner	O
of	O
posttranslational	O
modification	O
and	O
identify	O
a	O
novel	O
mechanism	O
for	O
regulating	O
the	O
function	O
of	O
AML1	O
.	O

Structural	O
mechanism	O
of	O
the	O
bromodomain	O
of	O
the	O
coactivator	O
CBP	O
in	O
p53	O
transcriptional	O
activation	O
.	O

Lysine	O
acetylation	O
of	O
the	O
tumor	O
suppressor	O
protein	O
p53	O
in	O
response	O
to	O
a	O
wide	O
variety	O
of	O
cellular	O
stress	O
signals	O
is	O
required	O
for	O
its	O
activation	O
as	O
a	O
transcription	O
factor	O
that	O
regulates	O
cell	O
cycle	O
arrest	O
,	O
senescence	O
,	O
or	O
apoptosis	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
conserved	O
bromo	O
-	O
domain	O
of	O
the	O
transcriptional	O
coactivator	O
CBP	O
(	O
CREB	O
binding	O
protein	O
)	O
binds	O
specifically	O
to	O
p53	O
at	O
the	O
C	O
-	O
terminal	O
acetylated	O
lysine	O
382	O
.	O

This	O
bromodomain	O
/	O
acetyl	O
-	O
lysine	O
binding	O
is	O
responsible	O
for	O
p53	O
acetylation	O
-	O
dependent	O
coactivator	O
recruitment	O
after	O
DNA	O
damage	O
,	O
a	O
step	O
essential	O
for	O
p53	O
-	O
induced	O
transcriptional	O
activation	O
of	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p21	O
in	O
G1	O
cell	O
cycle	O
arrest	O
.	O

We	O
further	O
present	O
the	O
three	O
-	O
dimensional	O
nuclear	O
magnetic	O
resonance	O
structure	O
of	O
the	O
CBP	O
bromodomain	O
in	O
complex	O
with	O
a	O
lysine	O
382	O
-	O
acetylated	O
p53	O
peptide	O
.	O

Using	O
structural	O
and	O
biochemical	O
analyses	O
,	O
we	O
define	O
the	O
molecular	O
determinants	O
for	O
the	O
specificity	O
of	O
this	O
molecular	O
recognition	O
.	O

Opposing	O
roles	O
for	O
ATF6alpha	O
and	O
ATF6beta	O
in	O
endoplasmic	O
reticulum	O
stress	O
response	O
gene	O
induction	O
.	O

The	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
transmembrane	O
proteins	O
,	O
ATF6alpha	O
and	O
ATF6beta	O
,	O
are	O
cleaved	O
in	O
response	O
to	O
ER	O
stress	O
,	O
which	O
can	O
be	O
induced	O
by	O
tunicamycin	O
.	O

The	O
resulting	O
N	O
-	O
terminal	O
fragments	O
of	O
both	O
ATF6	O
isoforms	O
,	O
which	O
have	O
conserved	O
basic	O
leucine	O
-	O
zipper	O
and	O
DNA	O
binding	O
domains	O
but	O
divergent	O
transcriptional	O
activation	O
domains	O
,	O
translocate	O
to	O
the	O
nucleus	O
where	O
they	O
bind	O
to	O
ER	O
stress	O
-	O
response	O
elements	O
(	O
ERSE	O
)	O
in	O
ER	O
stress	O
-	O
response	O
genes	O
(	O
ERSRG	O
)	O
,	O
such	O
as	O
GRP78	O
.	O

Although	O
it	O
is	O
known	O
that	O
ATF6alpha	O
is	O
a	O
potent	O
activator	O
of	O
ERSRGs	O
,	O
the	O
transcriptional	O
potency	O
and	O
functions	O
of	O
ATF6beta	O
remain	O
to	O
be	O
explored	O
.	O

Accordingly	O
,	O
N	O
-	O
terminal	O
fragments	O
of	O
each	O
ATF6	O
isoform	O
(	O
N	O
-	O
ATF6alpha	O
and	O
N	O
-	O
ATF6beta	O
)	O
were	O
overexpressed	O
in	O
HeLa	O
cells	O
and	O
the	O
effects	O
on	O
GRP78	O
induction	O
were	O
assessed	O
.	O

When	O
expressed	O
at	O
similar	O
levels	O
,	O
N	O
-	O
ATF6alpha	O
conferred	O
approximately	O
200	O
-	O
fold	O
greater	O
GRP78	O
promoter	O
activation	O
than	O
N	O
-	O
ATF6beta	O
.	O

Because	O
ER	O
stress	O
activates	O
nuclear	O
translocation	O
of	O
both	O
ATF6alpha	O
and	O
beta	O
and	O
because	O
both	O
bind	O
to	O
ERSEs	O
,	O
the	O
effect	O
of	O
co	O
-	O
expressing	O
them	O
on	O
GRP78	O
induction	O
was	O
assessed	O
.	O

Surprisingly	O
,	O
N	O
-	O
ATF6beta	O
inhibited	O
N	O
-	O
ATF6alpha	O
-	O
mediated	O
GRP78	O
promoter	O
activation	O
in	O
a	O
dominant	O
-	O
negative	O
manner	O
.	O

Moreover	O
,	O
N	O
-	O
ATF6beta	O
inhibited	O
TN	O
-	O
mediated	O
GRP78	O
promoter	O
activation	O
,	O
which	O
requires	O
endogenous	O
ATF6alpha	O
.	O

ATF6	O
isoform	O
-	O
specific	O
small	O
inhibitory	O
RNAs	O
were	O
used	O
to	O
show	O
that	O
,	O
as	O
expected	O
,	O
endogenous	O
ATF6alpha	O
was	O
required	O
for	O
maximal	O
ERSRG	O
induction	O
;	O
however	O
,	O
endogenous	O
ATF6beta	O
moderated	O
ERSRG	O
induction	O
.	O

These	O
results	O
indicate	O
that	O
compared	O
with	O
ATF6alpha	O
,	O
ATF6beta	O
is	O
a	O
very	O
poor	O
activator	O
of	O
ERSRG	O
induction	O
and	O
it	O
represses	O
ATF6alpha	O
-	O
mediated	O
ERSRG	O
induction	O
.	O

Thus	O
,	O
ATF6beta	O
may	O
serve	O
as	O
a	O
transcriptional	O
repressor	O
functioning	O
in	O
part	O
to	O
regulate	O
the	O
strength	O
and	O
duration	O
of	O
ATF6alpha	O
-	O
mediated	O
ERSRG	O
activation	O
during	O
the	O
ER	O
stress	O
response	O
.	O

PIASy	O
-	O
mediated	O
repression	O
of	O
the	O
androgen	O
receptor	O
is	O
independent	O
of	O
sumoylation	O
.	O

PIASy	O
,	O
a	O
member	O
of	O
the	O
protein	O
inhibitor	O
of	O
activated	O
STAT	O
(	O
PIAS	O
)	O
family	O
,	O
represses	O
the	O
transcriptional	O
activity	O
of	O
the	O
androgen	O
receptor	O
(	O
AR	O
)	O
.	O

In	O
this	O
report	O
,	O
we	O
investigate	O
the	O
mechanism	O
of	O
PIASy	O
-	O
mediated	O
repression	O
of	O
AR	O
.	O

We	O
show	O
that	O
AR	O
binds	O
to	O
the	O
RING	O
-	O
finger	O
like	O
domain	O
of	O
PIASy	O
.	O

PIASy	O
contains	O
two	O
transcriptional	O
repression	O
domains	O
,	O
RD1	O
and	O
RD2	O
.	O

RD1	O
,	O
but	O
not	O
RD2	O
,	O
is	O
required	O
for	O
PIASy	O
-	O
mediated	O
repression	O
of	O
AR	O
.	O

We	O
show	O
that	O
the	O
RD1	O
domain	O
binds	O
HDAC1	O
and	O
HDAC2	O
and	O
that	O
HDAC	O
activity	O
is	O
required	O
for	O
PIASy	O
-	O
mediated	O
AR	O
repression	O
.	O

PIAS	O
proteins	O
possess	O
small	O
ubiquitin	O
-	O
related	O
modifier	O
(	O
SUMO	O
)	O
E3	O
ligase	O
activity	O
.	O

Conjugation	O
of	O
SUMO	O
-	O
1	O
to	O
AR	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
AR	O
activity	O
.	O

We	O
examine	O
if	O
the	O
SUMO	O
ligase	O
activity	O
of	O
PIASy	O
is	O
required	O
for	O
PIASy	O
to	O
repress	O
AR	O
.	O

We	O
show	O
that	O
a	O
mutant	O
PIASy	O
,	O
defective	O
in	O
promoting	O
sumoylation	O
,	O
retains	O
the	O
ability	O
to	O
repress	O
AR	O
transcription	O
.	O

In	O
addition	O
,	O
mutation	O
of	O
all	O
the	O
known	O
sumoylation	O
acceptor	O
sites	O
of	O
AR	O
does	O
not	O
affect	O
the	O
transrepression	O
activity	O
of	O
PIASy	O
on	O
AR	O
.	O

Our	O
results	O
suggest	O
that	O
PIASy	O
may	O
repress	O
AR	O
by	O
recruiting	O
histone	O
deacetylases	O
,	O
independent	O
of	O
its	O
SUMO	O
ligase	O
activity	O
.	O

Characterization	O
of	O
oligomeric	O
human	O
half	O
-	O
ABC	O
transporter	O
ATP	O
-	O
binding	O
cassette	O
G2	O
.	O

Human	O
ATP	O
-	O
binding	O
cassette	O
G2	O
(	O
ABCG2	O
,	O
also	O
known	O
as	O
mitoxantrone	O
resistance	O
protein	O
,	O
breast	O
cancer	O
-	O
resistance	O
protein	O
,	O
ABC	O
placenta	O
)	O
is	O
a	O
member	O
of	O
the	O
superfamily	O
of	O
ATP	O
-	O
binding	O
cassette	O
(	O
ABC	O
)	O
transporters	O
that	O
have	O
a	O
wide	O
variety	O
of	O
substrates	O
.	O

Overexpression	O
of	O
human	O
ABCG2	O
in	O
model	O
cancer	O
cell	O
lines	O
causes	O
multidrug	O
resistance	O
by	O
actively	O
effluxing	O
anticancer	O
drugs	O
.	O

Unlike	O
most	O
of	O
the	O
other	O
ABC	O
transporters	O
which	O
usually	O
have	O
two	O
nucleotide	O
-	O
binding	O
domains	O
and	O
two	O
transmembrane	O
domains	O
,	O
ABCG2	O
consists	O
of	O
only	O
one	O
nucleotide	O
-	O
binding	O
domain	O
followed	O
by	O
one	O
transmembrane	O
domain	O
.	O

Thus	O
,	O
ABCG2	O
has	O
been	O
thought	O
to	O
be	O
a	O
half	O
-	O
transporter	O
that	O
may	O
function	O
as	O
a	O
homodimer	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
the	O
oligomeric	O
feature	O
of	O
human	O
ABCG2	O
using	O
non	O
-	O
denaturing	O
detergent	O
perfluoro	O
-	O
octanoic	O
acid	O
and	O
Triton	O
X	O
-	O
100	O
in	O
combination	O
with	O
gel	O
filtration	O
,	O
sucrose	O
density	O
gradient	O
sedimentation	O
,	O
and	O
gel	O
electrophoresis	O
.	O

Unexpectedly	O
,	O
we	O
found	O
that	O
human	O
ABCG2	O
exists	O
mainly	O
as	O
a	O
tetramer	O
,	O
with	O
a	O
possibility	O
of	O
a	O
higher	O
form	O
of	O
oligomerization	O
.	O

Monomeric	O
and	O
dimeric	O
ABCG2	O
did	O
not	O
appear	O
to	O
be	O
the	O
major	O
form	O
of	O
the	O
protein	O
.	O

Further	O
immunoprecipitation	O
analysis	O
showed	O
that	O
the	O
oligomeric	O
ABCG2	O
did	O
not	O
contain	O
any	O
other	O
proteins	O
.	O

Taken	O
together	O
,	O
we	O
conclude	O
that	O
human	O
ABCG2	O
likely	O
exists	O
and	O
functions	O
as	O
a	O
homotetramer	O
.	O

Integrin	O
-	O
dependent	O
apposition	O
of	O
Drosophila	O
extraembryonic	O
membranes	O
promotes	O
morphogenesis	O
and	O
prevents	O
anoikis	O
.	O

BACKGROUND	O
:	O
Two	O
extraembryonic	O
tissues	O
form	O
early	O
in	O
Drosophila	O
development	O
.	O

One	O
,	O
the	O
amnioserosa	O
,	O
has	O
been	O
implicated	O
in	O
the	O
morphogenetic	O
processes	O
of	O
germ	O
band	O
retraction	O
and	O
dorsal	O
closure	O
.	O

The	O
developmental	O
role	O
of	O
the	O
other	O
,	O
the	O
yolk	O
sac	O
,	O
is	O
obscure	O
.	O

RESULTS	O
:	O
By	O
using	O
live	O
-	O
imaging	O
techniques	O
,	O
we	O
report	O
intimate	O
interactions	O
between	O
the	O
amnioserosa	O
and	O
the	O
yolk	O
sac	O
during	O
germ	O
band	O
retraction	O
and	O
dorsal	O
closure	O
.	O

These	O
tissue	O
interactions	O
fail	O
in	O
a	O
subset	O
of	O
myospheroid	O
(	O
mys	O
:	O
betaPS	O
integrin	O
)	O
mutant	O
embryos	O
,	O
leading	O
to	O
failure	O
of	O
germ	O
band	O
retraction	O
and	O
dorsal	O
closure	O
.	O

The	O
Drosophila	O
homolog	O
of	O
mammalian	O
basigin	O
(	O
EMMPRIN	O
,	O
CD147	O
)	O
-	O
an	O
integrin	O
-	O
associated	O
transmembrane	O
glycoprotein	O
-	O
is	O
highly	O
enriched	O
in	O
the	O
extraembryonic	O
tissues	O
.	O

Strong	O
dominant	O
genetic	O
interactions	O
between	O
basigin	O
and	O
mys	O
mutations	O
cause	O
severe	O
defects	O
in	O
dorsal	O
closure	O
,	O
consistent	O
with	O
basigin	O
functioning	O
together	O
with	O
betaPS	O
integrin	O
in	O
extraembryonic	O
membrane	O
apposition	O
.	O

During	O
normal	O
development	O
,	O
JNK	O
signaling	O
is	O
upregulated	O
in	O
the	O
amnioserosa	O
,	O
as	O
midgut	O
closure	O
disrupts	O
contact	O
with	O
the	O
yolk	O
sac	O
.	O

Subsequently	O
,	O
the	O
amnioserosal	O
epithelium	O
degenerates	O
in	O
a	O
process	O
that	O
is	O
independent	O
of	O
the	O
reaper	O
,	O
hid	O
,	O
and	O
grim	O
cell	O
death	O
genes	O
.	O

In	O
mys	O
mutants	O
that	O
fail	O
to	O
establish	O
contact	O
between	O
the	O
extraembryonic	O
membranes	O
,	O
the	O
amnioserosa	O
undergoes	O
premature	O
disintegration	O
and	O
death	O
.	O

CONCLUSIONS	O
:	O
Intimate	O
apposition	O
of	O
the	O
amnioserosa	O
and	O
yolk	O
sac	O
prevents	O
anoikis	O
of	O
the	O
amnioserosa	O
.	O

Survival	O
of	O
the	O
amnioserosa	O
is	O
essential	O
for	O
germ	O
band	O
retraction	O
and	O
dorsal	O
closure	O
.	O

We	O
hypothesize	O
that	O
during	O
normal	O
development	O
,	O
loss	O
of	O
integrin	O
-	O
dependent	O
contact	O
between	O
the	O
extraembryonic	O
tissues	O
results	O
in	O
JNK	O
-	O
dependent	O
amnioserosal	O
disintegration	O
and	O
death	O
,	O
thus	O
representing	O
an	O
example	O
of	O
developmentally	O
programmed	O
anoikis	O
.	O

InsP3	O
-	O
mediated	O
intracellular	O
calcium	O
signalling	O
is	O
altered	O
by	O
expression	O
of	O
synaptojanin	O
-	O
1	O
.	O

Phosphatidylinositol	O
4	O
,	O
5	O
-	O
bisphosphate	O
[	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
]	O
plays	O
an	O
important	O
physiological	O
role	O
as	O
a	O
precursor	O
for	O
the	O
InsP3	O
-	O
mediated	O
intracellular	O
calcium	O
(	O
Ca2	O
+	O
)	O
signalling	O
cascade	O
.	O

It	O
also	O
regulates	O
membrane	O
trafficking	O
,	O
actin	O
function	O
and	O
transmembrane	O
proteins	O
.	O

SJ	O
-	O
1	O
(	O
synaptojanin	O
-	O
1	O
)	O
,	O
a	O
phosphoinositide	O
phosphatase	O
,	O
regulates	O
the	O
turnover	O
of	O
a	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
pool	O
involved	O
in	O
clathrin	B-Complex
and	O
actin	O
dynamics	O
at	O
the	O
cell	O
surface	O
.	O

We	O
tested	O
the	O
interrelationship	O
of	O
this	O
pool	O
with	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
pools	O
involved	O
in	O
Ca2	O
+	O
signalling	O
by	O
expressing	O
in	O
Chinese	O
-	O
hamster	O
ovary	O
cells	O
full	O
-	O
length	O
SJ	O
-	O
1	O
or	O
its	O
5	O
-	O
Pase	O
(	O
inositol	O
5	O
-	O
phosphatase	O
)	O
domain	O
.	O

SJ	O
-	O
1	O
significantly	O
attenuated	O
the	O
generation	O
of	O
Ca2	O
+	O
oscillations	O
induced	O
by	O
ATP	O
and	O
the	O
5	O
-	O
Pase	O
domain	O
mimicked	O
this	O
effect	O
.	O

These	O
changes	O
correlated	O
with	O
increased	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
phosphatase	O
activity	O
of	O
cellular	O
extracts	O
.	O

Overexpression	O
of	O
the	O
endoplasmic	O
reticulum	O
-	O
anchored	O
PtdIns	O
(	O
4	O
)	O
P	O
phosphatase	O
Sac1	O
did	O
not	O
affect	O
Ca2	O
+	O
oscillations	O
,	O
although	O
it	O
increased	O
the	O
Ca2	O
+	O
efflux	O
rate	O
from	O
intracellular	O
stores	O
.	O

The	O
ability	O
of	O
SJ	O
-	O
1	O
to	O
alter	O
intracellular	O
Ca2	O
+	O
signalling	O
indicates	O
a	O
close	O
functional	O
interrelationship	O
between	O
plasma	O
membrane	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
pools	O
that	O
control	O
actin	O
and	O
endocytosis	O
and	O
those	O
involved	O
in	O
the	O
regulation	O
of	O
specific	O
spatio	O
-	O
temporal	O
Ca2	O
+	O
signals	O
.	O

The	O
Human	O
hydroxyacylglutathione	O
hydrolase	O
(	O
HAGH	O
)	O
gene	O
encodes	O
both	O
cytosolic	O
and	O
mitochondrial	O
forms	O
of	O
glyoxalase	O
II	O
.	O

In	O
yeast	O
and	O
higher	O
plants	O
,	O
separate	O
genes	O
encode	O
the	O
cytosolic	O
and	O
mitochondrial	O
forms	O
of	O
glyoxalase	O
II	O
.	O

In	O
contrast	O
,	O
although	O
glyoxalase	O
II	O
activity	O
has	O
been	O
detected	O
both	O
in	O
the	O
cytosol	O
and	O
mitochondria	O
of	O
mammals	O
,	O
only	O
a	O
single	O
gene	O
encoding	O
glyoxalase	O
II	O
has	O
been	O
identified	O
.	O

Previously	O
it	O
was	O
thought	O
that	O
this	O
gene	O
(	O
the	O
hydroxyacylglutathione	O
hydrolase	O
gene	O
)	O
,	O
comprised	O
8	O
exons	O
that	O
are	O
transcribed	O
into	O
mRNA	O
and	O
that	O
the	O
resulting	O
mRNA	O
species	O
encoded	O
a	O
single	O
cytosolic	O
form	O
of	O
glyoxalase	O
II	O
.	O

Here	O
we	O
show	O
that	O
this	O
gene	O
gives	O
rise	O
to	O
two	O
distinct	O
mRNA	O
species	O
transcribed	O
from	O
9	O
and	O
10	O
exons	O
,	O
respectively	O
.	O

The	O
9	O
-	O
exon	O
-	O
derived	O
transcript	O
encodes	O
two	O
protein	O
species	O
:	O
mitochondrially	O
targeted	O
glyoxylase	O
II	O
,	O
which	O
is	O
initiated	O
from	O
an	O
AUG	O
codon	O
in	O
a	O
previously	O
uncharacterized	O
part	O
of	O
the	O
mRNA	O
sequence	O
,	O
and	O
cytosolic	O
glyoxalase	O
II	O
,	O
which	O
is	O
initiated	O
by	O
internal	O
ribosome	B-OOS
entry	O
at	O
a	O
downstream	O
AUG	O
codon	O
.	O

The	O
transcript	O
deriving	O
from	O
10	O
exons	O
has	O
an	O
in	O
-	O
frame	O
termination	O
codon	O
between	O
the	O
two	O
initiating	O
AUG	O
codons	O
and	O
hence	O
only	O
encodes	O
the	O
cytosolic	O
form	O
of	O
the	O
protein	O
.	O

Confocal	O
fluorescence	O
microscopy	O
indicates	O
that	O
the	O
mitochondrially	O
targeted	O
form	O
of	O
glyoxalase	O
II	O
is	O
directed	O
to	O
the	O
mitochondrial	O
matrix	O
.	O

Analysis	O
of	O
glyoxalase	O
II	O
mRNA	O
sequences	O
from	O
a	O
number	O
of	O
species	O
indicates	O
that	O
dual	O
initiation	O
from	O
alternative	O
AUG	O
codons	O
is	O
conserved	O
throughout	O
vertebrates	O
.	O

Proton	O
pump	O
coupled	O
to	O
cytochrome	B-Complex
c	I-Complex
oxidase	I-Complex
in	O
mitochondria	O
.	O

Differential	O
function	O
of	O
the	O
prolyl	O
hydroxylases	O
PHD1	O
,	O
PHD2	O
,	O
and	O
PHD3	O
in	O
the	O
regulation	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
.	O

Hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
is	O
a	O
transcriptional	O
regulator	O
that	O
plays	O
a	O
key	O
role	O
in	O
many	O
aspects	O
of	O
oxygen	O
homeostasis	O
.	O

The	O
heterodimeric	O
HIF	O
complex	O
is	O
regulated	O
by	O
proteolysis	O
of	O
its	O
alpha	O
-	O
subunits	O
,	O
following	O
oxygen	O
-	O
dependent	O
hydroxylation	O
of	O
specific	O
prolyl	O
residues	O
.	O

Although	O
three	O
HIF	O
prolyl	O
hydroxylases	O
,	O
PHD1	O
,	O
PHD2	O
,	O
and	O
PHD3	O
,	O
have	O
been	O
identified	O
that	O
have	O
the	O
potential	O
to	O
catalyze	O
this	O
reaction	O
,	O
the	O
contribution	O
of	O
each	O
isoform	O
to	O
the	O
physiological	O
regulation	O
of	O
HIF	O
remains	O
uncertain	O
.	O

Here	O
we	O
show	O
using	O
suppression	O
by	O
small	O
interference	O
RNA	O
that	O
each	O
of	O
the	O
three	O
PHD	O
isoforms	O
contributes	O
in	O
a	O
non	O
-	O
redundant	O
manner	O
to	O
the	O
regulation	O
of	O
both	O
HIF	O
-	O
1alpha	O
and	O
HIF	O
-	O
2alpha	O
subunits	O
and	O
that	O
the	O
contribution	O
of	O
each	O
PHD	O
under	O
particular	O
culture	O
conditions	O
is	O
strongly	O
dependent	O
on	O
the	O
abundance	O
of	O
the	O
enzyme	O
.	O

Thus	O
in	O
different	O
cell	O
types	O
,	O
isoform	O
-	O
specific	O
patterns	O
of	O
PHD	O
induction	O
by	O
hypoxia	O
and	O
estrogen	O
alter	O
both	O
the	O
relative	O
abundance	O
of	O
the	O
PHDs	O
and	O
their	O
relative	O
contribution	O
to	O
the	O
regulation	O
of	O
HIF	O
.	O

In	O
addition	O
,	O
the	O
PHDs	O
manifest	O
specificity	O
for	O
different	O
prolyl	O
hydroxylation	O
sites	O
within	O
each	O
HIF	O
-	O
alpha	O
subunit	O
,	O
and	O
a	O
degree	O
of	O
selectively	O
between	O
HIF	O
-	O
1alpha	O
and	O
HIF	O
-	O
2alpha	O
isoforms	O
,	O
indicating	O
that	O
differential	O
PHD	O
inhibition	O
has	O
the	O
potential	O
to	O
selectively	O
alter	O
the	O
characteristics	O
of	O
HIF	O
activation	O
.	O

Collagenase	O
unwinds	O
triple	O
-	O
helical	O
collagen	B-Complex
prior	O
to	O
peptide	O
bond	O
hydrolysis	O
.	O

Breakdown	O
of	O
triple	O
-	O
helical	O
interstitial	O
collagens	B-Complex
is	O
essential	O
in	O
embryonic	O
development	O
,	O
organ	O
morphogenesis	O
and	O
tissue	O
remodelling	O
and	O
repair	O
.	O

Aberrant	O
collagenolysis	O
may	O
result	O
in	O
diseases	O
such	O
as	O
arthritis	O
,	O
cancer	O
,	O
atherosclerosis	O
,	O
aneurysm	O
and	O
fibrosis	O
.	O

In	O
vertebrates	O
,	O
it	O
is	O
initiated	O
by	O
collagenases	O
belonging	O
to	O
the	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
family	O
.	O

The	O
three	O
-	O
dimensional	O
structure	O
of	O
a	O
prototypic	O
collagenase	O
,	O
MMP	O
-	O
1	O
,	O
indicates	O
that	O
the	O
substrate	O
-	O
binding	O
site	O
of	O
the	O
enzyme	O
is	O
too	O
narrow	O
to	O
accommodate	O
triple	O
-	O
helical	O
collagen	B-Complex
.	O

Here	O
we	O
report	O
that	O
collagenases	O
bind	O
and	O
locally	O
unwind	O
the	O
triple	O
-	O
helical	O
structure	O
before	O
hydrolyzing	O
the	O
peptide	O
bonds	O
.	O

Mutation	O
of	O
the	O
catalytically	O
essential	O
residue	O
Glu200	O
of	O
MMP	O
-	O
1	O
to	O
Ala	O
resulted	O
in	O
a	O
catalytically	O
inactive	O
enzyme	O
,	O
but	O
in	O
its	O
presence	O
noncollagenolytic	O
proteinases	O
digested	O
collagen	B-Complex
into	O
typical	O
3	O
/	O
4	O
and	O
1	O
/	O
4	O
fragments	O
,	O
indicating	O
that	O
the	O
MMP	O
-	O
1	O
(	O
E200A	O
)	O
mutant	O
unwinds	O
the	O
triple	O
-	O
helical	O
collagen	B-Complex
.	O

The	O
study	O
also	O
shows	O
that	O
MMP	O
-	O
1	O
preferentially	O
interacts	O
with	O
the	O
alpha2	O
(	O
I	O
)	O
chain	O
of	O
type	B-Complex
I	I-Complex
collagen	I-Complex
and	O
cleaves	O
the	O
three	O
alpha	O
chains	O
in	O
succession	O
.	O

Our	O
results	O
throw	O
light	O
on	O
the	O
basic	O
mechanisms	O
that	O
control	O
a	O
wide	O
range	O
of	O
biological	O
and	O
pathological	O
processes	O
associated	O
with	O
tissue	O
remodelling	O
.	O

Protein	O
-	O
protein	O
interactions	O
of	O
KChIP	O
proteins	O
and	O
Kv4	O
.	O
2	O
.	O

To	O
prove	O
heteromeric	O
assembly	O
of	O
KChIP	O
proteins	O
,	O
the	O
present	O
study	O
is	O
carried	O
out	O
.	O

The	O
results	O
of	O
chemical	O
crosslinking	O
and	O
pull	O
down	O
assay	O
revealed	O
that	O
KChIP1	O
,	O
KChIP2	O
.	O
1	O
,	O
and	O
KChIP2	O
.	O
2	O
could	O
form	O
homo	O
-	O
as	O
well	O
as	O
hetero	O
-	O
oligomer	O
,	O
and	O
this	O
oligomerization	O
exhibited	O
a	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
manner	O
.	O

Moreover	O
,	O
homomeric	O
and	O
heteromeric	O
assembly	O
of	O
KChIPs	O
did	O
not	O
perturb	O
their	O
interaction	O
with	O
Kv4	O
.	O
2	O
K	O
(	O
+	O
)	O
channel	O
,	O
indicating	O
that	O
the	O
region	O
associated	O
with	O
oligomerization	O
of	O
KChIPs	O
was	O
distinct	O
from	O
that	O
for	O
binding	O
with	O
Kv4	O
.	O
2	O
.	O

Together	O
with	O
previous	O
findings	O
that	O
the	O
net	O
effects	O
of	O
KChIP	O
proteins	O
on	O
the	O
molecular	O
properties	O
and	O
trafficking	O
of	O
Kv	O
channel	O
were	O
different	O
,	O
these	O
observations	O
open	O
a	O
fascinating	O
possibility	O
that	O
the	O
electrophysiological	O
properties	O
of	O
Kv	O
channel	O
may	O
be	O
differently	O
regulated	O
by	O
homomeric	O
and	O
heteromeric	O
assembly	O
of	O
KChIPs	O
.	O

Identification	O
of	O
residues	O
of	O
the	O
IFNAR1	O
chain	O
of	O
the	O
type	B-Complex
I	I-Complex
human	I-Complex
interferon	I-Complex
receptor	I-Complex
critical	O
for	O
ligand	O
binding	O
and	O
biological	O
activity	O
.	O

The	O
antiviral	O
and	O
antiproliferative	O
activities	O
of	O
human	O
type	O
I	O
interferons	O
(	O
IFNs	O
)	O
are	O
mediated	O
by	O
two	O
transmembrane	O
receptor	O
subunits	O
,	O
IFNAR1	O
and	O
IFNAR2	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
IFNAR1	O
in	O
IFN	O
binding	O
and	O
the	O
establishment	O
of	O
biological	O
activity	O
,	O
specific	O
residues	O
of	O
IFNAR1	O
were	O
mutated	O
.	O

Residues	O
(	O
62	O
)	O
FSSLKLNVY	O
(	O
70	O
)	O
of	O
the	O
S5	O
-	O
S6	O
loop	O
of	O
the	O
N	O
-	O
terminal	O
subdomain	O
of	O
IFNAR1	O
and	O
tryptophan	O
-	O
129	O
of	O
the	O
second	O
subdomain	O
of	O
IFNAR1	O
were	O
shown	O
to	O
be	O
crucial	O
for	O
IFN	O
-	O
alpha	O
binding	O
and	O
signaling	O
and	O
establishment	O
of	O
biological	O
activity	O
.	O

Mutagenesis	O
of	O
peptide	O
(	O
278	O
)	O
LRV	O
in	O
the	O
third	O
subdomain	O
shows	O
that	O
these	O
residues	O
are	O
critical	O
for	O
IFN	O
-	O
alpha	O
-	O
induced	O
biological	O
activity	O
but	O
not	O
for	O
ligand	O
binding	O
.	O

These	O
data	O
,	O
together	O
with	O
the	O
sequence	O
homology	O
of	O
IFNAR1	O
with	O
cytokine	O
receptors	O
of	O
known	O
structure	O
and	O
the	O
recently	O
resolved	O
NMR	O
structure	O
of	O
IFNAR2	O
,	O
led	O
to	O
the	O
establishment	O
of	O
a	O
three	O
-	O
dimensional	O
model	O
of	O
the	O
human	O
IFN	O
-	O
alpha	O
/	O
IFNAR1	O
/	O
IFNAR2	O
complex	O
.	O

This	O
model	O
predicts	O
that	O
following	O
binding	O
of	O
IFN	O
to	O
IFNAR1	O
and	O
IFNAR2	O
the	O
receptor	O
complex	O
assumes	O
a	O
"	O
closed	O
form	O
"	O
,	O
in	O
which	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
IFNAR1	O
acts	O
as	O
a	O
lid	O
,	O
resulting	O
in	O
the	O
activation	O
of	O
intracellular	O
kinases	O
.	O

Differences	O
in	O
the	O
primary	O
sequence	O
of	O
individual	O
IFN	O
-	O
alpha	O
subtypes	O
and	O
resulting	O
differences	O
in	O
binding	O
affinity	O
,	O
duration	O
of	O
ligand	O
/	O
receptor	O
association	O
,	O
or	O
both	O
would	O
explain	O
differences	O
in	O
intracellular	O
signal	O
intensities	O
and	O
biological	O
activity	O
observed	O
for	O
individual	O
IFN	O
-	O
alpha	O
subtypes	O
.	O

Disruption	O
of	O
the	O
Rb	O
-	O
-	O
Raf	O
-	O
1	O
interaction	O
inhibits	O
tumor	O
growth	O
and	O
angiogenesis	O
.	O

The	O
retinoblastoma	O
tumor	O
suppressor	O
protein	O
(	O
Rb	O
)	O
plays	O
a	O
vital	O
role	O
in	O
regulating	O
mammalian	O
cell	O
cycle	O
progression	O
and	O
inactivation	O
of	O
Rb	O
is	O
necessary	O
for	O
entry	O
into	O
S	O
phase	O
.	O

Rb	O
is	O
inactivated	O
by	O
phosphorylation	O
upon	O
growth	O
factor	O
stimulation	O
of	O
quiescent	O
cells	O
,	O
facilitating	O
the	O
transition	O
from	O
G	O
(	O
1	O
)	O
phase	O
to	O
S	O
phase	O
.	O

Although	O
the	O
signaling	O
events	O
after	O
growth	O
factor	O
stimulation	O
have	O
been	O
well	O
characterized	O
,	O
it	O
is	O
not	O
yet	O
clear	O
how	O
these	O
signals	O
contact	O
the	O
cell	O
cycle	O
machinery	O
.	O

We	O
had	O
found	O
previously	O
that	O
growth	O
factor	O
stimulation	O
of	O
quiescent	O
cells	O
lead	O
to	O
the	O
direct	O
binding	O
of	O
Raf	O
-	O
1	O
kinase	O
to	O
Rb	O
,	O
leading	O
to	O
its	O
inactivation	O
.	O

Here	O
we	O
show	O
that	O
the	O
Rb	O
-	O
Raf	O
-	O
1	O
interaction	O
occurs	O
prior	O
to	O
the	O
activation	O
of	O
cyclin	O
and	O
/	O
or	O
cyclin	O
-	O
dependent	O
kinases	O
and	O
facilitates	O
normal	O
cell	O
cycle	O
progression	O
.	O

Raf	O
-	O
1	O
-	O
mediated	O
inactivation	O
of	O
Rb	O
is	O
independent	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
cascade	O
,	O
as	O
well	O
as	O
cyclin	O
-	O
dependent	O
kinases	O
.	O

Binding	O
of	O
Raf	O
-	O
1	O
seemed	O
to	O
correlate	O
with	O
the	O
dissociation	O
of	O
the	O
chromatin	O
remodeling	O
protein	O
Brg1	O
from	O
Rb	O
.	O

Disruption	O
of	O
the	O
Rb	O
-	O
Raf	O
-	O
1	O
interaction	O
by	O
a	O
nine	O
-	O
amino	O
-	O
acid	O
peptide	O
inhibits	O
Rb	O
phosphorylation	O
,	O
cell	O
proliferation	O
,	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
mediated	O
capillary	O
tubule	O
formation	O
.	O

Delivery	O
of	O
this	O
peptide	O
by	O
a	O
carrier	O
molecule	O
led	O
to	O
a	O
79	O
%	O
reduction	O
in	O
tumor	O
volume	O
and	O
a	O
57	O
%	O
reduction	O
in	O
microvessel	O
formation	O
in	O
nude	O
mice	O
.	O

It	O
appears	O
that	O
Raf	O
-	O
1	O
links	O
mitogenic	O
signaling	O
to	O
Rb	O
and	O
that	O
disruption	O
of	O
this	O
interaction	O
could	O
aid	O
in	O
controlling	O
proliferative	O
disorders	O
.	O

TIFA	O
activates	O
IkappaB	B-Complex
kinase	I-Complex
(	O
IKK	B-Complex
)	O
by	O
promoting	O
oligomerization	O
and	O
ubiquitination	O
of	O
TRAF6	O
.	O

TRAF6	O
(	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factor	O
6	O
)	O
is	O
a	O
RING	O
(	O
really	O
interesting	O
new	O
gene	O
)	O
domain	O
ubiquitin	O
(	O
Ub	O
)	O
ligase	O
that	O
mediates	O
the	O
activation	O
of	O
protein	O
kinases	O
,	O
such	O
as	O
transforming	O
growth	O
factor	O
beta	O
-	O
activated	O
kinase	O
(	O
TAK1	O
)	O
and	O
IkappaB	B-Complex
kinase	I-Complex
(	O
IKK	B-Complex
)	O
,	O
by	O
catalyzing	O
the	O
formation	O
of	O
a	O
unique	O
polyubiquitin	O
chain	O
linked	O
through	O
Lys	O
-	O
63	O
of	O
Ub	O
.	O

Here	O
,	O
we	O
present	O
evidence	O
that	O
TIFA	O
(	O
TRAF	O
-	O
interacting	O
protein	O
with	O
a	O
forkhead	O
-	O
associated	O
domain	O
,	O
also	O
known	O
as	O
T2BP	O
)	O
activates	O
IKK	B-Complex
by	O
promoting	O
the	O
oligomerization	O
and	O
Ub	O
ligase	O
activity	O
of	O
TRAF6	O
.	O

We	O
show	O
that	O
recombinant	O
TIFA	O
protein	O
,	O
but	O
not	O
TRAF6	O
-	O
binding	O
-	O
defective	O
mutant	O
,	O
can	O
activate	O
IKK	B-Complex
in	O
crude	O
cytosolic	O
extracts	O
.	O

Furthermore	O
,	O
TIFA	O
activates	O
IKK	B-Complex
in	O
an	O
in	O
vitro	O
reconstitution	O
system	O
consisting	O
of	O
purified	O
proteins	O
,	O
including	O
TRAF6	O
,	O
the	O
TAK1	O
kinase	O
complex	O
,	O
and	O
Ub	O
-	O
conjugating	O
enzyme	O
complex	O
Ubc13	O
-	O
Uev1A	O
.	O

Interestingly	O
,	O
a	O
fraction	O
of	O
recombinant	O
TIFA	O
protein	O
exists	O
as	O
high	O
-	O
molecular	O
-	O
weight	O
oligomers	O
,	O
and	O
only	O
these	O
oligomeric	O
forms	O
of	O
TIFA	O
can	O
activate	O
IKK	B-Complex
.	O

Importantly	O
,	O
TIFA	O
induces	O
the	O
oligomerization	O
and	O
polyubiquitination	O
of	O
TRAF6	O
,	O
which	O
leads	O
to	O
the	O
activation	O
of	O
TAK1	O
and	O
IKK	B-Complex
through	O
a	O
proteasome	B-Complex
-	O
independent	O
mechanism	O
.	O

Multiple	O
activities	O
contribute	O
to	O
Pc2	O
E3	O
function	O
.	O

Pc2	O
is	O
a	O
polycomb	O
protein	O
,	O
which	O
has	O
SUMO	O
E3	O
activity	O
for	O
the	O
corepressors	O
CtBP	O
and	O
CtBP2	O
.	O

Here	O
we	O
demonstrate	O
that	O
,	O
in	O
vivo	O
,	O
Pc2	O
adapter	O
function	O
contributes	O
to	O
enhancement	O
of	O
CtBP	O
sumoylation	O
.	O

Mutation	O
of	O
the	O
CtBP	O
binding	O
site	O
on	O
Pc2	O
abolishes	O
E3	O
activity	O
toward	O
CtBP	O
.	O

However	O
,	O
a	O
carboxyl	O
-	O
terminal	O
fragment	O
of	O
Pc2	O
that	O
recruits	O
both	O
Ubc9	O
and	O
CtBP	O
lacks	O
E3	O
activity	O
.	O

We	O
identify	O
a	O
second	O
domain	O
,	O
which	O
,	O
when	O
coexpressed	O
with	O
the	O
carboxyl	O
-	O
terminal	O
adapter	O
region	O
,	O
restores	O
E3	O
function	O
.	O

In	O
vitro	O
,	O
this	O
domain	O
has	O
E3	O
activity	O
in	O
isolation	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
functional	O
domain	O
,	O
and	O
that	O
adapter	O
function	O
is	O
required	O
to	O
selectively	O
corecruit	O
E2	O
and	O
substrate	O
in	O
vivo	O
.	O

These	O
results	O
demonstrate	O
the	O
presence	O
of	O
two	O
domains	O
in	O
Pc2	O
that	O
contribute	O
to	O
full	O
in	O
vivo	O
E3	O
activity	O
,	O
and	O
suggest	O
that	O
SUMO	O
E3s	O
are	O
more	O
than	O
simple	O
platforms	O
to	O
which	O
E2	O
and	O
substrate	O
bind	O
.	O

Structures	O
of	O
the	O
SUMO	O
E1	O
provide	O
mechanistic	O
insights	O
into	O
SUMO	O
activation	O
and	O
E2	O
recruitment	O
to	O
E1	O
.	O

E1	O
enzymes	O
facilitate	O
conjugation	O
of	O
ubiquitin	O
and	O
ubiquitin	O
-	O
like	O
proteins	O
through	O
adenylation	O
,	O
thioester	O
transfer	O
within	O
E1	O
,	O
and	O
thioester	O
transfer	O
from	O
E1	O
to	O
E2	O
conjugating	O
proteins	O
.	O

Structures	O
of	O
human	O
heterodimeric	O
Sae1	O
/	O
Sae2	O
-	O
Mg	O
.	O
ATP	O
and	O
Sae1	O
/	O
Sae2	O
-	O
SUMO	O
-	O
1	O
-	O
Mg	O
.	O
ATP	O
complexes	O
were	O
determined	O
at	O
2	O
.	O
2	O
and	O
2	O
.	O
75	O
A	O
resolution	O
,	O
respectively	O
.	O

Despite	O
the	O
presence	O
of	O
Mg	O
.	O
ATP	O
,	O
the	O
Sae1	O
/	O
Sae2	O
-	O
SUMO	O
-	O
1	O
-	O
Mg	O
.	O
ATP	O
structure	O
reveals	O
a	O
substrate	O
complex	O
insomuch	O
as	O
the	O
SUMO	O
C	O
-	O
terminus	O
remains	O
unmodified	O
within	O
the	O
adenylation	O
site	O
and	O
35	O
A	O
from	O
the	O
catalytic	O
cysteine	O
,	O
suggesting	O
that	O
additional	O
changes	O
within	O
the	O
adenylation	O
site	O
may	O
be	O
required	O
to	O
facilitate	O
chemistry	O
prior	O
to	O
adenylation	O
and	O
thioester	O
transfer	O
.	O

A	O
mechanism	O
for	O
E2	O
recruitment	O
to	O
E1	O
is	O
suggested	O
by	O
biochemical	O
and	O
genetic	O
data	O
,	O
each	O
of	O
which	O
supports	O
a	O
direct	O
role	O
for	O
the	O
E1	O
C	O
-	O
terminal	O
ubiquitin	O
-	O
like	O
domain	O
for	O
E2	O
recruitment	O
during	O
conjugation	O
.	O

Cited1	O
is	O
a	O
bifunctional	O
transcriptional	O
cofactor	O
that	O
regulates	O
early	O
nephronic	O
patterning	O
.	O

In	O
a	O
screen	O
to	O
identify	O
factors	O
that	O
regulate	O
the	O
conversion	O
of	O
mesenchyme	O
to	O
epithelium	O
during	O
the	O
early	O
stages	O
of	O
nephrogenesis	O
,	O
it	O
was	O
found	O
that	O
the	O
Smad4	O
-	O
interacting	O
transcriptional	O
cofactor	O
,	O
Cited1	O
,	O
is	O
expressed	O
in	O
the	O
condensed	O
cap	O
mesenchyme	O
surrounding	O
the	O
tip	O
of	O
the	O
ureteric	O
bud	O
(	O
UB	O
)	O
,	O
is	O
downregulated	O
after	O
differentiation	O
into	O
epithelia	O
,	O
and	O
has	O
the	O
capacity	O
to	O
block	O
UB	O
branching	O
and	O
epithelial	O
morphogenesis	O
in	O
cultured	O
metanephroi	O
.	O

Cited1	O
represses	O
Wnt	O
/	O
beta	O
-	O
catenin	O
but	O
activates	O
Smad4	O
-	O
dependent	O
transcription	O
involved	O
in	O
TGF	O
-	O
beta	O
and	O
Bmp	O
signaling	O
.	O

By	O
modifying	O
these	O
pathways	O
,	O
Cited1	O
may	O
coordinate	O
cellular	O
differentiation	O
and	O
survival	O
signals	O
that	O
regulate	O
nephronic	O
patterning	O
in	O
the	O
metanephros	O
.	O

Requirement	O
of	O
Cul3	O
for	O
axonal	O
arborization	O
and	O
dendritic	O
elaboration	O
in	O
Drosophila	O
mushroom	O
body	O
neurons	O
.	O

Cul3	O
belongs	O
to	O
the	O
family	O
of	O
cullin	O
proteins	O
,	O
which	O
function	O
as	O
scaffold	O
proteins	O
of	O
E3	O
ubiquitin	O
ligase	O
complexes	O
.	O

Here	O
we	O
show	O
cell	O
-	O
autonomous	O
involvement	O
of	O
Cul3	O
in	O
axonal	O
arborization	O
and	O
dendritic	O
elaboration	O
of	O
Drosophila	O
mushroom	O
body	O
neurons	O
.	O

Cul3	O
mutant	O
neurons	O
are	O
defective	O
in	O
terminal	O
morphogenesis	O
of	O
neurites	O
.	O

Interestingly	O
,	O
mutant	O
axons	O
often	O
terminate	O
around	O
branching	O
points	O
.	O

In	O
addition	O
,	O
dendritic	O
elaboration	O
is	O
severely	O
affected	O
in	O
Cul3	O
mutant	O
neurons	O
.	O

However	O
,	O
loss	O
of	O
Cul3	O
function	O
does	O
not	O
affect	O
extension	O
of	O
the	O
axons	O
that	O
rarely	O
arborize	O
.	O

Function	O
of	O
cullin	O
-	O
type	O
proteins	O
has	O
been	O
shown	O
to	O
require	O
covalent	O
attachment	O
of	O
Nedd8	O
(	O
neural	O
precursor	O
cell	O
-	O
expressed	O
developmentally	O
downregulated	O
)	O
,	O
a	O
ubiquitin	O
-	O
like	O
protein	O
.	O

Consistent	O
with	O
this	O
notion	O
,	O
Cul3	O
is	O
inactivated	O
by	O
a	O
mutation	O
in	O
its	O
conserved	O
neddylation	O
site	O
,	O
and	O
Nedd8	O
mutant	O
neurons	O
exhibit	O
similar	O
neuronal	O
morphogenetic	O
defects	O
.	O

Together	O
,	O
Cul3	O
plays	O
an	O
essential	O
role	O
in	O
both	O
axonal	O
arborization	O
and	O
proper	O
elaboration	O
of	O
dendrites	O
and	O
may	O
require	O
neddylation	O
for	O
its	O
proper	O
function	O
.	O

Biochemical	O
properties	O
of	O
purified	O
human	O
retinol	O
dehydrogenase	O
12	O
(	O
RDH12	O
)	O
:	O
catalytic	O
efficiency	O
toward	O
retinoids	O
and	O
C9	O
aldehydes	O
and	O
effects	O
of	O
cellular	O
retinol	O
-	O
binding	O
protein	O
type	O
I	O
(	O
CRBPI	O
)	O
and	O
cellular	O
retinaldehyde	O
-	O
binding	O
protein	O
(	O
CRALBP	O
)	O
on	O
the	O
oxidation	O
and	O
reduction	O
of	O
retinoids	O
.	O

Retinol	O
dehydrogenase	O
12	O
(	O
RDH12	O
)	O
is	O
a	O
novel	O
member	O
of	O
the	O
short	O
-	O
chain	O
dehydrogenase	O
/	O
reductase	O
superfamily	O
of	O
proteins	O
that	O
was	O
recently	O
linked	O
to	O
Leber	O
'	O
s	O
congenital	O
amaurosis	O
3	O
(	O
LCA	O
)	O
.	O

We	O
report	O
the	O
first	O
biochemical	O
characterization	O
of	O
purified	O
human	O
RDH12	O
and	O
analysis	O
of	O
its	O
expression	O
in	O
human	O
tissues	O
.	O

RDH12	O
exhibits	O
approximately	O
2000	O
-	O
fold	O
lower	O
K	O
(	O
m	O
)	O
values	O
for	O
NADP	O
(	O
+	O
)	O
and	O
NADPH	O
than	O
for	O
NAD	O
(	O
+	O
)	O
and	O
NADH	O
and	O
recognizes	O
both	O
retinoids	O
and	O
lipid	O
peroxidation	O
products	O
(	O
C	O
(	O
9	O
)	O
aldehydes	O
)	O
as	O
substrates	O
.	O

The	O
k	O
(	O
cat	O
)	O
values	O
of	O
RDH12	O
for	O
retinaldehydes	O
and	O
C	O
(	O
9	O
)	O
aldehydes	O
are	O
similar	O
,	O
but	O
the	O
K	O
(	O
m	O
)	O
values	O
are	O
,	O
in	O
general	O
,	O
lower	O
for	O
retinoids	O
.	O

The	O
enzyme	O
exhibits	O
the	O
highest	O
catalytic	O
efficiency	O
for	O
all	O
-	O
trans	O
-	O
retinal	O
(	O
k	O
(	O
cat	O
)	O
/	O
K	O
(	O
m	O
)	O
approximately	O
900	O
min	O
(	O
-	O
)	O
(	O
1	O
)	O
microM	O
(	O
-	O
)	O
(	O
1	O
)	O
)	O
,	O
followed	O
by	O
11	O
-	O
cis	O
-	O
retinal	O
(	O
450	O
min	O
(	O
-	O
)	O
(	O
1	O
)	O
mM	O
(	O
-	O
)	O
(	O
1	O
)	O
)	O
and	O
9	O
-	O
cis	O
-	O
retinal	O
(	O
100	O
min	O
(	O
-	O
)	O
(	O
1	O
)	O
mM	O
(	O
-	O
)	O
(	O
1	O
)	O
)	O
.	O

Analysis	O
of	O
RDH12	O
activity	O
toward	O
retinoids	O
in	O
the	O
presence	O
of	O
cellular	O
retinol	O
-	O
binding	O
protein	O
(	O
CRBP	O
)	O
type	O
I	O
or	O
cellular	O
retinaldehyde	O
-	O
binding	O
protein	O
(	O
CRALBP	O
)	O
suggests	O
that	O
RDH12	O
utilizes	O
the	O
unbound	O
forms	O
of	O
all	O
-	O
trans	O
-	O
and	O
11	O
-	O
cis	O
-	O
retinoids	O
.	O

As	O
a	O
result	O
,	O
the	O
widely	O
expressed	O
CRBPI	O
,	O
which	O
binds	O
all	O
-	O
trans	O
-	O
retinol	O
with	O
much	O
higher	O
affinity	O
than	O
all	O
-	O
trans	O
-	O
retinaldehyde	O
,	O
restricts	O
the	O
oxidation	O
of	O
all	O
-	O
trans	O
-	O
retinol	O
by	O
RDH12	O
,	O
but	O
has	O
little	O
effect	O
on	O
the	O
reduction	O
of	O
all	O
-	O
trans	O
-	O
retinaldehyde	O
,	O
and	O
CRALBP	O
inhibits	O
the	O
reduction	O
of	O
11	O
-	O
cis	O
-	O
retinal	O
stronger	O
than	O
the	O
oxidation	O
of	O
11	O
-	O
cis	O
-	O
retinol	O
,	O
in	O
accord	O
with	O
its	O
higher	O
affinity	O
for	O
11	O
-	O
cis	O
-	O
retinal	O
.	O

Together	O
,	O
the	O
tissue	O
distribution	O
of	O
RDH12	O
and	O
its	O
catalytic	O
properties	O
suggest	O
that	O
,	O
in	O
most	O
tissues	O
,	O
RDH12	O
primarily	O
contributes	O
to	O
the	O
reduction	O
of	O
all	O
-	O
trans	O
-	O
retinaldehyde	O
;	O
however	O
,	O
at	O
saturating	O
concentrations	O
of	O
peroxidic	O
aldehydes	O
in	O
the	O
cells	O
undergoing	O
oxidative	O
stress	O
,	O
for	O
example	O
,	O
photoreceptors	O
,	O
RDH12	O
might	O
also	O
play	O
a	O
role	O
in	O
detoxification	O
of	O
lipid	O
peroxidation	O
products	O
.	O

Vav	O
-	O
family	O
proteins	O
in	O
T	O
-	O
cell	O
signalling	O
.	O

The	O
Vav	O
family	O
proteins	O
(	O
Vav1	O
,	O
Vav2	O
,	O
Vav3	O
)	O
are	O
cytoplasmic	O
guanine	O
nucleotide	O
exchange	O
factors	O
(	O
GEFs	O
)	O
for	O
Rho	O
-	O
family	O
GTPases	O
.	O

T	B-Complex
-	I-Complex
cell	I-Complex
antigen	I-Complex
receptor	I-Complex
(	O
TCR	B-Complex
)	O
signalling	O
results	O
in	O
the	O
tyrosine	O
phosphorylation	O
of	O
Vav	O
proteins	O
and	O
hence	O
their	O
activation	O
.	O

Results	O
from	O
mice	O
deficient	O
in	O
one	O
or	O
more	O
Vav	O
proteins	O
has	O
shown	O
that	O
they	O
play	O
critical	O
roles	O
in	O
T	O
-	O
cell	O
development	O
and	O
activation	O
.	O

Vav1	O
is	O
required	O
for	O
TCR	B-Complex
-	O
induced	O
calcium	O
flux	O
,	O
activation	O
of	O
the	O
ERK	O
MAP	O
kinase	O
pathway	O
,	O
activation	O
of	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
transcription	O
factor	O
,	O
inside	O
-	O
out	O
activation	O
of	O
the	O
integrin	O
LFA	O
-	O
1	O
,	O
TCR	B-Complex
clustering	O
,	O
and	O
polarisation	O
of	O
the	O
T	O
cell	O
.	O

Although	O
many	O
of	O
these	O
processes	O
may	O
require	O
the	O
GEF	O
activity	O
of	O
Vav1	O
,	O
it	O
is	O
possible	O
that	O
Vav1	O
also	O
has	O
adaptor	O
-	O
like	O
functions	O
.	O

Recent	O
evidence	O
suggests	O
that	O
Vav1	O
might	O
also	O
function	O
in	O
the	O
nucleus	O
,	O
where	O
it	O
undergoes	O
arginine	O
methylation	O
.	O

An	O
emerging	O
theme	O
is	O
that	O
Vav	O
proteins	O
may	O
have	O
important	O
functions	O
downstream	O
of	O
receptors	O
other	O
than	O
the	O
TCR	B-Complex
,	O
such	O
as	O
integrins	O
and	O
chemokine	O
receptors	O
.	O

Insights	O
into	O
Lafora	O
disease	O
:	O
malin	O
is	O
an	O
E3	O
ubiquitin	O
ligase	O
that	O
ubiquitinates	O
and	O
promotes	O
the	O
degradation	O
of	O
laforin	O
.	O

Lafora	O
disease	O
(	O
LD	O
)	O
is	O
a	O
fatal	O
form	O
of	O
progressive	O
myoclonus	O
epilepsy	O
caused	O
by	O
recessive	O
mutations	O
in	O
either	O
a	O
gene	O
encoding	O
a	O
dual	O
-	O
specificity	O
phosphatase	O
,	O
known	O
as	O
laforin	O
,	O
or	O
a	O
recently	O
identified	O
gene	O
encoding	O
the	O
protein	O
known	O
as	O
malin	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
malin	O
is	O
a	O
single	O
subunit	O
E3	O
ubiquitin	O
(	O
Ub	O
)	O
ligase	O
and	O
that	O
its	O
RING	O
domain	O
is	O
necessary	O
and	O
sufficient	O
to	O
mediate	O
ubiquitination	O
.	O

Additionally	O
,	O
malin	O
interacts	O
with	O
and	O
polyubiquitinates	O
laforin	O
,	O
leading	O
to	O
its	O
degradation	O
.	O

Missense	O
mutations	O
in	O
malin	O
that	O
are	O
present	O
in	O
LD	O
patients	O
abolish	O
its	O
ability	O
to	O
polyubiquitinate	O
and	O
signal	O
the	O
degradation	O
of	O
laforin	O
.	O

Our	O
results	O
demonstrate	O
that	O
laforin	O
is	O
a	O
physiologic	O
substrate	O
of	O
malin	O
,	O
and	O
we	O
propose	O
possible	O
models	O
to	O
explain	O
how	O
recessive	O
mutations	O
in	O
either	O
malin	O
or	O
laforin	O
result	O
in	O
LD	O
.	O

Furthermore	O
,	O
these	O
data	O
distinguish	O
malin	O
as	O
an	O
E3	O
Ub	O
ligase	O
whose	O
activity	O
is	O
necessary	O
to	O
prevent	O
a	O
neurodegenerative	O
disease	O
that	O
involves	O
formation	O
of	O
nonproteinacious	O
inclusion	O
bodies	O
.	O

Intracellular	O
trafficking	O
of	O
vitamin	O
E	O
in	O
hepatocytes	O
:	O
the	O
role	O
of	O
tocopherol	O
transfer	O
protein	O
.	O

The	O
term	O
vitamin	O
E	O
denotes	O
a	O
family	O
of	O
tocopherols	O
and	O
tocotrienols	O
,	O
plant	O
lipids	O
that	O
are	O
essential	O
for	O
vertebrate	O
fertility	O
and	O
health	O
.	O

The	O
principal	O
form	O
of	O
vitamin	O
E	O
found	O
in	O
humans	O
,	O
RRR	O
-	O
alpha	O
-	O
tocopherol	O
(	O
TOH	O
)	O
,	O
is	O
thought	O
to	O
protect	O
cells	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
quench	O
free	O
radicals	O
,	O
and	O
functions	O
as	O
the	O
main	O
lipid	O
-	O
soluble	O
antioxidant	O
.	O

Regulation	O
of	O
vitamin	O
E	O
homeostasis	O
occurs	O
in	O
the	O
liver	O
,	O
where	O
TOH	O
is	O
selectively	O
retained	O
while	O
other	O
forms	O
of	O
vitamin	O
E	O
are	O
degraded	O
.	O

Through	O
the	O
action	O
of	O
tocopherol	O
transfer	O
protein	O
(	O
TTP	O
)	O
,	O
TOH	O
is	O
then	O
secreted	O
from	O
the	O
liver	O
into	O
circulating	O
lipoproteins	O
that	O
deliver	O
the	O
vitamin	O
to	O
target	O
tissues	O
.	O

Presently	O
,	O
very	O
little	O
is	O
known	O
regarding	O
the	O
intracellular	O
transport	O
of	O
vitamin	O
E	O
.	O

We	O
utilized	O
biochemical	O
,	O
pharmacological	O
,	O
and	O
microscopic	O
approaches	O
to	O
study	O
this	O
process	O
in	O
cultured	O
hepatocytes	O
.	O

We	O
observe	O
that	O
tocopherol	O
-	O
HDL	B-Complex
complexes	O
are	O
efficiently	O
internalized	O
through	O
scavenger	O
receptor	O
class	O
B	O
type	O
I	O
.	O

Once	O
internalized	O
,	O
tocopherol	O
arrives	O
within	O
approximately	O
30	O
min	O
at	O
intracellular	O
vesicular	O
organelles	O
,	O
where	O
it	O
co	O
-	O
localizes	O
with	O
TTP	O
,	O
and	O
with	O
a	O
marker	O
of	O
the	O
lysosomal	O
compartment	O
(	O
LAMP1	O
)	O
,	O
before	O
being	O
transported	O
to	O
the	O
plasma	O
membrane	O
in	O
a	O
TTP	O
-	O
dependent	O
manner	O
.	O

We	O
further	O
show	O
that	O
intracellular	O
processing	O
of	O
tocopherol	O
involves	O
a	O
functional	O
interaction	O
between	O
TTP	O
and	O
an	O
ABC	O
-	O
type	O
transporter	O
.	O

The	O
kinesinlike	O
protein	O
Subito	O
contributes	O
to	O
central	O
spindle	O
assembly	O
and	O
organization	O
of	O
the	O
meiotic	O
spindle	O
in	O
Drosophila	O
oocytes	O
.	O

In	O
the	O
oocytes	O
of	O
many	O
species	O
,	O
bipolar	O
spindles	O
form	O
in	O
the	O
absence	O
of	O
centrosomes	O
.	O

Drosophila	O
melanogaster	O
oocyte	O
chromosomes	O
have	O
a	O
major	O
role	O
in	O
nucleating	O
microtubules	O
,	O
which	O
precedes	O
the	O
bundling	O
and	O
assembly	O
of	O
these	O
microtubules	O
into	O
a	O
bipolar	O
spindle	O
.	O

Here	O
we	O
present	O
evidence	O
that	O
a	O
region	O
similar	O
to	O
the	O
anaphase	O
central	O
spindle	O
functions	O
to	O
organize	O
acentrosomal	O
spindles	O
.	O

Subito	O
mutants	O
are	O
characterized	O
by	O
the	O
formation	O
of	O
tripolar	O
or	O
monopolar	O
spindles	O
and	O
nondisjunction	O
of	O
homologous	O
chromosomes	O
at	O
meiosis	O
I	O
.	O

Subito	O
encodes	O
a	O
kinesinlike	O
protein	O
and	O
associates	O
with	O
the	O
meiotic	O
central	O
spindle	O
,	O
consistent	O
with	O
its	O
classification	O
in	O
the	O
Kinesin	O
6	O
/	O
MKLP1	O
family	O
.	O

This	O
class	O
of	O
proteins	O
is	O
known	O
to	O
be	O
required	O
for	O
cytokinesis	O
,	O
but	O
our	O
results	O
suggest	O
a	O
new	O
function	O
in	O
spindle	O
formation	O
.	O

The	O
meiotic	O
central	O
spindle	O
appears	O
during	O
prometaphase	O
and	O
includes	O
passenger	O
complex	O
proteins	O
such	O
as	O
AurB	O
and	O
Incenp	O
.	O

Unlike	O
mitotic	O
cells	O
,	O
the	O
passenger	O
proteins	O
do	O
not	O
associate	O
with	O
centromeres	O
before	O
anaphase	O
.	O

In	O
the	O
absence	O
of	O
Subito	O
,	O
central	O
spindle	O
formation	O
is	O
defective	O
and	O
AurB	O
and	O
Incenp	O
fail	O
to	O
properly	O
localize	O
.	O

We	O
propose	O
that	O
Subito	O
is	O
required	O
for	O
establishing	O
and	O
/	O
or	O
maintaining	O
the	O
central	O
spindle	O
in	O
Drosophila	O
oocytes	O
,	O
and	O
this	O
substitutes	O
for	O
the	O
role	O
of	O
centrosomes	O
in	O
organizing	O
the	O
bipolar	O
spindle	O
.	O

The	O
adaptor	O
protein	O
3BP2	O
binds	O
human	O
CD244	O
and	O
links	O
this	O
receptor	O
to	O
Vav	O
signaling	O
,	O
ERK	O
activation	O
,	O
and	O
NK	O
cell	O
killing	O
.	O

Adaptor	O
proteins	O
,	O
molecules	O
that	O
mediate	O
intermolecular	O
interactions	O
,	O
are	O
crucial	O
for	O
cellular	O
activation	O
.	O

The	O
adaptor	O
3BP2	O
has	O
been	O
shown	O
to	O
positively	O
regulate	O
NK	O
cell	O
-	O
mediated	O
cytotoxicity	O
.	O

In	O
this	O
study	O
we	O
present	O
evidence	O
for	O
a	O
physical	O
interaction	O
between	O
3BP2	O
and	O
the	O
CD244	O
receptor	O
.	O

CD244	O
,	O
a	O
member	O
of	O
the	O
CD150	O
family	O
,	O
is	O
a	O
cell	O
surface	O
protein	O
expressed	O
on	O
NK	O
,	O
CD8	O
+	O
T	O
,	O
and	O
myeloid	O
cells	O
.	O

CD244	O
interacts	O
via	O
its	O
Src	O
homology	O
2	O
domain	O
with	O
the	O
X	O
-	O
linked	O
lymphoproliferative	O
disease	O
gene	O
product	O
signaling	O
lymphocytic	O
activation	O
molecule	O
-	O
associated	O
protein	O
(	O
SAP	O
)	O
/	O
SH2	O
domain	O
protein	O
1A	O
.	O

3BP2	O
interacts	O
with	O
human	O
but	O
not	O
murine	O
CD244	O
.	O

CD244	O
-	O
3BP2	O
interaction	O
was	O
direct	O
and	O
regulated	O
by	O
phosphorylation	O
,	O
as	O
shown	O
by	O
a	O
three	O
-	O
hybrid	O
analysis	O
in	O
yeast	O
and	O
NK	O
cells	O
.	O

Tyr337	O
on	O
CD244	O
,	O
part	O
of	O
a	O
consensus	O
motif	O
for	O
SAP	O
/	O
SH2	O
domain	O
protein	O
1A	O
binding	O
,	O
was	O
critical	O
for	O
the	O
3BP2	O
interaction	O
.	O

Although	O
mutation	O
of	O
Tyr337	O
to	O
phenylalanine	O
abrogated	O
human	O
3BP2	O
binding	O
,	O
we	O
still	O
observed	O
SAP	O
association	O
,	O
indicating	O
that	O
this	O
motif	O
is	O
not	O
essential	O
for	O
SAP	O
recruitment	O
.	O

CD244	O
ligation	O
induced	O
3BP2	O
phosphorylation	O
and	O
Vav	O
-	O
1	O
recruitment	O
.	O

Overexpression	O
of	O
3BP2	O
led	O
to	O
an	O
increase	O
in	O
the	O
magnitude	O
and	O
duration	O
of	O
ERK	O
activation	O
,	O
after	O
CD244	O
triggering	O
.	O

This	O
enhancement	O
was	O
concomitant	O
with	O
an	O
increase	O
in	O
cytotoxicity	O
due	O
to	O
CD244	O
ligation	O
.	O

However	O
,	O
no	O
differences	O
in	O
IFN	O
-	O
gamma	O
secretion	O
were	O
found	O
when	O
normal	O
and	O
3BP2	O
-	O
transfected	O
cells	O
were	O
compared	O
.	O

These	O
results	O
indicate	O
that	O
CD244	O
-	O
3BP2	O
association	O
regulates	O
cytolytic	O
function	O
but	O
not	O
IFN	O
-	O
gamma	O
release	O
,	O
reinforcing	O
the	O
hypothesis	O
that	O
,	O
in	O
humans	O
,	O
CD244	O
-	O
mediated	O
cytotoxicity	O
and	O
IFN	O
-	O
gamma	O
release	O
involve	O
distinct	O
NK	O
pathways	O
.	O

Structural	O
basis	O
of	O
the	O
Cks1	O
-	O
dependent	O
recognition	O
of	O
p27	O
(	O
Kip1	O
)	O
by	O
the	O
SCF	B-Complex
(	I-Complex
Skp2	I-Complex
)	I-Complex
ubiquitin	I-Complex
ligase	I-Complex
.	O

The	O
ubiquitin	O
-	O
mediated	O
proteolysis	O
of	O
the	O
Cdk2	O
inhibitor	O
p27	O
(	O
Kip1	O
)	O
plays	O
a	O
central	O
role	O
in	O
cell	O
cycle	O
progression	O
,	O
and	O
enhanced	O
degradation	O
of	O
p27	O
(	O
Kip1	O
)	O
is	O
associated	O
with	O
many	O
common	O
cancers	O
.	O

Proteolysis	O
of	O
p27	O
(	O
Kip1	O
)	O
is	O
triggered	O
by	O
Thr187	O
phosphorylation	O
,	O
which	O
leads	O
to	O
the	O
binding	O
of	O
the	O
SCF	B-Complex
(	I-Complex
Skp2	I-Complex
)	I-Complex
(	O
Skp1	O
-	O
Cul1	O
-	O
Rbx1	O
-	O
Skp2	O
)	O
ubiquitin	O
ligase	O
complex	O
.	O

Unlike	O
other	O
known	O
SCF	B-Complex
substrates	O
,	O
p27	O
(	O
Kip1	O
)	O
ubiquitination	O
also	O
requires	O
the	O
accessory	O
protein	O
Cks1	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
Skp1	O
-	O
Skp2	O
-	O
Cks1	O
complex	O
bound	O
to	O
a	O
p27	O
(	O
Kip1	O
)	O
phosphopeptide	O
shows	O
that	O
Cks1	O
binds	O
to	O
the	O
leucine	O
-	O
rich	O
repeat	O
(	O
LRR	O
)	O
domain	O
and	O
C	O
-	O
terminal	O
tail	O
of	O
Skp2	O
,	O
whereas	O
p27	O
(	O
Kip1	O
)	O
binds	O
to	O
both	O
Cks1	O
and	O
Skp2	O
.	O

The	O
phosphorylated	O
Thr187	O
side	O
chain	O
of	O
p27	O
(	O
Kip1	O
)	O
is	O
recognized	O
by	O
a	O
Cks1	O
phosphate	O
binding	O
site	O
,	O
whereas	O
the	O
side	O
chain	O
of	O
an	O
invariant	O
Glu185	O
inserts	O
into	O
the	O
interface	O
between	O
Skp2	O
and	O
Cks1	O
,	O
interacting	O
with	O
both	O
.	O

The	O
structure	O
and	O
biochemical	O
data	O
support	O
the	O
proposed	O
model	O
that	O
Cdk2	O
-	O
cyclin	O
A	O
contributes	O
to	O
the	O
recruitment	O
of	O
p27	O
(	O
Kip1	O
)	O
to	O
the	O
SCF	B-Complex
(	I-Complex
Skp2	I-Complex
)	I-Complex
-	O
Cks1	O
complex	O
.	O

Egr	O
-	O
1	O
induces	O
the	O
expression	O
of	O
its	O
corepressor	O
nab2	O
by	O
activation	O
of	O
the	O
nab2	O
promoter	O
thereby	O
establishing	O
a	O
negative	O
feedback	O
loop	O
.	O

The	O
transcription	O
factor	O
Egr	O
-	O
1	O
regulates	O
the	O
expression	O
of	O
numerous	O
genes	O
involved	O
in	O
differentiation	O
,	O
growth	O
,	O
and	O
in	O
response	O
to	O
environmental	O
signals	O
.	O

Egr	O
-	O
1	O
activity	O
is	O
modulated	O
in	O
part	O
through	O
the	O
binding	O
of	O
corepressors	O
Nab1	O
and	O
Nab2	O
.	O

Nab2	O
appears	O
crucial	O
for	O
controlling	O
Egr	O
-	O
1	O
-	O
mediated	O
transactivation	O
because	O
it	O
is	O
a	O
delayed	O
early	O
response	O
gene	O
,	O
induced	O
by	O
the	O
same	O
stimuli	O
that	O
induce	O
the	O
immediate	O
early	O
gene	O
Egr	O
-	O
1	O
.	O

To	O
identify	O
important	O
elements	O
regulating	O
Nab2	O
expression	O
,	O
we	O
cloned	O
the	O
human	O
Nab2	O
gene	O
and	O
investigated	O
the	O
5	O
'	O
-	O
region	O
.	O

The	O
TATA	O
-	O
and	O
initiator	O
-	O
less	O
Nab2	O
promoter	O
,	O
located	O
from	O
-	O
679	O
to	O
-	O
74	O
bp	O
,	O
contains	O
a	O
total	O
of	O
11	O
Egr	O
binding	O
sites	O
,	O
including	O
a	O
cluster	O
of	O
multiple	O
overlapping	O
Egr	O
/	O
Sp1	O
sites	O
between	O
-	O
329	O
and	O
-	O
260	O
bp	O
.	O

This	O
region	O
is	O
critical	O
for	O
basal	O
promoter	O
activity	O
as	O
well	O
as	O
for	O
maximum	O
induction	O
by	O
phorbol	O
esters	O
.	O

Electromobility	O
shifts	O
show	O
that	O
Sp1	O
binds	O
to	O
this	O
region	O
in	O
normal	O
and	O
stimulated	O
cells	O
,	O
whereas	O
stimulation	O
induces	O
binding	O
of	O
Egr	O
-	O
1	O
.	O

In	O
addition	O
Egr	O
-	O
1	O
activates	O
the	O
Nab2	O
promoter	O
in	O
a	O
pattern	O
similar	O
to	O
phorbol	O
esters	O
,	O
suggesting	O
that	O
Egr	O
-	O
1	O
is	O
a	O
major	O
inducer	O
of	O
protein	O
kinase	O
C	O
-	O
mediated	O
Nab2	O
induction	O
.	O

Depletion	O
of	O
Egr	O
-	O
1	O
by	O
each	O
of	O
two	O
distinct	O
Egr	O
-	O
1	O
short	O
-	O
interfering	O
RNAs	O
reduces	O
Nab2	O
expression	O
and	O
inducibility	O
,	O
confirming	O
that	O
Egr	O
-	O
1	O
is	O
an	O
important	O
regulator	O
of	O
Nab2	O
expression	O
.	O

Transfection	O
experiments	O
show	O
that	O
Egr	O
-	O
1	O
-	O
induced	O
Nab2	O
promoter	O
activity	O
is	O
itself	O
repressed	O
by	O
Nab2	O
.	O

These	O
results	O
indicate	O
that	O
Egr	O
-	O
1	O
mediates	O
the	O
induction	O
of	O
its	O
own	O
repressor	O
,	O
thereby	O
preventing	O
a	O
permanent	O
transactivation	O
of	O
Egr	O
-	O
1	O
target	O
genes	O
and	O
a	O
damaging	O
overreaction	O
in	O
response	O
to	O
environmental	O
signals	O
.	O

Functional	O
interactions	O
of	O
stimulatory	O
and	O
inhibitory	O
GDP	O
/	O
GTP	O
exchange	O
proteins	O
and	O
their	O
common	O
substrate	O
small	O
GTP	O
-	O
binding	O
protein	O
.	O

smg	O
GDS	O
and	O
rho	O
GDI	O
are	O
stimulatory	O
and	O
inhibitory	O
GDP	O
/	O
GTP	O
exchange	O
proteins	O
,	O
respectively	O
,	O
for	O
a	O
group	O
of	O
ras	O
p21	O
-	O
related	O
small	O
GTP	O
-	O
binding	O
proteins	O
(	O
G	O
proteins	O
)	O
.	O
rho	O
p21	O
is	O
a	O
common	O
substrate	O
small	O
G	O
protein	O
for	O
both	O
GDP	O
/	O
GTP	O
exchange	O
proteins	O
.	O

We	O
examined	O
here	O
the	O
functional	O
interactions	O
of	O
these	O
GDP	O
/	O
GTP	O
exchange	O
proteins	O
with	O
rho	O
p21	O
as	O
a	O
substrate	O
.	O
smg	O
GDS	O
and	O
rho	O
GDI	O
interacted	O
with	O
the	O
GDP	O
-	O
bound	O
form	O
of	O
rho	O
p21	O
and	O
thereby	O
stimulated	O
and	O
inhibited	O
,	O
respectively	O
,	O
the	O
dissociation	O
of	O
GDP	O
.	O

The	O
inhibitory	O
effect	O
of	O
rho	O
GDI	O
was	O
much	O
stronger	O
than	O
the	O
stimulatory	O
effect	O
of	O
smg	O
GDS	O
.	O

The	O
GDP	O
-	O
bound	O
form	O
of	O
rho	O
p21	O
formed	O
a	O
complex	O
with	O
rho	O
GDI	O
but	O
not	O
with	O
smg	O
GDS	O
in	O
their	O
simultaneous	O
presence	O
.	O

Since	O
the	O
content	O
of	O
smg	O
GDS	O
was	O
generally	O
less	O
than	O
that	O
of	O
rho	O
GDI	O
in	O
cells	O
,	O
these	O
results	O
suggest	O
that	O
there	O
is	O
some	O
mechanism	O
to	O
release	O
the	O
inhibitory	O
action	O
of	O
rho	O
GDI	O
and	O
to	O
make	O
rho	O
p21	O
sensitive	O
to	O
the	O
smg	O
GDS	O
action	O
during	O
the	O
conversion	O
of	O
rhoA	O
p21	O
from	O
the	O
GDP	O
-	O
bound	O
inactive	O
form	O
to	O
the	O
GTP	O
-	O
bound	O
active	O
form	O
in	O
intact	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
rho	O
p21	O
was	O
previously	O
shown	O
to	O
be	O
ADP	O
-	O
ribosylated	O
by	O
bacterial	O
ADP	O
-	O
ribosyltransferases	O
,	O
named	O
C3	O
and	O
EDIN	O
,	O
at	O
Asn41	O
in	O
the	O
putative	O
effector	O
region	O
of	O
rho	O
p21	O
.	O

This	O
ADP	O
-	O
ribosylation	O
was	O
inhibited	O
by	O
rho	O
GDI	O
much	O
more	O
efficiently	O
than	O
by	O
smg	O
GDS	O
.	O

These	O
results	O
suggest	O
that	O
rho	O
GDI	O
may	O
mask	O
the	O
putative	O
effector	O
region	O
of	O
rho	O
p21	O
and	O
thereby	O
inhibit	O
its	O
interaction	O
with	O
the	O
target	O
protein	O
even	O
in	O
the	O
presence	O
of	O
smg	O
GDS	O
.	O

Thus	O
,	O
both	O
smg	O
GDS	O
and	O
rho	O
GDI	O
are	O
important	O
to	O
regulate	O
the	O
rho	O
p21	O
activity	O
and	O
action	O
in	O
cooperation	O
with	O
each	O
other	O
.	O

In	O
the	O
standard	O
halo	O
assay	O
,	O
minimal	O
medium	O
with	O
allantoin	O
(	O
MMA	O
)	O
is	O
supplemented	O
with	O
30	O
mug	O
/	O
ml	O
leucine	O
to	O
induce	O
PTR2	O
expression	O
(	O
MMA	O
+	O
Leu	O
medium	O
)	O
.	O

Under	O
these	O
conditions	O
,	O
wild	O
-	O
type	O
strains	O
varied	O
substantially	O
in	O
sensitivity	O
to	O
Ala	O
-	O
Eth	O
toxicity	O
(	O
Figure	O
7	O
)	O
.	O

S288c	O
was	O
the	O
most	O
sensitive	O
to	O
the	O
dipeptide	O
,	O
whereas	O
W303	O
was	O
completely	O
resistant	O
.	O

In	O
the	O
absence	O
of	O
the	O
leucine	O
inducer	O
,	O
only	O
the	O
clinical	O
isolates	O
YAT17	O
and	O
YAT21	O
were	O
sensitive	O
to	O
Ala	O
-	O
Eth	O
(	O
Figure	O
7	O
)	O
.	O

Structure	O
of	O
tracheal	O
cytotoxin	O
in	O
complex	O
with	O
a	O
heterodimeric	O
pattern	O
-	O
recognition	O
receptor	O
.	O

Tracheal	O
cytotoxin	O
(	O
TCT	O
)	O
,	O
a	O
naturally	O
occurring	O
fragment	O
of	O
Gram	O
-	O
negative	O
peptidoglycan	O
,	O
is	O
a	O
potent	O
elicitor	O
of	O
innate	O
immune	O
responses	O
in	O
Drosophila	O
.	O

It	O
induces	O
the	O
heterodimerization	O
of	O
its	O
recognition	O
receptors	O
,	O
the	O
peptidoglycan	O
recognition	O
proteins	O
(	O
PGRPs	O
)	O
LCa	O
and	O
LCx	O
,	O
which	O
activates	O
the	O
immune	O
deficiency	O
pathway	O
.	O

The	O
crystal	O
structure	O
at	O
2	O
.	O
1	O
angstrom	O
resolution	O
of	O
TCT	O
in	O
complex	O
with	O
the	O
ectodomains	O
of	O
PGRP	O
-	O
LCa	O
and	O
PGRP	O
-	O
LCx	O
shows	O
that	O
TCT	O
is	O
bound	O
to	O
and	O
presented	O
by	O
the	O
LCx	O
ectodomain	O
for	O
recognition	O
by	O
the	O
LCa	O
ectodomain	O
;	O
the	O
latter	O
lacks	O
a	O
canonical	O
peptidoglycan	O
-	O
docking	O
groove	O
conserved	O
in	O
other	O
PGRPs	O
.	O

The	O
interface	O
,	O
revealed	O
in	O
atomic	O
detail	O
,	O
between	O
TCT	O
and	O
the	O
receptor	O
complex	O
highlights	O
the	O
importance	O
of	O
the	O
anhydro	O
-	O
containing	O
disaccharide	O
in	O
bridging	O
the	O
two	O
ectodomains	O
together	O
and	O
the	O
critical	O
role	O
of	O
diaminopimelic	O
acid	O
as	O
the	O
specificity	O
determinant	O
for	O
PGRP	O
interaction	O
.	O

Mechanism	O
of	O
assembly	O
of	O
G	B-OOS
protein	I-OOS
betagamma	I-OOS
subunits	O
by	O
protein	O
kinase	O
CK2	B-Complex
-	O
phosphorylated	O
phosducin	O
-	O
like	O
protein	O
and	O
the	O
cytosolic	B-Complex
chaperonin	I-Complex
complex	I-Complex
.	O

Phosducin	O
-	O
like	O
protein	O
(	O
PhLP	O
)	O
is	O
a	O
widely	O
expressed	O
binding	O
partner	O
of	O
the	O
G	B-OOS
protein	I-OOS
betagamma	I-OOS
subunit	O
complex	O
(	O
Gbetagamma	B-OOS
)	O
that	O
has	O
been	O
recently	O
shown	O
to	O
catalyze	O
the	O
formation	O
of	O
the	O
Gbetagamma	B-OOS
dimer	O
from	O
its	O
nascent	O
polypeptides	O
.	O

Phosphorylation	O
of	O
PhLP	O
at	O
one	O
or	O
more	O
of	O
three	O
consecutive	O
serines	O
(	O
Ser	O
-	O
18	O
,	O
Ser	O
-	O
19	O
,	O
and	O
Ser	O
-	O
20	O
)	O
is	O
necessary	O
for	O
Gbetagamma	B-OOS
dimer	O
formation	O
and	O
is	O
believed	O
to	O
be	O
mediated	O
by	O
the	O
protein	O
kinase	O
CK2	B-Complex
.	O

Moreover	O
,	O
several	O
lines	O
of	O
evidence	O
suggest	O
that	O
the	O
cytosolic	B-Complex
chaperonin	I-Complex
complex	I-Complex
(	O
CCT	B-Complex
)	O
may	O
work	O
in	O
concert	O
with	O
PhLP	O
in	O
the	O
Gbetagamma	B-OOS
-	O
assembly	O
process	O
.	O

The	O
results	O
reported	O
here	O
delineate	O
a	O
mechanism	O
for	O
Gbetagamma	B-OOS
assembly	O
in	O
which	O
a	O
stable	O
ternary	O
complex	O
is	O
formed	O
between	O
PhLP	O
,	O
the	O
nascent	O
Gbeta	O
subunit	O
,	O
and	O
CCT	B-Complex
that	O
does	O
not	O
include	O
Ggamma	O
.	O

PhLP	O
phosphorylation	O
permits	O
the	O
release	O
of	O
a	O
PhLP	O
x	O
Gbeta	O
intermediate	O
from	O
CCT	B-Complex
,	O
allowing	O
Ggamma	O
to	O
associate	O
with	O
Gbeta	O
in	O
this	O
intermediate	O
complex	O
.	O

Subsequent	O
interaction	O
of	O
Gbetagamma	B-OOS
with	O
membranes	O
releases	O
PhLP	O
for	O
another	O
round	O
of	O
assembly	O
.	O

Histone	O
deacetylase	O
1	O
-	O
mediated	O
histone	O
modification	O
regulates	O
osteoblast	O
differentiation	O
.	O

Osteogenesis	O
is	O
a	O
complex	O
process	O
associated	O
with	O
dramatic	O
changes	O
in	O
gene	O
expression	O
.	O

To	O
elucidate	O
whether	O
modifications	O
in	O
chromatin	O
structure	O
are	O
involved	O
in	O
osteoblast	O
differentiation	O
,	O
we	O
examined	O
the	O
expression	O
levels	O
of	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
and	O
the	O
degree	O
of	O
histone	O
acetylation	O
at	O
the	O
promoter	O
regions	O
of	O
osteogenic	O
genes	O
.	O

During	O
osteogenesis	O
,	O
total	O
HDAC	O
enzymatic	O
activity	O
was	O
decreased	O
with	O
significant	O
reduction	O
in	O
HDAC1	O
expression	O
.	O

Consistently	O
,	O
recruitment	O
of	O
HDAC1	O
to	O
the	O
promoters	O
of	O
osteoblast	O
marker	O
genes	O
,	O
including	O
osterix	O
and	O
osteocalcin	O
,	O
was	O
down	O
-	O
regulated	O
,	O
whereas	O
histone	O
H3	O
and	O
H4	O
were	O
hyperacetylated	O
at	O
those	O
promoters	O
during	O
osteoblast	O
differentiation	O
.	O

Moreover	O
,	O
suppression	O
of	O
HDAC	O
activity	O
with	O
a	O
HDAC	O
inhibitor	O
,	O
sodium	O
butyrate	O
,	O
accelerated	O
osteogenesis	O
by	O
inducing	O
osteoblast	O
marker	O
genes	O
including	O
osteopontin	O
and	O
alkaline	O
phosphatase	O
.	O

Consistently	O
,	O
knockdown	O
of	O
HDAC1	O
by	O
the	O
short	O
interference	O
RNA	O
system	O
stimulated	O
osteoblast	O
differentiation	O
.	O

Taken	O
together	O
,	O
these	O
data	O
propose	O
that	O
down	O
-	O
regulation	O
of	O
HDAC1	O
is	O
an	O
important	O
process	O
for	O
osteogenesis	O
.	O

Cell	O
-	O
type	O
-	O
specific	O
regulation	O
of	O
degradation	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
1	O
alpha	O
:	O
role	O
of	O
subcellular	O
compartmentalization	O
.	O

The	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
alpha	O
(	O
HIF	O
-	O
1	O
alpha	O
)	O
is	O
a	O
transcription	O
factor	O
that	O
mediates	O
adaptive	O
cellular	O
responses	O
to	O
decreased	O
oxygen	O
availability	O
(	O
hypoxia	O
)	O
.	O

At	O
normoxia	O
,	O
HIF	O
-	O
1	O
alpha	O
is	O
targeted	O
by	O
the	O
von	O
Hippel	O
-	O
Lindau	O
tumor	O
suppressor	O
protein	O
(	O
pVHL	O
)	O
for	O
degradation	O
by	O
the	O
ubiquitin	O
-	O
proteasome	B-Complex
pathway	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
observed	O
distinct	O
cell	O
-	O
type	O
-	O
specific	O
differences	O
in	O
the	O
ability	O
of	O
various	O
tested	O
pVHL	O
-	O
interacting	O
subfragments	O
to	O
stabilize	O
HIF	O
-	O
1	O
alpha	O
and	O
unmask	O
its	O
function	O
at	O
normoxia	O
.	O

These	O
properties	O
correlated	O
with	O
differences	O
in	O
subcellular	O
compartmentalization	O
and	O
degradation	O
of	O
HIF	O
-	O
1	O
alpha	O
.	O

We	O
observed	O
that	O
the	O
absence	O
or	O
presence	O
of	O
nuclear	O
localization	O
or	O
export	O
signals	O
differently	O
affected	O
the	O
ability	O
of	O
a	O
minimal	O
HIF	O
-	O
1	O
alpha	O
peptide	O
spanning	O
residues	O
559	O
to	O
573	O
of	O
mouse	O
HIF	O
-	O
1	O
alpha	O
to	O
stabilize	O
endogenous	O
HIFalpha	O
and	O
induce	O
HIF	O
-	O
driven	O
reporter	O
gene	O
activity	O
in	O
two	O
different	O
cell	O
types	O
(	O
primary	O
mouse	O
endothelial	O
and	O
HepG2	O
hepatoma	O
cells	O
)	O
.	O

Degradation	O
of	O
HIF	O
-	O
1	O
alpha	O
occurred	O
mainly	O
in	O
the	O
cytoplasm	O
of	O
HepG2	O
cells	O
,	O
whereas	O
it	O
occurs	O
with	O
equal	O
efficiency	O
in	O
nuclear	O
and	O
cytoplasmic	O
compartments	O
of	O
primary	O
endothelial	O
cells	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
green	O
fluorescent	O
protein	O
-	O
HIF	O
-	O
1	O
alpha	O
is	O
differently	O
distributed	O
during	O
hypoxia	O
and	O
reoxygenation	O
in	O
hepatoma	O
and	O
endothelial	O
cells	O
.	O

Consequently	O
,	O
we	O
propose	O
that	O
differential	O
compartmentalization	O
of	O
degradation	O
of	O
HIF	O
-	O
1	O
alpha	O
and	O
the	O
subcellular	O
distribution	O
of	O
HIF	O
-	O
1	O
alpha	O
may	O
account	O
for	O
cell	O
-	O
type	O
-	O
specific	O
differences	O
in	O
stabilizing	O
HIF	O
-	O
1	O
alpha	O
protein	O
levels	O
under	O
hypoxic	O
conditions	O
.	O

PGC	O
-	O
1	O
-	O
related	O
coactivator	O
:	O
immediate	O
early	O
expression	O
and	O
characterization	O
of	O
a	O
CREB	O
/	O
NRF	O
-	O
1	O
binding	O
domain	O
associated	O
with	O
cytochrome	O
c	O
promoter	O
occupancy	O
and	O
respiratory	O
growth	O
.	O

PGC	O
-	O
1	O
-	O
related	O
coactivator	O
(	O
PRC	O
)	O
was	O
initially	O
characterized	O
as	O
a	O
transcriptional	O
coactivator	O
that	O
shares	O
structural	O
and	O
functional	O
features	O
with	O
PGC	O
-	O
1alpha	O
.	O

Both	O
coactivators	O
interact	O
with	O
nuclear	O
respiratory	O
factor	O
1	O
(	O
NRF	O
-	O
1	O
)	O
and	O
activate	O
NRF	O
-	O
1	O
target	O
genes	O
required	O
for	O
respiratory	O
chain	O
expression	O
.	O

Here	O
,	O
we	O
establish	O
that	O
PRC	O
belongs	O
to	O
the	O
class	O
of	O
immediate	O
early	O
genes	O
that	O
are	O
rapidly	O
induced	O
in	O
the	O
transition	O
from	O
quiescence	O
to	O
proliferative	O
growth	O
.	O

As	O
observed	O
for	O
other	O
members	O
of	O
this	O
class	O
,	O
the	O
rapid	O
serum	O
induction	O
of	O
PRC	O
mRNA	O
does	O
not	O
require	O
de	O
novo	O
protein	O
synthesis	O
and	O
inhibition	O
of	O
protein	O
synthesis	O
stabilizes	O
PRC	O
mRNA	O
,	O
leading	O
to	O
its	O
superinduction	O
.	O

Previous	O
work	O
indicated	O
that	O
PRC	O
activation	O
of	O
cytochrome	O
c	O
expression	O
occurs	O
through	O
cis	O
-	O
acting	O
elements	O
that	O
bind	O
both	O
NRF	O
-	O
1	O
and	O
CREB	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
,	O
like	O
NRF	O
-	O
1	O
,	O
CREB	O
binds	O
PRC	O
in	O
vitro	O
and	O
exists	O
in	O
a	O
complex	O
with	O
PRC	O
in	O
cell	O
extracts	O
.	O

Both	O
CREB	O
and	O
NRF	O
-	O
1	O
bind	O
the	O
same	O
sites	O
on	O
PRC	O
,	O
and	O
the	O
interaction	O
with	O
CREB	O
requires	O
the	O
CREB	O
b	O
-	O
Zip	O
DNA	O
binding	O
domain	O
.	O

Moreover	O
,	O
a	O
CREB	O
/	O
NRF	O
-	O
1	O
interaction	O
domain	O
on	O
PRC	O
is	O
required	O
for	O
its	O
trans	O
activation	O
of	O
the	O
cytochrome	O
c	O
promoter	O
and	O
a	O
PRC	O
subfragment	O
containing	O
this	O
domain	O
inhibits	O
respiratory	O
growth	O
on	O
galactose	O
when	O
expressed	O
in	O
trans	O
from	O
a	O
lentivirus	O
vector	O
.	O

Finally	O
,	O
PRC	O
associates	O
with	O
the	O
cytochrome	O
c	O
promoter	O
in	O
vivo	O
and	O
its	O
occupancy	O
of	O
the	O
promoter	O
is	O
markedly	O
elevated	O
in	O
response	O
to	O
serum	O
induction	O
of	O
quiescent	O
fibroblasts	O
.	O

The	O
results	O
establish	O
that	O
PRC	O
is	O
an	O
immediate	O
early	O
gene	O
product	O
that	O
can	O
target	O
key	O
transcription	O
factors	O
as	O
an	O
early	O
event	O
in	O
the	O
program	O
of	O
cellular	O
proliferation	O
.	O

The	O
proprotein	O
convertase	O
(	O
PC	O
)	O
PCSK9	O
is	O
inactivated	O
by	O
furin	O
and	O
/	O
or	O
PC5	O
/	O
6A	O
:	O
functional	O
consequences	O
of	O
natural	O
mutations	O
and	O
post	O
-	O
translational	O
modifications	O
.	O

PCSK9	O
is	O
the	O
ninth	O
member	O
of	O
the	O
proprotein	O
convertase	O
(	O
PC	O
)	O
family	O
.	O

Some	O
of	O
its	O
natural	O
mutations	O
have	O
been	O
genetically	O
associated	O
with	O
the	O
development	O
of	O
a	O
dominant	O
form	O
of	O
familial	O
hyper	O
-	O
or	O
hypocholesterolemia	O
.	O

The	O
exact	O
mechanism	O
of	O
action	O
of	O
PCSK9	O
is	O
not	O
clear	O
,	O
although	O
it	O
is	O
known	O
to	O
enhance	O
the	O
intracellular	O
degradation	O
of	O
the	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
receptor	O
in	O
acidic	O
compartments	O
,	O
likely	O
the	O
endosomes	O
/	O
lysosomes	O
.	O

We	O
analyzed	O
the	O
post	O
-	O
translational	O
modifications	O
of	O
PCSK9	O
and	O
show	O
that	O
it	O
is	O
sulfated	O
within	O
its	O
prosegment	O
at	O
Tyr38	O
.	O

We	O
also	O
examined	O
the	O
susceptibility	O
of	O
PCSK9	O
to	O
proteolytic	O
cleavage	O
by	O
the	O
other	O
members	O
of	O
the	O
PC	O
family	O
.	O

The	O
data	O
show	O
that	O
the	O
natural	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
R218S	O
,	O
F216L	O
,	O
and	O
D374Y	O
associated	O
with	O
hypercholesterolemia	O
result	O
in	O
total	O
or	O
partial	O
loss	O
of	O
furin	O
/	O
PC5	O
/	O
6A	O
processing	O
at	O
the	O
motif	O
RFHR218	O
downward	O
arrow	O
.	O

In	O
contrast	O
,	O
the	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
A443T	O
and	O
C679X	O
lead	O
either	O
to	O
the	O
lack	O
of	O
trans	O
-	O
Golgi	O
network	O
/	O
recycling	O
endosome	O
localization	O
and	O
an	O
enhanced	O
susceptibility	O
to	O
furin	O
cleavage	O
(	O
A443T	O
)	O
or	O
to	O
the	O
inability	O
of	O
PCSK9	O
to	O
exit	O
the	O
endoplasmic	O
reticulum	O
(	O
C679X	O
)	O
.	O

Furthermore	O
,	O
we	O
report	O
the	O
presence	O
of	O
both	O
native	O
and	O
furin	O
-	O
like	O
cleaved	O
forms	O
of	O
PCSK9	O
in	O
circulating	O
human	O
plasma	O
.	O

Thus	O
,	O
we	O
propose	O
that	O
PCSK9	O
levels	O
are	O
finely	O
regulated	O
by	O
the	O
basic	O
amino	O
acid	O
convertases	O
furin	O
and	O
PC5	O
/	O
6A	O
.	O

The	O
latter	O
may	O
reduce	O
the	O
lifetime	O
of	O
this	O
proteinase	O
and	O
its	O
ability	O
to	O
degrade	O
the	O
cell	O
-	O
surface	O
LDL	B-OOS
receptor	I-OOS
,	O
thereby	O
regulating	O
the	O
levels	O
of	O
circulating	O
LDL	B-Complex
cholesterol	O
.	O

Negative	O
modulation	O
of	O
RXRalpha	O
transcriptional	O
activity	O
by	O
small	O
ubiquitin	O
-	O
related	O
modifier	O
(	O
SUMO	O
)	O
modification	O
and	O
its	O
reversal	O
by	O
SUMO	O
-	O
specific	O
protease	O
SUSP1	O
.	O

Retinoid	O
X	O
receptor	O
alpha	O
(	O
RXRalpha	O
)	O
belongs	O
to	O
a	O
family	O
of	O
ligand	O
-	O
activated	O
transcription	O
factors	O
that	O
regulate	O
many	O
aspects	O
of	O
metazoan	O
life	O
.	O

Here	O
we	O
demonstrate	O
that	O
RXRalpha	O
is	O
a	O
target	O
substrate	O
of	O
a	O
small	O
ubiquitin	O
-	O
related	O
modifier	O
(	O
SUMO	O
)	O
-	O
specific	O
protease	O
,	O
SUSP1	O
,	O
which	O
is	O
capable	O
of	O
controlling	O
the	O
transcriptional	O
activity	O
of	O
RXRalpha	O
.	O

RXRalpha	O
was	O
modified	O
by	O
SUMO	O
-	O
1	O
in	O
vivo	O
as	O
well	O
as	O
in	O
vitro	O
,	O
and	O
the	O
Lys	O
-	O
108	O
residue	O
within	O
the	O
IKPP	O
sequence	O
of	O
RXRalpha	O
AF	O
-	O
1	O
domain	O
was	O
identified	O
as	O
the	O
major	O
SUMO	O
-	O
1	O
acceptor	O
site	O
.	O

Prevention	O
of	O
SUMO	O
modification	O
by	O
Lys	O
-	O
to	O
-	O
Arg	O
mutation	O
led	O
to	O
an	O
increase	O
not	O
only	O
in	O
the	O
transcriptional	O
activity	O
of	O
RXRalpha	O
but	O
also	O
in	O
the	O
activity	O
of	O
its	O
heterodimeric	O
complex	O
with	O
retinoic	O
acid	O
receptor	O
-	O
alpha	O
or	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
-	O
gamma	O
(	O
PPARgamma	O
)	O
.	O

SUSP1	O
co	O
-	O
localized	O
with	O
RXRalpha	O
in	O
the	O
nucleus	O
and	O
removed	O
SUMO	O
-	O
1	O
from	O
RXRalpha	O
but	O
not	O
from	O
androgen	O
receptor	O
or	O
PPARgamma	O
.	O

Moreover	O
,	O
overexpression	O
of	O
SUSP1	O
caused	O
an	O
increase	O
in	O
the	O
transcriptional	O
activity	O
of	O
RXRalpha	O
,	O
whereas	O
small	O
hairpin	O
RNA	O
-	O
mediated	O
knockdown	O
of	O
endogenous	O
SUSP1	O
led	O
to	O
a	O
decrease	O
in	O
RXRalpha	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
SUSP1	O
plays	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
the	O
transcriptional	O
activity	O
of	O
RXRalpha	O
and	O
thus	O
in	O
the	O
RXRalpha	O
-	O
mediated	O
cellular	O
processes	O
.	O

Involvement	O
of	O
the	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
-	O
related	O
kinases	O
tank	O
-	O
binding	O
kinase	O
1	O
/	O
IKKi	O
and	O
cullin	O
-	O
based	O
ubiquitin	O
ligases	O
in	O
IFN	O
regulatory	O
factor	O
-	O
3	O
degradation	O
.	O

Activation	O
of	O
the	O
innate	O
arm	O
of	O
the	O
immune	O
system	O
following	O
pathogen	O
infection	O
relies	O
on	O
the	O
recruitment	O
of	O
latent	O
transcription	O
factors	O
involved	O
in	O
the	O
induction	O
of	O
a	O
subset	O
of	O
genes	O
responsible	O
for	O
viral	O
clearance	O
.	O

One	O
of	O
these	O
transcription	O
factors	O
,	O
IFN	O
regulatory	O
factor	O
3	O
(	O
IRF	O
-	O
3	O
)	O
,	O
is	O
targeted	O
for	O
proteosomal	O
degradation	O
following	O
virus	O
infection	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
this	O
process	O
are	O
still	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
polyubiquitination	O
of	O
IRF	O
-	O
3	O
increases	O
in	O
response	O
to	O
Sendai	O
virus	O
infection	O
.	O

Using	O
an	O
E1	O
temperature	O
-	O
sensitive	O
cell	O
line	O
,	O
we	O
demonstrate	O
that	O
polyubiquitination	O
is	O
required	O
for	O
the	O
observed	O
degradation	O
of	O
IRF	O
-	O
3	O
.	O

Inactivation	O
of	O
NEDD8	O
-	O
activating	O
E1	O
enzyme	O
also	O
results	O
in	O
stabilization	O
of	O
IRF	O
-	O
3	O
suggesting	O
the	O
NEDDylation	O
also	O
plays	O
a	O
role	O
in	O
IRF	O
-	O
3	O
degradation	O
following	O
Sendai	O
virus	O
infection	O
.	O

In	O
agreement	O
with	O
this	O
observation	O
,	O
IRF	O
-	O
3	O
is	O
recruited	O
to	O
Cullin1	O
following	O
virus	O
infection	O
and	O
overexpression	O
of	O
a	O
dominant	O
-	O
negative	O
mutant	O
of	O
Cullin1	O
significantly	O
inhibits	O
the	O
degradation	O
of	O
IRF	O
-	O
3	O
observed	O
in	O
infected	O
cells	O
.	O

We	O
also	O
asked	O
whether	O
the	O
C	O
-	O
terminal	O
cluster	O
of	O
phosphoacceptor	O
sites	O
of	O
IRF	O
-	O
3	O
could	O
serve	O
as	O
a	O
destabilization	O
signal	O
and	O
we	O
therefore	O
measured	O
the	O
half	O
-	O
life	O
of	O
C	O
-	O
terminal	O
phosphomimetic	O
IRF	O
-	O
3	O
mutants	O
.	O

Interestingly	O
,	O
we	O
found	O
them	O
to	O
be	O
short	O
-	O
lived	O
in	O
contrast	O
to	O
wild	O
-	O
type	O
IRF	O
-	O
3	O
.	O

In	O
addition	O
,	O
no	O
degradation	O
of	O
IRF	O
-	O
3	O
was	O
observed	O
in	O
TBK1	O
(	O
-	O
/	O
-	O
)	O
mouse	O
embryonic	O
fibroblasts	O
.	O

All	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
virus	O
infection	O
stimulates	O
a	O
host	O
cell	O
signaling	O
pathway	O
that	O
modulates	O
the	O
expression	O
level	O
of	O
IRF	O
-	O
3	O
through	O
its	O
C	O
-	O
terminal	O
phosphorylation	O
by	O
the	O
IkappaB	O
kinase	O
-	O
related	O
kinases	O
followed	O
by	O
its	O
polyubiquitination	O
,	O
which	O
is	O
mediated	O
in	O
part	O
by	O
a	O
Cullin	O
-	O
based	O
ubiquitin	O
ligase	O
.	O

NIPA1	O
(	O
SPG6	O
)	O
,	O
the	O
basis	O
for	O
autosomal	O
dominant	O
form	O
of	O
hereditary	O
spastic	O
paraplegia	O
,	O
encodes	O
a	O
functional	O
Mg2	O
+	O
transporter	O
.	O

Mutations	O
in	O
the	O
NIPA1	O
(	O
SPG6	O
)	O
gene	O
,	O
named	O
for	O
"	O
nonimprinted	O
in	O
Prader	O
-	O
Willi	O
/	O
Angelman	O
"	O
has	O
been	O
implicated	O
in	O
one	O
form	O
of	O
autosomal	O
dominant	O
hereditary	O
spastic	O
paraplegia	O
(	O
HSP	O
)	O
,	O
a	O
neurodegenerative	O
disorder	O
characterized	O
by	O
progressive	O
lower	O
limb	O
spasticity	O
and	O
weakness	O
.	O

However	O
,	O
the	O
function	O
of	O
NIPA1	O
is	O
unknown	O
.	O

Here	O
,	O
we	O
show	O
that	O
reduced	O
magnesium	O
concentration	O
enhances	O
expression	O
of	O
NIPA1	O
suggesting	O
a	O
role	O
in	O
cellular	O
magnesium	O
metabolism	O
.	O

Indeed	O
NIPA1	O
mediates	O
Mg2	O
+	O
uptake	O
that	O
is	O
electrogenic	O
,	O
voltage	O
-	O
dependent	O
,	O
and	O
saturable	O
with	O
a	O
Michaelis	O
constant	O
of	O
0	O
.	O
69	O
+	O
/	O
-	O
0	O
.	O
21	O
mM	O
when	O
expressed	O
in	O
Xenopus	O
oocytes	O
.	O

Subcellular	O
localization	O
with	O
immunofluorescence	O
showed	O
that	O
endogenous	O
NIPA1	O
protein	O
associates	O
with	O
early	O
endosomes	O
and	O
the	O
cell	O
surface	O
in	O
a	O
variety	O
of	O
neuronal	O
and	O
epithelial	O
cells	O
.	O

As	O
expected	O
of	O
a	O
magnesium	O
-	O
responsive	O
gene	O
,	O
we	O
find	O
that	O
altered	O
magnesium	O
concentration	O
leads	O
to	O
a	O
redistribution	O
between	O
the	O
endosomal	O
compartment	O
and	O
the	O
plasma	O
membrane	O
;	O
high	O
magnesium	O
results	O
in	O
diminished	O
cell	O
surface	O
NIPA1	O
whereas	O
low	O
magnesium	O
leads	O
to	O
accumulation	O
in	O
early	O
endosomes	O
and	O
recruitment	O
to	O
the	O
plasma	O
membrane	O
.	O

The	O
mouse	O
NIPA1	O
mutants	O
,	O
T39R	O
and	O
G100R	O
,	O
corresponding	O
to	O
the	O
respective	O
human	O
mutants	O
showed	O
a	O
loss	O
-	O
of	O
-	O
function	O
when	O
expressed	O
in	O
oocytes	O
and	O
altered	O
trafficking	O
in	O
transfected	O
COS7	O
cells	O
.	O

We	O
conclude	O
that	O
NIPA1	O
normally	O
encodes	O
a	O
Mg2	O
+	O
transporter	O
and	O
the	O
loss	O
-	O
of	O
function	O
of	O
NIPA1	O
(	O
SPG6	O
)	O
due	O
to	O
abnormal	O
trafficking	O
of	O
the	O
mutated	O
protein	O
provides	O
the	O
basis	O
of	O
the	O
HSP	O
phenotype	O
.	O

Two	O
novel	O
members	O
of	O
the	O
ABLIM	O
protein	O
family	O
,	O
ABLIM	O
-	O
2	O
and	O
-	O
3	O
,	O
associate	O
with	O
STARS	O
and	O
directly	O
bind	O
F	O
-	O
actin	O
.	O

In	O
addition	O
to	O
regulating	O
cell	O
motility	O
,	O
contractility	O
,	O
and	O
cytokinesis	O
,	O
the	O
actin	O
cytoskeleton	O
plays	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
transcription	O
and	O
gene	O
expression	O
.	O

We	O
have	O
previously	O
identified	O
a	O
novel	O
muscle	O
-	O
specific	O
actin	O
-	O
binding	O
protein	O
,	O
STARS	O
(	O
striated	O
muscle	O
activator	O
of	O
Rho	O
signaling	O
)	O
,	O
which	O
directly	O
binds	O
actin	O
and	O
stimulates	O
serum	O
-	O
response	O
factor	O
(	O
SRF	O
)	O
-	O
dependent	O
transcription	O
.	O

To	O
further	O
dissect	O
the	O
STARS	O
/	O
SRF	O
pathway	O
,	O
we	O
performed	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
of	O
a	O
skeletal	O
muscle	O
cDNA	O
library	O
using	O
STARS	O
as	O
bait	O
,	O
and	O
we	O
identified	O
two	O
novel	O
members	O
of	O
the	O
ABLIM	O
protein	O
family	O
,	O
ABLIM	O
-	O
2	O
and	O
-	O
3	O
,	O
as	O
STARS	O
-	O
interacting	O
proteins	O
.	O

ABLIM	O
-	O
1	O
,	O
which	O
is	O
expressed	O
in	O
retina	O
,	O
brain	O
,	O
and	O
muscle	O
tissue	O
,	O
has	O
been	O
postulated	O
to	O
function	O
as	O
a	O
tumor	O
suppressor	O
.	O

ABLIM	O
-	O
2	O
and	O
-	O
3	O
display	O
distinct	O
tissue	O
-	O
specific	O
expression	O
patterns	O
with	O
the	O
highest	O
expression	O
levels	O
in	O
muscle	O
and	O
neuronal	O
tissue	O
.	O

Moreover	O
,	O
these	O
novel	O
ABLIM	O
proteins	O
strongly	O
bind	O
F	O
-	O
actin	O
,	O
are	O
localized	O
to	O
actin	O
stress	O
fibers	O
,	O
and	O
synergistically	O
enhance	O
STARS	O
-	O
dependent	O
activation	O
of	O
SRF	O
.	O

Conversely	O
,	O
knockdown	O
of	O
endogenous	O
ABLIM	O
expression	O
utilizing	O
small	O
interfering	O
RNA	O
significantly	O
blunted	O
SRF	O
-	O
dependent	O
transcription	O
in	O
C2C12	O
skeletal	O
muscle	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
members	O
of	O
the	O
novel	O
ABLIM	O
protein	O
family	O
may	O
serve	O
as	O
a	O
scaffold	O
for	O
signaling	O
modules	O
of	O
the	O
actin	O
cytoskeleton	O
and	O
thereby	O
modulate	O
transcription	O
.	O

Cloning	O
and	O
characterization	O
of	O
cDNA	O
encoding	O
human	O
A	O
-	O
type	O
endothelin	O
receptor	O
.	O

A	O
cDNA	O
coding	O
for	O
the	O
human	O
A	O
-	O
type	O
endothelin	O
receptor	O
(	O
ETA	O
)	O
was	O
cloned	O
from	O
a	O
human	O
placenta	O
cDNA	O
library	O
.	O

The	O
cDNA	O
contained	O
the	O
entire	O
coding	O
sequence	O
for	O
the	O
427	O
amino	O
acid	O
protein	O
with	O
a	O
relative	O
Mr	O
of	O
48	O
,	O
722	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
human	O
ETA	O
was	O
,	O
respectively	O
,	O
94	O
%	O
and	O
93	O
%	O
homologous	O
with	O
the	O
sequence	O
of	O
bovine	O
ETA	O
and	O
rat	O
ETA	O
,	O
but	O
was	O
only	O
64	O
%	O
homologous	O
with	O
that	O
of	O
the	O
human	O
ETB	O
receptor	O
.	O

Upon	O
expression	O
in	O
COS	O
-	O
1	O
cells	O
,	O
the	O
human	O
ETA	O
receptor	O
showed	O
binding	O
activity	O
to	O
ETA	O
,	O
with	O
the	O
highest	O
selectivity	O
to	O
ET	O
-	O
1	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
the	O
mRNA	O
of	O
human	O
placenta	O
ETA	O
consists	O
of	O
one	O
species	O
5	O
kilo	O
-	O
nucleotides	O
in	O
length	O
,	O
and	O
the	O
same	O
analysis	O
for	O
the	O
uterus	O
,	O
testis	O
,	O
heart	O
and	O
adrenal	O
gland	O
of	O
Cynomolgus	O
monkey	O
showed	O
that	O
the	O
cognate	O
mRNAs	O
are	O
widely	O
distributed	O
.	O

Inhibitor	O
of	O
growth	O
4	O
suppresses	O
cell	O
spreading	O
and	O
cell	O
migration	O
by	O
interacting	O
with	O
a	O
novel	O
binding	O
partner	O
,	O
liprin	O
alpha1	O
.	O

Inhibitor	O
of	O
growth	O
4	O
(	O
ING4	O
)	O
is	O
a	O
candidate	O
tumor	O
suppressor	O
that	O
plays	O
a	O
major	O
role	O
in	O
gene	O
regulation	O
,	O
cell	O
cycle	O
control	O
,	O
apoptosis	O
,	O
and	O
angiogenesis	O
.	O

ING4	O
expression	O
is	O
down	O
-	O
regulated	O
in	O
glioblastoma	O
cells	O
and	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
.	O

Here	O
,	O
we	O
identified	O
liprin	O
alpha1	O
/	O
PPFIA1	O
,	O
a	O
cytoplasmic	O
protein	O
necessary	O
for	O
focal	O
adhesion	O
formation	O
and	O
axon	O
guidance	O
,	O
as	O
a	O
novel	O
interacting	O
protein	O
with	O
ING4	O
.	O

ING4	O
and	O
liprin	O
alpha1	O
colocalized	O
at	O
lamellipodia	O
in	O
the	O
vicinity	O
of	O
vinculin	O
.	O

Overexpressed	O
ING4	O
suppressed	O
cell	O
spreading	O
and	O
cell	O
migration	O
.	O

In	O
contrast	O
,	O
overexpressed	O
liprin	O
alpha1	O
enhanced	O
cell	O
spreading	O
and	O
cell	O
migration	O
.	O

Knockdown	O
of	O
endogenous	O
ING4	O
with	O
RNA	O
interference	O
induced	O
cell	O
motility	O
,	O
whereas	O
knockdown	O
of	O
endogenous	O
liprin	O
alpha1	O
suppressed	O
cell	O
motility	O
.	O

ING4	O
also	O
suppressed	O
cell	O
motility	O
that	O
was	O
enhanced	O
by	O
liprin	O
alpha1	O
.	O

However	O
,	O
ING4	O
did	O
not	O
further	O
suppress	O
cell	O
motility	O
when	O
liprin	O
alpha1	O
was	O
suppressed	O
with	O
RNA	O
interference	O
,	O
suggesting	O
a	O
functional	O
and	O
mechanistic	O
interdependence	O
between	O
these	O
proteins	O
.	O

In	O
addition	O
to	O
its	O
nuclear	O
functions	O
,	O
cytoplasmic	O
ING4	O
interacts	O
with	O
liprin	O
alpha1	O
to	O
regulate	O
cell	O
migration	O
and	O
,	O
with	O
its	O
known	O
antiangiogenic	O
function	O
,	O
may	O
prevent	O
invasion	O
and	O
metastasis	O
.	O

An	O
alternative	O
branch	O
of	O
the	O
nonsense	O
-	O
mediated	O
decay	O
pathway	O
.	O

The	O
T	B-Complex
-	I-Complex
cell	I-Complex
receptor	I-Complex
(	O
TCR	B-Complex
)	O
locus	O
undergoes	O
programmed	O
rearrangements	O
that	O
frequently	O
generate	O
premature	O
termination	O
codons	O
(	O
PTCs	O
)	O
.	O

The	O
PTC	O
-	O
bearing	O
transcripts	O
derived	O
from	O
such	O
nonproductively	O
rearranged	O
genes	O
are	O
dramatically	O
downregulated	O
by	O
the	O
nonsense	O
-	O
mediated	O
decay	O
(	O
NMD	O
)	O
pathway	O
.	O

Here	O
,	O
we	O
show	O
that	O
depletion	O
of	O
the	O
NMD	O
factor	O
UPF3b	O
does	O
not	O
impair	O
TCRbeta	O
NMD	O
,	O
thereby	O
distinguishing	O
it	O
from	O
classical	O
NMD	O
.	O

Depletion	O
of	O
the	O
related	O
factor	O
UPF3a	O
,	O
by	O
itself	O
or	O
in	O
combination	O
with	O
UPF3b	O
,	O
also	O
has	O
no	O
effect	O
on	O
TCRbeta	O
NMD	O
.	O

Mapping	O
experiments	O
revealed	O
the	O
identity	O
of	O
TCRbeta	O
sequences	O
that	O
elicit	O
a	O
switch	O
to	O
UPF3b	O
dependence	O
.	O

This	O
regulation	O
is	O
not	O
a	O
peculiarity	O
of	O
TCRbeta	O
,	O
as	O
we	O
identified	O
many	O
wild	O
-	O
type	O
genes	O
,	O
including	O
one	O
essential	O
for	O
NMD	O
,	O
that	O
transcribe	O
NMD	O
-	O
targeted	O
mRNAs	O
whose	O
downregulation	O
is	O
little	O
or	O
not	O
affected	O
by	O
UPF3a	O
and	O
UPF3b	O
depletion	O
.	O

We	O
propose	O
that	O
we	O
have	O
uncovered	O
an	O
alternative	O
branch	O
of	O
the	O
NMD	O
pathway	O
that	O
not	O
only	O
degrades	O
aberrant	O
mRNAs	O
but	O
also	O
regulates	O
normal	O
mRNAs	O
,	O
including	O
one	O
that	O
participates	O
in	O
a	O
negative	O
feedback	O
loop	O
controlling	O
the	O
magnitude	O
of	O
NMD	O
.	O

A	O
crucial	O
function	O
of	O
SGT1	O
and	O
HSP90	O
in	O
inflammasome	B-Complex
activity	O
links	O
mammalian	O
and	O
plant	O
innate	O
immune	O
responses	O
.	O

The	O
family	O
of	O
mammalian	O
Nod	O
-	O
like	O
receptors	O
(	O
NLRs	O
)	O
consists	O
of	O
critical	O
intracellular	O
immune	O
proteins	O
structurally	O
related	O
to	O
plant	O
resistance	O
proteins	O
.	O

The	O
NLRs	O
NALP3	O
and	O
IPAF	O
,	O
for	O
example	O
,	O
can	O
each	O
form	O
a	O
multiprotein	O
proinflammatory	O
complex	O
called	O
the	O
'	O
inflammasome	B-Complex
'	O
,	O
and	O
mutations	O
in	O
the	O
gene	O
encoding	O
Nod2	O
,	O
another	O
NLR	O
,	O
are	O
positively	O
associated	O
with	O
Crohn	O
disease	O
.	O

Here	O
we	O
show	O
that	O
many	O
NLRs	O
interacted	O
with	O
the	O
ubiquitin	O
ligase	O
-	O
associated	O
protein	O
SGT1	O
and	O
heat	O
-	O
shock	O
protein	O
90	O
(	O
HSP90	O
)	O
,	O
both	O
of	O
which	O
have	O
plant	O
orthologs	O
essential	O
for	O
R	O
-	O
protein	O
responses	O
.	O

'	O
Knockdown	O
'	O
of	O
SGT1	O
by	O
small	O
interfering	O
RNA	O
or	O
chemical	O
inhibition	O
of	O
HSP90	O
abrogated	O
inflammasome	B-Complex
activity	O
,	O
and	O
inhibition	O
of	O
HSP90	O
blocked	O
Nod2	O
-	O
mediated	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
and	O
reduced	O
NALP3	O
-	O
mediated	O
gout	O
-	O
like	O
inflammation	O
in	O
mice	O
.	O

Our	O
data	O
demonstrate	O
a	O
similarity	O
in	O
one	O
type	O
of	O
innate	O
immunity	O
in	O
plants	O
and	O
mammals	O
that	O
is	O
consistent	O
with	O
convergent	O
evolution	O
of	O
a	O
shared	O
mechanism	O
.	O

SCABP8	O
/	O
CBL10	O
,	O
a	O
putative	O
calcium	O
sensor	O
,	O
interacts	O
with	O
the	O
protein	O
kinase	O
SOS2	O
to	O
protect	O
Arabidopsis	O
shoots	O
from	O
salt	O
stress	O
.	O

The	O
SOS	O
(	O
for	O
Salt	O
Overly	O
Sensitive	O
)	O
pathway	O
plays	O
essential	O
roles	O
in	O
conferring	O
salt	O
tolerance	O
in	O
Arabidopsis	O
thaliana	O
.	O

Under	O
salt	O
stress	O
,	O
the	O
calcium	O
sensor	O
SOS3	O
activates	O
the	O
kinase	O
SOS2	O
that	O
positively	O
regulates	O
SOS1	O
,	O
a	O
plasma	O
membrane	O
sodium	O
/	O
proton	O
antiporter	O
.	O

We	O
show	O
that	O
SOS3	O
acts	O
primarily	O
in	O
roots	O
under	O
salt	O
stress	O
.	O

By	O
contrast	O
,	O
the	O
SOS3	O
homolog	O
SOS3	O
-	O
LIKE	O
CALCIUM	O
BINDING	O
PROTEIN8	O
(	O
SCABP8	O
)	O
/	O
CALCINEURIN	O
B	O
-	O
LIKE10	O
functions	O
mainly	O
in	O
the	O
shoot	O
response	O
to	O
salt	O
toxicity	O
.	O

While	O
root	O
growth	O
is	O
reduced	O
in	O
sos3	O
mutants	O
in	O
the	O
presence	O
of	O
NaCl	O
,	O
the	O
salt	O
sensitivity	O
of	O
scabp8	O
is	O
more	O
prominent	O
in	O
shoot	O
tissues	O
.	O

SCABP8	O
is	O
further	O
shown	O
to	O
bind	O
calcium	O
,	O
interact	O
with	O
SOS2	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
recruit	O
SOS2	O
to	O
the	O
plasma	O
membrane	O
,	O
enhance	O
SOS2	O
activity	O
in	O
a	O
calcium	O
-	O
dependent	O
manner	O
,	O
and	O
activate	O
SOS1	O
in	O
yeast	O
.	O

In	O
addition	O
,	O
sos3	O
scabp8	O
and	O
sos2	O
scabp8	O
display	O
a	O
phenotype	O
similar	O
to	O
sos2	O
,	O
which	O
is	O
more	O
sensitive	O
to	O
salt	O
than	O
either	O
sos3	O
or	O
scabp8	O
alone	O
.	O

Overexpression	O
of	O
SCABP8	O
in	O
sos3	O
partially	O
rescues	O
the	O
sos3	O
salt	O
-	O
sensitive	O
phenotype	O
.	O

However	O
,	O
overexpression	O
of	O
SOS3	O
fails	O
to	O
complement	O
scabp8	O
.	O

These	O
results	O
suggest	O
that	O
SCABP8	O
and	O
SOS3	O
are	O
only	O
partially	O
redundant	O
in	O
their	O
function	O
,	O
and	O
each	O
plays	O
additional	O
and	O
unique	O
roles	O
in	O
the	O
plant	O
salt	O
stress	O
response	O
.	O

The	O
E3	O
ligase	O
Aip4	O
/	O
Itch	O
ubiquitinates	O
and	O
targets	O
ErbB	O
-	O
4	O
for	O
degradation	O
.	O

The	O
ErbB	O
-	O
4	O
receptors	O
are	O
unique	O
in	O
the	O
EGFR	O
/	O
ErbB	O
family	O
for	O
the	O
ability	O
to	O
associate	O
with	O
WW	O
domain	O
-	O
containing	O
proteins	O
.	O

To	O
identify	O
new	O
ligands	O
of	O
the	O
cytoplasmic	O
tail	O
of	O
ErbB	O
-	O
4	O
,	O
we	O
panned	O
a	O
brain	O
cDNA	O
phage	O
library	O
with	O
ErbB	O
-	O
4	O
peptides	O
containing	O
sequence	O
motifs	O
corresponding	O
to	O
putative	O
docking	O
sites	O
for	O
class	O
-	O
I	O
WW	O
domains	O
.	O

This	O
approach	O
led	O
to	O
identification	O
of	O
AIP4	O
/	O
Itch	O
,	O
a	O
member	O
of	O
the	O
Nedd4	O
-	O
like	O
family	O
of	O
E3	O
ubiquitin	O
protein	O
ligases	O
,	O
as	O
a	O
protein	O
that	O
specifically	O
interacts	O
with	O
and	O
ubiquitinates	O
ErbB	O
-	O
4	O
in	O
vivo	O
.	O

Interaction	O
with	O
the	O
ErbB	O
-	O
4	O
receptors	O
occurs	O
via	O
the	O
WW	O
domains	O
of	O
AIP4	O
/	O
Itch	O
.	O

Functional	O
analyses	O
demonstrate	O
that	O
AIP4	O
/	O
Itch	O
is	O
recruited	O
to	O
the	O
ErbB	O
-	O
4	O
receptor	O
to	O
promote	O
its	O
polyubiquitination	O
and	O
degradation	O
,	O
thereby	O
regulating	O
stability	O
of	O
the	O
receptor	O
and	O
access	O
of	O
receptor	O
intracellular	O
domains	O
to	O
the	O
nuclear	O
compartment	O
.	O

These	O
findings	O
expand	O
our	O
understanding	O
of	O
the	O
mechanisms	O
contributing	O
to	O
the	O
integrity	O
of	O
the	O
ErbB	O
signaling	O
network	O
and	O
mechanistically	O
link	O
the	O
cellular	O
ubiquitination	O
pathway	O
of	O
AIP4	O
/	O
Itch	O
to	O
the	O
ErbB	O
-	O
4	O
receptor	O
.	O

Crystal	O
structure	O
of	O
pyruvate	O
dehydrogenase	O
phosphatase	O
1	O
and	O
its	O
functional	O
implications	O
.	O

Pyruvate	O
dehydrogenase	O
phosphatase	O
1	O
(	O
PDP1	O
)	O
catalyzes	O
dephosphorylation	O
of	O
pyruvate	B-Complex
dehydrogenase	I-Complex
(	O
E1	B-Complex
)	O
in	O
the	O
mammalian	O
pyruvate	B-Complex
dehydrogenase	I-Complex
complex	I-Complex
(	O
PDC	B-Complex
)	O
,	O
whose	O
activity	O
is	O
regulated	O
by	O
the	O
phosphorylation	O
-	O
dephosphorylation	O
cycle	O
by	O
the	O
corresponding	O
protein	O
kinases	O
(	O
PDHKs	O
)	O
and	O
phosphatases	O
.	O

The	O
activity	O
of	O
PDP1	O
is	O
greatly	O
enhanced	O
through	O
Ca2	O
+	O
-	O
dependent	O
binding	O
of	O
the	O
catalytic	O
subunit	O
(	O
PDP1c	O
)	O
to	O
the	O
L2	O
(	O
inner	O
lipoyl	O
)	O
domain	O
of	O
dihydrolipoyl	B-OOS
acetyltransferase	I-OOS
(	O
E2	B-OOS
)	O
,	O
which	O
is	O
also	O
integrated	O
in	O
PDC	B-Complex
.	O

Here	O
,	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
the	O
rat	O
PDP1c	O
at	O
1	O
.	O
8	O
A	O
resolution	O
.	O

The	O
structure	O
reveals	O
that	O
PDP1	O
belongs	O
to	O
the	O
PPM	O
family	O
of	O
protein	O
serine	O
/	O
threonine	O
phosphatases	O
,	O
which	O
,	O
in	O
spite	O
of	O
a	O
low	O
level	O
of	O
sequence	O
identity	O
,	O
share	O
the	O
structural	O
core	O
consisting	O
of	O
the	O
central	O
beta	O
-	O
sandwich	O
flanked	O
on	O
both	O
sides	O
by	O
loops	O
and	O
alpha	O
-	O
helices	O
.	O

Consistent	O
with	O
the	O
previous	O
studies	O
,	O
two	O
well	O
-	O
fixed	O
magnesium	O
ions	O
are	O
coordinated	O
by	O
five	O
active	O
site	O
residues	O
and	O
five	O
water	O
molecules	O
in	O
the	O
PDP1c	O
catalytic	O
center	O
.	O

Structural	O
analysis	O
indicates	O
that	O
,	O
while	O
the	O
central	O
portion	O
of	O
the	O
PDP1c	O
molecule	O
is	O
highly	O
conserved	O
among	O
the	O
members	O
of	O
the	O
PPM	O
protein	O
family	O
,	O
a	O
number	O
of	O
structural	O
insertions	O
and	O
deletions	O
located	O
at	O
the	O
periphery	O
of	O
PDP1c	O
likely	O
define	O
its	O
functional	O
specificity	O
towards	O
the	O
PDC	B-Complex
.	O

One	O
notable	O
feature	O
of	O
PDP1c	O
is	O
a	O
long	O
insertion	O
(	O
residues	O
98	O
-	O
151	O
)	O
forming	O
a	O
unique	O
hydrophobic	O
pocket	O
on	O
the	O
surface	O
that	O
likely	O
accommodates	O
the	O
lipoyl	O
moiety	O
of	O
the	O
E2	O
domain	O
in	O
a	O
fashion	O
similar	O
to	O
that	O
of	O
PDHKs	O
.	O

The	O
cavity	O
,	O
however	O
,	O
appears	O
more	O
open	O
than	O
in	O
PDHK	O
,	O
suggesting	O
that	O
its	O
closure	O
may	O
be	O
required	O
to	O
achieve	O
tight	O
,	O
specific	O
binding	O
of	O
the	O
lipoic	O
acid	O
.	O

We	O
propose	O
a	O
mechanism	O
in	O
which	O
the	O
closure	O
of	O
the	O
lipoic	O
acid	O
binding	O
site	O
is	O
triggered	O
by	O
the	O
formation	O
of	O
the	O
intermolecular	O
(	O
PDP1c	O
/	O
L2	O
)	O
Ca2	O
+	O
binding	O
site	O
in	O
a	O
manner	O
reminiscent	O
of	O
the	O
Ca2	O
+	O
-	O
induced	O
closure	O
of	O
the	O
regulatory	O
domain	O
of	O
troponin	O
C	O
.	O

Fra	O
-	O
1	O
and	O
Stat3	O
synergistically	O
regulate	O
activation	O
of	O
human	O
MMP	O
-	O
9	O
gene	O
.	O

Fra	O
-	O
1	O
is	O
overexpressed	O
in	O
a	O
variety	O
of	O
human	O
tumors	O
.	O

Whether	O
MMP	O
-	O
9	O
expression	O
is	O
regulated	O
by	O
Fra	O
-	O
1	O
has	O
been	O
contradictory	O
.	O

To	O
clarify	O
the	O
capability	O
of	O
Fra	O
-	O
1	O
in	O
activating	O
transcription	O
of	O
MMP	O
-	O
9	O
gene	O
,	O
we	O
analyzed	O
the	O
transcriptional	O
activity	O
of	O
the	O
MMP	O
-	O
9	O
promoter	O
through	O
the	O
measure	O
of	O
luciferase	O
activities	O
in	O
the	O
MCF	O
-	O
7	O
cells	O
transiently	O
transfected	O
with	O
Fra	O
-	O
1	O
.	O

The	O
positive	O
regulation	O
of	O
Fra	O
-	O
1	O
on	O
MMP	O
-	O
9	O
promoter	O
was	O
not	O
detectable	O
.	O

By	O
the	O
analysis	O
of	O
MMP	O
-	O
9	O
promoter	O
,	O
a	O
potential	O
Stat3	O
binding	O
site	O
,	O
just	O
juxtaposed	O
AP	B-Complex
-	I-Complex
1	I-Complex
consensus	O
sequence	O
,	O
was	O
noticed	O
.	O

The	O
reporter	O
assay	O
showed	O
that	O
MMP	O
-	O
9	O
promoter	O
was	O
activated	O
remarkably	O
by	O
cotransfection	O
with	O
Fra	O
-	O
1	O
and	O
Stat3C	O
.	O

DNA	O
affinity	O
precipitation	O
assay	O
confirmed	O
the	O
binding	O
of	O
Stat3	O
and	O
Fra	O
-	O
1	O
to	O
the	O
elements	O
of	O
MMP	O
-	O
9	O
promoter	O
and	O
also	O
revealed	O
c	O
-	O
Jun	O
recruited	O
to	O
Stat3	O
-	O
Fra	O
-	O
1	O
complex	O
.	O

By	O
immunoprecipitation	O
assay	O
,	O
the	O
Stat3	O
/	O
Fra	O
-	O
1	O
,	O
Stat3	O
/	O
c	O
-	O
Jun	O
and	O
Fra	O
-	O
1	O
/	O
c	O
-	O
Jun	O
complexes	O
were	O
identified	O
in	O
vivo	O
.	O

Our	O
study	O
demonstrated	O
that	O
the	O
activation	O
of	O
MMP	O
-	O
9	O
promoter	O
is	O
dependent	O
upon	O
interactions	O
of	O
Fra	O
-	O
1	O
/	O
c	O
-	O
Jun	O
with	O
Stat3	O
.	O

A	O
juxtaposed	O
Stat3	O
/	O
AP	B-Complex
-	I-Complex
1	I-Complex
element	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
manner	O
of	O
enhancersome	O
in	O
the	O
activation	O
of	O
MMP	O
-	O
9	O
gene	O
.	O

The	O
functional	O
cooperation	O
of	O
the	O
Stat3	O
and	O
AP	B-Complex
-	I-Complex
1	I-Complex
transcription	O
factors	O
is	O
required	O
for	O
the	O
transcription	O
of	O
MMP	O
-	O
9	O
gene	O
.	O

UBE1L2	O
,	O
a	O
novel	O
E1	O
enzyme	O
specific	O
for	O
ubiquitin	O
.	O

UBE1	O
is	O
known	O
as	O
the	O
human	O
ubiquitin	O
-	O
activating	O
enzyme	O
(	O
E1	O
)	O
,	O
which	O
activates	O
ubiquitin	O
in	O
an	O
ATP	O
-	O
dependent	O
manner	O
.	O

Here	O
,	O
we	O
identified	O
a	O
novel	O
human	O
ubiquitin	O
-	O
activating	O
enzyme	O
referred	O
to	O
as	O
UBE1L2	O
,	O
which	O
also	O
shows	O
specificity	O
for	O
ubiquitin	O
.	O

The	O
UBE1L2	O
sequence	O
displays	O
a	O
40	O
%	O
identity	O
to	O
UBE1	O
and	O
also	O
contains	O
an	O
ATP	O
-	O
binding	O
domain	O
and	O
an	O
active	O
site	O
cysteine	O
conserved	O
among	O
E1	O
family	O
proteins	O
.	O

UBE1L2	O
forms	O
a	O
covalent	O
link	O
with	O
ubiquitin	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
which	O
is	O
sensitive	O
to	O
reducing	O
conditions	O
.	O

In	O
an	O
in	O
vitro	O
polyubiquitylation	O
assay	O
,	O
recombinant	O
UBE1L2	O
could	O
activate	O
ubiquitin	O
and	O
transfer	O
it	O
onto	O
the	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
UbcH5b	O
.	O

Ubiquitin	O
activated	O
by	O
UBE1L2	O
could	O
be	O
used	O
for	O
ubiquitylation	O
of	O
p53	O
by	O
MDM2	O
and	O
supported	O
the	O
autoubiquitylation	O
of	O
the	O
E3	O
ubiquitin	O
ligases	O
HectH9	O
and	O
E6	O
-	O
AP	O
.	O

The	O
UBE1L2	O
mRNA	O
is	O
most	O
abundantly	O
expressed	O
in	O
the	O
testis	O
,	O
suggesting	O
an	O
organ	O
-	O
specific	O
regulation	O
of	O
ubiquitin	O
activation	O
.	O

A	O
functional	O
serine	O
118	O
phosphorylation	O
site	O
in	O
estrogen	O
receptor	O
-	O
alpha	O
is	O
required	O
for	O
down	O
-	O
regulation	O
of	O
gene	O
expression	O
by	O
17beta	O
-	O
estradiol	O
and	O
4	O
-	O
hydroxytamoxifen	O
.	O

To	O
evaluate	O
the	O
contribution	O
of	O
ERK1	O
/	O
2	O
phosphorylation	O
of	O
estrogen	O
receptor	O
(	O
ER	O
)	O
-	O
alpha	O
to	O
activation	O
and	O
repression	O
of	O
endogenous	O
genes	O
,	O
we	O
produced	O
stably	O
transfected	O
lines	O
of	O
HeLa	O
cells	O
with	O
functional	O
ERK1	O
/	O
2	O
pathways	O
that	O
express	O
similar	O
levels	O
of	O
wild	O
-	O
type	O
human	O
ERalpha	O
and	O
ERalpha	O
mutated	O
to	O
inactivate	O
the	O
well	O
-	O
known	O
MAPK	O
site	O
at	O
serine	O
118	O
(	O
ERalphaS118A	O
)	O
.	O

We	O
compared	O
effects	O
of	O
the	O
S118A	O
mutation	O
on	O
17beta	O
-	O
estradiol	O
(	O
E	O
(	O
2	O
)	O
)	O
-	O
mediated	O
transactivation	O
,	O
which	O
is	O
heavily	O
dependent	O
on	O
activation	O
function	O
(	O
AF	O
)	O
2	O
of	O
ERalpha	O
and	O
on	O
4	O
-	O
hydroxytamoxifen	O
(	O
OHT	O
)	O
-	O
mediated	O
transactivation	O
,	O
which	O
is	O
heavily	O
dependent	O
on	O
AF1	O
,	O
which	O
includes	O
S118	O
.	O

To	O
examine	O
whether	O
S118	O
was	O
the	O
key	O
ERK	O
/	O
MAPK	O
phosphorylation	O
site	O
in	O
ERalpha	O
action	O
,	O
we	O
compared	O
the	O
effects	O
of	O
the	O
S118A	O
mutant	O
and	O
the	O
ERK	O
inhibitor	O
U0126	O
on	O
expression	O
of	O
endogenous	O
genes	O
.	O

In	O
several	O
estrogen	O
response	O
element	O
-	O
containing	O
genes	O
,	O
the	O
S118A	O
mutation	O
strongly	O
reduced	O
induction	O
by	O
E	O
(	O
2	O
)	O
,	O
and	O
U0126	O
did	O
not	O
further	O
reduce	O
expression	O
.	O

Expression	O
of	O
another	O
group	O
of	O
estrogen	O
response	O
element	O
-	O
containing	O
genes	O
was	O
largely	O
unaffected	O
by	O
the	O
S118A	O
mutation	O
.	O

The	O
S118A	O
mutation	O
had	O
variable	O
effects	O
on	O
genes	O
induced	O
by	O
ER	O
tethering	O
or	O
binding	O
near	O
specificity	O
protein	O
-	O
1	O
and	O
activator	B-Complex
protein	I-Complex
-	I-Complex
1	I-Complex
sites	O
.	O

For	O
five	O
mRNAs	O
whose	O
expression	O
is	O
strongly	O
down	O
-	O
regulated	O
by	O
E	O
(	O
2	O
)	O
and	O
partially	O
or	O
completely	O
down	O
-	O
regulated	O
by	O
OHT	O
,	O
the	O
S118A	O
mutation	O
reduced	O
or	O
abolished	O
down	O
-	O
regulation	O
by	O
E	O
(	O
2	O
)	O
and	O
nearly	O
abolished	O
down	O
-	O
regulation	O
by	O
OHT	O
.	O

In	O
contrast	O
,	O
for	O
Sma	O
and	O
mothers	O
against	O
decapentaplegic	O
-	O
3	O
-	O
related	O
,	O
which	O
is	O
down	O
-	O
regulated	O
by	O
E	O
(	O
2	O
)	O
and	O
not	O
OHT	O
,	O
the	O
S118A	O
mutation	O
had	O
little	O
effect	O
.	O

These	O
data	O
suggest	O
that	O
there	O
may	O
be	O
distinct	O
groups	O
of	O
genes	O
down	O
-	O
regulated	O
by	O
ERalpha	O
and	O
suggest	O
a	O
novel	O
role	O
for	O
ERK	O
phosphorylation	O
at	O
serine	O
118	O
in	O
AF1	O
in	O
regulating	O
expression	O
of	O
the	O
set	O
of	O
genes	O
down	O
-	O
regulated	O
by	O
OHT	O
.	O

Increased	O
acylated	O
plasma	O
ghrelin	O
,	O
but	O
improved	O
lipid	O
profiles	O
24	O
-	O
h	O
after	O
consumption	O
of	O
carob	O
pulp	O
preparation	O
rich	O
in	O
dietary	O
fibre	O
and	O
polyphenols	O
.	O

We	O
have	O
recently	O
shown	O
that	O
a	O
polyphenol	O
-	O
rich	O
insoluble	O
dietary	O
fibre	O
preparation	O
from	O
carob	O
pulp	O
(	O
Ceratonia	O
siliqua	O
L	O
;	O
carob	O
fibre	O
)	O
decreased	O
postprandial	O
acylated	O
ghrelin	O
,	O
TAG	O
and	O
NEFA	O
during	O
an	O
acute	O
liquid	O
meal	O
challenge	O
test	O
.	O

However	O
,	O
delayed	O
effects	O
of	O
carob	O
fibre	O
consumption	O
are	O
unknown	O
.	O

Therefore	O
,	O
a	O
randomized	O
controlled	O
crossover	O
study	O
in	O
nineteen	O
healthy	O
volunteers	O
consuming	O
foods	O
with	O
or	O
without	O
50	O
g	O
carob	O
fibre	O
was	O
conducted	O
.	O

On	O
the	O
subsequent	O
day	O
(	O
day	O
2	O
)	O
,	O
glucose	O
,	O
TAG	O
,	O
total	O
and	O
acylated	O
ghrelin	O
as	O
well	O
as	O
insulin	O
,	O
NEFA	O
and	O
leptin	O
were	O
assessed	O
at	O
baseline	O
and	O
at	O
timed	O
intervals	O
for	O
300	O
min	O
after	O
ingestion	O
of	O
standardized	O
bread	O
.	O

Consumption	O
of	O
carob	O
fibre	O
-	O
enriched	O
foods	O
did	O
not	O
affect	O
fasting	O
concentrations	O
of	O
glucose	O
,	O
TAG	O
,	O
total	O
ghrelin	O
,	O
NEFA	O
,	O
insulin	O
and	O
leptin	O
.	O

Fasting	O
acylated	O
ghrelin	O
was	O
increased	O
on	O
the	O
day	O
subsequent	O
to	O
carob	O
fibre	O
consumption	O
compared	O
with	O
control	O
(	O
P	O
=	O
0	O
.	O
046	O
)	O
.	O

After	O
consumption	O
of	O
the	O
standard	O
bread	O
on	O
day	O
2	O
,	O
glucose	O
response	O
(	O
P	O
=	O
0	O
.	O
029	O
)	O
was	O
increased	O
,	O
and	O
TAG	O
(	O
P	O
=	O
0	O
.	O
033	O
)	O
and	O
NEFA	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
responses	O
were	O
decreased	O
compared	O
with	O
control	O
.	O

Postprandial	O
responses	O
of	O
total	O
and	O
acylated	O
ghrelin	O
,	O
insulin	O
and	O
leptin	O
on	O
day	O
2	O
were	O
unaffected	O
by	O
carob	O
fibre	O
consumption	O
the	O
previous	O
day	O
.	O

In	O
conclusion	O
,	O
an	O
increase	O
in	O
total	O
and	O
acylated	O
plasma	O
ghrelin	O
accompanied	O
by	O
enhanced	O
lipid	O
metabolism	O
after	O
carob	O
fibre	O
consumption	O
suggests	O
higher	O
lipid	O
utilization	O
and	O
suppressed	O
lipolysis	O
on	O
the	O
day	O
subsequent	O
to	O
carob	O
fibre	O
consumption	O
.	O

However	O
,	O
elevated	O
glucose	O
levels	O
after	O
carob	O
fibre	O
consumption	O
need	O
to	O
be	O
addressed	O
in	O
future	O
studies	O
.	O

High	O
occupancy	O
of	O
sigma	O
-	O
1	O
receptors	O
in	O
the	O
human	O
brain	O
after	O
single	O
oral	O
administration	O
of	O
fluvoxamine	O
:	O
a	O
positron	O
emission	O
tomography	O
study	O
using	O
[	O
11C	O
]	O
SA4503	O
.	O

BACKGROUND	O
:	O
Sigma	O
-	O
1	O
receptors	O
might	O
be	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
psychiatric	O
diseases	O
,	O
as	O
well	O
as	O
in	O
the	O
mechanisms	O
of	O
action	O
of	O
some	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
.	O

Among	O
the	O
several	O
SSRIs	O
,	O
fluvoxamine	O
has	O
the	O
highest	O
affinity	O
for	O
sigma	O
-	O
1	O
receptors	O
(	O
Ki	O
=	O
36	O
nM	O
)	O
,	O
whereas	O
paroxetine	O
shows	O
low	O
affinity	O
(	O
Ki	O
=	O
1893	O
nM	O
)	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
examine	O
whether	O
fluvoxamine	O
binds	O
to	O
sigma	O
-	O
1	O
receptors	O
in	O
living	O
human	O
brain	O
.	O

METHODS	O
:	O
A	O
dynamic	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
data	O
acquisition	O
using	O
the	O
selective	O
sigma	O
-	O
1	O
receptor	O
ligand	O
[	O
(	O
11	O
)	O
C	O
]	O
SA4503	O
was	O
performed	O
with	O
arterial	O
blood	O
sampling	O
to	O
evaluate	O
quantitatively	O
the	O
binding	O
of	O
[	O
(	O
11	O
)	O
C	O
]	O
SA4503	O
to	O
sigma	O
-	O
1	O
receptors	O
in	O
15	O
healthy	O
male	O
volunteers	O
.	O

Each	O
subject	O
had	O
two	O
PET	O
scans	O
before	O
and	O
after	O
randomly	O
receiving	O
a	O
single	O
dose	O
of	O
either	O
fluvoxamine	O
(	O
50	O
,	O
100	O
,	O
150	O
,	O
or	O
200	O
mg	O
)	O
or	O
paroxetine	O
(	O
20	O
mg	O
)	O
.	O

The	O
binding	O
potential	O
of	O
[	O
(	O
11	O
)	O
C	O
]	O
SA4503	O
in	O
9	O
regions	O
of	O
the	O
brain	O
was	O
calculated	O
by	O
a	O
2	O
-	O
tissue	O
3	O
-	O
compartment	O
model	O
.	O

In	O
addition	O
,	O
we	O
examined	O
the	O
effects	O
of	O
functional	O
polymorphisms	O
of	O
the	O
sigma	O
-	O
1	O
receptor	O
(	O
SIGMAR1	O
)	O
gene	O
on	O
the	O
binding	O
potential	O
of	O
[	O
(	O
11	O
)	O
C	O
]	O
SA4503	O
.	O

RESULTS	O
:	O
Fluvoxamine	O
bound	O
to	O
sigma	O
-	O
1	O
receptors	O
in	O
all	O
brain	O
regions	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
whereas	O
paroxetine	O
did	O
not	O
bind	O
to	O
sigma	O
-	O
1	O
receptors	O
.	O

However	O
,	O
there	O
was	O
no	O
association	O
between	O
the	O
SIGMAR1	O
gene	O
polymorphism	O
GC	O
-	O
241	O
-	O
240TT	O
and	O
binding	O
potential	O
.	O

CONCLUSIONS	O
:	O
The	O
study	O
demonstrated	O
that	O
fluvoxamine	O
bound	O
to	O
sigma	O
-	O
1	O
receptors	O
in	O
living	O
human	O
brain	O
at	O
therapeutic	O
doses	O
.	O

These	O
findings	O
suggest	O
that	O
sigma	O
-	O
1	O
receptors	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
fluvoxamine	O
.	O

Herpes	O
simplex	O
virus	O
protein	O
UL11	O
but	O
not	O
UL51	O
is	O
associated	O
with	O
lipid	O
rafts	O
.	O

The	O
UL11	O
and	O
UL51	O
gene	O
products	O
of	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
are	O
membrane	O
-	O
associated	O
tegument	O
proteins	O
that	O
are	O
incorporated	O
into	O
the	O
HSV	O
virion	O
.	O

UL11	O
and	O
UL51	O
are	O
conserved	O
throughout	O
the	O
herpesvirus	O
family	O
.	O

Both	O
UL11	O
and	O
UL51	O
,	O
either	O
singly	O
or	O
in	O
combination	O
,	O
are	O
involved	O
in	O
virion	O
envelopment	O
and	O
/	O
or	O
egress	O
.	O

Both	O
proteins	O
are	O
fatty	O
acylated	O
:	O
UL11	O
is	O
both	O
acylated	O
by	O
myristoic	O
and	O
palmitoic	O
acids	O
and	O
UL51	O
is	O
monoacylated	O
by	O
palmitoic	O
acid	O
.	O

Using	O
confocal	O
microscopy	O
and	O
sucrose	O
gradient	O
fractionations	O
in	O
transfected	O
or	O
HSV	O
-	O
infected	O
cells	O
,	O
we	O
found	O
that	O
HSV	O
-	O
2	O
UL11	O
but	O
not	O
UL51	O
was	O
associated	O
with	O
lipid	O
rafts	O
.	O

The	O
dual	O
acylation	O
of	O
UL11	O
was	O
necessary	O
for	O
lipid	O
raft	O
association	O
,	O
as	O
mutations	O
in	O
the	O
myristoylation	O
or	O
palmitoylation	O
sites	O
prevented	O
lipid	O
raft	O
association	O
.	O

These	O
differences	O
in	O
lipid	O
raft	O
association	O
may	O
contribute	O
to	O
the	O
functional	O
differences	O
between	O
UL11	O
and	O
UL51	O
.	O

Activation	O
of	O
RNA	B-Complex
polymerase	I-Complex
I	I-Complex
transcription	O
by	O
cockayne	O
syndrome	O
group	O
B	O
protein	O
and	O
histone	O
methyltransferase	O
G9a	O
.	O

Cockayne	O
syndrome	O
group	O
B	O
(	O
CSB	O
)	O
protein	O
plays	O
a	O
role	O
in	O
both	O
transcription	O
-	O
coupled	O
DNA	O
repair	O
and	O
transcriptional	O
regulation	O
of	O
all	O
three	O
classes	O
of	O
nuclear	O
RNA	O
polymerases	O
.	O

Here	O
we	O
show	O
that	O
a	O
complex	O
consisting	O
of	O
CSB	O
,	O
RNA	B-Complex
polymerase	I-Complex
I	I-Complex
(	O
Pol	B-Complex
I	I-Complex
)	O
,	O
and	O
histone	O
methyltransferase	O
G9a	O
is	O
present	O
at	O
active	O
rRNA	O
genes	O
.	O

G9a	O
methylates	O
histone	O
H3	O
on	O
lysine	O
9	O
(	O
H3K9me2	O
)	O
in	O
the	O
pre	O
-	O
rRNA	O
coding	O
region	O
and	O
facilitates	O
the	O
association	O
of	O
heterochromatin	O
protein	O
1gamma	O
(	O
HP1gamma	O
)	O
with	O
rDNA	O
.	O

Both	O
H3K9	O
methylation	O
and	O
HP1gamma	O
association	O
require	O
ongoing	O
transcription	O
.	O

Knockdown	O
of	O
CSB	O
prevents	O
the	O
association	O
of	O
Pol	B-Complex
I	I-Complex
with	O
rDNA	O
,	O
impairs	O
the	O
interaction	O
of	O
G9a	O
with	O
Pol	B-Complex
I	I-Complex
,	O
and	O
inhibits	O
pre	O
-	O
rRNA	O
synthesis	O
.	O

Likewise	O
,	O
knockdown	O
of	O
G9a	O
leads	O
to	O
decreased	O
levels	O
of	O
H3K9me2	O
in	O
the	O
transcribed	O
region	O
and	O
downregulation	O
of	O
pre	O
-	O
rRNA	O
synthesis	O
.	O

The	O
results	O
reveal	O
the	O
mechanism	O
underlying	O
CSB	O
-	O
mediated	O
activation	O
of	O
rDNA	O
transcription	O
and	O
link	O
G9a	O
-	O
dependent	O
H3K9	O
methylation	O
to	O
Pol	B-Complex
I	I-Complex
transcription	O
elongation	O
through	O
chromatin	O
.	O

Identification	O
of	O
the	O
substrate	O
binding	O
region	O
of	O
vesicular	O
monoamine	O
transporter	O
-	O
2	O
(	O
VMAT	O
-	O
2	O
)	O
using	O
iodoaminoflisopolol	O
as	O
a	O
novel	O
photoprobe	O
.	O

Monoamines	O
,	O
such	O
as	O
serotonin	O
,	O
dopamine	O
,	O
and	O
norepinephrine	O
,	O
are	O
sequestered	O
into	O
synaptic	O
vesicles	O
by	O
specific	O
transporters	O
(	O
vesicular	O
monoamine	O
transporter	O
-	O
2	O
;	O
VMAT2	O
)	O
using	O
energy	O
from	O
an	O
electrochemical	O
proton	O
gradient	O
across	O
the	O
vesicle	O
membranes	O
.	O

Based	O
on	O
our	O
previous	O
studies	O
using	O
photoaffinity	O
-	O
labeling	O
techniques	O
in	O
characterizing	O
the	O
VMAT2	O
-	O
specific	O
ligands	O
ketanserin	O
and	O
tetrabenazine	O
,	O
this	O
study	O
describes	O
the	O
synthesis	O
and	O
characterization	O
of	O
a	O
fluorenone	O
-	O
based	O
compound	O
,	O
iodoaminoflisopolol	O
(	O
IAmF	O
)	O
,	O
as	O
a	O
photoprobe	O
to	O
identify	O
the	O
substrate	O
binding	O
site	O
(	O
s	O
)	O
of	O
VMAT2	O
.	O

Using	O
vesicles	O
prepared	O
from	O
rat	O
VMAT2	O
containing	O
recombinant	O
baculovirus	O
-	O
infected	O
Sf9	O
cells	O
,	O
we	O
show	O
the	O
inhibition	O
of	O
[	O
3H	O
]	O
5	O
-	O
hydroxytryptamine	O
(	O
5	O
-	O
HT	O
)	O
uptake	O
and	O
[	O
3H	O
]	O
dihydrotetrabenazine	O
(	O
TBZOH	O
)	O
binding	O
by	O
aminoflisopolol	O
and	O
iodoaminoflisopolol	O
.	O

The	O
interaction	O
of	O
[	O
125I	O
]	O
IAmF	O
with	O
VMAT2	O
is	O
highly	O
dependent	O
on	O
the	O
presence	O
of	O
ATP	O
and	O
an	O
intact	O
proton	O
gradient	O
.	O

We	O
report	O
a	O
simple	O
and	O
novel	O
method	O
to	O
distinguish	O
between	O
a	O
ligand	O
and	O
substrate	O
using	O
classic	O
compounds	O
such	O
as	O
[	O
3H	O
]	O
5	O
-	O
HT	O
and	O
[	O
3H	O
]	O
TBZOH	O
by	O
incubating	O
the	O
compound	O
with	O
the	O
vesicles	O
followed	O
by	O
washes	O
with	O
isotonic	O
and	O
hypotonic	O
solutions	O
.	O

Using	O
this	O
method	O
,	O
we	O
confirm	O
the	O
characterization	O
of	O
IAmF	O
as	O
a	O
novel	O
VMAT2	O
substrate	O
.	O

Sf9	O
vesicles	O
expressing	O
VMAT2	O
show	O
reserpine	O
-	O
and	O
tetrabenazine	O
-	O
protectable	O
photolabeling	O
by	O
[	O
125I	O
]	O
IAmF	O
.	O

[	O
125I	O
]	O
IAmF	O
photolabeling	O
of	O
recombinant	O
VMAT2	O
,	O
expressed	O
in	O
SH	O
-	O
SY5Y	O
cells	O
with	O
an	O
engineered	O
thrombin	O
site	O
between	O
transmembranes	O
6	O
and	O
7	O
,	O
followed	O
by	O
thrombin	O
digestion	O
,	O
retained	O
photolabel	O
in	O
a	O
22	O
-	O
kDa	O
fragment	O
,	O
indicating	O
that	O
iodoaminoflisopolol	O
binds	O
to	O
the	O
C	O
-	O
terminal	O
half	O
of	O
the	O
VMAT2	O
molecule	O
.	O

Thus	O
,	O
IAmF	O
possesses	O
a	O
unique	O
combination	O
of	O
VMAT2	O
substrate	O
properties	O
and	O
a	O
photoprobe	O
and	O
is	O
,	O
therefore	O
,	O
useful	O
to	O
identify	O
the	O
substrate	O
binding	O
site	O
of	O
the	O
vesicular	O
transporter	O
.	O

Altered	O
pattern	O
of	O
Cul	O
-	O
1	O
protein	O
expression	O
and	O
neddylation	O
in	O
human	O
lung	O
tumours	O
:	O
relationships	O
with	O
CAND1	O
and	O
cyclin	O
E	O
protein	O
levels	O
.	O

The	O
Cul	O
-	O
1	O
protein	O
is	O
the	O
scaffold	O
element	O
of	O
SCF	B-Complex
complexes	O
that	O
are	O
involved	O
in	O
the	O
proteasomal	O
degradation	O
of	O
numerous	O
proteins	O
regulating	O
cell	O
cycle	O
progression	O
.	O

Owing	O
to	O
this	O
central	O
role	O
in	O
cell	O
growth	O
control	O
,	O
aberrant	O
expression	O
of	O
the	O
components	O
of	O
SCF	B-Complex
is	O
thought	O
to	O
play	O
a	O
role	O
during	O
tumourigenesis	O
.	O

Nothing	O
is	O
known	O
about	O
Cul	O
-	O
1	O
expression	O
in	O
human	O
tumours	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
analysed	O
its	O
status	O
in	O
a	O
series	O
of	O
128	O
human	O
lung	O
carcinomas	O
,	O
comprising	O
50	O
non	O
-	O
small	O
cell	O
lung	O
cancers	O
(	O
NSCLCs	O
;	O
29	O
squamous	O
cell	O
carcinomas	O
and	O
21	O
adenocarcinomas	O
)	O
and	O
78	O
neuroendocrine	O
(	O
NE	O
)	O
lung	O
tumours	O
(	O
24	O
typical	O
and	O
atypical	O
carcinoids	O
,	O
19	O
large	O
cell	O
NE	O
carcinomas	O
and	O
35	O
small	O
cell	O
lung	O
carcinomas	O
)	O
,	O
using	O
immunohistochemistry	O
.	O

We	O
report	O
for	O
the	O
first	O
time	O
an	O
altered	O
pattern	O
of	O
Cul	O
-	O
1	O
expression	O
in	O
human	O
tumours	O
;	O
indeed	O
,	O
we	O
show	O
that	O
Cul	O
-	O
1	O
expression	O
is	O
up	O
-	O
regulated	O
in	O
40	O
%	O
(	O
51	O
/	O
128	O
)	O
of	O
all	O
lung	O
tumours	O
as	O
compared	O
to	O
normal	O
lung	O
tissues	O
,	O
including	O
34	O
%	O
(	O
17	O
/	O
50	O
)	O
,	O
75	O
%	O
(	O
18	O
/	O
24	O
)	O
and	O
30	O
%	O
(	O
16	O
/	O
54	O
)	O
of	O
NSCLCs	O
,	O
carcinoids	O
and	O
high	O
grade	O
neuroendocrine	O
lung	O
carcinomas	O
,	O
respectively	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
high	O
levels	O
of	O
Cul	O
-	O
1	O
protein	O
are	O
associated	O
with	O
a	O
low	O
KI67	O
proliferative	O
index	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
and	O
with	O
a	O
decrease	O
in	O
the	O
cyclin	O
E	O
oncoprotein	O
(	O
p	O
=	O
0	O
.	O
0003	O
)	O
,	O
one	O
of	O
the	O
major	O
targets	O
of	O
SCF	B-Complex
complexes	O
.	O

These	O
data	O
suggest	O
that	O
up	O
-	O
regulation	O
of	O
Cul	O
-	O
1	O
could	O
protect	O
cells	O
from	O
hyperproliferative	O
signals	O
through	O
cyclin	O
E	O
down	O
-	O
regulation	O
.	O

Cul	O
-	O
1	O
is	O
modified	O
by	O
neddylation	O
,	O
a	O
post	O
-	O
translational	O
modification	O
that	O
grafts	O
ubiquitin	O
-	O
like	O
Nedd8	O
/	O
Rub1	O
residues	O
and	O
controls	O
Cul	O
-	O
1	O
activity	O
.	O

We	O
also	O
provide	O
evidence	O
that	O
neddylated	O
forms	O
of	O
Cul	O
-	O
1	O
are	O
specifically	O
expressed	O
in	O
high	O
-	O
grade	O
NE	O
lung	O
tumours	O
and	O
are	O
associated	O
with	O
down	O
-	O
regulation	O
of	O
the	O
Cul	O
-	O
1	O
inhibitor	O
CAND1	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
and	O
a	O
high	O
level	O
of	O
cyclin	O
E	O
(	O
p	O
=	O
0	O
.	O
0002	O
)	O
.	O

These	O
data	O
support	O
the	O
notion	O
that	O
alterations	O
in	O
the	O
Cul	O
-	O
1	O
neddylation	O
/	O
deneddylation	O
pathway	O
could	O
contribute	O
to	O
the	O
development	O
of	O
these	O
highly	O
aggressive	O
lung	O
tumours	O
.	O

Structural	O
requirements	O
for	O
the	O
BARD1	O
tumor	O
suppressor	O
in	O
chromosomal	O
stability	O
and	O
homology	O
-	O
directed	O
DNA	O
repair	O
.	O

The	O
BRCA1	O
tumor	O
suppressor	O
exists	O
as	O
a	O
heterodimeric	O
complex	O
with	O
BARD1	O
,	O
and	O
this	O
complex	O
is	O
thought	O
to	O
mediate	O
many	O
of	O
the	O
functions	O
ascribed	O
to	O
BRCA1	O
,	O
including	O
its	O
role	O
in	O
tumor	O
suppression	O
.	O

The	O
two	O
proteins	O
share	O
a	O
common	O
structural	O
organization	O
that	O
features	O
an	O
N	O
-	O
terminal	O
RING	O
domain	O
and	O
two	O
C	O
-	O
terminal	O
BRCT	O
motifs	O
,	O
whereas	O
BARD1	O
alone	O
also	O
contains	O
three	O
tandem	O
ankyrin	O
repeats	O
.	O

In	O
normal	O
cells	O
,	O
the	O
BRCA1	O
/	O
BARD1	O
heterodimer	O
is	O
believed	O
to	O
enhance	O
chromosome	O
stability	O
by	O
promoting	O
homology	O
-	O
directed	O
repair	O
(	O
HDR	O
)	O
of	O
double	O
strand	O
DNA	O
breaks	O
.	O

Here	O
we	O
have	O
investigated	O
the	O
structural	O
requirements	O
for	O
BARD1	O
in	O
this	O
process	O
by	O
complementation	O
of	O
Bard1	O
-	O
null	O
mouse	O
mammary	O
carcinoma	O
cells	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
ankyrin	O
and	O
BRCT	O
motifs	O
of	O
BARD1	O
are	O
each	O
essential	O
for	O
both	O
chromosome	O
stability	O
and	O
HDR	O
.	O

Tandem	O
BRCT	O
motifs	O
,	O
including	O
those	O
found	O
at	O
the	O
C	O
terminus	O
of	O
BARD1	O
,	O
are	O
known	O
to	O
form	O
a	O
phosphoprotein	O
recognition	O
module	O
.	O

Nonetheless	O
,	O
the	O
HDR	O
function	O
of	O
BARD1	O
was	O
not	O
perturbed	O
by	O
synthetic	O
mutations	O
predicted	O
to	O
ablate	O
the	O
phospho	O
-	O
recognition	O
activity	O
of	O
its	O
BRCT	O
sequences	O
,	O
suggesting	O
that	O
some	O
functions	O
of	O
the	O
BRCT	O
domains	O
are	O
not	O
dependent	O
on	O
their	O
ability	O
to	O
bind	O
phosphorylated	O
ligands	O
.	O

Also	O
,	O
cancer	O
-	O
associated	O
missense	O
mutations	O
in	O
the	O
BRCT	O
domains	O
of	O
BARD1	O
(	O
e	O
.	O
g	O
.	O
C557S	O
,	O
Q564H	O
,	O
V695L	O
,	O
and	O
S761N	O
)	O
have	O
been	O
observed	O
in	O
patients	O
with	O
breast	O
,	O
ovarian	O
,	O
and	O
endometrial	O
tumors	O
.	O

However	O
,	O
none	O
of	O
these	O
was	O
found	O
to	O
affect	O
the	O
HDR	O
activity	O
of	O
BARD1	O
,	O
suggesting	O
that	O
any	O
increased	O
cancer	O
risk	O
conferred	O
by	O
these	O
mutations	O
is	O
not	O
because	O
of	O
defects	O
in	O
this	O
repair	O
mechanism	O
.	O

Although	O
the	O
above	O
-	O
mentioned	O
simulation	O
must	O
be	O
regarded	O
as	O
very	O
preliminary	O
and	O
will	O
have	O
to	O
be	O
validated	O
by	O
more	O
advanced	O
computational	O
methods	O
and	O
perhaps	O
also	O
by	O
biophysical	O
measurements	O
,	O
it	O
generally	O
agrees	O
with	O
our	O
experimental	O
finding	O
that	O
mutations	O
of	O
residues	O
at	O
the	O
Trm6p	O
/	O
Trm61p	O
interface	O
do	O
not	O
disrupt	O
oligomerization	O
,	O
but	O
interfere	O
with	O
tRNA	O
binding	O
.	O

Thus	O
,	O
we	O
propose	O
that	O
the	O
presence	O
of	O
salt	O
bridges	O
in	O
the	O
yeast	O
m1A58	O
Mtase	O
(	O
Trm61p	O
-	O
E255	O
and	O
Trm6p	O
-	O
R420	O
,	O
and	O
between	O
Trm6p	O
-	O
E416	O
and	O
Trm61p	O
-	O
R259	O
)	O
,	O
and	O
most	O
likely	O
also	O
in	O
bacterial	O
TrmI	O
Mtases	O
(	O
e	O
.	O
g	O
.	O
E299	O
-	O
R233	O
in	O
Rv2118c	O
)	O
,	O
serves	O
to	O
establish	O
the	O
structure	O
of	O
the	O
tRNA	O
-	O
binding	O
region	O
rather	O
than	O
to	O
promote	O
binding	O
of	O
subunits	O
to	O
each	O
other	O
.	O

We	O
hypothesize	O
that	O
the	O
mutations	O
reported	O
in	O
this	O
work	O
could	O
have	O
long	O
-	O
range	O
structural	O
effects	O
on	O
the	O
conformation	O
of	O
the	O
positively	O
charged	O
loop	O
(	O
residues	O
265	O
-	O
345	O
)	O
in	O
the	O
Trm61p	O
subunit	O
,	O
which	O
may	O
be	O
involved	O
in	O
tRNA	O
binding	O
.	O

By	O
identifying	O
amino	O
acids	O
involved	O
in	O
tRNA	O
binding	O
,	O
this	O
study	O
has	O
provided	O
a	O
foundation	O
on	O
which	O
further	O
studies	O
can	O
be	O
built	O
,	O
such	O
as	O
experiments	O
to	O
address	O
our	O
hypothesis	O
regarding	O
tRNA	O
binding	O
and	O
to	O
determine	O
how	O
the	O
yeast	O
m1A58	O
Mtase	O
is	O
able	O
to	O
recognize	O
substrate	O
tRNAs	O
amongst	O
the	O
cellular	O
tRNA	O
pool	O
.	O

Tousled	O
-	O
like	O
kinase	O
in	O
a	O
microbial	O
eukaryote	O
regulates	O
spindle	O
assembly	O
and	O
S	O
-	O
phase	O
progression	O
by	O
interacting	O
with	O
Aurora	O
kinase	O
and	O
chromatin	O
assembly	O
factors	O
.	O

The	O
Tousled	O
-	O
like	O
kinases	O
are	O
an	O
evolutionarily	O
conserved	O
family	O
of	O
proteins	O
implicated	O
in	O
DNA	O
repair	O
,	O
DNA	O
replication	O
and	O
mitosis	O
in	O
metazoans	O
and	O
plants	O
.	O

Their	O
absence	O
from	O
the	O
yeasts	O
and	O
other	O
eukaryotic	O
'	O
microbes	O
'	O
suggests	O
a	O
specific	O
role	O
for	O
them	O
in	O
the	O
development	O
of	O
multicellular	O
organisms	O
.	O

In	O
this	O
study	O
,	O
two	O
closely	O
related	O
Tousled	O
-	O
like	O
kinase	O
homologs	O
,	O
TLK1	O
and	O
TLK2	O
,	O
were	O
identified	O
in	O
Trypanosoma	O
brucei	O
,	O
a	O
unicellular	O
protozoan	O
parasite	O
.	O

Only	O
TLK1	O
plays	O
an	O
essential	O
role	O
in	O
cell	O
growth	O
,	O
and	O
a	O
deficiency	O
in	O
TLK1	O
led	O
to	O
an	O
enrichment	O
of	O
S	O
-	O
phase	O
cells	O
,	O
defective	O
spindle	O
formation	O
and	O
aberrant	O
chromosome	O
segregation	O
.	O

Although	O
both	O
TLK	O
proteins	O
localize	O
to	O
the	O
nucleus	O
,	O
only	O
TLK1	O
also	O
concentrates	O
in	O
the	O
spindle	O
poles	O
during	O
mitosis	O
.	O

Both	O
TLK	O
proteins	O
are	O
phosphorylated	O
by	O
the	O
Aurora	O
kinase	O
(	O
AUK1	O
)	O
,	O
and	O
both	O
can	O
autophosphorylate	O
and	O
phosphorylate	O
histone	O
H3	O
and	O
the	O
chromatin	O
assembly	O
factors	O
Asf1A	O
and	O
Asf1B	O
in	O
vitro	O
,	O
but	O
only	O
TLK1	O
is	O
autophosphorylated	O
and	O
capable	O
of	O
oligomerizing	O
and	O
interacting	O
with	O
AUK1	O
,	O
Asf1A	O
and	O
Asf1B	O
in	O
vivo	O
.	O

These	O
discrepancies	O
between	O
the	O
two	O
TLK	O
proteins	O
can	O
be	O
attributed	O
to	O
minor	O
differences	O
between	O
their	O
N	O
-	O
and	O
C	O
-	O
terminal	O
sequences	O
.	O

In	O
summary	O
,	O
TLK1	O
cooperates	O
with	O
Aurora	O
kinase	O
to	O
regulate	O
spindle	O
assembly	O
and	O
chromosome	O
segregation	O
,	O
and	O
it	O
performs	O
a	O
role	O
in	O
DNA	O
replication	O
probably	O
by	O
regulating	O
histone	O
modification	O
in	O
trypanosomes	O
.	O

Regulation	O
of	O
histone	O
modification	O
and	O
cryptic	O
transcription	O
by	O
the	O
Bur1	O
and	O
Paf1	B-Complex
complexes	O
.	O

The	O
Bur1	O
-	O
Bur2	O
and	O
Paf1	B-Complex
complexes	O
function	O
during	O
transcription	O
elongation	O
and	O
affect	O
histone	O
modifications	O
.	O

Here	O
we	O
describe	O
new	O
roles	O
for	O
Bur1	O
-	O
Bur2	O
and	O
the	O
Paf1	B-Complex
complex	O
.	O

We	O
find	O
that	O
histone	O
H3	O
K36	O
tri	O
-	O
methylation	O
requires	O
specific	O
components	O
of	O
the	O
Paf1	B-Complex
complex	O
and	O
that	O
K36	O
tri	O
-	O
methylation	O
is	O
more	O
strongly	O
affected	O
at	O
the	O
5	O
'	O
ends	O
of	O
genes	O
in	O
paf1delta	O
and	O
bur2delta	O
strains	O
in	O
parallel	O
with	O
increased	O
acetylation	O
of	O
histones	O
H3	O
and	O
H4	O
.	O

Interestingly	O
,	O
the	O
5	O
'	O
increase	O
in	O
histone	O
acetylation	O
is	O
independent	O
of	O
K36	O
methylation	O
,	O
and	O
therefore	O
is	O
mechanistically	O
distinct	O
from	O
the	O
methylation	O
-	O
driven	O
deacetylation	O
that	O
occurs	O
at	O
the	O
3	O
'	O
ends	O
of	O
genes	O
.	O

Finally	O
,	O
Bur1	O
-	O
Bur2	O
and	O
the	O
Paf1	B-Complex
complex	O
have	O
a	O
second	O
methylation	O
-	O
independent	O
function	O
,	O
since	O
bur2delta	O
set2delta	O
and	O
paf1delta	O
set2delta	O
double	O
mutants	O
display	O
enhanced	O
histone	O
acetylation	O
at	O
the	O
3	O
'	O
ends	O
of	O
genes	O
and	O
increased	O
cryptic	O
transcription	O
initiation	O
.	O

These	O
findings	O
identify	O
new	O
functions	O
for	O
the	O
Paf1	B-Complex
and	O
Bur1	O
-	O
Bur2	O
complexes	O
,	O
provide	O
evidence	O
that	O
histone	O
modifications	O
at	O
the	O
5	O
'	O
and	O
3	O
'	O
ends	O
of	O
coding	O
regions	O
are	O
regulated	O
by	O
distinct	O
mechanisms	O
,	O
and	O
reveal	O
that	O
the	O
Bur1	O
-	O
Bur2	O
and	O
Paf1	B-Complex
complexes	O
repress	O
cryptic	O
transcription	O
through	O
a	O
Set2	O
-	O
independent	O
pathway	O
.	O

Brca1	O
in	O
immunoglobulin	O
gene	O
conversion	O
and	O
somatic	O
hypermutation	O
.	O

Defects	O
in	O
Brca1	O
confer	O
susceptibility	O
to	O
breast	O
cancer	O
and	O
genomic	O
instability	O
indicative	O
of	O
aberrant	O
repair	O
of	O
DNA	O
breaks	O
.	O

Brca1	O
was	O
previously	O
implicated	O
in	O
the	O
homologous	O
recombination	O
pathway	O
via	O
effects	O
on	O
the	O
assembly	O
of	O
recombinase	O
Rad51	O
.	O

Activation	O
-	O
induced	O
cytidine	O
deaminase	O
(	O
AID	O
)	O
deaminates	O
C	O
to	O
U	O
in	O
B	O
lymphocyte	O
immunoglobulin	O
(	O
Ig	O
)	O
DNA	O
to	O
initiate	O
programmed	O
DNA	O
breaks	O
.	O

Subsequent	O
uracil	O
-	O
glycosylase	O
mediated	O
U	O
removal	O
,	O
and	O
perhaps	O
further	O
processing	O
,	O
leads	O
to	O
four	O
known	O
classes	O
of	O
mutation	O
:	O
Ig	O
class	O
switch	O
recombination	O
that	O
results	O
in	O
a	O
region	O
-	O
specific	O
genomic	O
deletion	O
,	O
Ig	O
somatic	O
hypermutation	O
that	O
introduces	O
point	O
mutations	O
in	O
Ig	O
V	O
-	O
regions	O
,	O
Ig	O
gene	O
conversion	O
in	O
vertebrates	O
that	O
possess	O
Ig	O
pseudo	O
-	O
V	O
genes	O
,	O
and	O
translocations	O
common	O
to	O
B	O
cell	O
lymphomas	O
.	O

We	O
tested	O
the	O
involvement	O
of	O
Brca1	O
in	O
AID	O
-	O
dependent	O
Ig	O
diversification	O
in	O
chicken	O
DT40	O
cells	O
.	O

The	O
DT40	O
cell	O
line	O
diversifies	O
IgVlambda	O
mainly	O
by	O
gene	O
conversion	O
,	O
and	O
less	O
so	O
by	O
point	O
mutation	O
.	O

Brca1	O
-	O
deficiency	O
caused	O
a	O
shift	O
in	O
Vlambda	O
diversification	O
,	O
significantly	O
reducing	O
the	O
proportion	O
of	O
gene	O
conversions	O
relative	O
to	O
point	O
mutations	O
.	O

Thus	O
,	O
Brca1	O
regulates	O
AID	O
-	O
dependent	O
DNA	O
lesion	O
repair	O
.	O

Interestingly	O
,	O
while	O
Brca1	O
is	O
required	O
to	O
recruit	O
ubiquitinated	O
FancD2	O
to	O
DNA	O
damage	O
,	O
the	O
phenotype	O
of	O
Brca1	O
-	O
deficient	O
DT40	O
differs	O
from	O
the	O
one	O
of	O
FancD2	O
-	O
deficient	O
DT40	O
,	O
in	O
which	O
both	O
gene	O
conversion	O
and	O
non	O
-	O
templated	O
mutations	O
are	O
impaired	O
.	O

Ubiquitination	O
of	O
alpha	O
-	O
synuclein	O
by	O
Siah	O
-	O
1	O
promotes	O
alpha	O
-	O
synuclein	O
aggregation	O
and	O
apoptotic	O
cell	O
death	O
.	O

Point	O
mutations	O
and	O
gene	O
multiplication	O
of	O
alpha	O
-	O
synuclein	O
cause	O
autosomal	O
dominant	O
familial	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
.	O

Moreover	O
,	O
alpha	O
-	O
synuclein	O
-	O
and	O
ubiquitin	O
-	O
positive	O
inclusion	O
bodies	O
are	O
the	O
pathological	O
hallmarks	O
of	O
PD	O
and	O
several	O
other	O
neurodegenerative	O
diseases	O
,	O
such	O
as	O
dementia	O
with	O
Lewy	O
bodies	O
and	O
multiple	O
system	O
atrophy	O
.	O

Despite	O
the	O
presence	O
of	O
ubiquitinated	O
alpha	O
-	O
synuclein	O
species	O
in	O
Lewy	O
bodies	O
,	O
the	O
regulation	O
of	O
alpha	O
-	O
synuclein	O
ubiquitination	O
and	O
its	O
role	O
in	O
Lewy	O
body	O
formation	O
and	O
neurodegeneration	O
remain	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
report	O
that	O
alpha	O
-	O
synuclein	O
interacts	O
and	O
colocalizes	O
with	O
mammalian	O
seven	O
in	O
absentia	O
homologue	O
-	O
1	O
(	O
Siah	O
-	O
1	O
)	O
,	O
a	O
RING	O
-	O
type	O
E3	O
ubiquitin	O
-	O
protein	O
ligase	O
.	O

Siah	O
-	O
1	O
binds	O
the	O
brain	O
-	O
enriched	O
E2	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
UbcH8	O
and	O
facilitates	O
mono	O
-	O
and	O
di	O
-	O
ubiquitination	O
of	O
alpha	O
-	O
synuclein	O
in	O
vivo	O
.	O

The	O
ubiquitination	O
of	O
alpha	O
-	O
synuclein	O
by	O
Siah	O
-	O
1	O
is	O
disrupted	O
by	O
the	O
PD	O
-	O
linked	O
A30P	O
mutation	O
but	O
not	O
by	O
A53T	O
mutation	O
.	O

We	O
find	O
that	O
Siah	O
-	O
1	O
-	O
mediated	O
ubiquitination	O
does	O
not	O
target	O
alpha	O
-	O
synuclein	O
for	O
degradation	O
by	O
the	O
proteasome	B-Complex
,	O
but	O
rather	O
,	O
it	O
promotes	O
alpha	O
-	O
synuclein	O
aggregation	O
and	O
enhances	O
alpha	O
-	O
synuclein	O
toxicity	O
.	O

Our	O
findings	O
suggest	O
that	O
Siah	O
-	O
1	O
-	O
mediated	O
alpha	O
-	O
synuclein	O
ubiquitination	O
may	O
play	O
a	O
critical	O
role	O
in	O
Lewy	O
body	O
formation	O
and	O
PD	O
pathogenesis	O
.	O

Puf1p	O
acts	O
in	O
combination	O
with	O
other	O
yeast	O
Puf	O
proteins	O
to	O
control	O
mRNA	O
stability	O
.	O

The	O
eukaryotic	O
Puf	O
proteins	O
bind	O
3	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
sequence	O
elements	O
to	O
regulate	O
the	O
stability	O
and	O
translation	O
of	O
their	O
target	O
transcripts	O
,	O
and	O
such	O
regulatory	O
events	O
are	O
critical	O
for	O
cell	O
growth	O
and	O
development	O
.	O

Several	O
global	O
genome	O
analyses	O
have	O
identified	O
hundreds	O
of	O
potential	O
mRNA	O
targets	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
Puf	O
proteins	O
;	O
however	O
,	O
only	O
three	O
mRNA	O
targets	O
for	O
these	O
proteins	O
have	O
been	O
characterized	O
thus	O
far	O
.	O

After	O
direct	O
testing	O
of	O
nearly	O
40	O
candidate	O
mRNAs	O
,	O
we	O
established	O
two	O
of	O
these	O
as	O
true	O
mRNA	O
targets	O
of	O
Puf	O
-	O
mediated	O
decay	O
in	O
yeast	O
,	O
HXK1	O
and	O
TIF1	O
.	O

In	O
a	O
novel	O
finding	O
,	O
multiple	O
Puf	O
proteins	O
,	O
including	O
Puf1p	O
,	O
regulate	O
both	O
of	O
these	O
mRNAs	O
in	O
combination	O
.	O

TIF1	O
mRNA	O
decay	O
can	O
be	O
stimulated	O
individually	O
by	O
Puf1p	O
and	O
Puf5p	O
,	O
but	O
the	O
combination	O
of	O
both	O
proteins	O
is	O
required	O
for	O
full	O
regulation	O
.	O

This	O
Puf	O
-	O
mediated	O
decay	O
requires	O
the	O
presence	O
of	O
two	O
UGUA	O
binding	O
sites	O
within	O
the	O
TIF1	O
3	O
'	O
UTR	O
,	O
with	O
one	O
site	O
regulated	O
by	O
Puf5p	O
and	O
the	O
other	O
by	O
both	O
Puf1p	O
and	O
Puf5p	O
.	O

Alteration	O
of	O
the	O
UGUA	O
site	O
in	O
the	O
tif1	O
3	O
'	O
UTR	O
to	O
more	O
closely	O
resemble	O
the	O
Puf3p	O
binding	O
site	O
broadens	O
the	O
specificity	O
to	O
include	O
regulation	O
by	O
Puf3p	O
.	O

The	O
stability	O
of	O
the	O
endogenously	O
transcribed	O
HXK1	O
mRNA	O
,	O
cellular	O
levels	O
of	O
Hxk1	O
protein	O
activity	O
,	O
and	O
HXK1	O
3	O
'	O
UTR	O
-	O
directed	O
decay	O
are	O
affected	O
by	O
Puf1p	O
and	O
Puf5p	O
as	O
well	O
as	O
Puf4p	O
.	O

Together	O
these	O
results	O
identify	O
the	O
first	O
mRNA	O
targets	O
of	O
Puf1p	O
-	O
mediated	O
decay	O
,	O
describe	O
similar	O
yet	O
distinct	O
combinatorial	O
control	O
of	O
two	O
new	O
target	O
mRNAs	O
by	O
the	O
yeast	O
Puf	O
proteins	O
,	O
and	O
suggest	O
the	O
importance	O
of	O
direct	O
testing	O
to	O
evaluate	O
RNA	O
-	O
regulatory	O
mechanisms	O
.	O

FOXO3a	O
is	O
activated	O
in	O
response	O
to	O
hypoxic	O
stress	O
and	O
inhibits	O
HIF1	O
-	O
induced	O
apoptosis	O
via	O
regulation	O
of	O
CITED2	O
.	O

FOXO	O
transcription	O
factors	O
are	O
important	O
regulators	O
of	O
cell	O
survival	O
in	O
response	O
to	O
a	O
variety	O
of	O
stress	O
stimuli	O
,	O
among	O
which	O
are	O
oxidative	O
stress	O
,	O
DNA	O
damage	O
,	O
and	O
nutrient	O
deprivation	O
.	O

Here	O
we	O
report	O
a	O
role	O
for	O
FOXO3a	O
under	O
conditions	O
of	O
hypoxic	O
stress	O
.	O

In	O
response	O
to	O
hypoxia	O
,	O
FOXO3a	O
transcript	O
levels	O
accumulate	O
in	O
an	O
HIF1	O
-	O
dependent	O
way	O
,	O
resulting	O
in	O
enhanced	O
FOXO3a	O
activity	O
.	O

We	O
show	O
that	O
transcription	O
of	O
CITED2	O
,	O
a	O
transcriptional	O
cofactor	O
that	O
functions	O
in	O
a	O
negative	O
feedback	O
loop	O
to	O
control	O
HIF1	O
activity	O
,	O
is	O
induced	O
by	O
FOXO3a	O
during	O
hypoxia	O
.	O

In	O
fibroblasts	O
as	O
well	O
as	O
in	O
breast	O
cancer	O
cells	O
,	O
FOXO3a	O
inhibits	O
HIF1	O
-	O
induced	O
apoptosis	O
by	O
stimulating	O
the	O
transcription	O
of	O
CITED2	O
,	O
which	O
results	O
in	O
reduced	O
expression	O
of	O
the	O
proapoptotic	O
HIF1	O
target	O
genes	O
NIX	O
and	O
RTP801	O
.	O

Thus	O
,	O
by	O
fine	O
-	O
tuning	O
HIF1	O
activity	O
,	O
FOXO3a	O
plays	O
an	O
important	O
role	O
in	O
the	O
survival	O
response	O
of	O
normal	O
and	O
cancer	O
cells	O
in	O
response	O
to	O
hypoxic	O
stress	O
.	O

Acetylation	O
in	O
nuclear	O
receptor	O
signaling	O
and	O
the	O
role	O
of	O
sirtuins	O
.	O

It	O
has	O
been	O
known	O
since	O
the	O
early	O
1970s	O
that	O
nuclear	O
receptor	O
complexes	O
bind	O
DNA	O
in	O
association	O
with	O
coregulatory	O
proteins	O
.	O

Characterization	O
of	O
these	O
nuclear	O
receptor	O
coregulators	O
has	O
revealed	O
diverse	O
enzymatic	O
activities	O
that	O
temporally	O
and	O
spatially	O
coordinate	O
nuclear	O
receptor	O
activity	O
within	O
the	O
context	O
of	O
local	O
chromatin	O
in	O
response	O
to	O
diverse	O
hormone	O
signals	O
.	O

Chromatin	O
-	O
modifying	O
proteins	O
,	O
which	O
dictate	O
the	O
higher	O
-	O
order	O
chromatin	O
structure	O
in	O
which	O
DNA	O
is	O
packaged	O
,	O
in	O
turn	O
orchestrate	O
orderly	O
recruitment	O
of	O
nuclear	O
receptor	O
complexes	O
.	O

Modifications	O
of	O
histones	O
include	O
acetylation	O
,	O
methylation	O
,	O
phosphorylation	O
,	O
ubiquitylation	O
,	O
sumoylation	O
,	O
ADP	O
ribosylation	O
,	O
deimination	O
,	O
and	O
proline	O
isomerization	O
.	O

At	O
this	O
time	O
,	O
we	O
understand	O
how	O
a	O
subset	O
of	O
these	O
modifications	O
regulates	O
nuclear	O
receptor	O
signaling	O
.	O

However	O
,	O
the	O
effects	O
,	O
particularly	O
of	O
acetylation	O
and	O
demethylation	O
,	O
are	O
profound	O
.	O

The	O
finding	O
that	O
nuclear	O
receptors	O
are	O
directly	O
acetylated	O
and	O
that	O
acetylation	O
in	O
turn	O
directly	O
regulates	O
contact	O
-	O
independent	O
growth	O
has	O
broad	O
therapeutic	O
implications	O
.	O

Studies	O
over	O
the	O
past	O
7	O
yr	O
have	O
led	O
to	O
the	O
understanding	O
that	O
nuclear	O
receptor	O
acetylation	O
is	O
a	O
conserved	O
function	O
,	O
regulating	O
diverse	O
nuclear	O
receptor	O
activity	O
.	O

Furthermore	O
,	O
we	O
now	O
know	O
that	O
acetylation	O
of	O
multiple	O
and	O
distinct	O
substrates	O
within	O
nuclear	O
receptor	O
signaling	O
pathways	O
,	O
form	O
an	O
acetylation	O
signaling	O
network	O
from	O
the	O
cell	O
surface	O
to	O
the	O
nucleus	O
.	O

The	O
finding	O
that	O
nicotinamide	O
adenine	O
dinucleotide	O
(	O
NAD	O
)	O
-	O
dependent	O
histone	O
deacetylases	O
,	O
the	O
sirtuins	O
,	O
are	O
capable	O
of	O
deacetylating	O
nuclear	O
receptors	O
provides	O
a	O
new	O
level	O
of	O
complexity	O
in	O
the	O
control	O
of	O
nuclear	O
receptor	O
activity	O
in	O
which	O
local	O
intracellular	O
concentrations	O
of	O
NAD	O
may	O
regulate	O
nuclear	O
receptor	O
physiology	O
.	O

The	O
checkpoint	O
kinases	O
Chk1	O
and	O
Chk2	O
regulate	O
the	O
functional	O
associations	O
between	O
hBRCA2	O
and	O
Rad51	O
in	O
response	O
to	O
DNA	O
damage	O
.	O

The	O
cellular	O
response	O
to	O
the	O
introduction	O
of	O
double	O
strand	O
DNA	O
breaks	O
involves	O
complexes	O
of	O
protein	O
interactions	O
that	O
govern	O
cell	O
cycle	O
checkpoint	O
arrest	O
and	O
repair	O
of	O
the	O
DNA	O
lesions	O
.	O

The	O
checkpoint	O
kinases	O
Chk1	O
and	O
Chk2	O
phosphorylate	O
the	O
carboxy	O
-	O
terminal	O
domain	O
of	O
hBRCA2	O
,	O
a	O
protein	O
involved	O
in	O
recombination	O
-	O
mediated	O
DNA	O
repair	O
(	O
HRR	O
)	O
and	O
replication	O
fork	O
maintenance	O
.	O

Cells	O
deficient	O
in	O
hBRCA2	O
are	O
hypersensitive	O
to	O
DNA	O
damaging	O
agents	O
.	O

Phosphorylation	O
of	O
the	O
residue	O
in	O
hBRCA2	O
targeted	O
by	O
the	O
Chk1	O
and	O
Chk2	O
kinases	O
regulates	O
its	O
interaction	O
with	O
Rad51	O
.	O

Furthermore	O
,	O
the	O
cell	O
line	O
lex1	O
/	O
lex2	O
,	O
which	O
lacks	O
the	O
carboxy	O
-	O
terminal	O
domain	O
containing	O
the	O
phosphorylated	O
residue	O
,	O
does	O
not	O
support	O
localization	O
of	O
Rad51	O
to	O
nuclear	O
foci	O
after	O
exposure	O
to	O
UV	O
or	O
treatment	O
with	O
ionizing	O
radiation	O
(	O
IR	O
)	O
.	O

The	O
data	O
show	O
that	O
either	O
phosphorylation	O
of	O
Rad51	O
by	O
Chk1	O
or	O
phosphorylation	O
of	O
the	O
carboxy	O
-	O
terminal	O
domain	O
of	O
hBRCA2	O
by	O
Chk1	O
or	O
Chk2	O
plays	O
a	O
critical	O
role	O
in	O
the	O
binding	O
of	O
Rad51	O
to	O
hBRCA2	O
and	O
the	O
subsequent	O
recruitment	O
of	O
Rad51	O
to	O
sites	O
of	O
DNA	O
damage	O
.	O

While	O
depletion	O
of	O
Chk1	O
from	O
cells	O
leads	O
to	O
loss	O
of	O
Rad51	O
localization	O
to	O
nuclear	O
foci	O
in	O
response	O
to	O
replication	O
arrest	O
,	O
cells	O
lacking	O
Chk2	O
also	O
show	O
a	O
defect	O
in	O
Rad51	O
localization	O
,	O
but	O
only	O
in	O
presence	O
of	O
double	O
strand	O
DNA	O
breaks	O
,	O
indicating	O
that	O
each	O
of	O
these	O
kinases	O
may	O
contribute	O
somewhat	O
differently	O
to	O
the	O
formation	O
of	O
Rad51	O
nucleoprotein	O
filaments	O
depending	O
on	O
the	O
type	O
of	O
DNA	O
damage	O
incurred	O
by	O
the	O
cells	O
.	O

Regulation	O
of	O
actin	O
assembly	O
associated	O
with	O
protrusion	O
and	O
adhesion	O
in	O
cell	O
migration	O
.	O

To	O
migrate	O
,	O
a	O
cell	O
first	O
extends	O
protrusions	O
such	O
as	O
lamellipodia	O
and	O
filopodia	O
,	O
forms	O
adhesions	O
,	O
and	O
finally	O
retracts	O
its	O
tail	O
.	O

The	O
actin	O
cytoskeleton	O
plays	O
a	O
major	O
role	O
in	O
this	O
process	O
.	O

The	O
first	O
part	O
of	O
this	O
review	O
(	O
sect	O
.	O
II	O
)	O
describes	O
the	O
formation	O
of	O
the	O
lamellipodial	O
and	O
filopodial	O
actin	O
networks	O
.	O

In	O
lamellipodia	O
,	O
the	O
WASP	O
-	O
Arp2	B-Complex
/	I-Complex
3	I-Complex
pathways	O
generate	O
a	O
branched	O
filament	O
array	O
.	O

This	O
polarized	O
dendritic	O
actin	O
array	O
is	O
maintained	O
in	O
rapid	O
treadmilling	O
by	O
the	O
concerted	O
action	O
of	O
ADF	O
,	O
profilin	O
,	O
and	O
capping	O
proteins	O
.	O

In	O
filopodia	O
,	O
formins	O
catalyze	O
the	O
processive	O
assembly	O
of	O
nonbranched	O
actin	O
filaments	O
.	O

Cell	O
matrix	O
adhesions	O
mechanically	O
couple	O
actin	O
filaments	O
to	O
the	O
substrate	O
to	O
convert	O
the	O
treadmilling	O
into	O
protrusion	O
and	O
the	O
actomyosin	B-Complex
contraction	O
into	O
traction	O
of	O
the	O
cell	O
body	O
and	O
retraction	O
of	O
the	O
tail	O
.	O

The	O
second	O
part	O
of	O
this	O
review	O
(	O
sect	O
.	O
III	O
)	O
focuses	O
on	O
the	O
function	O
and	O
the	O
regulation	O
of	O
major	O
proteins	O
(	O
vinculin	O
,	O
talin	O
,	O
tensin	O
,	O
and	O
alpha	O
-	O
actinin	O
)	O
that	O
control	O
the	O
nucleation	O
,	O
the	O
binding	O
,	O
and	O
the	O
barbed	O
-	O
end	O
growth	O
of	O
actin	O
filaments	O
in	O
adhesions	O
.	O

Structure	O
of	O
tumor	O
suppressor	O
p53	O
and	O
its	O
intrinsically	O
disordered	O
N	O
-	O
terminal	O
transactivation	O
domain	O
.	O

Proteins	O
with	O
intrinsically	O
disordered	O
domains	O
are	O
implicated	O
in	O
a	O
vast	O
range	O
of	O
biological	O
processes	O
,	O
especially	O
in	O
cell	O
signaling	O
and	O
regulation	O
.	O

Having	O
solved	O
the	O
quaternary	O
structure	O
of	O
the	O
folded	O
domains	O
in	O
the	O
tumor	O
suppressor	O
p53	O
by	O
a	O
multidisciplinary	O
approach	O
,	O
we	O
have	O
now	O
determined	O
the	O
average	O
ensemble	O
structure	O
of	O
the	O
intrinsically	O
disordered	O
N	O
-	O
terminal	O
transactivation	O
domain	O
(	O
TAD	O
)	O
by	O
using	O
residual	O
dipolar	O
couplings	O
(	O
RDCs	O
)	O
from	O
NMR	O
spectroscopy	O
and	O
small	O
-	O
angle	O
x	O
-	O
ray	O
scattering	O
(	O
SAXS	O
)	O
.	O

Remarkably	O
,	O
not	O
only	O
were	O
we	O
able	O
to	O
measure	O
RDCs	O
of	O
the	O
isolated	O
TAD	O
,	O
but	O
we	O
were	O
also	O
able	O
to	O
do	O
so	O
for	O
the	O
TAD	O
in	O
both	O
the	O
full	O
-	O
length	O
tetrameric	O
p53	O
protein	O
and	O
in	O
its	O
complex	O
with	O
a	O
specific	O
DNA	O
response	O
element	O
.	O

We	O
determined	O
the	O
orientation	O
of	O
the	O
TAD	O
ensemble	O
relative	O
to	O
the	O
core	O
domain	O
,	O
found	O
that	O
the	O
TAD	O
was	O
stiffer	O
in	O
the	O
proline	O
-	O
rich	O
region	O
(	O
residues	O
64	O
-	O
92	O
)	O
,	O
which	O
has	O
a	O
tendency	O
to	O
adopt	O
a	O
polyproline	O
II	O
(	O
PPII	O
)	O
structure	O
,	O
and	O
projected	O
the	O
TAD	O
away	O
from	O
the	O
core	O
.	O

We	O
located	O
the	O
TAD	O
in	O
SAXS	O
experiments	O
on	O
a	O
complex	O
between	O
tetrameric	O
p53	O
and	O
four	O
Taz2	O
domains	O
that	O
bind	O
tightly	O
to	O
the	O
TAD	O
(	O
residues	O
1	O
-	O
57	O
)	O
and	O
acted	O
as	O
"	O
reporters	O
.	O
"	O
The	O
p53	O
-	O
Taz2	O
complex	O
was	O
an	O
extended	O
cross	O
-	O
shaped	O
structure	O
.	O

The	O
quality	O
of	O
the	O
SAXS	O
data	O
enabled	O
us	O
to	O
model	O
the	O
disordered	O
termini	O
and	O
the	O
folded	O
domains	O
in	O
the	O
complex	O
with	O
DNA	O
.	O

The	O
core	O
domains	O
enveloped	O
the	O
response	O
element	O
in	O
the	O
center	O
of	O
the	O
molecule	O
,	O
with	O
the	O
Taz2	O
-	O
bound	O
TADs	O
projecting	O
outward	O
from	O
the	O
core	O
.	O

Congenital	O
joint	O
dislocations	O
caused	O
by	O
carbohydrate	O
sulfotransferase	O
3	O
deficiency	O
in	O
recessive	O
Larsen	O
syndrome	O
and	O
humero	O
-	O
spinal	O
dysostosis	O
.	O

Deficiency	O
of	O
carbohydrate	O
sulfotransferase	O
3	O
(	O
CHST3	O
;	O
also	O
known	O
as	O
chondroitin	O
-	O
6	O
-	O
sulfotransferase	O
)	O
has	O
been	O
reported	O
in	O
a	O
single	O
kindred	O
so	O
far	O
and	O
in	O
association	O
with	O
a	O
phenotype	O
of	O
severe	O
chondrodysplasia	O
with	O
progressive	O
spinal	O
involvement	O
.	O

We	O
report	O
eight	O
CHST3	O
mutations	O
in	O
six	O
unrelated	O
individuals	O
who	O
presented	O
at	O
birth	O
with	O
congenital	O
joint	O
dislocations	O
.	O

These	O
patients	O
had	O
been	O
given	O
a	O
diagnosis	O
of	O
either	O
Larsen	O
syndrome	O
(	O
three	O
individuals	O
)	O
or	O
humero	O
-	O
spinal	O
dysostosis	O
(	O
three	O
individuals	O
)	O
,	O
and	O
their	O
clinical	O
features	O
included	O
congenital	O
dislocation	O
of	O
the	O
knees	O
,	O
elbow	O
joint	O
dysplasia	O
with	O
subluxation	O
and	O
limited	O
extension	O
,	O
hip	O
dysplasia	O
or	O
dislocation	O
,	O
clubfoot	O
,	O
short	O
stature	O
,	O
and	O
kyphoscoliosis	O
developing	O
in	O
late	O
childhood	O
.	O

Analysis	O
of	O
chondroitin	O
sulfate	O
proteoglycans	O
in	O
dermal	O
fibroblasts	O
showed	O
markedly	O
decreased	O
6	O
-	O
O	O
-	O
sulfation	O
but	O
enhanced	O
4	O
-	O
O	O
-	O
sulfation	O
,	O
confirming	O
functional	O
impairment	O
of	O
CHST3	O
and	O
distinguishing	O
them	O
from	O
diastrophic	O
dysplasia	O
sulphate	O
transporter	O
(	O
DTDST	O
)	O
-	O
deficient	O
cells	O
.	O

These	O
observations	O
provide	O
a	O
molecular	O
basis	O
for	O
recessive	O
Larsen	O
syndrome	O
and	O
indicate	O
that	O
recessive	O
Larsen	O
syndrome	O
,	O
humero	O
-	O
spinal	O
dysostosis	O
,	O
and	O
spondyloepiphyseal	O
dysplasia	O
Omani	O
type	O
form	O
a	O
phenotypic	O
spectrum	O
.	O

Constitutively	O
active	O
Rheb	O
induces	O
oncogenic	O
transformation	O
.	O

Rheb	O
(	O
Ras	O
-	O
homolog	O
enriched	O
in	O
brain	O
)	O
is	O
a	O
component	O
of	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
target	O
of	O
rapamycin	O
(	O
TOR	O
)	O
signaling	O
pathway	O
,	O
functioning	O
as	O
a	O
positive	O
regulator	O
of	O
TOR	O
.	O

Constitutively	O
active	O
mutants	O
of	O
Rheb	O
induce	O
oncogenic	O
transformation	O
in	O
cell	O
culture	O
.	O

The	O
transformed	O
cells	O
are	O
larger	O
and	O
contain	O
more	O
protein	O
than	O
their	O
normal	O
counterparts	O
.	O

They	O
show	O
constitutive	O
phosphorylation	O
of	O
the	O
ribosomal	O
protein	O
S6	O
kinase	O
and	O
the	O
eukaryotic	O
initiation	O
factor	O
4E	O
-	O
binding	O
protein	O
1	O
,	O
two	O
downstream	O
targets	O
of	O
TOR	O
.	O

The	O
TOR	O
-	O
specific	O
inhibitor	O
rapamycin	O
strongly	O
interferes	O
with	O
transformation	O
induced	O
by	O
constitutively	O
active	O
Rheb	O
,	O
suggesting	O
that	O
TOR	O
activity	O
is	O
essential	O
for	O
the	O
oncogenic	O
effects	O
of	O
mutant	O
Rheb	O
.	O

Rheb	O
-	O
induced	O
transformation	O
is	O
also	O
dependent	O
on	O
a	O
C	O
-	O
terminal	O
farnesylation	O
signal	O
that	O
mediates	O
localization	O
to	O
a	O
cellular	O
membrane	O
.	O

An	O
engineered	O
N	O
-	O
terminal	O
myristylation	O
signal	O
can	O
substitute	O
for	O
the	O
farnesylation	O
.	O

Immunofluorescence	O
localizes	O
wild	O
-	O
type	O
and	O
mutant	O
Rheb	O
to	O
vesicular	O
structures	O
in	O
the	O
cytoplasm	O
,	O
overlapping	O
with	O
the	O
endoplasmic	O
reticulum	O
.	O

Meta	O
-	O
analysis	O
of	O
human	O
cancer	O
microarrays	O
reveals	O
GATA3	O
is	O
integral	O
to	O
the	O
estrogen	O
receptor	O
alpha	O
pathway	O
.	O

The	O
transcription	O
factor	O
GATA3	O
has	O
recently	O
been	O
shown	O
to	O
be	O
necessary	O
for	O
mammary	O
gland	O
morphogenesis	O
and	O
luminal	O
cell	O
differentiation	O
.	O

There	O
is	O
also	O
an	O
increasing	O
body	O
of	O
data	O
linking	O
GATA3	O
to	O
the	O
estrogen	O
receptor	O
alpha	O
(	O
ERalpha	O
)	O
pathway	O
.	O

Among	O
these	O
it	O
was	O
shown	O
that	O
GATA3	O
associates	O
with	O
the	O
promoter	O
of	O
the	O
ERalpha	O
gene	O
and	O
ERalpha	O
can	O
reciprocally	O
associate	O
with	O
the	O
GATA3	O
gene	O
.	O

GATA3	O
has	O
also	O
been	O
directly	O
implicated	O
in	O
a	O
differentiated	O
phenotype	O
in	O
mouse	O
models	O
of	O
mammary	O
tumourigenesis	O
.	O

The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
compare	O
coexpressed	O
genes	O
,	O
by	O
meta	O
-	O
analysis	O
,	O
of	O
GATA3	O
and	O
relate	O
these	O
to	O
a	O
similar	O
analysis	O
for	O
ERalpha	O
to	O
determine	O
the	O
depth	O
of	O
overlap	O
.	O

We	O
have	O
used	O
a	O
newly	O
described	O
method	O
of	O
meta	O
-	O
analysis	O
of	O
multiple	O
cancer	O
studies	O
within	O
the	O
Oncomine	O
database	O
,	O
focusing	O
here	O
predominantly	O
upon	O
breast	O
cancer	O
studies	O
.	O

We	O
demonstrate	O
that	O
ERalpha	O
and	O
GATA3	O
reciprocally	O
have	O
the	O
highest	O
overlap	O
with	O
one	O
another	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
when	O
both	O
coexpression	O
meta	O
-	O
analysis	O
lists	O
for	O
ERalpha	O
and	O
GATA3	O
are	O
compared	O
there	O
is	O
a	O
significant	O
overlap	O
between	O
both	O
and	O
,	O
like	O
ERalpha	O
,	O
GATA3	O
coexpresses	O
with	O
ERalpha	O
pathway	O
partners	O
such	O
as	O
pS2	O
(	O
TFF1	O
)	O
,	O
TFF3	O
,	O
FOXA1	O
,	O
BCL2	O
,	O
ERBB4	O
,	O
XBP1	O
,	O
NRIP1	O
,	O
IL6ST	O
,	O
keratin	O
18	O
(	O
KRT18	O
)	O
and	O
cyclin	O
D1	O
(	O
CCND1	O
)	O
.	O

Moreover	O
,	O
as	O
these	O
data	O
are	O
derived	O
from	O
human	O
tumour	O
samples	O
this	O
adds	O
credence	O
to	O
previous	O
cell	O
-	O
culture	O
or	O
murine	O
based	O
studies	O
.	O

GATA3	O
is	O
hypothesized	O
to	O
be	O
integral	O
to	O
the	O
ERalpha	O
pathway	O
given	O
the	O
following	O
:	O
(	O
1	O
)	O
The	O
large	O
overlap	O
of	O
coexpressed	O
genes	O
as	O
seen	O
by	O
meta	O
-	O
analysis	O
,	O
between	O
GATA3	O
and	O
ERalpha	O
,	O
(	O
2	O
)	O
The	O
highest	O
coexpressing	O
gene	O
for	O
GATA3	O
was	O
ERalpha	O
and	O
vice	O
-	O
versa	O
,	O
(	O
3	O
)	O
GATA3	O
,	O
like	O
ERalpha	O
,	O
coexpresses	O
with	O
many	O
well	O
-	O
known	O
ERalpha	O
pathway	O
partners	O
such	O
as	O
pS2	O
.	O

Live	O
cell	O
imaging	O
and	O
electron	O
microscopy	O
reveal	O
dynamic	O
processes	O
of	O
BAF	O
-	O
directed	O
nuclear	O
envelope	O
assembly	O
.	O

Assembly	O
of	O
the	O
nuclear	O
envelope	O
(	O
NE	O
)	O
in	O
telophase	O
is	O
essential	O
for	O
higher	O
eukaryotic	O
cells	O
to	O
re	O
-	O
establish	O
a	O
functional	O
nucleus	O
.	O

Time	O
-	O
lapse	O
,	O
FRAP	O
and	O
FRET	O
analyses	O
in	O
human	O
cells	O
showed	O
that	O
barrier	O
-	O
to	O
-	O
autointegration	O
factor	O
(	O
BAF	O
)	O
,	O
a	O
DNA	O
-	O
binding	O
protein	O
,	O
assembled	O
first	O
at	O
the	O
distinct	O
;	O
core	O
'	O
region	O
of	O
the	O
telophase	O
chromosome	O
and	O
formed	O
an	O
immobile	O
complex	O
by	O
directly	O
binding	O
with	O
other	O
core	O
-	O
localizing	O
NE	O
proteins	O
,	O
such	O
as	O
lamin	O
A	O
and	O
emerin	O
.	O

Correlative	O
light	O
and	O
electron	O
microscopy	O
after	O
live	O
cell	O
imaging	O
,	O
further	O
showed	O
that	O
BAF	O
formed	O
an	O
electron	O
-	O
dense	O
structure	O
on	O
the	O
chromosome	O
surface	O
of	O
the	O
core	O
,	O
close	O
to	O
spindle	O
microtubules	O
(	O
MTs	O
)	O
prior	O
to	O
the	O
attachment	O
of	O
precursor	O
NE	O
membranes	O
,	O
suggesting	O
that	O
MTs	O
may	O
mediate	O
core	O
assembly	O
of	O
BAF	O
.	O

Disruption	O
of	O
the	O
spindle	O
MTs	O
consistently	O
abolished	O
BAF	O
accumulation	O
at	O
the	O
core	O
.	O

In	O
addition	O
,	O
RNAi	O
of	O
BAF	O
eliminated	O
the	O
core	O
assembly	O
of	O
lamin	O
A	O
and	O
emerin	O
,	O
caused	O
abnormal	O
cytoplasmic	O
accumulation	O
of	O
precursor	O
nuclear	O
membranes	O
and	O
resulted	O
in	O
a	O
significant	O
delay	O
of	O
NE	O
assembly	O
.	O

These	O
results	O
suggest	O
that	O
the	O
MT	O
-	O
mediated	O
BAF	O
accumulation	O
at	O
the	O
core	O
facilitates	O
NE	O
assembly	O
at	O
the	O
end	O
of	O
mitosis	O
.	O

Structural	O
basis	O
for	O
induced	O
formation	O
of	O
the	O
inflammatory	O
mediator	O
prostaglandin	O
E2	O
.	O

Prostaglandins	O
(	O
PG	O
)	O
are	O
bioactive	O
lipids	O
produced	O
from	O
arachidonic	O
acid	O
via	O
the	O
action	O
of	O
cyclooxygenases	O
and	O
terminal	O
PG	O
synthases	O
.	O

Microsomal	O
prostaglandin	O
E	O
synthase	O
1	O
(	O
MPGES1	O
)	O
constitutes	O
an	O
inducible	O
glutathione	O
-	O
dependent	O
integral	O
membrane	O
protein	O
that	O
catalyzes	O
the	O
oxidoreduction	O
of	O
cyclooxygenase	O
derived	O
PGH	O
(	O
2	O
)	O
into	O
PGE	O
(	O
2	O
)	O
.	O

MPGES1	O
has	O
been	O
implicated	O
in	O
a	O
number	O
of	O
human	O
diseases	O
or	O
pathological	O
conditions	O
,	O
such	O
as	O
rheumatoid	O
arthritis	O
,	O
fever	O
,	O
and	O
pain	O
,	O
and	O
is	O
therefore	O
regarded	O
as	O
a	O
primary	O
target	O
for	O
development	O
of	O
novel	O
antiinflammatory	O
drugs	O
.	O

To	O
provide	O
a	O
structural	O
basis	O
for	O
insight	O
in	O
the	O
catalytic	O
mechanism	O
,	O
we	O
determined	O
the	O
structure	O
of	O
MPGES1	O
in	O
complex	O
with	O
glutathione	O
by	O
electron	O
crystallography	O
from	O
2D	O
crystals	O
induced	O
in	O
the	O
presence	O
of	O
phospholipids	O
.	O

Together	O
with	O
results	O
from	O
site	O
-	O
directed	O
mutagenesis	O
and	O
activity	O
measurements	O
,	O
we	O
can	O
thereby	O
demonstrate	O
the	O
role	O
of	O
specific	O
amino	O
acid	O
residues	O
.	O

Glutathione	O
is	O
found	O
to	O
bind	O
in	O
a	O
U	O
-	O
shaped	O
conformation	O
at	O
the	O
interface	O
between	O
subunits	O
in	O
the	O
protein	O
trimer	O
.	O

It	O
is	O
exposed	O
to	O
a	O
site	O
facing	O
the	O
lipid	O
bilayer	O
,	O
which	O
forms	O
the	O
specific	O
environment	O
for	O
the	O
oxidoreduction	O
of	O
PGH	O
(	O
2	O
)	O
to	O
PGE	O
(	O
2	O
)	O
after	O
displacement	O
of	O
the	O
cytoplasmic	O
half	O
of	O
the	O
N	O
-	O
terminal	O
transmembrane	O
helix	O
.	O

Hence	O
,	O
insight	O
into	O
the	O
dynamic	O
behavior	O
of	O
MPGES1	O
and	O
homologous	O
membrane	O
proteins	O
in	O
inflammation	O
and	O
detoxification	O
is	O
provided	O
.	O

The	O
WW	O
domain	O
containing	O
E3	O
ubiquitin	O
protein	O
ligase	O
1	O
upregulates	O
ErbB2	O
and	O
EGFR	O
through	O
RING	O
finger	O
protein	O
11	O
.	O

The	O
WW	O
domain	O
containing	O
E3	O
ubiquitin	O
protein	O
ligase	O
1	O
(	O
WWP1	O
)	O
is	O
a	O
homologous	O
to	O
the	O
E6	O
-	O
associated	O
protein	O
C	O
terminus	O
-	O
type	O
E3	O
ligase	O
frequently	O
overexpressed	O
in	O
human	O
prostate	O
and	O
breast	O
cancers	O
due	O
to	O
gene	O
amplification	O
.	O

Previous	O
studies	O
suggest	O
that	O
WWP1	O
promotes	O
cell	O
proliferation	O
and	O
survival	O
;	O
however	O
,	O
the	O
mechanism	O
of	O
WWP1	O
action	O
is	O
still	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
showed	O
that	O
WWP1	O
upregulates	O
and	O
maintains	O
erythroblastic	O
leukemia	O
viral	O
oncogene	O
homolog	O
2	O
(	O
ErbB2	O
)	O
and	O
epithelial	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
in	O
multiple	O
cell	O
lines	O
.	O

WWP1	O
depletion	O
dramatically	O
attenuates	O
the	O
EGF	O
-	O
induced	O
ERK	O
phosphorylation	O
.	O

WWP1	O
forms	O
a	O
protein	O
complex	O
with	O
RING	O
finger	O
protein	O
11	O
(	O
RNF11	O
)	O
,	O
a	O
negative	O
regulator	O
of	O
ErbB2	O
and	O
EGFR	O
.	O

The	O
protein	O
-	O
protein	O
interaction	O
is	O
through	O
the	O
first	O
and	O
third	O
WW	O
domains	O
of	O
WWP1	O
and	O
the	O
PY	O
motif	O
of	O
RNF11	O
.	O

Although	O
WWP1	O
is	O
able	O
to	O
ubiquitinate	O
RNF11	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
WWP1	O
neither	O
targets	O
RNF11	O
for	O
degradation	O
nor	O
changes	O
RNF11	O
'	O
s	O
cellular	O
localization	O
.	O

Importantly	O
,	O
inhibition	O
of	O
RNF11	O
can	O
rescue	O
WWP1	O
siRNA	O
-	O
induced	O
ErbB2	O
and	O
EGFR	O
downregulation	O
and	O
growth	O
arrest	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
RNF11	O
is	O
overexpressed	O
in	O
a	O
panel	O
of	O
prostate	O
and	O
breast	O
cancer	O
cell	O
lines	O
with	O
WWP1	O
expression	O
.	O

These	O
findings	O
suggest	O
that	O
WWP1	O
may	O
promote	O
cell	O
proliferation	O
and	O
survival	O
partially	O
through	O
suppressing	O
RNF11	O
-	O
mediated	O
ErbB2	O
and	O
EGFR	O
downregulation	O
.	O

Differential	O
responses	O
of	O
FLIPLong	O
and	O
FLIPShort	O
-	O
overexpressing	O
human	O
myeloid	O
leukemia	O
cells	O
to	O
TNF	O
-	O
alpha	O
and	O
TRAIL	B-Complex
-	O
initiated	O
apoptotic	O
signals	O
.	O

Clonal	O
marrow	O
cells	O
from	O
patients	O
with	O
early	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
undergo	O
apoptosis	O
in	O
response	O
to	O
tumor	B-Complex
necrosis	I-Complex
factor	I-Complex
(	I-Complex
TNF	I-Complex
)	I-Complex
-	I-Complex
related	I-Complex
apoptosis	I-Complex
-	I-Complex
inducing	I-Complex
ligand	I-Complex
(	O
TRAIL	B-Complex
)	O
.	O

Cells	O
from	O
advanced	O
MDS	O
are	O
resistant	O
to	O
TRAIL	B-Complex
.	O

Two	O
isoforms	O
of	O
the	O
Flice	O
inhibitory	O
protein	O
(	O
FLIP	O
)	O
short	O
(	O
FLIPS	O
)	O
and	O
FLIP	O
long	O
(	O
FLIPL	O
)	O
,	O
which	O
modulate	O
TRAIL	B-Complex
signals	O
,	O
showed	O
disease	O
-	O
stage	O
-	O
dependent	O
differential	O
regulation	O
.	O

Therefore	O
,	O
we	O
aimed	O
at	O
characterizing	O
potential	O
differential	O
effects	O
of	O
FLIPL	O
and	O
FLIPS	O
,	O
on	O
TRAIL	B-Complex
and	O
TNF	O
-	O
alpha	O
-	O
induced	O
apoptosis	O
in	O
model	O
leukemic	O
cell	O
lines	O
.	O

Using	O
lentiviral	O
constructs	O
,	O
FLIPL	O
and	O
FLIPS	O
,	O
as	O
well	O
as	O
a	O
green	O
fluorescent	O
protein	O
control	O
were	O
overexpressed	O
in	O
ML	O
-	O
1	O
cells	O
,	O
which	O
constitutively	O
express	O
very	O
low	O
levels	O
of	O
FLIP	O
and	O
are	O
highly	O
sensitive	O
to	O
apoptosis	O
induction	O
.	O

Cells	O
were	O
then	O
exposed	O
to	O
TRAIL	B-Complex
or	O
TNF	O
-	O
alpha	O
,	O
and	O
effects	O
on	O
the	O
extrinsic	O
and	O
intrinsic	O
pathways	O
of	O
apoptosis	O
induction	O
were	O
assessed	O
.	O

Overexpression	O
of	O
FLIP	O
reduced	O
TRAIL	B-Complex
and	O
TNF	O
-	O
alpha	O
-	O
induced	O
apoptosis	O
in	O
ML	O
-	O
1	O
cells	O
.	O

However	O
,	O
while	O
FLIPL	O
completely	O
abrogated	O
apoptosis	O
,	O
FLIPS	O
allowed	O
for	O
BID	O
cleavage	O
and	O
caspase	O
-	O
3	O
activation	O
.	O

Concurrently	O
,	O
there	O
was	O
a	O
decline	O
of	O
Bcl	O
-	O
xL	O
and	O
X	O
-	O
linked	O
inhibitor	O
of	O
apoptosis	O
protein	O
(	O
XIAP	O
)	O
in	O
FLIPS	O
cells	O
followed	O
by	O
apoptosis	O
.	O

Further	O
,	O
inhibition	O
of	O
nuclear	B-Complex
factor	I-Complex
-	I-Complex
kappaB	I-Complex
(	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
)	O
activation	O
in	O
TNF	O
-	O
alpha	O
-	O
treated	O
cells	O
resulted	O
in	O
profound	O
apoptosis	O
in	O
FLIPS	O
,	O
but	O
not	O
in	O
FLIPL	O
-	O
overexpressing	O
cells	O
,	O
consistent	O
with	O
the	O
observations	O
in	O
patients	O
with	O
early	O
stage	O
MDS	O
.	O

Inhibition	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
had	O
only	O
minimal	O
effects	O
on	O
TRAIL	B-Complex
signaling	O
.	O

Thus	O
,	O
FLIPL	O
and	O
FLIPS	O
exerted	O
differential	O
effects	O
in	O
myeloid	O
leukemic	O
cell	O
lines	O
in	O
response	O
to	O
TRAIL	B-Complex
and	O
TNF	O
-	O
alpha	O
.	O

It	O
might	O
be	O
possible	O
to	O
therapeutically	O
exploit	O
those	O
differences	O
with	O
effector	O
molecules	O
specific	O
for	O
the	O
FLIP	O
isoforms	O
.	O

Biochemical	O
characterization	O
of	O
plasma	O
-	O
derived	O
tissue	O
factor	O
pathway	O
inhibitor	O
:	O
post	O
-	O
translational	O
modification	O
of	O
free	O
,	O
full	O
-	O
length	O
form	O
with	O
particular	O
reference	O
to	O
the	O
sugar	O
chain	O
.	O

BACKGROUND	O
:	O
Tissue	O
factor	O
pathway	O
inhibitor	O
(	O
TFPI	O
)	O
is	O
a	O
physiological	O
protease	O
inhibitor	O
that	O
inhibits	O
the	O
initial	O
reactions	O
of	O
the	O
extrinsic	O
blood	O
coagulation	O
pathway	O
.	O

Most	O
TFPI	O
in	O
human	O
plasma	O
is	O
associated	O
with	O
lipoproteins	O
;	O
however	O
,	O
the	O
most	O
functionally	O
active	O
form	O
is	O
thought	O
to	O
be	O
the	O
free	O
,	O
full	O
-	O
length	O
form	O
(	O
f	O
-	O
pTFPI	O
)	O
.	O

Cell	O
culture	O
derived	O
TFPI	O
and	O
recombinant	O
TFPI	O
(	O
rTFPI	O
)	O
exhibit	O
variations	O
in	O
their	O
respective	O
anticoagulant	O
activity	O
,	O
which	O
may	O
be	O
caused	O
by	O
post	O
-	O
translational	O
modifications	O
,	O
such	O
as	O
the	O
frequent	O
differences	O
in	O
sugar	O
chain	O
structures	O
among	O
recombinant	O
proteins	O
.	O

Sugar	O
chain	O
structures	O
in	O
rTFPI	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
have	O
been	O
reported	O
previously	O
,	O
but	O
those	O
of	O
plasma	O
TFPI	O
have	O
not	O
been	O
.	O

OBJECTIVES	O
:	O
To	O
purify	O
f	O
-	O
pTFPI	O
and	O
analyze	O
the	O
sugar	O
chain	O
structures	O
.	O

RESULTS	O
AND	O
CONCLUSION	O
:	O
f	O
-	O
pTFPI	O
was	O
purified	O
to	O
homogeneity	O
from	O
blood	O
plasma	O
using	O
a	O
combination	O
of	O
anion	O
-	O
exchange	O
,	O
heparin	O
affinity	O
,	O
immunoaffinity	O
,	O
and	O
reversed	O
-	O
phase	O
chromatographies	O
,	O
resulting	O
in	O
a	O
yield	O
of	O
76	O
%	O
.	O

f	O
-	O
pTFPI	O
showed	O
a	O
partially	O
phosphorylated	O
glycoprotein	O
comprising	O
a	O
total	O
of	O
276	O
amino	O
acids	O
by	O
peptide	O
mapping	O
.	O

The	O
sugar	O
chain	O
structures	O
were	O
analyzed	O
by	O
two	O
-	O
dimensional	O
sugar	O
mapping	O
combined	O
with	O
exoglycosidase	O
digestion	O
of	O
the	O
pyridylamino	O
sugar	O
chains	O
and	O
the	O
following	O
results	O
were	O
obtained	O
.	O

(	O
Sialyl	O
)	O
Galbeta1	O
-	O
3GalNAc	O
was	O
linked	O
to	O
Thr	O
(	O
175	O
)	O
,	O
partially	O
to	O
Thr	O
(	O
14	O
)	O
and	O
Ser	O
(	O
174	O
)	O
;	O
sialyl	O
complex	O
-	O
type	O
sugar	O
chains	O
to	O
Asn	O
(	O
117	O
)	O
and	O
Asn	O
(	O
167	O
)	O
,	O
whereas	O
Asn	O
(	O
228	O
)	O
was	O
not	O
glycosylated	O
.	O

Neuraminidase	O
-	O
resistant	O
acidic	O
sugar	O
chains	O
including	O
sulfated	O
sugar	O
chains	O
were	O
not	O
observed	O
significantly	O
.	O

The	O
protease	O
inhibitory	O
activities	O
of	O
f	O
-	O
pTFPI	O
towards	O
activated	O
factor	O
(	O
F	O
)	O
X	O
and	O
tissue	B-Complex
factor	I-Complex
-	I-Complex
activated	I-Complex
FVII	I-Complex
complex	O
were	O
identical	O
to	O
those	O
of	O
full	O
-	O
length	O
rTFPI	O
expressed	O
in	O
CHO	O
cells	O
.	O

Subcellular	O
localization	O
directs	O
signaling	O
specificity	O
of	O
the	O
Cryptococcus	O
neoformans	O
Ras1	O
protein	O
.	O

In	O
the	O
human	O
fungal	O
pathogen	O
Cryptococcus	O
neoformans	O
,	O
Ras	O
signaling	O
mediates	O
sexual	O
differentiation	O
,	O
morphogenesis	O
,	O
and	O
pathogenesis	O
.	O

By	O
studying	O
Ras	O
prenylation	O
and	O
palmitoylation	O
in	O
this	O
organism	O
,	O
we	O
have	O
found	O
that	O
the	O
subcellular	O
localization	O
of	O
this	O
protein	O
dictates	O
its	O
downstream	O
signaling	O
specificity	O
.	O

Inhibiting	O
C	O
.	O
neoformans	O
Ras1	O
prenylation	O
results	O
in	O
the	O
defective	O
general	O
membrane	O
targeting	O
of	O
this	O
protein	O
and	O
the	O
loss	O
of	O
all	O
Ras	O
function	O
.	O

In	O
contrast	O
,	O
palmitoylation	O
mediates	O
localization	O
of	O
Ras1	O
to	O
the	O
plasma	O
membrane	O
and	O
is	O
required	O
for	O
normal	O
morphogenesis	O
and	O
survival	O
at	O
high	O
temperatures	O
.	O

However	O
,	O
palmitoylation	O
and	O
plasma	O
membrane	O
localization	O
are	O
not	O
required	O
for	O
Ras	O
-	O
dependent	O
sexual	O
differentiation	O
.	O

Likely	O
as	O
a	O
result	O
of	O
its	O
effect	O
on	O
thermotolerance	O
,	O
Ras1	O
palmitoylation	O
is	O
also	O
required	O
for	O
the	O
pathogenesis	O
of	O
C	O
.	O
neoformans	O
.	O

These	O
data	O
support	O
an	O
emerging	O
paradigm	O
of	O
compartmentalized	O
Ras	O
signaling	O
.	O

However	O
,	O
our	O
studies	O
also	O
demonstrate	O
fundamental	O
differences	O
between	O
the	O
Ras	O
pathways	O
in	O
different	O
organisms	O
that	O
emphasize	O
the	O
functional	O
flexibility	O
of	O
conserved	O
signaling	O
cascades	O
.	O

Distinct	O
nucleotide	O
binding	O
/	O
hydrolysis	O
properties	O
and	O
molar	O
ratio	O
of	O
MutSalpha	B-Complex
and	O
MutSbeta	B-Complex
determine	O
their	O
differential	O
mismatch	O
binding	O
activities	O
.	O

MutSalpha	B-Complex
(	O
MSH2	O
/	O
MSH6	O
)	O
and	O
MutSbeta	B-Complex
(	O
MSH2	O
/	O
MSH3	O
)	O
are	O
eukaryotic	O
mismatch	O
recognition	O
proteins	O
that	O
preferentially	O
process	O
base	O
-	O
base	O
and	O
small	O
insertion	O
/	O
deletion	O
(	O
ID	O
)	O
mispairs	O
,	O
respectively	O
,	O
despite	O
the	O
fact	O
that	O
cells	O
contain	O
a	O
MutSalpha	B-Complex
:	O
MutSbeta	B-Complex
ratio	O
of	O
10	O
:	O
1	O
.	O

To	O
explore	O
the	O
mechanism	O
underlying	O
the	O
differential	O
mismatch	O
recognition	O
by	O
these	O
two	O
proteins	O
,	O
purified	O
human	O
MutSalpha	B-Complex
and	O
MutSbeta	B-Complex
were	O
analyzed	O
individually	O
and	O
competitively	O
for	O
their	O
abilities	O
to	O
interact	O
with	O
a	O
T	O
-	O
G	O
and	O
an	O
ID	O
substrate	O
.	O

We	O
show	O
that	O
MutSalpha	B-Complex
has	O
K	O
(	O
D	O
)	O
values	O
of	O
26	O
.	O
5	O
and	O
38	O
.	O
2	O
nm	O
for	O
the	O
G	O
-	O
T	O
and	O
ID	O
substrates	O
,	O
respectively	O
,	O
and	O
that	O
MutSbeta	B-Complex
has	O
K	O
(	O
D	O
)	O
values	O
of	O
76	O
.	O
5	O
and	O
23	O
.	O
5	O
nm	O
for	O
G	O
-	O
T	O
and	O
ID	O
,	O
respectively	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
competitive	O
binding	O
assays	O
revealed	O
the	O
following	O
relative	O
binding	O
affinities	O
:	O
MutSbeta	B-Complex
-	O
ID	O
>	O
MutSalpha	B-Complex
-	O
T	O
-	O
G	O
>	O
MutSalpha	B-Complex
-	O
ID	O
>	O
>	O
MutSbeta	B-Complex
-	O
T	O
-	O
G	O
.	O

Interestingly	O
,	O
binding	O
of	O
MutSbeta	B-Complex
to	O
ID	O
heteroduplexes	O
is	O
greatly	O
stimulated	O
when	O
the	O
MutSalpha	B-Complex
:	O
MutSbeta	B-Complex
ratio	O
is	O
>	O
or	O
=	O
10	O
.	O

Distinct	O
ATP	O
/	O
ADP	O
binding	O
and	O
ATPase	O
activities	O
of	O
MutSalpha	B-Complex
and	O
MutSbeta	B-Complex
were	O
also	O
observed	O
.	O

In	O
the	O
absence	O
of	O
DNA	O
,	O
ADP	O
binding	O
and	O
ATPase	O
activities	O
of	O
MutSbeta	B-Complex
are	O
significantly	O
higher	O
than	O
those	O
of	O
MutSalpha	B-Complex
.	O

However	O
,	O
interaction	O
with	O
DNA	O
significantly	O
stimulates	O
the	O
MutSalpha	B-Complex
ATPase	O
activity	O
and	O
reduces	O
the	O
MutSbeta	B-Complex
ATPase	O
activity	O
,	O
the	O
consequence	O
being	O
that	O
both	O
proteins	O
exhibit	O
the	O
same	O
level	O
of	O
hydrolytic	O
activity	O
.	O

We	O
conclude	O
that	O
the	O
preferential	O
processing	O
of	O
base	O
-	O
base	O
and	O
ID	O
heteroduplexes	O
by	O
MutSalpha	B-Complex
and	O
MutSbeta	B-Complex
is	O
determined	O
by	O
their	O
significant	O
differences	O
in	O
ATPase	O
activity	O
,	O
ADP	O
binding	O
activity	O
,	O
and	O
high	O
cellular	O
MutSalpha	B-Complex
:	O
MutSbeta	B-Complex
ratio	O
.	O

DDB1	O
targets	O
Chk1	O
to	O
the	O
Cul4	O
E3	O
ligase	O
complex	O
in	O
normal	O
cycling	O
cells	O
and	O
in	O
cells	O
experiencing	O
replication	O
stress	O
.	O

The	O
Chk1	O
protein	O
kinase	O
preserves	O
genome	O
integrity	O
in	O
normal	O
proliferating	O
cells	O
and	O
in	O
cells	O
experiencing	O
replicative	O
and	O
genotoxic	O
stress	O
.	O

Chk1	O
is	O
currently	O
being	O
targeted	O
in	O
anticancer	O
regimens	O
.	O

Here	O
,	O
we	O
identify	O
damaged	O
DNA	O
-	O
binding	O
protein	O
1	O
(	O
DDB1	O
)	O
as	O
a	O
novel	O
Chk1	O
-	O
interacting	O
protein	O
.	O

DDB1	O
is	O
part	O
of	O
an	O
E3	O
ligase	O
complex	O
that	O
includes	O
the	O
cullin	O
proteins	O
Cul4A	O
and	O
Cul4B	O
.	O

We	O
report	O
that	O
Cul4A	O
/	O
DDB1	O
negatively	O
regulates	O
Chk1	O
stability	O
in	O
vivo	O
.	O

Chk1	O
associates	O
with	O
Cul4A	O
/	O
DDB1	O
during	O
an	O
unperturbed	O
cell	O
division	O
cycle	O
and	O
both	O
Chk1	O
phosphorylation	O
and	O
replication	O
stress	O
enhanced	O
these	O
interactions	O
.	O

Cul4A	O
/	O
DDB1	O
regulates	O
Chk1	O
ubiquitination	O
in	O
vivo	O
and	O
Chk1	O
is	O
directly	O
ubiquitinated	O
in	O
vitro	O
in	O
a	O
Cul4A	O
/	O
DDB1	O
-	O
dependent	O
manner	O
.	O

Furthermore	O
,	O
Chk1	O
is	O
stabilized	O
in	O
cells	O
deficient	O
for	O
Cul4A	O
/	O
DDB1	O
.	O

This	O
study	O
shows	O
that	O
Chk1	O
abundance	O
is	O
regulated	O
by	O
the	O
Cul4A	O
/	O
DDB1	O
ubiquitin	O
ligase	O
during	O
an	O
unperturbed	O
cell	O
division	O
cycle	O
,	O
in	O
response	O
to	O
replicative	O
stress	O
and	O
on	O
heat	O
shock	O
protein	O
90	O
inhibition	O
,	O
and	O
that	O
deregulation	O
of	O
the	O
Chk1	O
/	O
Cul4A	O
/	O
DDB1	O
pathway	O
perturbs	O
the	O
ionizing	O
radiation	O
-	O
induced	O
G	O
(	O
2	O
)	O
checkpoint	O
.	O

Deletion	O
analysis	O
indicated	O
that	O
a	O
sizable	O
segment	O
,	O
residues	O
1	O
-	O
383	O
at	O
the	O
N	O
-	O
terminus	O
,	O
could	O
be	O
removed	O
,	O
along	O
with	O
a	O
shorter	O
segment	O
at	O
the	O
C	O
-	O
terminus	O
,	O
to	O
yield	O
a	O
core	O
region	O
that	O
is	O
active	O
in	O
V	O
(	O
D	O
)	O
J	O
recombination	O
in	O
vitro	O
and	O
in	O
cells	O
.	O

Despite	O
being	O
recognized	O
for	O
years	O
,	O
the	O
function	O
of	O
the	O
N	O
-	O
terminal	O
region	O
remains	O
mysterious	O
.	O

Its	O
existence	O
is	O
conserved	O
through	O
the	O
evolution	O
of	O
RAG1	O
,	O
yet	O
it	O
clearly	O
is	O
not	O
needed	O
for	O
the	O
central	O
enzymatic	O
role	O
as	O
a	O
recombinase	O
.	O

Sequence	O
alignments	O
show	O
that	O
this	O
region	O
exhibits	O
a	O
greater	O
divergence	O
through	O
evolution	O
than	O
the	O
enzymatic	O
core	O
.	O

Notable	O
in	O
such	O
alignments	O
is	O
the	O
absolute	O
conservation	O
of	O
a	O
cluster	O
of	O
cystine	O
and	O
histidine	O
residues	O
recognized	O
as	O
a	O
special	O
zinc	O
-	O
binding	O
motif	O
termed	O
a	O
'	O
RING	O
finger	O
'	O
.	O

RING	O
structures	O
have	O
been	O
found	O
in	O
enzymes	O
(	O
E3	O
ligases	O
)	O
that	O
help	O
modify	O
other	O
proteins	O
through	O
the	O
covalent	O
addition	O
of	O
small	O
modifier	O
proteins	O
.	O

In	O
biochemical	O
assays	O
,	O
the	O
RAG1	O
N	O
-	O
terminus	O
can	O
act	O
as	O
an	O
E3	O
ubiquitin	O
ligase	O
.	O

While	O
characterizing	O
the	O
structural	O
requirements	O
for	O
Fra	O
-	O
mediated	O
axon	O
attraction	O
,	O
we	O
observed	O
that	O
neuronal	O
expression	O
of	O
a	O
dominant	O
negative	O
form	O
of	O
Fra	O
(	O
FraDeltaC	O
)	O
leads	O
to	O
a	O
dose	O
-	O
dependent	O
"	O
commissureless	O
"	O
phenotype	O
.	O

Searching	O
for	O
candidate	O
genes	O
that	O
modify	O
this	O
phenotype	O
,	O
we	O
found	O
that	O
removing	O
one	O
copy	O
of	O
comm	O
enhances	O
the	O
midline	O
crossing	O
defects	O
caused	O
by	O
expressing	O
UASFraDeltaC	O
(	O
fig	O
.	O
S1	O
)	O
,	O
suggesting	O
a	O
role	O
for	O
Fra	O
in	O
regulating	O
Comm	O
during	O
midline	O
guidance	O
.	O

Consistent	O
with	O
this	O
idea	O
,	O
removing	O
one	O
copy	O
of	O
comm	O
in	O
hypomorphic	O
fra	O
mutants	O
increases	O
the	O
commissural	O
defects	O
as	O
shown	O
by	O
thin	O
or	O
missing	O
commissures	O
in	O
many	O
segments	O
,	O
as	O
well	O
as	O
an	O
increased	O
frequency	O
of	O
non	O
-	O
crossing	O
defects	O
in	O
a	O
subset	O
of	O
commissural	O
neurons	O
:	O
the	O
eagle	O
neurons	O
(	O
Fig	O
.	O
1	O
and	O
Table	O
S1	O
)	O
.	O

Similar	O
genetic	O
interactions	O
are	O
also	O
observed	O
using	O
additional	O
alleles	O
of	O
both	O
fra	O
and	O
comm	O
(	O
fig	O
.	O
S2	O
and	O
Table	O
S1	O
)	O
.	O

These	O
dose	O
-	O
dependent	O
genetic	O
interactions	O
suggest	O
that	O
fra	O
and	O
comm	O
may	O
function	O
in	O
the	O
same	O
pathway	O
to	O
control	O
commissural	O
axon	O
guidance	O
.	O

Initiation	O
of	O
protein	O
synthesis	O
in	O
animal	O
mitochondria	O
.	O

Purification	O
and	O
characterization	O
of	O
translational	O
initiation	O
factor	O
2	O
.	O

Bovine	O
liver	O
mitochondrial	O
translational	O
initiation	O
factor	O
2	O
(	O
IF	O
-	O
2mt	O
)	O
has	O
been	O
purified	O
to	O
near	O
homogeneity	O
.	O

The	O
scheme	O
developed	O
results	O
in	O
a	O
24	O
,	O
000	O
-	O
fold	O
purification	O
of	O
the	O
factor	O
with	O
about	O
26	O
%	O
recovery	O
of	O
activity	O
.	O

SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
indicates	O
that	O
IF	O
-	O
2mt	O
has	O
a	O
subunit	O
molecular	O
mass	O
of	O
85	O
kDa	O
.	O

IF	O
-	O
2mt	O
promotes	O
the	O
binding	O
of	O
formyl	O
(	O
f	O
)	O
Met	O
-	O
tRNA	O
to	O
mitochondrial	B-OOS
ribosomes	I-OOS
but	O
is	O
inactive	O
with	O
the	O
nonformylated	O
derivative	O
.	O

IF	O
-	O
2mt	O
is	O
active	O
on	O
chloroplast	O
30	B-Complex
S	I-Complex
ribosomal	I-Complex
subunits	I-Complex
,	O
but	O
IF	O
-	O
2chl	O
has	O
no	O
activity	O
in	O
promoting	O
fMet	O
-	O
tRNA	O
binding	O
to	O
animal	O
mitochondrial	B-OOS
ribosomes	I-OOS
.	O

IF	O
-	O
2mt	O
is	O
sensitive	O
to	O
elevated	O
temperatures	O
and	O
is	O
inactivated	O
by	O
treatment	O
with	O
N	O
-	O
ethylmaleimide	O
.	O

It	O
is	O
partially	O
protected	O
from	O
heat	O
and	O
N	O
-	O
ethylmaleimide	O
inactivation	O
by	O
the	O
presence	O
of	O
either	O
GTP	O
or	O
GDP	O
suggesting	O
that	O
guanine	O
nucleotides	O
may	O
bind	O
to	O
this	O
factor	O
directly	O
.	O

The	O
binding	O
of	O
fMet	O
-	O
tRNA	O
to	O
mitochondrial	B-OOS
ribosomes	I-OOS
requires	O
the	O
presence	O
of	O
GTP	O
and	O
is	O
inhibited	O
by	O
GDP	O
.	O

DeoxyGTP	O
is	O
very	O
effective	O
in	O
replacing	O
GTP	O
in	O
promoting	O
fMet	O
-	O
tRNA	O
binding	O
to	O
ribosomes	B-OOS
and	O
some	O
activity	O
is	O
also	O
observed	O
with	O
ITP	O
.	O

No	O
activity	O
is	O
observed	O
with	O
ATP	O
,	O
CTP	O
,	O
or	O
UTP	O
.	O

Nonhydrolyzable	O
analogs	O
of	O
GTP	O
can	O
promote	O
formation	O
of	O
both	O
28	B-Complex
S	I-Complex
and	O
55	B-OOS
S	I-OOS
initiation	I-OOS
complexes	I-OOS
indicating	O
that	O
GTP	O
hydrolysis	O
is	O
not	O
required	O
for	O
subunit	O
joining	O
in	O
the	O
animal	O
mitochondrial	O
system	O
.	O

At	O
low	O
expression	O
levels	O
,	O
GFP	O
-	O
MinCC	O
/	O
MinD	O
localizes	O
to	O
the	O
Z	O
ring	O
without	O
disrupting	O
it	O
.	O

This	O
localization	O
is	O
dependent	O
upon	O
FtsZ	O
but	O
not	O
other	O
early	O
division	O
proteins	O
such	O
as	O
FtsA	O
,	O
ZipA	O
and	O
ZapA	O
,	O
suggesting	O
that	O
MinCC	O
/	O
MinD	O
interacts	O
with	O
FtsZ	O
directly	O
.	O

An	O
interaction	O
between	O
FtsZ	O
and	O
MinCC	O
/	O
MinD	O
was	O
observed	O
in	O
an	O
in	O
vitro	O
assay	O
,	O
which	O
strongly	O
supports	O
this	O
idea	O
.	O

In	O
this	O
paper	O
we	O
further	O
investigate	O
the	O
mechanism	O
by	O
which	O
MinCC	O
/	O
MinD	O
antagonizes	O
Z	O
ring	O
formation	O
.	O

We	O
isolated	O
FtsZ	O
mutants	O
that	O
are	O
resistant	O
to	O
MinCC	O
/	O
MinD	O
and	O
then	O
used	O
these	O
mutants	O
to	O
study	O
the	O
MinCC	O
/	O
MinD	O
-	O
FtsZ	O
interaction	O
and	O
the	O
basis	O
of	O
the	O
toxicity	O
associated	O
with	O
MinCC	O
/	O
MinD	O
.	O

We	O
have	O
previously	O
shown	O
that	O
forced	O
expression	O
of	O
Optix	O
in	O
the	O
developing	O
eye	O
leads	O
to	O
severe	O
alterations	O
in	O
eye	O
structure	O
.	O

This	O
activity	O
was	O
mapped	O
to	O
the	O
nonconserved	O
C	O
-	O
terminal	O
tail	O
as	O
the	O
replacement	O
of	O
the	O
So	O
CT	O
with	O
that	O
of	O
Optix	O
leads	O
to	O
the	O
same	O
degree	O
of	O
roughening	O
as	O
full	O
-	O
length	O
Optix	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
extended	O
this	O
early	O
observation	O
by	O
functionally	O
dissecting	O
the	O
C	O
-	O
terminal	O
segment	O
of	O
the	O
Optix	O
protein	O
and	O
(	O
1	O
)	O
demonstrated	O
that	O
while	O
the	O
CT	O
is	O
necessary	O
for	O
inhibiting	O
eye	O
development	O
,	O
it	O
also	O
requires	O
the	O
activity	O
of	O
the	O
protein	O
-	O
protein	O
interaction	O
and	O
DNA	O
binding	O
regions	O
;	O
(	O
2	O
)	O
identified	O
that	O
regions	O
A	O
,	O
C	O
,	O
and	O
D	O
of	O
the	O
CT	O
are	O
required	O
for	O
blocking	O
retinal	O
formation	O
;	O
(	O
3	O
)	O
shown	O
that	O
region	O
D	O
is	O
specifically	O
conserved	O
just	O
within	O
the	O
Drosophilids	O
;	O
(	O
4	O
)	O
demonstrated	O
that	O
the	O
CT	O
is	O
required	O
for	O
the	O
ability	O
of	O
Optix	O
to	O
induce	O
ectopic	O
eyes	O
;	O
(	O
5	O
)	O
shown	O
that	O
none	O
of	O
the	O
vertebrate	O
SIX	O
proteins	O
are	O
capable	O
of	O
inducing	O
ectopic	O
eyes	O
in	O
flies	O
;	O
and	O
(	O
6	O
)	O
demonstrated	O
that	O
in	O
addition	O
to	O
so	O
homologs	O
,	O
expression	O
of	O
DSix4	O
and	O
Six4	O
can	O
also	O
rescue	O
so1	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
.	O

E2	O
interaction	O
and	O
dimerization	O
in	O
the	O
crystal	O
structure	O
of	O
TRAF6	O
.	O

Tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
-	O
associated	O
factor	O
(	O
TRAF	O
)	O
-	O
6	O
mediates	O
Lys63	O
-	O
linked	O
polyubiquitination	O
for	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
via	O
its	O
N	O
-	O
terminal	O
RING	O
and	O
zinc	O
finger	O
domains	O
.	O

Here	O
we	O
report	O
the	O
crystal	O
structures	O
of	O
TRAF6	O
and	O
its	O
complex	O
with	O
the	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
(	O
E2	O
)	O
Ubc13	O
.	O

The	O
RING	O
and	O
zinc	O
fingers	O
of	O
TRAF6	O
assume	O
a	O
rigid	O
,	O
elongated	O
structure	O
.	O

Interaction	O
of	O
TRAF6	O
with	O
Ubc13	O
involves	O
direct	O
contacts	O
of	O
the	O
RING	O
and	O
the	O
preceding	O
residues	O
,	O
and	O
the	O
first	O
zinc	O
finger	O
has	O
a	O
structural	O
role	O
.	O

Unexpectedly	O
,	O
this	O
region	O
of	O
TRAF6	O
is	O
dimeric	O
both	O
in	O
the	O
crystal	O
and	O
in	O
solution	O
,	O
different	O
from	O
the	O
trimeric	O
C	O
-	O
terminal	O
TRAF	O
domain	O
.	O

Structure	O
-	O
based	O
mutagenesis	O
reveals	O
that	O
TRAF6	O
dimerization	O
is	O
crucial	O
for	O
polyubiquitin	O
synthesis	O
and	O
autoubiquitination	O
.	O

Fluorescence	O
resonance	O
energy	O
transfer	O
analysis	O
shows	O
that	O
TRAF6	O
dimerization	O
induces	O
higher	O
-	O
order	O
oligomerization	O
of	O
full	O
-	O
length	O
TRAF6	O
.	O

The	O
mismatch	O
of	O
dimeric	O
and	O
trimeric	O
symmetry	O
may	O
provide	O
a	O
mode	O
of	O
infinite	O
oligomerization	O
that	O
facilitates	O
ligand	O
-	O
dependent	O
signal	O
transduction	O
of	O
many	O
immune	O
receptors	O
.	O

Regulation	O
of	O
AMPA	B-Complex
receptor	I-Complex
extrasynaptic	O
insertion	O
by	O
4	O
.	O
1N	O
,	O
phosphorylation	O
and	O
palmitoylation	O
.	O

The	O
insertion	O
of	O
AMPA	B-Complex
receptors	I-Complex
(	O
AMPARs	B-Complex
)	O
into	O
the	O
plasma	O
membrane	O
is	O
an	O
important	O
step	O
in	O
the	O
synaptic	O
delivery	O
of	O
AMPARs	B-Complex
during	O
the	O
expression	O
of	O
synaptic	O
plasticity	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
regulating	O
AMPAR	B-Complex
insertion	O
remain	O
elusive	O
.	O

By	O
directly	O
visualizing	O
individual	O
insertion	O
events	O
of	O
the	O
AMPAR	B-Complex
subunit	O
GluR1	O
in	O
rodents	O
,	O
we	O
found	O
that	O
the	O
protein	O
4	O
.	O
1N	O
was	O
required	O
for	O
activity	O
-	O
dependent	O
GluR1	O
insertion	O
.	O

Protein	O
kinase	O
C	O
(	O
PKC	O
)	O
phosphorylation	O
of	O
the	O
serine	O
816	O
(	O
S816	O
)	O
and	O
S818	O
residues	O
of	O
GluR1	O
enhanced	O
4	O
.	O
1N	O
binding	O
to	O
GluR1	O
and	O
facilitated	O
GluR1	O
insertion	O
.	O

In	O
addition	O
,	O
palmitoylation	O
of	O
GluR1	O
C811	O
residue	O
modulated	O
PKC	O
phosphorylation	O
and	O
GluR1	O
insertion	O
.	O

Finally	O
,	O
disrupting	O
4	O
.	O
1N	O
-	O
dependent	O
GluR1	O
insertion	O
decreased	O
surface	O
expression	O
of	O
GluR1	O
and	O
the	O
expression	O
of	O
long	O
-	O
term	O
potentiation	O
.	O

Our	O
study	O
uncovers	O
a	O
previously	O
unknown	O
mechanism	O
that	O
governs	O
activity	O
-	O
dependent	O
GluR1	O
trafficking	O
,	O
reveals	O
an	O
interaction	O
between	O
AMPAR	B-Complex
palmitoylation	O
and	O
phosphorylation	O
,	O
and	O
underscores	O
the	O
functional	O
importance	O
of	O
4	O
.	O
1N	O
in	O
AMPAR	B-Complex
trafficking	O
and	O
synaptic	O
plasticity	O
.	O

Characterization	O
of	O
subcellular	O
localization	O
of	O
duck	O
enteritis	O
virus	O
UL51	O
protein	O
.	O

BACKGROUND	O
:	O
Knowledge	O
of	O
the	O
subcellular	O
localization	O
of	O
a	O
protein	O
can	O
provide	O
useful	O
insights	O
about	O
its	O
function	O
.	O

While	O
the	O
subcellular	O
localization	O
of	O
many	O
alphaherpesvirus	O
UL51	O
proteins	O
has	O
been	O
well	O
characterized	O
,	O
little	O
is	O
known	O
about	O
where	O
duck	O
enteritis	O
virus	O
(	O
DEV	O
)	O
UL51	O
protein	O
(	O
pUL51	O
)	O
is	O
targeted	O
to	O
.	O

Thus	O
,	O
in	O
this	O
study	O
,	O
we	O
investigated	O
the	O
subcellular	O
localization	O
and	O
distribution	O
of	O
DEV	O
pUL51	O
by	O
computer	O
aided	O
analysis	O
,	O
as	O
well	O
as	O
indirect	O
immunofluorescence	O
(	O
IIF	O
)	O
and	O
transmission	O
immunoelectron	O
microscopy	O
(	O
TIEM	O
)	O
approaches	O
in	O
DEV	O
-	O
infected	O
cells	O
.	O

RESULTS	O
:	O
The	O
DEV	O
UL51	O
gene	O
product	O
was	O
identified	O
as	O
an	O
approximate	O
34	O
kDa	O
protein	O
in	O
DEV	O
-	O
infected	O
cells	O
analyzed	O
by	O
western	O
blotting	O
.	O

Computer	O
aided	O
analysis	O
suggested	O
that	O
DEV	O
pUL51	O
is	O
not	O
targeted	O
to	O
the	O
mitochondrial	O
,	O
extra	O
-	O
cellular	O
or	O
nucleus	O
,	O
but	O
be	O
targeted	O
to	O
the	O
cytoplasmic	O
in	O
host	O
cells	O
,	O
more	O
specifically	O
,	O
palmitoylation	O
of	O
the	O
pUL51	O
through	O
the	O
N	O
-	O
terminal	O
cysteine	O
at	O
position	O
9	O
makes	O
membrane	O
association	O
and	O
Golgi	O
localization	O
possible	O
.	O

Using	O
IIF	O
analysis	O
,	O
we	O
found	O
that	O
DEV	O
pUL51	O
was	O
first	O
detected	O
in	O
a	O
juxtanuclear	O
region	O
of	O
DEV	O
-	O
infected	O
cells	O
at	O
9	O
h	O
postinfection	O
(	O
p	O
.	O
i	O
.	O
)	O
,	O
and	O
then	O
was	O
detected	O
widely	O
distributed	O
in	O
the	O
cytoplasm	O
and	O
especially	O
was	O
stronger	O
in	O
the	O
juxtanuclear	O
region	O
from	O
12	O
to	O
60	O
h	O
p	O
.	O
i	O
.	O

TIEM	O
analysis	O
revealed	O
that	O
DEV	O
pUL51	O
was	O
mainly	O
associated	O
with	O
cytoplasmic	O
virions	O
and	O
also	O
with	O
some	O
membranous	O
structure	O
near	O
the	O
pUL51	O
-	O
specific	O
immuno	O
-	O
labeling	O
intracellular	O
virion	O
in	O
the	O
cytoplasmic	O
vesicles	O
;	O
moreover	O
,	O
the	O
pUL51	O
efficiently	O
accumulated	O
in	O
the	O
Golgi	O
apparatus	O
at	O
first	O
,	O
and	O
then	O
was	O
sent	O
to	O
the	O
plasma	O
membrane	O
from	O
the	O
Golgi	O
by	O
some	O
unknown	O
mechanism	O
.	O

CONCLUSION	O
:	O
In	O
this	O
work	O
,	O
we	O
described	O
the	O
basic	O
characteristics	O
of	O
pUL51	O
subcellular	O
localization	O
and	O
distribution	O
for	O
the	O
first	O
time	O
.	O

From	O
these	O
results	O
,	O
we	O
concluded	O
that	O
palmitoylation	O
at	O
the	O
N	O
-	O
terminal	O
cysteine	O
,	O
which	O
is	O
conserved	O
in	O
all	O
alphaherpesvirus	O
UL51	O
homologs	O
,	O
is	O
required	O
for	O
its	O
membrane	O
association	O
and	O
Golgi	O
localization	O
,	O
and	O
the	O
pUL51	O
mainly	O
localized	O
to	O
the	O
juxtanuclear	O
region	O
of	O
DEV	O
-	O
infected	O
cells	O
,	O
as	O
well	O
seemed	O
to	O
be	O
incorporated	O
into	O
mature	O
virions	O
as	O
a	O
component	O
of	O
the	O
tegument	O
.	O

The	O
research	O
will	O
provide	O
useful	O
clues	O
for	O
DEV	O
pUL51	O
functional	O
analysis	O
,	O
and	O
will	O
be	O
usefull	O
for	O
further	O
understanding	O
the	O
localization	O
properties	O
of	O
alphaherpesvirus	O
UL51	O
homologs	O
.	O

Heat	O
shock	O
protein	O
27	O
phosphorylation	O
:	O
kinases	O
,	O
phosphatases	O
,	O
functions	O
and	O
pathology	O
.	O

The	O
small	O
heat	O
shock	O
protein	O
Hsp27	O
or	O
its	O
murine	O
homologue	O
Hsp25	O
acts	O
as	O
an	O
ATP	O
-	O
independent	O
chaperone	O
in	O
protein	O
folding	O
,	O
but	O
is	O
also	O
implicated	O
in	O
architecture	O
of	O
the	O
cytoskeleton	O
,	O
cell	O
migration	O
,	O
metabolism	O
,	O
cell	O
survival	O
,	O
growth	O
/	O
differentiation	O
,	O
mRNA	O
stabilization	O
,	O
and	O
tumor	O
progression	O
.	O

A	O
variety	O
of	O
stimuli	O
induce	O
phosphorylation	O
of	O
serine	O
residues	O
15	O
,	O
78	O
,	O
and	O
82	O
in	O
Hsp27	O
and	O
serines	O
15	O
and	O
86	O
in	O
Hsp25	O
.	O

This	O
post	O
-	O
translational	O
modification	O
affects	O
some	O
of	O
the	O
cellular	O
functions	O
of	O
Hsp25	O
/	O
27	O
.	O

As	O
a	O
consequence	O
of	O
the	O
functional	O
importance	O
of	O
Hsp25	O
/	O
27	O
phosphorylation	O
,	O
aberrant	O
Hsp27	O
phosphorylation	O
has	O
been	O
linked	O
to	O
several	O
clinical	O
conditions	O
.	O

This	O
review	O
focuses	O
on	O
the	O
different	O
Hsp25	O
/	O
27	O
kinases	O
and	O
phosphatases	O
that	O
regulate	O
the	O
phosphorylation	O
pattern	O
of	O
Hsp25	O
/	O
27	O
,	O
and	O
discusses	O
the	O
recent	O
findings	O
of	O
the	O
biological	O
implications	O
of	O
these	O
phosphorylation	O
events	O
in	O
physiological	O
and	O
pathological	O
processes	O
.	O

Novel	O
therapeutic	O
strategies	O
aimed	O
at	O
restoring	O
anomalous	O
Hsp27	O
phosphorylation	O
in	O
human	O
diseases	O
will	O
be	O
presented	O
.	O

Palmitoylation	O
of	O
the	O
sphingosine	O
1	O
-	O
phosphate	O
receptor	O
S1P	O
is	O
involved	O
in	O
its	O
signaling	O
functions	O
and	O
internalization	O
.	O

The	O
lipid	O
mediator	O
sphingosine	O
1	O
-	O
phosphate	O
(	O
S1P	O
)	O
regulates	O
several	O
cellular	O
processes	O
through	O
binding	O
to	O
its	O
receptors	O
(	O
S1P	O
(	O
1	O
)	O
-	O
S1P	O
(	O
5	O
)	O
)	O
,	O
which	O
are	O
heterotrimeric	O
G	O
protein	O
-	O
coupled	O
receptors	O
.	O

Here	O
,	O
we	O
report	O
that	O
all	O
S1P	O
receptors	O
are	O
palmitoylated	O
.	O

In	O
S1P	O
(	O
1	O
)	O
,	O
three	O
Cys	O
residues	O
in	O
the	O
cytoplasmic	O
tail	O
are	O
palmitoylated	O
.	O

We	O
examined	O
the	O
roles	O
of	O
palmitoylation	O
of	O
S1P	O
(	O
1	O
)	O
using	O
model	O
cells	O
in	O
which	O
wild	O
-	O
type	O
S1P	O
(	O
1	O
)	O
or	O
a	O
non	O
-	O
palmitoylated	O
mutant	O
S1P	O
(	O
1	O
)	O
was	O
overproduced	O
.	O

Compared	O
with	O
wild	O
-	O
type	O
S1P	O
(	O
1	O
)	O
,	O
the	O
non	O
-	O
palmitoylated	O
S1P	O
(	O
1	O
)	O
exhibited	O
binding	O
affinity	O
similar	O
to	O
the	O
natural	O
ligand	O
S1P	O
but	O
lower	O
to	O
the	O
synthetic	O
ligand	O
FTY720	O
phosphate	O
(	O
FTY720	O
-	O
P	O
)	O
,	O
the	O
active	O
form	O
of	O
the	O
immunomodulator	O
FTY720	O
.	O

However	O
,	O
downstream	O
signaling	O
of	O
non	O
-	O
palmitoylated	O
S1P	O
(	O
1	O
)	O
was	O
similarly	O
affected	O
by	O
S1P	O
and	O
FTY720	O
-	O
P	O
stimulation	O
.	O

Moreover	O
,	O
upon	O
stimulation	O
with	O
S1P	O
,	O
internalization	O
of	O
the	O
mutant	O
non	O
-	O
palmitoylated	O
S1P	O
(	O
1	O
)	O
was	O
retarded	O
,	O
compared	O
with	O
that	O
of	O
the	O
wild	O
-	O
type	O
protein	O
.	O

This	O
effect	O
was	O
much	O
more	O
pronounced	O
with	O
FTY720	O
-	O
P	O
stimulation	O
.	O

Similar	O
differences	O
were	O
observed	O
for	O
the	O
phosphorylation	O
of	O
S1P	O
(	O
1	O
)	O
and	O
its	O
mutant	O
.	O

These	O
findings	O
may	O
provide	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
of	O
the	O
pharmacological	O
effects	O
of	O
FTY720	O
.	O

Finally	O
,	O
palmitoylation	O
of	O
wild	O
-	O
type	O
S1P	O
(	O
1	O
)	O
increased	O
upon	O
treatment	O
with	O
S1P	O
,	O
suggesting	O
that	O
S1P	O
(	O
1	O
)	O
undergoes	O
a	O
palmitoylation	O
/	O
depalmitoylation	O
cycle	O
after	O
stimulation	O
by	O
its	O
ligands	O
.	O

Dvl	O
is	O
a	O
critical	O
regulator	O
of	O
Wnt	O
signaling	O
pathways	O
.	O

In	O
the	O
canonical	O
Wnt	O
signaling	O
pathway	O
,	O
Wnt	O
signal	O
is	O
passed	O
from	O
the	O
membrane	O
Wnt	O
receptor	O
Fz	O
to	O
Dvl	O
,	O
which	O
then	O
relays	O
the	O
signal	O
to	O
downstream	O
components	O
.	O

The	O
direct	O
recognition	O
between	O
Dvl	O
PDZ	O
domain	O
and	O
a	O
conserved	O
sequence	O
(	O
KTXXXW	O
)	O
in	O
Fz	O
,	O
localized	O
two	O
residues	O
after	O
the	O
seventh	O
transmembrane	O
domain	O
,	O
is	O
the	O
key	O
interaction	O
in	O
the	O
pathway	O
.	O

Indeed	O
,	O
Dvl	O
PDZ	O
-	O
binding	O
peptides	O
as	O
well	O
as	O
small	O
molecules	O
targeting	O
the	O
Dvl	O
PDZ	O
domain	O
can	O
effectively	O
block	O
Wnt	O
signaling	O
.	O

Here	O
we	O
show	O
that	O
sulindac	O
and	O
sulindac	O
sulfone	O
bind	O
the	O
peptide	O
-	O
binding	O
site	O
of	O
the	O
Dvl	O
PDZ	O
domain	O
with	O
an	O
affinity	O
comparable	O
to	O
that	O
of	O
the	O
native	O
binding	O
partners	O
and	O
that	O
,	O
like	O
other	O
Dvl	O
PDZ	O
inhibitors	O
,	O
sulindac	O
blocks	O
Wnt	O
signaling	O
at	O
the	O
Dvl	O
level	O
in	O
Xenopus	O
.	O

Therefore	O
,	O
we	O
propose	O
that	O
sulindac	O
exerts	O
its	O
chemoprotective	O
anticancer	O
effect	O
not	O
only	O
by	O
inhibiting	O
COX	B-Complex
enzymes	O
but	O
also	O
by	O
inhibiting	O
Wnt	O
signaling	O
via	O
Dvl	O
.	O

Tyrosine	O
sulfation	O
:	O
an	O
increasingly	O
recognised	O
post	O
-	O
translational	O
modification	O
of	O
secreted	O
proteins	O
.	O

The	O
post	O
-	O
translational	O
sulfation	O
of	O
tyrosine	O
residues	O
occurs	O
in	O
numerous	O
secreted	O
and	O
integral	O
membrane	O
proteins	O
and	O
,	O
in	O
many	O
cases	O
,	O
plays	O
a	O
crucial	O
role	O
in	O
controlling	O
the	O
interactions	O
of	O
these	O
proteins	O
with	O
physiological	O
binding	O
partners	O
as	O
well	O
as	O
invading	O
pathogens	O
.	O

Recent	O
advances	O
in	O
our	O
understanding	O
of	O
protein	O
tyrosine	O
sulfation	O
have	O
come	O
about	O
owing	O
to	O
the	O
cloning	O
of	O
two	O
human	O
tyrosylprotein	O
sulfotransferases	O
(	O
TPST	O
-	O
1	O
and	O
TPST	O
-	O
2	O
)	O
,	O
the	O
development	O
of	O
novel	O
analytical	O
and	O
synthetic	O
methodologies	O
and	O
detailed	O
studies	O
of	O
proteins	O
and	O
peptides	O
containing	O
sulfotyrosine	O
residues	O
.	O

In	O
this	O
article	O
,	O
we	O
describe	O
the	O
TPST	O
enzymes	O
,	O
review	O
the	O
major	O
techniques	O
available	O
for	O
studying	O
the	O
presence	O
,	O
location	O
and	O
function	O
of	O
tyrosine	O
sulfation	O
in	O
proteins	O
and	O
discuss	O
the	O
biological	O
functions	O
and	O
biochemical	O
interactions	O
of	O
several	O
proteins	O
(	O
or	O
protein	O
families	O
)	O
in	O
which	O
tyrosine	O
sulfation	O
influences	O
the	O
protein	O
function	O
.	O

In	O
particular	O
,	O
we	O
describe	O
the	O
detailed	O
evidence	O
supporting	O
the	O
importance	O
of	O
tyrosine	O
sulfation	O
in	O
the	O
cellular	O
adhesion	O
function	O
of	O
P	O
-	O
selectin	O
glycoprotein	O
ligand	O
-	O
1	O
,	O
the	O
leukocyte	O
trafficking	O
and	O
pathogen	O
invasion	O
functions	O
of	O
chemokine	O
receptors	O
and	O
the	O
ligand	O
binding	O
and	O
activation	O
of	O
other	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
by	O
complement	O
proteins	O
,	O
phospholipdis	O
and	O
glycoprotein	O
hormones	O
.	O

The	O
miRNA	O
pathway	O
involves	O
the	O
loading	O
of	O
a	O
miRNA	O
into	O
RISC	B-Complex
(	O
miRISC	B-Complex
)	O
,	O
and	O
the	O
active	O
association	O
of	O
miRISC	B-Complex
with	O
target	O
mRNAs	O
.	O

We	O
visualized	O
the	O
distribution	O
of	O
all	O
miRISC	B-Complex
complexes	O
(	O
active	O
,	O
loaded	O
,	O
and	O
inactive	O
)	O
in	O
Drosophila	O
cells	O
using	O
an	O
antibody	O
recognizing	O
the	O
Ago1	O
protein	O
,	O
a	O
key	O
subunit	O
of	O
miRISC	B-Complex
.	O

Ago1	O
was	O
detected	O
in	O
the	O
cytoplasm	O
of	O
cells	O
,	O
and	O
was	O
enriched	O
in	O
the	O
perinuclear	O
region	O
(	O
Fig	O
.	O
3f	O
)	O
,	O
where	O
lysosomes	O
tend	O
to	O
localize	O
.	O

In	O
dHPS4	O
mutant	O
cells	O
,	O
Ago1	O
was	O
not	O
enriched	O
in	O
the	O
perinuclear	O
region	O
but	O
was	O
more	O
dispersed	O
throughout	O
the	O
cytoplasm	O
(	O
Fig	O
.	O
3g	O
)	O
.	O

This	O
result	O
suggests	O
that	O
Ago1	O
localization	O
correlates	O
with	O
trafficking	O
endosomes	O
.	O

As	O
further	O
evidence	O
,	O
cells	O
mutant	O
for	O
vps25	O
and	O
the	O
ESCRT	B-Complex
regulator	O
myopic	O
showed	O
Ago1	O
concentrated	O
around	O
large	O
cytoplasmic	O
vesicles	O
(	O
Fig	O
.	O
3h	O
-	O
i	O
)	O
.	O

These	O
mutations	O
generate	O
cells	O
with	O
enlarged	O
early	O
endosomes	O
because	O
they	O
block	O
sorting	O
of	O
early	O
endosomes	O
into	O
MVBs	O
.	O

Hence	O
,	O
the	O
distribution	O
of	O
miRISC	B-Complex
appears	O
to	O
correlate	O
with	O
the	O
status	O
of	O
MVBs	O
;	O
blocking	O
MVB	O
formation	O
concentrates	O
miRISC	B-Complex
in	O
early	O
endosomes	O
while	O
blocking	O
MVB	O
turnover	O
disperses	O
miRISC	B-Complex
from	O
lysosomes	O
.	O

Even	O
though	O
Ago1	O
is	O
dispersed	O
in	O
dHPS4	O
cells	O
,	O
it	O
is	O
still	O
associated	O
with	O
membranes	O
in	O
the	O
cytoplasm	O
(	O
SFig	O
.	O
3a	O
)	O
.	O

We	O
separated	O
cytoplasmic	O
membrane	O
from	O
cytosol	O
by	O
OptiPrep	O
density	O
gradient	O
centrifugation	O
,	O
and	O
found	O
a	O
substantial	O
fraction	O
of	O
Ago1	O
protein	O
associated	O
with	O
membrane	O
.	O

There	O
was	O
little	O
change	O
in	O
its	O
association	O
with	O
membrane	O
in	O
dHPS4	O
mutant	O
preparations	O
.	O

A	O
similar	O
result	O
was	O
observed	O
with	O
Ago2	O
protein	O
(	O
SFig	O
.	O
3a	O
)	O
.	O

GSK	O
-	O
3	O
phosphorylates	O
delta	O
-	O
catenin	O
and	O
negatively	O
regulates	O
its	O
stability	O
via	O
ubiquitination	O
/	O
proteosome	B-Complex
-	O
mediated	O
proteolysis	O
.	O

Delta	O
-	O
catenin	O
was	O
first	O
identified	O
because	O
of	O
its	O
interaction	O
with	O
presenilin	O
-	O
1	O
,	O
and	O
its	O
aberrant	O
expression	O
has	O
been	O
reported	O
in	O
various	O
human	O
tumors	O
and	O
in	O
patients	O
with	O
Cri	O
-	O
du	O
-	O
Chat	O
syndrome	O
,	O
a	O
form	O
of	O
mental	O
retardation	O
.	O

However	O
,	O
the	O
mechanism	O
whereby	O
delta	O
-	O
catenin	O
is	O
regulated	O
in	O
cells	O
has	O
not	O
been	O
fully	O
elucidated	O
.	O

We	O
investigated	O
the	O
possibility	O
that	O
glycogen	O
-	O
synthase	O
kinase	O
-	O
3	O
(	O
GSK	O
-	O
3	O
)	O
phosphorylates	O
delta	O
-	O
catenin	O
and	O
thus	O
affects	O
its	O
stability	O
.	O

Initially	O
,	O
we	O
found	O
that	O
the	O
level	O
of	O
delta	O
-	O
catenin	O
was	O
greater	O
and	O
the	O
half	O
-	O
life	O
of	O
delta	O
-	O
catenin	O
was	O
longer	O
in	O
GSK	O
-	O
3beta	O
(	O
-	O
/	O
-	O
)	O
fibroblasts	O
than	O
those	O
in	O
GSK	O
-	O
3beta	O
(	O
+	O
/	O
+	O
)	O
fibroblasts	O
.	O

Furthermore	O
,	O
four	O
different	O
approaches	O
designed	O
to	O
specifically	O
inhibit	O
GSK	O
-	O
3	O
activity	O
,	O
i	O
.	O
e	O
.	O
GSK	O
-	O
3	O
-	O
specific	O
chemical	O
inhibitors	O
,	O
Wnt	O
-	O
3a	O
conditioned	O
media	O
,	O
small	O
interfering	O
RNAs	O
,	O
and	O
GSK	O
-	O
3alpha	O
and	O
-	O
3beta	O
kinase	O
dead	O
constructs	O
,	O
consistently	O
showed	O
that	O
the	O
levels	O
of	O
endogenous	O
delta	O
-	O
catenin	O
in	O
CWR22Rv	O
-	O
1	O
prostate	O
carcinoma	O
cells	O
and	O
primary	O
cortical	O
neurons	O
were	O
increased	O
by	O
inhibiting	O
GSK	O
-	O
3	O
activity	O
.	O

In	O
addition	O
,	O
it	O
was	O
found	O
that	O
both	O
GSK	O
-	O
3alpha	O
and	O
-	O
3beta	O
interact	O
with	O
and	O
phosphorylate	O
delta	O
-	O
catenin	O
.	O

The	O
phosphorylation	O
of	O
DeltaC207	O
-	O
delta	O
-	O
catenin	O
(	O
lacking	O
207	O
C	O
-	O
terminal	O
residues	O
)	O
and	O
T1078A	O
delta	O
-	O
catenin	O
by	O
GSK	O
-	O
3	O
was	O
noticeably	O
reduced	O
compared	O
with	O
that	O
of	O
wild	O
type	O
delta	O
-	O
catenin	O
,	O
and	O
the	O
data	O
from	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
analyses	O
suggest	O
that	O
the	O
Thr	O
(	O
1078	O
)	O
residue	O
of	O
delta	O
-	O
catenin	O
is	O
one	O
of	O
the	O
GSK	O
-	O
3	O
phosphorylation	O
sites	O
.	O

Treatment	O
with	O
MG132	O
or	O
ALLN	O
,	O
specific	O
inhibitors	O
of	O
proteosome	B-Complex
-	O
dependent	O
proteolysis	O
,	O
increased	O
delta	O
-	O
catenin	O
levels	O
and	O
caused	O
an	O
accumulation	O
of	O
ubiquitinated	O
delta	O
-	O
catenin	O
.	O

It	O
was	O
also	O
found	O
that	O
GSK	O
-	O
3	O
triggers	O
the	O
ubiquitination	O
of	O
delta	O
-	O
catenin	O
.	O

These	O
results	O
suggest	O
that	O
GSK	O
-	O
3	O
interacts	O
with	O
and	O
phosphorylates	O
delta	O
-	O
catenin	O
and	O
thereby	O
negatively	O
affects	O
its	O
stability	O
by	O
enabling	O
its	O
ubiquitination	O
/	O
proteosome	B-Complex
-	O
mediated	O
proteolysis	O
.	O

In	O
order	O
to	O
successfully	O
infect	O
human	O
cells	O
,	O
HIV	O
-	O
1	O
has	O
to	O
neutralize	O
cellular	O
restriction	O
factors	O
that	O
impede	O
its	O
replication	O
at	O
multiple	O
steps	O
.	O

HIV	O
-	O
1	O
Vpu	O
serves	O
this	O
goal	O
by	O
counteracting	O
a	O
blockade	O
imposed	O
by	O
the	O
newly	O
identified	O
protein	O
tetherin	O
.	O

Under	O
basal	O
conditions	O
,	O
tetherin	O
is	O
expressed	O
in	O
B	O
and	O
T	O
cells	O
,	O
plasmacytoid	O
dendritic	O
cells	O
and	O
myeloid	O
cells	O
.	O

In	O
addition	O
,	O
tetherin	O
expression	O
is	O
strongly	O
upregulated	O
in	O
many	O
cell	O
types	O
by	O
type	O
-	O
I	O
interferon	O
(	O
IFN	O
)	O
,	O
a	O
situation	O
typically	O
encountered	O
in	O
viral	O
infections	O
.	O

Tetherin	O
is	O
a	O
heavily	O
glycosylated	O
type	O
-	O
II	O
transmembrane	O
protein	O
with	O
an	O
unusual	O
topology	O
,	O
which	O
is	O
otherwise	O
only	O
found	O
in	O
mammals	O
in	O
a	O
minor	O
but	O
pathologically	O
important	O
topological	O
variant	O
of	O
the	O
prion	O
protein	O
.	O

Tetherin	O
is	O
indeed	O
linked	O
to	O
membranes	O
both	O
by	O
its	O
one	O
-	O
pass	O
transmembrane	O
domain	O
and	O
by	O
a	O
C	O
-	O
ter	O
GPI	O
anchor	O
.	O

This	O
anti	O
-	O
viral	O
factor	O
is	O
mostly	O
intracellular	O
,	O
but	O
it	O
is	O
also	O
localized	O
at	O
the	O
cell	O
surface	O
in	O
lipid	O
rafts	O
,	O
from	O
where	O
it	O
is	O
continually	O
recycled	O
to	O
the	O
trans	O
-	O
Golgi	O
network	O
.	O

In	O
cells	O
expressing	O
tetherin	O
,	O
HIV	O
-	O
1	O
viruses	O
deleted	O
for	O
the	O
Vpu	O
gene	O
can	O
bud	O
normally	O
but	O
remain	O
tethered	O
to	O
the	O
cell	O
surface	O
through	O
a	O
protein	O
bond	O
.	O

The	O
mechanistic	O
details	O
of	O
this	O
phenomenon	O
remain	O
to	O
be	O
clarified	O
.	O

A	O
hypothesis	O
,	O
that	O
still	O
awaits	O
confirmation	O
,	O
is	O
that	O
tetherin	O
itself	O
forms	O
the	O
protein	O
tether	O
between	O
the	O
cell	O
surface	O
and	O
the	O
virion	O
owing	O
to	O
its	O
ability	O
to	O
form	O
stable	O
dimers	O
.	O

The	O
affected	O
virions	O
are	O
then	O
endocytosed	O
and	O
probably	O
degraded	O
in	O
lysosomes	O
.	O

In	O
addition	O
to	O
inhibiting	O
HIV	O
-	O
1	O
,	O
tetherin	O
also	O
blocks	O
the	O
replication	O
of	O
numerous	O
retroviruses	O
,	O
as	O
well	O
as	O
other	O
non	O
-	O
related	O
enveloped	O
viruses	O
.	O

The	O
importance	O
of	O
this	O
restriction	O
in	O
the	O
cellular	O
antiviral	O
arsenal	O
is	O
underscored	O
by	O
the	O
apparent	O
positive	O
selection	O
that	O
tetherin	O
undergoes	O
,	O
which	O
is	O
the	O
hallmark	O
of	O
an	O
ongoing	O
molecular	O
fight	O
with	O
pathogens	O
.	O

Although	O
we	O
do	O
not	O
have	O
sufficient	O
data	O
to	O
model	O
the	O
replisome	O
,	O
the	O
electrostatic	O
surface	O
potential	O
of	O
Pol	O
gammaA	O
is	O
informative	O
.	O

As	O
expected	O
,	O
the	O
putative	O
DNA	O
-	O
binding	O
channel	O
is	O
lined	O
with	O
positively	O
charged	O
residues	O
but	O
the	O
opposite	O
surface	O
of	O
the	O
protein	O
presents	O
a	O
large	O
negatively	O
charged	O
region	O
near	O
the	O
exo	O
domain	O
and	O
the	O
tip	O
of	O
the	O
AID	O
subdomain	O
also	O
contains	O
four	O
sequential	O
glutamates	O
(	O
535EEEE538	O
,	O
E	O
-	O
tract	O
;	O
Fig	O
.	O
5A	O
)	O
.	O

The	O
human	O
mitochondrial	O
helicase	O
,	O
Twinkle	O
,	O
has	O
a	O
highly	O
positively	O
charged	O
C	O
-	O
terminal	O
region	O
that	O
could	O
contact	O
one	O
of	O
these	O
regions	O
.	O

If	O
the	O
interaction	O
is	O
through	O
the	O
negatively	O
charged	O
E	O
-	O
tract	O
in	O
the	O
replisome	O
,	O
Twinkle	O
would	O
be	O
positioned	O
in	O
a	O
location	O
close	O
to	O
that	O
of	O
the	O
363RKK365	O
and	O
328RK329	O
,	O
residues	O
important	O
in	O
Twinkle	O
-	O
dependent	O
replication	O
of	O
duplex	O
DNA	O
.	O

Validation	O
of	O
a	O
method	O
for	O
the	O
quantitation	O
of	O
ghrelin	O
and	O
unacylated	O
ghrelin	O
by	O
HPLC	O
.	O

An	O
HPLC	O
/	O
UV	O
method	O
was	O
first	O
optimized	O
for	O
the	O
separation	O
and	O
quantitation	O
of	O
human	O
acylated	O
and	O
unacylated	O
(	O
or	O
des	O
-	O
acyl	O
)	O
ghrelin	O
from	O
aqueous	O
solutions	O
.	O

This	O
method	O
was	O
validated	O
by	O
an	O
original	O
approach	O
using	O
accuracy	O
profiles	O
based	O
on	O
tolerance	O
intervals	O
for	O
the	O
total	O
error	O
measurement	O
.	O

The	O
concentration	O
range	O
that	O
achieved	O
adequate	O
accuracy	O
extended	O
from	O
1	O
.	O
85	O
to	O
59	O
.	O
30microM	O
and	O
1	O
.	O
93	O
to	O
61	O
.	O
60microM	O
for	O
acylated	O
and	O
unacylated	O
ghrelin	O
,	O
respectively	O
.	O

Then	O
,	O
optimal	O
temperature	O
,	O
pH	O
and	O
buffer	O
for	O
sample	O
storage	O
were	O
determined	O
.	O

Unacylated	O
ghrelin	O
was	O
found	O
to	O
be	O
stable	O
in	O
all	O
conditions	O
tested	O
.	O

At	O
37	O
degrees	O
C	O
acylated	O
ghrelin	O
was	O
stable	O
at	O
pH	O
4	O
but	O
unstable	O
at	O
pH	O
7	O
.	O
4	O
,	O
the	O
main	O
degradation	O
product	O
was	O
unacylated	O
ghrelin	O
.	O

Finally	O
,	O
this	O
validated	O
HPLC	O
/	O
UV	O
method	O
was	O
used	O
to	O
evaluate	O
the	O
binding	O
of	O
acylated	O
and	O
unacylated	O
ghrelin	O
to	O
liposomes	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
gp120	O
envelope	O
glycoprotein	O
regions	O
important	O
for	O
association	O
with	O
the	O
gp41	O
transmembrane	O
glycoprotein	O
.	O

Insertion	O
of	O
four	O
amino	O
acids	O
into	O
various	O
locations	O
within	O
the	O
amino	O
-	O
terminal	O
halves	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
gp120	O
or	O
gp41	O
envelope	O
glycoprotein	O
disrupts	O
the	O
noncovalent	O
association	O
of	O
these	O
two	O
envelope	O
subunits	O
(	O
M	O
.	O
Kowalski	O
,	O
J	O
.	O
Potz	O
,	O
L	O
.	O
Basiripour	O
,	O
T	O
.	O
Dorfman	O
,	O
W	O
.	O
C	O
.	O
Goh	O
,	O
E	O
.	O
Terwilliger	O
,	O
A	O
.	O
Dayton	O
,	O
C	O
.	O
Rosen	O
,	O
W	O
.	O
A	O
.	O
Haseltine	O
,	O
and	O
J	O
.	O
Sodroski	O
,	O
Science	O
237	O
:	O
1351	O
-	O
1355	O
,	O
1987	O
)	O
.	O

To	O
localize	O
the	O
determinants	O
on	O
the	O
gp120	O
envelope	O
glycoprotein	O
important	O
for	O
subunit	O
association	O
,	O
amino	O
acids	O
conserved	O
among	O
primate	O
immunodeficiency	O
viruses	O
were	O
changed	O
.	O

Substitution	O
mutations	O
affecting	O
either	O
of	O
two	O
highly	O
conserved	O
regions	O
located	O
at	O
the	O
amino	O
(	O
residues	O
36	O
to	O
45	O
)	O
and	O
carboxyl	O
(	O
residues	O
491	O
to	O
501	O
)	O
ends	O
of	O
the	O
mature	O
gp120	O
molecule	O
resulted	O
in	O
nearly	O
complete	O
dissociation	O
of	O
the	O
envelope	O
glycoprotein	O
subunits	O
.	O

Partial	O
dissociation	O
phenotypes	O
were	O
observed	O
for	O
some	O
changes	O
affecting	O
residues	O
in	O
the	O
third	O
and	O
fourth	O
conserved	O
gp120	O
regions	O
.	O

These	O
results	O
suggest	O
that	O
hydrophobic	O
regions	O
at	O
both	O
ends	O
of	O
the	O
gp120	O
glycoprotein	O
contribute	O
to	O
noncovalent	O
association	O
with	O
the	O
gp41	O
transmembrane	O
glycoprotein	O
.	O

Activation	O
of	O
the	O
Drosophila	O
IMD	O
pathway	O
by	O
DAP	O
-	O
type	O
peptidoglycan	O
(	O
PGN	O
)	O
leads	O
to	O
the	O
robust	O
and	O
rapid	O
production	O
of	O
a	O
battery	O
of	O
antimicrobial	O
peptides	O
(	O
AMPs	O
)	O
and	O
other	O
immune	O
responsive	O
genes	O
.	O

Two	O
peptidoglycan	O
recognition	O
protein	O
(	O
PGRP	O
)	O
receptors	O
are	O
responsible	O
for	O
the	O
recognition	O
of	O
DAP	O
-	O
type	O
PGN	O
,	O
the	O
cell	O
surface	O
receptor	O
PGRP	O
-	O
LC	O
and	O
the	O
cytosolic	O
receptor	O
PGRP	O
-	O
LE	O
.	O

DAP	O
-	O
type	O
PGN	O
binding	O
causes	O
these	O
receptors	O
to	O
multimerize	O
or	O
cluster	O
triggering	O
signal	O
transduction	O
.	O

IMD	O
signaling	O
culminates	O
in	O
activation	O
of	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
precursor	O
Relish	O
and	O
transcriptional	O
induction	O
of	O
AMP	O
genes	O
.	O

Primase	O
directs	O
the	O
release	O
of	O
DnaC	O
from	O
DnaB	O
.	O

An	O
AAA	O
+	O
ATPase	O
,	O
DnaC	O
,	O
delivers	O
DnaB	O
helicase	O
at	O
the	O
E	O
.	O
coli	O
chromosomal	O
origin	O
by	O
a	O
poorly	O
understood	O
process	O
.	O

This	O
report	O
shows	O
that	O
mutant	O
proteins	O
bearing	O
alanine	O
substitutions	O
for	O
two	O
conserved	O
arginines	O
in	O
a	O
motif	O
named	O
box	O
VII	O
are	O
defective	O
in	O
DNA	O
replication	O
,	O
but	O
this	O
deficiency	O
does	O
not	O
arise	O
from	O
impaired	O
interactions	O
with	O
ATP	O
,	O
DnaB	O
,	O
or	O
single	O
-	O
stranded	O
DNA	O
.	O

Despite	O
their	O
ability	O
to	O
deliver	O
DnaB	O
to	O
the	O
chromosomal	O
origin	O
to	O
form	O
the	O
prepriming	O
complex	O
,	O
this	O
intermediate	O
is	O
inactive	O
.	O

Quantitative	O
analysis	O
of	O
the	O
prepriming	O
complex	O
suggests	O
that	O
the	O
DnaB	O
-	O
DnaC	O
complex	O
contains	O
three	O
DnaC	O
monomers	O
per	O
DnaB	O
hexamer	O
and	O
that	O
the	O
interaction	O
of	O
primase	O
with	O
DnaB	O
and	O
primer	O
formation	O
triggers	O
the	O
release	O
of	O
DnaC	O
,	O
but	O
not	O
the	O
mutants	O
,	O
from	O
DnaB	O
.	O

The	O
interaction	O
of	O
primase	O
with	O
DnaB	O
and	O
the	O
release	O
of	O
DnaC	O
mark	O
discrete	O
events	O
in	O
the	O
transition	O
from	O
initiation	O
to	O
the	O
elongation	O
stage	O
of	O
DNA	O
replication	O
.	O

Three	O
-	O
dimensional	O
organization	O
of	O
promyelocytic	O
leukemia	O
nuclear	O
bodies	O
.	O

Promyelocytic	O
leukemia	O
nuclear	O
bodies	O
(	O
PML	O
-	O
NBs	O
)	O
are	O
mobile	O
subnuclear	O
organelles	O
formed	O
by	O
PML	O
and	O
Sp100	O
protein	O
.	O

They	O
have	O
been	O
reported	O
to	O
have	O
a	O
role	O
in	O
transcription	O
,	O
DNA	O
replication	O
and	O
repair	O
,	O
telomere	O
lengthening	O
,	O
cell	O
cycle	O
control	O
and	O
tumor	O
suppression	O
.	O

We	O
have	O
conducted	O
high	O
-	O
resolution	O
4Pi	O
fluorescence	O
laser	O
-	O
scanning	O
microscopy	O
studies	O
complemented	O
with	O
correlative	O
electron	O
microscopy	O
and	O
investigations	O
of	O
the	O
accessibility	O
of	O
the	O
PML	O
-	O
NB	O
subcompartment	O
.	O

During	O
interphase	O
PML	O
-	O
NBs	O
adopt	O
a	O
spherical	O
organization	O
characterized	O
by	O
the	O
assembly	O
of	O
PML	O
and	O
Sp100	O
proteins	O
into	O
patches	O
within	O
a	O
50	O
-	O
to	O
100	O
-	O
nm	O
-	O
thick	O
shell	O
.	O

This	O
spherical	O
shell	O
of	O
PML	O
and	O
Sp100	O
imposes	O
little	O
constraint	O
to	O
the	O
exchange	O
of	O
components	O
between	O
the	O
PML	O
-	O
NB	O
interior	O
and	O
the	O
nucleoplasm	O
.	O

Post	O
-	O
translational	O
SUMO	O
modifications	O
,	O
telomere	O
repeats	O
and	O
heterochromatin	O
protein	O
1	O
were	O
found	O
to	O
localize	O
in	O
characteristic	O
patterns	O
with	O
respect	O
to	O
PML	O
and	O
Sp100	O
.	O

From	O
our	O
findings	O
,	O
we	O
derived	O
a	O
model	O
that	O
explains	O
how	O
the	O
three	O
-	O
dimensional	O
organization	O
of	O
PML	O
-	O
NBs	O
serves	O
to	O
concentrate	O
different	O
biological	O
activities	O
while	O
allowing	O
for	O
an	O
efficient	O
exchange	O
of	O
components	O
.	O

Electrostatics	O
of	O
aquaporin	O
and	O
aquaglyceroporin	O
channels	O
correlates	O
with	O
their	O
transport	O
selectivity	O
.	O

Aquaporins	O
are	O
homotetrameric	O
channel	O
proteins	O
,	O
which	O
allow	O
the	O
diffusion	O
of	O
water	O
and	O
small	O
solutes	O
across	O
biological	O
membranes	O
.	O

According	O
to	O
their	O
transport	O
function	O
,	O
aquaporins	O
can	O
be	O
divided	O
into	O
"	O
orthodox	O
aquaporins	O
"	O
,	O
which	O
allow	O
the	O
flux	O
of	O
water	O
molecules	O
only	O
,	O
and	O
"	O
aquaglyceroporins	O
"	O
,	O
which	O
facilitate	O
the	O
diffusion	O
of	O
glycerol	O
and	O
other	O
small	O
solutes	O
in	O
addition	O
to	O
water	O
.	O

The	O
contribution	O
of	O
individual	O
residues	O
in	O
the	O
pore	O
to	O
the	O
selectivity	O
of	O
orthodox	O
aquaporins	O
and	O
aquaglyceroporins	O
is	O
not	O
yet	O
fully	O
understood	O
.	O

To	O
gain	O
insights	O
into	O
aquaporin	O
selectivity	O
,	O
we	O
focused	O
on	O
the	O
sequence	O
variation	O
and	O
electrostatics	O
of	O
their	O
channels	O
.	O

The	O
continuum	O
Poisson	O
-	O
Boltzmann	O
electrostatic	O
potential	O
along	O
the	O
channel	O
was	O
calculated	O
and	O
compared	O
for	O
ten	O
three	O
-	O
dimensional	O
-	O
structures	O
which	O
are	O
representatives	O
of	O
different	O
aquaporin	O
subfamilies	O
,	O
and	O
a	O
panel	O
of	O
functionally	O
characterized	O
mutants	O
,	O
for	O
which	O
high	O
-	O
accuracy	O
three	O
-	O
dimensional	O
-	O
models	O
could	O
be	O
derived	O
.	O

Interestingly	O
,	O
specific	O
electrostatic	O
profiles	O
associated	O
with	O
the	O
main	O
selectivity	O
to	O
water	O
or	O
glycerol	O
could	O
be	O
identified	O
.	O

In	O
particular	O
:	O
(	O
i	O
)	O
orthodox	O
aquaporins	O
showed	O
a	O
distinctive	O
electrostatic	O
potential	O
maximum	O
at	O
the	O
periplasmic	O
side	O
of	O
the	O
channel	O
around	O
the	O
aromatic	O
/	O
Arg	O
(	O
ar	O
/	O
R	O
)	O
constriction	O
site	O
;	O
(	O
ii	O
)	O
aquaporin	O
-	O
0	O
(	O
AQP0	O
)	O
,	O
a	O
mammalian	O
aquaporin	O
with	O
considerably	O
low	O
water	O
permeability	O
,	O
had	O
an	O
additional	O
deep	O
minimum	O
at	O
the	O
cytoplasmic	O
side	O
;	O
(	O
iii	O
)	O
aquaglyceroporins	O
showed	O
a	O
rather	O
flat	O
potential	O
all	O
along	O
the	O
channel	O
;	O
and	O
(	O
iv	O
)	O
the	O
bifunctional	O
protozoan	O
PfAQP	O
had	O
an	O
unusual	O
all	O
negative	O
profile	O
.	O

Evaluation	O
of	O
electrostatics	O
of	O
the	O
mutants	O
,	O
along	O
with	O
a	O
thorough	O
sequence	O
analysis	O
of	O
the	O
aquaporin	O
pore	O
-	O
lining	O
residues	O
,	O
illuminated	O
the	O
contribution	O
of	O
specific	O
residues	O
to	O
the	O
electrostatics	O
of	O
the	O
channels	O
and	O
possibly	O
to	O
their	O
selectivity	O
.	O

FGFR1	O
amplification	O
drives	O
endocrine	O
therapy	O
resistance	O
and	O
is	O
a	O
therapeutic	O
target	O
in	O
breast	O
cancer	O
.	O

Amplification	O
of	O
fibroblast	O
growth	O
factor	O
receptor	O
1	O
(	O
FGFR1	O
)	O
occurs	O
in	O
approximately	O
10	O
%	O
of	O
breast	O
cancers	O
and	O
is	O
associated	O
with	O
poor	O
prognosis	O
.	O

However	O
,	O
it	O
is	O
uncertain	O
whether	O
overexpression	O
of	O
FGFR1	O
is	O
causally	O
linked	O
to	O
the	O
poor	O
prognosis	O
of	O
amplified	O
cancers	O
.	O

Here	O
,	O
we	O
show	O
that	O
FGFR1	O
overexpression	O
is	O
robustly	O
associated	O
with	O
FGFR1	O
amplification	O
in	O
two	O
independent	O
series	O
of	O
breast	O
cancers	O
.	O

Breast	O
cancer	O
cell	O
lines	O
with	O
FGFR1	O
overexpression	O
and	O
amplification	O
show	O
enhanced	O
ligand	O
-	O
dependent	O
signaling	O
,	O
with	O
increased	O
activation	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
and	O
phosphoinositide	O
3	O
-	O
kinase	O
-	O
AKT	O
signaling	O
pathways	O
in	O
response	O
to	O
FGF2	O
,	O
but	O
also	O
show	O
basal	O
ligand	O
-	O
independent	O
signaling	O
,	O
and	O
are	O
dependent	O
on	O
FGFR	O
signaling	O
for	O
anchorage	O
-	O
independent	O
growth	O
.	O

FGFR1	O
-	O
amplified	O
cell	O
lines	O
show	O
resistance	O
to	O
4	O
-	O
hydroxytamoxifen	O
,	O
which	O
is	O
reversed	O
by	O
small	O
interfering	O
RNA	O
silencing	O
of	O
FGFR1	O
,	O
suggesting	O
that	O
FGFR1	O
overexpression	O
also	O
promotes	O
endocrine	O
therapy	O
resistance	O
.	O

FGFR1	O
signaling	O
suppresses	O
progesterone	O
receptor	O
(	O
PR	O
)	O
expression	O
in	O
vitro	O
,	O
and	O
likewise	O
,	O
amplified	O
cancers	O
are	O
frequently	O
PR	O
negative	O
,	O
identifying	O
a	O
potential	O
biomarker	O
for	O
FGFR1	O
activity	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
amplified	O
cancers	O
have	O
a	O
high	O
proliferative	O
rate	O
assessed	O
by	O
Ki67	O
staining	O
and	O
that	O
FGFR1	O
amplification	O
is	O
found	O
in	O
16	O
%	O
to	O
27	O
%	O
of	O
luminal	O
B	O
-	O
type	O
breast	O
cancers	O
.	O

Our	O
data	O
suggest	O
that	O
amplification	O
and	O
overexpression	O
of	O
FGFR1	O
may	O
be	O
a	O
major	O
contributor	O
to	O
poor	O
prognosis	O
in	O
luminal	O
-	O
type	O
breast	O
cancers	O
,	O
driving	O
anchorage	O
-	O
independent	O
proliferation	O
and	O
endocrine	O
therapy	O
resistance	O
.	O

Cross	O
talk	O
between	O
microRNA	O
and	O
epigenetic	O
regulation	O
in	O
adult	O
neurogenesis	O
.	O

Both	O
microRNAs	O
(	O
miRNAs	O
)	O
and	O
epigenetic	O
regulation	O
have	O
important	O
functions	O
in	O
stem	O
cell	O
biology	O
,	O
although	O
the	O
interactions	O
between	O
these	O
two	O
pathways	O
are	O
not	O
well	O
understood	O
.	O

Here	O
,	O
we	O
show	O
that	O
MeCP2	O
,	O
a	O
DNA	O
methyl	O
-	O
CpG	O
-	O
binding	O
protein	O
,	O
can	O
epigenetically	O
regulate	O
specific	O
miRNAs	O
in	O
adult	O
neural	O
stem	O
cells	O
(	O
aNSCs	O
)	O
.	O

MeCP2	O
-	O
mediated	O
epigenetic	O
regulation	O
of	O
one	O
such	O
miRNA	O
,	O
miR	O
-	O
137	O
,	O
involves	O
coregulation	O
by	O
Sox2	O
,	O
a	O
core	O
transcription	O
factor	O
in	O
stem	O
cells	O
.	O

miR	O
-	O
137	O
modulates	O
the	O
proliferation	O
and	O
differentiation	O
of	O
aNSCs	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Overexpression	O
of	O
miR	O
-	O
137	O
promotes	O
the	O
proliferation	O
of	O
aNSCs	O
,	O
whereas	O
a	O
reduction	O
of	O
miR	O
-	O
137	O
enhances	O
aNSC	O
differentiation	O
.	O

We	O
further	O
show	O
that	O
miR	O
-	O
137	O
post	O
-	O
transcriptionally	O
represses	O
the	O
expression	O
of	O
Ezh2	O
,	O
a	O
histone	O
methyltransferase	O
and	O
Polycomb	O
group	O
(	O
PcG	O
)	O
protein	O
.	O

The	O
miR	O
-	O
137	O
-	O
mediated	O
repression	O
of	O
Ezh2	O
feeds	O
back	O
to	O
chromatin	O
,	O
resulting	O
in	O
a	O
global	O
decrease	O
in	O
histone	O
H3	O
trimethyl	O
lysine	O
27	O
.	O

Coexpression	O
of	O
Ezh2	O
can	O
rescue	O
phenotypes	O
associated	O
with	O
miR	O
-	O
137	O
overexpression	O
.	O

These	O
results	O
demonstrate	O
that	O
cross	O
talk	O
between	O
miRNA	O
and	O
epigenetic	O
regulation	O
contributes	O
to	O
the	O
modulation	O
of	O
adult	O
neurogenesis	O
.	O

Negative	O
role	O
of	O
RIG	O
-	O
I	O
serine	O
8	O
phosphorylation	O
in	O
the	O
regulation	O
of	O
interferon	O
-	O
beta	O
production	O
.	O

RIG	O
-	O
I	O
(	O
retinoic	O
acid	O
-	O
inducible	O
gene	O
I	O
)	O
and	O
TRIM25	O
(	O
tripartite	O
motif	O
protein	O
25	O
)	O
have	O
emerged	O
as	O
key	O
regulatory	O
factors	O
to	O
induce	O
interferon	O
(	O
IFN	O
)	O
-	O
mediated	O
innate	O
immune	O
responses	O
to	O
limit	O
viral	O
replication	O
.	O

Upon	O
recognition	O
of	O
viral	O
RNA	O
,	O
TRIM25	O
E3	O
ligase	O
binds	O
the	O
first	O
caspase	O
recruitment	O
domain	O
(	O
CARD	O
)	O
of	O
RIG	O
-	O
I	O
and	O
subsequently	O
induces	O
lysine	O
172	O
ubiquitination	O
of	O
the	O
second	O
CARD	O
of	O
RIG	O
-	O
I	O
,	O
which	O
is	O
essential	O
for	O
the	O
interaction	O
with	O
downstream	O
MAVS	O
/	O
IPS	O
-	O
1	O
/	O
CARDIF	O
/	O
VISA	O
and	O
,	O
thereby	O
,	O
IFN	O
-	O
beta	O
mRNA	O
production	O
.	O

Although	O
ubiquitination	O
has	O
emerged	O
as	O
a	O
major	O
factor	O
involved	O
in	O
RIG	O
-	O
I	O
activation	O
,	O
the	O
potential	O
contribution	O
of	O
other	O
post	O
-	O
translational	O
modifications	O
,	O
such	O
as	O
phosphorylation	O
,	O
to	O
the	O
regulation	O
of	O
RIG	O
-	O
I	O
activity	O
has	O
not	O
been	O
addressed	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
serine	O
8	O
phosphorylation	O
at	O
the	O
first	O
CARD	O
of	O
RIG	O
-	O
I	O
as	O
a	O
negative	O
regulatory	O
mechanism	O
of	O
RIG	O
-	O
I	O
-	O
mediated	O
IFN	O
-	O
beta	O
production	O
.	O

Immunoblot	O
analysis	O
with	O
a	O
phosphospecific	O
antibody	O
showed	O
that	O
RIG	O
-	O
I	O
serine	O
8	O
phosphorylation	O
steady	O
-	O
state	O
levels	O
were	O
decreased	O
upon	O
stimulation	O
of	O
cells	O
with	O
IFN	O
-	O
beta	O
or	O
virus	O
infection	O
.	O

Substitution	O
of	O
serine	O
8	O
in	O
the	O
CARD	O
RIG	O
-	O
I	O
functional	O
domain	O
with	O
phosphomimetic	O
aspartate	O
or	O
glutamate	O
results	O
in	O
decreased	O
TRIM25	O
binding	O
,	O
RIG	O
-	O
I	O
ubiquitination	O
,	O
MAVS	O
binding	O
,	O
and	O
downstream	O
signaling	O
.	O

Finally	O
,	O
sequence	O
comparison	O
reveals	O
that	O
only	O
primate	O
species	O
carry	O
serine	O
8	O
,	O
whereas	O
other	O
animal	O
species	O
carry	O
an	O
asparagine	O
,	O
indicating	O
that	O
serine	O
8	O
phosphorylation	O
may	O
represent	O
a	O
primate	O
-	O
specific	O
regulation	O
of	O
RIG	O
-	O
I	O
activation	O
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
the	O
phosphorylation	O
of	O
RIG	O
-	O
I	O
serine	O
8	O
operates	O
as	O
a	O
negative	O
switch	O
of	O
RIG	O
-	O
I	O
activation	O
by	O
suppressing	O
TRIM25	O
interaction	O
,	O
further	O
underscoring	O
the	O
importance	O
of	O
RIG	O
-	O
I	O
and	O
TRIM25	O
connection	O
in	O
type	O
I	O
IFN	O
signal	O
transduction	O
.	O

Deltamba1	O
/	O
Deltamdm38	O
mitochondria	O
show	O
severe	O
defects	O
in	O
complexes	B-Complex
III	I-Complex
and	O
IV	B-Complex
of	O
the	O
respiratory	O
chain	O
.	O

(	O
A	O
-	O
C	O
)	O
.	O

Complex	B-Complex
III	I-Complex
,	O
complex	B-Complex
IV	I-Complex
,	O
and	O
malate	B-OOS
dehydrogenase	I-OOS
activities	O
were	O
measured	O
in	O
isolated	O
mitochondria	O
from	O
the	O
strains	O
indicated	O
.	O

SEs	O
were	O
calculated	O
from	O
three	O
independent	O
experiments	O
.	O

(	O
D	O
)	O
Mitochondrial	O
protein	O
complexes	O
were	O
resolved	O
by	O
BN	O
-	O
PAGE	O
,	O
transferred	O
to	O
PVDF	O
membranes	O
,	O
and	O
probed	O
with	O
antibodies	O
against	O
Rip1	O
(	O
complex	B-Complex
III	I-Complex
)	O
,	O
Cox4	O
(	O
complex	B-Complex
IV	I-Complex
)	O
,	O
Tim54	O
(	O
TIM22	B-Complex
complex	O
)	O
,	O
and	O
Atp5	O
(	O
FoF1	B-Complex
-	I-Complex
ATPase	I-Complex
)	O
.	O

Positions	O
of	O
molecular	O
-	O
weight	O
markers	O
in	O
kDa	O
are	O
indicated	O
.	O

(	O
E	O
)	O
Mitochondria	O
(	O
50	O
mug	O
)	O
of	O
the	O
indicated	O
strains	O
were	O
analyzed	O
by	O
Western	O
blotting	O
with	O
antibodies	O
against	O
the	O
indicated	O
proteins	O
.	O

Cyt	O
b	O
,	O
cytochrome	O
b	O
;	O
Cytc1	O
,	O
cytochrome	O
c1	O
;	O
F1alpha	O
,	O
alpha	O
subunit	O
of	O
the	O
FoF1	B-Complex
-	I-Complex
ATPase	I-Complex
.	O

The	O
arrows	O
indicate	O
proteins	O
that	O
show	O
diminished	O
levels	O
in	O
the	O
double	O
mutant	O
.	O

An	O
S	O
-	O
acylation	O
switch	O
of	O
conserved	O
G	O
domain	O
cysteines	O
is	O
required	O
for	O
polarity	O
signaling	O
by	O
ROP	O
GTPases	O
.	O

Rho	O
GTPases	O
are	O
master	O
regulators	O
of	O
cell	O
polarity	O
.	O

For	O
their	O
function	O
,	O
Rhos	O
must	O
associate	O
with	O
discrete	O
plasma	O
membrane	O
domains	O
.	O

Rho	O
of	O
Plants	O
(	O
ROPs	O
)	O
or	O
RACs	O
comprise	O
a	O
single	O
family	O
.	O

Prenylation	O
and	O
S	O
-	O
acylation	O
of	O
hypervariable	O
domain	O
cysteines	O
of	O
Ras	O
and	O
Rho	O
GTPases	O
are	O
required	O
for	O
their	O
function	O
;	O
however	O
,	O
lipid	O
modifications	O
in	O
the	O
G	O
domain	O
have	O
never	O
been	O
reported	O
.	O

Reversible	O
S	O
-	O
acylation	O
involves	O
the	O
attachment	O
of	O
palmitate	O
(	O
C16	O
:	O
0	O
)	O
or	O
other	O
saturated	O
lipids	O
to	O
cysteines	O
through	O
a	O
thioester	O
linkage	O
and	O
was	O
implicated	O
in	O
the	O
regulation	O
of	O
signaling	O
.	O

Here	O
we	O
show	O
that	O
transient	O
S	O
-	O
acylation	O
of	O
Arabidopsis	O
AtROP6	O
takes	O
place	O
on	O
two	O
conserved	O
G	O
domain	O
cysteine	O
residues	O
,	O
C21	O
and	O
C156	O
.	O

C21	O
is	O
relatively	O
exposed	O
and	O
is	O
accessible	O
for	O
modification	O
,	O
but	O
C156	O
is	O
not	O
,	O
implying	O
that	O
its	O
S	O
-	O
acylation	O
involves	O
a	O
conformational	O
change	O
.	O

Fluorescence	O
recovery	O
after	O
photobleaching	O
beam	O
-	O
size	O
analysis	O
shows	O
that	O
S	O
-	O
acylation	O
of	O
AtROP6	O
regulates	O
its	O
membrane	O
-	O
association	O
dynamics	O
,	O
and	O
detergent	O
-	O
solubilization	O
studies	O
indicate	O
that	O
it	O
regulates	O
AtROP6	O
association	O
with	O
lipid	O
rafts	O
.	O

Site	O
-	O
specific	O
acylation	O
-	O
deficient	O
AtROP6	O
mutants	O
can	O
bind	O
and	O
hydrolyze	O
GTP	O
but	O
display	O
compromised	O
effects	O
on	O
polar	O
cell	O
growth	O
,	O
endocytic	O
uptake	O
of	O
the	O
tracer	O
dye	O
FM4	O
-	O
64	O
,	O
and	O
distribution	O
of	O
reactive	O
oxygen	O
species	O
.	O

These	O
data	O
reveal	O
an	O
S	O
-	O
acylation	O
switch	O
that	O
regulates	O
Rho	O
signaling	O
.	O

Post	O
-	O
replication	O
repair	O
suppresses	O
duplication	O
-	O
mediated	O
genome	O
instability	O
.	O

RAD6	O
is	O
known	O
to	O
suppress	O
duplication	O
-	O
mediated	O
gross	O
chromosomal	O
rearrangements	O
(	O
GCRs	O
)	O
but	O
not	O
single	O
-	O
copy	O
sequence	O
mediated	O
GCRs	O
.	O

Here	O
,	O
we	O
found	O
that	O
the	O
RAD6	O
-	O
and	O
RAD18	O
-	O
dependent	O
post	O
-	O
replication	O
repair	O
(	O
PRR	O
)	O
and	O
the	O
RAD5	O
-	O
,	O
MMS2	O
-	O
,	O
UBC13	O
-	O
dependent	O
error	O
-	O
free	O
PRR	O
branch	O
acted	O
in	O
concert	O
with	O
the	O
replication	O
stress	O
checkpoint	O
to	O
suppress	O
duplication	O
-	O
mediated	O
GCRs	O
formed	O
by	O
homologous	O
recombination	O
(	O
HR	O
)	O
.	O

The	O
Rad5	O
helicase	O
activity	O
,	O
but	O
not	O
its	O
RING	O
finger	O
,	O
was	O
required	O
to	O
prevent	O
duplication	O
-	O
mediated	O
GCRs	O
,	O
although	O
the	O
function	O
of	O
Rad5	O
remained	O
dependent	O
upon	O
modification	O
of	O
PCNA	O
at	O
Lys164	O
.	O

The	O
SRS2	O
,	O
SGS1	O
,	O
and	O
HCS1	O
encoded	O
helicases	O
appeared	O
to	O
interact	O
with	O
Rad5	O
,	O
and	O
epistasis	O
analysis	O
suggested	O
that	O
Srs2	O
and	O
Hcs1	O
act	O
upstream	O
of	O
Rad5	O
.	O

In	O
contrast	O
,	O
Sgs1	O
likely	O
functions	O
downstream	O
of	O
Rad5	O
,	O
potentially	O
by	O
resolving	O
DNA	O
structures	O
formed	O
by	O
Rad5	O
.	O

Our	O
analysis	O
is	O
consistent	O
with	O
models	O
in	O
which	O
PRR	O
prevents	O
replication	O
damage	O
from	O
becoming	O
double	O
strand	O
breaks	O
(	O
DSBs	O
)	O
and	O
/	O
or	O
regulates	O
the	O
activity	O
of	O
HR	O
on	O
DSBs	O
.	O

DYRK1B	O
-	O
dependent	O
autocrine	O
-	O
to	O
-	O
paracrine	O
shift	O
of	O
Hedgehog	O
signaling	O
by	O
mutant	O
RAS	O
.	O

Synergism	O
between	O
the	O
RAS	O
and	O
Hedgehog	O
(	O
HH	O
)	O
pathways	O
has	O
been	O
suggested	O
for	O
carcinogenesis	O
in	O
the	O
pancreas	O
,	O
lung	O
and	O
colon	O
.	O

We	O
investigated	O
the	O
molecular	O
cross	O
-	O
talk	O
between	O
RAS	O
and	O
HH	O
signaling	O
and	O
found	O
that	O
,	O
although	O
mutant	O
RAS	O
induces	O
or	O
enhances	O
SHH	O
expression	O
and	O
favors	O
paracrine	O
HH	O
signaling	O
,	O
it	O
antagonizes	O
autocrine	O
HH	O
signal	O
transduction	O
.	O

Activated	O
RAS	O
can	O
be	O
found	O
in	O
primary	O
cilia	O
,	O
the	O
central	O
organelle	O
of	O
HH	O
signal	O
transduction	O
,	O
but	O
functions	O
in	O
a	O
cilium	O
-	O
independent	O
manner	O
and	O
interferes	O
with	O
Gli2	O
function	O
and	O
Gli3	O
processing	O
.	O

In	O
addition	O
,	O
the	O
cell	O
-	O
autonomous	O
negative	O
regulation	O
of	O
HH	O
signal	O
transduction	O
involves	O
the	O
RAS	O
effector	O
molecule	O
dual	O
specificity	O
tyrosine	O
phosphorylated	O
and	O
regulated	O
kinase	O
1B	O
(	O
DYRK1B	O
)	O
.	O

In	O
line	O
with	O
a	O
redirection	O
of	O
autocrine	O
toward	O
paracrine	O
HH	O
signaling	O
by	O
a	O
KRAS	O
-	O
DYRK1B	O
network	O
,	O
we	O
find	O
high	O
levels	O
of	O
GLI1	O
expression	O
restricted	O
to	O
the	O
stromal	O
compartment	O
and	O
not	O
to	O
SHH	O
-	O
expressing	O
tumor	O
cells	O
in	O
human	O
pancreatic	O
adenocarcinoma	O
.	O

dHIP14	O
-	O
dependent	O
palmitoylation	O
promotes	O
secretion	O
of	O
the	O
BMP	O
antagonist	O
Sog	O
.	O

Analysis	O
of	O
diverse	O
signaling	O
systems	O
has	O
revealed	O
that	O
one	O
important	O
level	O
of	O
control	O
is	O
regulation	O
of	O
membrane	O
trafficking	O
of	O
ligands	O
and	O
receptors	O
.	O

The	O
activities	O
of	O
some	O
ligands	O
are	O
also	O
regulated	O
by	O
whether	O
they	O
are	O
membrane	O
bound	O
or	O
secreted	O
.	O

In	O
Drosophila	O
,	O
several	O
morphogenetic	O
signals	O
that	O
play	O
critical	O
roles	O
in	O
development	O
have	O
been	O
found	O
to	O
be	O
subject	O
to	O
such	O
regulation	O
.	O

For	O
example	O
,	O
activity	O
of	O
the	O
Hedgehog	O
(	O
Hh	O
)	O
is	O
regulated	O
by	O
Raspberry	O
,	O
which	O
palmitoylates	O
Hh	O
.	O

Similarly	O
,	O
the	O
palmitoylases	O
Porcupine	O
and	O
Raspberry	O
increase	O
the	O
activities	O
of	O
Wingless	O
(	O
Wg	O
)	O
and	O
the	O
EGF	O
-	O
ligand	O
Spitz	O
(	O
Spi	O
)	O
,	O
respectively	O
.	O

In	O
contrast	O
to	O
its	O
vertebrate	O
homologues	O
,	O
which	O
have	O
typical	O
N	O
-	O
terminal	O
signal	O
sequences	O
,	O
the	O
precursor	O
form	O
of	O
Drosophila	O
Hh	O
contains	O
an	O
internal	O
type	O
-	O
II	O
secretory	O
signal	O
motif	O
.	O

The	O
Short	O
Gastrulation	O
(	O
Sog	O
)	O
protein	O
is	O
another	O
secreted	O
Drosophila	O
protein	O
that	O
contains	O
a	O
type	O
-	O
II	O
signal	O
and	O
differs	O
from	O
its	O
vertebrate	O
ortholog	O
Chordin	O
which	O
contains	O
a	O
standard	O
signal	O
peptide	O
.	O

In	O
this	O
study	O
,	O
we	O
examine	O
the	O
regulation	O
of	O
Sog	O
secretion	O
and	O
regulation	O
by	O
dHIP14	O
,	O
the	O
ortholog	O
of	O
a	O
mammalian	O
palmitoylase	O
first	O
identified	O
as	O
Huntington	O
Interacting	O
Protein	O
(	O
HIP	O
)	O
.	O

We	O
show	O
that	O
dHIP14	O
binds	O
to	O
Sog	O
and	O
that	O
Sog	O
is	O
palmitoylated	O
.	O

In	O
S2	O
cells	O
,	O
dHIP14	O
promotes	O
secretion	O
of	O
Sog	O
as	O
well	O
as	O
stabilizing	O
a	O
membrane	O
associated	O
form	O
of	O
Sog	O
.	O

We	O
examined	O
the	O
requirement	O
for	O
candidate	O
cysteine	O
residues	O
in	O
the	O
N	O
-	O
terminal	O
predicted	O
cytoplasmic	O
domain	O
of	O
Sog	O
and	O
find	O
that	O
Cys27	O
,	O
one	O
of	O
two	O
adjacent	O
cysteines	O
(	O
Cys27	O
and	O
Cys28	O
)	O
,	O
is	O
essential	O
for	O
the	O
full	O
activity	O
of	O
dHIP14	O
and	O
its	O
effect	O
on	O
Sog	O
.	O

Finally	O
,	O
we	O
find	O
that	O
dHIP14	O
promotes	O
the	O
activity	O
of	O
Sog	O
in	O
vivo	O
.	O

These	O
studies	O
highlight	O
the	O
growing	O
importance	O
of	O
lipid	O
modification	O
in	O
regulating	O
signaling	O
at	O
the	O
level	O
of	O
ligand	O
production	O
and	O
localization	O
.	O

FAN1	O
is	O
easily	O
identifiable	O
in	O
Dictyostelium	O
discoideum	O
,	O
which	O
has	O
orthologs	O
of	O
several	O
Fanconi	O
anemia	O
proteins	O
but	O
no	O
obvious	O
orthologs	O
are	O
apparent	O
in	O
Drosophila	O
or	O
Xenopus	O
.	O

Interestingly	O
,	O
an	O
S	O
.	O
pombe	O
ortholog	O
of	O
FAN1	O
has	O
a	O
SAP	O
domain	O
,	O
TRP	O
domain	O
and	O
a	O
nuclease	O
domain	O
,	O
thus	O
it	O
is	O
predicted	O
to	O
also	O
function	O
in	O
DNA	O
repair	O
transactions	O
.	O

Fission	O
yeast	O
does	O
not	O
possess	O
the	O
classical	O
FA	O
proteins	O
except	O
for	O
an	O
ortholog	O
of	O
FANCM	O
,	O
Fml1	O
,	O
which	O
promotes	O
Rad51	O
-	O
dependent	O
gene	O
conversion	O
at	O
stalled	O
replication	O
forks	O
and	O
limits	O
crossing	O
over	O
during	O
mitotic	O
double	O
-	O
strand	O
break	O
repair	O
.	O

It	O
will	O
be	O
interesting	O
to	O
test	O
if	O
the	O
S	O
.	O
pombe	O
FAN1	O
mutant	O
is	O
sensitive	O
to	O
crosslinking	O
agents	O
and	O
if	O
so	O
,	O
how	O
it	O
functions	O
without	O
the	O
other	O
proteins	O
present	O
in	O
human	O
cells	O
.	O

This	O
could	O
shed	O
light	O
on	O
alternative	O
pathways	O
for	O
crosslink	O
repair	O
in	O
human	O
cells	O
.	O

Interplay	O
of	O
palmitoylation	O
and	O
phosphorylation	O
in	O
the	O
trafficking	O
and	O
localization	O
of	O
phosphodiesterase	O
10A	O
:	O
implications	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
.	O

Phosphodiesterase	O
10A	O
(	O
PDE10A	O
)	O
is	O
a	O
striatum	O
-	O
enriched	O
,	O
dual	O
-	O
specific	O
cyclic	O
nucleotide	O
phosphodiesterase	O
that	O
has	O
gained	O
considerable	O
attention	O
as	O
a	O
potential	O
therapeutic	O
target	O
for	O
psychiatric	O
disorders	O
such	O
as	O
schizophrenia	O
.	O

As	O
such	O
,	O
a	O
PDE10A	O
-	O
selective	O
inhibitor	O
compound	O
,	O
MP	O
-	O
10	O
,	O
has	O
recently	O
entered	O
clinical	O
testing	O
.	O

Since	O
little	O
is	O
known	O
about	O
the	O
cellular	O
regulation	O
of	O
PDE10A	O
,	O
we	O
sought	O
to	O
elucidate	O
the	O
mechanisms	O
that	O
govern	O
its	O
subcellular	O
localization	O
in	O
striatal	O
medium	O
spiny	O
neurons	O
.	O

Previous	O
reports	O
suggest	O
that	O
PDE10A	O
is	O
primarily	O
membrane	O
bound	O
and	O
is	O
transported	O
throughout	O
medium	O
spiny	O
neuron	O
axons	O
and	O
dendrites	O
.	O

Moreover	O
,	O
it	O
has	O
been	O
shown	O
in	O
PC12	O
cells	O
that	O
the	O
localization	O
of	O
the	O
major	O
splice	O
form	O
,	O
PDE10A2	O
,	O
may	O
be	O
regulated	O
by	O
protein	O
kinase	O
A	O
phosphorylation	O
at	O
threonine	O
16	O
(	O
Thr	O
-	O
16	O
)	O
.	O

Using	O
an	O
antibody	O
that	O
specifically	O
recognizes	O
phosphorylated	O
Thr	O
-	O
16	O
(	O
pThr	O
-	O
16	O
)	O
of	O
PDE10A2	O
,	O
we	O
provide	O
evidence	O
that	O
phosphorylation	O
at	O
Thr	O
-	O
16	O
is	O
critical	O
for	O
the	O
regulation	O
of	O
PDE10A	O
subcellular	O
localization	O
in	O
vivo	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
in	O
primary	O
mouse	O
striatal	O
neuron	O
cultures	O
that	O
PDE10A	O
membrane	O
association	O
and	O
transport	O
throughout	O
dendritic	O
processes	O
requires	O
palmitoylation	O
of	O
cysteine	O
11	O
(	O
Cys	O
-	O
11	O
)	O
of	O
PDE10A2	O
,	O
likely	O
by	O
the	O
palmitoyl	O
acyltransferases	O
DHHC	O
-	O
7	O
and	O
-	O
19	O
.	O

Finally	O
,	O
we	O
show	O
that	O
Thr	O
-	O
16	O
phosphorylation	O
regulates	O
PDE10A	O
trafficking	O
and	O
localization	O
by	O
preventing	O
palmitoylation	O
of	O
Cys	O
-	O
11	O
rather	O
than	O
by	O
interfering	O
with	O
palmitate	O
-	O
lipid	O
interactions	O
.	O

These	O
data	O
support	O
a	O
model	O
whereby	O
PDE10A	O
trafficking	O
and	O
localization	O
can	O
be	O
regulated	O
in	O
response	O
to	O
local	O
fluctuations	O
in	O
cAMP	O
levels	O
.	O

Given	O
this	O
,	O
we	O
propose	O
that	O
excessive	O
striatal	O
dopamine	O
release	O
,	O
as	O
occurs	O
in	O
schizophrenia	O
,	O
might	O
exert	O
differential	O
effects	O
on	O
the	O
regulation	O
of	O
PDE10A	O
localization	O
in	O
the	O
two	O
striatal	O
output	O
pathways	O
.	O

Hypoxia	O
-	O
inducible	O
protein	O
2	O
is	O
a	O
novel	O
lipid	O
droplet	O
protein	O
and	O
a	O
specific	O
target	O
gene	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
.	O

Hypoxia	O
-	O
inducible	O
protein	O
2	O
(	O
HIG2	O
)	O
has	O
been	O
implicated	O
in	O
canonical	O
Wnt	O
signaling	O
,	O
both	O
as	O
target	O
and	O
activator	O
.	O

The	O
potential	O
link	O
between	O
hypoxia	O
and	O
an	O
oncogenic	O
signaling	O
pathway	O
might	O
play	O
a	O
pivotal	O
role	O
in	O
renal	O
clear	O
-	O
cell	O
carcinoma	O
characterized	O
by	O
constitutive	O
activation	O
of	O
hypoxia	O
-	O
inducible	O
factors	O
(	O
HIFs	O
)	O
,	O
and	O
hence	O
prompted	O
us	O
to	O
analyze	O
HIG2	O
regulation	O
and	O
function	O
in	O
detail	O
.	O

HIG2	O
was	O
up	O
-	O
regulated	O
by	O
hypoxia	O
and	O
HIF	O
inducers	O
in	O
all	O
cell	O
types	O
and	O
mouse	O
organs	O
investigated	O
and	O
abundantly	O
expressed	O
in	O
renal	O
clear	O
-	O
cell	O
carcinomas	O
.	O

Promoter	O
analyses	O
,	O
gel	O
shifts	O
,	O
and	O
siRNA	O
studies	O
revealed	O
that	O
HIG2	O
is	O
a	O
direct	O
and	O
specific	O
target	O
of	O
HIF	O
-	O
1	O
,	O
but	O
not	O
responsive	O
to	O
HIF	O
-	O
2	O
.	O

Surprisingly	O
,	O
HIG2	O
was	O
not	O
secreted	O
,	O
and	O
HIG2	O
overexpression	O
neither	O
stimulated	O
proliferation	O
nor	O
activated	O
Wnt	O
signaling	O
.	O

Instead	O
,	O
we	O
show	O
that	O
HIG2	O
decorates	O
the	O
hemimembrane	O
of	O
lipid	O
droplets	O
,	O
whose	O
number	O
and	O
size	O
increase	O
on	O
hypoxic	O
inhibition	O
of	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
,	O
and	O
colocalizes	O
with	O
the	O
lipid	O
droplet	O
proteins	O
adipophilin	O
and	O
TIP47	O
.	O

Normoxic	O
overexpression	O
of	O
HIG2	O
was	O
sufficient	O
to	O
increase	O
neutral	O
lipid	O
deposition	O
in	O
HeLa	O
cells	O
and	O
stimulated	O
cytokine	O
expression	O
.	O

HIG2	O
could	O
be	O
detected	O
in	O
atherosclerotic	O
arteries	O
and	O
fatty	O
liver	O
disease	O
,	O
suggesting	O
that	O
this	O
ubiquitously	O
inducible	O
HIF	O
-	O
1	O
target	O
gene	O
may	O
play	O
an	O
important	O
functional	O
role	O
in	O
diseases	O
associated	O
with	O
pathological	O
lipid	O
accumulation	O
.	O

Protein	O
tyrosine	O
phosphatases	O
(	O
PTPs	O
)	O
remove	O
phosphate	O
groups	O
from	O
phosphorylated	O
tyrosine	O
residues	O
,	O
and	O
play	O
critical	O
roles	O
in	O
cell	O
communication	O
,	O
shape	O
,	O
motility	O
,	O
proliferation	O
and	O
differentiation	O
.	O

One	O
well	O
-	O
known	O
PTP	O
,	O
protein	O
tyrosine	O
phosphatase	O
receptor	O
type	O
C	O
(	O
PTPRC	O
,	O
CD45	O
)	O
,	O
is	O
important	O
for	O
thymocyte	O
development	O
and	O
T	O
cell	O
activation	O
,	O
and	O
is	O
expressed	O
on	O
all	O
nucleated	O
cells	O
of	O
hemopoietic	O
origin	O
.	O

The	O
association	O
between	O
MBL	O
and	O
CD45	O
in	O
immature	O
T	O
cells	O
influences	O
thymocyte	O
development	O
.	O

The	O
SpMyh1	O
-	O
Chimera	O
construct	O
was	O
derived	O
from	O
pET11a	O
-	O
SpMyh1	O
.	O

First	O
,	O
the	O
QuikChange	O
XL	O
Site	O
-	O
Directed	O
Mutagenesis	O
Kit	O
(	O
Stratagene	O
)	O
was	O
used	O
to	O
create	O
a	O
SalI	O
restriction	O
enzyme	O
cut	O
site	O
within	O
the	O
Spmyh1	O
+	O
gene	O
using	O
primers	O
,	O
SpMyh	O
-	O
Sal	O
-	O
F	O
and	O
SpMyh	O
-	O
Sal	O
-	O
R	O
.	O

The	O
SalI	O
site	O
was	O
created	O
immediately	O
3	O
'	O
to	O
the	O
segment	O
of	O
DNA	O
that	O
encodes	O
for	O
the	O
SpMyh1	O
IDC	O
region	O
and	O
immediately	O
5	O
'	O
to	O
the	O
segment	O
of	O
DNA	O
that	O
encodes	O
for	O
the	O
SpMyh1	O
C	O
-	O
terminal	O
domain	O
.	O

The	O
pET11a	O
-	O
SpMyh1	O
-	O
SalI	O
mutagenesis	O
product	O
was	O
digested	O
with	O
NdeI	O
and	O
SalI	O
and	O
the	O
digested	O
DNA	O
fragment	O
containing	O
the	O
pET11a	O
vector	O
and	O
the	O
DNA	O
encoding	O
for	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
SpMyh1	O
(	O
pET11a	O
-	O
CTDSpMyh1	O
)	O
was	O
gel	O
purified	O
.	O

Simultaneously	O
,	O
PCR	O
was	O
completed	O
to	O
amplify	O
DNA	O
containing	O
a	O
5	O
'	O
-	O
NdeI	O
cut	O
site	O
and	O
the	O
5	O
'	O
-	O
end	O
of	O
the	O
Spmyh1	O
+	O
gene	O
up	O
to	O
the	O
beginning	O
of	O
the	O
section	O
of	O
DNA	O
that	O
encodes	O
for	O
the	O
SpMyh1	O
linker	O
region	O
with	O
primers	O
SpMyh	O
-	O
NdeI	O
and	O
SpMyh	O
-	O
SalI	O
.	O

The	O
SpMyh	O
-	O
SalI	O
primer	O
used	O
in	O
the	O
PCR	O
reaction	O
included	O
DNA	O
to	O
synthesize	O
the	O
specified	O
section	O
of	O
Spmyh1	O
+	O
,	O
the	O
E	O
.	O
coli	O
MutY	O
linker	O
region	O
,	O
and	O
a	O
SalI	O
cut	O
site	O
.	O

This	O
PCR	O
product	O
was	O
digested	O
with	O
NdeI	O
and	O
SalI	O
and	O
ligated	O
into	O
the	O
NdeI	O
-	O
SalI	O
digested	O
pET11a	O
-	O
CTDSpMyh1	O
.	O

Using	O
the	O
QuikChange	O
XL	O
Site	O
-	O
Directed	O
Mutagenesis	O
Kit	O
(	O
Stratagene	O
)	O
and	O
primers	O
,	O
SpCHIM	O
-	O
Sal	O
-	O
to	O
-	O
Nat	O
-	O
F	O
and	O
SpCHIM	O
-	O
Sal	O
-	O
to	O
-	O
Nat	O
-	O
R	O
,	O
mutagenesis	O
was	O
completed	O
again	O
to	O
remove	O
the	O
SalI	O
site	O
.	O

The	O
pET11a	O
-	O
SpMyh1	O
-	O
Chimera	O
construct	O
was	O
used	O
as	O
a	O
template	O
for	O
subcloning	O
into	O
the	O
pLM303	O
vector	O
.	O

BMK1	O
is	O
activated	O
by	O
mitogens	O
and	O
oncogenic	O
signals	O
and	O
,	O
thus	O
,	O
is	O
strongly	O
implicated	O
in	O
tumorigenesis	O
.	O

We	O
found	O
that	O
BMK1	O
interacted	O
with	O
promyelocytic	O
leukemia	O
protein	O
(	O
PML	O
)	O
,	O
and	O
inhibited	O
its	O
tumor	O
-	O
suppressor	O
function	O
through	O
phosphorylation	O
.	O

Furthermore	O
,	O
activated	O
BMK1	O
notably	O
inhibited	O
PML	O
-	O
dependent	O
activation	O
of	O
p21	O
.	O

To	O
further	O
investigate	O
the	O
BMK	O
-	O
mediated	O
inhibition	O
of	O
the	O
tumor	O
suppressor	O
activity	O
of	O
PML	O
in	O
tumor	O
cells	O
,	O
we	O
developed	O
a	O
small	O
-	O
molecule	O
inhibitor	O
of	O
the	O
kinase	O
activity	O
of	O
BMK1	O
,	O
XMD8	O
-	O
92	O
.	O

Inhibition	O
of	O
BMK1	O
by	O
XMD8	O
-	O
92	O
blocked	O
tumor	O
cell	O
proliferation	O
in	O
vitro	O
and	O
significantly	O
inhibited	O
tumor	O
growth	O
in	O
vivo	O
by	O
95	O
%	O
,	O
demonstrating	O
the	O
efficacy	O
and	O
tolerability	O
of	O
BMK1	O
-	O
targeted	O
cancer	O
treatment	O
in	O
animals	O
.	O

The	O
protein	O
stability	O
of	O
Axin	O
,	O
a	O
negative	O
regulator	O
of	O
Wnt	O
signaling	O
,	O
is	O
regulated	O
by	O
Smad	O
ubiquitination	O
regulatory	O
factor	O
2	O
(	O
Smurf2	O
)	O
.	O

Axin	O
is	O
a	O
negative	O
regulator	O
of	O
Wnt	O
/	O
beta	O
-	O
catenin	O
signaling	O
via	O
regulating	O
the	O
level	O
of	O
beta	O
-	O
catenin	O
,	O
which	O
is	O
a	O
key	O
effector	O
molecule	O
.	O

Therefore	O
,	O
controlling	O
the	O
level	O
of	O
Axin	O
is	O
a	O
critical	O
step	O
for	O
the	O
regulation	O
of	O
Wnt	O
/	O
beta	O
-	O
catenin	O
signaling	O
.	O

It	O
has	O
been	O
shown	O
that	O
ubiquitination	O
-	O
mediated	O
proteasomal	O
degradation	O
may	O
play	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
Axin	O
;	O
however	O
,	O
the	O
E3	O
ubiquitin	O
ligase	O
(	O
s	O
)	O
,	O
which	O
attaches	O
ubiquitin	O
to	O
a	O
target	O
protein	O
in	O
combination	O
with	O
an	O
E2	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
,	O
for	O
Axin	O
has	O
not	O
yet	O
been	O
identified	O
.	O

Here	O
,	O
we	O
show	O
that	O
Smurf2	O
is	O
an	O
E3	O
ubiquitin	O
ligase	O
for	O
Axin	O
.	O

Transient	O
expression	O
of	O
Smurf2	O
down	O
-	O
regulated	O
the	O
level	O
of	O
Axin	O
and	O
increased	O
the	O
ubiquitination	O
of	O
Axin	O
.	O

Conversely	O
,	O
shRNA	O
specific	O
to	O
Smurf2	O
blocked	O
Axin	O
ubiquitination	O
.	O

Essential	O
domains	O
of	O
Axin	O
responsible	O
for	O
Smurf2	O
interaction	O
as	O
well	O
as	O
Smurf2	O
-	O
mediated	O
down	O
-	O
regulation	O
and	O
ubiquitination	O
were	O
identified	O
.	O

In	O
vitro	O
ubiquitination	O
assays	O
followed	O
by	O
analysis	O
using	O
mass	O
spectroscopy	O
revealed	O
that	O
Smurf2	O
specifically	O
ubiquitinylated	O
Lys	O
(	O
505	O
)	O
of	O
Axin	O
and	O
that	O
the	O
Axin	O
(	O
K505R	O
)	O
mutant	O
resisted	O
degradation	O
.	O

Knockdown	O
of	O
endogenous	O
Smurf2	O
increased	O
the	O
level	O
of	O
endogenous	O
Axin	O
and	O
resulted	O
in	O
reduced	O
beta	O
-	O
catenin	O
/	O
Tcf	O
reporter	O
activity	O
.	O

Overall	O
,	O
our	O
data	O
strongly	O
suggest	O
that	O
Smurf2	O
is	O
a	O
genuine	O
E3	O
ligase	O
for	O
Axin	O
.	O

Cloning	O
of	O
a	O
cDNA	O
encoding	O
adenylosuccinate	O
lyase	O
by	O
functional	O
complementation	O
in	O
Escherichia	O
coli	O
.	O

Adenylosuccinate	O
lyase	O
was	O
cloned	O
by	O
functional	O
complementation	O
of	O
an	O
Escherichia	O
coli	O
purB	O
mutant	O
using	O
an	O
avian	O
liver	O
cDNA	O
expression	O
library	O
.	O

The	O
derived	O
amino	O
acid	O
sequence	O
is	O
homologous	O
to	O
the	O
bacterial	O
purB	O
-	O
encoded	O
adenylosuccinate	O
lyase	O
which	O
catalyzes	O
the	O
same	O
two	O
steps	O
in	O
purine	O
biosynthesis	O
as	O
the	O
enzyme	O
from	O
animals	O
.	O

Avian	O
adenylosuccinate	O
lyase	O
also	O
shows	O
regions	O
of	O
extensive	O
sequence	O
similarity	O
to	O
the	O
urea	O
cycle	O
enzyme	O
,	O
argininosuccinate	O
lyase	O
.	O

This	O
homology	O
suggests	O
a	O
similar	O
mechanism	O
for	O
catalysis	O
.	O

Homology	O
of	O
adenylosuccinate	O
and	O
argininosuccinate	O
lyases	O
is	O
intriguing	O
because	O
chickens	O
do	O
not	O
utilize	O
the	O
urea	O
cycle	O
in	O
nitrogen	O
excretion	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
cloning	O
of	O
a	O
eukaryotic	O
cDNA	O
encoding	O
adenylosuccinate	O
lyase	O
,	O
and	O
it	O
affords	O
a	O
route	O
to	O
isolate	O
the	O
corresponding	O
human	O
gene	O
which	O
has	O
been	O
suggested	O
to	O
be	O
defective	O
in	O
autistic	O
children	O
.	O

Actin	O
filament	O
associated	O
protein	O
mediates	O
c	O
-	O
Src	O
related	O
SRE	O
/	O
AP	B-Complex
-	I-Complex
1	I-Complex
transcriptional	O
activation	O
.	O

AFAP	O
is	O
an	O
adaptor	O
protein	O
involved	O
in	O
cytoskeletal	O
organization	O
and	O
intracellular	O
signaling	O
.	O

AFAP	O
binds	O
and	O
activates	O
c	O
-	O
Src	O
;	O
however	O
,	O
the	O
downstream	O
signals	O
of	O
this	O
interaction	O
remain	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
co	O
-	O
expression	O
of	O
AFAP	O
and	O
c	O
-	O
Src	O
induce	O
transcriptional	O
activation	O
of	O
SRE	O
and	O
AP	B-Complex
-	I-Complex
1	I-Complex
in	O
a	O
c	O
-	O
Src	O
activity	O
dependent	O
fashion	O
.	O

Structural	O
-	O
functional	O
studies	O
suggest	O
that	O
the	O
proline	O
-	O
rich	O
motif	O
in	O
the	O
N	O
-	O
terminus	O
of	O
AFAP	O
is	O
critical	O
for	O
c	O
-	O
Src	O
activation	O
,	O
and	O
subsequent	O
SRE	O
/	O
AP	B-Complex
-	I-Complex
1	I-Complex
transactivation	O
and	O
the	O
actin	O
-	O
binding	O
domain	O
in	O
the	O
AFAP	O
C	O
-	O
terminus	O
is	O
negatively	O
involved	O
in	O
the	O
regulation	O
of	O
AFAP	O
/	O
c	O
-	O
Src	O
mediated	O
SRE	O
/	O
AP	B-Complex
-	I-Complex
1	I-Complex
transactivation	O
.	O

Selective	O
deletion	O
of	O
this	O
domain	O
enhances	O
transactivation	O
of	O
SRE	O
.	O

We	O
conclude	O
that	O
in	O
addition	O
to	O
its	O
role	O
in	O
the	O
regulation	O
of	O
cytoskeletal	O
structures	O
,	O
AFAP	O
may	O
also	O
be	O
involved	O
in	O
the	O
c	O
-	O
Src	O
related	O
transcriptional	O
activities	O
.	O

Saccharomyces	O
cerevisiae	O
protein	O
phosphatase	O
Ppz1	O
and	O
protein	O
kinases	O
Sat4	O
and	O
Hal5	O
are	O
involved	O
in	O
the	O
control	O
of	O
subcellular	O
localization	O
of	O
Gln3	O
by	O
likely	O
regulating	O
its	O
phosphorylation	O
state	O
.	O

A	O
Saccharomyces	O
cerevisiae	O
mutant	O
lacking	O
PPZ1	O
,	O
encoding	O
a	O
serine	O
/	O
threonine	O
protein	O
phosphatase	O
(	O
PPase	O
)	O
,	O
is	O
caffeine	O
-	O
sensitive	O
.	O

To	O
clarify	O
the	O
function	O
of	O
Ppz1	O
in	O
resistance	O
to	O
caffeine	O
,	O
we	O
attempted	O
systematically	O
to	O
identify	O
protein	O
kinase	O
(	O
PKase	O
)	O
whose	O
disruption	O
lead	O
to	O
suppression	O
of	O
caffeine	O
sensitive	O
phenotype	O
of	O
the	O
incrementppz1	O
disruptant	O
since	O
disruption	O
of	O
PPZ1	O
might	O
cause	O
caffeine	O
sensitivity	O
by	O
increasing	O
its	O
phosphorylated	O
substrates	O
and	O
we	O
presumed	O
that	O
disruption	O
of	O
genes	O
for	O
PKase	O
sharing	O
the	O
substrate	O
with	O
Ppz1	O
could	O
restore	O
the	O
resistance	O
through	O
bypassing	O
necessity	O
for	O
dephosphorylation	O
of	O
substrates	O
.	O

Among	O
the	O
102	O
viable	O
pkase	O
disruptions	O
,	O
disruption	O
of	O
either	O
SAT4	O
or	O
HAL5	O
suppressed	O
the	O
caffeine	O
sensitivity	O
phenotype	O
and	O
increased	O
expression	O
of	O
ENA1	O
,	O
encoding	O
a	O
P	O
-	O
type	O
ATPase	O
of	O
the	O
incrementppz1	O
disruptant	O
.	O

Because	O
increased	O
expression	O
of	O
ENA1	O
in	O
the	O
incrementppz1	O
disruptant	O
was	O
found	O
to	O
be	O
suppressed	O
by	O
disruption	O
of	O
GLN3	O
,	O
localization	O
and	O
phosphorylation	O
of	O
Gln3	O
in	O
the	O
incrementppz1	O
disruptant	O
was	O
compared	O
to	O
that	O
in	O
the	O
incrementppz1incrementsat4	O
and	O
incrementppz1incrementhal5	O
double	O
disruptants	O
.	O

Gln3	O
was	O
found	O
to	O
accumulate	O
in	O
the	O
nucleus	O
in	O
the	O
incrementppz1	O
disruptant	O
,	O
and	O
this	O
nuclear	O
localization	O
was	O
abolished	O
by	O
disruption	O
of	O
either	O
SAT4	O
or	O
HAL5	O
.	O

Interestingly	O
,	O
the	O
level	O
of	O
Gln3	O
phosphorylation	O
in	O
the	O
incrementppz1incrementsat4	O
and	O
incrementppz1incrementhal5	O
disruptants	O
decreased	O
relative	O
to	O
wild	O
type	O
independent	O
of	O
caffeine	O
.	O

From	O
these	O
observations	O
,	O
we	O
conclude	O
that	O
Ppz1	O
controls	O
Gln3	O
localization	O
by	O
regulating	O
its	O
phosphorylation	O
state	O
in	O
combination	O
with	O
Sat4	O
and	O
Hal5	O
.	O

Feedback	O
regulation	O
of	O
Drosophila	O
BMP	O
signaling	O
by	O
the	O
novel	O
extracellular	O
protein	O
larval	O
translucida	O
.	O

The	O
cellular	O
response	O
to	O
the	O
Drosophila	O
BMP	O
2	O
/	O
4	O
-	O
like	O
ligand	O
Decapentaplegic	O
(	O
DPP	O
)	O
serves	O
as	O
one	O
of	O
the	O
best	O
-	O
studied	O
models	O
for	O
understanding	O
the	O
long	O
-	O
range	O
control	O
of	O
tissue	O
growth	O
and	O
pattern	O
formation	O
during	O
animal	O
development	O
.	O

Nevertheless	O
,	O
fundamental	O
questions	O
remain	O
unanswered	O
regarding	O
extracellular	O
regulation	O
of	O
the	O
ligand	O
itself	O
,	O
as	O
well	O
as	O
the	O
nature	O
of	O
the	O
downstream	O
transcriptional	O
response	O
to	O
BMP	O
pathway	O
activation	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
larval	O
translucida	O
(	O
ltl	O
)	O
,	O
a	O
novel	O
target	O
of	O
BMP	O
activity	O
in	O
Drosophila	O
.	O

Both	O
gain	O
-	O
and	O
loss	O
-	O
of	O
-	O
function	O
analyses	O
implicate	O
LTL	O
,	O
a	O
leucine	O
-	O
rich	O
repeat	O
protein	O
,	O
in	O
the	O
regulation	O
of	O
wing	O
growth	O
and	O
vein	O
patterning	O
.	O

At	O
the	O
molecular	O
level	O
,	O
we	O
demonstrate	O
that	O
LTL	O
is	O
a	O
secreted	O
protein	O
that	O
antagonizes	O
BMP	O
-	O
dependent	O
MAD	O
phosphorylation	O
,	O
indicating	O
that	O
it	O
regulates	O
DPP	O
/	O
BMP	O
signaling	O
at	O
or	O
above	O
the	O
level	O
of	O
ligand	O
-	O
receptor	O
interactions	O
.	O

Furthermore	O
,	O
based	O
on	O
genetic	O
interactions	O
with	O
the	O
DPP	O
-	O
binding	O
protein	O
Crossveinless	O
2	O
and	O
biochemical	O
interactions	O
with	O
the	O
glypican	O
Dally	O
-	O
like	O
,	O
we	O
propose	O
that	O
LTL	O
acts	O
in	O
the	O
extracellular	O
space	O
where	O
it	O
completes	O
a	O
novel	O
auto	O
-	O
regulatory	O
loop	O
that	O
modulates	O
BMP	O
activity	O
.	O

As	O
is	O
the	O
case	O
with	O
bur2Delta	O
cells	O
,	O
deletion	O
of	O
DST1	O
,	O
LEO1	O
,	O
or	O
SPT4	O
renders	O
cells	O
sensitive	O
to	O
6	O
-	O
AU	O
,	O
thus	O
indicating	O
their	O
roles	O
in	O
regulating	O
transcription	O
.	O

To	O
determine	O
whether	O
U2	O
snRNA	O
alleles	O
affect	O
the	O
6	O
-	O
AU	O
sensitivity	O
of	O
these	O
strains	O
we	O
tested	O
the	O
growth	O
of	O
the	O
double	O
mutants	O
on	O
medium	O
containing	O
6	O
-	O
AU	O
.	O

Alterations	O
in	O
the	O
U2	O
snRNA	O
secondary	O
structure	O
failed	O
to	O
produce	O
significant	O
changes	O
in	O
the	O
6	O
-	O
AU	O
sensitivity	O
of	O
these	O
strains	O
(	O
data	O
not	O
shown	O
and	O
Table	O
1	O
)	O
.	O

Taken	O
together	O
,	O
the	O
genetic	O
analyses	O
summarized	O
in	O
Table	O
1	O
suggest	O
that	O
neither	O
CUS2	O
nor	O
the	O
U2	O
snRNA	O
conformation	O
mutants	O
exhibit	O
functional	O
overlap	O
with	O
transcription	O
factors	O
that	O
interact	O
with	O
the	O
CDK	O
complexes	O
.	O

Although	O
Sp3	O
is	O
the	O
only	O
protein	O
in	O
the	O
Sp	O
subfamily	O
that	O
can	O
either	O
positively	O
or	O
negatively	O
modulate	O
the	O
Sp1	O
-	O
dependent	O
gene	O
expression	O
,	O
our	O
experiments	O
demonstrated	O
that	O
Sp3	O
positively	O
regulates	O
the	O
exon	O
1b	O
promoter	O
activity	O
in	O
SL2	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
establish	O
that	O
Sp1	O
and	O
Sp3	O
are	O
biologically	O
essential	O
regulators	O
of	O
the	O
SVCT2	O
exon	O
1b	O
gene	O
expression	O
along	O
with	O
YY1	O
.	O

RR	O
is	O
regulated	O
by	O
an	O
intricate	O
allosteric	O
mechanism	O
.	O

The	O
two	O
allosteric	O
sites	O
of	O
RR	O
are	O
the	O
specificity	O
site	O
(	O
S	O
-	O
site	O
)	O
,	O
which	O
determines	O
substrate	O
preference	O
,	O
and	O
the	O
activity	O
site	O
(	O
A	O
-	O
site	O
)	O
,	O
which	O
stimulates	O
or	O
inhibits	O
RR	O
activity	O
depending	O
on	O
whether	O
ATP	O
or	O
dATP	O
is	O
bound	O
.	O

While	O
it	O
is	O
known	O
that	O
dATP	O
,	O
which	O
is	O
less	O
abundant	O
in	O
the	O
cell	O
than	O
ATP	O
,	O
has	O
a	O
100	O
-	O
fold	O
higher	O
affinity	O
for	O
RR	O
,	O
the	O
mechanism	O
for	O
this	O
is	O
unknown	O
.	O

Most	O
of	O
our	O
knowledge	O
on	O
RR	O
has	O
been	O
derived	O
from	O
studies	O
on	O
the	O
E	O
.	O
coli	O
and	O
other	O
prokaryotic	O
enzymes	O
,	O
which	O
exist	O
as	O
alpha2beta2	O
hetero	O
-	O
tetramers	O
.	O

This	O
organization	O
failed	O
,	O
however	O
,	O
to	O
mechanistically	O
explain	O
how	O
dATP	O
inactivates	O
and	O
ATP	O
activates	O
the	O
enzyme	O
.	O

Recent	O
biochemical	O
studies	O
suggest	O
that	O
both	O
dATP	O
and	O
ATP	O
regulate	O
mouse	O
RR	O
(	O
mRR	O
)	O
by	O
altering	O
its	O
oligomeric	O
state	O
in	O
an	O
ATP	O
/	O
dATP	O
concentration	O
-	O
dependent	O
manner	O
.	O

The	O
Cooperman	O
group	O
proposed	O
that	O
dATP	O
induces	O
an	O
inactive	O
mRR1	O
tetramer	O
,	O
while	O
ATP	O
induces	O
active	O
mRR1	O
dimers	O
and	O
hexamers	O
.	O

Interestingly	O
,	O
in	O
a	O
previous	O
study	O
Thelander	O
and	O
co	O
-	O
workers	O
observed	O
dATP	O
and	O
ATP	O
induced	O
tetramers	O
for	O
calf	O
thymus	O
RR1	O
.	O

In	O
contrast	O
,	O
the	O
Hofer	O
group	O
proposed	O
that	O
both	O
dATP	O
and	O
ATP	O
induce	O
mRR1	O
hexamers	O
.	O

In	O
fact	O
,	O
the	O
cancer	O
drug	O
gemcitabine	O
has	O
been	O
shown	O
to	O
inactivate	O
a	O
higher	O
order	O
oligomer	O
of	O
human	O
RR	O
.	O

Additionally	O
,	O
recent	O
reports	O
suggest	O
that	O
the	O
E	O
.	O
coli	O
RR1	O
instead	O
of	O
forming	O
hexamers	O
forms	O
tetramers	O
.	O

However	O
,	O
the	O
structural	O
basis	O
for	O
dNTP	O
regulation	O
by	O
RR	O
oligomerization	O
is	O
not	O
known	O
.	O

This	O
paper	O
describes	O
the	O
discovery	O
,	O
through	O
blind	O
mutant	O
screens	O
,	O
of	O
yeast	O
Ctf18	O
-	O
RFC	B-Complex
mutants	O
that	O
destabilize	O
triplet	O
repeats	O
.	O

Genetic	O
analysis	O
indicates	O
Ctf18	O
-	O
RFC	B-Complex
likely	O
acts	O
through	O
replication	O
fork	O
stabilization	O
and	O
/	O
or	O
post	O
-	O
replication	O
repair	O
(	O
PRR	O
)	O
,	O
not	O
SCC	O
,	O
to	O
prevent	O
triplet	O
repeat	O
instability	O
,	O
chromosome	O
fragility	O
and	O
cell	O
cycle	O
delays	O
in	O
S	O
and	O
G2	O
/	O
M	O
phases	O
.	O

Our	O
data	O
also	O
support	O
a	O
general	O
role	O
for	O
the	O
Ctf18	O
-	O
RFC	B-Complex
complex	O
in	O
preventing	O
DNA	O
damage	O
,	O
a	O
role	O
which	O
becomes	O
more	O
crucial	O
in	O
the	O
presence	O
of	O
an	O
at	O
-	O
risk	O
sequence	O
such	O
as	O
an	O
expanded	O
trinucleotide	O
repeat	O
tract	O
.	O

Two	O
TPX2	O
-	O
dependent	O
switches	O
control	O
the	O
activity	O
of	O
Aurora	O
A	O
.	O

Aurora	O
A	O
is	O
an	O
important	O
oncogenic	O
kinase	O
for	O
mitotic	O
spindle	O
assembly	O
and	O
a	O
potentially	O
attractive	O
target	O
for	O
human	O
cancers	O
.	O

Its	O
activation	O
could	O
be	O
regulated	O
by	O
ATP	O
cycle	O
and	O
its	O
activator	O
TPX2	O
.	O

To	O
understand	O
the	O
activation	O
mechanism	O
of	O
Aurora	O
A	O
,	O
a	O
series	O
of	O
20	O
ns	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
were	O
performed	O
on	O
both	O
the	O
wild	O
-	O
type	O
kinase	O
and	O
its	O
mutants	O
.	O

Analyzing	O
the	O
three	O
dynamic	O
trajectories	O
(	O
Aurora	O
A	O
-	O
ATP	O
,	O
Aurora	O
A	O
-	O
ADP	O
,	O
and	O
Aurora	O
A	O
-	O
ADP	O
-	O
TPX2	O
)	O
at	O
the	O
residue	O
level	O
,	O
for	O
the	O
first	O
time	O
we	O
find	O
two	O
TPX2	O
-	O
dependent	O
switches	O
,	O
i	O
.	O
e	O
.	O
,	O
switch	O
-	O
1	O
(	O
Lys	O
-	O
143	O
)	O
and	O
switch	O
-	O
2	O
(	O
Arg	O
-	O
180	O
)	O
,	O
which	O
are	O
tightly	O
associated	O
with	O
Aurora	O
A	O
activation	O
.	O

In	O
the	O
absence	O
of	O
TPX2	O
,	O
Lys	O
-	O
143	O
exhibits	O
a	O
"	O
closed	O
"	O
state	O
,	O
and	O
becomes	O
hydrogen	O
-	O
bonded	O
to	O
ADP	O
.	O

Once	O
TPX2	O
binding	O
occurs	O
,	O
switch	O
-	O
1	O
is	O
forced	O
to	O
"	O
open	O
"	O
the	O
binding	O
site	O
,	O
thus	O
pulling	O
ADP	O
away	O
from	O
Aurora	O
A	O
.	O
Without	O
facilitation	O
of	O
TPX2	O
,	O
switch	O
-	O
2	O
exits	O
in	O
an	O
"	O
open	O
"	O
conformation	O
which	O
accompanies	O
the	O
outward	O
-	O
flipping	O
movement	O
of	O
P	O
*	O
Thr288	O
(	O
in	O
an	O
inactive	O
conformation	O
)	O
,	O
leading	O
to	O
the	O
crucial	O
phosphothreonine	O
exposed	O
and	O
accessible	O
for	O
deactivation	O
.	O

However	O
,	O
with	O
the	O
binding	O
of	O
TPX2	O
,	O
switch	O
-	O
2	O
is	O
forced	O
to	O
undergo	O
a	O
"	O
closed	O
"	O
movement	O
,	O
thus	O
capturing	O
P	O
*	O
Thr288	O
into	O
a	O
buried	O
position	O
and	O
locking	O
its	O
active	O
conformation	O
.	O

Analysis	O
of	O
two	O
Aurora	O
A	O
(	O
K143A	O
and	O
R180A	O
)	O
mutants	O
for	O
the	O
two	O
switches	O
further	O
verifies	O
their	O
functionality	O
and	O
reliability	O
in	O
controlling	O
Aurora	O
activity	O
.	O

Our	O
systems	O
therefore	O
suggest	O
two	O
switches	O
determining	O
Aurora	O
A	O
activation	O
,	O
which	O
are	O
important	O
for	O
the	O
development	O
of	O
aurora	O
kinase	O
inhibitors	O
.	O

We	O
next	O
measured	O
the	O
impact	O
of	O
malin	O
pathogenic	O
mutations	O
on	O
the	O
glycogenic	O
capacity	O
of	O
R5	O
/	O
PTG	O
protein	O
.	O

The	O
cotransfection	O
of	O
laforin	O
with	O
wild	O
-	O
type	O
malin	O
led	O
to	O
a	O
marked	O
decrease	O
of	O
glycogen	O
levels	O
in	O
HEK293	O
cells	O
expressing	O
R5	O
/	O
PTG	O
compared	O
to	O
cells	O
overexpressing	O
only	O
R5	O
/	O
PTG	O
(	O
Fig	O
.	O
8	O
)	O
.	O

This	O
result	O
is	O
consistent	O
with	O
the	O
fact	O
that	O
the	O
laforin	O
-	O
malin	O
complex	O
downregulates	O
R5	O
/	O
PTG	O
via	O
a	O
proteasomal	O
degradation	O
pathway	O
.	O

In	O
contrast	O
,	O
malinC46Y	O
,	O
malinP69A	O
,	O
malinD146N	O
,	O
and	O
malinL261P	O
mutants	O
all	O
failed	O
to	O
reduce	O
glycogen	O
levels	O
.	O

As	O
illustrated	O
in	O
Fig	O
.	O

8	O
,	O
accumulation	O
of	O
glycogen	O
levels	O
was	O
detected	O
in	O
cells	O
expressing	O
malin	O
mutants	O
but	O
not	O
in	O
cells	O
expressing	O
wild	O
-	O
type	O
malin	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Interleukin	O
enhancer	O
-	O
binding	O
factor	O
3	O
functions	O
as	O
a	O
liver	O
receptor	O
homologue	O
-	O
1	O
co	O
-	O
activator	O
in	O
synergy	O
with	O
the	O
nuclear	O
receptor	O
co	O
-	O
activators	O
PRMT1	O
and	O
PGC	O
-	O
1alpha	O
.	O

LRH	O
-	O
1	O
(	O
liver	O
receptor	O
homologue	O
-	O
1	O
)	O
,	O
a	O
transcription	O
factor	O
and	O
member	O
of	O
the	O
nuclear	O
receptor	O
superfamily	O
,	O
regulates	O
the	O
expression	O
of	O
its	O
target	O
genes	O
,	O
which	O
are	O
involved	O
in	O
bile	O
acid	O
and	O
cholesterol	O
homoeostasis	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
of	O
transcriptional	O
control	O
by	O
LRH	O
-	O
1	O
are	O
not	O
completely	O
understood	O
.	O

Previously	O
,	O
we	O
identified	O
Ku80	O
and	O
Ku70	O
as	O
LRH	O
-	O
1	O
-	O
binding	O
proteins	O
and	O
reported	O
that	O
they	O
function	O
as	O
co	O
-	O
repressors	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
an	O
additional	O
LRH	O
-	O
1	O
-	O
binding	O
protein	O
,	O
ILF3	O
(	O
interleukin	O
enhancer	O
-	O
binding	O
factor	O
3	O
)	O
.	O

ILF3	O
formed	O
a	O
complex	O
with	O
LRH	O
-	O
1	O
and	O
the	O
other	O
two	O
nuclear	O
receptor	O
co	O
-	O
activators	O
PRMT1	O
(	O
protein	O
arginine	O
methyltransferase	O
1	O
)	O
and	O
PGC	O
-	O
1alpha	O
(	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
gamma	O
co	O
-	O
activator	O
-	O
1alpha	O
)	O
.	O

We	O
demonstrated	O
that	O
ILF3	O
,	O
PRMT1	O
and	O
PGC	O
-	O
1alpha	O
were	O
recruited	O
to	O
the	O
promoter	O
region	O
of	O
the	O
LRH	O
-	O
1	O
-	O
regulated	O
SHP	O
(	O
small	O
heterodimer	O
partner	O
)	O
gene	O
,	O
encoding	O
one	O
of	O
the	O
nuclear	O
receptors	O
.	O

ILF3	O
enhanced	O
SHP	O
gene	O
expression	O
in	O
co	O
-	O
operation	O
with	O
PRMT1	O
and	O
PGC	O
-	O
1alpha	O
through	O
the	O
C	O
-	O
terminal	O
region	O
of	O
ILF3	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
the	O
small	O
interfering	O
RNA	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
ILF3	O
expression	O
led	O
to	O
a	O
reduction	O
in	O
the	O
occupancy	O
of	O
PGC	O
-	O
1alpha	O
at	O
the	O
SHP	O
promoter	O
and	O
SHP	O
expression	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
ILF3	O
functions	O
as	O
a	O
novel	O
LRH	O
-	O
1	O
co	O
-	O
activator	O
by	O
acting	O
synergistically	O
with	O
PRMT1	O
and	O
PGC	O
-	O
1alpha	O
,	O
thereby	O
promoting	O
LRH	O
-	O
1	O
-	O
dependent	O
gene	O
expression	O
.	O

Our	O
results	O
suggest	O
a	O
two	O
-	O
step	O
model	O
for	O
PFN	O
delivery	O
of	O
Gzms	O
in	O
which	O
PFN	O
first	O
forms	O
transient	O
pores	O
in	O
the	O
cell	O
membrane	O
that	O
trigger	O
the	O
target	O
cell	O
membrane	O
repair	O
response	O
leading	O
to	O
coendocytosis	O
of	O
Gzms	O
and	O
PFN	O
.	O

PFN	O
then	O
forms	O
larger	O
,	O
more	O
stable	O
,	O
pores	O
in	O
the	O
endosomal	O
membrane	O
to	O
trigger	O
release	O
of	O
Gzms	O
.	O

Although	O
the	O
experiments	O
presented	O
here	O
used	O
GzmB	O
,	O
we	O
obtained	O
similar	O
results	O
when	O
the	O
other	O
major	O
Gzm	O
(	O
GzmA	O
)	O
was	O
substituted	O
(	O
data	O
not	O
shown	O
)	O
.	O

Therefore	O
we	O
expect	O
this	O
model	O
applies	O
to	O
all	O
the	O
Gzms	O
.	O

This	O
model	O
,	O
which	O
suggests	O
that	O
PFN	O
can	O
form	O
at	O
least	O
two	O
types	O
of	O
pores	O
of	O
different	O
size	O
and	O
stability	O
,	O
is	O
supported	O
by	O
a	O
recent	O
study	O
that	O
measured	O
conductance	O
through	O
various	O
sorts	O
of	O
membranes	O
(	O
planar	O
lipid	O
bilayers	O
and	O
unilamellar	O
vesicles	O
of	O
different	O
lipid	O
composition	O
and	O
size	O
)	O
treated	O
with	O
PFN	O
.	O

There	O
was	O
a	O
good	O
deal	O
of	O
heterogeneity	O
in	O
PFN	O
pores	O
;	O
in	O
particular	O
formation	O
of	O
small	O
,	O
highly	O
unstable	O
pores	O
preceded	O
the	O
development	O
of	O
more	O
stable	O
and	O
larger	O
pores	O
with	O
a	O
distribution	O
in	O
size	O
.	O

Heterogeneous	O
pore	O
formation	O
was	O
confirmed	O
by	O
cryoelectron	O
microscopy	O
.	O

We	O
therefore	O
hypothesize	O
that	O
the	O
rapid	O
membrane	O
repair	O
response	O
interferes	O
with	O
the	O
formation	O
of	O
larger	O
pores	O
on	O
the	O
plasma	O
membrane	O
,	O
but	O
that	O
PFN	O
multimerizes	O
into	O
larger	O
stable	O
pores	O
on	O
the	O
gigantosome	O
membrane	O
that	O
increase	O
in	O
size	O
within	O
5	O
-	O
15	O
min	O
after	O
adding	O
PFN	O
.	O

Based	O
on	O
the	O
kinetics	O
of	O
early	O
endosome	O
acidification	O
,	O
our	O
data	O
suggest	O
that	O
the	O
smaller	O
pores	O
form	O
within	O
the	O
gigantosome	O
membrane	O
almost	O
immediately	O
to	O
interfere	O
with	O
acidification	O
and	O
allow	O
PFN	O
to	O
remain	O
active	O
.	O

As	O
deleting	O
its	O
initiation	O
motif	O
abolished	O
geminin	O
degradation	O
,	O
we	O
used	O
this	O
substrate	O
to	O
identify	O
key	O
residues	O
required	O
for	O
promoting	O
initiation	O
.	O

We	O
found	O
that	O
mutation	O
of	O
charged	O
residues	O
(	O
RE40	O
;	O
KRK50	O
-	O
52	O
;	O
HR53	O
/	O
54	O
)	O
to	O
alanine	O
interfered	O
with	O
the	O
APC	O
/	O
C	O
-	O
dependent	O
ubiquitination	O
and	O
degradation	O
of	O
geminin	O
(	O
Figure	O
2A	O
;	O
Figure	O
S2A	O
)	O
.	O

Assays	O
with	O
methylubiquitin	O
revealed	O
that	O
RE40	O
/	O
41	O
,	O
KRK50	O
-	O
52	O
,	O
and	O
HR53	O
/	O
54	O
were	O
required	O
for	O
efficient	O
chain	O
initiation	O
(	O
Figure	O
2B	O
)	O
.	O

Interestingly	O
,	O
changing	O
all	O
Lys	O
residues	O
to	O
arginine	O
did	O
not	O
strongly	O
affect	O
geminin	O
degradation	O
or	O
chain	O
initiation	O
,	O
showing	O
that	O
the	O
initiation	O
motif	O
has	O
functions	O
in	O
addition	O
to	O
providing	O
ubiquitin	O
acceptor	O
sites	O
.	O

As	O
expected	O
for	O
a	O
motif	O
controlling	O
the	O
degradation	O
of	O
a	O
key	O
cell	O
cycle	O
regulator	O
,	O
functionally	O
important	O
,	O
but	O
not	O
irrelevant	O
,	O
residues	O
are	O
highly	O
conserved	O
among	O
geminin	O
homologs	O
from	O
different	O
organisms	O
(	O
Figure	O
S2B	O
)	O
.	O

The	O
COG	O
complex	O
interacts	O
directly	O
with	O
Syntaxin	O
6	O
and	O
positively	O
regulates	O
endosome	O
-	O
to	O
-	O
TGN	O
retrograde	O
transport	O
.	O

The	O
conserved	O
oligomeric	O
Golgi	O
(	O
COG	O
)	O
complex	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
endosome	O
to	O
trans	O
-	O
Golgi	O
network	O
(	O
TGN	O
)	O
retrograde	O
trafficking	O
in	O
both	O
yeast	O
and	O
mammals	O
.	O

However	O
,	O
the	O
exact	O
mechanisms	O
by	O
which	O
it	O
regulates	O
this	O
transport	O
route	O
remain	O
largely	O
unknown	O
.	O

In	O
this	O
paper	O
,	O
we	O
show	O
that	O
COG	O
interacts	O
directly	O
with	O
the	O
target	O
membrane	O
SNARE	O
(	O
t	O
-	O
SNARE	O
)	O
Syntaxin	O
6	O
via	O
the	O
Cog6	O
subunit	O
.	O

In	O
Cog6	O
-	O
depleted	O
cells	O
,	O
the	O
steady	O
-	O
state	O
level	O
of	O
Syntaxin	O
6	O
was	O
markedly	O
reduced	O
,	O
and	O
concomitantly	O
,	O
endosome	O
-	O
to	O
-	O
TGN	O
retrograde	O
traffic	O
was	O
significantly	O
attenuated	O
.	O

Cog6	O
knockdown	O
also	O
affected	O
the	O
steady	O
-	O
state	O
levels	O
and	O
/	O
or	O
subcellular	O
distributions	O
of	O
Syntaxin	O
16	O
,	O
Vti1a	O
,	O
and	O
VAMP4	O
and	O
impaired	O
the	O
assembly	O
of	O
the	O
Syntaxin	O
6	O
-	O
Syntaxin16	O
-	O
Vti1a	O
-	O
VAMP4	O
SNARE	B-Complex
complex	O
.	O

Remarkably	O
,	O
overexpression	O
of	O
VAMP4	O
,	O
but	O
not	O
of	O
Syntaxin	O
6	O
,	O
bypassed	O
the	O
requirement	O
for	O
COG	O
and	O
restored	O
endosome	O
-	O
to	O
-	O
TGN	O
trafficking	O
in	O
Cog6	O
-	O
depleted	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
COG	O
directly	O
interacts	O
with	O
specific	O
t	O
-	O
SNAREs	O
and	O
positively	O
regulates	O
SNARE	B-Complex
complex	O
assembly	O
,	O
thereby	O
affecting	O
their	O
associated	O
trafficking	O
steps	O
.	O

A	O
yeast	O
two	O
hybrid	O
screen	O
identifies	O
SPATA4	O
as	O
a	O
TRAPP	B-Complex
interactor	O
.	O

The	O
TRAPP	B-Complex
vesicle	O
-	O
tethering	O
complex	O
consists	O
of	O
more	O
than	O
10	O
distinct	O
polypeptides	O
and	O
is	O
involved	O
in	O
protein	O
transport	O
.	O

Using	O
the	O
C2	O
subunit	O
as	O
bait	O
we	O
identified	O
SPATA4	O
,	O
a	O
spermatocyte	O
-	O
specific	O
protein	O
of	O
unknown	O
function	O
,	O
as	O
an	O
interacting	O
partner	O
in	O
a	O
yeast	O
two	O
hybrid	O
screen	O
.	O

Further	O
studies	O
indicate	O
SPATA4	O
interacts	O
with	O
the	O
C2	O
portion	O
of	O
the	O
TRAPP	B-Complex
complex	O
.	O

SPATA4	O
fractionates	O
with	O
both	O
cytosolic	O
and	O
nuclear	O
fractions	O
suggesting	O
it	O
may	O
have	O
several	O
distinct	O
functions	O
.	O

SPATA4	O
is	O
one	O
of	O
only	O
three	O
human	O
proteins	O
that	O
contain	O
a	O
DUF1042	O
domain	O
and	O
we	O
show	O
that	O
C2	O
does	O
not	O
interact	O
with	O
another	O
one	O
of	O
the	O
DUF1042	O
domain	O
-	O
containing	O
proteins	O
.	O

Our	O
results	O
suggest	O
a	O
role	O
for	O
SPATA4	O
in	O
membrane	O
traffic	O
and	O
a	O
specialized	O
function	O
for	O
TRAPP	B-Complex
in	O
spermatocytes	O
.	O

MDM2	O
promotes	O
SUMO	O
-	O
2	O
/	O
3	O
modification	O
of	O
p53	O
to	O
modulate	O
transcriptional	O
activity	O
.	O

The	O
tumor	O
suppressor	O
p53	O
is	O
extensively	O
regulated	O
by	O
post	O
-	O
translational	O
modification	O
,	O
including	O
modification	O
by	O
the	O
small	O
ubiquitin	O
-	O
related	O
modifier	O
SUMO	O
.	O

We	O
show	O
here	O
that	O
MDM2	O
,	O
previously	O
shown	O
to	O
promote	O
ubiquitin	O
,	O
Nedd8	O
and	O
SUMO	O
-	O
1	O
modification	O
of	O
p53	O
,	O
can	O
also	O
enhance	O
conjugation	O
of	O
endogenous	O
SUMO	O
-	O
2	O
/	O
3	O
to	O
p53	O
.	O

Sumoylation	O
activity	O
requires	O
p53	O
-	O
MDM2	O
binding	O
but	O
does	O
not	O
depend	O
on	O
an	O
intact	O
RING	O
finger	O
.	O

Both	O
ARF	O
and	O
L11	O
can	O
promote	O
SUMO	O
-	O
2	O
/	O
3	O
conjugation	O
of	O
p53	O
.	O

However	O
,	O
unlike	O
the	O
previously	O
described	O
SUMO	O
-	O
1	O
conjugation	O
of	O
p53	O
by	O
an	O
MDM2	O
-	O
ARF	O
complex	O
,	O
this	O
activity	O
does	O
not	O
depend	O
on	O
the	O
ability	O
of	O
MDM2	O
to	O
relocalize	O
to	O
the	O
nucleolus	O
.	O

Interestingly	O
,	O
the	O
SUMO	O
consensus	O
is	O
not	O
conserved	O
in	O
mouse	O
p53	O
,	O
which	O
is	O
therefore	O
not	O
modified	O
by	O
SUMO	O
-	O
2	O
/	O
3	O
.	O

Finally	O
,	O
we	O
show	O
that	O
conjugation	O
of	O
SUMO	O
-	O
2	O
/	O
3	O
to	O
p53	O
correlates	O
with	O
a	O
reduction	O
of	O
both	O
activation	O
and	O
repression	O
of	O
a	O
subset	O
of	O
p53	O
-	O
target	O
genes	O
.	O

The	O
endonuclease	O
activity	O
of	O
Mili	O
fuels	O
piRNA	O
amplification	O
that	O
silences	O
LINE1	O
elements	O
.	O

Piwi	O
proteins	O
and	O
Piwi	O
-	O
interacting	O
RNAs	O
(	O
piRNAs	O
)	O
have	O
conserved	O
functions	O
in	O
transposon	O
silencing	O
.	O

The	O
murine	O
Piwi	O
proteins	O
Mili	O
and	O
Miwi2	O
(	O
also	O
called	O
Piwil2	O
and	O
Piwil4	O
,	O
respectively	O
)	O
direct	O
epigenetic	O
LINE1	O
and	O
intracisternal	O
A	O
particle	O
transposon	O
silencing	O
during	O
genome	O
reprogramming	O
in	O
the	O
embryonic	O
male	O
germ	O
line	O
.	O

Piwi	O
proteins	O
are	O
proposed	O
to	O
be	O
piRNA	O
-	O
guided	O
endonucleases	O
that	O
initiate	O
secondary	O
piRNA	O
biogenesis	O
;	O
however	O
,	O
the	O
actual	O
contribution	O
of	O
their	O
endonuclease	O
activities	O
to	O
piRNA	O
biogenesis	O
and	O
transposon	O
silencing	O
remain	O
unknown	O
.	O

To	O
investigate	O
the	O
role	O
of	O
Piwi	O
-	O
catalysed	O
endonucleolytic	O
activity	O
,	O
we	O
engineered	O
point	O
mutations	O
in	O
mice	O
that	O
substitute	O
the	O
second	O
aspartic	O
acid	O
to	O
an	O
alanine	O
in	O
the	O
DDH	O
catalytic	O
triad	O
of	O
Mili	O
and	O
Miwi2	O
,	O
generating	O
the	O
Mili	O
(	O
DAH	O
)	O
and	O
Miwi2	O
(	O
DAH	O
)	O
alleles	O
,	O
respectively	O
.	O

Analysis	O
of	O
Mili	O
-	O
bound	O
piRNAs	O
from	O
homozygous	O
Mili	O
(	O
DAH	O
)	O
fetal	O
gonadocytes	O
revealed	O
a	O
failure	O
of	O
transposon	O
piRNA	O
amplification	O
,	O
resulting	O
in	O
the	O
marked	O
reduction	O
of	O
piRNA	O
bound	O
within	O
Miwi2	O
ribonuclear	O
particles	O
.	O

We	O
find	O
that	O
Mili	O
-	O
mediated	O
piRNA	O
amplification	O
is	O
selectively	O
required	O
for	O
LINE1	O
,	O
but	O
not	O
intracisternal	O
A	O
particle	O
,	O
silencing	O
.	O

The	O
defective	O
piRNA	O
pathway	O
in	O
Mili	O
(	O
DAH	O
)	O
mice	O
results	O
in	O
spermatogenic	O
failure	O
and	O
sterility	O
.	O

Surprisingly	O
,	O
homozygous	O
Miwi2	O
(	O
DAH	O
)	O
mice	O
are	O
fertile	O
,	O
transposon	O
silencing	O
is	O
established	O
normally	O
and	O
no	O
defects	O
in	O
secondary	O
piRNA	O
biogenesis	O
are	O
observed	O
.	O

In	O
addition	O
,	O
the	O
hallmarks	O
of	O
piRNA	O
amplification	O
are	O
observed	O
in	O
Miwi2	O
-	O
deficient	O
gonadocytes	O
.	O

We	O
conclude	O
that	O
cycles	O
of	O
intra	O
-	O
Mili	O
secondary	O
piRNA	O
biogenesis	O
fuel	O
piRNA	O
amplification	O
that	O
is	O
absolutely	O
required	O
for	O
LINE1	O
silencing	O
.	O

Fission	O
yeast	O
Swi5	O
-	O
Sfr1	O
protein	O
complex	O
,	O
an	O
activator	O
of	O
Rad51	O
recombinase	O
,	O
forms	O
an	O
extremely	O
elongated	O
dogleg	O
-	O
shaped	O
structure	O
.	O

In	O
eukaryotes	O
,	O
DNA	O
strand	O
exchange	O
is	O
the	O
central	O
reaction	O
of	O
homologous	O
recombination	O
,	O
which	O
is	O
promoted	O
by	O
Rad51	O
recombinases	O
forming	O
a	O
right	O
-	O
handed	O
nucleoprotein	O
filament	O
on	O
single	O
-	O
stranded	O
DNA	O
,	O
also	O
known	O
as	O
a	O
presynaptic	O
filament	O
.	O

Accessory	O
proteins	O
known	O
as	O
recombination	O
mediators	O
are	O
required	O
for	O
the	O
formation	O
of	O
the	O
active	O
presynaptic	O
filament	O
.	O

One	O
such	O
mediator	O
in	O
the	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
is	O
the	O
Swi5	O
-	O
Sfr1	O
complex	O
,	O
which	O
has	O
been	O
identified	O
as	O
an	O
activator	O
of	O
Rad51	O
that	O
assists	O
in	O
presynaptic	O
filament	O
formation	O
and	O
stimulates	O
its	O
strand	O
exchange	O
reaction	O
.	O

Here	O
,	O
we	O
determined	O
the	O
1	O
:	O
1	O
binding	O
stoichiometry	O
between	O
the	O
two	O
subunits	O
of	O
the	O
Swi5	O
-	O
Sfr1	O
complex	O
using	O
analytical	O
ultracentrifugation	O
and	O
electrospray	O
ionization	O
mass	O
spectrometry	O
.	O

Small	O
-	O
angle	O
x	O
-	O
ray	O
scattering	O
experiments	O
revealed	O
that	O
the	O
Swi5	O
-	O
Sfr1	O
complex	O
displays	O
an	O
extremely	O
elongated	O
dogleg	O
-	O
shaped	O
structure	O
in	O
solution	O
,	O
which	O
is	O
consistent	O
with	O
its	O
exceptionally	O
high	O
frictional	O
ratio	O
(	O
f	O
/	O
f	O
(	O
0	O
)	O
)	O
of	O
2	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
2	O
obtained	O
by	O
analytical	O
ultracentrifugation	O
.	O

Furthermore	O
,	O
we	O
determined	O
a	O
rough	O
topology	O
of	O
the	O
complex	O
by	O
comparing	O
the	O
small	O
-	O
angle	O
x	O
-	O
ray	O
scattering	O
-	O
based	O
structures	O
of	O
the	O
Swi5	O
-	O
Sfr1	O
complex	O
and	O
four	O
Swi5	O
-	O
Sfr1	O
-	O
Fab	O
complexes	O
,	O
in	O
which	O
the	O
Fab	O
fragments	O
of	O
monoclonal	O
antibodies	O
were	O
specifically	O
bound	O
to	O
experimentally	O
determined	O
sites	O
of	O
Sfr1	O
.	O

We	O
propose	O
a	O
model	O
for	O
how	O
the	O
Swi5	O
-	O
Sfr1	O
complex	O
binds	O
to	O
the	O
Rad51	O
filament	O
,	O
in	O
which	O
the	O
Swi5	O
-	O
Sfr1	O
complex	O
fits	O
into	O
the	O
groove	O
of	O
the	O
Rad51	O
filament	O
,	O
leading	O
to	O
an	O
active	O
and	O
stable	O
presynaptic	O
filament	O
.	O

A	O
novel	O
protein	O
LZTFL1	O
regulates	O
ciliary	O
trafficking	O
of	O
the	O
BBSome	B-Complex
and	O
Smoothened	O
.	O

Many	O
signaling	O
proteins	O
including	O
G	O
protein	O
-	O
coupled	O
receptors	O
localize	O
to	O
primary	O
cilia	O
,	O
regulating	O
cellular	O
processes	O
including	O
differentiation	O
,	O
proliferation	O
,	O
organogenesis	O
,	O
and	O
tumorigenesis	O
.	O

Bardet	O
-	O
Biedl	O
Syndrome	O
(	O
BBS	O
)	O
proteins	O
are	O
involved	O
in	O
maintaining	O
ciliary	O
function	O
by	O
mediating	O
protein	O
trafficking	O
to	O
the	O
cilia	O
.	O

However	O
,	O
the	O
mechanisms	O
governing	O
ciliary	O
trafficking	O
by	O
BBS	O
proteins	O
are	O
not	O
well	O
understood	O
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
novel	O
protein	O
,	O
Leucine	O
-	O
zipper	O
transcription	O
factor	O
-	O
like	O
1	O
(	O
LZTFL1	O
)	O
,	O
interacts	O
with	O
a	O
BBS	O
protein	O
complex	O
known	O
as	O
the	O
BBSome	B-Complex
and	O
regulates	O
ciliary	O
trafficking	O
of	O
this	O
complex	O
.	O

We	O
also	O
show	O
that	O
all	O
BBSome	B-Complex
subunits	O
and	O
BBS3	O
(	O
also	O
known	O
as	O
ARL6	O
)	O
are	O
required	O
for	O
BBSome	B-Complex
ciliary	O
entry	O
and	O
that	O
reduction	O
of	O
LZTFL1	O
restores	O
BBSome	B-Complex
trafficking	O
to	O
cilia	O
in	O
BBS3	O
and	O
BBS5	O
depleted	O
cells	O
.	O

Finally	O
,	O
we	O
found	O
that	O
BBS	O
proteins	O
and	O
LZTFL1	O
regulate	O
ciliary	O
trafficking	O
of	O
hedgehog	O
signal	O
transducer	O
,	O
Smoothened	O
.	O

Our	O
findings	O
suggest	O
that	O
LZTFL1	O
is	O
an	O
important	O
regulator	O
of	O
BBSome	B-Complex
ciliary	O
trafficking	O
and	O
hedgehog	O
signaling	O
.	O

Germline	O
inactivation	O
of	O
the	O
VHL	O
tumor	O
suppressor	O
gene	O
is	O
linked	O
with	O
development	O
of	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
disease	O
,	O
an	O
autosomal	O
dominantly	O
inherited	O
cancer	O
syndrome	O
.	O

VHL	O
patients	O
are	O
predisposed	O
to	O
develop	O
various	O
vascular	O
tumors	O
,	O
including	O
hemangioblastomas	O
of	O
the	O
retinas	O
and	O
central	O
nervous	O
system	O
,	O
clear	O
cell	O
RCC	O
,	O
pancreatic	O
cysts	O
and	O
adenocarcinomas	O
,	O
and	O
adrenal	O
pheochromocytomas	O
.	O

The	O
VHL	O
gene	O
is	O
also	O
inactivated	O
in	O
the	O
majority	O
of	O
patients	O
with	O
sporadic	O
clear	O
cell	O
RCC	O
.	O

The	O
VHL	O
gene	O
encodes	O
proteins	O
(	O
pVHL	O
)	O
of	O
25	O
and	O
19	O
kDa	O
through	O
use	O
of	O
alternative	O
translation	O
initiation	O
codons	O
,	O
and	O
both	O
isoforms	O
appear	O
to	O
possess	O
tumor	O
suppressor	O
activity	O
.	O

pVHL	O
has	O
alpha	O
and	O
beta	O
structural	O
domains	O
that	O
are	O
critical	O
to	O
its	O
function	O
as	O
the	O
substrate	O
recognition	O
component	O
of	O
a	O
cullin	O
-	O
RING	O
E3	O
ubiquitin	O
ligase	O
(	O
CRL	O
)	O
.	O

The	O
N	O
-	O
terminal	O
beta	O
domain	O
is	O
associated	O
with	O
target	O
protein	O
recognition	O
,	O
while	O
the	O
alpha	O
domain	O
contains	O
a	O
SOCS	O
box	O
that	O
interacts	O
with	O
elongin	O
C	O
and	O
links	O
pVHL	O
to	O
the	O
ubiquitin	O
-	O
ligase	O
complex	O
containing	O
elongin	O
B	O
and	O
C	O
and	O
Cul2	O
.	O

Perhaps	O
the	O
best	O
characterized	O
pVHL	O
CRL	O
targets	O
are	O
the	O
alpha	O
subunits	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
.	O

Hydroxylation	O
of	O
conserved	O
prolines	O
on	O
HIFalpha	O
subunits	O
under	O
normoxic	O
(	O
21	O
%	O
O2	O
)	O
conditions	O
provides	O
a	O
substrate	O
recognition	O
motif	O
for	O
pVHL	O
polyubiquitylation	O
,	O
and	O
proteasomal	O
degradation	O
.	O

In	O
hypoxia	O
(	O
1	O
%	O
O2	O
)	O
prolyl	O
hydroxylase	O
activity	O
is	O
inhibited	O
,	O
unmodified	O
HIFalpha	O
subunits	O
are	O
stabilized	O
,	O
and	O
the	O
hypoxia	O
response	O
is	O
initiated	O
.	O

We	O
recently	O
demonstrated	O
that	O
pVHL	O
levels	O
are	O
suppressed	O
in	O
hypoxia	O
,	O
providing	O
an	O
additional	O
mechanism	O
for	O
HIFalpha	O
upregulation	O
in	O
hypoxia	O
.	O

A	O
sulfurtransferase	O
is	O
essential	O
for	O
activity	O
of	O
formate	O
dehydrogenases	O
in	O
Escherichia	O
coli	O
.	O

l	O
-	O
Cysteine	O
desulfurases	O
provide	O
sulfur	O
to	O
several	O
metabolic	O
pathways	O
in	O
the	O
form	O
of	O
persulfides	O
on	O
specific	O
cysteine	O
residues	O
of	O
an	O
acceptor	O
protein	O
for	O
the	O
eventual	O
incorporation	O
of	O
sulfur	O
into	O
an	O
end	O
product	O
.	O

IscS	O
is	O
one	O
of	O
the	O
three	O
Escherichia	O
coli	O
l	O
-	O
cysteine	O
desulfurases	O
.	O

It	O
interacts	O
with	O
FdhD	O
,	O
a	O
protein	O
essential	O
for	O
the	O
activity	O
of	O
formate	O
dehydrogenases	O
(	O
FDHs	O
)	O
,	O
which	O
are	O
iron	O
/	O
molybdenum	O
/	O
selenium	O
-	O
containing	O
enzymes	O
.	O

Here	O
,	O
we	O
address	O
the	O
role	O
played	O
by	O
this	O
interaction	O
in	O
the	O
activity	O
of	O
FDH	O
-	O
H	O
(	O
FdhF	O
)	O
in	O
E	O
.	O
coli	O
.	O

The	O
interaction	O
of	O
IscS	O
with	O
FdhD	O
results	O
in	O
a	O
sulfur	O
transfer	O
between	O
IscS	O
and	O
FdhD	O
in	O
the	O
form	O
of	O
persulfides	O
.	O

Substitution	O
of	O
the	O
strictly	O
conserved	O
residue	O
Cys	O
-	O
121	O
of	O
FdhD	O
impairs	O
both	O
sulfur	O
transfer	O
from	O
IscS	O
to	O
FdhD	O
and	O
FdhF	O
activity	O
.	O

Furthermore	O
,	O
inactive	O
FdhF	O
produced	O
in	O
the	O
absence	O
of	O
FdhD	O
contains	O
both	O
metal	O
centers	O
,	O
albeit	O
the	O
molybdenum	O
cofactor	O
is	O
at	O
a	O
reduced	O
level	O
.	O

Finally	O
,	O
FdhF	O
activity	O
is	O
sulfur	O
-	O
dependent	O
,	O
as	O
it	O
shows	O
reversible	O
sensitivity	O
to	O
cyanide	O
treatment	O
.	O

Conclusively	O
,	O
FdhD	O
is	O
a	O
sulfurtransferase	O
between	O
IscS	O
and	O
FdhF	O
and	O
is	O
thereby	O
essential	O
to	O
yield	O
FDH	O
activity	O
.	O

Yeast	O
transcription	O
termination	O
factor	O
Rtt103	O
functions	O
in	O
DNA	O
damage	O
response	O
.	O

YKu70	O
/	O
YKu80	O
is	O
a	O
heterodimer	O
that	O
is	O
essential	O
for	O
repair	O
of	O
DNA	O
double	O
strand	O
breaks	O
through	O
non	O
-	O
homologous	O
end	O
joining	O
pathway	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

Yku70	O
/	O
80	O
proteins	O
are	O
associated	O
with	O
telomeres	O
and	O
are	O
important	O
for	O
maintaining	O
the	O
integrity	O
of	O
telomeres	O
.	O

These	O
proteins	O
protect	O
telomeres	O
from	O
recombination	O
events	O
,	O
nuclease	O
attacks	O
,	O
support	O
the	O
formation	O
of	O
heterochromatin	O
at	O
telomeres	O
and	O
anchor	O
telomeres	O
to	O
the	O
nuclear	O
periphery	O
.	O

To	O
identify	O
components	O
in	O
molecular	O
networks	O
involved	O
in	O
the	O
multiple	O
functions	O
of	O
Yku70	O
/	O
80	O
complex	O
,	O
we	O
performed	O
a	O
genetic	O
screen	O
for	O
suppressors	O
of	O
yku70	O
deletion	O
.	O

One	O
of	O
the	O
suppressors	O
identified	O
was	O
RTT103	O
,	O
which	O
encodes	O
a	O
protein	O
implicated	O
in	O
transcription	O
termination	O
.	O

We	O
show	O
that	O
rtt103Delta	O
are	O
sensitive	O
to	O
multiple	O
forms	O
of	O
genome	O
insults	O
and	O
that	O
RTT103	O
is	O
essential	O
for	O
recovery	O
from	O
DNA	O
double	O
strand	O
breaks	O
in	O
the	O
chromosome	O
.	O

We	O
further	O
show	O
that	O
Rtt103	O
associates	O
with	O
sites	O
of	O
DNA	O
breaks	O
and	O
hence	O
is	O
likely	O
to	O
play	O
a	O
direct	O
role	O
in	O
response	O
to	O
DNA	O
damage	O
.	O

To	O
compare	O
our	O
low	O
resolution	O
SAXS	O
data	O
with	O
the	O
crystal	O
structure	O
,	O
we	O
computed	O
the	O
theoretical	O
SAXS	O
curves	O
and	O
the	O
pair	O
-	O
distance	O
distribution	O
function	O
for	O
the	O
crystal	O
structures	O
of	O
hPPARgamma	O
DBD	O
-	O
LBD	O
monomer	O
and	O
hPPARgamma	O
/	O
hRXRalpha	O
DBD	O
-	O
LBD	O
heterodimer	O
(	O
Figure	O
5	O
)	O
.	O

The	O
crystallographic	O
models	O
do	O
not	O
fit	O
well	O
to	O
the	O
DAMs	O
derived	O
from	O
our	O
SAXS	O
experiments	O
.	O

The	O
profiles	O
of	O
the	O
distance	O
distribution	O
functions	O
p	O
(	O
r	O
)	O
corresponding	O
to	O
DAMs	O
and	O
generated	O
for	O
crystallography	O
structures	O
are	O
typical	O
for	O
elongated	O
particles	O
.	O

Nevertheless	O
,	O
the	O
Dmax	O
of	O
the	O
DAMs	O
are	O
larger	O
than	O
the	O
crystallographic	O
structure	O
,	O
which	O
indicates	O
that	O
the	O
protein	O
in	O
solution	O
is	O
more	O
elongated	O
than	O
in	O
the	O
crystal	O
.	O

RAC1	O
activation	O
mediates	O
Twist1	O
-	O
induced	O
cancer	O
cell	O
migration	O
.	O

Epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
,	O
which	O
is	O
characterized	O
by	O
the	O
suppression	O
of	O
the	O
adhesion	O
protein	O
E	O
-	O
cadherin	O
,	O
is	O
a	O
crucial	O
process	O
that	O
promotes	O
metastasis	O
and	O
stem	O
-	O
like	O
properties	O
of	O
cancer	O
cells	O
.	O

However	O
,	O
the	O
dissociation	O
of	O
cellular	O
aggregates	O
is	O
not	O
sufficient	O
to	O
explain	O
why	O
cancer	O
cells	O
move	O
,	O
and	O
the	O
motile	O
nature	O
of	O
cancer	O
cells	O
undergoing	O
EMT	O
remains	O
elusive	O
.	O

Here	O
,	O
we	O
identify	O
a	O
mechanism	O
in	O
which	O
the	O
EMT	O
inducer	O
Twist1	O
elicits	O
cancer	O
cell	O
movement	O
through	O
activation	O
of	O
RAC1	O
.	O

Twist1	O
cooperates	O
with	O
BMI1	O
to	O
suppress	O
let	O
-	O
7i	O
expression	O
,	O
which	O
results	O
in	O
upregulation	O
of	O
NEDD9	O
and	O
DOCK3	O
,	O
leading	O
to	O
RAC1	O
activation	O
and	O
enabling	O
mesenchymal	O
-	O
mode	O
movement	O
in	O
three	O
-	O
dimensional	O
environments	O
.	O

Moreover	O
,	O
the	O
suppression	O
of	O
let	O
-	O
7i	O
contributes	O
to	O
Twist1	O
-	O
induced	O
stem	O
-	O
like	O
properties	O
.	O

Clinically	O
,	O
activation	O
of	O
the	O
Twist1	O
-	O
let	O
-	O
7i	O
-	O
NEDD9	O
axis	O
in	O
head	O
and	O
neck	O
cancer	O
patients	O
correlates	O
with	O
tumour	O
invasiveness	O
and	O
worse	O
outcome	O
.	O

Our	O
results	O
uncover	O
an	O
essential	O
mechanism	O
to	O
explain	O
how	O
Twist1	O
induces	O
the	O
motile	O
stem	O
-	O
like	O
cancer	O
cell	O
phenotype	O
beyond	O
simply	O
suppressing	O
E	O
-	O
cadherin	O
.	O

All	O
dysc	O
alleles	O
were	O
recessive	O
;	O
trans	O
-	O
heterozygotic	O
combinations	O
of	O
the	O
three	O
alleles	O
were	O
largely	O
arrhythmic	O
;	O
and	O
heterozygosity	O
for	O
both	O
dysc	O
s168	O
and	O
dysc	O
c03838	O
in	O
combination	O
with	O
a	O
deficiency	O
removing	O
the	O
dysc	O
locus	O
also	O
resulted	O
in	O
arrhythmia	O
(	O
Table	O
1	O
)	O
.	O

In	O
addition	O
,	O
precise	O
excision	O
of	O
the	O
dysc	O
s168	O
P	O
-	O
element	O
restored	O
wild	O
-	O
type	O
patterns	O
of	O
locomotion	O
(	O
Table	O
1	O
)	O
,	O
indicating	O
that	O
the	O
P	O
-	O
element	O
insertion	O
is	O
responsible	O
for	O
arrhythmicity	O
.	O

Finally	O
,	O
to	O
test	O
whether	O
transgenic	O
expression	O
of	O
dysc	O
could	O
restore	O
rhythmic	O
behavior	O
,	O
we	O
generated	O
flies	O
carrying	O
a	O
UAS	O
-	O
dysc	O
transgene	O
encoding	O
a	O
long	O
isoform	O
of	O
DYSC	O
.	O

Pan	O
-	O
neuronal	O
expression	O
of	O
the	O
UAS	O
-	O
dysc	O
transgene	O
in	O
dysc	O
mutants	O
was	O
sufficient	O
to	O
rescue	O
rhythmic	O
behavior	O
(	O
Figure	O
2E	O
and	O
Table	O
2	O
)	O
.	O

Consistent	O
with	O
the	O
fact	O
that	O
dysc	O
s168	O
homozygotes	O
,	O
which	O
express	O
normal	O
levels	O
of	O
the	O
short	O
isoform	O
,	O
are	O
arrhythmic	O
,	O
transgenic	O
expression	O
of	O
a	O
short	O
DYSC	O
isoform	O
did	O
not	O
restore	O
rhythmicity	O
in	O
dysc	O
c03838	O
mutants	O
(	O
Table	O
2	O
;	O
see	O
Figure	O
S3	O
for	O
expression	O
levels	O
of	O
long	O
and	O
short	O
dysc	O
transgenes	O
)	O
.	O

Over	O
-	O
expression	O
of	O
either	O
the	O
long	O
or	O
short	O
isoforms	O
of	O
DYSC	O
in	O
a	O
wild	O
-	O
type	O
background	O
did	O
not	O
affect	O
circadian	O
rhythmicity	O
(	O
Table	O
2	O
)	O
.	O

These	O
results	O
comprehensively	O
demonstrate	O
that	O
DYSC	O
is	O
required	O
for	O
circadian	O
alterations	O
in	O
locomotor	O
activity	O
,	O
and	O
furthermore	O
indicate	O
that	O
correct	O
circadian	O
output	O
requires	O
DYSC	O
expression	O
in	O
the	O
nervous	O
system	O
.	O

Rab14	O
and	O
its	O
exchange	O
factor	O
FAM116	O
link	O
endocytic	O
recycling	O
and	O
adherens	O
junction	O
stability	O
in	O
migrating	O
cells	O
.	O

Rab	O
GTPases	O
define	O
the	O
vesicle	O
trafficking	O
pathways	O
underpinning	O
cell	O
polarization	O
and	O
migration	O
.	O

Here	O
,	O
we	O
find	O
that	O
Rab4	O
,	O
Rab11	O
,	O
and	O
Rab14	O
and	O
the	O
candidate	O
Rab	O
GDP	O
-	O
GTP	O
exchange	O
factors	O
(	O
GEFs	O
)	O
FAM116A	O
and	O
AVL9	O
are	O
required	O
for	O
cell	O
migration	O
.	O

Rab14	O
and	O
its	O
GEF	O
FAM116A	O
localize	O
to	O
and	O
act	O
on	O
an	O
intermediate	O
compartment	O
of	O
the	O
transferrin	O
-	O
recycling	O
pathway	O
prior	O
to	O
Rab11	O
and	O
after	O
Rab5	O
and	O
Rab4	O
.	O

This	O
Rab14	O
intermediate	O
recycling	O
compartment	O
has	O
specific	O
functions	O
in	O
migrating	O
cells	O
discrete	O
from	O
early	O
and	O
recycling	O
endosomes	O
.	O

Rab14	O
-	O
depleted	O
cells	O
show	O
increased	O
N	O
-	O
cadherin	O
levels	O
at	O
junctional	O
complexes	O
and	O
cannot	O
resolve	O
cell	O
-	O
cell	O
junctions	O
.	O

This	O
is	O
due	O
to	O
decreased	O
shedding	O
of	O
cell	O
-	O
surface	O
N	O
-	O
cadherin	O
by	O
the	O
ADAM	O
family	O
protease	O
ADAM10	O
/	O
Kuzbanian	O
.	O

In	O
FAM116A	O
-	O
and	O
Rab14	O
-	O
depleted	O
cells	O
,	O
ADAM10	O
accumulates	O
in	O
a	O
transferrin	O
-	O
positive	O
endocytic	O
compartment	O
,	O
and	O
the	O
cell	O
-	O
surface	O
level	O
of	O
ADAM10	O
is	O
correspondingly	O
reduced	O
.	O

FAM116	O
and	O
Rab14	O
therefore	O
define	O
an	O
endocytic	O
recycling	O
pathway	O
needed	O
for	O
ADAM	O
protease	O
trafficking	O
and	O
regulation	O
of	O
cell	O
-	O
cell	O
junctions	O
.	O

Secondly	O
,	O
we	O
determined	O
the	O
molar	O
binding	O
ratio	O
of	O
GFP	O
-	O
Ligase	O
III	O
to	O
RFP	O
-	O
Xrcc1	O
.	O

Xrcc1	O
binds	O
in	O
a	O
molar	O
ratio	O
of	O
0	O
.	O
61	O
+	O
/	O
-	O
0	O
.	O
14	O
to	O
Ligase	O
III	O
but	O
did	O
not	O
bind	O
to	O
other	O
proteins	O
such	O
as	O
GFP	O
-	O
PBD	O
,	O
GFP	O
-	O
Dnmt1DeltaPBD	O
or	O
GFP	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
DNA	O
Ligase	O
III	O
was	O
recruited	O
to	O
DNA	O
repair	O
sites	O
via	O
its	O
BRCT	O
domain	O
mediated	O
interaction	O
with	O
Xrcc1	O
.	O

Investigation	O
of	O
prolactin	O
receptor	O
activation	O
and	O
blockade	O
using	O
time	O
-	O
resolved	O
fluorescence	O
resonance	O
energy	O
transfer	O
.	O

The	O
prolactin	O
receptor	O
(	O
PRLR	O
)	O
is	O
emerging	O
as	O
a	O
therapeutic	O
target	O
in	O
oncology	O
.	O

Knowledge	O
-	O
based	O
drug	O
design	O
led	O
to	O
the	O
development	O
of	O
a	O
pure	O
PRLR	O
antagonist	O
(	O
Del1	O
-	O
9	O
-	O
G129R	O
-	O
hPRL	O
)	O
that	O
was	O
recently	O
shown	O
to	O
prevent	O
PRL	O
-	O
induced	O
mouse	O
prostate	O
tumorogenesis	O
.	O

In	O
humans	O
,	O
the	O
first	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
of	O
the	O
PRLR	O
(	O
PRLR	O
(	O
I146L	O
)	O
)	O
was	O
recently	O
identified	O
in	O
breast	O
tumor	O
patients	O
.	O

At	O
the	O
molecular	O
level	O
,	O
the	O
actual	O
mechanism	O
of	O
action	O
of	O
these	O
two	O
novel	O
players	O
in	O
the	O
PRL	O
system	O
remains	O
elusive	O
.	O

In	O
this	O
study	O
,	O
we	O
addressed	O
whether	O
constitutive	O
PRLR	O
activation	O
(	O
PRLR	O
(	O
I146L	O
)	O
)	O
or	O
PRLR	O
blockade	O
(	O
antagonist	O
)	O
involved	O
alteration	O
of	O
receptor	O
oligomerization	O
and	O
/	O
or	O
of	O
inter	O
-	O
chain	O
distances	O
compared	O
to	O
unstimulated	O
and	O
PRL	O
-	O
stimulated	O
PRLR	O
.	O

Using	O
a	O
combination	O
of	O
various	O
biochemical	O
and	O
spectroscopic	O
approaches	O
(	O
co	O
-	O
IP	O
,	O
blue	O
native	O
electrophoresis	O
,	O
BRET	O
(	O
1	O
)	O
)	O
,	O
we	O
demonstrated	O
that	O
preformed	O
PRLR	O
homodimers	O
are	O
altered	O
neither	O
by	O
PRL	O
-	O
or	O
I146L	O
-	O
induced	O
receptor	O
triggering	O
,	O
nor	O
by	O
antagonist	O
-	O
mediated	O
blockade	O
.	O

These	O
findings	O
were	O
confirmed	O
using	O
a	O
novel	O
time	O
-	O
resolved	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
TR	O
-	O
FRET	O
)	O
technology	O
that	O
allows	O
monitoring	O
distance	O
changes	O
between	O
cell	O
surface	O
tagged	O
receptors	O
.	O

This	O
technology	O
revealed	O
that	O
PRLR	O
blockade	O
or	O
activation	O
did	O
not	O
involve	O
detectable	O
distance	O
changes	O
between	O
extracellular	O
domains	O
of	O
receptor	O
chains	O
within	O
the	O
dimer	O
.	O

This	O
study	O
merges	O
with	O
our	O
previous	O
structural	O
investigations	O
suggesting	O
that	O
the	O
mechanism	O
of	O
PRLR	O
activation	O
solely	O
involves	O
intermolecular	O
contact	O
adaptations	O
leading	O
to	O
subtle	O
intramolecular	O
rearrangements	O
.	O

Identification	O
and	O
characterization	O
of	O
an	O
extramitochondrial	O
human	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
-	O
CoA	O
lyase	O
.	O

3	O
-	O
Hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
-	O
CoA	O
lyase	O
-	O
like	O
protein	O
(	O
HMGCLL1	O
)	O
has	O
been	O
annotated	O
in	O
the	O
Mammalian	O
Genome	O
Collection	O
as	O
a	O
previously	O
unidentified	O
human	O
HMG	O
-	O
CoA	O
lyase	O
(	O
HMGCL	O
)	O
.	O

To	O
test	O
the	O
validity	O
of	O
this	O
annotation	O
and	O
evaluate	O
the	O
physiological	O
role	O
of	O
the	O
protein	O
,	O
plasmids	O
were	O
constructed	O
for	O
protein	O
expression	O
in	O
Escherichia	O
coli	O
and	O
Pichia	O
pastoris	O
.	O

Protein	O
expression	O
in	O
E	O
.	O
coli	O
produced	O
insoluble	O
material	O
.	O

In	O
contrast	O
,	O
active	O
HMGCLL1	O
could	O
be	O
recovered	O
upon	O
expression	O
in	O
P	O
.	O
pastoris	O
.	O

Antibodies	O
were	O
prepared	O
against	O
a	O
unique	O
peptide	O
sequence	O
found	O
in	O
the	O
N	O
terminus	O
of	O
the	O
protein	O
.	O

In	O
immunodetection	O
experiments	O
,	O
the	O
antibodies	O
discriminated	O
between	O
HMGCLL1	O
and	O
mitochondrial	O
HMGCL	O
.	O

Purified	O
enzyme	O
was	O
characterized	O
and	O
demonstrated	O
to	O
cleave	O
HMG	O
-	O
CoA	O
to	O
acetoacetate	O
and	O
acetyl	O
-	O
CoA	O
with	O
catalytic	O
and	O
affinity	O
properties	O
comparable	O
with	O
human	O
mitochondrial	O
HMGCL	O
.	O

The	O
deduced	O
HMGCLL1	O
sequence	O
contains	O
an	O
N	O
-	O
terminal	O
myristoylation	O
motif	O
;	O
the	O
putative	O
modification	O
site	O
was	O
eliminated	O
by	O
construction	O
of	O
a	O
G2A	O
HMGCLL1	O
.	O

Modification	O
of	O
both	O
proteins	O
was	O
attempted	O
using	O
human	O
N	O
-	O
myristoyltransferase	O
and	O
[	O
(	O
3	O
)	O
H	O
]	O
myristoyl	O
-	O
CoA	O
.	O

Wild	O
-	O
type	O
protein	O
was	O
clearly	O
modified	O
,	O
whereas	O
G2A	O
protein	O
was	O
not	O
labeled	O
.	O

Myristoylation	O
of	O
HMGCLL1	O
affects	O
its	O
cellular	O
localization	O
.	O

Upon	O
transfection	O
of	O
appropriate	O
expression	O
plasmids	O
into	O
COS1	O
cells	O
,	O
immunofluorescence	O
detection	O
indicates	O
that	O
G2A	O
HMGCLL1	O
exhibits	O
a	O
diffuse	O
pattern	O
,	O
suggesting	O
a	O
cytosolic	O
location	O
.	O

In	O
contrast	O
,	O
wild	O
-	O
type	O
HMGCLL1	O
exhibits	O
a	O
punctate	O
as	O
well	O
as	O
a	O
perinuclear	O
immunostaining	O
pattern	O
,	O
indicating	O
myristoylation	O
dependent	O
association	O
with	O
nonmitochondrial	O
membrane	O
compartments	O
.	O

In	O
control	O
experiments	O
with	O
the	O
HMGCL	O
expression	O
plasmid	O
,	O
protein	O
is	O
localized	O
in	O
the	O
mitochondria	O
,	O
as	O
anticipated	O
.	O

The	O
available	O
results	O
for	O
COS1	O
cell	O
expression	O
,	O
as	O
well	O
as	O
endogenous	O
expression	O
in	O
U87	O
cells	O
,	O
indicate	O
that	O
HMGCLL1	O
is	O
an	O
extramitochondrial	O
hydroxymethylglutaryl	O
-	O
CoA	O
lyase	O
.	O

To	O
identify	O
the	O
putative	O
interacting	O
protein	O
,	O
we	O
used	O
an	O
unbiased	O
forward	O
genetic	O
strategy	O
and	O
discovered	O
SOL	O
-	O
2	O
,	O
a	O
CUB	O
-	O
domain	O
transmembrane	O
protein	O
that	O
is	O
the	O
homologue	O
of	O
the	O
vertebrate	O
Neto	O
proteins	O
,	O
with	O
2	O
CUB	O
-	O
domains	O
and	O
a	O
LDLa	O
-	O
domain	O
.	O

As	O
predicted	O
,	O
we	O
found	O
that	O
s	O
-	O
SOL	O
-	O
1	O
function	O
was	O
dependent	O
on	O
SOL	O
-	O
2	O
and	O
that	O
SOL	O
-	O
2	O
associates	O
with	O
the	O
GLR	O
-	O
1	O
signaling	O
complex	O
.	O

We	O
show	O
that	O
surface	O
delivery	O
of	O
GLR	O
-	O
1	O
and	O
SOL	O
-	O
1	O
occurs	O
in	O
the	O
absence	O
of	O
SOL	O
-	O
2	O
;	O
however	O
,	O
the	O
stability	O
or	O
function	O
of	O
the	O
complex	O
appears	O
compromised	O
in	O
sol	O
-	O
2	O
mutants	O
.	O

In	O
sol	O
-	O
1	O
mutants	O
,	O
the	O
remaining	O
components	O
of	O
the	O
GLR	O
-	O
1	O
complex	O
are	O
also	O
delivered	O
to	O
the	O
postsynaptic	O
membrane	O
,	O
indicating	O
that	O
SOL	O
-	O
1	O
does	O
not	O
have	O
an	O
essential	O
role	O
in	O
assembly	O
or	O
trafficking	O
of	O
the	O
signaling	O
complex	O
.	O

We	O
demonstrate	O
that	O
GLR	O
-	O
1	O
-	O
mediated	O
currents	O
depend	O
on	O
both	O
SOL	O
-	O
1	O
and	O
SOL	O
-	O
2	O
,	O
and	O
that	O
currents	O
in	O
sol	O
-	O
1	O
and	O
sol	O
-	O
2	O
mutants	O
can	O
be	O
rescued	O
in	O
adults	O
,	O
thus	O
demonstrating	O
an	O
ongoing	O
role	O
for	O
these	O
CUB	O
-	O
domain	O
proteins	O
in	O
synaptic	O
transmission	O
.	O

The	O
NDP52	O
CLIR	O
was	O
disordered	O
in	O
crystals	O
of	O
apo	O
-	O
NDP52	O
but	O
became	O
structured	O
in	O
the	O
2	O
.	O
5	O
Aa	O
complex	O
structure	O
of	O
NDP52	O
bound	O
to	O
LC3C	O
(	O
Figure	O
4B	O
)	O
.	O

Similar	O
to	O
other	O
LC3	O
-	O
LIR	O
complexes	O
and	O
to	O
SUMO	O
-	O
SIM	O
interactions	O
,	O
the	O
CLIR	O
forms	O
a	O
short	O
beta	O
strand	O
(	O
Figure	O
4B	O
)	O
that	O
fits	O
into	O
the	O
canonical	O
,	O
hydrophobic	O
LIR	O
binding	O
groove	O
of	O
LC3C	O
(	O
Figures	O
4C	O
and	O
4D	O
)	O
.	O

As	O
expected	O
from	O
the	O
NMR	O
data	O
and	O
mutational	O
analysis	O
(	O
Figure	O
3	O
)	O
,	O
the	O
interaction	O
is	O
driven	O
by	O
extensive	O
hydrophobic	O
interactions	O
of	O
Leu134	O
,	O
Val135	O
,	O
and	O
Val136	O
.	O

We	O
also	O
wanted	O
to	O
determine	O
if	O
the	O
interaction	O
with	O
ABI	O
-	O
1	O
is	O
isoform	O
specific	O
with	O
respect	O
to	O
MIG	O
-	O
10	O
.	O

As	O
described	O
previously	O
,	O
the	O
three	O
predicted	O
splice	O
variants	O
of	O
mig	O
-	O
10	O
encode	O
isoforms	O
that	O
differ	O
only	O
in	O
their	O
N	O
-	O
termini	O
(	O
Fig	O
.	O
1	O
)	O
.	O

In	O
particular	O
,	O
the	O
N	O
-	O
terminus	O
of	O
MIG	O
-	O
10A	O
contains	O
a	O
proline	O
-	O
rich	O
region	O
with	O
a	O
putative	O
SH3	O
binding	O
site	O
that	O
is	O
missing	O
in	O
MIG	O
-	O
10B	O
,	O
the	O
smallest	O
isoform	O
.	O

MIG	O
-	O
10B	O
:	O
V5	O
also	O
co	O
-	O
immunoprecipitated	O
with	O
wild	O
type	O
ABI	O
-	O
1	O
:	O
GFP	O
(	O
Fig	O
.	O
2E	O
)	O
,	O
demonstrating	O
that	O
both	O
isoforms	O
are	O
capable	O
of	O
interaction	O
with	O
ABI	O
-	O
1	O
,	O
and	O
suggesting	O
that	O
the	O
N	O
-	O
termini	O
of	O
the	O
MIG	O
-	O
10	O
isoforms	O
are	O
not	O
essential	O
to	O
the	O
interaction	O
.	O

Domain	O
organization	O
of	O
Drosophila	O
melanogaster	O
GW182	O
,	O
Hs	O
TNRC6C	O
and	O
the	O
corresponding	O
chimeric	O
proteins	O
.	O

ABD	O
,	O
AGO	O
-	O
binding	O
domain	O
;	O
ABD2	O
,	O
AGO	O
-	O
binding	O
domain	O
from	O
Caenorhabditis	O
elegans	O
AIN	O
-	O
2	O
;	O
NED	O
,	O
N	O
-	O
terminal	O
effector	O
domain	O
;	O
UBA	O
,	O
ubiquitin	O
associated	O
-	O
like	O
domain	O
;	O
QQQ	O
,	O
region	O
rich	O
in	O
glutamine	O
;	O
Mid	O
,	O
middle	O
region	O
containing	O
the	O
PAM2	O
motif	O
(	O
dark	O
blue	O
)	O
,	O
which	O
divides	O
the	O
Mid	O
region	O
into	O
the	O
M1	O
and	O
M2	O
regions	O
;	O
RRM	O
,	O
RNA	O
recognition	O
motif	O
;	O
C	O
-	O
term	O
,	O
C	O
-	O
terminal	O
region	O
;	O
SD	O
,	O
silencing	O
domain	O
.	O

The	O
position	O
of	O
the	O
conserved	O
CIM	O
-	O
1	O
,	O
CIM	O
-	O
2	O
and	O
P	O
-	O
GL	O
motifs	O
are	O
indicated	O
.	O

Amino	O
acid	O
positions	O
at	O
domain	O
boundaries	O
are	O
indicated	O
below	O
the	O
protein	O
outlines	O
.	O

Vertical	O
red	O
lines	O
indicate	O
the	O
positions	O
of	O
GW	O
repeats	O
.	O

Vertical	O
green	O
lines	O
indicate	O
the	O
positions	O
of	O
tryptophan	O
residues	O
in	O
the	O
M2	O
region	O
that	O
are	O
involved	O
in	O
NOT1	O
-	O
binding	O
.	O

Sequence	O
alignments	O
of	O
the	O
PAM2	O
,	O
CIM	O
-	O
1	O
,	O
CIM	O
-	O
2	O
and	O
P	O
-	O
GL	O
motifs	O
and	O
the	O
amino	O
acids	O
mutated	O
in	O
this	O
study	O
are	O
shown	O
in	O
Supplementary	O
Figure	O
S7	O
.	O

Novel	O
interactions	O
between	O
FOXM1	O
and	O
CDC25A	O
regulate	O
the	O
cell	O
cycle	O
.	O

FOXM1	O
is	O
a	O
critical	O
regulator	O
of	O
the	O
G1	O
/	O
S	O
and	O
G2	O
/	O
M	O
cell	O
cycle	O
transitions	O
,	O
as	O
well	O
as	O
of	O
the	O
mitotic	O
spindle	O
assembly	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
FOXM1	O
regulates	O
CDC25A	O
gene	O
transcription	O
,	O
but	O
the	O
mechanism	O
remains	O
unknown	O
.	O

Here	O
,	O
we	O
provide	O
evidence	O
that	O
FOXM1	O
directly	O
regulates	O
CDC25A	O
gene	O
transcription	O
via	O
direct	O
promoter	O
binding	O
and	O
indirect	O
activation	O
of	O
E2F	O
-	O
dependent	O
pathways	O
.	O

Prior	O
literature	O
reported	O
that	O
CDC25B	O
and	O
CDC25C	O
activate	O
CDK1	O
/	O
cyclinB	O
complexes	O
in	O
order	O
to	O
enable	O
phosphorylation	O
of	O
FOXM1	O
.	O

It	O
was	O
unknown	O
if	O
CDC25A	O
functions	O
in	O
a	O
similar	O
manner	O
.	O

We	O
report	O
that	O
FOXM1	O
transcriptional	O
activity	O
is	O
synergistically	O
enhanced	O
when	O
co	O
-	O
expressed	O
with	O
CDC25A	O
.	O

The	O
increase	O
is	O
dependent	O
upon	O
CDK1	O
phosphorylation	O
of	O
FOXM1	O
at	O
T600	O
,	O
T611	O
and	O
T620	O
residues	O
.	O

We	O
also	O
report	O
a	O
novel	O
protein	O
interaction	O
between	O
FOXM1	O
and	O
CDC25A	O
via	O
the	O
C	O
-	O
terminus	O
of	O
FOXM1	O
.	O

We	O
demonstrate	O
that	O
the	O
phosphorylation	O
of	O
Thr	O
600	O
and	O
Thr	O
611	O
residues	O
of	O
FOXM1	O
enhanced	O
this	O
interaction	O
,	O
and	O
that	O
the	O
interaction	O
is	O
dependent	O
upon	O
CDC25A	O
phosphatase	O
activity	O
.	O

Our	O
work	O
provides	O
novel	O
insight	O
into	O
the	O
underlying	O
mechanisms	O
by	O
which	O
FOXM1	O
controls	O
the	O
cell	O
cycle	O
through	O
its	O
association	O
with	O
CDC25A	O
.	O

The	O
Newton	O
-	O
Raphson	O
algorithm	O
(	O
Equation	O
9	O
)	O
uses	O
known	O
values	O
of	O
PT	O
(	O
i	O
)	O
,	O
FPAT	O
(	O
i	O
)	O
and	O
RT	O
(	O
i	O
)	O
and	O
chosen	O
values	O
of	O
Ka1	O
and	O
Ka2	O
where	O
iterations	O
(	O
i	O
)	O
proceed	O
to	O
convergence	O
where	O
F1	O
=	O
F2	O
=	O
0	O
.	O
where	O
V	O
is	O
a	O
column	O
vector	O
with	O
rows	O
P	O
and	O
FPA	O
,	O
and	O
F	O
is	O
a	O
column	O
vector	O
with	O
rows	O
F1	O
and	O
F2	O
.	O

We	O
next	O
followed	O
the	O
vesicular	O
movement	O
of	O
full	O
-	O
length	O
Serp	O
-	O
GFP	O
,	O
and	O
found	O
that	O
it	O
was	O
associated	O
with	O
the	O
Rab9	O
-	O
positive	O
endosomal	O
membrane	O
,	O
and	O
some	O
of	O
the	O
Serp	O
-	O
GFP	O
was	O
concentrated	O
at	O
the	O
Rab9	O
-	O
enriched	O
domains	O
(	O
white	O
arrowheads	O
in	O
Fig	O
.	O
5f	O
)	O
.	O

Importantly	O
,	O
the	O
Serp	O
puncta	O
colocalized	O
with	O
small	O
GFP	O
-	O
Rab9	O
vesicles	O
that	O
were	O
budding	O
from	O
larger	O
endosomes	O
(	O
blue	O
arrowheads	O
in	O
Fig	O
.	O
5f	O
)	O
.	O

In	O
Arabidopsis	O
,	O
CBL1	O
is	O
activated	O
by	O
various	O
abiotic	O
stresses	O
and	O
functions	O
as	O
a	O
positive	O
regulator	O
in	O
salt	O
or	O
drought	O
stress	O
responses	O
.	O

It	O
was	O
also	O
described	O
as	O
a	O
negative	O
regulator	O
of	O
cold	O
response	O
.	O

By	O
contrast	O
,	O
VDAC1	O
was	O
stable	O
under	O
salt	O
,	O
cold	O
or	O
drought	O
stresses	O
in	O
Arabidopsis	O
during	O
24	O
h	O
detected	O
by	O
semi	O
-	O
quantitative	O
RT	O
-	O
PCR	O
,	O
whereas	O
its	O
expression	O
was	O
enhanced	O
in	O
mature	O
plants	O
after	O
48	O
h	O
under	O
cold	O
stress	O
examined	O
by	O
real	O
-	O
time	O
PCR	O
method	O
(	O
Figure	O
1b	O
)	O
,	O
indicating	O
a	O
possible	O
role	O
in	O
cold	O
stress	O
response	O
.	O

Overexpression	O
of	O
VDAC1	O
reduced	O
freezing	O
tolerance	O
,	O
whereas	O
vdac1	O
mutant	O
plants	O
showed	O
superior	O
performance	O
to	O
WT	O
under	O
freezing	O
stress	O
,	O
suggesting	O
that	O
VDAC1	O
functions	O
as	O
a	O
negative	O
regulator	O
in	O
cold	O
stress	O
response	O
.	O

This	O
is	O
consistent	O
with	O
the	O
role	O
of	O
CBL1	O
in	O
cold	O
stress	O
response	O
.	O

CBL1	O
was	O
shown	O
to	O
alter	O
the	O
expression	O
of	O
a	O
series	O
of	O
cold	O
-	O
induced	O
genes	O
when	O
subjected	O
to	O
cold	O
stress	O
.	O

To	O
test	O
if	O
VDAC1	O
and	O
CBL1	O
could	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
a	O
common	O
set	O
of	O
genes	O
,	O
the	O
expression	O
of	O
genes	O
found	O
to	O
be	O
altered	O
by	O
CBL1	O
under	O
cold	O
treatment	O
were	O
quantified	O
in	O
VDAC1	O
overexpressing	O
and	O
vdac1	O
mutant	O
lines	O
.	O

Among	O
these	O
genes	O
,	O
the	O
expression	O
of	O
DREB1A	O
,	O
a	O
gene	O
specifically	O
responsive	O
to	O
cold	O
,	O
was	O
inhibited	O
in	O
VDAC1	O
-	O
overexpressing	O
plants	O
,	O
suggesting	O
that	O
VDAC1	O
overexpression	O
exerted	O
negative	O
regulation	O
on	O
DREB1A	O
.	O

On	O
the	O
contrary	O
,	O
DREB1A	O
was	O
highly	O
induced	O
in	O
vdac1	O
mutant	O
plants	O
(	O
Figure	O
2f	O
)	O
.	O

These	O
results	O
indicate	O
that	O
VDAC1	O
and	O
CBL1	O
have	O
similar	O
effects	O
on	O
the	O
expression	O
of	O
DREB1A	O
.	O

The	O
vdac1	O
mutant	O
also	O
showed	O
superior	O
performance	O
during	O
seed	O
germination	O
under	O
low	O
temperature	O
,	O
and	O
the	O
phenotypes	O
observed	O
for	O
cbl1	O
resembled	O
those	O
of	O
vdac1	O
(	O
Figure	O
4c	O
)	O
.	O

To	O
determine	O
if	O
the	O
visual	O
phenotypes	O
of	O
the	O
mutants	O
at	O
4	O
degreesC	O
were	O
due	O
to	O
quicker	O
germination	O
,	O
but	O
not	O
faster	O
growth	O
,	O
seeds	O
were	O
germinated	O
at	O
22	O
degreesC	O
for	O
two	O
days	O
before	O
being	O
transferred	O
to	O
4	O
degreesC	O
.	O

The	O
mutants	O
did	O
not	O
present	O
any	O
obvious	O
morphological	O
differences	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
results	O
demonstrated	O
that	O
both	O
VDAC1	O
and	O
CBL1	O
function	O
during	O
seed	O
germination	O
at	O
low	O
temperature	O
,	O
suggesting	O
a	O
biological	O
relevance	O
of	O
the	O
two	O
genes	O
.	O

Cohesin	B-Complex
is	O
highly	O
enriched	O
throughout	O
the	O
pericentromere	O
,	O
yet	O
the	O
Scc2	O
/	O
4	O
cohesin	B-Complex
loader	O
shows	O
strong	O
enrichment	O
only	O
within	O
the	O
core	O
~	O
125	O
bp	O
centromere	O
(	O
see	O
Figures	O
S1A	O
and	O
S1B	O
available	O
online	O
)	O
.	O

Enrichment	O
of	O
Scc2	O
at	O
centromeres	O
,	O
but	O
not	O
at	O
a	O
control	O
tRNA	O
site	O
,	O
requires	O
Ctf19	B-OOS
complex	O
components	O
(	O
Figures	O
S1C	O
and	O
S1D	O
)	O
.	O

Scc2	O
turns	O
over	O
rapidly	O
near	O
kinetochores	O
and	O
does	O
not	O
stably	O
associate	O
with	O
the	O
Ctf19	B-OOS
complex	O
(	O
Figures	O
S1E	O
,	O
S1F	O
,	O
and	O
Table	O
S3	O
)	O
.	O

Even	O
when	O
the	O
Ctf19	B-OOS
complex	O
was	O
purified	O
from	O
cells	O
producing	O
a	O
version	O
of	O
Smc3	O
(	O
Smc3E1155Q	O
)	O
blocked	O
at	O
an	O
early	O
step	O
in	O
cohesin	B-Complex
loading	O
,	O
virtually	O
the	O
entire	O
kinetochore	O
,	O
yet	O
only	O
very	O
few	O
peptides	O
of	O
cohesin	B-Complex
and	O
its	O
loader	O
,	O
were	O
recovered	O
(	O
Figure	O
S1E	O
and	O
Table	O
S3	O
)	O
.	O

These	O
data	O
suggest	O
that	O
the	O
Ctf19	B-OOS
complex	O
promotes	O
cohesin	B-Complex
enrichment	O
throughout	O
the	O
pericentromere	O
by	O
enabling	O
the	O
transient	O
association	O
of	O
the	O
Scc2	O
/	O
4	O
cohesin	B-Complex
loader	O
with	O
centromeres	O
.	O

The	O
association	O
of	O
BAG6	O
with	O
SGTA	O
and	O
tail	O
-	O
anchored	O
proteins	O
.	O

The	O
BAG6	O
protein	O
is	O
a	O
subunit	O
of	O
a	O
heterotrimeric	O
complex	O
that	O
binds	O
a	O
range	O
of	O
membrane	O
and	O
secretory	O
protein	O
precursors	O
localized	O
to	O
the	O
cytosol	O
,	O
enforcing	O
quality	O
control	O
and	O
influencing	O
their	O
subsequent	O
fate	O
.	O

BAG6	O
has	O
an	O
N	O
-	O
terminal	O
ubiquitin	O
-	O
like	O
domain	O
,	O
and	O
a	O
C	O
-	O
terminal	O
Bcl	O
-	O
2	O
-	O
associated	O
athanogene	O
domain	O
,	O
separated	O
by	O
a	O
large	O
central	O
proline	O
-	O
rich	O
region	O
.	O

We	O
have	O
used	O
in	O
vitro	O
binding	O
approaches	O
to	O
identify	O
regions	O
of	O
BAG6	O
important	O
for	O
its	O
interactions	O
with	O
:	O
i	O
)	O
the	O
small	O
-	O
glutamine	O
rich	O
tetratricopeptide	O
repeat	O
-	O
containing	O
protein	O
alpha	O
(	O
SGTA	O
)	O
and	O
ii	O
)	O
two	O
model	O
tail	O
-	O
anchored	O
membrane	O
proteins	O
as	O
a	O
paradigm	O
for	O
its	O
hydrophobic	O
substrates	O
.	O

We	O
show	O
that	O
the	O
BAG6	O
-	O
UBL	O
is	O
essential	O
for	O
binding	O
to	O
SGTA	O
,	O
and	O
find	O
that	O
the	O
UBL	O
of	O
a	O
second	O
subunit	O
of	O
the	O
BAG6	O
-	O
complex	O
,	O
ubiquitin	O
-	O
like	O
protein	O
4A	O
(	O
UBL4A	O
)	O
,	O
competes	O
for	O
SGTA	O
binding	O
.	O

Our	O
data	O
show	O
that	O
this	O
binding	O
is	O
selective	O
,	O
and	O
suggest	O
that	O
SGTA	O
can	O
bind	O
either	O
BAG6	O
,	O
or	O
UBL4A	O
,	O
but	O
not	O
both	O
at	O
the	O
same	O
time	O
.	O

We	O
adapted	O
our	O
in	O
vitro	O
binding	O
assay	O
to	O
study	O
the	O
association	O
of	O
BAG6	O
with	O
an	O
immobilized	O
tail	O
-	O
anchored	O
protein	O
,	O
Sec61Beta	O
,	O
and	O
find	O
both	O
the	O
UBL	O
and	O
BAG	O
domains	O
are	O
dispensable	O
for	O
binding	O
this	O
substrate	O
.	O

This	O
conclusion	O
was	O
further	O
supported	O
using	O
a	O
heterologous	O
subcellular	O
localization	O
assay	O
in	O
yeast	O
,	O
where	O
the	O
BAG6	O
-	O
dependent	O
nuclear	O
relocalization	O
of	O
a	O
second	O
tail	O
-	O
anchored	O
protein	O
,	O
GFP	O
-	O
Sed5	O
,	O
also	O
required	O
neither	O
the	O
UBL	O
,	O
nor	O
the	O
BAG	O
domain	O
of	O
BAG6	O
.	O

On	O
the	O
basis	O
of	O
these	O
findings	O
,	O
we	O
propose	O
a	O
working	O
model	O
where	O
the	O
large	O
central	O
region	O
of	O
the	O
BAG6	O
protein	O
provides	O
a	O
binding	O
site	O
for	O
a	O
diverse	O
group	O
of	O
substrates	O
,	O
many	O
of	O
which	O
expose	O
a	O
hydrophobic	O
stretch	O
of	O
polypeptide	O
.	O

This	O
arrangement	O
would	O
enable	O
the	O
BAG6	O
complex	O
to	O
bring	O
together	O
its	O
substrates	O
with	O
potential	O
effectors	O
including	O
those	O
recruited	O
via	O
its	O
N	O
-	O
terminal	O
UBL	O
.	O

Such	O
effectors	O
may	O
include	O
SGTA	O
,	O
and	O
the	O
resulting	O
assemblies	O
influence	O
the	O
subsequent	O
fate	O
of	O
the	O
hydrophobic	O
BAG6	O
substrates	O
.	O

The	O
p21	O
-	O
activated	O
kinase	O
Mbt	O
is	O
a	O
component	O
of	O
the	O
apical	O
protein	O
complex	O
in	O
central	O
brain	O
neuroblasts	O
and	O
controls	O
cell	O
proliferation	O
.	O

The	O
final	O
size	O
of	O
the	O
central	O
nervous	O
system	O
is	O
determined	O
by	O
precisely	O
controlled	O
generation	O
,	O
proliferation	O
and	O
death	O
of	O
neural	O
stem	O
cells	O
.	O

We	O
show	O
here	O
that	O
the	O
Drosophila	O
PAK	O
protein	O
Mushroom	O
bodies	O
tiny	O
(	O
Mbt	O
)	O
is	O
expressed	O
in	O
central	O
brain	O
progenitor	O
cells	O
(	O
neuroblasts	O
)	O
and	O
becomes	O
enriched	O
to	O
the	O
apical	O
cortex	O
of	O
neuroblasts	O
in	O
a	O
cell	O
cycle	O
-	O
and	O
Cdc42	O
-	O
dependent	O
manner	O
.	O

Using	O
mushroom	O
body	O
neuroblasts	O
as	O
a	O
model	O
system	O
,	O
we	O
demonstrate	O
that	O
in	O
the	O
absence	O
of	O
Mbt	O
function	O
,	O
neuroblasts	O
and	O
their	O
progeny	O
are	O
correctly	O
specified	O
and	O
are	O
able	O
to	O
generate	O
different	O
neuron	O
subclasses	O
as	O
in	O
the	O
wild	O
type	O
,	O
but	O
are	O
impaired	O
in	O
their	O
proliferation	O
activity	O
throughout	O
development	O
.	O

In	O
general	O
,	O
loss	O
of	O
Mbt	O
function	O
does	O
not	O
interfere	O
with	O
establishment	O
or	O
maintenance	O
of	O
cell	O
polarity	O
,	O
orientation	O
of	O
the	O
mitotic	O
spindle	O
and	O
organization	O
of	O
the	O
actin	O
or	O
tubulin	O
cytoskeleton	O
in	O
central	O
brain	O
neuroblasts	O
.	O

However	O
,	O
we	O
show	O
that	O
mbt	O
mutant	O
neuroblasts	O
are	O
significantly	O
reduced	O
in	O
cell	O
size	O
during	O
different	O
stages	O
of	O
development	O
,	O
which	O
is	O
most	O
pronounced	O
for	O
mushroom	O
body	O
neuroblasts	O
.	O

This	O
phenotype	O
correlates	O
with	O
reduced	O
mitotic	O
activity	O
throughout	O
development	O
.	O

Additionally	O
,	O
postembryonic	O
neuroblasts	O
are	O
lost	O
prematurely	O
owing	O
to	O
apoptosis	O
.	O

Yet	O
,	O
preventing	O
apoptosis	O
did	O
not	O
rescue	O
the	O
loss	O
of	O
neurons	O
seen	O
in	O
the	O
adult	O
mushroom	O
body	O
of	O
mbt	O
mutants	O
.	O

From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
Mbt	O
is	O
part	O
of	O
a	O
regulatory	O
network	O
that	O
is	O
required	O
for	O
neuroblast	O
growth	O
and	O
thereby	O
allows	O
proper	O
proliferation	O
of	O
neuroblasts	O
throughout	O
development	O
.	O

With	O
the	O
discovery	O
of	O
the	O
diverse	O
functions	O
of	O
RNA	O
transcripts	O
,	O
increasing	O
interest	O
has	O
been	O
placed	O
upon	O
the	O
role	O
of	O
alternative	O
splicing	O
in	O
tumor	O
progression	O
.	O

Although	O
neoplastic	O
tissues	O
have	O
been	O
reported	O
to	O
display	O
a	O
perturbation	O
in	O
mRNA	O
isoform	O
expression	O
compared	O
to	O
matched	O
normal	O
tissues	O
,	O
the	O
precise	O
role	O
of	O
this	O
altered	O
transcriptome	O
and	O
splicing	O
pattern	O
in	O
tumorigenesis	O
remains	O
uncertain	O
.	O

Previously	O
,	O
it	O
was	O
shown	O
that	O
the	O
metastasis	O
suppressor	O
Nm23	O
-	O
H1	O
regulates	O
changes	O
in	O
the	O
expression	O
of	O
RNA	O
post	O
-	O
transcriptional	O
modification	O
proteins	O
,	O
including	O
Gemin5	O
,	O
a	O
component	O
of	O
the	O
spliceosome	B-Complex
.	O

Yet	O
,	O
a	O
direct	O
role	O
for	O
metastasis	O
modifiers	O
in	O
splicing	O
has	O
not	O
yet	O
been	O
reported	O
,	O
although	O
it	O
seems	O
that	O
many	O
factors	O
involved	O
in	O
splicing	O
have	O
a	O
variety	O
of	O
cellular	O
functions	O
.	O

Here	O
,	O
using	O
RNA	O
-	O
seq	O
in	O
combination	O
with	O
other	O
biochemical	O
methods	O
,	O
the	O
metastasis	O
modifier	O
RRP1B	O
has	O
been	O
demonstrated	O
to	O
directly	O
regulate	O
alternative	O
isoform	O
expression	O
.	O

This	O
suggests	O
that	O
alternative	O
splicing	O
,	O
and	O
the	O
diverse	O
isoforms	O
generated	O
from	O
that	O
process	O
,	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
various	O
factors	O
implicated	O
in	O
metastasis	O
.	O

While	O
HOT1	O
localizes	O
to	O
a	O
subset	O
of	O
telomeres	O
together	O
with	O
shelterin	B-Complex
components	O
,	O
our	O
HOT1	O
immunoprecipitation	O
experiments	O
failed	O
to	O
establish	O
any	O
putative	O
association	O
between	O
HOT1	O
and	O
shelterin	B-Complex
complex	O
members	O
.	O

Likewise	O
,	O
we	O
could	O
not	O
retrieve	O
HOT1	O
after	O
a	O
POT1	O
-	O
IP	O
,	O
which	O
is	O
in	O
agreement	O
with	O
several	O
other	O
studies	O
that	O
searched	O
for	O
shelterin	B-Complex
-	O
associated	O
factors	O
either	O
by	O
immunoprecipitation	O
or	O
by	O
bimolecular	O
fluorescence	O
complementation	O
.	O

Our	O
comparison	O
of	O
the	O
cocrystal	O
structures	O
of	O
telomeric	O
DNA	O
with	O
the	O
HOT1	O
,	O
TRF1	O
and	O
TRF2	O
homeodomains	O
indicates	O
that	O
while	O
HOT1	O
is	O
shifted	O
'	O
down	O
'	O
in	O
5	O
'	O
-	O
-	O
>	O
3	O
'	O
direction	O
by	O
one	O
base	O
towards	O
the	O
following	O
telomeric	O
repeat	O
,	O
the	O
binding	O
sites	O
are	O
largely	O
overlapping	O
.	O

Hence	O
,	O
it	O
is	O
intriguing	O
how	O
these	O
proteins	O
coexist	O
at	O
telomeres	O
,	O
how	O
they	O
compete	O
for	O
binding	O
sites	O
and	O
whether	O
the	O
shelterin	B-Complex
proteins	O
are	O
found	O
interspersed	O
on	O
telomeres	O
or	O
whether	O
there	O
are	O
discrete	O
,	O
mutually	O
exclusive	O
patches	O
along	O
the	O
telomeric	O
tracts	O
.	O

This	O
might	O
further	O
contribute	O
to	O
answering	O
the	O
question	O
how	O
HOT1	O
is	O
selectively	O
restricted	O
to	O
a	O
subset	O
of	O
telomeres	O
.	O

Synthesis	O
,	O
in	O
vitro	O
,	O
and	O
in	O
cell	O
studies	O
of	O
a	O
new	O
series	O
of	O
[	O
indoline	O
-	O
3	O
,	O
2	O
'	O
-	O
thiazolidine	O
]	O
-	O
based	O
p53	O
modulators	O
.	O

Analogues	O
of	O
the	O
previously	O
described	O
spiro	O
[	O
imidazo	O
[	O
1	O
,	O
5	O
-	O
c	O
]	O
thiazole	O
-	O
3	O
,	O
3	O
'	O
-	O
indoline	O
]	O
-	O
2	O
'	O
,	O
5	O
,	O
7	O
(	O
6H	O
,	O
7aH	O
)	O
-	O
trione	O
p53	O
modulators	O
were	O
prepared	O
to	O
explore	O
new	O
structural	O
requirements	O
at	O
the	O
thiazolidine	O
domain	O
for	O
the	O
antiproliferative	O
activity	O
and	O
p53	O
modulation	O
.	O

In	O
cell	O
,	O
antiproliferative	O
activity	O
was	O
evaluated	O
against	O
two	O
human	O
tumor	O
cell	O
lines	O
.	O

Derivative	O
5	O
-	O
bromo	O
-	O
3	O
'	O
-	O
(	O
cyclohexane	O
carbonyl	O
)	O
-	O
1	O
-	O
methyl	O
-	O
2	O
-	O
oxospiro	O
[	O
indoline	O
-	O
3	O
,	O
2	O
'	O
-	O
thiazolidine	O
]	O
(	O
4n	O
)	O
emerged	O
as	O
the	O
most	O
potent	O
compound	O
of	O
this	O
series	O
,	O
inhibiting	O
in	O
vitro	O
30	O
%	O
of	O
p53	O
-	O
MDM2	O
interaction	O
at	O
5	O
muM	O
and	O
the	O
cell	O
growth	O
of	O
different	O
human	O
tumor	O
cells	O
at	O
nanomolar	O
concentrations	O
.	O

Docking	O
studies	O
confirmed	O
the	O
interactions	O
of	O
4n	O
with	O
the	O
well	O
-	O
known	O
Trp23	O
and	O
Phe19	O
clefts	O
,	O
explaining	O
the	O
reasons	O
for	O
its	O
binding	O
affinity	O
for	O
MDM2	O
.	O

4n	O
at	O
50	O
nM	O
is	O
capable	O
of	O
inducing	O
the	O
accumulation	O
of	O
p53	O
protein	O
,	O
inducing	O
significant	O
apoptotic	O
cell	O
death	O
without	O
affecting	O
the	O
cell	O
cycle	O
progression	O
.	O

Comparative	O
studies	O
using	O
nutlin	O
in	O
the	O
same	O
cellular	O
system	O
confirm	O
the	O
potential	O
of	O
4n	O
as	O
a	O
tool	O
for	O
increasing	O
understanding	O
of	O
the	O
process	O
involved	O
in	O
the	O
nontranscriptional	O
proapoptotic	O
activities	O
of	O
p53	O
.	O

Negative	O
regulation	O
of	O
RIG	O
-	O
I	O
-	O
mediated	O
antiviral	O
signaling	O
by	O
TRK	O
-	O
fused	O
gene	O
(	O
TFG	O
)	O
protein	O
.	O

RIG	O
-	O
I	O
(	O
retinoic	O
acid	O
inducible	O
gene	O
I	O
)	O
-	O
mediated	O
antiviral	O
signaling	O
serves	O
as	O
the	O
first	O
line	O
of	O
defense	O
against	O
viral	O
infection	O
.	O

Upon	O
detection	O
of	O
viral	O
RNA	O
,	O
RIG	O
-	O
I	O
undergoes	O
TRIM25	O
(	O
tripartite	O
motif	O
protein	O
25	O
)	O
-	O
mediated	O
K63	O
-	O
linked	O
ubiquitination	O
,	O
leading	O
to	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
production	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
TRK	O
-	O
fused	O
gene	O
(	O
TFG	O
)	O
protein	O
,	O
previously	O
identified	O
as	O
a	O
TRIM25	O
-	O
interacting	O
protein	O
,	O
binds	O
TRIM25	O
upon	O
virus	O
infection	O
and	O
negatively	O
regulates	O
RIG	O
-	O
I	O
-	O
mediated	O
type	O
-	O
I	O
IFN	O
signaling	O
.	O

RIG	O
-	O
I	O
-	O
mediated	O
IFN	O
production	O
and	O
nuclear	B-Complex
factor	I-Complex
(	I-Complex
NF	I-Complex
)	I-Complex
-	I-Complex
kappaB	I-Complex
signaling	O
pathways	O
were	O
upregulated	O
by	O
the	O
suppression	O
of	O
TFG	O
expression	O
.	O

Furthermore	O
,	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
replication	O
was	O
significantly	O
inhibited	O
by	O
small	O
inhibitory	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
-	O
mediated	O
knockdown	O
of	O
TFG	O
,	O
supporting	O
the	O
suppressive	O
role	O
of	O
TFG	O
in	O
RIG	O
-	O
I	O
-	O
mediated	O
antiviral	O
signaling	O
.	O

Interestingly	O
,	O
suppression	O
of	O
TFG	O
expression	O
increased	O
not	O
only	O
RIG	O
-	O
I	O
-	O
mediated	O
signaling	O
but	O
also	O
MAVS	O
(	O
mitochondrial	O
antiviral	O
signaling	O
protein	O
)	O
-	O
induced	O
signaling	O
,	O
suggesting	O
that	O
TFG	O
plays	O
a	O
pivotal	O
role	O
in	O
negative	O
regulation	O
of	O
RNA	O
-	O
sensing	O
,	O
RIG	O
-	O
I	O
-	O
like	O
receptor	O
(	O
RLR	O
)	O
family	O
signaling	O
pathways	O
.	O

The	O
Vps33	O
family	O
of	O
SM	O
proteins	O
,	O
unlike	O
the	O
Sec1	O
/	O
Munc18	O
,	O
Sly1	O
,	O
and	O
Vps45	O
families	O
,	O
does	O
not	O
appear	O
to	O
interact	O
with	O
the	O
N	O
-	O
peptides	O
of	O
Qa	O
-	O
SNAREs	O
.	O

The	O
structural	O
basis	O
for	O
this	O
key	O
distinction	O
among	O
SM	O
protein	O
families	O
can	O
be	O
understood	O
by	O
superimposing	O
domain	O
1	O
of	O
Vps33	O
upon	O
that	O
of	O
other	O
,	O
N	O
-	O
peptide	O
-	O
binding	O
SM	O
proteins	O
.	O

This	O
analysis	O
reveals	O
that	O
the	O
binding	O
site	O
normally	O
occupied	O
by	O
the	O
N	O
-	O
peptide	O
'	O
s	O
conserved	O
Arg	O
side	O
chain	O
(	O
Fig	O
.	O
5A	O
)	O
is	O
,	O
uniquely	O
in	O
the	O
case	O
of	O
Vps33	O
,	O
filled	O
by	O
Arg	O
-	O
115	O
of	O
the	O
SM	O
protein	O
itself	O
(	O
Fig	O
.	O
5B	O
)	O
.	O

The	O
positioning	O
of	O
the	O
Arg	O
-	O
115	O
side	O
chain	O
is	O
reinforced	O
by	O
a	O
salt	O
-	O
bridge	O
formed	O
with	O
Asp	O
-	O
120	O
.	O

Also	O
blocked	O
-	O
and	O
only	O
in	O
Vps33	O
-	O
is	O
the	O
pocket	O
that	O
normally	O
accommodates	O
a	O
conserved	O
hydrophobic	O
residue	O
located	O
four	O
residues	O
C	O
-	O
terminal	O
to	O
the	O
N	O
-	O
peptide	O
Arg	O
residue	O
(	O
Fig	O
.	O
5C	O
,	O
D	O
)	O
.	O

In	O
this	O
case	O
a	O
displacement	O
of	O
the	O
Vps33	O
backbone	O
,	O
relative	O
to	O
other	O
SM	O
proteins	O
,	O
causes	O
the	O
side	O
chain	O
of	O
Leu	O
-	O
129	O
to	O
occupy	O
the	O
binding	O
pocket	O
.	O

Thus	O
,	O
both	O
of	O
the	O
pockets	O
that	O
in	O
other	O
SM	O
proteins	O
accommodate	O
conserved	O
Qa	O
-	O
SNARE	O
N	O
-	O
peptide	O
residues	O
are	O
missing	O
in	O
Vps33	O
.	O

Likewise	O
,	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
relevant	O
Qa	O
-	O
SNARE	O
Vam3	O
lacks	O
the	O
sequence	O
determinants	O
-	O
including	O
the	O
conserved	O
Arg	O
-	O
found	O
in	O
the	O
N	O
-	O
peptides	O
of	O
the	O
Qa	O
-	O
SNAREs	O
that	O
bind	O
SM	O
proteins	O
.	O

Chondrosarcoma	O
(	O
CS	O
)	O
is	O
the	O
second	O
most	O
common	O
primary	O
malignant	O
bone	O
tumour	O
.	O

When	O
such	O
tumours	O
arise	O
as	O
solitary	O
lesions	O
in	O
the	O
medullary	O
cavity	O
(	O
central	O
CS	O
)	O
or	O
more	O
rarely	O
in	O
the	O
periosteum	O
,	O
~	O
50	O
%	O
harbour	O
either	O
a	O
somatic	O
IDH1	O
(	O
isocitrate	O
dehydrogenase	O
1	O
)	O
or	O
IDH2	O
heterozygous	O
mutation	O
.	O

In	O
a	O
minority	O
of	O
individuals	O
,	O
these	O
tumours	O
are	O
multiple	O
,	O
and	O
affected	O
individuals	O
are	O
at	O
risk	O
of	O
developing	O
other	O
neoplasms	O
,	O
including	O
spindle	O
cell	O
haemangiomas	O
,	O
and	O
high	O
-	O
grade	O
gliomas	O
/	O
secondary	O
glioblastomas	O
,	O
among	O
others	O
.	O

In	O
this	O
setting	O
,	O
the	O
mosaic	O
distribution	O
of	O
tumours	O
is	O
caused	O
by	O
somatic	O
early	O
post	O
-	O
zygotic	O
mutations	O
of	O
IDH1	O
and	O
IDH2	O
(	O
ref	O
.	O
)	O
.	O

The	O
same	O
mutations	O
have	O
been	O
previously	O
identified	O
in	O
~	O
70	O
%	O
of	O
sporadic	O
high	O
-	O
grade	O
gliomas	O
and	O
secondary	O
glioblastomas	O
,	O
~	O
10	O
%	O
of	O
acute	O
myeloid	O
leukemias	O
(	O
AMLs	O
)	O
and	O
cholangiocarcinomas	O
(	O
CCs	O
)	O
,	O
and	O
much	O
less	O
commonly	O
in	O
other	O
neoplasms	O
.	O

The	O
mutant	O
(	O
mt	O
)	O
IDH	O
enzyme	O
catalyses	O
the	O
reduction	O
of	O
alpha	O
-	O
ketoglutarate	O
(	O
alpha	O
-	O
KG	O
)	O
to	O
D	O
-	O
2	O
-	O
hydroxyglutarate	O
(	O
2	O
-	O
HG	O
)	O
,	O
an	O
oncometabolite	O
affecting	O
the	O
activity	O
of	O
alpha	O
-	O
KG	O
-	O
dependent	O
dioxygenases	O
:	O
these	O
events	O
affect	O
a	O
number	O
of	O
cellular	O
responses	O
,	O
and	O
have	O
been	O
shown	O
to	O
induce	O
CpG	O
island	O
DNA	O
hypermethylation	O
in	O
low	O
-	O
grade	O
gliomas	O
(	O
LGGs	O
)	O
,	O
CCs	O
and	O
AMLs	O
harbouring	O
IDH1	O
and	O
IDH2	O
mutations	O
.	O

The	O
TET	O
dioxygenases	O
are	O
responsible	O
for	O
the	O
conversion	O
of	O
5	O
-	O
methylcytosine	O
to	O
5	O
-	O
hydroxymethylcytosine	O
(	O
5hmC	O
)	O
,	O
an	O
intermediate	O
metabolite	O
in	O
the	O
recently	O
discovered	O
active	O
demethylation	O
pathway	O
,	O
and	O
it	O
is	O
possible	O
that	O
mt	O
IDH1	O
enzyme	O
mediates	O
the	O
observed	O
hypermethylation	O
phenotype	O
through	O
inhibition	O
of	O
TET	O
by	O
2	O
-	O
HG	O
.	O

To	O
screen	O
for	O
correct	O
formation	O
and	O
localization	O
of	O
the	O
septum	O
,	O
we	O
stained	O
the	O
cells	O
with	O
Calcofluor	O
,	O
together	O
with	O
DAPI	O
to	O
visualize	O
the	O
nuclei	O
.	O

Figure	O
3D	O
shows	O
the	O
fraction	O
of	O
normally	O
dividing	O
,	O
septated	O
cells	O
with	O
normal	O
septa	O
at	O
25degreesC	O
(	O
t	O
=	O
0	O
)	O
,	O
and	O
at	O
times	O
after	O
transfer	O
to	O
the	O
restrictive	O
temperature	O
for	O
overexpression	O
of	O
three	O
of	O
the	O
mutants	O
.	O

At	O
t	O
=	O
0	O
nearly	O
all	O
septa	O
were	O
normal	O
.	O

After	O
4	O
hours	O
,	O
~	O
30	O
%	O
of	O
the	O
cells	O
with	O
'	O
vector	O
only	O
'	O
had	O
normal	O
septa	O
.	O

In	O
cells	O
over	O
-	O
expressing	O
wildtype	O
or	O
mutant	O
Cdc8p	O
,	O
after	O
4	O
hours	O
there	O
were	O
~	O
50	O
%	O
normal	O
septa	O
reflecting	O
the	O
residual	O
ts	O
phenotype	O
(	O
multiple	O
,	O
poorly	O
organized	O
septa	O
and	O
abnormal	O
morphologies	O
)	O
.	O

After	O
17	O
-	O
24	O
hours	O
,	O
almost	O
no	O
cdc8	O
-	O
27	O
cells	O
were	O
normal	O
;	O
most	O
had	O
>	O
2	O
nuclei	O
,	O
abnormal	O
and	O
multiple	O
septa	O
,	O
and	O
were	O
branched	O
.	O

By	O
17	O
hours	O
most	O
cells	O
expressing	O
wildtype	O
and	O
E104A	O
had	O
normal	O
septa	O
while	O
D16A	O
and	O
R121A	O
.	O
D131A	O
.	O
E138A	O
had	O
an	O
elevated	O
fraction	O
of	O
cells	O
with	O
an	O
abnormal	O
morphology	O
and	O
number	O
of	O
septa	O
(	O
Figure	O
3D	O
)	O
.	O

Certain	O
other	O
mutants	O
divided	O
normally	O
based	O
on	O
nuclear	O
number	O
,	O
yet	O
had	O
a	O
higher	O
percentage	O
of	O
abnormalities	O
including	O
shape	O
,	O
position	O
or	O
number	O
of	O
septa	O
(	O
E6A	O
,	O
D16A	O
,	O
E107A	O
.	O
R110A	O
,	O
for	O
example	O
;	O
Table	O
S3	O
in	O
File	O
S1	O
)	O
.	O

Two	O
mutants	O
(	O
E82A	O
,	O
V114S	O
.	O
E117A	O
.	O
H118A	O
)	O
were	O
so	O
variable	O
from	O
one	O
transformation	O
to	O
the	O
next	O
that	O
we	O
did	O
not	O
report	O
values	O
in	O
Table	O
S3	O
in	O
File	O
S1	O
.	O

In	O
general	O
,	O
however	O
,	O
overexpression	O
of	O
mutant	O
Cdc8p	O
had	O
poor	O
penetrance	O
;	O
most	O
cells	O
were	O
morphologically	O
similar	O
to	O
wildtype	O
.	O

(	O
A	O
)	O
AZI1	O
-	O
myc	O
protein	O
levels	O
are	O
reduced	O
in	O
mpk3	O
mutants	O
.	O

Proteins	O
were	O
extracted	O
from	O
seedlings	O
of	O
35S	O
:	O
:	O
AZI1	O
and	O
from	O
35S	O
:	O
:	O
AZI1	O
/	O
mpk3	O
(	O
homozygous	O
crossings	O
of	O
line	O
35S	O
:	O
:	O
AZI1	O
_	O
11	O
.	O
8	O
with	O
mpk3	O
)	O
.	O

AZI1	O
-	O
myc	O
expression	O
was	O
detected	O
by	O
immunoblotting	O
with	O
an	O
antibody	O
directed	O
against	O
the	O
myc	O
epitope	O
tag	O
.	O

Protein	O
loading	O
was	O
visualized	O
by	O
subsequent	O
Coomassie	O
Blue	O
staining	O
of	O
the	O
membrane	O
(	O
CBB	O
)	O
.	O

Homozygous	O
35S	O
:	O
:	O
AZI1	O
/	O
mpk3	O
lines	O
(	O
three	O
are	O
shown	O
)	O
have	O
consistently	O
less	O
AZI1	O
-	O
myc	O
protein	O
.	O

The	O
experiment	O
was	O
repeated	O
three	O
times	O
,	O
with	O
similar	O
results	O
.	O

27	O
-	O
Hydroxycholesterol	O
links	O
hypercholesterolemia	O
and	O
breast	O
cancer	O
pathophysiology	O
.	O

Hypercholesterolemia	O
is	O
a	O
risk	O
factor	O
for	O
estrogen	O
receptor	O
(	O
ER	O
)	O
-	O
positive	O
breast	O
cancers	O
and	O
is	O
associated	O
with	O
a	O
decreased	O
response	O
of	O
tumors	O
to	O
endocrine	O
therapies	O
.	O

Here	O
,	O
we	O
show	O
that	O
27	O
-	O
hydroxycholesterol	O
(	O
27HC	O
)	O
,	O
a	O
primary	O
metabolite	O
of	O
cholesterol	O
and	O
an	O
ER	O
and	O
liver	O
X	O
receptor	O
(	O
LXR	O
)	O
ligand	O
,	O
increases	O
ER	O
-	O
dependent	O
growth	O
and	O
LXR	O
-	O
dependent	O
metastasis	O
in	O
mouse	O
models	O
of	O
breast	O
cancer	O
.	O

The	O
effects	O
of	O
cholesterol	O
on	O
tumor	O
pathology	O
required	O
its	O
conversion	O
to	O
27HC	O
by	O
the	O
cytochrome	O
P450	O
oxidase	O
CYP27A1	O
and	O
were	O
attenuated	O
by	O
treatment	O
with	O
CYP27A1	O
inhibitors	O
.	O

In	O
human	O
breast	O
cancer	O
specimens	O
,	O
CYP27A1	O
expression	O
levels	O
correlated	O
with	O
tumor	O
grade	O
.	O

In	O
high	O
-	O
grade	O
tumors	O
,	O
both	O
tumor	O
cells	O
and	O
tumor	O
-	O
associated	O
macrophages	O
exhibited	O
high	O
expression	O
levels	O
of	O
the	O
enzyme	O
.	O

Thus	O
,	O
lowering	O
circulating	O
cholesterol	O
levels	O
or	O
interfering	O
with	O
its	O
conversion	O
to	O
27HC	O
may	O
be	O
a	O
useful	O
strategy	O
to	O
prevent	O
and	O
/	O
or	O
treat	O
breast	O
cancer	O
.	O

The	O
ability	O
to	O
form	O
homodimers	O
is	O
essential	O
for	O
RDM1	O
to	O
function	O
in	O
RNA	O
-	O
directed	O
DNA	O
methylation	O
.	O

RDM1	O
(	O
RNA	O
-	O
DIRECTED	O
DNA	O
METHYLATION1	O
)	O
is	O
a	O
small	O
plant	O
-	O
specific	O
protein	O
required	O
for	O
RNA	O
-	O
directed	O
DNA	O
methylation	O
(	O
RdDM	O
)	O
.	O

RDM1	O
interacts	O
with	O
RNA	B-Complex
polymerase	I-Complex
II	I-Complex
(	O
Pol	B-Complex
II	I-Complex
)	O
,	O
ARGONAUTE4	O
(	O
AGO4	O
)	O
,	O
and	O
the	O
de	O
novo	O
DNA	O
methyltransferase	O
DOMAINS	O
REARRANGED	O
METHYLTRANSFERASE2	O
(	O
DRM2	O
)	O
and	O
binds	O
to	O
methylated	O
single	O
stranded	O
DNA	O
.	O

As	O
the	O
only	O
protein	O
identified	O
so	O
far	O
that	O
interacts	O
directly	O
with	O
DRM2	O
,	O
RDM1	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
RdDM	O
mechanism	O
by	O
linking	O
the	O
de	O
novo	O
DNA	O
methyltransferase	O
activity	O
to	O
AGO4	O
,	O
which	O
binds	O
short	O
interfering	O
RNAs	O
(	O
siRNAs	O
)	O
that	O
presumably	O
base	O
-	O
pair	O
with	O
Pol	B-Complex
II	I-Complex
or	O
Pol	B-Complex
V	I-Complex
scaffold	O
transcripts	O
synthesized	O
at	O
target	O
loci	O
.	O

RDM1	O
also	O
acts	O
together	O
with	O
the	O
chromatin	O
remodeler	O
DEFECTIVE	O
IN	O
RNA	O
-	O
DIRECTED	O
DNA	O
METHYLATION1	O
(	O
DRD1	O
)	O
and	O
the	O
structural	O
-	O
maintenance	O
-	O
of	O
-	O
chromosomes	O
solo	O
hinge	O
protein	O
DEFECTIVE	O
IN	O
MERISTEM	O
SILENCING3	O
(	O
DMS3	O
)	O
to	O
form	O
the	O
DDR	B-Complex
complex	O
,	O
which	O
facilitates	O
synthesis	O
of	O
Pol	B-Complex
V	I-Complex
scaffold	O
transcripts	O
.	O

The	O
manner	O
in	O
which	O
RDM1	O
acts	O
in	O
both	O
the	O
DDR	B-Complex
complex	O
and	O
as	O
a	O
factor	O
bridging	O
DRM2	O
and	O
AGO4	O
remains	O
unclear	O
.	O

RDM1	O
contains	O
no	O
known	O
protein	O
domains	O
but	O
a	O
prior	O
structural	O
analysis	O
suggested	O
distinct	O
regions	O
that	O
create	O
a	O
hydrophobic	O
pocket	O
and	O
promote	O
homodimer	O
formation	O
,	O
respectively	O
.	O

We	O
have	O
tested	O
several	O
mutated	O
forms	O
of	O
RDM1	O
altered	O
in	O
the	O
predicted	O
pocket	O
and	O
dimerization	O
regions	O
for	O
their	O
ability	O
to	O
complement	O
defects	O
in	O
RdDM	O
and	O
transcriptional	O
gene	O
silencing	O
,	O
support	O
synthesis	O
of	O
Pol	B-Complex
V	I-Complex
transcripts	O
,	O
form	O
homodimers	O
,	O
and	O
interact	O
with	O
DMS3	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
ability	O
to	O
form	O
homodimers	O
is	O
essential	O
for	O
RDM1	O
to	O
function	O
fully	O
in	O
the	O
RdDM	O
pathway	O
and	O
may	O
be	O
particularly	O
important	O
during	O
the	O
de	O
novo	O
methylation	O
step	O
.	O

Tau	O
-	O
crystallin	O
/	O
alpha	O
-	O
enolase	O
:	O
one	O
gene	O
encodes	O
both	O
an	O
enzyme	O
and	O
a	O
lens	O
structural	O
protein	O
.	O

tau	O
-	O
Crystallin	O
has	O
been	O
a	O
major	O
component	O
of	O
the	O
cellular	O
lenses	O
of	O
species	O
throughout	O
vertebrate	O
evolution	O
,	O
from	O
lamprey	O
to	O
birds	O
.	O

Immunofluorescence	O
analysis	O
of	O
the	O
embryonic	O
turtle	O
lens	O
,	O
using	O
antiserum	O
to	O
lamprey	O
tau	O
-	O
crystallin	O
showed	O
that	O
the	O
protein	O
is	O
expressed	O
throughout	O
embryogenesis	O
and	O
is	O
present	O
at	O
high	O
concentrations	O
in	O
all	O
parts	O
of	O
the	O
lens	O
.	O

Partial	O
peptide	O
sequence	O
for	O
the	O
isolated	O
turtle	O
protein	O
and	O
deduced	O
sequences	O
for	O
several	O
lamprey	O
peptides	O
all	O
revealed	O
a	O
close	O
similarity	O
to	O
the	O
glycolytic	O
enzyme	O
enolase	O
(	O
E	O
.	O
C	O
.	O
4	O
.	O
2	O
.	O
1	O
.	O
11	O
)	O
.	O

A	O
full	O
-	O
sized	O
cDNA	O
for	O
putative	O
duck	O
tau	O
-	O
crystallin	O
was	O
obtained	O
and	O
sequenced	O
,	O
confirming	O
the	O
close	O
relationship	O
with	O
alpha	O
-	O
enolase	O
.	O

Southern	O
blot	O
analysis	O
showed	O
that	O
the	O
duck	O
genome	O
contains	O
a	O
single	O
alpha	O
-	O
enolase	O
gene	O
,	O
while	O
Northern	O
blot	O
analysis	O
showed	O
that	O
the	O
message	O
for	O
tau	O
-	O
crystallin	O
/	O
alpha	O
-	O
enolase	O
is	O
present	O
in	O
embryonic	O
duck	O
lens	O
at	O
25	O
times	O
the	O
abundance	O
found	O
in	O
liver	O
.	O

tau	O
-	O
Crystallin	O
possesses	O
enolase	O
activity	O
,	O
but	O
the	O
activity	O
is	O
greatly	O
reduced	O
,	O
probably	O
because	O
of	O
age	O
-	O
related	O
posttranslational	O
modification	O
.	O

It	O
thus	O
appears	O
that	O
a	O
highly	O
conserved	O
,	O
important	O
glycolytic	O
enzyme	O
has	O
been	O
used	O
as	O
a	O
structural	O
component	O
of	O
lens	O
since	O
the	O
start	O
of	O
vertebrate	O
evolution	O
.	O

Apparently	O
the	O
enzyme	O
has	O
not	O
been	O
recruited	O
for	O
its	O
catalytic	O
activity	O
but	O
for	O
some	O
distinct	O
structural	O
property	O
.	O

tau	O
-	O
Crystallin	O
/	O
alpha	O
-	O
enolase	O
is	O
an	O
example	O
of	O
a	O
multifunctional	O
protein	O
playing	O
two	O
very	O
different	O
roles	O
in	O
evolution	O
but	O
encoded	O
by	O
a	O
single	O
gene	O
.	O

Modification	O
of	O
PCNA	O
by	O
ISG15	O
plays	O
a	O
crucial	O
role	O
in	O
termination	O
of	O
error	O
-	O
prone	O
translesion	O
DNA	O
synthesis	O
.	O

In	O
response	O
to	O
DNA	O
damage	O
,	O
PCNA	O
is	O
mono	O
-	O
ubiquitinated	O
and	O
triggers	O
translesion	O
DNA	O
synthesis	O
(	O
TLS	O
)	O
by	O
recruiting	O
polymerase	O
-	O
eta	O
.	O

However	O
,	O
it	O
remained	O
unknown	O
how	O
error	O
-	O
prone	O
TLS	O
is	O
turned	O
off	O
after	O
DNA	O
lesion	O
bypass	O
to	O
prevent	O
mutagenesis	O
.	O

Here	O
we	O
showed	O
that	O
ISG15	O
modification	O
(	O
ISGylation	O
)	O
of	O
PCNA	O
plays	O
a	O
key	O
role	O
in	O
TLS	O
termination	O
.	O

Upon	O
UV	O
irradiation	O
,	O
EFP	O
,	O
an	O
ISG15	O
E3	O
ligase	O
,	O
bound	O
to	O
mono	O
-	O
ubiquitinated	O
PCNA	O
and	O
promoted	O
its	O
ISGylation	O
.	O

ISGylated	O
PCNA	O
then	O
tethered	O
USP10	O
for	O
deubiquitination	O
and	O
in	O
turn	O
the	O
release	O
of	O
polymerase	O
-	O
eta	O
from	O
PCNA	O
.	O

Eventually	O
,	O
PCNA	O
was	O
deISGylated	O
by	O
UBP43	O
for	O
reloading	O
of	O
replicative	O
DNA	O
polymerases	O
and	O
resuming	O
normal	O
DNA	O
replication	O
.	O

However	O
,	O
ISGylation	O
-	O
defective	O
Lys	O
-	O
to	O
-	O
Arg	O
mutations	O
in	O
PCNA	O
or	O
knockdown	O
of	O
any	O
of	O
ISG15	O
,	O
EFP	O
,	O
or	O
USP10	O
led	O
to	O
persistent	O
recruitment	O
of	O
mono	O
-	O
ubiquitinated	O
PCNA	O
and	O
polymerase	O
-	O
eta	O
to	O
nuclear	O
foci	O
,	O
causing	O
an	O
increase	O
in	O
mutation	O
frequency	O
.	O

These	O
findings	O
establish	O
a	O
crucial	O
role	O
of	O
PCNA	O
ISGylation	O
in	O
termination	O
of	O
error	O
-	O
prone	O
TLS	O
for	O
preventing	O
excessive	O
mutagenesis	O
.	O

Interestingly	O
,	O
when	O
we	O
stimulated	O
the	O
nerve	O
at	O
a	O
high	O
frequency	O
(	O
10	O
Hz	O
)	O
for	O
a	O
prolonged	O
period	O
(	O
10	O
min	O
)	O
,	O
mnb1	O
showed	O
significantly	O
faster	O
rundown	O
than	O
controls	O
(	O
Fig	O
.	O
3e	O
-	O
f	O
)	O
.	O

This	O
result	O
suggests	O
that	O
Mnb	O
promotes	O
efficient	O
synaptic	O
vesicle	O
recycling	O
during	O
conditions	O
of	O
high	O
activity	O
.	O

Presynaptic	O
overexpression	O
of	O
mnb	O
-	O
F	O
alone	O
did	O
not	O
affect	O
basal	O
synaptic	O
transmission	O
and	O
responses	O
to	O
high	O
frequency	O
stimulation	O
as	O
compared	O
to	O
the	O
control	O
,	O
but	O
restored	O
maintenance	O
of	O
synaptic	O
transmission	O
when	O
expressed	O
in	O
mnb1	O
mutant	O
background	O
(	O
Fig	O
.	O
3a	O
-	O
f	O
)	O
.	O

Together	O
,	O
these	O
data	O
indicate	O
neuronal	O
Mnb	O
is	O
required	O
for	O
rapid	O
synaptic	O
vesicle	O
recycling	O
.	O

The	O
PTK7	O
-	O
related	O
transmembrane	O
proteins	O
off	O
-	O
track	O
and	O
off	O
-	O
track	O
2	O
are	O
co	O
-	O
receptors	O
for	O
Drosophila	O
Wnt2	O
required	O
for	O
male	O
fertility	O
.	O

Wnt	O
proteins	O
regulate	O
many	O
developmental	O
processes	O
and	O
are	O
required	O
for	O
tissue	O
homeostasis	O
in	O
adult	O
animals	O
.	O

The	O
cellular	O
responses	O
to	O
Wnts	O
are	O
manifold	O
and	O
are	O
determined	O
by	O
the	O
respective	O
Wnt	O
ligand	O
and	O
its	O
specific	O
receptor	O
complex	O
in	O
the	O
plasma	O
membrane	O
.	O

Wnt	O
receptor	O
complexes	O
contain	O
a	O
member	O
of	O
the	O
Frizzled	O
family	O
of	O
serpentine	O
receptors	O
and	O
a	O
co	O
-	O
receptor	O
,	O
which	O
commonly	O
is	O
a	O
single	O
-	O
pass	O
transmembrane	O
protein	O
.	O

Vertebrate	O
protein	O
tyrosine	O
kinase	O
7	O
(	O
PTK7	O
)	O
was	O
identified	O
as	O
a	O
Wnt	O
co	O
-	O
receptor	O
required	O
for	O
control	O
of	O
planar	O
cell	O
polarity	O
(	O
PCP	O
)	O
in	O
frogs	O
and	O
mice	O
.	O

We	O
found	O
that	O
flies	O
homozygous	O
for	O
a	O
complete	O
knock	O
-	O
out	O
of	O
the	O
Drosophila	O
PTK7	O
homolog	O
off	O
track	O
(	O
otk	O
)	O
are	O
viable	O
and	O
fertile	O
and	O
do	O
not	O
show	O
PCP	O
phenotypes	O
.	O

We	O
discovered	O
an	O
otk	O
paralog	O
(	O
otk2	O
,	O
CG8964	O
)	O
,	O
which	O
is	O
co	O
-	O
expressed	O
with	O
otk	O
throughout	O
embryonic	O
and	O
larval	O
development	O
.	O

Otk	O
and	O
Otk2	O
bind	O
to	O
each	O
other	O
and	O
form	O
complexes	O
with	O
Frizzled	O
,	O
Frizzled2	O
and	O
Wnt2	O
,	O
pointing	O
to	O
a	O
function	O
as	O
Wnt	O
co	O
-	O
receptors	O
.	O

Flies	O
lacking	O
both	O
otk	O
and	O
otk2	O
are	O
viable	O
but	O
male	O
sterile	O
due	O
to	O
defective	O
morphogenesis	O
of	O
the	O
ejaculatory	O
duct	O
.	O

Overexpression	O
of	O
Otk	O
causes	O
female	O
sterility	O
due	O
to	O
malformation	O
of	O
the	O
oviduct	O
,	O
indicating	O
that	O
Otk	O
and	O
Otk2	O
are	O
specifically	O
involved	O
in	O
the	O
sexually	O
dimorphic	O
development	O
of	O
the	O
genital	O
tract	O
.	O

Structural	O
efforts	O
have	O
attempted	O
to	O
elucidate	O
the	O
mechanistic	O
details	O
of	O
signal	O
transduction	O
spanning	O
several	O
domains	O
from	O
the	O
periplasmic	O
sensors	O
to	O
the	O
cytoplasmic	O
DHp	O
domain	O
,	O
and	O
numerous	O
structures	O
have	O
been	O
reported	O
.	O

Crystal	O
structures	O
are	O
now	O
available	O
for	O
multiple	O
domains	O
of	O
two	O
-	O
component	O
and	O
chemotaxis	O
systems	O
,	O
including	O
a	O
structure	O
of	O
the	O
periplasmic	O
sensor	O
domain	O
of	O
PhoQ	O
.	O

NMR	O
and	O
X	O
-	O
ray	O
structures	O
have	O
been	O
solved	O
for	O
HAMP	O
domains	O
as	O
well	O
as	O
TM	O
regions	O
.	O

Many	O
recent	O
multi	O
-	O
domain	O
crystal	O
structures	O
give	O
us	O
detailed	O
view	O
of	O
the	O
connections	O
between	O
cytoplasmic	O
domains	O
.	O

A	O
full	O
length	O
structure	O
of	O
an	O
engineered	O
,	O
cytoplasmic	O
two	O
-	O
component	O
sensor	O
(	O
lacking	O
a	O
TM	O
domain	O
)	O
was	O
determined	O
,	O
as	O
was	O
the	O
structure	O
of	O
the	O
cytoplasmic	O
region	O
of	O
VicK	O
,	O
from	O
Streptococcus	O
mutans	O
.	O

Despite	O
these	O
advances	O
,	O
several	O
competing	O
proposals	O
still	O
remain	O
for	O
a	O
mechanism	O
of	O
transmembrane	O
signaling	O
.	O

A	O
role	O
of	O
OCRL	O
in	O
clathrin	B-Complex
-	O
coated	O
pit	O
dynamics	O
and	O
uncoating	O
revealed	O
by	O
studies	O
of	O
Lowe	O
syndrome	O
cells	O
.	O

Mutations	O
in	O
the	O
inositol	O
5	O
-	O
phosphatase	O
OCRL	O
cause	O
Lowe	O
syndrome	O
and	O
Dent	O
'	O
s	O
disease	O
.	O

Although	O
OCRL	O
,	O
a	O
direct	O
clathrin	B-Complex
interactor	O
,	O
is	O
recruited	O
to	O
late	O
-	O
stage	O
clathrin	B-Complex
-	O
coated	O
pits	O
,	O
clinical	O
manifestations	O
have	O
been	O
primarily	O
attributed	O
to	O
intracellular	O
sorting	O
defects	O
.	O

Here	O
we	O
show	O
that	O
OCRL	O
loss	O
in	O
Lowe	O
syndrome	O
patient	O
fibroblasts	O
impacts	O
clathrin	O
-	O
mediated	O
endocytosis	O
and	O
results	O
in	O
an	O
endocytic	O
defect	O
.	O

These	O
cells	O
exhibit	O
an	O
accumulation	O
of	O
clathrin	B-Complex
-	O
coated	O
vesicles	O
and	O
an	O
increase	O
in	O
U	O
-	O
shaped	O
clathrin	B-Complex
-	O
coated	O
pits	O
,	O
which	O
may	O
result	O
from	O
sequestration	O
of	O
coat	O
components	O
on	O
uncoated	O
vesicles	O
.	O

Endocytic	O
vesicles	O
that	O
fail	O
to	O
lose	O
their	O
coat	O
nucleate	O
the	O
majority	O
of	O
the	O
numerous	O
actin	O
comets	O
present	O
in	O
patient	O
cells	O
.	O

SNX9	O
,	O
an	O
adaptor	O
that	O
couples	O
late	O
-	O
stage	O
endocytic	O
coated	O
pits	O
to	O
actin	O
polymerization	O
and	O
which	O
we	O
found	O
to	O
bind	O
OCRL	O
directly	O
,	O
remains	O
associated	O
with	O
such	O
vesicles	O
.	O

These	O
results	O
indicate	O
that	O
OCRL	O
acts	O
as	O
an	O
uncoating	O
factor	O
and	O
that	O
defects	O
in	O
clathrin	B-Complex
-	O
mediated	O
endocytosis	O
likely	O
contribute	O
to	O
pathology	O
in	O
patients	O
with	O
OCRL	O
mutations	O
.	O

A	O
hallmark	O
property	O
of	O
circadian	O
rhythms	O
is	O
that	O
the	O
period	O
length	O
is	O
very	O
constant	O
over	O
a	O
wide	O
range	O
of	O
physiologically	O
relevant	O
temperatures	O
,	O
termed	O
temperature	O
compensation	O
.	O

To	O
investigate	O
whether	O
phosphorylation	O
of	O
dCLK	O
might	O
have	O
a	O
role	O
in	O
temperature	O
compensation	O
,	O
we	O
analyzed	O
behavioral	O
rhythms	O
at	O
three	O
standard	O
temperatures	O
(	O
i	O
.	O
e	O
.	O
,	O
18degrees	O
,	O
25degrees	O
and	O
29degreesC	O
)	O
.	O

Although	O
we	O
noted	O
a	O
decrease	O
in	O
rhythmicity	O
for	O
dClk	O
-	O
15A	O
;	O
Clk	O
out	O
flies	O
at	O
29degreesC	O
,	O
the	O
periods	O
were	O
quite	O
similar	O
over	O
the	O
temperature	O
range	O
tested	O
(	O
Table	O
2	O
)	O
,	O
suggesting	O
that	O
global	O
phosphorylation	O
of	O
dCLK	O
does	O
not	O
play	O
a	O
major	O
role	O
in	O
temperature	O
compensation	O
.	O

Emerging	O
optical	O
tools	O
allow	O
much	O
finer	O
control	O
and	O
observation	O
of	O
cellular	O
processes	O
using	O
light	O
,	O
an	O
actuator	O
that	O
can	O
be	O
delivered	O
immediately	O
and	O
with	O
subcellular	O
spatial	O
resolution	O
.	O

Optogenetic	O
actuators	O
allow	O
light	O
control	O
of	O
specific	O
processes	O
such	O
as	O
neuronal	O
firing	O
,	O
but	O
more	O
general	O
tools	O
have	O
also	O
been	O
developed	O
to	O
manipulate	O
protein	O
transcription	O
,	O
protein	O
-	O
protein	O
interactions	O
,	O
and	O
a	O
variety	O
of	O
other	O
cellular	O
biochemical	O
events	O
.	O

In	O
previous	O
work	O
,	O
we	O
developed	O
one	O
such	O
tool	O
,	O
a	O
system	O
using	O
the	O
Arabidopsis	O
flavoprotein	O
cryptochrome	O
2	O
(	O
CRY2	O
)	O
and	O
its	O
interacting	O
partner	O
CIB1	O
to	O
inducibly	O
control	O
protein	O
interactions	O
with	O
light	O
.	O

While	O
these	O
proteins	O
do	O
not	O
interact	O
in	O
the	O
dark	O
,	O
blue	O
light	O
absorption	O
triggers	O
a	O
conformational	O
change	O
in	O
CRY2	O
allowing	O
binding	O
to	O
CIB1	O
that	O
is	O
reversible	O
after	O
several	O
minutes	O
(	O
t	O
(	O
1	O
/	O
2	O
)	O
~	O
5	O
.	O
5	O
min	O
)	O
.	O

When	O
attached	O
to	O
diverse	O
target	O
proteins	O
,	O
the	O
CRY2	O
and	O
CIB1	O
modules	O
allow	O
tight	O
light	O
regulation	O
of	O
target	O
protein	O
activity	O
.	O

A	O
HYL1	O
promoter	O
region	O
(	O
1240	O
bp	O
upstream	O
of	O
the	O
translation	O
start	O
site	O
)	O
and	O
a	O
full	O
-	O
length	O
coding	O
sequence	O
(	O
1257	O
bp	O
)	O
were	O
amplified	O
from	O
Columbia	O
seedlings	O
.	O

Then	O
both	O
sequences	O
were	O
cloned	O
into	O
pCAMBIA1301	O
binary	O
vectors	O
to	O
obtain	O
the	O
pHYL1	O
:	O
:	O
HYL1	O
constructs	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
was	O
performed	O
,	O
and	O
the	O
primers	O
used	O
for	O
polymerase	O
chain	O
reactions	O
(	O
PCRs	O
)	O
are	O
listed	O
in	O
Supplementary	O
Table	O
S3	O
.	O

The	O
cDNA	O
encoding	O
RCD1	O
was	O
cloned	O
into	O
the	O
bait	O
vector	O
pGBT9	O
and	O
the	O
Rap2	O
.	O
4a	O
cDNA	O
into	O
the	O
prey	O
vector	O
pACT2	O
.	O

Double	O
transformants	O
of	O
the	O
yeast	O
strain	O
HF7c	O
showed	O
protein	O
-	O
protein	O
interaction	O
by	O
complementation	O
of	O
the	O
histidine	O
auxotrophy	O
of	O
the	O
yeast	O
strain	O
.	O

On	O
20	O
mM	O
3	O
-	O
AT	O
,	O
which	O
increases	O
the	O
stringency	O
by	O
inhibiting	O
histidine	O
biosynthesis	O
,	O
the	O
double	O
transformant	O
grew	O
almost	O
as	O
good	O
as	O
the	O
commonly	O
used	O
positive	O
control	O
,	O
pVA	O
-	O
pTD1	O
double	O
transformants	O
(	O
Figure	O
4	O
left	O
)	O
(	O
Li	O
et	O
al	O
.	O
,	O
)	O
.	O

The	O
pAct2	O
-	O
Rap2	O
.	O
4a	O
-	O
empty	O
pGBT9	O
double	O
transformants	O
(	O
negative	O
control	O
)	O
did	O
not	O
grow	O
.	O

Rap1GAP	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
GTPase	O
-	O
activating	O
proteins	O
(	O
GAPs	O
)	O
that	O
specifically	O
stimulate	O
the	O
GTP	O
hydrolysis	O
of	O
Rap1	O
GTPases	O
.	O

Rap1	O
is	O
one	O
of	O
the	O
Ras	O
-	O
like	O
small	O
GTPases	O
that	O
are	O
critical	O
players	O
in	O
signaling	O
pathways	O
that	O
control	O
cell	O
growth	O
,	O
migration	O
,	O
and	O
differentiation	O
.	O

Rap1	O
shuttles	O
between	O
an	O
inactive	O
GDP	O
-	O
and	O
active	O
GTP	O
-	O
bound	O
form	O
.	O

Activation	O
of	O
Rap1	O
(	O
Rap1	O
-	O
GTP	O
)	O
is	O
mediated	O
by	O
guanine	O
nucleotide	O
exchange	O
factors	O
(	O
GEFs	O
)	O
,	O
including	O
C3G	O
,	O
PDZ	O
-	O
GEF	O
,	O
Epac	O
,	O
and	O
CalDAG	O
.	O

Inactivation	O
of	O
Rap1	O
is	O
mediated	O
by	O
GTPase	O
activating	O
proteins	O
(	O
GAPs	O
)	O
,	O
including	O
Rap1GAP	O
and	O
Rap1GAP2	O
,	O
SPA	O
-	O
1	O
/	O
SIPA1	O
and	O
SIPA1L1	O
/	O
SPAR	O
.	O

(	O
A	O
)	O
Hierarchical	O
clustering	O
of	O
No	O
-	O
0	O
and	O
slh1	O
temperature	O
-	O
dependent	O
differential	O
gene	O
expression	O
.	O

Fold	O
-	O
change	O
values	O
of	O
5611	O
genes	O
(	O
differentially	O
expressed	O
at	O
least	O
in	O
one	O
time	O
point	O
)	O
are	O
shown	O
.	O

The	O
numbers	O
on	O
top	O
of	O
the	O
heat	O
map	O
indicate	O
the	O
time	O
(	O
h	O
)	O
after	O
temperature	O
shift	O
.	O

Black	O
,	O
red	O
and	O
green	O
colours	O
indicate	O
no	O
change	O
,	O
up	O
-	O
regulated	O
and	O
down	O
-	O
regulated	O
,	O
respectively	O
.	O

(	O
B	O
)	O
qRT	O
-	O
PCR	O
analysis	O
of	O
selected	O
RRS1SLH1	O
-	O
regulated	O
genes	O
following	O
the	O
temperature	O
shift	O
(	O
28degreesC	O
to	O
19degreesC	O
)	O
in	O
4	O
week	O
-	O
old	O
No	O
-	O
0	O
and	O
slh1	O
plants	O
.	O

Transcript	O
accumulation	O
is	O
presented	O
relative	O
to	O
No	O
-	O
0	O
before	O
temperature	O
shift	O
(	O
28degreesC	O
)	O
.	O

Our	O
previous	O
proteomic	O
screens	O
identified	O
a	O
number	O
of	O
proteins	O
associated	O
with	O
AP	O
-	O
3	O
that	O
could	O
coordinate	O
both	O
the	O
interaction	O
of	O
SEPT6	O
or	O
SEPT7	O
with	O
F	O
-	O
actin	O
and	O
that	O
of	O
AP	O
-	O
3	O
with	O
membranes	O
or	O
could	O
regulate	O
a	O
switch	O
from	O
F	O
-	O
actin	O
to	O
microtubules	O
during	O
MVB	O
biogenesis	O
.	O

Their	O
function	O
can	O
now	O
be	O
tested	O
in	O
the	O
light	O
of	O
our	O
current	O
findings	O
.	O

Structure	O
of	O
the	O
Kti11	O
/	O
Kti13	O
heterodimer	O
and	O
its	O
double	O
role	O
in	O
modifications	O
of	O
tRNA	O
and	O
eukaryotic	O
elongation	O
factor	O
2	O
.	O

The	O
small	O
,	O
highly	O
conserved	O
Kti11	O
alias	O
Dph3	O
protein	O
encoded	O
by	O
the	O
Kluyveromyces	O
lactis	O
killer	O
toxin	O
insensitive	O
gene	O
KTI11	O
/	O
DPH3	O
is	O
involved	O
in	O
the	O
diphthamide	O
modification	O
of	O
eukaryotic	O
elongation	O
factor	O
2	O
and	O
,	O
together	O
with	O
Kti13	O
,	O
in	O
Elongator	O
-	O
dependent	O
tRNA	O
wobble	O
base	O
modifications	O
,	O
thereby	O
affecting	O
the	O
speed	O
and	O
accuracy	O
of	O
protein	O
biosynthesis	O
through	O
two	O
distinct	O
mechanisms	O
.	O

We	O
have	O
solved	O
the	O
crystal	O
structures	O
of	O
Saccharomyces	O
cerevisiae	O
Kti13	O
and	O
the	O
Kti11	O
/	O
Kti13	O
heterodimer	O
at	O
2	O
.	O
4	O
and	O
2	O
.	O
9	O
Aa	O
resolution	O
,	O
respectively	O
,	O
and	O
validated	O
interacting	O
residues	O
through	O
mutational	O
analysis	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
show	O
that	O
metal	O
coordination	O
by	O
Kti11	O
and	O
its	O
heterodimerization	O
with	O
Kti13	O
are	O
essential	O
for	O
both	O
translational	O
control	O
mechanisms	O
.	O

Our	O
structural	O
and	O
functional	O
analyses	O
identify	O
Kti13	O
as	O
an	O
additional	O
component	O
of	O
the	O
diphthamide	O
modification	O
pathway	O
and	O
provide	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
that	O
allow	O
the	O
Kti11	O
/	O
Kti13	O
heterodimer	O
to	O
coregulate	O
two	O
consecutive	O
steps	O
in	O
ribosomal	O
protein	O
synthesis	O
.	O

elp1Delta	O
yeast	O
strains	O
expressing	O
myc	O
-	O
tagged	O
ELP2	O
and	O
either	O
HA	O
-	O
tagged	O
ELP3	O
(	O
A	O
)	O
or	O
ELP5	O
(	O
B	O
)	O
were	O
transformed	O
with	O
either	O
empty	O
vector	O
or	O
plasmids	O
expressing	O
the	O
indicated	O
ELP1	O
alleles	O
(	O
Table	O
S2	O
)	O
.	O

Elp2	O
-	O
myc	O
was	O
immunoprecipitated	O
from	O
extracts	O
and	O
immunoprecipitates	O
were	O
examined	O
by	O
Western	O
blotting	O
with	O
anti	O
-	O
myc	O
and	O
anti	O
-	O
HA	O
antibodies	O
to	O
detect	O
co	O
-	O
immunoprecipitated	O
Elp1	O
,	O
Elp3	O
and	O
Elp5	O
as	O
indicated	O
.	O

Note	O
that	O
Elp1	O
runs	O
as	O
a	O
doublet	O
as	O
observed	O
previously	O
.	O

CDC28	O
phosphorylates	O
Cac1p	O
and	O
regulates	O
the	O
association	O
of	O
chromatin	O
assembly	O
factor	O
I	O
with	O
chromatin	O
.	O

Chromatin	O
Assembly	O
Factor	O
I	O
(	O
CAF	O
-	O
I	O
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
replication	O
-	O
coupled	O
assembly	O
of	O
nucleosomes	O
.	O

It	O
is	O
expected	O
that	O
its	O
function	O
is	O
linked	O
to	O
the	O
regulation	O
of	O
the	O
cell	O
cycle	O
,	O
but	O
little	O
detail	O
is	O
available	O
.	O

Current	O
models	O
suggest	O
that	O
CAF	O
-	O
I	O
is	O
recruited	O
to	O
replication	O
forks	O
and	O
to	O
chromatin	O
via	O
an	O
interaction	O
between	O
its	O
Cac1p	O
subunit	O
and	O
the	O
replication	O
sliding	O
clamp	O
,	O
PCNA	O
,	O
and	O
that	O
this	O
interaction	O
is	O
stimulated	O
by	O
the	O
kinase	O
CDC7	O
.	O

Here	O
we	O
show	O
that	O
another	O
kinase	O
,	O
CDC28	O
,	O
phosphorylates	O
Cac1p	O
on	O
serines	O
94	O
and	O
515	O
in	O
early	O
S	O
phase	O
and	O
regulates	O
its	O
association	O
with	O
chromatin	O
,	O
but	O
not	O
its	O
association	O
with	O
PCNA	O
.	O

Mutations	O
in	O
the	O
Cac1p	O
-	O
phosphorylation	O
sites	O
of	O
CDC28	O
but	O
not	O
of	O
CDC7	O
substantially	O
reduce	O
the	O
in	O
vivo	O
phosphorylation	O
of	O
Cac1p	O
.	O

However	O
,	O
mutations	O
in	O
the	O
putative	O
CDC7	O
target	O
sites	O
on	O
Cac1p	O
reduce	O
its	O
stability	O
.	O

The	O
association	O
of	O
CAF	O
-	O
I	O
with	O
chromatin	O
is	O
impaired	O
in	O
a	O
cdc28	O
-	O
1	O
mutant	O
and	O
to	O
a	O
lesser	O
extent	O
in	O
a	O
cdc7	O
-	O
1	O
mutant	O
.	O

In	O
addition	O
,	O
mutations	O
in	O
the	O
Cac1p	O
-	O
phosphorylation	O
sites	O
by	O
both	O
CDC28	O
and	O
CDC7	O
reduce	O
gene	O
silencing	O
at	O
the	O
telomeres	O
.	O

We	O
propose	O
that	O
this	O
phosphorylation	O
represents	O
a	O
regulatory	O
step	O
in	O
the	O
recruitment	O
of	O
CAF	O
-	O
I	O
to	O
chromatin	O
in	O
early	O
S	O
phase	O
that	O
is	O
distinct	O
from	O
the	O
association	O
of	O
CAF	O
-	O
I	O
with	O
PCNA	O
.	O

Hence	O
,	O
we	O
implicate	O
CDC28	O
in	O
the	O
regulation	O
of	O
chromatin	O
reassembly	O
during	O
DNA	O
replication	O
.	O

These	O
findings	O
provide	O
novel	O
mechanistic	O
insights	O
on	O
the	O
links	O
between	O
cell	O
-	O
cycle	O
regulation	O
,	O
DNA	O
replication	O
and	O
chromatin	O
reassembly	O
.	O

Concerted	O
and	O
differential	O
actions	O
of	O
two	O
enzymatic	O
domains	O
underlie	O
Rad5	O
contributions	O
to	O
DNA	O
damage	O
tolerance	O
.	O

Many	O
genome	O
maintenance	O
factors	O
have	O
multiple	O
enzymatic	O
activities	O
.	O

In	O
most	O
cases	O
,	O
how	O
their	O
distinct	O
activities	O
functionally	O
relate	O
with	O
each	O
other	O
is	O
unclear	O
.	O

Here	O
we	O
examined	O
the	O
conserved	O
budding	O
yeast	O
Rad5	O
protein	O
that	O
has	O
both	O
ubiquitin	O
ligase	O
and	O
DNA	O
helicase	O
activities	O
.	O

The	O
Rad5	O
ubiquitin	O
ligase	O
activity	O
mediates	O
PCNA	O
poly	O
-	O
ubiquitination	O
and	O
subsequently	O
recombination	O
-	O
based	O
DNA	O
lesion	O
tolerance	O
.	O

Interestingly	O
,	O
the	O
ligase	O
domain	O
is	O
embedded	O
in	O
a	O
larger	O
helicase	O
domain	O
comprising	O
seven	O
consensus	O
motifs	O
.	O

How	O
features	O
of	O
the	O
helicase	O
domain	O
influence	O
ligase	O
function	O
is	O
controversial	O
.	O

To	O
clarify	O
this	O
issue	O
,	O
we	O
use	O
genetic	O
,	O
2D	O
gel	O
and	O
biochemical	O
analyses	O
and	O
show	O
that	O
a	O
Rad5	O
helicase	O
motif	O
important	O
for	O
ATP	O
binding	O
is	O
also	O
required	O
for	O
PCNA	O
poly	O
-	O
ubiquitination	O
and	O
recombination	O
-	O
based	O
lesion	O
tolerance	O
.	O

We	O
determine	O
that	O
this	O
requirement	O
is	O
due	O
to	O
a	O
previously	O
unrecognized	O
contribution	O
of	O
the	O
motif	O
to	O
the	O
PCNA	O
and	O
ubiquitination	O
enzyme	O
interaction	O
,	O
and	O
not	O
due	O
to	O
its	O
canonical	O
role	O
in	O
supporting	O
helicase	O
activity	O
.	O

We	O
further	O
show	O
that	O
Rad5	O
'	O
s	O
helicase	O
-	O
mediated	O
contribution	O
to	O
replication	O
stress	O
survival	O
is	O
separable	O
from	O
recombination	O
.	O

These	O
findings	O
delineate	O
how	O
two	O
Rad5	O
enzymatic	O
domains	O
concertedly	O
influence	O
PCNA	O
modification	O
,	O
and	O
unveil	O
their	O
discrete	O
contributions	O
to	O
stress	O
tolerance	O
.	O

To	O
gain	O
new	O
functional	O
insights	O
into	O
Brc1	O
we	O
carried	O
out	O
an	O
E	O
-	O
MAP	O
analysis	O
to	O
quantify	O
the	O
genetic	O
interactions	O
between	O
brc1Delta	O
and	O
a	O
S	O
.	O
pombe	O
gene	O
deletion	O
library	O
of	O
nonessential	O
genes	O
.	O

E	O
-	O
MAP	O
values	O
were	O
determined	O
with	O
a	O
simple	O
growth	O
phenotype	O
that	O
measures	O
negative	O
(	O
aggravating	O
)	O
interactions	O
,	O
such	O
as	O
synthetic	O
sick	O
/	O
lethal	O
(	O
SSL	O
)	O
interactions	O
,	O
as	O
well	O
as	O
positive	O
(	O
alleviating	O
)	O
interactions	O
in	O
which	O
the	O
double	O
mutant	O
is	O
healthier	O
than	O
would	O
be	O
expected	O
based	O
on	O
the	O
growth	O
of	O
the	O
two	O
single	O
mutants	O
.	O

An	O
SSL	O
interaction	O
often	O
identifies	O
proteins	O
that	O
function	O
in	O
distinct	O
but	O
parallel	O
pathways	O
,	O
whereas	O
a	O
positive	O
interaction	O
score	O
may	O
indicate	O
either	O
suppression	O
or	O
masking	O
effects	O
,	O
in	O
which	O
loss	O
of	O
one	O
gene	O
masks	O
the	O
effect	O
of	O
losing	O
another	O
,	O
as	O
seen	O
when	O
two	O
proteins	O
act	O
together	O
in	O
a	O
common	O
complex	O
or	O
pathway	O
.	O

The	O
RGMCND	O
-	O
BMP2	O
complex	O
was	O
solved	O
by	O
molecular	O
replacement	O
in	O
PHASER	O
using	O
the	O
structure	O
of	O
the	O
disulfide	O
bonded	O
BMP2	O
dimer	O
(	O
PDB	O
3BMP	B-OOS
)	O
as	O
a	O
search	O
model	O
.	O

Extra	O
electron	O
density	O
for	O
two	O
molecules	O
of	O
RGMCND	O
in	O
the	O
asymmetric	O
unit	O
was	O
immediately	O
discernible	O
after	O
density	O
modification	O
in	O
PARROT	O
(	O
Supplementary	O
Fig	O
.	O
2a	O
,	O
b	O
)	O
.	O

The	O
RGMC	O
polypeptide	O
chain	O
was	O
traced	O
using	O
iterative	O
rounds	O
of	O
BUCCANEER	O
,	O
manual	O
building	O
in	O
COOT	O
and	O
refinement	O
in	O
autoBUSTER	O
and	O
PHENIX	O
.	O

This	O
resulted	O
in	O
a	O
well	O
-	O
defined	O
model	O
for	O
the	O
RGMCND	O
-	O
BMP2	O
complex	O
that	O
included	O
two	O
molecules	O
of	O
RGMC	O
(	O
residues	O
Q36	O
-	O
P129	O
)	O
bound	O
to	O
a	O
disulfide	O
linked	O
BMP2	O
dimer	O
(	O
residues	O
K293	O
-	O
R396	O
)	O
(	O
Supplementary	O
Fig	O
.	O
2c	O
)	O
.	O

The	O
RGMAND	O
-	O
BMP2	O
and	O
RGMBND	O
-	O
BMP2	O
complexes	O
were	O
solved	O
by	O
molecular	O
replacement	O
using	O
PHASER	O
with	O
the	O
RGMCND	O
-	O
BMP2	O
complex	O
as	O
a	O
search	O
model	O
.	O

Molecular	O
replacement	O
with	O
PHASER	O
was	O
applied	O
to	O
solve	O
the	O
BMP2	O
-	O
eRGMB	O
-	O
NEO1FN56	O
structure	O
using	O
the	O
RGMBND	O
-	O
BMP2	O
Form	O
1	O
(	O
from	O
this	O
study	O
)	O
and	O
the	O
NEO1FN56	O
-	O
RGMB	O
(	O
PDB	O
ID	O
.	O
4BQ6	B-OOS
)	O
structures	O
.	O

The	O
complexes	O
were	O
refined	O
using	O
autoBUSTER	O
and	O
PHENIX	O
and	O
,	O
where	O
applicable	O
,	O
non	O
-	O
crystallographic	O
restraints	O
were	O
applied	O
.	O

For	O
the	O
BMP2	O
-	O
eRGMB	O
-	O
NEO1FN56	O
structure	O
target	O
weight	O
refinement	O
using	O
the	O
individual	O
high	O
resolution	O
structures	O
of	O
the	O
BMP2	O
,	O
RGMBND	O
,	O
eRGMB	O
,	O
NEO1FN5	O
and	O
NEO1FN6	O
domains	O
as	O
targets	O
was	O
applied	O
.	O

Crystallographic	O
statistics	O
are	O
given	O
in	O
Table	O
1	O
.	O

Stereochemical	O
properties	O
were	O
assessed	O
by	O
MOLPROBITY	O
.	O

Superpositions	O
were	O
calculated	O
using	O
the	O
program	O
COOT	O
and	O
electrostatic	O
potentials	O
were	O
generated	O
using	O
APBS	O
as	O
implemented	O
in	O
PYMOL	O
.	O

Buried	O
surface	O
areas	O
of	O
protein	O
-	O
protein	O
interactions	O
were	O
calculated	O
using	O
the	O
PISA	O
webserver	O
for	O
a	O
probe	O
radius	O
of	O
1	O
.	O
4	O
Aa	O
.	O

The	O
first	O
crystal	O
structures	O
of	O
a	O
complete	O
ECF	B-Complex
transporter	I-Complex
revealed	O
the	O
subunits	O
associated	O
in	O
a	O
1A	O
'	O
:	O
1A	O
:	O
1T	O
:	O
1S	O
quaternary	O
architecture	O
as	O
anticipated	O
from	O
solution	O
studies	O
on	O
ECF	B-Complex
transporters	I-Complex
from	O
L	O
.	O
lactis	O
.	O

The	O
nucleotide	O
-	O
free	O
EcfAA	O
'	O
ATPase	O
subunits	O
were	O
observed	O
in	O
an	O
open	O
conformation	O
.	O

EcfT	O
displayed	O
a	O
novel	O
L	O
-	O
shaped	O
fold	O
in	O
which	O
a	O
parallel	O
bundle	O
of	O
five	O
TM	O
helices	O
is	O
roughly	O
perpendicular	O
to	O
three	O
cytoplasmic	O
helices	O
(	O
CH1	O
-	O
3	O
)	O
.	O

The	O
S	O
subunit	O
in	O
each	O
structure	O
interacts	O
exclusively	O
with	O
EcfT	O
.	O

Unexpectedly	O
,	O
the	O
substrate	O
-	O
binding	O
site	O
is	O
facing	O
the	O
cytoplasm	O
,	O
as	O
if	O
the	O
entire	O
EcfS	O
subunit	O
has	O
been	O
"	O
toppled	O
"	O
from	O
an	O
extracellular	O
-	O
facing	O
,	O
substrate	O
-	O
capturing	O
orientation	O
.	O

As	O
a	O
result	O
,	O
these	O
crystal	O
structures	O
may	O
have	O
captured	O
a	O
post	O
-	O
translocation	O
state	O
in	O
which	O
nucleotides	O
had	O
dissociated	O
and	O
the	O
transport	O
substrate	O
was	O
released	O
into	O
the	O
cytoplasm	O
.	O

Osteocalcin	O
and	O
matrix	O
Gla	O
protein	O
:	O
vitamin	O
K	O
-	O
dependent	O
proteins	O
in	O
bone	O
.	O

If	O
TMEM106B	O
associates	O
with	O
CHMP2B	O
,	O
what	O
is	O
its	O
role	O
in	O
the	O
ESCRT	B-Complex
-	O
involved	O
endolysosomal	O
pathway	O
?	O

Because	O
TMEM106B	O
associates	O
with	O
CHMP2B	O
in	O
endosomal	O
pathways	O
and	O
functions	O
in	O
lysosomes	O
,	O
TMEM106B	O
might	O
be	O
involved	O
in	O
autophagy	O
with	O
reference	O
to	O
its	O
association	O
with	O
CHMP2B	O
.	O

In	O
order	O
to	O
investigate	O
this	O
question	O
,	O
we	O
examined	O
whether	O
the	O
expression	O
of	O
the	O
TMEM106B	O
variants	O
affected	O
autophagic	O
flux	O
.	O

In	O
order	O
to	O
measure	O
autophagic	O
flux	O
,	O
the	O
levels	O
of	O
microtubule	O
-	O
associated	O
protein	O
1A	O
/	O
1B	O
-	O
light	O
chain	O
3	O
(	O
LC3	O
)	O
-	O
II	O
in	O
cells	O
expressing	O
T185	O
or	O
S185	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
lysosomotrophic	O
reagent	O
ammonium	O
chloride	O
(	O
NH4Cl	O
)	O
were	O
quantified	O
in	O
a	O
western	O
blot	O
analysis	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

2e	O
-	O
f	O
,	O
cells	O
expressing	O
T185	O
showed	O
a	O
slight	O
reduction	O
in	O
autophagic	O
flux	O
compared	O
to	O
cells	O
expressing	O
S185	O
.	O

These	O
results	O
suggested	O
that	O
the	O
enhanced	O
sequestration	O
of	O
CHMP2B	O
might	O
reduce	O
autophagic	O
flux	O
.	O

Morpholino	O
oligonucleotides	O
,	O
mRNA	O
,	O
and	O
plasmids	O
were	O
injected	O
into	O
two	O
animal	O
dorsal	O
blastomeres	O
at	O
the	O
eight	O
-	O
cell	O
stage	O
for	O
observation	O
of	O
embryo	O
phenotypes	O
and	O
RT	O
-	O
PCR	O
analysis	O
,	O
into	O
four	O
animal	O
blastomeres	O
for	O
western	O
blot	O
analysis	O
,	O
or	O
into	O
two	O
ventral	O
blastomeres	O
at	O
the	O
four	O
-	O
cell	O
stage	O
for	O
RT	O
-	O
PCR	O
analysis	O
.	O

The	O
cytoplasmic	O
and	O
nuclear	O
fractions	O
were	O
prepared	O
as	O
described	O
with	O
modifications	O
23	O
.	O

Quantitative	O
RT	O
-	O
PCR	O
analysis	O
:	O
Total	O
RNA	O
was	O
prepared	O
using	O
TRIzol	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
from	O
the	O
injected	O
region	O
at	O
the	O
gastrula	O
or	O
neurula	O
stage	O
.	O

cDNA	O
synthesis	O
was	O
carried	O
out	O
using	O
Moloney	O
murine	O
leukemia	O
virus	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
.	O

The	O
sequences	O
of	O
the	O
primer	O
pairs	O
were	O
previously	O
reported	O
24	O
,	O
25	O
,	O
26	O
and	O
as	O
follows	O
:	O
xWDR26	O
:	O
Forward	O
5	O
'	O
-	O
ATGGCAACCTGCTTGACTCC	O
-	O
3	O
'	O
;	O
Reverse	O
5	O
'	O
-	O
ACAGTACCGTCGTCAGAAGC	O
-	O
3	O
'	O
.	O

hWDR26	O
:	O
Forward	O
5	O
'	O
-	O
CCGGAACTCGCCTGCTTGTC	O
-	O
3	O
'	O
;	O
Reverse	O
5	O
'	O
-	O
TGACATCCTCATCTGACTGG	O
-	O
3	O
'	O
.	O

Xnr3	O
:	O
Forward	O
5	O
'	O
-	O
CTTCTGCACTAGATTCTG	O
-	O
3	O
'	O
;	O
Reverse	O
5	O
'	O
-	O
CAGCTTCTGGCCAAGACT	O
-	O
3	O
'	O
.	O

Xtwn	O
:	O
Forward	O
5	O
'	O
-	O
AACCCAAGAAGGCGACACTATC	O
-	O
3	O
'	O
;	O
Reverse	O
5	O
'	O
-	O
GTGCCGATGGTAGGAAATGATC	O
-	O
3	O
'	O
.	O

Xenopus	O
embryonic	O
ornithine	O
decarboxylase	O
(	O
xODC	O
)	O
was	O
used	O
for	O
normalization	O
of	O
cDNA	O
samples	O
.	O

Molecular	O
mechanism	O
of	O
APC	B-Complex
/	I-Complex
C	I-Complex
activation	O
by	O
mitotic	O
phosphorylation	O
.	O

In	O
eukaryotes	O
,	O
the	O
anaphase	B-Complex
-	I-Complex
promoting	I-Complex
complex	I-Complex
(	O
APC	B-Complex
/	I-Complex
C	I-Complex
,	O
also	O
known	O
as	O
the	O
cyclosome	B-Complex
)	O
regulates	O
the	O
ubiquitin	O
-	O
dependent	O
proteolysis	O
of	O
specific	O
cell	O
-	O
cycle	O
proteins	O
to	O
coordinate	O
chromosome	O
segregation	O
in	O
mitosis	O
and	O
entry	O
into	O
the	O
G1	O
phase	O
.	O

The	O
catalytic	O
activity	O
of	O
the	O
APC	B-Complex
/	I-Complex
C	I-Complex
and	O
its	O
ability	O
to	O
specify	O
the	O
destruction	O
of	O
particular	O
proteins	O
at	O
different	O
phases	O
of	O
the	O
cell	O
cycle	O
are	O
controlled	O
by	O
its	O
interaction	O
with	O
two	O
structurally	O
related	O
coactivator	O
subunits	O
,	O
Cdc20	O
and	O
Cdh1	O
.	O

Coactivators	O
recognize	O
substrate	O
degrons	O
,	O
and	O
enhance	O
the	O
affinity	O
of	O
the	O
APC	B-Complex
/	I-Complex
C	I-Complex
for	O
its	O
cognate	O
E2	O
(	O
refs	O
4	O
-	O
6	O
)	O
.	O

During	O
mitosis	O
,	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
Cdk	O
)	O
and	O
polo	O
-	O
like	O
kinase	O
(	O
Plk	O
)	O
control	O
Cdc20	O
-	O
and	O
Cdh1	O
-	O
mediated	O
activation	O
of	O
the	O
APC	B-Complex
/	I-Complex
C	I-Complex
.	O

Hyperphosphorylation	O
of	O
APC	B-Complex
/	I-Complex
C	I-Complex
subunits	O
,	O
notably	O
Apc1	O
and	O
Apc3	O
,	O
is	O
required	O
for	O
Cdc20	O
to	O
activate	O
the	O
APC	B-Complex
/	I-Complex
C	I-Complex
,	O
whereas	O
phosphorylation	O
of	O
Cdh1	O
prevents	O
its	O
association	O
with	O
the	O
APC	B-Complex
/	I-Complex
C	I-Complex
.	O

Since	O
both	O
coactivators	O
associate	O
with	O
the	O
APC	B-Complex
/	I-Complex
C	I-Complex
through	O
their	O
common	O
C	O
-	O
box	O
and	O
Ile	O
-	O
Arg	O
tail	O
motifs	O
,	O
the	O
mechanism	O
underlying	O
this	O
differential	O
regulation	O
is	O
unclear	O
,	O
as	O
is	O
the	O
role	O
of	O
specific	O
APC	B-Complex
/	I-Complex
C	I-Complex
phosphorylation	O
sites	O
.	O

Here	O
,	O
using	O
cryo	O
-	O
electron	O
microscopy	O
and	O
biochemical	O
analysis	O
,	O
we	O
define	O
the	O
molecular	O
basis	O
of	O
how	O
phosphorylation	O
of	O
human	O
APC	B-Complex
/	I-Complex
C	I-Complex
allows	O
for	O
its	O
control	O
by	O
Cdc20	O
.	O

An	O
auto	O
-	O
inhibitory	O
segment	O
of	O
Apc1	O
acts	O
as	O
a	O
molecular	O
switch	O
that	O
in	O
apo	O
unphosphorylated	O
APC	B-Complex
/	I-Complex
C	I-Complex
interacts	O
with	O
the	O
C	O
-	O
box	O
binding	O
site	O
and	O
obstructs	O
engagement	O
of	O
Cdc20	O
.	O

Phosphorylation	O
of	O
the	O
auto	O
-	O
inhibitory	O
segment	O
displaces	O
it	O
from	O
the	O
C	O
-	O
box	O
-	O
binding	O
site	O
.	O

Efficient	O
phosphorylation	O
of	O
the	O
auto	O
-	O
inhibitory	O
segment	O
,	O
and	O
thus	O
relief	O
of	O
auto	O
-	O
inhibition	O
,	O
requires	O
the	O
recruitment	O
of	O
Cdk	O
-	O
cyclin	O
in	O
complex	O
with	O
a	O
Cdk	O
regulatory	O
subunit	O
(	O
Cks	O
)	O
to	O
a	O
hyperphosphorylated	O
loop	O
of	O
Apc3	O
.	O

We	O
also	O
find	O
that	O
the	O
small	O
-	O
molecule	O
inhibitor	O
,	O
tosyl	O
-	O
l	O
-	O
arginine	O
methyl	O
ester	O
,	O
preferentially	O
suppresses	O
APC	B-Complex
/	I-Complex
C	I-Complex
(	O
Cdc20	O
)	O
rather	O
than	O
APC	B-Complex
/	I-Complex
C	I-Complex
(	O
Cdh1	O
)	O
,	O
and	O
interacts	O
with	O
the	O
binding	O
sites	O
of	O
both	O
the	O
C	O
-	O
box	O
and	O
Ile	O
-	O
Arg	O
tail	O
motifs	O
.	O

Our	O
results	O
reveal	O
the	O
mechanism	O
for	O
the	O
regulation	O
of	O
mitotic	O
APC	B-Complex
/	I-Complex
C	I-Complex
by	O
phosphorylation	O
and	O
provide	O
a	O
rationale	O
for	O
the	O
development	O
of	O
selective	O
inhibitors	O
of	O
this	O
state	O
.	O

Mutant	O
allele	O
of	O
rna14	O
in	O
fission	O
yeast	O
affects	O
pre	O
-	O
mRNA	O
splicing	O
.	O

Spliceosome	B-Complex
and	O
3	B-Complex
'	I-Complex
-	I-Complex
end	I-Complex
processing	I-Complex
complexes	O
are	O
necessary	O
for	O
the	O
precursor	O
mRNA	O
(	O
pre	O
-	O
mRNA	O
)	O
maturation	O
.	O

Spliceosome	B-Complex
complex	O
removes	O
noncoding	O
introns	O
,	O
while	O
3	B-Complex
'	I-Complex
-	I-Complex
end	I-Complex
processing	I-Complex
involves	O
in	O
cleavage	O
and	O
addition	O
of	O
poly	O
(	O
A	O
)	O
tails	O
to	O
the	O
nascent	O
transcript	O
.	O

Rna14	O
protein	O
in	O
budding	O
yeast	O
has	O
been	O
implicated	O
in	O
cleavage	O
and	O
polyadenylation	O
of	O
mRNA	O
in	O
the	O
nucleus	O
but	O
their	O
role	O
in	O
the	O
pre	O
-	O
mRNA	O
splicing	O
has	O
not	O
been	O
studied	O
.	O

Here	O
,	O
we	O
report	O
the	O
isolation	O
of	O
a	O
mutant	O
allele	O
of	O
rna14	O
in	O
fission	O
yeast	O
,	O
Schizosaccharomyces	O
pombe	O
that	O
exhibits	O
reduction	O
in	O
protein	O
level	O
of	O
Chk1	O
at	O
the	O
nonpermissive	O
temperature	O
,	O
primarily	O
due	O
to	O
the	O
defects	O
in	O
posttranscriptional	O
processing	O
.	O

Reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
analysis	O
reveals	O
defective	O
splicing	O
of	O
the	O
chk1	O
(	O
+	O
)	O
transcript	O
at	O
the	O
nonpermissive	O
temperature	O
.	O

Apart	O
from	O
chk1	O
(	O
+	O
)	O
,	O
the	O
splicing	O
of	O
some	O
other	O
genes	O
were	O
also	O
found	O
to	O
be	O
defective	O
at	O
the	O
nonpermissive	O
temperature	O
suggesting	O
that	O
Rna14	O
might	O
be	O
involved	O
in	O
pre	O
-	O
mRNA	O
splicing	O
.	O

Subsequently	O
,	O
genetic	O
interaction	O
of	O
Rna14	O
with	O
prp1	O
and	O
physical	O
interactions	O
with	O
Prp28	O
suggest	O
that	O
the	O
Rna14	O
might	O
be	O
part	O
of	O
a	O
larger	O
protein	O
complex	O
responsible	O
for	O
the	O
pre	O
-	O
mRNA	O
maturation	O
.	O

IKKepsilon	O
inhibits	O
PKC	O
to	O
promote	O
Fascin	O
-	O
dependent	O
actin	O
bundling	O
.	O

Signaling	O
molecules	O
have	O
pleiotropic	O
functions	O
and	O
are	O
activated	O
by	O
various	O
extracellular	O
stimuli	O
.	O

Protein	O
kinase	O
C	O
(	O
PKC	O
)	O
is	O
activated	O
by	O
diverse	O
receptors	O
,	O
and	O
its	O
dysregulation	O
is	O
associated	O
with	O
diseases	O
including	O
cancer	O
.	O

However	O
,	O
how	O
the	O
undesired	O
activation	O
of	O
PKC	O
is	O
prevented	O
during	O
development	O
remains	O
poorly	O
understood	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
protein	O
kinase	O
,	O
IKKepsilon	O
,	O
is	O
active	O
at	O
the	O
growing	O
bristle	O
tip	O
and	O
regulates	O
actin	O
bundle	O
organization	O
during	O
Drosophila	O
bristle	O
morphogenesis	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
IKKepsilon	O
regulates	O
the	O
actin	O
bundle	O
localization	O
of	O
a	O
dynamic	O
actin	O
cross	O
-	O
linker	O
,	O
Fascin	O
.	O

IKKepsilon	O
inhibits	O
PKC	O
,	O
thereby	O
protecting	O
Fascin	O
from	O
inhibitory	O
phosphorylation	O
.	O

Excess	O
PKC	O
activation	O
is	O
responsible	O
for	O
the	O
actin	O
bundle	O
defects	O
in	O
IKKepsilon	O
-	O
deficient	O
bristles	O
,	O
whereas	O
PKC	O
is	O
dispensable	O
for	O
bristle	O
morphogenesis	O
in	O
wild	O
-	O
type	O
bristles	O
,	O
indicating	O
that	O
PKC	O
is	O
repressed	O
by	O
IKKepsilon	O
in	O
wild	O
-	O
type	O
bristle	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
IKKepsilon	O
prevents	O
excess	O
activation	O
of	O
PKC	O
during	O
bristle	O
morphogenesis	O
.	O

Role	O
of	O
variant	O
prealbumin	O
in	O
the	O
pathogenesis	O
of	O
familial	O
amyloidotic	O
polyneuropathy	O
:	O
fate	O
of	O
normal	O
and	O
variant	O
prealbumin	O
in	O
the	O
circulation	O
.	O

According	O
to	O
recent	O
studies	O
on	O
protein	O
chemistry	O
and	O
genetic	O
engineering	O
,	O
replacement	O
of	O
the	O
Val30	O
residue	O
of	O
prealbumin	O
by	O
methionine	O
is	O
believed	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
formation	O
of	O
amyloid	O
deposit	O
and	O
the	O
pathogenesis	O
of	O
familial	O
amyloidotic	O
polyneuropathy	O
(	O
FAP	O
)	O
.	O

However	O
,	O
only	O
limited	O
information	O
is	O
available	O
concerning	O
the	O
behavior	O
of	O
prealbumin	O
in	O
the	O
circulation	O
.	O

To	O
obtain	O
the	O
molecular	O
insight	O
into	O
the	O
mechanism	O
of	O
amyloid	O
deposition	O
,	O
it	O
is	O
indispensable	O
to	O
know	O
the	O
fates	O
of	O
normal	O
and	O
variant	O
prealbumin	O
in	O
vivo	O
.	O

Thus	O
,	O
the	O
fates	O
of	O
prealbumin	O
samples	O
from	O
normal	O
and	O
FAP	O
patients	O
were	O
studied	O
in	O
normal	O
rats	O
as	O
well	O
as	O
in	O
animals	O
that	O
were	O
challenged	O
with	O
acute	O
inflammation	O
induced	O
by	O
turpentine	O
.	O

The	O
effect	O
of	O
in	O
vitro	O
photooxidation	O
of	O
prealbumin	O
samples	O
on	O
their	O
behavior	O
was	O
also	O
examined	O
in	O
vivo	O
.	O

Kinetic	O
analysis	O
revealed	O
no	O
appreciable	O
difference	O
between	O
prealbumin	O
samples	O
from	O
normal	O
and	O
FAP	O
patients	O
.	O

These	O
results	O
suggest	O
that	O
factors	O
other	O
than	O
the	O
rate	O
of	O
transfer	O
of	O
the	O
variant	O
form	O
prealbumin	O
from	O
plasma	O
to	O
an	O
extravascular	O
compartment	O
may	O
play	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
amyloid	O
deposition	O
in	O
FAP	O
patients	O
.	O

An	O
Mcm10	O
Mutant	O
Defective	O
in	O
ssDNA	O
Binding	O
Shows	O
Defects	O
in	O
DNA	O
Replication	O
Initiation	O
.	O

Mcm10	O
is	O
an	O
essential	O
protein	O
that	O
functions	O
to	O
initiate	O
DNA	O
replication	O
after	O
the	O
formation	O
of	O
the	O
replication	O
fork	O
helicase	O
.	O

In	O
this	O
manuscript	O
,	O
we	O
identified	O
a	O
budding	O
yeast	O
Mcm10	O
mutant	O
(	O
Mcm10	O
-	O
m2	O
,	O
3	O
,	O
4	O
)	O
that	O
is	O
defective	O
in	O
DNA	O
binding	O
in	O
vitro	O
.	O

Moreover	O
,	O
this	O
Mcm10	O
-	O
m2	O
,	O
3	O
,	O
4	O
mutant	O
does	O
not	O
stimulate	O
the	O
phosphorylation	O
of	O
Mcm2	O
by	O
Dbf4	O
-	O
dependent	O
kinase	O
(	O
DDK	O
)	O
in	O
vitro	O
.	O

When	O
we	O
expressed	O
wild	O
-	O
type	O
levels	O
of	O
mcm10	O
-	O
m2	O
,	O
3	O
,	O
4	O
in	O
budding	O
yeast	O
cells	O
,	O
we	O
observed	O
a	O
severe	O
growth	O
defect	O
and	O
a	O
substantially	O
decreased	O
DNA	O
replication	O
.	O

We	O
also	O
observed	O
a	O
substantially	O
reduced	O
replication	O
protein	O
A	O
-	O
chromatin	O
immunoprecipitation	O
signal	O
at	O
origins	O
of	O
replication	O
,	O
reduced	O
levels	O
of	O
DDK	O
-	O
phosphorylated	O
Mcm2	O
,	O
and	O
diminished	O
Go	O
,	O
Ichi	O
,	O
Ni	O
,	O
and	O
San	O
(	O
GINS	B-Complex
)	O
association	O
with	O
Mcm2	O
-	O
7	O
in	O
vivo	O
.	O

mcm5	O
-	O
bob1	O
bypasses	O
the	O
growth	O
defect	O
conferred	O
by	O
DDK	O
-	O
phosphodead	O
Mcm2	O
in	O
budding	O
yeast	O
.	O

However	O
,	O
the	O
growth	O
defect	O
observed	O
by	O
expressing	O
mcm10	O
-	O
m2	O
,	O
3	O
,	O
4	O
is	O
not	O
bypassed	O
by	O
the	O
mcm5	O
-	O
bob1	O
mutation	O
.	O

Furthermore	O
,	O
origin	O
melting	O
and	O
GINS	B-Complex
association	O
with	O
Mcm2	O
-	O
7	O
are	O
substantially	O
decreased	O
for	O
cells	O
expressing	O
mcm10	O
-	O
m2	O
,	O
3	O
,	O
4	O
in	O
the	O
mcm5	O
-	O
bob1	O
background	O
.	O

Thus	O
,	O
the	O
origin	O
melting	O
and	O
GINS	B-Complex
-	O
Mcm2	O
-	O
7	O
interaction	O
defects	O
we	O
observed	O
for	O
mcm10	O
-	O
m2	O
,	O
3	O
,	O
4	O
are	O
not	O
explained	O
by	O
decreased	O
Mcm2	O
phosphorylation	O
by	O
DDK	O
,	O
since	O
the	O
defects	O
persist	O
in	O
an	O
mcm5	O
-	O
bob1	O
background	O
.	O

These	O
data	O
suggest	O
that	O
DNA	O
binding	O
by	O
Mcm10	O
is	O
essential	O
for	O
the	O
initiation	O
of	O
DNA	O
replication	O
.	O

Nuclear	O
/	O
cytoplasmic	O
distribution	O
and	O
phosphorylation	O
of	O
YAP	O
significantly	O
influence	O
its	O
stabilization	O
.	O

To	O
find	O
out	O
if	O
TNFAIP8	O
could	O
stabilize	O
YAP	O
protein	O
,	O
we	O
treated	O
HCC	O
cells	O
with	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
(	O
CHX	O
)	O
after	O
40	O
hours	O
of	O
transfection	O
.	O

Relative	O
protein	O
intensity	O
was	O
shown	O
in	O
Supplementary	O
Figure	O
S4A	O
.	O

We	O
observed	O
that	O
,	O
after	O
6	O
hours	O
of	O
CHX	O
treatment	O
,	O
TNFAIP8	O
overexpression	O
significantly	O
upregulated	O
total	O
YAP	O
protein	O
.	O

TNFAIP8	O
siRNA	O
showed	O
the	O
opposite	O
effects	O
(	O
Figure	O
4C	O
&	O
Supplementary	O
Figure	O
S4A	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
half	O
-	O
life	O
of	O
endogenous	O
YAP	O
increased	O
with	O
TNFAIP8	O
transfection	O
and	O
decreased	O
after	O
siRNA	O
treatment	O
.	O

Then	O
we	O
performed	O
luciferase	O
reporter	O
assay	O
using	O
reporter	O
plasmid	O
with	O
8xGTIIC	O
-	O
luciferase	O
.	O

The	O
activity	O
of	O
TEAD	O
luciferase	O
reporter	O
indicates	O
transcriptional	O
activity	O
of	O
YAP	O
.	O

Upregulation	O
of	O
TEAD	O
luciferase	O
activity	O
correlates	O
with	O
inhibition	O
of	O
Hippo	O
signaling	O
pathway	O
.	O

As	O
shown	O
in	O
Figure	O
4D	O
,	O
TNFAIP8	O
positively	O
regulated	O
transcription	O
of	O
YAP	O
/	O
TEAD	O
.	O

Based	O
on	O
the	O
above	O
results	O
,	O
we	O
assumed	O
that	O
TNFAIP8	O
could	O
stabilize	O
the	O
YAP	O
protein	O
and	O
thus	O
increase	O
its	O
steady	O
-	O
state	O
protein	O
level	O
and	O
nuclear	O
localization	O
,	O
leading	O
to	O
inhibition	O
of	O
Hippo	O
signaling	O
.	O

Breast	O
cancer	O
tissue	O
microarray	O
(	O
TMA	O
)	O
of	O
334	O
cases	O
of	O
invasive	O
ductal	O
carcinomas	O
is	O
obtained	O
from	O
the	O
tissue	O
bank	O
at	O
the	O
Markey	O
Cancer	O
Center	O
'	O
s	O
tissue	O
repository	O
at	O
our	O
institute	O
.	O

Tissue	O
samples	O
were	O
stained	O
with	O
anti	O
-	O
Dub3	O
(	O
Abcam	O
,	O
ab12991	O
,	O
1	O
:	O
100	O
dilution	O
)	O
and	O
anti	O
-	O
Snail1	O
(	O
Abcam	O
,	O
ab53519	O
,	O
1	O
:	O
250	O
dilution	O
)	O
antibodies	O
,	O
and	O
each	O
sample	O
was	O
scored	O
by	O
an	O
H	O
-	O
score	O
method	O
that	O
combines	O
the	O
values	O
of	O
immunoreaction	O
intensity	O
and	O
the	O
percentage	O
of	O
tumour	O
cell	O
staining	O
as	O
described	O
previously	O
.	O

Chi	O
-	O
square	O
analysis	O
was	O
used	O
to	O
analyse	O
the	O
relationship	O
between	O
Dub3	O
and	O
Snail1	O
expression	O
;	O
statistical	O
significance	O
was	O
defined	O
as	O
P	O
<	O
0	O
.	O
05	O
.	O

In	O
vivo	O
characterization	O
of	O
the	O
poly	O
(	O
ADP	O
-	O
ribosylation	O
)	O
of	O
SV40	O
chromatin	O
and	O
large	O
T	O
antigen	O
by	O
immunofractionation	O
.	O

We	O
have	O
confirmed	O
the	O
poly	O
(	O
ADP	O
-	O
ribosylation	O
)	O
of	O
large	O
T	O
antigen	O
of	O
SV40	O
by	O
using	O
antibodies	O
to	O
both	O
large	O
T	O
antigen	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
and	O
consequently	O
have	O
begun	O
to	O
characterize	O
how	O
this	O
post	O
-	O
translational	O
nuclear	O
modification	O
of	O
the	O
viral	O
protein	O
modulates	O
its	O
biological	O
functions	O
.	O

SV40	O
minichromosomal	O
subpopulation	O
containing	O
replicative	O
intermediate	O
DNA	O
was	O
shown	O
to	O
have	O
a	O
significantly	O
higher	O
affinity	O
for	O
anti	O
-	O
poly	O
(	O
ADP	O
-	O
Rib	O
)	O
-	O
Sepharose	O
than	O
viral	O
chromatin	O
fractions	O
containing	O
mature	O
minichromosomal	O
DNA	O
.	O

An	O
anti	O
-	O
large	O
T	O
-	O
Sepharose	O
column	O
was	O
used	O
to	O
isolate	O
T	O
antigen	O
from	O
crude	O
extracts	O
by	O
two	O
different	O
approaches	O
:	O
(	O
1	O
)	O
large	O
T	O
antigen	O
was	O
labeled	O
with	O
[	O
35S	O
]	O
methionine	O
in	O
vivo	O
and	O
the	O
infected	O
cell	O
extract	O
was	O
immunofractionated	O
to	O
isolate	O
large	O
T	O
antigen	O
and	O
(	O
2	O
)	O
large	O
T	O
antigen	O
from	O
infected	O
cell	O
extracts	O
was	O
immunofractionated	O
followed	O
by	O
immunostaining	O
.	O

Using	O
these	O
techniques	O
,	O
1	O
-	O
10	O
%	O
of	O
the	O
total	O
T	O
antigen	O
from	O
infected	O
cells	O
was	O
found	O
to	O
be	O
poly	O
(	O
ADP	O
-	O
ribosylated	O
)	O
.	O

Minichromosome	O
preparations	O
per	O
se	O
were	O
also	O
subjected	O
to	O
immunofractionation	O
on	O
anti	O
-	O
large	O
T	O
-	O
Sepharose	O
.	O

The	O
high	O
level	O
of	O
retention	O
of	O
poly	O
(	O
ADP	O
-	O
ribosylated	O
)	O
species	O
of	O
minichromosomes	O
on	O
this	O
matrix	O
suggested	O
that	O
this	O
post	O
-	O
translational	O
modification	O
of	O
viral	O
chromatin	O
may	O
be	O
related	O
to	O
those	O
steps	O
in	O
viral	O
replication	O
and	O
transcription	O
under	O
regulation	O
by	O
large	O
T	O
antigen	O
.	O

Functional	O
diversity	O
among	O
putative	O
E2	O
isozymes	O
in	O
the	O
mechanism	O
of	O
ubiquitin	O
-	O
histone	O
ligation	O
.	O

The	O
covalent	O
ligation	O
of	O
the	O
8	O
.	O
6	O
-	O
kDa	O
protein	O
ubiquitin	O
to	O
histones	O
within	O
transcriptionally	O
poised	O
regions	O
is	O
believed	O
to	O
participate	O
in	O
the	O
localized	O
regulation	O
of	O
chromatin	O
structure	O
.	O

This	O
unique	O
post	O
-	O
translational	O
modification	O
is	O
thought	O
to	O
be	O
distinct	O
from	O
similar	O
cytosolic	O
reactions	O
in	O
requiring	O
ubiquitin	O
-	O
activating	O
enzyme	O
(	O
E1	O
)	O
and	O
one	O
or	O
more	O
putative	O
ubiquitin	O
carrier	O
proteins	O
(	O
E2	O
)	O
but	O
not	O
isopeptide	O
ligase	O
(	O
E3	O
)	O
.	O

Apparently	O
homogeneous	O
preparations	O
of	O
the	O
E2	O
isozymes	O
were	O
tested	O
for	O
their	O
ability	O
to	O
catalyze	O
the	O
E3	O
-	O
independent	O
conjugation	O
of	O
ubiquitin	O
to	O
linker	O
histone	O
H1	O
and	O
core	O
histones	O
H2A	O
,	O
H2B	O
,	O
H3	O
,	O
and	O
H4	O
in	O
the	O
presence	O
of	O
catalytic	O
amounts	O
of	O
E1	O
.	O

Significant	O
rates	O
of	O
nonprocessive	O
core	O
histone	O
monoubiquitination	O
were	O
catalyzed	O
by	O
the	O
E2	O
(	O
14kDa	O
)	O
,	O
E2	O
(	O
20kDa	O
)	O
,	O
and	O
E2	O
(	O
32kDa	O
)	O
isozymes	O
but	O
not	O
by	O
either	O
E2	O
(	O
17kDa	O
)	O
or	O
E2	O
(	O
24kDa	O
)	O
.	O

The	O
former	O
three	O
E2	O
isozymes	O
also	O
supported	O
slow	O
rates	O
of	O
direct	O
multiple	O
ubiquitination	O
to	O
secondary	O
ligation	O
sites	O
on	O
the	O
histones	O
.	O

Rate	O
studies	O
for	O
the	O
monoubiquitination	O
of	O
H2A	O
and	O
H2B	O
revealed	O
that	O
:	O
1	O
)	O
E2	O
(	O
14kDa	O
)	O
catalyzed	O
a	O
second	O
order	O
reaction	O
with	O
respect	O
to	O
histone	O
concentration	O
;	O
2	O
)	O
E2	O
(	O
32kDa	O
)	O
-	O
mediated	O
ligation	O
proceeded	O
by	O
hyperbolic	O
kinetics	O
,	O
yielding	O
Km	O
values	O
of	O
2	O
.	O
8	O
and	O
12	O
microM	O
for	O
H2A	O
and	O
H2B	O
,	O
respectively	O
;	O
and	O
3	O
)	O
E2	O
(	O
20kDa	O
)	O
exhibited	O
complex	O
kinetics	O
composed	O
of	O
both	O
second	O
order	O
and	O
hyperbolic	O
pathways	O
,	O
the	O
latter	O
having	O
Km	O
values	O
of	O
0	O
.	O
83	O
and	O
1	O
.	O
5	O
microM	O
for	O
H2A	O
and	O
H2B	O
,	O
respectively	O
.	O

Pulse	O
-	O
chase	O
kinetics	O
suggested	O
that	O
both	O
ubiquitin	O
thiol	O
esters	O
formed	O
to	O
E2	O
(	O
20kDa	O
)	O
were	O
catalytically	O
competent	O
in	O
H2A	O
ligation	O
.	O

The	O
active	O
E2	O
isozymes	O
also	O
catalyzed	O
the	O
processive	O
multiple	O
ubiquitination	O
of	O
calf	O
thymus	O
H1	O
.	O

Other	O
rate	O
studies	O
determined	O
that	O
Kd	O
values	O
for	O
binding	O
of	O
the	O
active	O
E2	O
species	O
to	O
E1	O
ternary	O
complex	O
were	O
0	O
.	O
1	O
nM	O
for	O
E2	O
(	O
14kDa	O
)	O
,	O
0	O
.	O
4	O
nM	O
for	O
E2	O
(	O
32kDa	O
)	O
,	O
and	O
3	O
.	O
6	O
nM	O
for	O
E2	O
(	O
20kDa	O
)	O
.	O

The	O
data	O
indicate	O
that	O
E2	O
(	O
20kDa	O
)	O
and	O
E2	O
(	O
32kDa	O
)	O
are	O
specific	O
but	O
mechanistically	O
distinct	O
ligation	O
enzymes	O
responsible	O
for	O
the	O
conjugation	O
of	O
ubiquitin	O
to	O
nucleosomal	O
proteins	O
.	O

In	O
contrast	O
to	O
other	O
cyclins	O
involved	O
in	O
cell	O
cycle	O
progression	O
,	O
CycC	O
does	O
not	O
oscillate	O
.	O

Instead	O
,	O
Cdk8	O
/	O
CycC	O
activity	O
appears	O
to	O
be	O
regulated	O
by	O
other	O
Mediator	B-Complex
subunits	O
.	O

In	O
line	O
with	O
a	O
model	O
previously	O
suggested	O
by	O
others	O
and	O
us	O
,	O
we	O
believe	O
that	O
Med12	O
and	O
Med13	O
keep	O
the	O
Cdk8	O
/	O
CycC	O
pair	O
in	O
a	O
repressed	O
state	O
,	O
which	O
can	O
be	O
released	O
when	O
activators	O
and	O
/	O
or	O
signaling	O
pathways	O
induce	O
structural	O
changes	O
in	O
the	O
Mediator	B-Complex
complex	O
.	O

Loss	O
of	O
Med12	O
and	O
/	O
or	O
Med13	O
may	O
abolish	O
this	O
repressive	O
effect	O
,	O
which	O
explains	O
the	O
early	O
entry	O
into	O
mitosis	O
observed	O
in	O
med12Delta	O
and	O
med13Delta	O
cells	O
.	O

In	O
fact	O
,	O
loss	O
of	O
Med12	O
and	O
Med13	O
leads	O
to	O
the	O
release	O
of	O
CycC	O
and	O
Cdk8	O
from	O
Mediator	B-Complex
.	O

We	O
reasoned	O
that	O
a	O
free	O
pool	O
of	O
CycC	O
and	O
Cdk8	O
might	O
affect	O
cell	O
cycle	O
progression	O
by	O
interacting	O
with	O
alternative	O
cyclins	O
and	O
Cdks	O
.	O

In	O
support	O
of	O
this	O
idea	O
,	O
a	O
previous	O
study	O
of	O
human	O
CycC	O
showed	O
that	O
the	O
protein	O
can	O
interact	O
with	O
an	O
alternative	O
Cdk	O
,	O
namely	O
CDK3	O
.	O

To	O
address	O
this	O
possibility	O
experimentally	O
,	O
here	O
we	O
fused	O
CycC	O
to	O
Cdk8	O
,	O
thereby	O
restricting	O
interaction	O
to	O
the	O
cognate	O
partner	O
and	O
analyzed	O
the	O
effects	O
of	O
med12	O
+	O
and	O
med13	O
+	O
deletion	O
on	O
cell	O
cycle	O
progression	O
.	O

As	O
demonstrated	O
here	O
,	O
the	O
effects	O
of	O
med12Deltamed13Delta	O
on	O
mitotic	O
progression	O
are	O
identical	O
in	O
the	O
Cdk8	O
-	O
L	O
-	O
CycC	O
strain	O
to	O
the	O
effects	O
observed	O
in	O
wt	O
cells	O
,	O
strongly	O
suggesting	O
that	O
Cdk8	O
and	O
CycC	O
act	O
in	O
concert	O
to	O
regulate	O
timing	O
of	O
mitosis	O
.	O

Loss	O
of	O
Med12	O
and	O
Med13	O
also	O
causes	O
early	O
entry	O
into	O
S	O
phase	O
.	O

Of	O
interest	O
,	O
this	O
effect	O
is	O
not	O
observed	O
in	O
CycC	O
-	O
L	O
-	O
Cdk8	O
cells	O
.	O

The	O
data	O
suggest	O
that	O
eliminating	O
the	O
possibility	O
for	O
Cdk8	O
and	O
CycC	O
to	O
interact	O
with	O
alternative	O
cyclins	O
and	O
Cdks	O
can	O
restrict	O
the	O
effects	O
of	O
med12	O
+	O
and	O
med13	O
+	O
deletions	O
on	O
cell	O
cycle	O
progression	O
.	O

Both	O
overproduction	O
of	O
Cdk8	O
and	O
mutations	O
in	O
CycC	O
are	O
observed	O
in	O
human	O
tumors	O
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
these	O
mutagenic	O
changes	O
may	O
cause	O
the	O
formation	O
of	O
a	O
free	O
Cdk8	O
pool	O
in	O
mammalian	O
cells	O
,	O
which	O
could	O
result	O
in	O
spontaneous	O
interactions	O
with	O
alternative	O
cyclins	O
and	O
promote	O
S	O
-	O
phase	O
progression	O
.	O

Limited	O
information	O
is	O
available	O
on	O
the	O
role	O
of	O
Cdk8	O
and	O
CycC	O
in	O
M	O
-	O
phase	O
progression	O
in	O
mammalian	O
cells	O
.	O

We	O
hope	O
that	O
our	O
findings	O
will	O
stimulate	O
others	O
to	O
elucidate	O
whether	O
the	O
effects	O
we	O
observe	O
in	O
fission	O
yeast	O
are	O
also	O
conserved	O
in	O
higher	O
organisms	O
.	O

2	O
ODs	O
of	O
cells	O
grown	O
in	O
SD	O
media	O
to	O
exponential	O
phase	O
(	O
OD600	O
=	O
0	O
.	O
5	O
-	O
1	O
)	O
were	O
spheroplasted	O
by	O
treatment	O
with	O
2	O
.	O
5	O
U	O
per	O
OD	O
of	O
Zymolyase	O
(	O
Zymo	O
Research	O
;	O
Orange	O
,	O
CA	O
)	O
.	O

The	O
total	O
RNA	O
was	O
extracted	O
using	O
the	O
NucleoSpin	O
RNA	O
extraction	O
kit	O
(	O
Macherey	O
Nagel	O
)	O
.	O

1	O
mug	O
of	O
resulting	O
RNAs	O
were	O
then	O
treated	O
with	O
DNase	O
I	O
(	O
NEB	O
)	O
and	O
subjected	O
to	O
reverse	O
transcriptionusing	O
Maxima	O
First	O
Strand	O
cDNA	O
synthesis	O
Kit	O
for	O
quantitative	O
PCR	O
with	O
reverse	O
transcription	O
(	O
Thermo	O
Scientific	O
)	O
.	O

Quantitative	O
real	O
time	O
PCR	O
was	O
performed	O
with	O
Maxima	O
SYBR	O
Green	O
qPCR	O
Master	O
Mix	O
(	O
Thermo	O
Scientific	O
)	O
in	O
a	O
Bio	O
-	O
Rad	O
CFX96	O
Real	O
-	O
Time	O
PCR	O
system	O
using	O
OLE1	O
and	O
ACT1	O
specific	O
primers	O
.	O

The	O
OLE1	O
mRNA	O
abundance	O
in	O
mutants	O
was	O
normalized	O
to	O
ACT1	O
mRNA	O
levels	O
and	O
expressed	O
relative	O
to	O
OLE1	O
expression	O
in	O
WT	O
using	O
the	O
Livak	O
method	O
.	O

Six	O
experiments	O
were	O
performed	O
and	O
the	O
relative	O
mRNA	O
levels	O
were	O
averaged	O
.	O

Nedd4	O
-	O
2	O
mis	O
-	O
localization	O
in	O
PCK	O
kidney	O
is	O
associated	O
with	O
increased	O
apical	O
ENaC	O
and	O
enhanced	O
sodium	O
reabsorption	O
.	O

(	O
a	O
)	O
Kidneys	O
from	O
12	O
-	O
week	O
old	O
strain	O
control	O
(	O
Crj	O
:	O
CD	O
/	O
SD	O
)	O
(	O
Wt	O
)	O
;	O
left	O
)	O
and	O
PCK	O
(	O
right	O
)	O
rats	O
immunostained	O
for	O
Nedd4	O
-	O
2	O
(	O
red	O
)	O
,	O
Lamp1	O
(	O
green	O
)	O
and	O
DAPI	O
(	O
blue	O
)	O
.	O

Similar	O
patterns	O
were	O
observed	O
in	O
sections	O
from	O
three	O
different	O
mutants	O
,	O
and	O
abnormalities	O
were	O
restricted	O
to	O
collecting	O
ducts	O
.	O

Scale	O
bars	O
,	O
20	O
mum	O
.	O

(	O
b	O
)	O
Kidneys	O
from	O
12	O
-	O
week	O
old	O
strain	O
control	O
(	O
Wt	O
)	O
and	O
PCK	O
rats	O
immunostained	O
for	O
each	O
of	O
the	O
three	O
subunits	O
of	O
ENaC	O
(	O
red	O
)	O
,	O
DBA	O
(	O
green	O
)	O
and	O
DAPI	O
(	O
blue	O
)	O
.	O

Scale	O
bars	O
,	O
20	O
mum	O
.	O

(	O
c	O
)	O
Primary	O
CD	O
cells	O
from	O
12	O
-	O
week	O
old	O
strain	O
control	O
and	O
PCK	O
rats	O
were	O
isolated	O
and	O
cultured	O
on	O
Transwell	O
filters	O
and	O
then	O
immunostained	O
for	O
each	O
of	O
the	O
three	O
ENaC	O
subunits	O
(	O
red	O
)	O
and	O
DAPI	O
(	O
blue	O
)	O
.	O

Scale	O
bars	O
,	O
10	O
mum	O
.	O

(	O
d	O
)	O
Open	O
-	O
circuit	O
measurements	O
of	O
primary	O
CD	O
cells	O
from	O
three	O
12	O
-	O
week	O
old	O
strain	O
control	O
rats	O
(	O
Wt1	O
,	O
Wt2	O
and	O
Wt3	O
)	O
and	O
three	O
PCK	O
rats	O
(	O
PCK1	O
,	O
PCK2	O
,	O
PCK3	O
)	O
cultured	O
on	O
Transwell	O
filters	O
either	O
in	O
the	O
absence	O
or	O
presence	O
(	O
"	O
+	O
Amil	O
)	O
of	O
50	O
muM	O
amiloride	O
in	O
the	O
apical	O
side	O
.	O

Measurements	O
were	O
collected	O
from	O
at	O
least	O
10	O
independent	O
wells	O
per	O
animal	O
.	O

*	O
P	O
<	O
0	O
.	O
05	O
,	O
*	O
*	O
P	O
<	O
0	O
.	O
01	O
.	O

To	O
confirm	O
that	O
plasma	O
cBIN1	O
-	O
MPs	O
are	O
of	O
cardiomyocyte	O
origin	O
,	O
we	O
took	O
advantage	O
of	O
mice	O
with	O
cardiac	O
-	O
specific	O
heterozygous	O
deletion	O
of	O
the	O
Bin1	O
gene	O
(	O
Bin1	O
HT	O
)	O
.	O

Bin1	O
HT	O
mice	O
are	O
grossly	O
phenotypically	O
normal	O
with	O
normal	O
cardiac	O
contractile	O
function	O
at	O
young	O
adulthood	O
(	O
2	O
-	O
4	O
months	O
)	O
.	O

Yet	O
,	O
their	O
cardiomyocytes	O
lose	O
cBIN1	O
-	O
microfolds	O
at	O
t	O
-	O
tubules	O
,	O
and	O
t	O
-	O
tubule	O
remodeling	O
occurs	O
with	O
this	O
loss	O
of	O
microfolds	O
within	O
the	O
t	O
-	O
tubule	O
membrane	O
.	O

Plasma	O
for	O
MP	O
acquisition	O
was	O
obtained	O
from	O
Bin1	O
HT	O
mice	O
and	O
their	O
wild	O
-	O
type	O
(	O
WT	O
)	O
littermate	O
controls	O
.	O

Purified	O
MPs	O
were	O
fixed	O
and	O
colabeled	O
with	O
anti	O
-	O
cBIN1	O
-	O
Alexa	O
647	O
and	O
annexin	O
V	O
-	O
Alexa	O
488	O
.	O

Plasma	O
MPs	O
were	O
loaded	O
in	O
TruCount	O
tubes	O
,	O
and	O
a	O
total	O
of	O
20	O
,	O
000	O
events	O
were	O
counted	O
.	O

Based	O
on	O
the	O
known	O
concentration	O
of	O
TruCount	O
reference	O
beads	O
,	O
the	O
plasma	O
concentration	O
of	O
MPs	O
could	O
be	O
determined	O
.	O

Both	O
the	O
total	O
MP	O
population	O
and	O
the	O
subpopulation	O
of	O
double	O
positive	O
in	O
cBIN1	O
and	O
annexin	O
V	O
(	O
cBIN1	O
-	O
MPs	O
)	O
were	O
quantified	O
and	O
compared	O
between	O
WT	O
and	O
Bin1	O
HT	O
mice	O
.	O

As	O
indicated	O
in	O
Fig	O
1D	O
,	O
although	O
total	O
plasma	O
MP	O
concentration	O
is	O
not	O
significantly	O
altered	O
in	O
Bin1	O
HT	O
mice	O
(	O
Fig	O
1D	O
,	O
left	O
panel	O
)	O
,	O
the	O
plasma	O
concentration	O
of	O
cBIN1	O
-	O
MPs	O
(	O
Fig	O
1D	O
,	O
right	O
panel	O
;	O
representative	O
flow	O
scatter	O
plots	O
against	O
IgG	B-Complex
isotype	O
control	O
are	O
in	O
S1C	O
Fig	O
)	O
in	O
Bin1	O
HT	O
mice	O
(	O
251	O
.	O
8	O
+	O
/	O
-	O
48	O
.	O
3	O
MPs	O
/	O
ml	O
)	O
is	O
significantly	O
decreased	O
by	O
47	O
%	O
from	O
WT	O
mice	O
(	O
470	O
.	O
4	O
+	O
/	O
-	O
67	O
.	O
8	O
MPs	O
/	O
ml	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
1D	O
)	O
.	O

Consistent	O
with	O
less	O
cBIN1	O
-	O
MPs	O
,	O
biochemical	O
immunoprecipitation	O
followed	O
by	O
western	O
blot	O
detection	O
further	O
confirmed	O
that	O
the	O
cBIN1	O
protein	O
level	O
is	O
reduced	O
in	O
plasma	O
from	O
Bin1	O
HT	O
mice	O
,	O
corresponding	O
to	O
a	O
similar	O
reduction	O
of	O
cBIN1	O
protein	O
in	O
heart	O
lysates	O
from	O
the	O
same	O
mice	O
(	O
Fig	O
1E	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
support	O
that	O
cBIN1	O
in	O
plasma	O
is	O
present	O
in	O
MPs	O
of	O
cardiomyocyte	O
origin	O
.	O

Exomer	B-Complex
is	O
an	O
adaptor	O
complex	O
required	O
for	O
the	O
direct	O
transport	O
of	O
a	O
selected	O
number	O
of	O
cargoes	O
from	O
the	O
<	O
i	O
>	O
trans	O
<	O
/	O
i	O
>	O
-	O
Golgi	O
network	O
(	O
TGN	O
)	O
to	O
the	O
plasma	O
membrane	O
in	O
<	O
i	O
>	O
Saccharomyces	O
cerevisiae	O
<	O
/	O
i	O
>	O
However	O
,	O
exomer	B-Complex
mutants	O
are	O
highly	O
sensitive	O
to	O
increased	O
concentrations	O
of	O
alkali	O
metal	O
cations	O
,	O
a	O
situation	O
that	O
remains	O
unexplained	O
by	O
the	O
lack	O
of	O
transport	O
of	O
any	O
known	O
cargoes	O
.	O

Here	O
we	O
identify	O
several	O
<	O
i	O
>	O
HAL	O
<	O
/	O
i	O
>	O
genes	O
that	O
act	O
as	O
multicopy	O
suppressors	O
of	O
this	O
sensitivity	O
and	O
are	O
connected	O
to	O
the	O
reduced	O
function	O
of	O
the	O
sodium	O
ATPase	O
Ena1	O
.	O

Furthermore	O
,	O
we	O
find	O
that	O
Ena1	O
is	O
dependent	O
on	O
exomer	B-Complex
function	O
.	O

Even	O
though	O
Ena1	O
can	O
reach	O
the	O
plasma	O
membrane	O
independently	O
of	O
exomer	B-Complex
,	O
polarized	O
delivery	O
of	O
Ena1	O
to	O
the	O
bud	O
requires	O
functional	O
exomer	B-Complex
.	O

Moreover	O
,	O
exomer	B-Complex
is	O
required	O
for	O
full	O
induction	O
of	O
Ena1	O
expression	O
after	O
cationic	O
stress	O
by	O
facilitating	O
the	O
plasma	O
membrane	O
recruitment	O
of	O
the	O
molecular	O
machinery	O
involved	O
in	O
Rim101	O
processing	O
and	O
activation	O
of	O
the	O
RIM101	O
pathway	O
in	O
response	O
to	O
stress	O
.	O

Both	O
the	O
defective	O
localization	O
and	O
the	O
reduced	O
levels	O
of	O
Ena1	O
contribute	O
to	O
the	O
sensitivity	O
of	O
exomer	B-Complex
mutants	O
to	O
alkali	O
metal	O
cations	O
.	O

Our	O
work	O
thus	O
expands	O
the	O
spectrum	O
of	O
exomer	B-Complex
-	O
dependent	O
proteins	O
and	O
provides	O
a	O
link	O
to	O
a	O
more	O
general	O
role	O
of	O
exomer	B-Complex
in	O
TGN	O
organization	O
.	O

We	O
identified	O
slam	O
as	O
an	O
mRNA	O
with	O
noncoding	O
information	O
for	O
localization	O
and	O
translational	O
control	O
in	O
addition	O
to	O
its	O
coding	O
information	O
.	O

On	O
the	O
molecular	O
level	O
,	O
slam	O
is	O
special	O
in	O
that	O
mRNA	O
and	O
protein	O
associate	O
in	O
a	O
complex	O
as	O
demonstrated	O
by	O
co	O
-	O
immunoprecipitation	O
.	O

This	O
unconventional	O
relationship	O
of	O
slam	O
RNA	O
and	O
protein	O
may	O
be	O
important	O
for	O
the	O
tightly	O
restricted	O
subcellular	O
localization	O
and	O
strong	O
increase	O
in	O
protein	O
levels	O
at	O
the	O
FC	O
.	O

The	O
functional	O
interaction	O
of	O
slam	O
RNA	O
and	O
protein	O
constitutes	O
a	O
positive	O
feedback	O
loop	O
,	O
which	O
contributes	O
to	O
the	O
fast	O
increase	O
in	O
Slam	O
protein	O
levels	O
at	O
the	O
FC	O
.	O

In	O
an	O
established	O
model	O
of	O
metastatic	O
lung	O
cancer	O
,	O
H460	O
cells	O
with	O
IGF2BP3	O
overexpression	O
were	O
injected	O
into	O
the	O
tail	O
vein	O
of	O
nude	O
mice	O
.	O

Animals	O
were	O
sacrificed	O
at	O
day	O
21	O
and	O
the	O
lungs	O
were	O
resected	O
and	O
photographed	O
.	O

The	O
number	O
of	O
tumor	O
nodules	O
in	O
lungs	O
was	O
significantly	O
enhanced	O
in	O
IGF2BP3	O
overexpressing	O
group	O
compared	O
with	O
control	O
group	O
(	O
Figure	O
4A	O
and	O
4B	O
)	O
.	O

In	O
agreement	O
with	O
the	O
subcutaneous	O
lung	O
cancer	O
model	O
,	O
IGF2BP3	O
overexpressing	O
group	O
in	O
the	O
metastatic	O
lung	O
cancer	O
model	O
also	O
showed	O
reduced	O
survival	O
rate	O
(	O
Figure	O
4C	O
)	O
.	O

To	O
support	O
this	O
,	O
we	O
also	O
analyzed	O
the	O
survival	O
rate	O
of	O
lung	O
cancer	O
patients	O
by	O
an	O
online	O
tool	O
"	O
Kaplan	O
-	O
Meier	O
Plotter	O
"	O
analysis	O
(	O
http	O
:	O
/	O
/	O
kmplot	O
.	O
com	O
/	O
analysis	O
/	O
)	O
.	O

As	O
shown	O
in	O
Figure	O
4D	O
,	O
lung	O
cancer	O
patients	O
with	O
high	O
expression	O
of	O
IGF2BP3	O
had	O
shorter	O
survival	O
rate	O
compared	O
to	O
those	O
with	O
low	O
expression	O
of	O
IGF2BP3	O
.	O
Thus	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
assays	O
suggest	O
that	O
overexpression	O
of	O
IGF2BP3	O
promotes	O
proliferation	O
,	O
metastasis	O
and	O
tumorigenicity	O
of	O
lung	O
cancer	O
cells	O
.	O

RAD4	O
and	O
RAD23	O
/	O
HMR	O
Contribute	O
to	O
Arabidopsis	O
UV	O
Tolerance	O
.	O

In	O
plants	O
,	O
exposure	O
to	O
solar	O
ultraviolet	O
(	O
UV	O
)	O
light	O
is	O
unavoidable	O
,	O
resulting	O
in	O
DNA	O
damage	O
.	O

Damaged	O
DNA	O
causes	O
mutations	O
,	O
replication	O
arrest	O
,	O
and	O
cell	O
death	O
,	O
thus	O
efficient	O
repair	O
of	O
the	O
damaged	O
DNA	O
is	O
essential	O
.	O

A	O
light	O
-	O
independent	O
DNA	O
repair	O
pathway	O
called	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
is	O
conserved	O
throughout	O
evolution	O
.	O

For	O
example	O
,	O
the	O
damaged	O
DNA	O
-	O
binding	O
protein	O
Radiation	O
sensitive	O
4	O
(	O
Rad4	O
)	O
in	O
Saccharomyces	O
cerevisiae	O
is	O
homologous	O
to	O
the	O
mammalian	O
NER	O
protein	O
Xeroderma	O
Pigmentosum	O
complementation	O
group	O
C	O
(	O
XPC	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
role	O
of	O
the	O
Arabidopsis	O
thaliana	O
Rad4	O
/	O
XPC	O
homologue	O
(	O
AtRAD4	O
)	O
in	O
plant	O
UV	O
tolerance	O
by	O
generating	O
overexpression	O
lines	O
.	O

AtRAD4	O
overexpression	O
,	O
both	O
with	O
and	O
without	O
an	O
N	O
-	O
terminal	O
yellow	O
fluorescent	O
protein	O
(	O
YFP	O
)	O
tag	O
,	O
resulted	O
in	O
increased	O
UV	O
tolerance	O
.	O

YFP	O
-	O
RAD4	O
localized	O
to	O
the	O
nucleus	O
,	O
and	O
UV	O
treatment	O
did	O
not	O
alter	O
this	O
localization	O
.	O

We	O
also	O
used	O
yeast	O
two	O
-	O
hybrid	O
analysis	O
to	O
examine	O
the	O
interaction	O
of	O
AtRAD4	O
with	O
Arabidopsis	O
RAD23	O
and	O
found	O
that	O
RAD4	O
interacted	O
with	O
RAD23B	O
as	O
well	O
as	O
with	O
the	O
structurally	O
similar	O
protein	O
HEMERA	O
(	O
HMR	O
)	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
hmr	O
and	O
rad23	O
mutants	O
exhibited	O
increased	O
UV	O
sensitivity	O
.	O

Thus	O
,	O
our	O
analysis	O
suggests	O
a	O
role	O
for	O
RAD4	O
and	O
RAD23	O
/	O
HMR	O
in	O
plant	O
UV	O
tolerance	O
.	O

Glycogen	O
debranching	O
enzyme	O
:	O
purification	O
,	O
antibody	O
characterization	O
,	O
and	O
immunoblot	O
analyses	O
of	O
type	O
III	O
glycogen	O
storage	O
disease	O
.	O

Type	O
III	O
glycogen	O
storage	O
disease	O
is	O
caused	O
by	O
a	O
deficiency	O
of	O
glycogen	O
debranching	O
-	O
enzyme	O
activity	O
.	O

Many	O
patients	O
with	O
this	O
disease	O
have	O
both	O
liver	O
and	O
muscle	O
involvement	O
,	O
whereas	O
others	O
have	O
only	O
liver	O
involvement	O
without	O
clinical	O
or	O
laboratory	O
evidence	O
of	O
myopathy	O
.	O

To	O
improve	O
our	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
the	O
disease	O
,	O
debranching	O
enzyme	O
was	O
purified	O
238	O
-	O
fold	O
from	O
porcine	O
skeletal	O
muscle	O
.	O

In	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
the	O
purified	O
enzyme	O
gave	O
a	O
single	O
band	O
with	O
a	O
relative	O
molecular	O
weight	O
of	O
160	O
,	O
000	O
that	O
migrated	O
to	O
the	O
same	O
position	O
as	O
purified	O
rabbit	O
-	O
muscle	O
debranching	O
enzyme	O
.	O

Antiserum	O
against	O
porcine	O
debranching	O
enzyme	O
was	O
prepared	O
in	O
rabbit	O
.	O

The	O
antiserum	O
reacted	O
against	O
porcine	O
debranching	O
enzyme	O
with	O
a	O
single	O
precipitin	O
line	O
and	O
demonstrated	O
a	O
reaction	O
having	O
complete	O
identity	O
to	O
those	O
of	O
both	O
the	O
enzyme	O
present	O
in	O
crude	O
muscle	O
and	O
the	O
enzyme	O
present	O
in	O
liver	O
extracts	O
.	O

Incubation	O
of	O
antiserum	O
with	O
purified	O
porcine	O
debranching	O
enzyme	O
inhibited	O
almost	O
all	O
enzyme	O
activity	O
,	O
whereas	O
such	O
treatment	O
with	O
preimmune	O
serum	O
had	O
little	O
effect	O
.	O

The	O
antiserum	O
also	O
inhibited	O
debranching	O
-	O
enzyme	O
activity	O
in	O
crude	O
liver	O
extracts	O
from	O
both	O
pigs	O
and	O
humans	O
to	O
the	O
same	O
extent	O
as	O
was	O
observed	O
in	O
muscle	O
.	O

Immunoblot	O
analysis	O
probed	O
with	O
anti	O
-	O
porcine	O
-	O
muscle	O
debranching	O
-	O
enzyme	O
antiserum	O
showed	O
that	O
the	O
antiserum	O
can	O
detect	O
debranching	O
enzyme	O
in	O
both	O
human	O
muscle	O
and	O
human	O
liver	O
.	O

The	O
bands	O
detected	O
in	O
human	O
samples	O
by	O
the	O
antiserum	O
were	O
the	O
same	O
size	O
as	O
the	O
one	O
detected	O
in	O
porcine	O
muscle	O
.	O

Five	O
patients	O
with	O
Type	O
III	O
and	O
six	O
patients	O
with	O
other	O
types	O
of	O
glycogen	O
storage	O
disease	O
were	O
subjected	O
to	O
immunoblot	O
analysis	O
.	O

Although	O
anti	O
-	O
porcine	O
antiserum	O
detected	O
specific	O
bands	O
in	O
all	O
liver	O
and	O
muscle	O
samples	O
from	O
patients	O
with	O
other	O
types	O
of	O
glycogen	O
storage	O
disease	O
(	O
Types	O
I	O
,	O
II	O
,	O
and	O
IX	O
)	O
,	O
the	O
antiserum	O
detected	O
no	O
cross	O
-	O
reactive	O
material	O
in	O
any	O
of	O
the	O
liver	O
or	O
muscle	O
samples	O
from	O
patients	O
with	O
Type	O
III	O
glycogen	O
storage	O
disease	O
.	O

These	O
data	O
indicate	O
(	O
1	O
)	O
immunochemical	O
similarity	O
of	O
debranching	O
enzyme	O
in	O
liver	O
and	O
muscle	O
and	O
(	O
2	O
)	O
that	O
deficiency	O
of	O
debranching	O
-	O
enzyme	O
activity	O
in	O
Type	O
III	O
glycogen	O
storage	O
disease	O
is	O
due	O
to	O
absence	O
of	O
debrancher	O
protein	O
in	O
the	O
patients	O
that	O
we	O
studied	O
.	O

Deubiquitylation	O
and	O
stabilization	O
of	O
p21	O
by	O
USP11	O
is	O
critical	O
for	O
cell	O
-	O
cycle	O
progression	O
and	O
DNA	O
damage	O
responses	O
.	O

p21WAF1	O
/	O
CIP1	O
is	O
a	O
broad	O
-	O
acting	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
.	O

Its	O
stability	O
is	O
essential	O
for	O
proper	O
cell	O
-	O
cycle	O
progression	O
and	O
cell	O
fate	O
decision	O
.	O

Ubiquitylation	O
by	O
the	O
multiple	O
E3	O
ubiquitin	O
ligase	O
complexes	O
is	O
the	O
major	O
regulatory	O
mechanism	O
of	O
p21	O
,	O
which	O
induces	O
p21	O
degradation	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
ubiquitylated	O
p21	O
can	O
be	O
recycled	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
USP11	O
as	O
a	O
deubiquitylase	O
of	O
p21	O
.	O

In	O
the	O
nucleus	O
,	O
USP11	O
binds	O
to	O
p21	O
,	O
catalyzes	O
the	O
removal	O
of	O
polyubiquitin	O
chains	O
conjugated	O
onto	O
p21	O
,	O
and	O
stabilizes	O
p21	O
protein	O
.	O

As	O
a	O
result	O
,	O
USP11	O
reverses	O
p21	O
polyubiquitylation	O
and	O
degradation	O
mediated	O
by	O
SCFSKP2	O
,	O
CRL4CDT2	O
,	O
and	O
APC	O
/	O
CCDC20	O
in	O
a	O
cell	O
-	O
cycle	O
-	O
independent	O
manner	O
.	O

Loss	O
of	O
USP11	O
causes	O
the	O
destabilization	O
of	O
p21	O
and	O
induces	O
the	O
G1	O
/	O
S	O
transition	O
in	O
unperturbed	O
cells	O
.	O

Furthermore	O
,	O
p21	O
accumulation	O
mediated	O
by	O
DNA	O
damage	O
is	O
completely	O
abolished	O
in	O
cells	O
depleted	O
of	O
USP11	O
,	O
which	O
results	O
in	O
abrogation	O
of	O
the	O
G2	O
checkpoint	O
and	O
induction	O
of	O
apoptosis	O
.	O

Functionally	O
,	O
USP11	O
-	O
mediated	O
stabilization	O
of	O
p21	O
inhibits	O
cell	O
proliferation	O
and	O
tumorigenesis	O
in	O
vivo	O
.	O

These	O
findings	O
reveal	O
an	O
important	O
mechanism	O
by	O
which	O
p21	O
can	O
be	O
stabilized	O
by	O
direct	O
deubiquitylation	O
,	O
and	O
they	O
pinpoint	O
a	O
crucial	O
role	O
of	O
the	O
USP11	O
-	O
p21	O
axis	O
in	O
regulating	O
cell	O
-	O
cycle	O
progression	O
and	O
DNA	O
damage	O
responses	O
.	O

The	O
human	O
receptor	O
for	O
T	O
-	O
cell	O
growth	O
factor	O
.	O

Evidence	O
for	O
variable	O
post	O
-	O
translational	O
processing	O
,	O
phosphorylation	O
,	O
sulfation	O
,	O
and	O
the	O
ability	O
of	O
precursor	O
forms	O
of	O
the	O
receptor	O
to	O
bind	O
T	O
-	O
cell	O
growth	O
factor	O
.	O

The	O
T	O
-	O
cell	O
growth	O
factor	O
(	O
TCGF	O
)	O
receptor	O
on	O
phytohemagglutinin	O
-	O
activated	O
normal	O
peripheral	O
blood	O
T	O
-	O
cells	O
is	O
characterized	O
as	O
a	O
glycoprotein	O
with	O
an	O
apparent	O
Mr	O
=	O
55	O
,	O
000	O
that	O
contains	O
N	O
-	O
linked	O
and	O
O	O
-	O
linked	O
carbohydrate	O
with	O
only	O
approximately	O
33	O
,	O
000	O
daltons	O
of	O
peptide	O
structure	O
(	O
p33	O
)	O
as	O
evaluated	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

There	O
are	O
two	O
N	O
-	O
linked	O
glycosylated	O
intermediate	O
precursor	O
forms	O
(	O
apparent	O
Mr	O
=	O
35	O
,	O
000	O
(	O
p35	O
)	O
and	O
37	O
,	O
000	O
(	O
p37	O
]	O
.	O

This	O
receptor	O
differs	O
from	O
the	O
TCGF	O
receptor	O
on	O
HUT	O
-	O
102B2	O
cells	O
(	O
apparent	O
Mr	O
=	O
50	O
,	O
000	O
)	O
because	O
of	O
differences	O
in	O
post	O
-	O
translational	O
processing	O
.	O

Experiments	O
with	O
the	O
carboxylic	O
ionophore	O
monensin	O
demonstrate	O
blockade	O
of	O
the	O
transition	O
of	O
the	O
p35	O
and	O
p37	O
receptor	O
precursor	O
forms	O
to	O
the	O
mature	O
receptor	O
,	O
presumably	O
secondary	O
to	O
inhibition	O
of	O
Golgi	O
-	O
associated	O
receptor	O
processing	O
.	O

We	O
identify	O
the	O
primary	O
translation	O
product	O
of	O
TCGF	O
receptor	O
mRNA	O
as	O
intermediate	O
in	O
size	O
between	O
the	O
p33	O
and	O
the	O
p35	O
/	O
p37	O
forms	O
.	O

We	O
further	O
demonstrate	O
that	O
the	O
p33	O
,	O
p35	O
,	O
and	O
p37	O
precursor	O
forms	O
,	O
but	O
not	O
the	O
primary	O
translation	O
product	O
,	O
are	O
all	O
capable	O
of	O
binding	O
TCGF	O
.	O

Thus	O
,	O
the	O
removal	O
of	O
the	O
signal	O
peptide	O
and	O
/	O
or	O
conformational	O
changes	O
of	O
the	O
primary	O
translation	O
product	O
are	O
necessary	O
for	O
ligand	O
binding	O
;	O
however	O
,	O
the	O
extensive	O
post	O
-	O
translational	O
modifications	O
are	O
not	O
.	O

Lastly	O
,	O
we	O
demonstrate	O
that	O
at	O
least	O
some	O
TCGF	O
receptors	O
are	O
phosphorylated	O
and	O
sulfated	O
,	O
and	O
that	O
TCGF	O
receptors	O
on	O
phytohemagglutinin	O
-	O
activated	O
normal	O
T	O
-	O
cells	O
are	O
more	O
heavily	O
sulfated	O
than	O
those	O
on	O
HUT	O
-	O
102B2	O
cells	O
.	O

Pex30	O
has	O
an	O
N	O
-	O
terminal	O
reticulon	O
homology	O
domain	O
(	O
RHD	O
)	O
.	O

Reticulons	O
and	O
reticulon	O
-	O
like	O
proteins	O
are	O
abundant	O
conserved	O
ER	O
-	O
shaping	O
membrane	O
proteins	O
that	O
stabilize	O
the	O
highly	O
curved	O
portions	O
of	O
the	O
ER	O
,	O
tubules	O
,	O
and	O
the	O
edges	O
of	O
ER	O
sheets	O
through	O
the	O
RHDs	O
forming	O
wedge	O
-	O
shaped	O
hydrophobic	O
hairpins	O
.	O

We	O
found	O
that	O
overexpression	O
of	O
the	O
RHD	O
domain	O
of	O
Pex30	O
restores	O
ER	O
structure	O
in	O
S	O
.	O
cerevisiae	O
cells	O
lacking	O
the	O
reticulons	O
.	O

Endogenously	O
expressed	O
Pex30	O
is	O
in	O
ER	O
subdomains	O
in	O
tubules	O
and	O
the	O
edges	O
of	O
sheets	O
,	O
as	O
are	O
reticulons	O
.	O

The	O
function	O
of	O
Pex30	O
is	O
not	O
known	O
but	O
it	O
may	O
play	O
a	O
role	O
in	O
peroxisome	O
biogenesis	O
since	O
the	O
size	O
and	O
number	O
of	O
peroxisomes	O
is	O
altered	O
in	O
cells	O
lacking	O
Pex30	O
.	O

Pex30	O
has	O
also	O
been	O
suggested	O
to	O
reside	O
at	O
ER	O
-	O
peroxisome	O
contacts	O
.	O

The	O
screen	O
highlighted	O
9	O
loci	O
in	O
IKZF3	O
ZF2	O
whose	O
amino	O
acid	O
identities	O
were	O
critical	O
for	O
degradation	O
(	O
Fig	O
.	O
3	O
,	O
B	O
and	O
C	O
,	O
and	O
fig	O
.	O
S3	O
,	O
C	O
and	O
D	O
)	O
.	O

These	O
loci	O
again	O
included	O
residues	O
that	O
maintain	O
the	O
tertiary	O
ZF	O
fold	O
(	O
IKZF3	O
C148	O
,	O
C151	O
,	O
F155	O
,	O
L161	O
,	O
H164	O
,	O
H168	O
)	O
and	O
the	O
beta	O
-	O
hairpin	O
glycine	O
residue	O
(	O
IKZF3	O
G152	O
)	O
.	O

In	O
addition	O
,	O
the	O
screen	O
highlighted	O
two	O
non	O
-	O
structural	O
residues	O
(	O
IKZF3	O
Q147	O
and	O
A153	O
)	O
that	O
varied	O
among	O
the	O
other	O
ZF	O
degrons	O
(	O
Fig	O
.	O
3A	O
)	O
,	O
but	O
were	O
important	O
for	O
degradation	O
of	O
the	O
IKZF3	O
ZF2	O
reporter	O
(	O
Fig	O
.	O
3	O
,	O
B	O
and	O
C	O
)	O
.	O

Mutation	O
of	O
these	O
two	O
residues	O
impaired	O
degradation	O
in	O
validation	O
experiments	O
,	O
whereas	O
N149	O
,	O
a	O
residue	O
that	O
was	O
not	O
highlighted	O
in	O
the	O
mutagenesis	O
screen	O
,	O
tolerated	O
mutation	O
(	O
Fig	O
.	O
3D	O
)	O
.	O

These	O
data	O
show	O
that	O
in	O
addition	O
to	O
the	O
residues	O
maintaining	O
the	O
ZF	O
fold	O
,	O
non	O
-	O
structural	O
amino	O
acids	O
(	O
IKZF3	O
Q147	O
,	O
G152	O
and	O
A153	O
)	O
contribute	O
to	O
degron	O
specificity	O
.	O

The	O
above	O
experiments	O
suggested	O
,	O
that	O
the	O
CTR	O
plays	O
a	O
RENT	B-Complex
complex	O
-	O
independent	O
role	O
supporting	O
cellular	O
growth	O
,	O
presumably	O
by	O
interacting	O
with	O
the	O
35S	O
rDNA	O
promoter	O
.	O

We	O
therefore	O
tested	O
if	O
the	O
CTR	O
harbors	O
the	O
Pol	O
I	O
transcription	O
stimulating	O
function	O
of	O
Net1	O
.	O

Haploid	O
yeast	O
strains	O
carrying	O
a	O
NET1	O
or	O
a	O
net1Deltactr	O
allele	O
and	O
co	O
-	O
expressing	O
MNHA	O
fusion	O
proteins	O
of	O
the	O
Pol	O
I	O
subunits	O
Rpa43	O
or	O
Rpa190	O
were	O
subjected	O
to	O
ChEC	O
and	O
ChIP	O
experiments	O
.	O

ChEC	O
analyses	O
revealed	O
that	O
Rpa43	O
-	O
MNHA	O
and	O
Rpa190	O
-	O
MNHA	O
cleavage	O
events	O
at	O
the	O
35S	O
rDNA	O
promoter	O
region	O
and	O
at	O
the	O
35S	O
rDNA	O
transcription	O
termination	O
site	O
upstream	O
of	O
the	O
RFB	O
were	O
reduced	O
in	O
net1Deltactr	O
strains	O
,	O
when	O
compared	O
to	O
cleavages	O
in	O
NET1	O
strains	O
(	O
Fig	O
5A	O
compare	O
lanes	O
1	O
-	O
4	O
with	O
lanes	O
5	O
-	O
8	O
,	O
and	O
lanes	O
17	O
-	O
20	O
with	O
lanes	O
21	O
-	O
24	O
)	O
.	O

This	O
pointed	O
to	O
a	O
lower	O
occupancy	O
of	O
Pol	O
I	O
molecules	O
within	O
the	O
35S	O
rRNA	O
gene	O
region	O
.	O

ChIP	O
experiments	O
strongly	O
supported	O
this	O
finding	O
,	O
since	O
co	O
-	O
precipitation	O
of	O
35S	O
rDNA	O
fragments	O
with	O
the	O
tagged	O
Pol	O
I	O
subunits	O
was	O
substantially	O
impaired	O
in	O
net1Deltactr	O
strains	O
when	O
compared	O
with	O
ChIP	O
in	O
NET1	O
strains	O
(	O
Fig	O
5B	O
,	O
ChIP	O
of	O
fragments	O
2	O
-	O
4	O
)	O
.	O

Importantly	O
,	O
ChEC	O
and	O
ChIP	O
experiments	O
indicated	O
that	O
expression	O
of	O
FLAGCTR	O
in	O
trans	O
could	O
fully	O
restore	O
Pol	O
I	O
association	O
with	O
the	O
35S	O
rDNA	O
in	O
net1Deltactr	O
cells	O
to	O
wild	O
-	O
type	O
levels	O
,	O
in	O
good	O
correlation	O
with	O
the	O
re	O
-	O
establishment	O
of	O
normal	O
cell	O
growth	O
in	O
these	O
strains	O
(	O
Fig	O
5A	O
,	O
compare	O
lanes	O
9	O
-	O
12	O
,	O
and	O
25	O
-	O
28	O
with	O
lanes	O
13	O
-	O
16	O
,	O
and	O
29	O
-	O
32	O
,	O
respectively	O
;	O
Fig	O
5B	O
,	O
ChIP	O
of	O
fragments	O
2	O
-	O
4	O
;	O
S3	O
Table	O
,	O
doubling	O
times	O
)	O
.	O

To	O
verify	O
that	O
Abf2	O
and	O
Mhr1	O
are	O
required	O
for	O
mtDNA	O
maintenance	O
,	O
we	O
analyzed	O
mtDNA	O
levels	O
relative	O
to	O
nuclear	O
DNA	O
using	O
quantitative	O
PCR	O
.	O

We	O
observed	O
that	O
the	O
mtDNA	O
level	O
in	O
incrementabf2	O
cells	O
was	O
less	O
than	O
half	O
(	O
46	O
.	O
3	O
+	O
/	O
-	O
8	O
.	O
6	O
%	O
)	O
that	O
of	O
WT	O
cells	O
grown	O
in	O
YPGly	O
medium	O
(	O
Fig	O
.	O
6a	O
)	O
.	O

Consistent	O
with	O
our	O
previous	O
results	O
,	O
a	O
large	O
proportion	O
(	O
83	O
.	O
9	O
+	O
/	O
-	O
15	O
.	O
3	O
%	O
)	O
of	O
mtDNA	O
content	O
was	O
retained	O
in	O
mhr1	O
-	O
1	O
cells	O
grown	O
in	O
glycerol	O
medium	O
,	O
while	O
we	O
observed	O
no	O
additive	O
effect	O
on	O
the	O
depletion	O
of	O
mtDNA	O
in	O
incrementabf2	O
mhr1	O
-	O
1	O
double	O
-	O
mutant	O
cells	O
(	O
51	O
.	O
4	O
+	O
/	O
-	O
8	O
.	O
8	O
%	O
)	O
,	O
suggesting	O
Abf2	O
is	O
dispensable	O
for	O
Mhr1	O
-	O
driven	O
mtDNA	O
replication	O
(	O
Fig	O
.	O
6a	O
)	O
.	O

Arginine	O
methylation	O
of	O
SARS	O
-	O
Cov	O
-	O
2	O
nucleocapsid	O
protein	O
regulates	O
RNA	O
binding	O
,	O
its	O
ability	O
to	O
suppress	O
stress	O
granule	O
formation	O
,	O
and	O
viral	O
replication	O
.	O

Viral	O
proteins	O
are	O
known	O
to	O
be	O
methylated	O
by	O
host	O
protein	O
arginine	O
methyltransferases	O
(	O
PRMTs	O
)	O
necessary	O
for	O
the	O
viral	O
life	O
cycle	O
,	O
but	O
it	O
remains	O
unknown	O
whether	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
2	O
(	O
SARS	O
-	O
CoV	O
-	O
2	O
)	O
proteins	O
are	O
methylated	O
.	O

Herein	O
,	O
we	O
show	O
that	O
PRMT1	O
methylates	O
SARS	O
-	O
CoV	O
-	O
2	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
at	O
residues	O
R95	O
and	O
R177	O
within	O
RGG	O
/	O
RG	O
motifs	O
,	O
preferred	O
PRMT	O
target	O
sequences	O
.	O

We	O
confirmed	O
arginine	O
methylation	O
of	O
N	O
protein	O
by	O
immunoblotting	O
viral	O
proteins	O
extracted	O
from	O
SARS	O
-	O
CoV	O
-	O
2	O
virions	O
isolated	O
from	O
cell	O
culture	O
.	O

Type	O
I	O
PRMT	O
inhibitor	O
(	O
MS023	O
)	O
or	O
substitution	O
of	O
R95	O
or	O
R177	O
with	O
lysine	O
inhibited	O
interaction	O
of	O
N	O
protein	O
with	O
the	O
5	O
'	O
-	O
UTR	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
genomic	O
RNA	O
,	O
a	O
property	O
required	O
for	O
viral	O
packaging	O
.	O

We	O
also	O
defined	O
the	O
N	O
protein	O
interactome	O
in	O
HEK293	O
cells	O
,	O
which	O
identified	O
PRMT1	O
and	O
many	O
of	O
its	O
RGG	O
/	O
RG	O
substrates	O
,	O
including	O
the	O
known	O
interacting	O
protein	O
G3BP1	O
as	O
well	O
as	O
other	O
components	O
of	O
stress	O
granules	O
(	O
SGs	O
)	O
,	O
which	O
are	O
part	O
of	O
the	O
host	O
antiviral	O
response	O
.	O

Methylation	O
of	O
R95	O
regulated	O
the	O
ability	O
of	O
N	O
protein	O
to	O
suppress	O
the	O
formation	O
of	O
SGs	O
,	O
as	O
R95K	O
substitution	O
or	O
MS023	O
treatment	O
blocked	O
N	O
-	O
mediated	O
suppression	O
of	O
SGs	O
.	O

Also	O
,	O
the	O
coexpression	O
of	O
methylarginine	O
reader	O
Tudor	O
domain	O
-	O
containing	O
protein	O
3	O
quenched	O
N	O
protein	O
-	O
mediated	O
suppression	O
of	O
SGs	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Finally	O
,	O
pretreatment	O
of	O
VeroE6	O
cells	O
with	O
MS023	O
significantly	O
reduced	O
SARS	O
-	O
CoV	O
-	O
2	O
replication	O
.	O

Because	O
type	O
I	O
PRMT	O
inhibitors	O
are	O
already	O
undergoing	O
clinical	O
trials	O
for	O
cancer	O
treatment	O
,	O
inhibiting	O
arginine	O
methylation	O
to	O
target	O
the	O
later	O
stages	O
of	O
the	O
viral	O
life	O
cycle	O
such	O
as	O
viral	O
genome	O
packaging	O
and	O
assembly	O
of	O
virions	O
may	O
represent	O
an	O
additional	O
therapeutic	O
application	O
of	O
these	O
drugs	O
.	O

Cloning	O
and	O
expression	O
of	O
human	O
apolipoprotein	O
D	O
cDNA	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
human	O
apolipoprotein	O
D	O
,	O
a	O
component	O
of	O
high	B-Complex
density	I-Complex
lipoprotein	I-Complex
,	O
has	O
been	O
obtained	O
from	O
the	O
cloned	O
cDNA	O
sequence	O
.	O

The	O
169	O
-	O
amino	O
acid	O
protein	O
has	O
no	O
marked	O
similarity	O
to	O
other	O
apolipoprotein	O
sequences	O
,	O
but	O
has	O
a	O
high	O
degree	O
of	O
homology	O
to	O
plasma	O
retinol	O
-	O
binding	O
protein	O
and	O
other	O
members	O
of	O
the	O
alpha	O
2u	O
-	O
globulin	O
protein	O
superfamily	O
.	O

Apolipoprotein	O
D	O
mRNA	O
has	O
been	O
detected	O
in	O
human	O
liver	O
,	O
intestine	O
,	O
pancreas	O
,	O
kidney	O
,	O
placenta	O
,	O
adrenal	O
,	O
spleen	O
,	O
and	O
fetal	O
brain	O
tissue	O
.	O

Tissue	O
culture	O
cells	O
transfected	O
with	O
the	O
cloned	O
cDNA	O
secrete	O
material	O
that	O
reacts	O
with	O
anti	O
-	O
apoD	O
antibodies	O
.	O

Purification	O
and	O
postsynthetic	O
modifications	O
of	O
Friend	O
erythroleukemic	O
cell	O
high	O
mobility	O
group	O
protein	O
HMG	O
-	O
I	O
.	O

We	O
have	O
previously	O
detected	O
and	O
purified	O
a	O
Friend	O
erythroleukemic	O
mouse	O
cell	O
nonhistone	O
chromatin	O
protein	O
having	O
extraction	O
and	O
acid	O
-	O
solubility	O
properties	O
like	O
the	O
low	O
molecular	O
weight	O
"	O
high	O
mobility	O
group	O
"	O
(	O
HMG	O
)	O
nuclear	O
proteins	O
.	O

We	O
show	O
here	O
that	O
the	O
electrophoretic	O
properties	O
and	O
the	O
amino	O
acid	O
composition	O
of	O
this	O
mouse	O
cell	O
"	O
HMG	O
-	O
like	O
"	O
protein	O
is	O
comparable	O
to	O
those	O
of	O
the	O
HMG	O
-	O
I	O
proteins	O
isolated	O
from	O
human	O
HeLa	O
S3	O
cells	O
,	O
African	O
green	O
monkey	O
cells	O
,	O
Ehrlich	O
ascites	O
mouse	O
cells	O
,	O
and	O
rat	O
fibroblast	O
cells	O
.	O

Therefore	O
,	O
we	O
have	O
also	O
designated	O
the	O
Friend	O
erythroleukemic	O
mouse	O
cell	O
protein	O
as	O
HMG	O
-	O
I	O
.	O

In	O
common	O
with	O
the	O
other	O
HMG	O
proteins	O
the	O
Friend	O
cell	O
HMG	O
-	O
I	O
protein	O
can	O
undergo	O
a	O
variety	O
of	O
post	O
-	O
translational	O
biochemical	O
modifications	O
including	O
acetylation	O
,	O
ADP	O
-	O
ribosylation	O
,	O
glycosylation	O
,	O
and	O
phosphorylation	O
.	O

Surprisingly	O
,	O
in	O
the	O
course	O
of	O
these	O
studies	O
we	O
found	O
that	O
in	O
vivo	O
radiolabeling	O
experiments	O
revealed	O
that	O
only	O
two	O
minor	O
HMG	O
-	O
14	O
subspecies	O
(	O
and	O
/	O
or	O
possibly	O
a	O
minor	O
HMG	O
-	O
I	O
subspecies	O
)	O
are	O
phosphorylated	O
whereas	O
HMG	O
-	O
1	O
,	O
-	O
2	O
,	O
-	O
17	O
,	O
and	O
the	O
major	O
HMG	O
-	O
14	O
are	O
not	O
heavily	O
phosphorylated	O
.	O

cDNA	O
sequence	O
of	O
human	O
beta	O
-	O
preprotachykinin	O
,	O
the	O
common	O
precursor	O
to	O
substance	O
P	O
and	O
neurokinin	O
A	O
.	O

The	O
nucleotide	O
sequence	O
of	O
cDNA	O
encoding	O
the	O
human	O
substance	O
P	O
precursor	O
,	O
beta	O
-	O
preprotachykinin	O
(	O
beta	O
-	O
PPT	O
)	O
,	O
has	O
been	O
determined	O
.	O

The	O
source	O
of	O
mRNA	O
was	O
a	O
human	O
laryngeal	O
carcinoid	O
tumour	O
that	O
contained	O
a	O
high	O
concentration	O
of	O
immunoreactive	O
substance	O
P	O
.	O

The	O
human	O
beta	O
-	O
PPT	O
polypeptide	O
is	O
129	O
amino	O
acids	O
long	O
and	O
contains	O
regions	O
encoding	O
substance	O
P	O
and	O
neurokinin	O
A	O
,	O
each	O
flanked	O
by	O
basic	O
amino	O
acid	O
residues	O
.	O

Residues	O
72	O
-	O
107	O
of	O
the	O
human	O
beta	O
-	O
PPT	O
polypeptide	O
encode	O
the	O
sequence	O
of	O
neuropeptide	O
K	O
,	O
an	O
N	O
-	O
terminally	O
extended	O
form	O
of	O
neurokinin	O
A	O
recently	O
isolated	O
from	O
porcine	O
brain	O
.	O

Anaphylatoxin	O
inactivator	O
of	O
human	O
plasma	O
:	O
its	O
isolation	O
and	O
characterization	O
as	O
a	O
carboxypeptidase	O
.	O

The	O
failure	O
of	O
human	O
serum	O
to	O
give	O
rise	O
to	O
anaphylatoxin	O
activity	O
could	O
be	O
attributed	O
to	O
the	O
presence	O
of	O
a	O
potent	O
inactivator	O
of	O
anaphylatoxin	O
in	O
human	O
serum	O
.	O

The	O
inactivator	O
was	O
isolated	O
and	O
characterized	O
as	O
an	O
alpha	O
-	O
globulin	O
with	O
a	O
molecular	O
weight	O
of	O
approximately	O
310	O
,	O
000	O
.	O

It	O
was	O
found	O
to	O
abolish	O
the	O
activity	O
of	O
both	O
anaphylatoxins	O
,	O
which	O
are	O
derived	O
respectively	O
from	O
the	O
third	O
and	O
the	O
fifth	O
component	O
of	O
complement	O
,	O
and	O
of	O
bradykinin	O
.	O

Inactivation	O
of	O
C3	O
-	O
derived	O
anaphylatoxin	O
and	O
of	O
bradykinin	O
was	O
accompanied	O
by	O
release	O
of	O
C	O
-	O
terminal	O
arginine	O
from	O
these	O
peptides	O
.	O

The	O
anaphylatoxin	O
inactivator	O
was	O
shown	O
to	O
hydrolyze	O
the	O
synthetic	O
substrates	O
hippuryl	O
-	O
L	O
-	O
arginine	O
and	O
hippuryl	O
-	O
L	O
-	O
lysine	O
and	O
to	O
be	O
inhibited	O
by	O
ethylenediaminetetraacetate	O
(	O
EDTA	O
)	O
or	O
phenanthroline	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
anaphylatoxin	O
inactivator	O
constitutes	O
a	O
metal	O
-	O
dependent	O
enzyme	O
resembling	O
in	O
specificity	O
pancreatic	O
carboxypeptidase	O
B	O
.	O

Reduced	O
but	O
accurate	O
translation	O
from	O
a	O
mutant	O
AUA	O
initiation	O
codon	O
in	O
the	O
mitochondrial	O
COX2	O
mRNA	O
of	O
Saccharomyces	O
cerevisiae	O
.	O

We	O
have	O
changed	O
the	O
translation	O
initiation	O
codon	O
of	O
the	O
COX2	O
mRNA	O
of	O
Saccharomyces	O
cerevisiae	O
from	O
AUG	O
to	O
AUA	O
,	O
generating	O
a	O
mutation	O
termed	O
cox2	O
-	O
10	O
.	O

This	O
mutation	O
reduced	O
translation	O
of	O
the	O
COX2	O
mRNA	O
at	O
least	O
five	O
-	O
fold	O
without	O
affecting	O
the	O
steady	O
-	O
state	O
level	O
of	O
the	O
mRNA	O
,	O
and	O
produced	O
a	O
leaky	O
nonrespiratory	O
growth	O
phenotype	O
.	O

To	O
address	O
the	O
question	O
of	O
whether	O
residual	O
translation	O
of	O
the	O
cox2	O
-	O
10	O
mRNA	O
was	O
initiating	O
at	O
the	O
altered	O
initiation	O
codon	O
or	O
at	O
the	O
next	O
AUG	O
codon	O
downstream	O
(	O
at	O
position	O
14	O
)	O
,	O
we	O
took	O
advantage	O
of	O
the	O
fact	O
that	O
the	O
mature	O
coxII	O
protein	O
is	O
generated	O
from	O
the	O
electrophoretically	O
distinguishable	O
coxII	O
precursor	O
by	O
removal	O
of	O
the	O
amino	O
-	O
terminal	O
15	O
residues	O
,	O
and	O
that	O
this	O
processing	O
can	O
be	O
blocked	O
by	O
a	O
mutation	O
in	O
the	O
nuclear	O
gene	O
PET2858	O
.	O

We	O
constructed	O
a	O
pet2858	O
,	O
cox2	O
-	O
10	O
double	O
mutant	O
strain	O
using	O
a	O
pet2858	O
allele	O
from	O
our	O
mutant	O
collection	O
.	O

The	O
double	O
mutant	O
accumulated	O
low	O
levels	O
of	O
a	O
polypeptide	O
which	O
comigrated	O
with	O
the	O
coxII	O
precursor	O
protein	O
,	O
not	O
the	O
mature	O
species	O
,	O
providing	O
strong	O
evidence	O
that	O
residual	O
initiation	O
was	O
occurring	O
at	O
the	O
mutant	O
AUA	O
codon	O
.	O

Residual	O
translation	O
of	O
the	O
mutant	O
mRNA	O
required	O
the	O
COX2	O
mRNA	O
-	O
specific	O
activator	O
PET111	O
.	O

Furthermore	O
,	O
growth	O
of	O
cox2	O
-	O
10	O
mutant	O
strains	O
was	O
sensitive	O
to	O
alterations	O
in	O
PET111	O
gene	O
dosage	O
:	O
the	O
respiratory	O
-	O
defective	O
growth	O
phenotype	O
was	O
partially	O
suppressed	O
in	O
haploid	O
strains	O
containing	O
PET111	O
on	O
a	O
high	O
-	O
copy	O
-	O
number	O
vector	O
,	O
but	O
became	O
more	O
severe	O
in	O
diploid	O
strains	O
containing	O
only	O
one	O
functional	O
copy	O
of	O
PET111	O
.	O

Molecular	O
cloning	O
of	O
a	O
functional	O
human	O
galanin	O
receptor	O
.	O

The	O
ubiquitous	O
neuropeptide	O
galanin	O
controls	O
numerous	O
functions	O
such	O
as	O
endocrine	O
secretions	O
,	O
intestinal	O
motility	O
,	O
and	O
behavioral	O
activities	O
.	O

These	O
regulatory	O
effects	O
of	O
galanin	O
are	O
mediated	O
through	O
the	O
interaction	O
with	O
specific	O
membrane	O
receptors	O
and	O
involve	O
the	O
pertussis	O
toxin	O
-	O
sensitive	O
guanine	O
nucleotide	O
binding	O
proteins	O
Gi	B-OOS
/	O
Go	B-OOS
as	O
transducing	O
elements	O
.	O

We	O
report	O
here	O
the	O
isolation	O
of	O
a	O
cDNA	O
coding	O
for	O
a	O
human	O
galanin	O
receptor	O
from	O
a	O
Bowes	O
melanoma	O
cell	O
line	O
cDNA	O
expression	O
library	O
,	O
by	O
using	O
a	O
radioligand	O
binding	O
strategy	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
cloned	O
receptor	O
reveals	O
an	O
open	O
reading	O
frame	O
encoding	O
a	O
349	O
-	O
amino	O
acid	O
protein	O
with	O
seven	O
putative	O
hydrophobic	O
transmembrane	O
domains	O
and	O
significant	O
homology	O
with	O
members	O
of	O
the	O
guanine	O
nucleotide	O
binding	O
protein	O
-	O
coupled	O
neuropeptide	O
receptor	O
family	O
.	O

The	O
cloned	O
receptor	O
expressed	O
in	O
COS	O
cells	O
specifically	O
binds	O
human	O
,	O
porcine	O
,	O
and	O
rat	O
galanin	O
with	O
high	O
affinity	O
(	O
Kd	O
in	O
the	O
nanomolar	O
range	O
)	O
and	O
mediates	O
the	O
galanin	O
inhibition	O
of	O
adenylate	O
cyclase	O
.	O

A	O
2	O
.	O
8	O
-	O
kb	O
galanin	O
receptor	O
transcript	O
was	O
identified	O
in	O
several	O
human	O
tissues	O
.	O

Cloning	O
of	O
this	O
galanin	O
receptor	O
should	O
enhance	O
our	O
knowledge	O
of	O
its	O
distribution	O
,	O
structure	O
,	O
and	O
function	O
in	O
human	O
physiology	O
and	O
pathophysiology	O
.	O

Biosynthesis	O
of	O
GlyCAM	O
-	O
1	O
,	O
a	O
mucin	O
-	O
like	O
ligand	O
for	O
L	O
-	O
selectin	O
.	O

L	O
-	O
selectin	O
,	O
a	O
member	O
of	O
the	O
selectin	O
family	O
of	O
leukocyte	O
-	O
endothelial	O
adhesion	O
proteins	O
,	O
mediates	O
the	O
initial	O
attachment	O
of	O
lymphocytes	O
to	O
lymph	O
node	O
high	O
endothelial	O
venules	O
during	O
lymphocyte	O
recirculation	O
.	O

One	O
of	O
the	O
endothelial	O
-	O
associated	O
ligands	O
for	O
L	O
-	O
selectin	O
is	O
GlyCAM	O
-	O
1	O
,	O
a	O
mucin	O
-	O
like	O
glycoprotein	O
,	O
which	O
presents	O
novel	O
sulfated	O
,	O
sialylated	O
and	O
fucosylated	O
O	O
-	O
glycans	O
.	O

In	O
order	O
to	O
understand	O
the	O
generation	O
of	O
these	O
glycans	O
,	O
we	O
have	O
examined	O
the	O
biosynthesis	O
of	O
GlyCAM	O
-	O
1	O
in	O
lymph	O
node	O
organ	O
culture	O
.	O

Using	O
peptide	O
-	O
specific	O
antibodies	O
,	O
lectins	O
,	O
and	O
recombinant	O
L	O
-	O
selectin	O
,	O
we	O
detected	O
the	O
following	O
species	O
of	O
GlyCAM	O
-	O
1	O
:	O
unglycosylated	O
(	O
<	O
28	O
kDa	O
)	O
;	O
modified	O
with	O
GalNAc	O
only	O
(	O
28	O
-	O
33	O
kDa	O
)	O
;	O
modified	O
with	O
sialic	O
acid	O
,	O
fucose	O
,	O
and	O
sulfate	O
but	O
lacking	O
L	O
-	O
selectin	O
reactivity	O
(	O
40	O
-	O
50	O
kDa	O
)	O
;	O
and	O
mature	O
(	O
L	O
-	O
selectin	O
-	O
reactive	O
)	O
ligand	O
(	O
50	O
-	O
60	O
kDa	O
)	O
.	O

Pulse	O
-	O
chase	O
labeling	O
at	O
15	O
degrees	O
C	O
suggested	O
that	O
GalNAc	O
is	O
added	O
in	O
a	O
pre	O
-	O
Golgi	O
compartment	O
.	O

Treatment	O
with	O
brefeldin	O
A	O
almost	O
completely	O
blocked	O
sulfation	O
,	O
indicating	O
that	O
this	O
modification	O
occurs	O
in	O
the	O
trans	O
-	O
Golgi	O
network	O
.	O

Two	O
distinct	O
sialylation	O
events	O
occurred	O
in	O
the	O
presence	O
of	O
brefeldin	O
A	O
,	O
while	O
fucosylation	O
was	O
partially	O
blocked	O
.	O

We	O
conclude	O
that	O
sialylation	O
precedes	O
both	O
fucosylation	O
and	O
sulfation	O
during	O
biosynthesis	O
.	O

This	O
ordering	O
will	O
help	O
to	O
identify	O
the	O
critical	O
acceptor	O
structures	O
recognized	O
by	O
lymph	O
node	O
glycosyltransferases	O
and	O
sulfotransferases	O
.	O

Transforming	O
p21ras	O
mutants	O
and	O
c	O
-	O
Ets	O
-	O
2	O
activate	O
the	O
cyclin	O
D1	O
promoter	O
through	O
distinguishable	O
regions	O
.	O

Several	O
different	O
oncogenes	O
and	O
growth	O
factors	O
promote	O
G1	O
phase	O
progression	O
.	O

Cyclin	O
D1	O
,	O
the	O
regulatory	O
subunit	O
of	O
several	O
cyclin	O
-	O
dependent	O
kinases	O
,	O
is	O
required	O
for	O
,	O
and	O
capable	O
of	O
shortening	O
,	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
transforming	O
mutants	O
of	O
p21ras	O
(	O
Ras	O
Val	O
-	O
12	O
,	O
Ras	O
Leu	O
-	O
61	O
)	O
induce	O
the	O
cyclin	O
D1	O
promoter	O
in	O
human	O
trophoblasts	O
(	O
JEG	O
-	O
3	O
)	O
,	O
mink	O
lung	O
epithelial	O
(	O
Mv1	O
.	O
Lu	O
)	O
,	O
and	O
in	O
Chinese	O
hamster	O
ovary	O
fibroblast	O
cell	O
lines	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
AP	B-Complex
-	I-Complex
1	I-Complex
-	O
like	O
sequences	O
at	O
-	O
954	O
abolished	O
p21ras	O
-	O
dependent	O
activation	O
of	O
cyclin	O
D1	O
expression	O
.	O

The	O
AP	B-Complex
-	I-Complex
1	I-Complex
-	O
like	O
sequences	O
were	O
also	O
required	O
for	O
activation	O
of	O
the	O
cyclin	O
D1	O
promoter	O
by	O
c	O
-	O
Jun	O
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays	O
using	O
nuclear	O
extracts	O
from	O
cultured	O
cells	O
and	O
primary	O
tissues	O
,	O
several	O
AP	B-Complex
-	I-Complex
1	I-Complex
proteins	O
(	O
c	O
-	O
Jun	O
,	O
JunB	O
,	O
JunD	O
,	O
and	O
c	O
-	O
Fos	O
)	O
bound	O
the	O
cyclin	O
D1	O
-	O
954	O
region	O
.	O

Cyclin	O
D1	O
promoter	O
activity	O
was	O
stimulated	O
by	O
overexpression	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
p41MAPK	O
)	O
or	O
c	O
-	O
Ets	O
-	O
2	O
through	O
the	O
proximal	O
22	O
base	O
pairs	O
.	O

Expression	O
of	O
plasmids	O
encoding	O
either	O
dominant	O
negative	O
MAPK	O
(	O
p41MAPKi	O
)	O
or	O
dominant	O
negatives	O
of	O
ETS	O
activation	O
(	O
Ets	O
-	O
LacZ	O
)	O
,	O
antagonized	O
MAPK	O
-	O
dependent	O
induction	O
of	O
cyclin	O
D1	O
promoter	O
activity	O
.	O

Epidermal	O
growth	O
factor	O
induction	O
of	O
cyclin	O
D1	O
transcription	O
,	O
through	O
the	O
proximal	O
promoter	O
region	O
,	O
was	O
antagonized	O
by	O
either	O
p41MAPKi	O
or	O
Ets	O
-	O
LacZ	O
,	O
suggesting	O
that	O
ETS	O
functions	O
downstream	O
of	O
epidermal	O
growth	O
factor	O
and	O
MAPK	O
in	O
the	O
context	O
of	O
the	O
cyclin	O
D1	O
promoter	O
.	O

The	O
activation	O
of	O
cyclin	O
D1	O
transcription	O
by	O
p21ras	O
provides	O
evidence	O
for	O
cross	O
-	O
talk	O
between	O
the	O
p21ras	O
and	O
cell	O
cycle	O
regulatory	O
pathways	O
.	O

P	O
-	O
selectin	O
is	O
acylated	O
with	O
palmitic	O
acid	O
and	O
stearic	O
acid	O
at	O
cysteine	O
766	O
through	O
a	O
thioester	O
linkage	O
.	O

We	O
report	O
that	O
the	O
adhesion	O
receptor	O
P	O
-	O
selectin	O
can	O
be	O
metabolically	O
labeled	O
with	O
[	O
3H	O
]	O
palmitic	O
acid	O
in	O
human	O
platelets	O
.	O

Analysis	O
of	O
alkaline	O
methanolysis	O
products	O
from	O
labeled	O
protein	O
demonstrated	O
that	O
the	O
radioactivity	O
associated	O
with	O
P	O
-	O
selectin	O
was	O
covalently	O
bound	O
palmitic	O
acid	O
.	O

[	O
3H	O
]	O
Palmitic	O
acid	O
was	O
cleaved	O
by	O
hydroxylamine	O
treatment	O
at	O
neutral	O
pH	O
and	O
by	O
reducing	O
agents	O
,	O
indicating	O
that	O
acylation	O
occurred	O
through	O
a	O
thioester	O
linkage	O
.	O

Both	O
stearic	O
acid	O
and	O
palmitic	O
acid	O
were	O
detected	O
by	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
analysis	O
of	O
alkaline	O
hydrolysates	O
of	O
purified	O
P	O
-	O
selectin	O
.	O

Deletion	O
or	O
mutation	O
of	O
Cys766	O
eliminated	O
[	O
3H	O
]	O
palmitic	O
acid	O
labeling	O
of	O
P	O
-	O
selectin	O
in	O
transfected	O
COS	O
-	O
7	O
cells	O
.	O

We	O
conclude	O
that	O
the	O
cytoplasmic	O
domain	O
of	O
P	O
-	O
selectin	O
is	O
acylated	O
at	O
Cys766	O
through	O
a	O
thioester	O
bond	O
.	O

Fatty	O
acid	O
acylation	O
may	O
regulate	O
intracellular	O
trafficking	O
or	O
other	O
functions	O
of	O
P	O
-	O
selectin	O
.	O

Terminal	O
marking	O
of	O
avian	O
triosephosphate	O
isomerases	O
by	O
deamidation	O
and	O
oxidation	O
.	O

Triosephosphate	O
isomerase	O
(	O
TPI	O
)	O
provides	O
an	O
excellent	O
model	O
for	O
terminal	O
marking	O
and	O
protein	O
degradation	O
.	O

Mammalian	O
TPI	O
is	O
terminally	O
modified	O
by	O
deamidation	O
at	O
Asn71	O
-	O
Gly	O
,	O
resulting	O
in	O
unfolding	O
,	O
dissociation	O
,	O
and	O
proteolysis	O
.	O

In	O
contrast	O
,	O
chicken	O
TPI	O
,	O
which	O
contains	O
a	O
lysine	O
at	O
position	O
71	O
,	O
is	O
terminally	O
modified	O
by	O
the	O
oxidation	O
of	O
Cys126	O
.	O

Thus	O
,	O
both	O
deamidation	O
and	O
oxidation	O
initiate	O
degradation	O
of	O
TPI	O
from	O
different	O
species	O
.	O

To	O
explore	O
the	O
terminal	O
marking	O
in	O
other	O
avians	O
,	O
we	O
have	O
purified	O
the	O
turkey	O
TPI	O
to	O
homogeneity	O
and	O
determined	O
its	O
characteristics	O
.	O

Although	O
the	O
molecular	O
properties	O
of	O
the	O
turkey	O
and	O
chicken	O
TPI	O
were	O
very	O
similar	O
,	O
their	O
tolerances	O
to	O
temperature	O
,	O
oxidants	O
,	O
and	O
alkaline	O
pH	O
were	O
very	O
different	O
.	O

For	O
example	O
,	O
chicken	O
TPI	O
was	O
inactivated	O
80	O
%	O
in	O
either	O
10	O
mM	O
oxidized	O
glutathione	O
or	O
H2O2	O
,	O
whereas	O
120	O
mM	O
GSSG	O
had	O
no	O
effect	O
on	O
turkey	O
TPI	O
,	O
and	O
>	O
120	O
mM	O
H2O2	O
was	O
needed	O
for	O
80	O
%	O
inactivation	O
.	O

Under	O
alkaline	O
conditions	O
that	O
cause	O
rapid	O
deamidation	O
of	O
the	O
mammalian	O
TPI	O
,	O
neither	O
avian	O
enzyme	O
deamidated	O
.	O

Chicken	O
TPI	O
,	O
however	O
,	O
aggregated	O
.	O

Aggregation	O
was	O
reversed	O
by	O
2	O
-	O
mercaptoethanol	O
.	O

Under	O
prolonged	O
exposure	O
to	O
milder	O
conditions	O
the	O
turkey	O
enzyme	O
was	O
completely	O
inactivated	O
and	O
deamidated	O
at	O
Asn15	O
-	O
Gly	O
.	O

Thus	O
,	O
there	O
are	O
marked	O
differences	O
in	O
the	O
susceptibility	O
of	O
these	O
two	O
avian	O
enzymes	O
to	O
oxidation	O
and	O
deamidation	O
,	O
and	O
their	O
terminal	O
marking	O
mechanisms	O
appear	O
to	O
be	O
different	O
.	O

Isolation	O
of	O
a	O
cDNA	O
for	O
chicken	O
liver	O
6	O
-	O
phosphofructo	O
-	O
2	O
-	O
kinase	O
/	O
fructose	O
-	O
2	O
,	O
6	O
-	O
bisphosphatase	O
.	O

A	O
chicken	O
liver	O
cDNA	O
for	O
6	O
-	O
phosphofructo	O
-	O
2	O
-	O
kinase	O
/	O
fructose	O
-	O
2	O
,	O
6	O
-	O
bisphosphatase	O
was	O
isolated	O
from	O
a	O
Lambda	O
ZAP2	O
phage	O
library	O
.	O

The	O
chicken	O
liver	O
cDNA	O
codes	O
for	O
a	O
protein	O
that	O
has	O
89	O
.	O
1	O
,	O
88	O
.	O
4	O
and	O
88	O
.	O
0	O
%	O
amino	O
acid	O
identity	O
with	O
the	O
human	O
,	O
rat	O
and	O
bovine	O
liver	O
isoforms	O
,	O
respectively	O
.	O

The	O
kinetic	O
properties	O
of	O
the	O
rat	O
and	O
chicken	O
liver	O
enzymes	O
,	O
purified	O
to	O
homogeneity	O
after	O
expression	O
in	O
E	O
.	O
coli	O
,	O
were	O
different	O
including	O
negative	O
cooperativity	O
for	O
ATP	O
binding	O
and	O
inhibition	O
by	O
Mg2	O
+	O
for	O
the	O
chicken	O
liver	O
6	O
-	O
phosphofructo	O
-	O
2	O
-	O
kinase	O
but	O
not	O
for	O
the	O
rat	O
liver	O
kinase	O
.	O

Differences	O
in	O
the	O
beta	O
-	O
loop	O
ATP	O
signature	O
sequences	O
in	O
the	O
chicken	O
and	O
rat	O
liver	O
kinase	O
domains	O
may	O
explain	O
the	O
kinetic	O
differences	O
and	O
represent	O
the	O
major	O
divergence	O
in	O
the	O
evolution	O
of	O
the	O
enzyme	O
from	O
birds	O
to	O
mammals	O
.	O

Molecular	O
cloning	O
of	O
ras	O
and	O
rap	O
genes	O
from	O
Entamoeba	O
histolytica	O
.	O

To	O
better	O
understand	O
growth	O
regulation	O
in	O
the	O
protozoan	O
parasite	O
Entamoeba	O
histolytica	O
,	O
ameba	O
genes	O
homologous	O
to	O
the	O
ras	O
oncogene	O
and	O
rap	O
(	O
Krev	O
-	O
1	O
)	O
anti	O
-	O
oncogene	O
were	O
cloned	O
.	O

Two	O
putative	O
ameba	O
ras	O
genes	O
(	O
Ehras1	O
and	O
Ehras2	O
)	O
were	O
identified	O
,	O
which	O
contain	O
205	O
and	O
203	O
amino	O
acid	O
(	O
aa	O
)	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
,	O
respectively	O
.	O

The	O
Ehras1	O
ORF	O
shows	O
an	O
91	O
%	O
positional	O
identity	O
with	O
that	O
of	O
Ehras2	O
,	O
a	O
55	O
%	O
identity	O
with	O
Dictyostelium	O
discoideum	O
(	O
Dd	O
)	O
ras	O
,	O
and	O
a	O
47	O
%	O
identity	O
with	O
human	O
(	O
Hs	O
)	O
ras	O
.	O

Two	O
ameba	O
rap	O
genes	O
(	O
Ehrap1	O
and	O
Ehrap2	O
)	O
were	O
identified	O
,	O
both	O
of	O
which	O
contain	O
184	O
-	O
aa	O
ORFs	O
.	O

The	O
Ehrap1	O
ORF	O
shows	O
a	O
93	O
%	O
positional	O
identity	O
with	O
that	O
of	O
Ehrap2	O
,	O
a	O
60	O
%	O
identity	O
with	O
Dd	O
rap	O
,	O
a	O
61	O
%	O
identity	O
with	O
Hs	O
Krev	O
-	O
1	O
,	O
and	O
a	O
45	O
%	O
identity	O
with	O
that	O
of	O
Ehras1	O
.	O

Conserved	O
aa	O
in	O
each	O
ameba	O
ras	O
and	O
rap	O
ORF	O
include	O
GTP	O
-	O
binding	O
sites	O
,	O
effector	O
site	O
,	O
site	O
of	O
ADP	O
-	O
ribosylation	O
by	O
Pseudomonas	O
exoenzyme	O
S	O
,	O
and	O
COOH	O
-	O
terminus	O
CAAX	O
.	O

As	O
all	O
Xs	O
=	O
Leu	O
or	O
Phe	O
,	O
ameba	O
ras	O
and	O
rap	O
proteins	O
may	O
be	O
gerenylgerenylated	O
and	O
not	O
farnesylated	O
.	O

Both	O
ras	O
and	O
rap	O
genes	O
are	O
transcribed	O
by	O
trophozoites	O
.	O

A	O
single	O
21	O
-	O
kDa	O
ameba	O
ras	O
protein	O
reacts	O
with	O
the	O
rat	O
Y13	O
-	O
259	O
anti	O
-	O
ras	O
monoclonal	O
antibody	O
,	O
which	O
is	O
located	O
on	O
the	O
cytosolic	O
side	O
of	O
the	O
plasma	O
membrane	O
.	O

These	O
are	O
the	O
first	O
ras	O
and	O
rap	O
genes	O
identified	O
from	O
a	O
protozoan	O
parasite	O
.	O

Isoprenylation	O
of	O
large	O
hepatitis	O
delta	O
antigen	O
is	O
necessary	O
but	O
not	O
sufficient	O
for	O
hepatitis	O
delta	O
virus	O
assembly	O
.	O

Hepatitis	O
delta	O
virus	O
(	O
HDV	O
)	O
encodes	O
two	O
proteins	O
,	O
the	O
small	O
hepatitis	O
delta	O
antigen	O
(	O
SHDAg	O
)	O
and	O
large	O
hepatitis	O
delta	O
antigen	O
(	O
LHDAg	O
)	O
.	O

Both	O
proteins	O
are	O
identical	O
except	O
for	O
the	O
presence	O
of	O
additional	O
19	O
amino	O
acids	O
at	O
the	O
C	O
terminus	O
of	O
LHDAg	O
.	O

While	O
SHDAg	O
is	O
required	O
for	O
HDV	O
RNA	O
replication	O
,	O
LHDAg	O
inhibits	O
replication	O
and	O
is	O
required	O
together	O
with	O
hepatitis	O
B	O
surface	O
antigen	O
for	O
the	O
assembly	O
of	O
HDV	O
.	O

The	O
C	O
-	O
terminal	O
last	O
4	O
amino	O
acids	O
of	O
LHDAg	O
(	O
Cys	O
-	O
Arg	O
-	O
Pro	O
-	O
Gln	O
)	O
is	O
an	O
isoprenylation	O
motif	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
the	O
mutation	O
of	O
the	O
Cys	O
inhibited	O
the	O
assembly	O
of	O
HDV	O
.	O

In	O
order	O
to	O
discern	O
whether	O
this	O
effect	O
is	O
due	O
to	O
change	O
of	O
amino	O
acid	O
residue	O
or	O
abolition	O
of	O
isoprenylation	O
,	O
we	O
constructed	O
several	O
LHDAg	O
mutants	O
of	O
the	O
terminal	O
three	O
amino	O
acid	O
residues	O
and	O
tested	O
their	O
abilities	O
to	O
be	O
packaged	O
with	O
HBsAg	O
by	O
cotransfection	O
experiments	O
.	O

We	O
also	O
made	O
GST	O
-	O
fusion	O
proteins	O
of	O
these	O
mutants	O
and	O
tested	O
their	O
abilities	O
to	O
be	O
isoprenylated	O
in	O
rabbit	O
reticulocyte	O
lysate	O
system	O
.	O

We	O
found	O
that	O
some	O
,	O
but	O
not	O
all	O
,	O
of	O
the	O
substitutions	O
of	O
the	O
amino	O
acid	O
residues	O
other	O
than	O
the	O
Cys	O
also	O
inhibited	O
isoprenylation	O
and	O
that	O
the	O
status	O
of	O
isoprenylation	O
of	O
these	O
mutant	O
proteins	O
correlated	O
well	O
with	O
their	O
abilities	O
to	O
be	O
packaged	O
with	O
HBsAg	O
into	O
virions	O
.	O

This	O
result	O
indicates	O
that	O
isoprenylation	O
,	O
rather	O
than	O
the	O
primary	O
amino	O
acid	O
sequence	O
,	O
is	O
required	O
for	O
LHDAg	O
packaging	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
attachment	O
of	O
an	O
isoprenylation	O
motif	O
to	O
SHDAg	O
did	O
not	O
enable	O
it	O
to	O
be	O
packaged	O
with	O
HBsAg	O
and	O
that	O
the	O
deletions	O
of	O
any	O
5	O
amino	O
acids	O
in	O
the	O
last	O
15	O
amino	O
acids	O
(	O
amino	O
acids	O
196	O
to	O
210	O
)	O
unique	O
to	O
the	O
LHDAg	O
abolished	O
the	O
packaging	O
ability	O
.	O

In	O
contrast	O
,	O
the	O
deletion	O
of	O
33	O
amino	O
acids	O
(	O
amino	O
acids	O
163	O
to	O
195	O
)	O
upstream	O
of	O
the	O
last	O
C	O
-	O
terminal	O
19	O
amino	O
acids	O
of	O
LHDAg	O
did	O
not	O
interfere	O
with	O
its	O
packaging	O
ability	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
the	O
15	O
amino	O
acids	O
upstream	O
of	O
the	O
isoprenylation	O
site	O
of	O
LHDAg	O
are	O
also	O
essential	O
for	O
HDV	O
assembly	O
,	O
and	O
a	O
large	O
portion	O
of	O
the	O
alleged	O
C	O
-	O
terminal	O
Pro	O
/	O
Gly	O
-	O
rich	O
region	O
(	O
amino	O
acids	O
146	O
to	O
195	O
)	O
is	O
not	O
required	O
for	O
the	O
assembly	O
process	O
.	O

The	O
mevalonate	O
pathway	O
:	O
importance	O
in	O
mesangial	O
cell	O
biology	O
and	O
glomerular	O
disease	O
.	O

Products	O
of	O
intracellular	O
mevalonate	O
metabolism	O
are	O
critical	O
for	O
the	O
growth	O
and	O
proliferation	O
of	O
eukaryotic	O
cells	O
.	O

These	O
products	O
include	O
cholesterol	O
and	O
several	O
nonsterol	O
isoprenoids	O
.	O

The	O
isoprenoid	O
farnesyl	O
is	O
a	O
particularly	O
important	O
intermediate	O
in	O
the	O
mevalonate	O
pathway	O
.	O

Farnesyl	O
can	O
be	O
used	O
to	O
synthesize	O
cholesterol	O
and	O
can	O
also	O
bind	O
covalently	O
to	O
several	O
low	O
molecular	O
mass	O
GTP	O
-	O
binding	O
proteins	O
such	O
as	O
p21	O
ras	O
.	O

Farnesylated	O
p21	O
ras	O
may	O
be	O
critical	O
for	O
mitogenic	O
signalling	O
stimulated	O
by	O
growth	O
factors	O
such	O
as	O
platelet	O
-	O
derived	O
growth	O
factor	O
.	O

Inhibitors	O
of	O
the	O
enzyme	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
coenzyme	O
A	O
reductase	O
,	O
such	O
as	O
lovastatin	O
and	O
compactin	O
,	O
block	O
the	O
production	O
of	O
mevalonate	O
and	O
its	O
metabolites	O
.	O

These	O
agents	O
have	O
been	O
shown	O
to	O
inhibit	O
proliferation	O
of	O
many	O
cell	O
types	O
.	O

Recently	O
we	O
demonstrated	O
that	O
lovastatin	O
inhibited	O
proliferation	O
of	O
cultured	O
glomerular	O
mesangial	O
cells	O
.	O

Lovastatin	O
inhibition	O
was	O
overcome	O
by	O
the	O
simultaneous	O
addition	O
of	O
either	O
mevalonate	O
or	O
farnesol	O
,	O
but	O
not	O
by	O
exogenous	O
low	B-Complex
density	I-Complex
lipoprotein	I-Complex
cholesterol	O
.	O

These	O
results	O
suggested	O
that	O
farnesyl	O
is	O
critical	O
for	O
mesangial	O
cell	O
proliferation	O
.	O

In	O
several	O
experimental	O
models	O
of	O
renal	O
disease	O
,	O
chronic	O
lovastatin	O
administration	O
reduced	O
the	O
extent	O
of	O
glomerular	O
injury	O
.	O

The	O
beneficial	O
effects	O
of	O
lovastatin	O
have	O
been	O
attributed	O
to	O
lowering	O
of	O
circulating	O
lipid	O
and	O
lipoprotein	O
levels	O
.	O

In	O
view	O
of	O
recent	O
data	O
,	O
however	O
,	O
it	O
is	O
possible	O
that	O
lovastatin	O
may	O
act	O
to	O
reduce	O
glomerular	O
injury	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
a	O
direct	O
action	O
on	O
mesangial	O
cell	O
proliferation	O
.	O

Vitamin	O
K	O
-	O
dependent	O
carboxylase	O
activity	O
,	O
prothrombin	O
mRNA	O
,	O
and	O
prothrombin	O
production	O
in	O
two	O
cultured	O
rat	O
hepatoma	O
cell	O
lines	O
.	O

The	O
presence	O
of	O
under	O
-	O
gamma	O
-	O
carboxylated	O
forms	O
of	O
plasma	O
prothrombin	O
is	O
a	O
marker	O
for	O
human	O
primary	O
hepatocellular	O
carcinoma	O
.	O

A	O
rat	O
hepatoma	O
cell	O
line	O
(	O
7777	O
)	O
which	O
was	O
previously	O
shown	O
to	O
secrete	O
undercarboxylated	O
prothrombin	O
when	O
grown	O
as	O
a	O
solid	O
tumor	O
has	O
now	O
been	O
grown	O
in	O
monolayer	O
culture	O
.	O

This	O
cell	O
line	O
has	O
a	O
decreased	O
activity	O
of	O
the	O
microsomal	O
vitamin	O
K	O
-	O
dependent	O
carboxylase	O
when	O
compared	O
to	O
a	O
control	O
(	O
H4IIEC3	O
)	O
hepatoma	O
line	O
,	O
does	O
not	O
increase	O
intracellular	O
prothrombin	O
concentrations	O
in	O
response	O
to	O
vitamin	O
K	O
depletion	O
,	O
and	O
secretes	O
undercarboxylated	O
prothrombin	O
even	O
when	O
grown	O
in	O
vitamin	O
K	O
supplemented	O
media	O
.	O

Prothrombin	O
gene	O
expression	O
in	O
the	O
7777	O
cell	O
line	O
,	O
as	O
measured	O
by	O
prothrombin	O
mRNA	O
levels	O
,	O
was	O
not	O
altered	O
in	O
the	O
7777	O
cell	O
line	O
.	O

This	O
cell	O
line	O
appears	O
to	O
be	O
a	O
model	O
for	O
assessing	O
the	O
cellular	O
alterations	O
responsible	O
for	O
undercarboxylated	O
prothrombin	O
excretion	O
by	O
human	O
hepatocellular	O
tumors	O
.	O

Interaction	O
between	O
a	O
complex	O
of	O
RNA	B-Complex
polymerase	I-Complex
III	I-Complex
subunits	O
and	O
the	O
70	O
-	O
kDa	O
component	O
of	O
transcription	O
factor	O
IIIB	O
.	O

A	O
system	O
that	O
detects	O
the	O
formation	O
of	O
complexes	O
between	O
different	O
proteins	O
by	O
linking	O
them	O
to	O
separate	O
domains	O
of	O
the	O
GAL4	O
transcription	O
activator	O
protein	O
has	O
been	O
used	O
to	O
study	O
protein	O
-	O
protein	O
interactions	O
between	O
four	O
essential	O
and	O
unique	O
subunits	O
of	O
yeast	O
RNA	B-Complex
polymerase	I-Complex
III	I-Complex
(	O
C82	O
,	O
C53	O
,	O
C34	O
and	O
C31	O
)	O
,	O
the	O
70	O
-	O
kDa	O
component	O
of	O
the	O
initiation	O
transcription	O
factor	O
IIIB	O
(	O
TFIIIB70	O
)	O
and	O
the	O
TATA	O
-	O
binding	O
protein	O
.	O

We	O
found	O
that	O
C82	O
,	O
C34	O
,	O
and	O
C31	O
are	O
able	O
to	O
combine	O
with	O
each	O
other	O
in	O
vivo	O
and	O
that	O
C34	O
interacts	O
with	O
TFIIIB70	O
.	O

These	O
results	O
suggest	O
that	O
C34	O
and	O
TFIIIB70	O
are	O
specificity	O
determinants	O
of	O
the	O
RNA	B-Complex
polymerase	I-Complex
III	I-Complex
-	O
TFIIIB	B-Complex
interaction	O
.	O

Human	O
lysozyme	O
gene	O
mutations	O
cause	O
hereditary	O
systemic	O
amyloidosis	O
.	O

Hereditary	O
non	O
-	O
neuropathic	O
systemic	O
amyloidosis	O
(	O
Ostertag	O
-	O
type	O
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
disease	O
in	O
which	O
amyloid	O
deposition	O
in	O
the	O
viscera	O
is	O
usually	O
fatal	O
by	O
the	O
fifth	O
decade	O
.	O

In	O
some	O
families	O
it	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
apolipoprotein	O
AI	O
gene	O
but	O
in	O
two	O
unrelated	O
English	O
families	O
under	O
our	O
care	O
the	O
amyloid	O
deposits	O
did	O
not	O
contain	O
apoAI	O
,	O
despite	O
a	O
report	O
that	O
this	O
may	O
have	O
been	O
the	O
case	O
in	O
one	O
of	O
them	O
.	O

Lysozyme	O
is	O
a	O
ubiquitous	O
bacteriolytic	O
enzyme	O
present	O
in	O
external	O
secretions	O
and	O
in	O
polymorphs	O
and	O
macrophages	O
,	O
but	O
its	O
physiological	O
role	O
is	O
not	O
always	O
clear	O
.	O

Here	O
we	O
report	O
that	O
in	O
these	O
two	O
families	O
,	O
lysozyme	O
is	O
the	O
amyloid	O
fibril	O
protein	O
.	O

Affected	O
individuals	O
are	O
heterozygous	O
for	O
point	O
mutations	O
in	O
the	O
lysozyme	O
gene	O
that	O
cause	O
substitution	O
of	O
highly	O
conserved	O
residues	O
,	O
namely	O
threonine	O
for	O
isoleucine	O
at	O
position	O
56	O
in	O
one	O
family	O
,	O
and	O
histidine	O
for	O
aspartic	O
acid	O
at	O
residue	O
67	O
in	O
the	O
other	O
.	O

Amyloid	O
fibrils	O
from	O
one	O
individual	O
were	O
composed	O
of	O
the	O
full	O
-	O
length	O
Thr	O
-	O
56	O
variant	O
lysozyme	O
molecule	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
naturally	O
occurring	O
variants	O
of	O
human	O
lysozyme	O
and	O
of	O
lysozyme	O
-	O
associated	O
disease	O
.	O

As	O
the	O
structures	O
of	O
human	O
and	O
hen	O
egg	O
-	O
white	O
lysozyme	O
are	O
known	O
to	O
atomic	O
resolution	O
and	O
their	O
folding	O
and	O
structure	O
-	O
function	O
relationships	O
have	O
been	O
exhaustively	O
analysed	O
,	O
our	O
observations	O
should	O
provide	O
a	O
powerful	O
model	O
for	O
understanding	O
amyloidogenesis	O
.	O

Visual	O
arrestin	O
interaction	O
with	O
rhodopsin	O
.	O

Sequential	O
multisite	O
binding	O
ensures	O
strict	O
selectivity	O
toward	O
light	O
-	O
activated	O
phosphorylated	O
rhodopsin	O
.	O

Visual	O
arrestin	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
light	O
responsiveness	O
via	O
its	O
ability	O
to	O
specifically	O
bind	O
to	O
the	O
phosphorylated	O
and	O
light	O
-	O
activated	O
form	O
of	O
rhodopsin	O
.	O

Previously	O
,	O
we	O
utilized	O
an	O
in	O
vitro	O
translation	O
system	O
to	O
express	O
and	O
characterize	O
the	O
full	O
-	O
length	O
(	O
404	O
amino	O
acids	O
)	O
and	O
two	O
truncated	O
forms	O
of	O
visual	O
arrestin	O
.	O

Here	O
we	O
have	O
extended	O
these	O
studies	O
to	O
include	O
a	O
total	O
of	O
33	O
different	O
truncation	O
and	O
deletion	O
mutants	O
of	O
arrestin	O
,	O
ranging	O
from	O
69	O
to	O
391	O
amino	O
acids	O
in	O
length	O
.	O

Mutants	O
were	O
produced	O
by	O
cutting	O
within	O
the	O
open	O
reading	O
frame	O
of	O
the	O
bovine	O
arrestin	O
cDNA	O
with	O
selective	O
restriction	O
enzymes	O
followed	O
by	O
in	O
vitro	O
translation	O
of	O
the	O
transcribed	O
truncated	O
mRNAs	O
.	O

Mutant	O
arrestin	O
binding	O
to	O
dark	O
,	O
light	O
-	O
activated	O
,	O
dark	O
phosphorylated	O
,	O
and	O
light	O
-	O
activated	O
phosphorylated	O
rhodopsin	O
as	O
well	O
as	O
to	O
opsin	O
,	O
phosphoopsin	O
,	O
and	O
truncated	O
rhodopsin	O
was	O
then	O
extensively	O
characterized	O
.	O

In	O
addition	O
,	O
the	O
sensitivity	O
of	O
arrestin	O
/	O
rhodopsin	O
interactions	O
to	O
conditions	O
of	O
increasing	O
ionic	O
strength	O
was	O
measured	O
.	O

These	O
studies	O
suggest	O
the	O
localization	O
of	O
multiple	O
functional	O
domains	O
within	O
the	O
arrestin	O
molecule	O
that	O
include	O
:	O
1	O
)	O
a	O
"	O
phosphorylation	O
recognition	O
"	O
domain	O
,	O
which	O
interacts	O
with	O
the	O
phosphorylated	O
carboxyl	O
terminus	O
of	O
rhodopsin	O
,	O
was	O
localized	O
predominately	O
between	O
residues	O
158	O
-	O
185	O
;	O
2	O
)	O
an	O
"	O
activation	O
recognition	O
"	O
domain	O
,	O
which	O
interacts	O
with	O
those	O
portions	O
of	O
the	O
rhodopsin	O
molecule	O
that	O
change	O
conformation	O
upon	O
light	O
activation	O
,	O
was	O
found	O
to	O
consist	O
of	O
at	O
least	O
three	O
regions	O
within	O
the	O
first	O
191	O
residues	O
of	O
the	O
arrestin	O
molecule	O
;	O
3	O
)	O
a	O
hydrophobic	O
interaction	O
domain	O
,	O
localized	O
between	O
residues	O
191	O
and	O
365	O
,	O
appears	O
to	O
be	O
mobilized	O
upon	O
binding	O
of	O
arrestin	O
to	O
activated	O
phosphorylated	O
rhodopsin	O
;	O
4	O
)	O
a	O
regulatory	O
domain	O
,	O
localized	O
in	O
the	O
COOH	O
-	O
terminal	O
region	O
of	O
arrestin	O
(	O
residues	O
365	O
-	O
391	O
)	O
,	O
was	O
found	O
to	O
play	O
a	O
role	O
in	O
controlling	O
the	O
conformational	O
change	O
in	O
arrestin	O
necessary	O
for	O
mobilization	O
of	O
the	O
hydrophobic	O
interaction	O
domain	O
;	O
and	O
5	O
)	O
The	O
NH2	O
terminus	O
of	O
arrestin	O
(	O
residues	O
2	O
-	O
16	O
)	O
was	O
found	O
to	O
be	O
important	O
for	O
interacting	O
with	O
the	O
regulatory	O
COOH	O
-	O
terminal	O
region	O
as	O
well	O
as	O
maintaining	O
the	O
conformation	O
of	O
the	O
NH2	O
-	O
terminal	O
half	O
of	O
arrestin	O
.	O

A	O
mechanism	O
which	O
ensures	O
strict	O
arrestin	O
binding	O
selectivity	O
toward	O
phosphorylated	O
light	O
-	O
activated	O
rhodopsin	O
is	O
proposed	O
.	O

Cytotoxicity	O
-	O
dependent	O
APO	O
-	O
1	O
(	O
Fas	O
/	O
CD95	O
)	O
-	O
associated	O
proteins	O
form	O
a	O
death	B-Complex
-	I-Complex
inducing	I-Complex
signaling	I-Complex
complex	I-Complex
(	O
DISC	B-Complex
)	O
with	O
the	O
receptor	O
.	O

APO	O
-	O
1	O
(	O
Fas	O
/	O
CD95	O
)	O
,	O
a	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
superfamily	O
,	O
induces	O
apoptosis	O
upon	O
receptor	O
oligomerization	O
.	O

In	O
a	O
search	O
to	O
identify	O
intracellular	O
signaling	O
molecules	O
coupling	O
to	O
oligomerized	O
APO	O
-	O
1	O
,	O
several	O
cytotoxicity	O
-	O
dependent	O
APO	O
-	O
1	O
-	O
associated	O
proteins	O
(	O
CAP	O
)	O
were	O
immunoprecipitated	O
from	O
the	O
apoptosis	O
-	O
sensitive	O
human	O
leukemic	O
T	O
cell	O
line	O
HUT78	O
and	O
the	O
lymphoblastoid	O
B	O
cell	O
line	O
SKW6	O
.	O
4	O
.	O

CAP1	O
-	O
3	O
(	O
27	O
-	O
29	O
kDa	O
)	O
and	O
CAP4	O
(	O
55	O
kDa	O
)	O
,	O
instantly	O
detectable	O
after	O
the	O
crosslinking	O
of	O
APO	O
-	O
1	O
,	O
were	O
associated	O
only	O
with	O
aggregated	O
(	O
the	O
signaling	O
form	O
of	O
APO	O
-	O
1	O
)	O
and	O
not	O
with	O
monomeric	O
APO	O
-	O
1	O
.	O

CAP1	O
and	O
CAP2	O
were	O
identified	O
as	O
serine	O
phosphorylated	O
MORT1	O
/	O
FADD	O
.	O

The	O
association	O
of	O
CAP1	O
-	O
4	O
with	O
APO	O
-	O
1	O
was	O
not	O
observed	O
with	O
C	O
-	O
terminally	O
truncated	O
non	O
-	O
signaling	O
APO	O
-	O
1	O
.	O

In	O
addition	O
,	O
CAP1	O
and	O
CAP2	O
did	O
not	O
associate	O
with	O
an	O
APO	O
-	O
1	O
cytoplasmic	O
tail	O
carrying	O
the	O
lprcg	O
amino	O
acid	O
replacement	O
.	O

Moreover	O
,	O
no	O
APO	O
-	O
1	O
-	O
CAP	O
association	O
was	O
found	O
in	O
the	O
APO	O
-	O
1	O
+	O
,	O
anti	O
-	O
APO	O
-	O
1	O
-	O
resistant	O
pre	O
-	O
B	O
cell	O
line	O
Boe	O
.	O

Our	O
data	O
suggest	O
that	O
in	O
vivo	O
CAP1	O
-	O
4	O
are	O
the	O
APO	O
-	O
1	O
apoptosis	O
-	O
transducing	O
molecules	O
.	O

Multiple	O
palmitoylation	O
of	O
synaptotagmin	O
and	O
the	O
t	O
-	O
SNARE	O
SNAP	O
-	O
25	O
.	O

Synaptotagmin	O
,	O
a	O
likely	O
calcium	O
sensor	O
for	O
synaptic	O
transmission	O
,	O
and	O
SNAP	O
-	O
25	O
,	O
a	O
t	O
-	O
SNARE	O
of	O
the	O
presynaptic	O
plasma	O
membrane	O
,	O
are	O
key	O
proteins	O
for	O
the	O
docking	O
and	O
fusion	O
of	O
synaptic	O
and	O
other	O
vesicles	O
.	O

We	O
report	O
that	O
both	O
synaptotagmin	O
and	O
SNAP	O
-	O
25	O
are	O
palmitoylated	O
with	O
their	O
fatty	O
acids	O
attached	O
in	O
a	O
labile	O
thioester	O
-	O
type	O
bond	O
.	O

A	O
SNAP	O
-	O
25	O
mutant	O
with	O
deleted	O
palmitoylation	O
sites	O
is	O
found	O
exclusively	O
in	O
the	O
cytosol	O
after	O
cell	O
fractionation	O
,	O
whereas	O
the	O
palmitoylated	O
form	O
of	O
SNAP	O
-	O
25	O
is	O
membrane	O
-	O
bound	O
,	O
establishing	O
that	O
SNAP	O
-	O
25	O
is	O
membrane	O
-	O
anchored	O
via	O
covalently	O
linked	O
palmitate	O
.	O

Molecular	O
cloning	O
and	O
functional	O
expression	O
of	O
the	O
K	O
-	O
Cl	O
cotransporter	O
from	O
rabbit	O
,	O
rat	O
,	O
and	O
human	O
.	O

A	O
new	O
member	O
of	O
the	O
cation	O
-	O
chloride	O
cotransporter	O
family	O
.	O

We	O
report	O
the	O
cloning	O
,	O
sequence	O
analysis	O
,	O
tissue	O
distribution	O
,	O
and	O
functional	O
expression	O
of	O
the	O
K	O
-	O
Cl	O
cotransport	O
protein	O
,	O
KCC1	O
.	O

KCC1	O
was	O
identified	O
by	O
searching	O
the	O
human	O
expressed	O
sequence	O
tag	O
data	O
base	O
,	O
based	O
on	O
the	O
expectation	O
that	O
it	O
would	O
be	O
distantly	O
related	O
to	O
the	O
Na	O
-	O
K	O
-	O
Cl	O
cotransporter	O
.	O

Rabbit	O
KCC1	O
(	O
rbKCC1	O
)	O
and	O
rat	O
KCC1	O
(	O
rtKCC1	O
)	O
were	O
cloned	O
by	O
screening	O
rabbit	O
kidney	O
and	O
rat	O
brain	O
cDNA	O
libraries	O
using	O
homologous	O
cDNA	O
probes	O
.	O

Human	O
KCC1	O
(	O
hKCC1	O
)	O
was	O
obtained	O
from	O
I	O
.	O
M	O
.	O
A	O
.	O
G	O
.	O
E	O
.	O
clones	O
and	O
in	O
part	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
;	O
it	O
exhibits	O
97	O
%	O
identity	O
with	O
rbKCC1	O
.	O

KCC1	O
encodes	O
a	O
1085	O
-	O
residue	O
polypeptide	O
with	O
substantial	O
sequence	O
homology	O
(	O
24	O
-	O
25	O
%	O
identity	O
)	O
to	O
the	O
bumetanide	O
-	O
sensitive	O
Na	O
-	O
K	O
-	O
Cl	O
cotransporter	O
(	O
NKCC	O
or	O
BSC	O
)	O
and	O
the	O
thiazide	O
-	O
sensitive	O
Na	O
-	O
Cl	O
cotransporter	O
(	O
NCC	O
or	O
TSC	O
)	O
.	O

Hydropathy	O
analysis	O
of	O
KCC1	O
indicates	O
structural	O
homology	O
to	O
NKCC	O
,	O
including	O
12	O
transmembrane	O
domains	O
,	O
a	O
large	O
extracellular	O
loop	O
with	O
potential	O
N	O
-	O
linked	O
glycosylation	O
sites	O
,	O
and	O
cytoplasmic	O
N	O
-	O
and	O
C	O
-	O
terminal	O
regions	O
.	O

Northern	O
blot	O
analysis	O
revealed	O
a	O
ubiquitously	O
expressed	O
3	O
.	O

8	O
-	O
kilobase	O
transcript	O
.	O

Much	O
of	O
the	O
genomic	O
sequence	O
of	O
hKCC1	O
is	O
in	O
the	O
data	O
base	O
,	O
and	O
the	O
gene	O
has	O
been	O
previously	O
localized	O
to	O
16q22	O
.	O
1	O
(	O
Larsen	O
,	O
F	O
.	O
,	O
Solhein	O
,	O
J	O
.	O
,	O
Kristensen	O
,	O
T	O
.	O
,	O
Kolsto	O
,	O
A	O
.	O
B	O
.	O
,	O
and	O
Prydz	O
,	O
H	O
.	O
(	O
1993	O
)	O
Hum	O
.	O
Mol	O
.	O
Genet	O
.	O
2	O
,	O
1589	O
-	O
1595	O
)	O
.	O

Epitope	O
-	O
tagged	O
rbKCC1	O
was	O
stably	O
expressed	O
in	O
human	O
embryonic	O
kidney	O
(	O
HEK	O
293	O
)	O
cells	O
,	O
resulting	O
in	O
production	O
of	O
a	O
approximately150	O
-	O
kDa	O
glycoprotein	O
.	O

The	O
initial	O
rate	O
of	O
86Rb	O
efflux	O
from	O
cells	O
expressing	O
rbKCC1	O
was	O
more	O
than	O
7	O
times	O
greater	O
than	O
efflux	O
from	O
control	O
cells	O
and	O
was	O
inhibited	O
by	O
2	O
mM	O
furosemide	O
;	O
86Rb	O
efflux	O
was	O
stimulated	O
by	O
cell	O
swelling	O
.	O

Uptake	O
of	O
86Rb	O
into	O
rbKCC1	O
cells	O
after	O
a	O
15	O
-	O
min	O
pretreatment	O
with	O
1	O
mM	O
N	O
-	O
ethylmaleimide	O
was	O
dependent	O
on	O
external	O
chloride	O
but	O
not	O
on	O
external	O
sodium	O
,	O
and	O
was	O
inhibited	O
by	O
furosemide	O
with	O
a	O
Ki	O
of	O
approximately	O
40	O
microM	O
and	O
by	O
bumetanide	O
with	O
a	O
Ki	O
of	O
approximately	O
60	O
microM	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
KCC1	O
cDNAs	O
encode	O
a	O
widely	O
expressed	O
K	O
-	O
Cl	O
cotransporter	O
with	O
the	O
characteristics	O
of	O
the	O
K	O
-	O
Cl	O
transporter	O
that	O
has	O
been	O
characterized	O
in	O
red	O
cells	O
.	O

Purification	O
of	O
a	O
protein	O
palmitoyltransferase	O
that	O
acts	O
on	O
H	O
-	O
Ras	O
protein	O
and	O
on	O
a	O
C	O
-	O
terminal	O
N	O
-	O
Ras	O
peptide	O
.	O

Mammalian	O
H	O
-	O
Ras	O
and	O
N	O
-	O
Ras	O
are	O
GTP	O
-	O
binding	O
proteins	O
that	O
must	O
be	O
post	O
-	O
translationally	O
lipidated	O
to	O
function	O
as	O
molecular	O
switches	O
in	O
signal	O
transduction	O
cascades	O
controlling	O
cell	O
growth	O
and	O
differentiation	O
.	O

These	O
proteins	O
contain	O
a	O
C	O
-	O
terminal	O
farnesyl	O
-	O
cysteine	O
alpha	O
-	O
methyl	O
ester	O
and	O
palmitoyl	O
groups	O
attached	O
to	O
nearby	O
cysteines	O
.	O

Data	O
is	O
presented	O
showing	O
that	O
rat	O
liver	O
microsomes	O
contain	O
an	O
enzyme	O
that	O
transfers	O
the	O
palmitoyl	O
group	O
from	O
palmitoyl	O
-	O
coenzyme	O
A	O
to	O
cysteine	O
residues	O
of	O
H	O
-	O
Ras	O
protein	O
and	O
of	O
a	O
synthetic	O
peptide	O
having	O
the	O
structure	O
of	O
the	O
C	O
terminus	O
of	O
N	O
-	O
Ras	O
.	O

This	O
protein	O
palmitoyltransferase	O
(	O
PPT	O
)	O
was	O
solubilized	O
from	O
membranes	O
and	O
purified	O
10	O
,	O
500	O
-	O
fold	O
to	O
apparent	O
homogeneity	O
with	O
an	O
overall	O
yield	O
of	O
10	O
%	O
.	O

On	O
an	O
SDS	O
gel	O
,	O
PPT	O
appears	O
as	O
two	O
proteins	O
of	O
molecular	O
masses	O
of	O
approximately	O
30	O
and	O
approximately	O
33	O
kDa	O
.	O

If	O
the	O
palmitoylation	O
sites	O
of	O
the	O
N	O
-	O
Ras	O
peptide	O
(	O
the	O
non	O
-	O
farnesylated	O
cysteine	O
)	O
or	O
H	O
-	O
Ras	O
protein	O
(	O
cysteines	O
181	O
and	O
184	O
)	O
are	O
changed	O
to	O
serine	O
,	O
palmitoylation	O
by	O
PPT	O
does	O
not	O
occur	O
.	O

Non	O
-	O
farnesylated	O
H	O
-	O
Ras	O
produced	O
in	O
bacteria	O
as	O
well	O
as	O
in	O
vitro	O
farnesylated	O
bacterial	O
H	O
-	O
Ras	O
are	O
not	O
substrates	O
for	O
PPT	O
nor	O
is	O
the	O
non	O
-	O
farnesylated	O
,	O
methylated	O
N	O
-	O
Ras	O
peptide	O
.	O

These	O
results	O
suggest	O
,	O
but	O
do	O
not	O
prove	O
,	O
that	O
farnesylation	O
and	O
possibly	O
C	O
-	O
terminal	O
methylation	O
are	O
prerequisites	O
for	O
Ras	O
palmitoylation	O
.	O

PPT	O
shows	O
a	O
large	O
preference	O
for	O
palmitoyl	O
-	O
coenzyme	O
A	O
over	O
myristoyl	O
-	O
coenzyme	O
as	O
the	O
acyl	O
donor	O
.	O

Values	O
of	O
Km	O
for	O
palmitoyl	O
-	O
CoA	O
and	O
H	O
-	O
Ras	O
are	O
4	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
2	O
and	O
0	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
3	O
microM	O
,	O
respectively	O
.	O

PPT	O
is	O
the	O
first	O
protein	O
palmitoyltransferase	O
to	O
be	O
purified	O
,	O
and	O
the	O
availability	O
of	O
pure	O
enzyme	O
should	O
contribute	O
to	O
our	O
understanding	O
of	O
the	O
function	O
and	O
regulation	O
of	O
Ras	O
palmitoylation	O
in	O
cells	O
.	O

The	O
human	O
AQP4	O
gene	O
:	O
definition	O
of	O
the	O
locus	O
encoding	O
two	O
water	O
channel	O
polypeptides	O
in	O
brain	O
.	O

The	O
aquaporin	O
family	O
of	O
membrane	O
water	O
transport	O
proteins	O
are	O
expressed	O
in	O
diverse	O
tissues	O
,	O
and	O
in	O
brain	O
the	O
predominant	O
water	O
channel	O
protein	O
is	O
AQP4	O
.	O

Here	O
we	O
report	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
human	O
AQP4	O
cDNAs	O
and	O
genomic	O
DNA	O
.	O

Two	O
cDNAs	O
were	O
isolated	O
corresponding	O
to	O
the	O
two	O
initiating	O
methionines	O
(	O
M1	O
in	O
a	O
323	O
-	O
aa	O
polypeptide	O
and	O
M23	O
in	O
a	O
301	O
-	O
aa	O
polypeptide	O
)	O
previously	O
identified	O
in	O
rat	O
[	O
Jung	O
,	O
J	O
.	O
S	O
.	O
,	O
Bhat	O
,	O
R	O
.	O
V	O
.	O
,	O
Preston	O
,	O
G	O
.	O
M	O
.	O
,	O
Guggino	O
,	O
W	O
.	O
B	O
.	O
&	O
Agre	O
,	O
P	O
.	O
(	O
1994	O
)	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
91	O
,	O
13052	O
-	O
13056	O
]	O
.	O

Similar	O
to	O
other	O
aquaporins	O
,	O
the	O
AQP4	O
gene	O
is	O
composed	O
of	O
four	O
exons	O
encoding	O
127	O
,	O
55	O
,	O
27	O
,	O
and	O
92	O
amino	O
acids	O
separated	O
by	O
introns	O
of	O
0	O
.	O
8	O
,	O
0	O
.	O
3	O
,	O
and	O
5	O
.	O
2	O
kb	O
.	O

Unlike	O
other	O
aquaporins	O
,	O
an	O
alternative	O
coding	O
initiation	O
sequence	O
(	O
designated	O
exon	O
0	O
)	O
was	O
located	O
2	O
.	O
7	O
kb	O
upstream	O
of	O
exon	O
1	O
.	O

When	O
spliced	O
together	O
,	O
M1	O
and	O
the	O
subsequent	O
10	O
amino	O
acids	O
are	O
encoded	O
by	O
exon	O
0	O
;	O
the	O
next	O
11	O
amino	O
acids	O
and	O
M23	O
are	O
encoded	O
by	O
exon	O
1	O
.	O

Transcription	O
initiation	O
sites	O
have	O
been	O
mapped	O
in	O
the	O
proximal	O
promoters	O
of	O
exons	O
0	O
and	O
1	O
.	O

RNase	O
protection	O
revealed	O
distinct	O
transcripts	O
corresponding	O
to	O
M1	O
and	O
M23	O
mRNAs	O
,	O
and	O
AQP4	O
immunoblots	O
of	O
cerebellum	O
demonstrated	O
reactive	O
polypeptides	O
of	O
31	O
and	O
34	O
kDa	O
.	O

Using	O
a	O
P1	O
and	O
a	O
lambda	O
EMBL	O
subclone	O
,	O
the	O
chromosomal	O
site	O
of	O
the	O
human	O
AQP4	O
gene	O
was	O
mapped	O
to	O
chromosome	O
18	O
at	O
the	O
junction	O
of	O
q11	O
.	O
2	O
and	O
q12	O
.	O
1	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

These	O
studies	O
may	O
now	O
permit	O
molecular	O
characterization	O
of	O
AQP4	O
during	O
human	O
development	O
and	O
in	O
clinical	O
disorders	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
nlpH	O
,	O
encoding	O
a	O
novel	O
,	O
surface	O
-	O
exposed	O
,	O
polymorphic	O
,	O
plasmid	O
-	O
encoded	O
33	O
-	O
kilodalton	O
lipoprotein	O
of	O
Borrelia	O
afzelii	O
.	O

Borrelia	O
burgdorferi	O
sensu	O
lato	O
organisms	O
,	O
comprising	O
B	O
.	O
burgdorferi	O
sensu	O
stricto	O
,	O
Borrelia	O
afzelii	O
,	O
and	O
Borrelia	O
garinii	O
,	O
are	O
tick	O
-	O
borne	O
pathogens	O
causing	O
Lyme	O
borreliosis	O
in	O
humans	O
.	O

To	O
identify	O
putative	O
virulence	O
determinants	O
,	O
a	O
B	O
.	O
afzelii	O
DNA	O
library	O
was	O
screened	O
for	O
Congo	O
red	O
dye	O
binding	O
,	O
a	O
property	O
associated	O
with	O
virulence	O
in	O
pathogenic	O
bacteria	O
.	O

One	O
clone	O
was	O
found	O
to	O
carry	O
a	O
663	O
-	O
nucleotide	O
-	O
long	O
open	O
reading	O
frame	O
encoding	O
a	O
Congo	O
red	O
dye	O
-	O
binding	O
protein	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
25	O
,	O
660	O
Da	O
.	O

The	O
amino	O
acid	O
sequence	O
deduced	O
from	O
its	O
nucleotide	O
sequence	O
was	O
found	O
to	O
include	O
a	O
consensus	O
bacterial	O
lipidation	O
site	O
present	O
at	O
residues	O
15	O
to	O
18	O
(	O
Leu	O
-	O
Ser	O
-	O
Gly	O
-	O
Cys	O
)	O
.	O

The	O
lipoprotein	O
nature	O
was	O
demonstrated	O
by	O
incorporation	O
of	O
radioactive	O
palmitate	O
;	O
hence	O
,	O
this	O
protein	O
has	O
been	O
termed	O
NlpH	O
,	O
for	O
new	O
lipoprotein	O
H	O
.	O

NlpH	O
is	O
located	O
on	O
the	O
surface	O
of	O
B	O
.	O
afzelii	O
,	O
and	O
the	O
nlpH	O
gene	O
is	O
found	O
on	O
a	O
circular	O
plasmid	O
.	O

The	O
nlpH	O
gene	O
is	O
also	O
found	O
in	O
B	O
.	O
burgdorferi	O
sensu	O
stricto	O
and	O
B	O
.	O
garinii	O
.	O

Immediately	O
upstream	O
of	O
nlpH	O
is	O
located	O
a	O
smaller	O
reading	O
frame	O
encoding	O
a	O
polypeptide	O
containing	O
the	O
casein	O
kinase	O
II	O
phosphorylation	O
recognition	O
sequence	O
,	O
(	O
Ser	O
/	O
Thr	O
)	O
-	O
X	O
-	O
Y	O
-	O
(	O
Glu	O
/	O
Asp	O
)	O
,	O
repeated	O
10	O
times	O
.	O

Restricted	O
expression	O
of	O
a	O
novel	O
murine	O
atonal	O
-	O
related	O
bHLH	O
protein	O
in	O
undifferentiated	O
neural	O
precursors	O
.	O

Tissue	O
-	O
specific	O
bHLH	O
proteins	O
play	O
important	O
roles	O
in	O
the	O
specification	O
and	O
differentiation	O
of	O
neural	O
cell	O
lineages	O
in	O
invertebrate	O
and	O
vertebrate	O
organisms	O
.	O

Two	O
groups	O
of	O
bHLH	O
proteins	O
,	O
atonal	O
and	O
achaete	O
-	O
scute	O
,	O
have	O
proneural	O
activities	O
in	O
Drosophila	O
,	O
and	O
the	O
mouse	O
achaete	O
-	O
scute	O
homolog	O
MASH1	O
is	O
required	O
for	O
the	O
differentiation	O
of	O
several	O
neural	O
lineages	O
.	O

In	O
a	O
screen	O
for	O
proteins	O
interacting	O
with	O
MASH1	O
,	O
we	O
have	O
isolated	O
a	O
novel	O
bHLH	O
protein	O
related	O
to	O
atonal	O
,	O
named	O
MATH4A	O
,	O
which	O
is	O
broadly	O
expressed	O
in	O
neural	O
precursor	O
cells	O
in	O
the	O
mouse	O
embryonic	O
CNS	O
and	O
PNS	O
.	O

Interaction	O
assays	O
in	O
yeast	O
and	O
in	O
vitro	O
demonstrate	O
that	O
MATH4A	O
interacts	O
efficiently	O
with	O
both	O
MASH1	O
and	O
the	O
ubiquitous	O
bHLH	O
protein	O
E12	O
.	O

MATH4A	O
-	O
E12	O
heterodimers	O
,	O
but	O
not	O
MATH4A	O
-	O
MASH1	O
,	O
bind	O
to	O
a	O
consensus	O
E	O
-	O
box	O
sequence	O
.	O

Math4A	O
expression	O
is	O
restricted	O
to	O
undifferentiated	O
neural	O
precursors	O
and	O
is	O
complementary	O
to	O
that	O
of	O
Mash1	O
in	O
most	O
regions	O
of	O
the	O
nervous	O
system	O
.	O

In	O
particular	O
,	O
Math4A	O
is	O
transcribed	O
at	O
high	O
levels	O
in	O
the	O
cerebral	O
cortex	O
,	O
dorsal	O
thalamus	O
,	O
and	O
epibranchial	O
placodes	O
,	O
which	O
present	O
little	O
or	O
no	O
Mash1	O
expression	O
.	O

However	O
,	O
expression	O
of	O
the	O
two	O
genes	O
shows	O
limited	O
overlap	O
in	O
certain	O
CNS	O
regions	O
(	O
retina	O
,	O
preoptic	O
area	O
of	O
the	O
hypothalamus	O
,	O
midbrain	O
,	O
hindbrain	O
)	O
.	O

Its	O
structure	O
and	O
expression	O
pattern	O
suggest	O
that	O
MATH4A	O
may	O
regulate	O
an	O
early	O
step	O
of	O
neural	O
development	O
,	O
either	O
as	O
a	O
partner	O
of	O
ubiquitous	O
bHLH	O
proteins	O
or	O
associated	O
with	O
other	O
neural	O
-	O
specific	O
bHLH	O
proteins	O
.	O

Functional	O
association	O
between	O
the	O
insulin	O
receptor	O
and	O
the	O
transmembrane	O
protein	O
-	O
tyrosine	O
phosphatase	O
LAR	O
in	O
intact	O
cells	O
.	O

The	O
receptor	O
-	O
type	O
protein	O
-	O
tyrosine	O
phosphatase	O
LAR	O
(	O
for	O
leukocyte	O
common	O
antigen	O
-	O
related	O
)	O
has	O
been	O
implicated	O
as	O
a	O
physiological	O
regulator	O
of	O
the	O
insulin	O
receptor	O
.	O

To	O
demonstrate	O
a	O
functional	O
interaction	O
between	O
LAR	O
and	O
the	O
insulin	O
receptor	O
,	O
we	O
incubated	O
CHO	O
cells	O
overexpressing	O
the	O
human	O
insulin	O
receptor	O
with	O
an	O
antibody	O
to	O
the	O
extracellular	O
domain	O
of	O
LAR	O
and	O
found	O
a	O
47	O
%	O
decrease	O
in	O
insulin	O
receptor	O
autophosphorylation	O
and	O
kinase	O
activity	O
.	O

A	O
physical	O
association	O
between	O
LAR	O
and	O
the	O
insulin	O
receptor	O
was	O
then	O
shown	O
by	O
immunoprecipitation	O
of	O
LAR	O
from	O
cell	O
lysates	O
and	O
immunoblotting	O
with	O
antibody	O
to	O
the	O
insulin	O
receptor	O
,	O
or	O
vice	O
versa	O
.	O

Up	O
to	O
11	O
.	O
8	O
%	O
of	O
the	O
LAR	O
protein	O
in	O
the	O
lysates	O
of	O
CHO	O
cells	O
overexpressing	O
both	O
the	O
insulin	O
receptor	O
and	O
LAR	O
co	O
-	O
immunoprecipitated	O
with	O
the	O
insulin	O
receptor	O
.	O

The	O
LAR	O
/	O
insulin	O
receptor	O
association	O
was	O
related	O
to	O
the	O
level	O
of	O
LAR	O
or	O
insulin	O
receptor	O
overexpression	O
and	O
was	O
increased	O
6	O
.	O
5	O
-	O
fold	O
by	O
chemical	O
cross	O
-	O
linking	O
and	O
3	O
.	O
9	O
-	O
fold	O
by	O
treatment	O
with	O
insulin	O
,	O
suggesting	O
that	O
receptor	O
activation	O
influences	O
the	O
affinity	O
of	O
LAR	O
for	O
the	O
insulin	O
receptor	O
.	O

In	O
insulin	O
-	O
stimulated	O
rat	O
liver	O
,	O
LAR	O
was	O
temporally	O
enriched	O
in	O
endosomes	O
with	O
the	O
insulin	O
receptor	O
,	O
and	O
incubation	O
of	O
endosomes	O
with	O
neutralizing	O
LAR	O
antibodies	O
decreased	O
insulin	O
receptor	O
dephosphorylation	O
in	O
situ	O
by	O
28	O
%	O
(	O
p	O
=	O
0	O
.	O
01	O
versus	O
control	O
)	O
.	O

These	O
data	O
provide	O
more	O
direct	O
evidence	O
of	O
a	O
role	O
for	O
LAR	O
in	O
the	O
physiological	O
regulation	O
of	O
insulin	O
action	O
at	O
the	O
receptor	O
level	O
.	O

A	O
single	O
STAT	O
recruitment	O
module	O
in	O
a	O
chimeric	O
cytokine	O
receptor	O
complex	O
is	O
sufficient	O
for	O
STAT	O
activation	O
.	O

We	O
established	O
a	O
system	O
of	O
receptor	O
chimeras	O
that	O
enabled	O
us	O
to	O
induce	O
heterodimerization	O
of	O
different	O
cytoplasmic	O
tails	O
.	O

Fusion	O
constructs	O
were	O
created	O
that	O
are	O
composed	O
of	O
the	O
extracellular	O
parts	O
of	O
the	O
interleukin	B-Complex
-	I-Complex
5	I-Complex
receptor	I-Complex
alpha	O
and	O
beta	O
chains	O
,	O
respectively	O
,	O
and	O
the	O
transmembrane	O
and	O
intracellular	O
parts	O
of	O
gp130	O
,	O
the	O
signal	O
transducing	O
chain	O
of	O
the	O
interleukin	B-Complex
-	I-Complex
6	I-Complex
receptor	I-Complex
complex	O
.	O

In	O
COS	O
-	O
7	O
transfectants	O
we	O
observed	O
a	O
dose	O
-	O
dependent	O
interleukin	O
-	O
5	O
-	O
inducible	O
STAT1	O
activation	O
for	O
which	O
the	O
presence	O
of	O
both	O
the	O
alpha	O
and	O
the	O
beta	O
chain	O
chimera	O
was	O
needed	O
.	O

No	O
STAT	O
activity	O
was	O
detected	O
if	O
one	O
of	O
the	O
cytoplasmic	O
tails	O
of	O
the	O
receptor	O
complex	O
was	O
deleted	O
,	O
indicating	O
that	O
STAT	O
activity	O
resulted	O
from	O
a	O
receptor	O
dimer	O
rather	O
than	O
from	O
higher	O
receptor	O
aggregates	O
.	O

We	O
further	O
investigated	O
whether	O
dimerization	O
of	O
STAT1	O
depends	O
on	O
the	O
juxtaposition	O
of	O
two	O
STAT	O
recruitment	O
modules	O
in	O
a	O
receptor	O
complex	O
.	O

We	O
show	O
that	O
a	O
receptor	O
dimer	O
with	O
only	O
a	O
single	O
STAT1	O
docking	O
site	O
was	O
still	O
able	O
to	O
lead	O
to	O
STAT1	O
activation	O
.	O

This	O
indicates	O
that	O
the	O
formation	O
of	O
a	O
paired	O
set	O
of	O
STAT	O
binding	O
sites	O
in	O
a	O
receptor	O
complex	O
is	O
not	O
the	O
prerequisite	O
for	O
STAT	O
factor	O
dimerization	O
.	O

Our	O
findings	O
are	O
discussed	O
in	O
view	O
of	O
alternative	O
STAT	O
dimerization	O
models	O
.	O

Cloning	O
,	O
expression	O
and	O
chromosomal	O
mapping	O
of	O
human	O
lysosomal	O
sialidase	O
and	O
characterization	O
of	O
mutations	O
in	O
sialidosis	O
.	O

Sialidase	O
(	O
neuraminidase	O
,	O
EC	O
3	O
.	O
2	O
.	O
1	O
.	O
18	O
)	O
catalyses	O
the	O
hydrolysis	O
of	O
terminal	O
sialic	O
acid	O
residues	O
of	O
glyconjugates	O
.	O

Sialidase	O
has	O
been	O
well	O
studied	O
in	O
viruses	O
and	O
bacteria	O
where	O
it	O
destroys	O
the	O
sialic	O
acid	O
-	O
containing	O
receptors	O
at	O
the	O
surface	O
of	O
host	O
cells	O
,	O
and	O
mobilizes	O
bacterial	O
nutrients	O
.	O

In	O
mammals	O
,	O
three	O
types	O
of	O
sialidases	O
,	O
lysosomal	O
,	O
plasma	O
membrane	O
and	O
cytosolic	O
,	O
have	O
been	O
described	O
.	O

For	O
lysosomal	O
sialidase	O
in	O
humans	O
,	O
the	O
primary	O
genetic	O
deficiency	O
results	O
in	O
an	O
autosomal	O
recessive	O
disease	O
,	O
sialidosis	O
,	O
associated	O
with	O
tissue	O
accumulation	O
and	O
urinary	O
excretion	O
of	O
sialylated	O
oligosaccharides	O
and	O
glycolipids	O
.	O

Sialidosis	O
includes	O
two	O
main	O
clinical	O
variants	O
:	O
late	O
-	O
onset	O
,	O
sialidosis	O
type	O
I	O
,	O
characterized	O
by	O
bilateral	O
macular	O
cherry	O
-	O
red	O
spots	O
and	O
myoclonus	O
,	O
and	O
infantile	O
-	O
onset	O
,	O
sialidosis	O
type	O
II	O
,	O
characterized	O
by	O
skeletal	O
dysplasia	O
,	O
mental	O
retardation	O
and	O
hepatosplenomegaly	O
.	O

We	O
report	O
the	O
identification	O
of	O
human	O
lysosomal	O
sialidase	O
cDNA	O
,	O
its	O
cloning	O
,	O
sequencing	O
and	O
expression	O
.	O

Examination	O
of	O
six	O
sialidosis	O
patients	O
revealed	O
three	O
mutations	O
,	O
one	O
frameshift	O
insertion	O
and	O
two	O
missense	O
.	O

We	O
mapped	O
the	O
lysosomal	O
sialidase	O
gene	O
to	O
human	O
chromosome	O
6	O
(	O
6p21	O
.	O
3	O
)	O
,	O
which	O
is	O
consistent	O
with	O
the	O
previous	O
chromosomal	O
assignment	O
of	O
this	O
gene	O
in	O
proximity	O
to	O
the	O
HLA	O
locus	O
.	O

Molecular	O
cloning	O
of	O
SLAP	O
-	O
130	O
,	O
an	O
SLP	O
-	O
76	O
-	O
associated	O
substrate	O
of	O
the	O
T	O
cell	O
antigen	O
receptor	O
-	O
stimulated	O
protein	O
tyrosine	O
kinases	O
.	O

Previous	O
work	O
has	O
demonstrated	O
that	O
SLP	O
-	O
76	O
,	O
a	O
Grb2	O
-	O
associated	O
tyrosine	O
-	O
phosphorylated	O
protein	O
,	O
augments	O
Interleukin	O
-	O
2	O
promoter	O
activity	O
when	O
overexpressed	O
in	O
the	O
Jurkat	O
T	O
cell	O
line	O
.	O

This	O
activity	O
requires	O
regions	O
of	O
SLP	O
-	O
76	O
that	O
mediate	O
protein	O
-	O
protein	O
interactions	O
with	O
other	O
molecules	O
in	O
T	O
cells	O
,	O
suggesting	O
that	O
SLP	O
-	O
76	O
-	O
associated	O
proteins	O
also	O
function	O
to	O
regulate	O
signal	O
transduction	O
.	O

Here	O
we	O
describe	O
the	O
molecular	O
cloning	O
of	O
SLAP	O
-	O
130	O
,	O
a	O
SLP	O
-	O
76	O
-	O
associated	O
phosphoprotein	O
of	O
130	O
kDa	O
.	O

We	O
demonstrate	O
that	O
SLAP	O
-	O
130	O
is	O
hematopoietic	O
cell	O
-	O
specific	O
and	O
associates	O
with	O
the	O
SH2	O
domain	O
of	O
SLP	O
-	O
76	O
.	O

Additionally	O
,	O
we	O
show	O
that	O
SLAP	O
-	O
130	O
is	O
a	O
substrate	O
of	O
the	O
T	O
cell	O
antigen	O
receptor	O
-	O
induced	O
protein	O
tyrosine	O
kinases	O
.	O

Interestingly	O
,	O
we	O
find	O
that	O
in	O
contrast	O
to	O
SLP	O
-	O
76	O
,	O
overexpression	O
of	O
SLAP	O
-	O
130	O
diminishes	O
T	O
cell	O
antigen	O
receptor	O
-	O
induced	O
activation	O
of	O
the	O
interleukin	O
-	O
2	O
promoter	O
in	O
Jurkat	O
T	O
cells	O
and	O
interferes	O
with	O
the	O
augmentation	O
of	O
interleukin	O
-	O
2	O
promoter	O
activity	O
seen	O
when	O
SLP	O
-	O
76	O
is	O
overexpressed	O
in	O
these	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
SLP	O
-	O
76	O
recruits	O
a	O
negative	O
regulator	O
,	O
SLAP	O
-	O
130	O
,	O
as	O
well	O
as	O
positive	O
regulators	O
of	O
signal	O
transduction	O
in	O
T	O
cells	O
.	O

Transcription	O
elongation	O
factor	O
S	O
-	O
II	O
is	O
not	O
required	O
for	O
transcription	O
-	O
coupled	O
repair	O
in	O
yeast	O
.	O

Two	O
different	O
subpathways	O
play	O
a	O
role	O
in	O
removal	O
of	O
UV	O
-	O
induced	O
cyclobutane	O
pyrimidine	O
dimers	O
(	O
CPDs	O
)	O
by	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
.	O

The	O
relatively	O
slow	O
global	O
genome	O
repair	O
subpathway	O
operates	O
on	O
all	O
CPDs	O
irrespective	O
of	O
their	O
position	O
in	O
the	O
DNA	O
,	O
whereas	O
the	O
transcription	O
-	O
coupled	O
repair	O
subpathway	O
is	O
responsible	O
for	O
the	O
rapid	O
removal	O
of	O
CPDs	O
from	O
transcribed	O
strands	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
the	O
RAD26	O
gene	O
is	O
implicated	O
in	O
transcription	O
-	O
coupled	O
repair	O
.	O

However	O
,	O
transcription	O
-	O
coupled	O
repair	O
is	O
not	O
completely	O
absent	O
in	O
rad26	O
mutants	O
,	O
and	O
therefore	O
other	O
gene	O
products	O
are	O
possibly	O
involved	O
in	O
this	O
subpathway	O
.	O

Based	O
on	O
in	O
vitro	O
experiments	O
with	O
purified	O
components	O
,	O
the	O
transcription	O
elongation	O
factor	O
S	O
-	O
II	O
appeared	O
to	O
be	O
a	O
candidate	O
for	O
a	O
function	O
in	O
transcription	O
-	O
coupled	O
repair	O
.	O

To	O
investigate	O
a	O
possible	O
role	O
of	O
S	O
-	O
II	O
in	O
transcription	O
-	O
coupled	O
repair	O
in	O
vivo	O
in	O
yeast	O
,	O
S	O
-	O
II	O
null	O
mutations	O
were	O
introduced	O
into	O
various	O
genetic	O
backgrounds	O
differing	O
in	O
NER	O
capacity	O
.	O

UV	O
sensitivity	O
was	O
not	O
altered	O
by	O
disruption	O
of	O
the	O
S	O
-	O
II	O
gene	O
in	O
a	O
RAD	O
+	O
(	O
NER	O
proficient	O
)	O
strain	O
,	O
or	O
in	O
rad26	O
(	O
impaired	O
in	O
efficient	O
transcription	O
-	O
coupled	O
repair	O
)	O
,	O
rad7	O
(	O
lacking	O
global	O
genome	O
repair	O
)	O
,	O
or	O
rad7	O
rad26	O
(	O
lacking	O
global	O
genome	O
repair	O
,	O
but	O
having	O
residual	O
transcription	O
-	O
coupled	O
repair	O
capacity	O
)	O
mutants	O
.	O

Moreover	O
,	O
S	O
-	O
II	O
did	O
not	O
influence	O
the	O
repair	O
rate	O
on	O
the	O
transcribed	O
strand	O
of	O
the	O
RPB2	O
gene	O
,	O
either	O
in	O
repair	O
-	O
proficient	O
or	O
in	O
rad7	O
rad26	O
backgrounds	O
.	O

Hence	O
,	O
transcription	O
-	O
coupled	O
repair	O
is	O
fully	O
functional	O
in	O
yeast	O
cells	O
lacking	O
the	O
gene	O
encoding	O
S	O
-	O
II	O
.	O

Furthermore	O
,	O
S	O
-	O
II	O
is	O
not	O
required	O
for	O
the	O
Rad26	O
-	O
independent	O
residual	O
transcription	O
-	O
coupled	O
repair	O
in	O
vivo	O
.	O

Distinct	O
retinoid	O
X	O
receptor	O
-	O
retinoic	O
acid	O
receptor	O
heterodimers	O
are	O
differentially	O
involved	O
in	O
the	O
control	O
of	O
expression	O
of	O
retinoid	O
target	O
genes	O
in	O
F9	O
embryonal	O
carcinoma	O
cells	O
.	O

The	O
F9	O
murine	O
embryonal	O
carcinoma	O
cell	O
line	O
represents	O
a	O
well	O
-	O
established	O
system	O
for	O
the	O
study	O
of	O
retinoid	O
signaling	O
in	O
vivo	O
.	O

We	O
have	O
investigated	O
the	O
functional	O
specificity	O
of	O
different	O
retinoid	O
X	O
receptor	O
(	O
RXR	O
)	O
-	O
retinoic	O
acid	O
(	O
RA	O
)	O
receptor	O
(	O
RAR	O
)	O
isotype	O
pairs	O
for	O
the	O
control	O
of	O
expression	O
of	O
endogenous	O
RA	O
-	O
responsive	O
genes	O
,	O
by	O
using	O
wild	O
-	O
type	O
(	O
WT	O
)	O
,	O
RXR	O
alpha	O
(	O
-	O
/	O
-	O
)	O
,	O
RAR	O
alpha	O
(	O
-	O
/	O
-	O
)	O
,	O
RAR	O
gamma	O
(	O
-	O
/	O
-	O
)	O
,	O
RXR	O
alpha	O
(	O
-	O
/	O
-	O
)	O
-	O
RAR	O
alpha	O
(	O
-	O
/	O
-	O
)	O
,	O
and	O
RXR	O
alpha	O
(	O
-	O
/	O
-	O
)	O
-	O
RAR	O
gamma	O
(	O
-	O
/	O
-	O
)	O
F9	O
cells	O
,	O
as	O
well	O
as	O
panRXR	O
and	O
RAR	O
isotype	O
(	O
alpha	O
,	O
beta	O
,	O
and	O
gamma	O
)	O
-	O
selective	O
retinoids	O
.	O

We	O
show	O
that	O
in	O
these	O
cells	O
the	O
control	O
of	O
expression	O
of	O
different	O
sets	O
of	O
RA	O
-	O
responsive	O
genes	O
is	O
preferentially	O
mediated	O
by	O
distinct	O
RXR	O
-	O
RAR	O
isotype	O
combinations	O
.	O

Our	O
data	O
support	O
the	O
conclusion	O
that	O
RXR	O
-	O
RAR	O
heterodimers	O
are	O
the	O
functional	O
units	O
transducing	O
the	O
retinoid	O
signal	O
and	O
indicate	O
in	O
addition	O
that	O
these	O
heterodimers	O
exert	O
both	O
specific	O
and	O
redundant	O
functions	O
on	O
the	O
expression	O
of	O
particular	O
sets	O
of	O
RA	O
-	O
responsive	O
genes	O
.	O

We	O
also	O
show	O
that	O
the	O
presence	O
of	O
a	O
given	O
receptor	O
isotype	O
can	O
hinder	O
the	O
activity	O
of	O
another	O
isotype	O
and	O
therefore	O
that	O
functional	O
redundancy	O
between	O
retinoid	O
receptor	O
isotypes	O
can	O
be	O
artifactually	O
generated	O
by	O
gene	O
knockouts	O
.	O

A	O
modulator	O
of	O
rho	O
family	O
G	O
proteins	O
,	O
rhoGDI	O
,	O
binds	O
these	O
G	O
proteins	O
via	O
an	O
immunoglobulin	O
-	O
like	O
domain	O
and	O
a	O
flexible	O
N	O
-	O
terminal	O
arm	O
.	O

BACKGROUND	O
:	O
The	O
rho	O
family	O
of	O
small	O
G	O
proteins	O
,	O
including	O
rho	O
,	O
rac	O
and	O
cdc42	O
,	O
are	O
involved	O
in	O
many	O
cellular	O
processes	O
,	O
including	O
cell	O
transformation	O
by	O
ras	O
and	O
the	O
organization	O
of	O
the	O
actin	O
cytoskeleton	O
.	O

Additionally	O
,	O
rac	O
has	O
a	O
role	O
in	O
the	O
regulation	O
of	O
phagocyte	O
NADPH	O
oxidase	O
.	O

Guanine	O
nucleotide	O
dissociation	O
inhibitors	O
(	O
GDIs	O
)	O
of	O
the	O
rhoGDI	O
family	O
bind	O
to	O
these	O
G	O
proteins	O
and	O
regulate	O
their	O
activity	O
by	O
preventing	O
nucleotide	O
dissociation	O
and	O
by	O
controlling	O
their	O
interaction	O
with	O
membranes	O
.	O

RESULTS	O
:	O
We	O
report	O
the	O
structure	O
of	O
rhoGDI	O
,	O
determined	O
by	O
a	O
combination	O
of	O
X	O
-	O
ray	O
crystallography	O
and	O
NMR	O
spectroscopy	O
.	O

NMR	O
spectroscopy	O
and	O
selective	O
proteolysis	O
show	O
that	O
the	O
N	O
-	O
terminal	O
50	O
-	O
60	O
residues	O
of	O
rhoGDI	O
are	O
flexible	O
and	O
unstructured	O
in	O
solution	O
.	O

The	O
2	O
.	O
5	O
A	O
crystal	O
structure	O
of	O
the	O
folded	O
core	O
of	O
rhoGDI	O
,	O
comprising	O
residues	O
59	O
-	O
204	O
,	O
shows	O
it	O
to	O
have	O
an	O
immunoglobulin	O
-	O
like	O
fold	O
,	O
with	O
an	O
unprecedented	O
insertion	O
of	O
two	O
short	O
beta	O
strands	O
and	O
a	O
310	O
helix	O
.	O

There	O
is	O
an	O
unusual	O
pocket	O
between	O
the	O
beta	O
sheets	O
of	O
the	O
immunoglobulin	O
fold	O
which	O
may	O
bind	O
the	O
C	O
-	O
terminal	O
isoprenyl	O
group	O
of	O
rac	O
.	O

NMR	O
spectroscopy	O
shows	O
that	O
the	O
N	O
-	O
terminal	O
arm	O
is	O
necessary	O
for	O
binding	O
rac	O
,	O
although	O
it	O
remains	O
largely	O
flexible	O
even	O
in	O
the	O
complex	O
.	O

CONCLUSIONS	O
:	O
The	O
rhoGDI	O
structure	O
is	O
notable	O
for	O
the	O
existence	O
of	O
both	O
a	O
structured	O
and	O
a	O
highly	O
flexible	O
domain	O
,	O
both	O
of	O
which	O
appear	O
to	O
be	O
required	O
for	O
the	O
interaction	O
with	O
rac	O
.	O

The	O
immunoglobulin	O
-	O
like	O
fold	O
of	O
the	O
structured	O
domain	O
is	O
unusual	O
for	O
a	O
cytoplasmic	O
protein	O
.	O

The	O
presence	O
of	O
equivalent	O
cleavage	O
sites	O
in	O
rhoGDI	O
and	O
the	O
closely	O
related	O
D4	O
/	O
Ly	O
-	O
GDI	O
(	O
rhoGDI	O
-	O
2	O
)	O
suggest	O
that	O
proteolytic	O
cleavage	O
between	O
the	O
flexible	O
and	O
structured	O
regions	O
of	O
rhoGDI	O
may	O
have	O
a	O
role	O
in	O
the	O
regulation	O
of	O
the	O
activity	O
of	O
members	O
of	O
this	O
family	O
.	O

There	O
is	O
no	O
detectable	O
similarity	O
between	O
the	O
structure	O
of	O
rhoGDI	O
and	O
the	O
recently	O
reported	O
structure	O
of	O
rabGDI	O
,	O
which	O
performs	O
the	O
same	O
function	O
as	O
rhoGDI	O
for	O
the	O
rab	O
family	O
of	O
small	O
G	O
proteins	O
.	O

Missense	O
mutation	O
of	O
FUT1	O
and	O
deletion	O
of	O
FUT2	O
are	O
responsible	O
for	O
Indian	O
Bombay	O
phenotype	O
of	O
ABO	O
blood	O
group	O
system	O
.	O

The	O
Bombay	O
phenotype	O
fails	O
to	O
express	O
the	O
ABH	O
antigens	O
of	O
ABO	O
blood	O
group	O
system	O
on	O
red	O
blood	O
cells	O
and	O
in	O
secretions	O
because	O
of	O
a	O
lack	O
in	O
activities	O
of	O
the	O
H	O
gene	O
(	O
FUT1	O
)	O
-	O
and	O
Secretor	O
gene	O
(	O
FUT2	O
)	O
-	O
encoded	O
alpha	O
(	O
1	O
,	O
2	O
)	O
fucosyltransferases	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
examined	O
the	O
FUT1	O
and	O
the	O
FUT2	O
from	O
three	O
unrelated	O
Indian	O
individuals	O
with	O
the	O
Bombay	O
phenotype	O
.	O

These	O
three	O
individuals	O
were	O
found	O
to	O
be	O
homozygous	O
for	O
a	O
T725G	O
mutation	O
in	O
the	O
coding	O
region	O
of	O
the	O
FUT1	O
,	O
which	O
inactivated	O
the	O
enzyme	O
activity	O
.	O

In	O
addition	O
,	O
we	O
did	O
not	O
detect	O
any	O
hybridized	O
band	O
corresponding	O
to	O
the	O
FUT2	O
by	O
Southern	O
blot	O
analysis	O
using	O
the	O
catalytic	O
domain	O
of	O
the	O
FUT2	O
as	O
a	O
probe	O
,	O
indicating	O
that	O
the	O
three	O
individuals	O
were	O
homozygous	O
for	O
a	O
gene	O
deletion	O
in	O
the	O
FUT2	O
.	O

These	O
results	O
suggest	O
that	O
the	O
T725G	O
mutation	O
of	O
FUT1	O
and	O
the	O
gene	O
deletion	O
of	O
FUT2	O
are	O
responsible	O
for	O
the	O
classical	O
Indian	O
Bombay	O
phenotype	O
.	O

An	O
interesting	O
property	O
of	O
plakoglobin	O
is	O
that	O
it	O
binds	O
to	O
both	O
classical	O
and	O
desmosomal	O
cadherins	O
.	O

The	O
observation	O
that	O
DP	O
-	O
NTP	O
binds	O
to	O
plakoglobin	O
and	O
clusters	O
desmosomal	O
cadherin	O
-	O
plakoglobin	O
complexes	O
implies	O
that	O
desmoplakin	O
binds	O
to	O
plakoglobin	O
that	O
is	O
associated	O
with	O
the	O
desmosomal	O
cadherin	O
cytoplasmic	O
domain	O
.	O

In	O
contrast	O
,	O
plakoglobin	O
that	O
is	O
associated	O
with	O
the	O
desmosomal	O
cadherin	O
cytoplasmic	O
domain	O
is	O
unable	O
to	O
bind	O
to	O
alpha	O
-	O
catenin	O
(	O
Fig	O
.	O
8	O
)	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
the	O
alpha	O
-	O
catenin	O
and	O
Dsg1	O
binding	O
sites	O
on	O
plakoglobin	O
overlap	O
in	O
the	O
amino	O
-	O
terminal	O
armadillo	O
repeats	O
of	O
plakoglobin	O
,	O
suggesting	O
that	O
Dsg1	O
and	O
alpha	O
-	O
catenin	O
cannot	O
bind	O
to	O
the	O
same	O
plakoglobin	O
molecule	O
simultaneously	O
.	O

However	O
,	O
the	O
classical	O
cadherins	O
bind	O
to	O
the	O
central	O
armadillo	O
repeats	O
of	O
plakoglobin	O
,	O
leaving	O
the	O
amino	O
-	O
terminal	O
armadillo	O
repeats	O
of	O
plakoglobin	O
available	O
to	O
bind	O
alpha	O
-	O
catenin	O
.	O

In	O
the	O
present	O
study	O
,	O
deletion	O
mutants	O
of	O
plakoglobin	O
lacking	O
either	O
the	O
amino	O
-	O
or	O
carboxyl	O
-	O
terminal	O
domain	O
co	O
-	O
immunoprecipitated	O
with	O
DP	O
-	O
NTP	O
and	O
were	O
clustered	O
in	O
L	O
-	O
cells	O
co	O
-	O
expressing	O
DP	O
-	O
NTP	O
.	O

These	O
results	O
,	O
along	O
with	O
the	O
ability	O
of	O
the	O
amino	O
-	O
terminal	O
plakoglobin	O
deletion	O
to	O
interact	O
with	O
DP	O
-	O
NTP	O
in	O
the	O
two	O
hybrid	O
system	O
,	O
suggest	O
that	O
desmoplakin	O
may	O
bind	O
to	O
the	O
central	O
armadillo	O
repeats	O
of	O
plakoglobin	O
.	O

In	O
A431	O
cells	O
,	O
the	O
expression	O
of	O
plakoglobin	O
deletion	O
mutants	O
lacking	O
the	O
amino	O
-	O
and	O
carboxyl	O
-	O
terminal	O
end	O
domains	O
promoted	O
the	O
assembly	O
of	O
elongated	O
and	O
fused	O
desmosomes	O
,	O
suggesting	O
that	O
the	O
central	O
armadillo	O
repeats	O
of	O
plakoglobin	O
can	O
promote	O
interactions	O
between	O
desmosomal	O
proteins	O
,	O
which	O
may	O
include	O
desmoplakin	O
.	O

Future	O
studies	O
will	O
be	O
directed	O
at	O
mapping	O
precisely	O
where	O
desmoplakin	O
binds	O
to	O
plakoglobin	O
in	O
relation	O
to	O
the	O
sites	O
on	O
plakoglobin	O
that	O
bind	O
to	O
the	O
desmosomal	O
cadherins	O
.	O

Such	O
studies	O
should	O
provide	O
insight	O
into	O
the	O
mechanisms	O
by	O
which	O
the	O
cadherin	O
cytoplasmic	O
tails	O
govern	O
the	O
domains	O
on	O
plakoglobin	O
that	O
are	O
available	O
for	O
interactions	O
with	O
either	O
alpha	O
-	O
catenin	O
or	O
desmoplakin	O
.	O

It	O
appears	O
that	O
the	O
removal	O
of	O
alpha	O
-	O
SNAP	O
stimulation	O
of	O
NSF	O
ATPase	O
activity	O
results	O
in	O
a	O
mutant	O
unable	O
to	O
stimulate	O
exocytosis	O
in	O
permeabilized	O
chromaffin	O
cells	O
.	O

It	O
is	O
probable	O
that	O
exogenously	O
added	O
alpha	O
-	O
SNAP	O
must	O
first	O
interact	O
with	O
an	O
endogenous	O
factor	O
,	O
probably	O
SNAREs	O
,	O
before	O
the	O
stimulation	O
of	O
NSF	O
.	O

Addition	O
of	O
an	O
alpha	O
-	O
SNAP	O
mutant	O
that	O
is	O
able	O
to	O
bind	O
but	O
not	O
stimulate	O
NSF	O
would	O
be	O
predicted	O
to	O
inhibit	O
the	O
action	O
of	O
exogenously	O
added	O
alpha	O
-	O
SNAP	O
in	O
chromaffin	O
cells	O
.	O

To	O
test	O
this	O
possibility	O
,	O
digitonin	O
-	O
permeabilized	O
chromaffin	O
cells	O
were	O
preincubated	O
with	O
either	O
buffer	O
,	O
alpha	O
-	O
SNAP	O
(	O
1	O
-	O
160	O
)	O
(	O
as	O
a	O
control	O
)	O
,	O
alpha	O
-	O
SNAP	O
(	O
1	O
-	O
285	O
)	O
,	O
or	O
alpha	O
-	O
SNAP	O
(	O
L294A	O
)	O
for	O
25	O
min	O
and	O
stimulated	O
with	O
10	O
muM	O
Ca2	O
+	O
for	O
30	O
min	O
with	O
or	O
without	O
25	O
mug	O
/	O
ml	O
alpha	O
-	O
SNAP	O
.	O

The	O
results	O
of	O
four	O
separate	O
experiments	O
were	O
averaged	O
,	O
and	O
the	O
results	O
were	O
expressed	O
as	O
a	O
percentage	O
of	O
the	O
10	O
muM	O
Ca2	O
+	O
stimulation	O
.	O

When	O
preincubated	O
with	O
buffer	O
alone	O
,	O
alpha	O
-	O
SNAP	O
stimulated	O
exocytosis	O
above	O
control	O
levels	O
(	O
Fig	O
.	O
5	O
B	O
)	O
.	O

Preincubation	O
with	O
alpha	O
-	O
SNAP	O
(	O
1	O
-	O
160	O
)	O
had	O
no	O
inhibitory	O
effect	O
on	O
alpha	O
-	O
SNAP	O
action	O
(	O
Fig	O
.	O
5	O
B	O
)	O
,	O
which	O
would	O
be	O
predicted	O
because	O
such	O
a	O
large	O
truncation	O
would	O
abolish	O
the	O
ability	O
to	O
interact	O
with	O
SNAREs	O
.	O

However	O
,	O
addition	O
of	O
25	O
mug	O
/	O
ml	O
of	O
either	O
alpha	O
-	O
SNAP	O
(	O
1	O
-	O
285	O
)	O
or	O
alpha	O
-	O
SNAP	O
(	O
L294A	O
)	O
resulted	O
in	O
the	O
complete	O
inhibition	O
of	O
the	O
stimulatory	O
activity	O
of	O
exogenous	O
alpha	O
-	O
SNAP	O
.	O

The	O
inhibitory	O
effect	O
of	O
these	O
mutants	O
was	O
still	O
seen	O
,	O
even	O
when	O
an	O
additional	O
10	O
-	O
min	O
wash	O
step	O
was	O
added	O
between	O
incubation	O
of	O
mutant	O
proteins	O
and	O
the	O
stimulation	O
in	O
the	O
presence	O
of	O
alpha	O
-	O
SNAP	O
(	O
data	O
not	O
shown	O
)	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
mutants	O
alpha	O
-	O
SNAP	O
(	O
1	O
-	O
285	O
)	O
and	O
alpha	O
-	O
SNAP	O
(	O
L294A	O
)	O
had	O
little	O
effect	O
on	O
endogenous	O
exocytosis	O
in	O
the	O
absence	O
of	O
added	O
alpha	O
-	O
SNAP	O
,	O
nor	O
did	O
they	O
do	O
so	O
even	O
up	O
to	O
concentrations	O
as	O
high	O
as	O
150	O
mug	O
/	O
ml	O
(	O
data	O
not	O
shown	O
)	O
.	O

Integrins	O
mediate	O
adhesion	O
to	O
agrin	O
and	O
modulate	O
agrin	O
signaling	O
.	O

Agrin	O
,	O
a	O
basal	O
lamina	O
-	O
associated	O
proteoglycan	O
,	O
is	O
a	O
crucial	O
nerve	O
-	O
derived	O
organizer	O
of	O
postsynaptic	O
differentiation	O
at	O
the	O
skeletal	O
neuromuscular	O
junction	O
.	O

Because	O
integrins	O
serve	O
as	O
cellular	O
receptors	O
for	O
many	O
basal	O
lamina	O
components	O
,	O
we	O
asked	O
whether	O
agrin	O
interacts	O
with	O
integrins	O
.	O

Agrin	O
-	O
induced	O
aggregation	O
of	O
acetylcholine	O
receptors	O
on	O
cultured	O
myotubes	O
was	O
completely	O
blocked	O
by	O
antibodies	O
to	O
the	O
beta1	O
integrin	O
subunit	O
and	O
partially	O
blocked	O
by	O
antibodies	O
to	O
the	O
alpha	O
(	O
v	O
)	O
integrin	O
subunit	O
.	O

Agrin	O
-	O
induced	O
clustering	O
was	O
also	O
inhibited	O
by	O
antisense	O
oligonucleotides	O
to	O
alpha	O
(	O
v	O
)	O
and	O
a	O
peptide	O
that	O
blocks	O
the	O
alpha	O
(	O
v	O
)	O
binding	O
site	O
.	O

Non	O
-	O
muscle	O
cells	O
that	O
expressed	O
alpha	O
(	O
v	O
)	O
and	O
beta1	O
integrin	O
subunits	O
adhered	O
to	O
immobilized	O
agrin	O
,	O
and	O
this	O
adhesion	O
was	O
blocked	O
by	O
anti	O
-	O
alpha	O
(	O
v	O
)	O
and	O
anti	O
-	O
beta1	O
antibodies	O
.	O

Integrin	O
alpha	O
(	O
v	O
)	O
-	O
negative	O
cells	O
that	O
did	O
not	O
adhere	O
to	O
agrin	O
were	O
rendered	O
adherent	O
by	O
introduction	O
of	O
alpha	O
(	O
v	O
)	O
.	O

Together	O
,	O
these	O
results	O
implicate	O
integrins	O
,	O
including	O
alpha	B-Complex
(	I-Complex
v	I-Complex
)	I-Complex
beta1	I-Complex
,	O
as	O
components	O
or	O
modulators	O
of	O
agrin	O
'	O
s	O
signal	O
transduction	O
pathway	O
.	O

POU	O
transcription	O
factors	O
Brn	O
-	O
3a	O
and	O
Brn	O
-	O
3b	O
interact	O
with	O
the	O
estrogen	O
receptor	O
and	O
differentially	O
regulate	O
transcriptional	O
activity	O
via	O
an	O
estrogen	O
response	O
element	O
.	O

The	O
estrogen	O
receptor	O
(	O
ER	O
)	O
modulates	O
transcription	O
by	O
forming	O
complexes	O
with	O
other	O
proteins	O
and	O
then	O
binding	O
to	O
the	O
estrogen	O
response	O
element	O
(	O
ERE	O
)	O
.	O

We	O
have	O
identified	O
a	O
novel	O
interaction	O
of	O
this	O
receptor	O
with	O
the	O
POU	O
transcription	O
factors	O
Brn	O
-	O
3a	O
and	O
Brn	O
-	O
3b	O
which	O
was	O
independent	O
of	O
ligand	O
binding	O
.	O

By	O
pull	O
-	O
down	O
assays	O
and	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
,	O
the	O
POU	O
domain	O
of	O
Brn	O
-	O
3a	O
and	O
Brn	O
-	O
3b	O
was	O
shown	O
to	O
interact	O
with	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
ER	O
.	O

Brn	O
-	O
3	O
-	O
ER	O
interactions	O
also	O
affect	O
transcriptional	O
activity	O
of	O
an	O
ERE	O
-	O
containing	O
promoter	O
,	O
such	O
that	O
in	O
estradiol	O
-	O
stimulated	O
cells	O
,	O
Brn	O
-	O
3b	O
strongly	O
activated	O
the	O
promoter	O
via	O
the	O
ERE	O
,	O
while	O
Brn	O
-	O
3a	O
had	O
a	O
mild	O
inhibitory	O
effect	O
.	O

The	O
POU	O
domain	O
of	O
Brn	O
-	O
3b	O
which	O
interacts	O
with	O
the	O
ER	O
was	O
sufficient	O
to	O
confer	O
this	O
activation	O
potential	O
,	O
and	O
the	O
change	O
of	O
a	O
single	O
amino	O
acid	O
in	O
the	O
first	O
helix	O
of	O
the	O
POU	O
homeodomain	O
of	O
Brn	O
-	O
3a	O
to	O
its	O
equivalent	O
in	O
Brn	O
-	O
3b	O
can	O
change	O
the	O
mild	O
repressive	O
effect	O
of	O
Brn	O
-	O
3a	O
to	O
a	O
stimulatory	O
Brn	O
-	O
3b	O
-	O
like	O
effect	O
.	O

These	O
observations	O
and	O
their	O
implications	O
for	O
transcriptional	O
regulation	O
by	O
the	O
ER	O
are	O
discussed	O
.	O

Lack	O
of	O
homozygotes	O
for	O
the	O
most	O
frequent	O
disease	O
allele	O
in	O
carbohydrate	O
-	O
deficient	O
glycoprotein	O
syndrome	O
type	O
1A	O
.	O

Carbohydrate	O
-	O
deficient	O
-	O
glycoprotein	O
syndrome	O
type	O
1	O
(	O
CDG1	O
;	O
also	O
known	O
as	O
"	O
Jaeken	O
syndrome	O
"	O
)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
defective	O
glycosylation	O
.	O

Most	O
patients	O
show	O
a	O
deficiency	O
of	O
phosphomannomutase	O
(	O
PMM	O
)	O
,	O
the	O
enzyme	O
that	O
converts	O
mannose	O
6	O
-	O
phosphate	O
to	O
mannose	O
1	O
-	O
phosphate	O
in	O
the	O
synthesis	O
of	O
GDP	O
-	O
mannose	O
.	O

The	O
disease	O
is	O
linked	O
to	O
chromosome	O
16p13	O
,	O
and	O
mutations	O
have	O
recently	O
been	O
identified	O
in	O
the	O
PMM2	O
gene	O
in	O
CDG1	O
patients	O
with	O
a	O
PMM	O
deficiency	O
(	O
CDG1A	O
)	O
.	O

The	O
availability	O
of	O
the	O
genomic	O
sequences	O
of	O
PMM2	O
allowed	O
us	O
to	O
screen	O
for	O
mutations	O
in	O
56	O
CDG1	O
patients	O
from	O
different	O
geographic	O
origins	O
.	O

By	O
SSCP	O
analysis	O
and	O
by	O
sequencing	O
,	O
we	O
identified	O
23	O
different	O
missense	O
mutations	O
and	O
1	O
single	O
-	O
base	O
-	O
pair	O
deletion	O
.	O

In	O
total	O
,	O
mutations	O
were	O
found	O
on	O
99	O
%	O
of	O
the	O
disease	O
chromosomes	O
in	O
CDG1A	O
patients	O
.	O

The	O
R141H	O
substitution	O
is	O
present	O
on	O
43	O
of	O
the	O
112	O
disease	O
alleles	O
.	O

However	O
,	O
this	O
mutation	O
was	O
never	O
observed	O
in	O
the	O
homozygous	O
state	O
,	O
suggesting	O
that	O
homozygosity	O
for	O
these	O
alterations	O
is	O
incompatible	O
with	O
life	O
.	O

On	O
the	O
other	O
hand	O
,	O
patients	O
were	O
found	O
homozygous	O
for	O
the	O
D65Y	O
and	O
F119L	O
mutations	O
,	O
which	O
must	O
therefore	O
be	O
mild	O
mutations	O
.	O

One	O
particular	O
genotype	O
,	O
R141H	O
/	O
D188G	O
,	O
which	O
is	O
prevalent	O
in	O
Belgium	O
and	O
the	O
Netherlands	O
,	O
is	O
associated	O
with	O
a	O
severe	O
phenotype	O
and	O
a	O
high	O
mortality	O
.	O

Apart	O
from	O
this	O
,	O
there	O
is	O
only	O
a	O
limited	O
relation	O
between	O
the	O
genotype	O
and	O
the	O
clinical	O
phenotype	O
.	O

The	O
epidermal	O
growth	O
factor	O
receptor	O
associates	O
with	O
and	O
recruits	O
phosphatidylinositol	O
3	O
-	O
kinase	O
to	O
the	O
platelet	O
-	O
derived	O
growth	O
factor	O
beta	O
receptor	O
.	O

Receptor	O
tyrosine	O
kinases	O
are	O
classified	O
into	O
subfamilies	O
,	O
which	O
are	O
believed	O
to	O
function	O
independently	O
,	O
with	O
heterodimerization	O
occurring	O
only	O
within	O
the	O
same	O
subfamily	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
evidence	O
suggesting	O
a	O
direct	O
interaction	O
between	O
the	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
receptor	O
(	O
EGFR	O
)	O
and	O
the	O
platelet	O
-	O
derived	O
growth	O
factor	O
beta	O
(	O
PDGFbeta	O
)	O
receptor	O
(	O
PDGFbetaR	O
)	O
,	O
members	O
of	O
different	O
receptor	O
tyrosine	O
kinase	O
subfamilies	O
.	O

We	O
find	O
that	O
the	O
addition	O
of	O
EGF	O
to	O
COS	O
-	O
7	O
cells	O
and	O
to	O
human	O
foreskin	O
Hs27	O
fibroblasts	O
results	O
in	O
a	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
the	O
PDGFbetaR	O
and	O
results	O
in	O
the	O
recruitment	O
of	O
phosphatidylinositol	O
3	O
-	O
kinase	O
to	O
the	O
PDGFbetaR	O
.	O

In	O
R1hER	O
cells	O
,	O
which	O
overexpress	O
the	O
EGFR	O
,	O
we	O
find	O
ligand	O
-	O
independent	O
tyrosine	O
phosphorylation	O
of	O
the	O
PDGFbetaR	O
and	O
the	O
constitutive	O
binding	O
of	O
a	O
substantial	O
amount	O
of	O
PI	O
-	O
3	O
kinase	O
activity	O
to	O
it	O
,	O
mimicking	O
the	O
effect	O
of	O
ligand	O
in	O
untransfected	O
cells	O
.	O

In	O
support	O
of	O
the	O
possibility	O
that	O
this	O
may	O
be	O
a	O
direct	O
interaction	O
,	O
we	O
show	O
that	O
the	O
two	O
receptors	O
can	O
be	O
coimmunoprecipitated	O
from	O
untransfected	O
Hs27	O
fibroblasts	O
and	O
from	O
COS	O
-	O
7	O
cells	O
.	O

This	O
association	O
can	O
be	O
reconstituted	O
by	O
introducing	O
the	O
two	O
receptors	O
into	O
293	O
EBNA	O
cells	O
.	O

The	O
EGFR	O
/	O
PDGFbetaR	O
association	O
is	O
ligand	O
-	O
independent	O
in	O
all	O
cell	O
lines	O
tested	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
fraction	O
of	O
PDGFbetaR	O
bound	O
to	O
the	O
EGFR	O
in	O
R1hER	O
cells	O
undergoes	O
an	O
EGF	O
-	O
induced	O
mobility	O
shift	O
on	O
Western	O
blots	O
indicative	O
of	O
phosphorylation	O
.	O

Our	O
findings	O
indicate	O
that	O
direct	O
interactions	O
between	O
receptor	O
tyrosine	O
kinases	O
classified	O
under	O
different	O
subfamilies	O
may	O
be	O
more	O
widespread	O
than	O
previously	O
believed	O
.	O

Myoblast	O
city	O
,	O
the	O
Drosophila	O
homolog	O
of	O
DOCK180	O
/	O
CED	O
-	O
5	O
,	O
is	O
required	O
in	O
a	O
Rac	O
signaling	O
pathway	O
utilized	O
for	O
multiple	O
developmental	O
processes	O
.	O

The	O
Rac	O
and	O
Cdc42	O
GTPases	O
share	O
several	O
regulators	O
and	O
effectors	O
,	O
yet	O
perform	O
distinct	O
biological	O
functions	O
.	O

The	O
factors	O
determining	O
such	O
specificity	O
in	O
vivo	O
have	O
not	O
been	O
identified	O
.	O

In	O
a	O
mutational	O
screen	O
in	O
Drosophila	O
to	O
identify	O
Rac	O
-	O
specific	O
signaling	O
components	O
,	O
we	O
isolated	O
11	O
alleles	O
of	O
myoblast	O
city	O
(	O
mbc	O
)	O
.	O
mbc	O
mutant	O
embryos	O
exhibit	O
defects	O
in	O
dorsal	O
closure	O
,	O
myogenesis	O
,	O
and	O
neural	O
development	O
.	O

DOCK180	O
,	O
the	O
mammalian	O
homolog	O
of	O
Mbc	O
,	O
associates	O
with	O
Rac	O
,	O
but	O
not	O
Cdc42	O
,	O
in	O
a	O
nucleotide	O
-	O
independent	O
manner	O
.	O

These	O
results	O
suggest	O
that	O
Mbc	O
is	O
a	O
specific	O
upstream	O
regulator	O
of	O
Rac	O
activity	O
that	O
mediates	O
several	O
morphogenetic	O
processes	O
in	O
Drosophila	O
embryogenesis	O
.	O

Crm1p	O
mediates	O
regulated	O
nuclear	O
export	O
of	O
a	O
yeast	O
AP	O
-	O
1	O
-	O
like	O
transcription	O
factor	O
.	O

The	O
yeast	O
AP	O
-	O
1	O
-	O
like	O
transcription	O
factor	O
,	O
Yap1p	O
,	O
activates	O
genes	O
required	O
for	O
the	O
response	O
to	O
oxidative	O
stress	O
.	O

Yap1p	O
is	O
normally	O
cytoplasmic	O
and	O
inactive	O
,	O
but	O
will	O
activate	O
by	O
nuclear	O
translocation	O
if	O
cells	O
are	O
placed	O
in	O
an	O
oxidative	O
environment	O
.	O

Here	O
we	O
show	O
that	O
Yap1p	O
is	O
a	O
target	O
of	O
the	O
beta	O
-	O
karyopherin	O
-	O
like	O
nuclear	O
exporter	O
,	O
Crm1p	O
.	O

Yap1p	O
is	O
constitutively	O
nuclear	O
in	O
a	O
crm1	O
mutant	O
,	O
and	O
Crm1p	O
binds	O
to	O
a	O
nuclear	O
export	O
sequence	O
(	O
NES	O
)	O
-	O
like	O
sequence	O
in	O
Yap1p	O
in	O
the	O
presence	O
of	O
RanGTP	O
.	O

Recognition	O
of	O
Yap1p	O
by	O
Crm1p	O
is	O
inhibited	O
by	O
oxidation	O
,	O
and	O
this	O
inhibition	O
requires	O
at	O
least	O
one	O
of	O
the	O
three	O
cysteine	O
residues	O
flanking	O
the	O
NES	O
.	O

These	O
results	O
suggest	O
that	O
Yap1p	O
localization	O
is	O
largely	O
regulated	O
at	O
the	O
level	O
of	O
nuclear	O
export	O
,	O
and	O
that	O
the	O
oxidation	O
state	O
affects	O
the	O
accessibility	O
of	O
the	O
Yap1p	O
NES	O
to	O
Crm1p	O
directly	O
.	O

We	O
also	O
show	O
that	O
a	O
mutation	O
in	O
RanGAP	O
(	O
rna1	O
-	O
1	O
)	O
is	O
synthetically	O
lethal	O
with	O
crm1	O
mutants	O
.	O

Yap1p	O
export	O
is	O
inhibited	O
in	O
both	O
rna1	O
-	O
1	O
and	O
prp20	O
(	O
RanGNRF	O
)	O
mutant	O
strains	O
,	O
but	O
Yap1p	O
rapidly	O
accumulates	O
at	O
the	O
nuclear	O
periphery	O
after	O
shifting	O
rna1	O
-	O
1	O
,	O
but	O
not	O
other	O
mutant	O
cells	O
to	O
the	O
non	O
-	O
permissive	O
temperature	O
.	O

Thus	O
,	O
disassembly	O
of	O
export	O
complexes	O
in	O
response	O
to	O
RanGTP	O
hydrolysis	O
may	O
be	O
required	O
for	O
release	O
of	O
substrate	O
from	O
a	O
terminal	O
binding	O
site	O
at	O
the	O
nuclear	B-Complex
pore	I-Complex
complex	I-Complex
(	O
NPC	B-Complex
)	O
.	O

hnRNP	O
H	O
is	O
a	O
component	O
of	O
a	O
splicing	O
enhancer	O
complex	O
that	O
activates	O
a	O
c	O
-	O
src	O
alternative	O
exon	O
in	O
neuronal	O
cells	O
.	O

The	O
regulation	O
of	O
the	O
c	O
-	O
src	O
N1	O
exon	O
is	O
mediated	O
by	O
an	O
intronic	O
splicing	O
enhancer	O
downstream	O
of	O
the	O
N1	O
5	O
'	O
splice	O
site	O
.	O

Previous	O
experiments	O
showed	O
that	O
a	O
set	O
of	O
proteins	O
assembles	O
onto	O
the	O
most	O
conserved	O
core	O
of	O
this	O
enhancer	O
sequence	O
specifically	O
in	O
neuronal	O
WERI	O
-	O
1	O
cell	O
extracts	O
.	O

The	O
most	O
prominent	O
components	O
of	O
this	O
enhancer	O
complex	O
are	O
the	O
proteins	O
hnRNP	O
F	O
,	O
KSRP	O
,	O
and	O
an	O
unidentified	O
protein	O
of	O
58	O
kDa	O
(	O
p58	O
)	O
.	O

This	O
p58	O
protein	O
was	O
purified	O
from	O
the	O
WERI	O
-	O
1	O
cell	O
nuclear	O
extract	O
by	O
ammonium	O
sulfate	O
precipitation	O
,	O
Mono	O
Q	O
chromatography	O
,	O
and	O
immunoprecipitation	O
with	O
anti	O
-	O
Sm	O
antibody	O
Y12	O
.	O

Peptide	O
sequence	O
analysis	O
of	O
purified	O
p58	O
protein	O
identified	O
it	O
as	O
hnRNP	O
H	O
.	O

Immunoprecipitation	O
of	O
hnRNP	O
H	O
cross	O
-	O
linked	O
to	O
the	O
N1	O
enhancer	O
RNA	O
,	O
as	O
well	O
as	O
gel	O
mobility	O
shift	O
analysis	O
of	O
the	O
enhancer	O
complex	O
in	O
the	O
presence	O
of	O
hnRNP	O
H	O
-	O
specific	O
antibodies	O
,	O
confirmed	O
that	O
hnRNP	O
H	O
is	O
a	O
protein	O
component	O
of	O
the	O
splicing	O
enhancer	O
complex	O
.	O

Immunoprecipitation	O
of	O
splicing	O
intermediates	O
from	O
in	O
vitro	O
splicing	O
reactions	O
with	O
anti	O
-	O
hnRNP	O
H	O
antibody	O
indicated	O
that	O
hnRNP	O
H	O
remains	O
bound	O
to	O
the	O
src	O
pre	O
-	O
mRNA	O
after	O
the	O
assembly	O
of	O
spliceosome	B-Complex
.	O

Partial	O
immunodepletion	O
of	O
hnRNP	O
H	O
from	O
the	O
nuclear	O
extract	O
partially	O
inactivated	O
the	O
splicing	O
of	O
the	O
N1	O
exon	O
in	O
vitro	O
.	O

This	O
inhibition	O
of	O
splicing	O
can	O
be	O
restored	O
by	O
the	O
addition	O
of	O
recombinant	O
hnRNP	O
H	O
,	O
indicating	O
that	O
hnRNP	O
H	O
is	O
an	O
important	O
factor	O
for	O
N1	O
splicing	O
.	O

Finally	O
,	O
in	O
vitro	O
binding	O
assays	O
demonstrate	O
that	O
hnRNP	O
H	O
can	O
interact	O
with	O
the	O
related	O
protein	O
hnRNP	O
F	O
,	O
suggesting	O
that	O
hnRNPs	O
H	O
and	O
F	O
may	O
exist	O
as	O
a	O
heterodimer	O
in	O
a	O
single	O
enhancer	O
complex	O
.	O

These	O
two	O
proteins	O
presumably	O
cooperate	O
with	O
each	O
other	O
and	O
with	O
other	O
enhancer	O
complex	O
proteins	O
to	O
direct	O
splicing	O
to	O
the	O
N1	O
exon	O
upstream	O
.	O

